<SEC-DOCUMENT>0001549084-21-000012.txt : 20210225
<SEC-HEADER>0001549084-21-000012.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225161452
ACCESSION NUMBER:		0001549084-21-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EKSO BIONICS HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001549084
		STANDARD INDUSTRIAL CLASSIFICATION:	GENERAL INDUSTRIAL MACHINERY & EQUIPMENT, NEC [3569]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37854
		FILM NUMBER:		21680502

	BUSINESS ADDRESS:	
		STREET 1:		1414 HARBOUR WAY SOUTH
		STREET 2:		SUITE 1201
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		510-984-1761

	MAIL ADDRESS:	
		STREET 1:		1414 HARBOUR WAY SOUTH
		STREET 2:		SUITE 1201
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PN Med Group Inc
		DATE OF NAME CHANGE:	20120503
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ekso-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:019e24a5-8506-4b4f-a6ec-39d6306edf95,g:9d00d04a-17f2-484e-b0d0-858320403c94,d:3e979bd8812343be80d8bde3987d68dd--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ekso="http://www.eksobionics.com/20201231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ekso-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF80L2ZyYWc6NWIzOTJmYmRiOGMwNDFlYzg3OGMwYWMyMWQ3YmEzNWMvdGFibGU6ZmQ3ZGU1OTc1M2I5NDUzMTkxOGNlMzY5YjdiMzkxMWMvdGFibGVyYW5nZTpmZDdkZTU5NzUzYjk0NTMxOTE4Y2UzNjliN2IzOTExY18zLTEtMS0xLTA_8fb17b65-e904-4187-81d7-8edf31a11e0c">false</ix:nonNumeric><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF80L2ZyYWc6NWIzOTJmYmRiOGMwNDFlYzg3OGMwYWMyMWQ3YmEzNWMvdGFibGU6ZmQ3ZGU1OTc1M2I5NDUzMTkxOGNlMzY5YjdiMzkxMWMvdGFibGVyYW5nZTpmZDdkZTU5NzUzYjk0NTMxOTE4Y2UzNjliN2IzOTExY181LTEtMS0xLTA_6a541dfc-160a-4cbb-bdc7-cc0c4033c6b4">2020</ix:nonNumeric><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF80L2ZyYWc6NWIzOTJmYmRiOGMwNDFlYzg3OGMwYWMyMWQ3YmEzNWMvdGFibGU6ZmQ3ZGU1OTc1M2I5NDUzMTkxOGNlMzY5YjdiMzkxMWMvdGFibGVyYW5nZTpmZDdkZTU5NzUzYjk0NTMxOTE4Y2UzNjliN2IzOTExY182LTEtMS0xLTA_06138954-3810-411e-8572-81ca8f349f54">FY</ix:nonNumeric><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF80L2ZyYWc6NWIzOTJmYmRiOGMwNDFlYzg3OGMwYWMyMWQ3YmEzNWMvdGFibGU6ZmQ3ZGU1OTc1M2I5NDUzMTkxOGNlMzY5YjdiMzkxMWMvdGFibGVyYW5nZTpmZDdkZTU5NzUzYjk0NTMxOTE4Y2UzNjliN2IzOTExY184LTEtMS0xLTA_e7778bc2-d04c-48dc-b27d-8e21760be113">0001549084</ix:nonNumeric><ix:nonNumeric contextRef="id643b591bbe442ff89d7f6fedbd8777a_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTIxNDU_cd4dc075-4b7e-413d-b6dc-6727130d268c">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i34328fdb308e40c6bf10ef8dcd50adb7_D20200324-20200324" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjI3L2ZyYWc6MmViN2ZiNTg3ZWFhNGFmN2IxNmM2OGI4NzNhMzk4ZGIvdGV4dHJlZ2lvbjoyZWI3ZmI1ODdlYWE0YWY3YjE2YzY4Yjg3M2EzOThkYl8zMjk4NTM0ODgzMzM4_bc77d192-0955-4c7c-b9f1-11ebf91f869d">0.0667</ix:nonFraction><ix:nonNumeric contextRef="i63834f56293d4e708f774c76a532f46f_I20201231" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85Ny9mcmFnOjMyNmFjMWM5ZDc0ZDRlZDhhN2I3ZjRjODA3N2JjYzRjL3RhYmxlOmMxMTRlOTI1ZTQ4YjQyYmM4NmNkYTBhMmVhZWFmYjE5L3RhYmxlcmFuZ2U6YzExNGU5MjVlNDhiNDJiYzg2Y2RhMGEyZWFlYWZiMTlfMC0xLTEtMS0w_0aa57a83-4601-432f-8fd6-11cad36c63aa">1</ix:nonNumeric><ix:nonNumeric contextRef="i3036960b630e4dc68acd1c3ce4478d07_I20201231" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85Ny9mcmFnOjMyNmFjMWM5ZDc0ZDRlZDhhN2I3ZjRjODA3N2JjYzRjL3RhYmxlOmMxMTRlOTI1ZTQ4YjQyYmM4NmNkYTBhMmVhZWFmYjE5L3RhYmxlcmFuZ2U6YzExNGU5MjVlNDhiNDJiYzg2Y2RhMGEyZWFlYWZiMTlfMS0xLTEtMS0w_bf543942-4a5e-45de-adb1-1d49f3fa33b4">1</ix:nonNumeric><ix:nonNumeric contextRef="i1189ad224a9542f99ef6b9177be8258c_I20201231" xsi:nil="true" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85Ny9mcmFnOjMyNmFjMWM5ZDc0ZDRlZDhhN2I3ZjRjODA3N2JjYzRjL3RhYmxlOmMxMTRlOTI1ZTQ4YjQyYmM4NmNkYTBhMmVhZWFmYjE5L3RhYmxlcmFuZ2U6YzExNGU5MjVlNDhiNDJiYzg2Y2RhMGEyZWFlYWZiMTlfMi0xLTEtMS0w_6f5bf3e4-362f-4f0b-909b-1a94c4954b31"></ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i34328fdb308e40c6bf10ef8dcd50adb7_D20200324-20200324" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjM0L2ZyYWc6NzY1Y2YwNzgwZmFhNDEzOTgxNTdiMTliMmZkNWNjZDAvdGV4dHJlZ2lvbjo3NjVjZjA3ODBmYWE0MTM5ODE1N2IxOWIyZmQ1Y2NkMF8zODQ4MjkwNjk3MjIw_bc77d192-0955-4c7c-b9f1-11ebf91f869d">0.0667</ix:nonFraction><ix:nonNumeric contextRef="id396d3085bb24e85baf89441852a463a_D20190101-20191231" name="ekso:ClassOfWarrantOrRightPutOptionDurationOfPayPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NTAwMTE_96686e94-4d73-4fcb-ac01-69c8e1bec88a">P5D</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i34328fdb308e40c6bf10ef8dcd50adb7_D20200324-20200324" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjgzL2ZyYWc6ZGE2OGNiNWE3YjI2NDUzMzkwODZlN2Q1MDNjM2UyZGIvdGV4dHJlZ2lvbjpkYTY4Y2I1YTdiMjY0NTMzOTA4NmU3ZDUwM2MzZTJkYl8zMjk4NTM0ODgzMzgy_fbdd8d3b-31bc-4ee8-a5f0-a22a7f40f153">0.067</ix:nonFraction><ix:nonNumeric contextRef="iff2bfb667f574925a5837174b1cdfc30_D20200101-20201231" format="ixt-sec:durwordsen" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjgzL2ZyYWc6ZGE2OGNiNWE3YjI2NDUzMzkwODZlN2Q1MDNjM2UyZGIvdGV4dHJlZ2lvbjpkYTY4Y2I1YTdiMjY0NTMzOTA4NmU3ZDUwM2MzZTJkYl8zMjk4NTM0ODgzMzQz_2ef14bef-3cae-4924-b30b-fa2ef18f7327">five years, six months</ix:nonNumeric><ix:nonNumeric contextRef="ifd9f002eb2a44d11aabd8c0f84f46008_D20200101-20201231" format="ixt-sec:duryear" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjgzL2ZyYWc6ZGE2OGNiNWE3YjI2NDUzMzkwODZlN2Q1MDNjM2UyZGIvdGV4dHJlZ2lvbjpkYTY4Y2I1YTdiMjY0NTMzOTA4NmU3ZDUwM2MzZTJkYl8zMjk4NTM0ODgzMzY2_59ffbb29-db07-4282-a84d-e6b120af2f70">5.5</ix:nonNumeric><ix:nonNumeric contextRef="i4b49ea1876014fb7ab34d29c8ee87415_D20200101-20201231" format="ixt-sec:durwordsen" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjgzL2ZyYWc6ZGE2OGNiNWE3YjI2NDUzMzkwODZlN2Q1MDNjM2UyZGIvdGV4dHJlZ2lvbjpkYTY4Y2I1YTdiMjY0NTMzOTA4NmU3ZDUwM2MzZTJkYl8zMjk4NTM0ODgzMzk2_4c180010-2c87-4c6f-b86d-4b9ecb8b9a71">six months, one day</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ekso-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2d6f176932954c3ea9bd0f2f47990c67_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i725a7c78af424676baf1ece165c91377_I20210219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c95c1de992348a3bd61ef233bf1c041_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id632c7032c4140109d9f983f53b19765_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846dd5585ada4e0498b73873e27cdcdc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i771c5968601e4ebbaee595d0efedc2df_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i001a198ae0ad4ccaabceb0a88f0757da_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b330504326e4a9bbc4d3e4b7244e5fb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed408484abc4ce88899f293e7cfe8ad_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cd59b28ca904e409d6a180ec9f55846_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c5a8bcf1214cdea5e114d7188288c6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f045d0163b47d080fcc09d4ec9b298_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fdf493d0b2b4110824781819eb0a66c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0387f9eb02e44e3b6ba26b31874ce98_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i355702e247f64033a0ce80c82800d085_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164b98fab8ca484db400c50acb2bde32_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id633f108918a485b94dd3575f357c6d1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8437b75fb864b51a8daec69829e7ede_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1244662c4107454f9abedb0d2c7dd95a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fb8ef54637c4de2a9b1091027aa5962_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56dbcebcd6d641bdb0fa75661fc45501_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4b0ba326b044c5d8a0bb299a3ec93ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic126d0c0305a496bb377ee4b4e95f356_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7fef623934b4bd19b22ecc59a17e7ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a01f618e3f9488cb29bae5e918482c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ef9cf6430ff4f8e9422f488739fa849_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92564e533c5b46fca6e27927910f77db_D20210101-20210225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb89bd35b9ca4d7680abe71e8e1cb17e_D20210101-20210225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7b032681769845018b20e932f7d48c5b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic845df26b7574c9688eaf63d2b286340_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ekso:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:PWBLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6806a66d666343109c438a29d2361243_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ekso:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6634dcaf84414ad4a2238d4e3b472d60_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ekso:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c852fde248a46429a59913a353fcd78_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5526a54efe4b4f308ec50b4abcc4ccc1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i425546ef7c404c1fb5e6ce43069f77b8_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id643b591bbe442ff89d7f6fedbd8777a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b4652764f7496fae43691e5665e11e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc2375e404df4bee8066cbe643660925_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fdcba7194b1415db1370657080e8199_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55263caaaf314901a8c536dda2b3d628_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34328fdb308e40c6bf10ef8dcd50adb7_D20200324-20200324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-24</xbrli:startDate><xbrli:endDate>2020-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67594e576125433d9c1e6603131224a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde6413b3f484fbb82f25ef7d5c4d24b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c51e051811a48169af92a76d27be60a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd0c434eb694450b138a39e7717b97d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40711bfb573748f5b097264402445a5e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8fcc63d43e042fb816a4a8bb922bd22_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50bf1458d43243298850ecebb3a893ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2bdafc8b87643a8940a27e6b36684f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb140a2a8bd1427c8038bc9cc6fc4ddd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84e30bf53c5f4d90befcffe3dcd462ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80a48682c16b4e88b27b2fa322d058d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i649dad9fb14749e9996c2dc8928958e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84a84e7d32604e62861e794eea7d7ca1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab6a2c45f8a47ecba7fe4b30e1dda70_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9396d4559e45441f873fc24b5a39358d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i411cf8f5b27a4e37a9f9854d5abc3f48_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ekso:ContingentSuccessFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42740a38dd614cefb84f83af69916e8d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ekso:ContingentSuccessFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0440a5ac3cb444bf8c87c1ca6ea5f57a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2871a384ac049ccbda9e8abc03f027c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ekso:ContingentSuccessFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63834f56293d4e708f774c76a532f46f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3036960b630e4dc68acd1c3ce4478d07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1189ad224a9542f99ef6b9177be8258c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f8795be88184c80b93b87063b29336c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5d78b1f57364d88a58dd74bda2ee22e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2a856fa0deb4f4bbebb18b45f3772fe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b6f83daf3c4c15b23e671334f13579_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i889b78375c774b5687a5747a1b43cb23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c6f90a20b044e3acc886642e9c1309_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id38da83df0b94a2b83b0d1f8a9f1dc30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e574a2fabc1499f884fcd1b5951b4e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i033d5839f04849bfb1ee07ea7dc6b0f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cd34bb1047b430b85a6b141bc79a7c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia43ebf9f36cf41eba45fa05244dc8ac4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i322cf066e9f44f9cbb3ec118a91e904c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8235348a80e487c9f3e8030b4d8ce9a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3162a8935b1c4ff380fbdae542396c82_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic14005e4eb1146e986a9ef76f055084d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib881b817aa7445709d8070f5fe391132_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a7edc5f16340378382788c4c0dc691_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27aec484daea4c1dbfd941c2654431bb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if26d674e4b5d49679bf4f50fdb4b6c18_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95975cc540d54a198ad22e25ed0dcb73_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5078e9375e6b4702909ac2925b30c4bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f73b9d15a3b46ef9fe037af79d4534d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e152e2c14f448a681c80c12f29fa109_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6c52ce74dc42cc9138e832cd3dd672_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1098ca438a48cd9e106e5843d6cd36_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6d3ffd252aa43aa8bf3e178360945c2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28c029fe6658433091f9348fc9d54912_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f6ebc39e4f40b78d40104fb7855d08_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7abf2a1ea34998ba75e15db09892c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2cedde1fd8d4e13817c08df4f3817d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ed2b595380454aa4357b1f8bbc92f8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia41bb0fad4e647a688e43967bb0bb7be_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabb99287795245cead94469bb0004c47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015e0abf22814adbb2132f59a1724e19_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f70fd4ec65c4972b421c5aa5b36941b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TransportationEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i660e36a98e0746cf8a42c3b13e52a56b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TransportationEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id479e8c373654ebbb87b0a250bcc1e8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TransportationEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd0c5c2bb3c4768abec83b24e2a64d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TransportationEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f923f15e82d409bac227a17e3701888_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2e914eb0a5485b9d8820fc1baacc8d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i658969b097ae4314a93b0abea1d13868_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i763c0e7c9c9d44dcb6a9636b86af9d12_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i130b8496b8734097b3481b467f0807f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03553d669ad34441ba31a9b58507f565_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54e4f7da48f45918ff0109be65c5330_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2abecebb024344bea34c7c37ce810974_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ec4203661dc40138fda63b48b530a85_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i049203243d424699b4e0dd6029b0888a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165ec35cb06746f8ab56f69fe0d5c964_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f933f335564a9fac29ff916331aa4e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d35bea06791470faea4c0d59dbb1e5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2005fc6b0f7943b3ba42ed850a5c303e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9feb071f8b40bfbfab0e7da695b5dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dd9eb144ecd423dade80dac3f927d7c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56395207f3fa42a797c5ba80cfdfc6b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia18e0975d5f84534ac0b1db267f24d9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d7b8be94cd47d2b55ddb60df657ed4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09b4c0d4a24e49a0a8ffd3a7005294c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27ca24a6e01a4c5e818349f32894630b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac816c78ecee495db3e143bd5054df3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57a91e8c1fb344769e0f47516a30046c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ekso:OtherliabilitiesAxis">ekso:WarrantyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79e076985ae14c239cf28cb82308d69e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ekso:OtherliabilitiesAxis">ekso:WarrantyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i663e54f1b87347028c8829a7b346f7be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ekso:OtherliabilitiesAxis">ekso:WarrantyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc8ff9bb9094f2ca094767c70c3d73f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ekso:OtherliabilitiesAxis">ekso:WarrantyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2406d983ae408d82890348c4593fe2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ekso:OtherliabilitiesAxis">ekso:WarrantyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b6df24c948e48979ba8b93b03bc8282_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia26aaae57e1a4c82bb8d24f30b52abe8_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75e32a08cd3c442a9b9ba9304b50179b_D20200429-20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820fe364817646f793de1bd99129025e_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ekso:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:PWBLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414af477b5eb412594fd4faab7f47ca1_D20200801-20200830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ekso:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:PWBLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f6e46cb0a00471f82de8d8582d4cbe4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ekso:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:PWBLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied25b6065fd04927890a9579112ce304_I20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id59142af679b474d9606680f4928a206_D20200420-20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc71209ac60845e382225b8a55a86c3d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie41cddf1a88a4eeab4f0e94b552e1cad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ekso:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4013c40327cb4b46bc304ebb13174011_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ekso:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae9cf36b522d452a848dfea8122fdd50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ekso:HamburgGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff102119cd6a456596f0197f90723327_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ekso:AngelPondCapitalLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66089c57ef3447548266d31fba65e3f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ekso:AngelPondCapitalLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7783a67c59429aa5c50cce7d3f36a4_I20190916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="days"><xbrli:measure>ekso:days</xbrli:measure></xbrli:unit><xbrli:context id="i1332f3e466ea4d9886d520016e1fe9a9_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdfb6150e11040dbbad6a66db73b4fdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cc3408bdfbe4b5f8276263fd666f8e1_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20c3fa9143d1494f9fa80ba4773d37c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8146ef51059a4e8588f8cfa2a49cc7c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f4d4c9162e4396a697be5d9061262e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae50490cbb4b480698dbb2b1ea92f87e_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6260ae69ccdc47afb974156191ec17ed_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i656a19543c2446298336599b639f4ed9_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60337cf454184d3fab3c487c42a73b04_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia03e27ee3b474253a9b6b29d30ad3245_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16884269eeb946c9a8d814ed9a37da17_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic069febcd575454ba36115614e1e67f4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c7551fdba7443329e59bdddaaf0a8c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentsWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18a8a6dd04bb4af0a97b953a6edf6367_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentsWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ecc4c18109a4778a6436d117e42e20d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentsWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06d98523cf3c41fc9f81c5db24a92b70_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43dcca06f1114b118c295c1360b5597c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib21914757ec84913b068b738154fc31c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8eab057d5354f54a6a1f4b6e697e1fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i883563dff2a0452fb06639ade8f1ec83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae106f6d2ac4c01ae9d3275ad51c856_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16f2fc5bc8324b9c95780543103873be_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425ea3e27fe44ae8ababe62ca6a2566d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2017InformationAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474fb265033b492d99eef7003d923965_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2017InformationAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e758452b88142cebe39df57428e5d23_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2017InformationAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic67e632c480a4a389d734d7b66ce5c48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie460538640c64e2cba78df79c4755d79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c1742f015b49289941792b99828fec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0318eadd0412421d9ab7a16182414edb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:Pre2014WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i493d79f55e7241dc9784879e595c2d55_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:Pre2014WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32847a63786c4c40911455a3c40434a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:Pre2014WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e9a44a009bc4cff8921788207667b9b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:Pre2014WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66dedf87145f4fc990355ef06fe907ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:Pre2014WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73bddff44ca4b2f9d2a82edae8e117f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b04630ec1374a39bd730200d9ce743a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia50fed56d7e846008e27b2faa05cf892_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a3cb75354a8437c97c6a048fbb71d72_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i606b7f43b71a44adb687cff9e4202f75_I20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15042960a2014c12aeb3b609cd137087_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93802bef0c2445c789f2445d0a127497_D20200610-20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-10</xbrli:startDate><xbrli:endDate>2020-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba22e1721af04a2e9319870ded4bd2de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3aa1cf0746c4b5baceaeb908424df8d_I20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084accc9ec374285be3b0a73a7a1090a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b12218955364d9da56354373add4e0a_I20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd9481bf7e0140ac800169b45355f91d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5038cfc88eee4338ae569f8f794e2d53_I20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c0e3631de7946a9b5dd656a12e3ee57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917d2e433bec4af6a5015a89dffd0ec1_I20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic719e6ce8263469b8620118bde4798db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87826571264a49058ae7d9ecedc374f7_D20200610-20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-10</xbrli:startDate><xbrli:endDate>2020-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i970ae68e19f845e0a61ab8293e716384_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b14b8e6815740a780625da52773615e_I20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i265b24fe236d4a33a086749d8f3bc1d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ffd06e2b41643a5851058ccd43c25f4_I20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i885b3e5d68a84f4e90e8c7922cef7995_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a2440d2a3b4d3d84b38c26002ea3ff_I20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e10eafaaf69412a980b03f834b1e6dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b5955b1efd4de9a0856fc1539f6432_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3687529f69424becaeceedf73f6828ec_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id396d3085bb24e85baf89441852a463a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide46f57c594c4d7e8de120bbe04cf45a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bc70242a8314a19af7cff0da761421c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0145713900c94e918e32d701921d1975_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b034ea5e3e4dc5851a3ccb19e99abf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aecd5d37d3b4bb4b4adf7077dc24cde_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6293a6a35cfd4251acaaf9a8e93b0369_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7f8299a4e214d92957aee41ce77fb46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7e5c100ba04f8687538cfb181146ee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6df92243b17458caf062b597eca0bb0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8c6706df2ef4faca8ee7e3eab8da237_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia91c98835d204cc08859c956d9414520_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3215b84b357a450a985217089ba29281_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i069a96fbc276471e994ddb6c40a43503_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1857924bad947049734ec580f40b921_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e863bdfa06a4bdda07cfb2cdc16b526_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i054e3c8419c84d5cbbdb1d4f07127102_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4998d0b3b84c4399a118546128a7647b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e0af14fe5042aa8dc04877b3a4299a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2f59b7ba4641e584ab2ac68b96fe24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d99f049683342dab1c5c4e16251a30b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic650ec13b1084703a7916113f5898f77_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e15a98c6ae4762a3a129475340835f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie223919cfb0644d4b99679da636b322e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84041bbc80d94707bdd1c71475762b9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78706eee04a546a7a74922c746e3304a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c63f0a4b66643c095e667bc8734eabc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i460359c10d04485b8f24e8e8000ce638_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie74af6c07ea14138ab2b4641dd046986_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283ae8fe845b4608857dda0e19da19e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i584a64da65b8465189421614a29d1307_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i163a45d096374a6caa35072e4bb91628_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f9096b4594d4ef887154e71f8bc2cfd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf0c791c34846d7948b3a5350feab73_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:InformationAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d2869ade03c4be1a192746ea93a57ed_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67dc8fa5926e44009110a64d1f17ab86_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ef49a5dee2d41ff9b68a844e92232cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:TwothousandFifteenWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579155917cc84c16b497230e8d059707_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:TwothousandFifteenWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i918faac37d3648509a88395256f45bfe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff2bfb667f574925a5837174b1cdfc30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9f002eb2a44d11aabd8c0f84f46008_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b49ea1876014fb7ab34d29c8ee87415_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2019WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb64e100a4ea46aeaf2e021efaf9fc23_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i877dabd6d9f1456b80f4388fc9919198_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b635d7791d4729a41246f37fdd5040_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fba51ad7cb8481bae70c35bf580f079_D20170601-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa56f65ff31460b927499357c824471_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66f66be5e4ca4a3fbef0430494cb2a38_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8347ac776ecd461e8415e7b0e8c4a7fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607f7ac1d3694172a81a41007edb3395_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4579f566e42442e9e3dc9eb88d2d447_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10a66b0cab964a889263784aee1901fe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec71a31edf584b3fbbe26a8ef6da1b57_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8724e49e7c1c44f9ae22762caedea6d7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eccbe0a4d6f46a7beb0bc1fe08e5bab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57345e588804cfe860c750737f00dd8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37bd0dc0daa4fb7b83159c71d2bfa17_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i311beee139874abaaa623022d8afd3cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0686788f1e24c1290b7f0d92818a8ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32119daf61d74b55a3c8238a0cb3d15b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87e27b2516f148d697ece33f11777fc4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i082ff8dadd2c49fa8fbb80b8ffef3976_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e851d50c5564e38abf2c0a93b86475f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2948b44d394340328fd63500766a8e47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6df990af732247609512a586b14ed964_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9584796b78247a691fb1d74e4e04c73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd5100ca7f64a00831c51a479b855ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i214faac982094d0986fd63789ae5cc48_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2cb1ee725d64b848c8abc9e90945dbb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3cd9b4295544ce39f97760979ddef45_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i983c680de266493eb3b87d6e84973e71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e43a3b8d704169bc941d426832f568_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0580d79d27744dfa79750de680b753e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c9bf3c95d404943b8b37bf228a87293_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie50e530344ba4276bb503495928f0afe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f8787b85d56465398b389abe5c50313_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb6a31fa69b42789b1e10282b4ace5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c35f66e6034eec83024df6ac610e24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ekso:GeneratedBefore2018Expire2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a5e4922e5c349469514d98ce6786b33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ekso:GeneratedBefore2018CarryforwardIndefinitelyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i319319b8233c4303ad3523ef6efcc360_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df6497f41704a339bcb35d3d532dc6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6b25f2478684c8396497673025f1b5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia06204e374c64847aa8ca39f1c059324_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="license_agreement"><xbrli:measure>ekso:license_agreement</xbrli:measure></xbrli:unit><xbrli:context id="i8c8907ba268e43a890f1228c1a43a77e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ekso:SalesRevenueGoodsNetExcludingGovernmentSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2504c7ec30a492e9cc1f890fccd8252_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ekso:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4123648869a94d87948d26689a8190ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b339ba80adf48a59e5a09a23f722e4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ekso:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d1eb01e13aa4edd802e72c1ca0af002_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ekso:FacilityOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ekso:segment</xbrli:measure></xbrli:unit><xbrli:context id="i3cb3927a9fbf4e13a0140f4d17c94c07_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ekso:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie155c69f21734a16917958178e1f51a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d6cdf8903fd44d7852fe7584e4e99cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0989d807f24270a4bd9f5c3d8d8d32_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3552c786c174ef89dfaa1c2526fc4e1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i632f81a051354fdf864a43648798ddbe_D20210201-20210226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaad6ab00ad864f69a9e847781dc8db64_I20210226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b5c460bf8c84b56a0349fb3c3d0e654_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16bf31763ef74fad820cf6aed9bb0918_I20210226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb8fcd93e684118ad89bca6e3dc19c7_D20210101-20210225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i226916c19ca6463c961b406e024eca43_I20210226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic513e7ac66894d34b00b95cd51300460_D20210225-20210225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549084</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-25</xbrli:startDate><xbrli:endDate>2021-02-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3e979bd8812343be80d8bde3987d68dd_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:54.532%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDQ4_53a012be-1309-464b-bcd1-78b801a8d0f2">10-K</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:495.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6NjZhZjEzZTBlZThhNDQzMTlhZDQ2MWM4OTg2MTcwOGYvdGFibGVyYW5nZTo2NmFmMTNlMGVlOGE0NDMxOWFkNDYxYzg5ODYxNzA4Zl8wLTAtMS0xLTE0MA_a8cf93e0-5faf-4e94-b522-1c6982e8b052">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDg1_46ef9cf7-6791-4999-b220-795023b47fcd"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDg1_664b86db-1e42-435e-a383-cfff658df062">December 31</ix:nonNumeric>, 2020</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:495.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6MDI3ZWE0ZmE5ZTE0NGE0MjlhYjkyYmFkNTEzYmI3N2IvdGFibGVyYW5nZTowMjdlYTRmYTllMTQ0YTQyOWFiOTJiYWQ1MTNiYjc3Yl8wLTAtMS0xLTE0Mg_0463c821-73f9-4f6d-9aa9-86d82d4a2ed3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDg2_7426e21a-a16f-47e8-b7f1-f26f8c4a8ee3">001-37854</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDg4_1f3806d9-821e-46af-adb9-1293c699fadd">Ekso Bionics Holdings, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:48.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6ZTNjNDQwZjM2YTdkNDM0OWJkZTU5ZjJkYjI1YjMwMWMvdGFibGVyYW5nZTplM2M0NDBmMzZhN2Q0MzQ5YmRlNTlmMmRiMjViMzAxY18wLTAtMS0xLTE2Mg_be65bf50-23f1-4371-bfad-486de378c496">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6ZTNjNDQwZjM2YTdkNDM0OWJkZTU5ZjJkYjI1YjMwMWMvdGFibGVyYW5nZTplM2M0NDBmMzZhN2Q0MzQ5YmRlNTlmMmRiMjViMzAxY18wLTEtMS0xLTE2Mg_447f21e9-fd97-4391-afb4-227dcb26376a">99-0367049</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDg5_9613e467-1807-49cc-bd44-5617c6774667">1414 Harbour Way South</ix:nonNumeric>, <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDkw_d2728153-0689-42c8-bbb4-994d92343c19">Suite 1201</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTA1_a25100f1-8b96-490b-bb2b-b29a2abf29eb">Richmond</ix:nonNumeric>, <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTA2_233fc2f4-d3d1-4c6e-8b4f-de5b928a15c0">California</ix:nonNumeric> <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDky_453f5d6a-4a9d-4d04-8d4d-59c78630be49">94804</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTA5_b4a3c9ad-e8a3-48cc-8fa6-4c730789e0f9">510</ix:nonNumeric>) <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTA3_0c58b56d-3881-4fda-a730-cc34dc08b0d8">984-1761</ix:nonNumeric>&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to section&#160;12(b) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6MmVmOWVlZjIyOWI4NDM5YjlkZjc0ODFiY2FlYWZhODIvdGFibGVyYW5nZToyZWY5ZWVmMjI5Yjg0MzliOWRmNzQ4MWJjYWVhZmE4Ml8xLTAtMS0xLTA_686ed1be-d4e4-4c93-a15c-802a7728a924">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6MmVmOWVlZjIyOWI4NDM5YjlkZjc0ODFiY2FlYWZhODIvdGFibGVyYW5nZToyZWY5ZWVmMjI5Yjg0MzliOWRmNzQ4MWJjYWVhZmE4Ml8xLTEtMS0xLTIxNQ_8c3d4907-f8d2-4707-ae19-a48b46199575">EKSO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6MmVmOWVlZjIyOWI4NDM5YjlkZjc0ODFiY2FlYWZhODIvdGFibGVyYW5nZToyZWY5ZWVmMjI5Yjg0MzliOWRmNzQ4MWJjYWVhZmE4Ml8xLTItMS0xLTMwNC90ZXh0cmVnaW9uOjhkN2IyMzE2ZTdhNjRmMjRhMjdhZmVlNmFlMDhhMjE1XzMyOTg1MzQ4ODMzNjE_ad61c234-bc44-416b-b6c7-49f2060a3149">Nasdaq</ix:nonNumeric> Stock Market LLC</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Nasdaq Capital Market)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to section&#160;12(g) of the Act: None</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:68.274%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160; Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;<ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTE4_7aebfdc2-e610-4403-936e-2bcd2e7a7166">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160; Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;<ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTE5_72e0daae-53b4-4716-a13e-c963b48afd74">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTIw_be2f01e2-32ae-41c8-943d-1cb01d93fcf6">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTIx_1761478a-4522-4e23-9563-94ba006d573f">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.  Large accelerated filer &#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; &#160;&#160; &#160;Accelerated filer&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;<ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTU3_62ae5926-4a2f-4289-baac-11f1559c70a2">Non-accelerated filer</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Smaller reporting company&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTI1_69bfa75f-f1f7-44f5-a3ab-c9ec551ec067">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;Emerging growth company&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTI4_049bbf16-f8fb-45f6-8e8e-1fdc79215d33">&#9744;</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160; Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTM1_da42bcff-8a6e-46ab-a50b-27e17253fb0e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the registrant's common stock held by non-affiliates of the registrant was $<ix:nonFraction unitRef="usd" contextRef="i2d6f176932954c3ea9bd0f2f47990c67_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8yNTE2_811ad4bd-9086-4b41-a36a-667fac10de6a">52,257,307</ix:nonFraction> based on the last sale price for such stock on June 30, 2020, the last business day of the registrant's most recently completed second fiscal quarter.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;19, 2021 the registrant had <ix:nonFraction unitRef="shares" contextRef="i725a7c78af424676baf1ece165c91377_I20210219" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8yNjk4_cb3a6acf-8b0b-436f-87a1-def3510de3d3">12,599,900</ix:nonFraction> outstanding shares of common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTM2_0cf9bbec-cfac-4b0f-991a-0fd8fd5ff3de" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s Proxy Statement for the 2021 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2020.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Year Ended December 31, 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_13">Part I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_16">Item&#160;1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_16">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_16">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_19">Item&#160;1A</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_19">14</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_22">Item&#160;1B</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_22">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_25">Item&#160;2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_25">Properties</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_25">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_28">Item&#160;3</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_28">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_28">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_31">Item&#160;4</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_31">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_34">Part II</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_37">Item&#160;5</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_37">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_1655">Item 6</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_1655">Selected Financial Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_1655">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_43">Item&#160;7</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_43">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_46">Item&#160;7A</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_46">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_46">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_49">Item&#160;8</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_49">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_49">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_151">Item&#160;9</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_151">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_151">73</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_154">Item&#160;9A</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_154">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_154">73</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_157">Item&#160;9B</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_157">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_157">73</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_160">Part III</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_163">Item&#160;10</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_163">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_163">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_166">Item&#160;11</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_166">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_166">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_169">Item&#160;12</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_169">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_169">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_172">Item&#160;13</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_172">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_172">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_175">Item&#160;14</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_175">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_175">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_178">Part IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_181">Item&#160;15</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_181">Exhibits, Financial Statements and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_181">75</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_1662">Item 16</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_1662">10-K Summary</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_1662">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_187">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_187">81</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements, including, without limitation, in the sections captioned &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and elsewhere. Any and all statements contained in this Annual Report that are not statements of historical fact may be deemed forward-looking statements. Terms such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;pro-forma,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;strategy,&#8221; &#8220;anticipate,&#8221; &#8220;attempt,&#8221; &#8220;develop,&#8221; &#8220;plan,&#8221; &#8220;help,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;future,&#8221; and terms of similar import (including the negative of any of the foregoing) may be intended to identify forward-looking statements. However, not all forward-looking statements may contain one or more of these identifying terms. Forward-looking statements in this Annual Report may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of exoskeleton products for humans, (ii) the manufacturing of our products and strengthening our supply chain, and potential opportunities for strategic partnerships, (iii) future financial performance, including any projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iv) our future financial performance, including any statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"), (v) our beliefs regarding the potential for commercial opportunities, including for exoskeleton technology in general and, our exoskeleton products in particular and for strategic partnerships, (vi) our beliefs regarding potential clinical and other health benefits of our medical devices, (vii) the impact and effects of the COVID-19 pandemic and other risk factors on our business, results of operations or prospects, and (viii) the assumptions underlying or relating to any statement described in points (i) through (viii) above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon our current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which we have no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the ongoing COVID-19 pandemic and its impact on the Company&#8217;s financial condition and business, the highly competitive markets in which the Company&#8217;s products are sold, the Company's significant losses to date and anticipated future losses, the new and unproven nature of the market for the Company&#8217;s products, the long and variable sales cycles for the Company&#8217;s products, the factors outside the Company&#8217;s control that affect the international sales of its products, the costs related to and impacts of potential failure of the Company to obtain or maintain protection for the Company's intellectual property rights, the failure of the Company to obtain or maintain regulatory approval to market the Company's medical devices, risks related to product liability, recall and warranty claims, the volatility of the market price of and limited trading in our common stock. A description of some of the risks and uncertainties that could cause our actual results to differ materially from those described by the forward-looking statements in this Annual Report appears in the section captioned &#8220;Risk Factors&#8221; and elsewhere in this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them and to the risk factors. We disclaim any obligation to update the forward-looking statements contained in this Annual Report to reflect any new information or future events or circumstances or otherwise.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Readers should read this Annual Report in conjunction with the discussion under the caption &#8220;Risk Factors,&#8221; our financial statements and the related notes thereto in this Annual Report, and other documents which we may file from time to time with the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes regarding references to Ekso Bionics</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Annual Report, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;its&#8221; and &#8220;our&#8221; refers to Ekso Bionics Holdings, Inc. and its wholly-owned subsidiaries, and &#8220;Ekso Bionics&#8221; refers to Ekso Bionics, Inc. as it existed prior to the January 15, 2014 merger of our wholly-owned subsidiary, Ekso Acquisition Corp., with and into Ekso Bionics, Inc. or the Merger. Ekso Bionics was the surviving corporation in the Merger and became our wholly-owned subsidiary, and all of the outstanding Ekso Bionics stock was converted into shares of our common stock. Ekso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ekso Bionics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EksoVest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EksoWorks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EksoGT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EksoNR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EksoZeroG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EVO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EksoUE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and EksoPulse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are registered and unregistered trademarks of the Company. All other trademarks that may appear in this Annual Report are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design, develop, sell, and rent exoskeleton products that augment human strength, endurance and mobility. Our exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and persons with physical disabilities. We have sold or rented devices that (i) enable individuals with neurological conditions affecting gait (acquired brain injury, or ABI, and spinal cord injury, or SCI) to rehabilitate, and in some cases, to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the commercial opportunity for exoskeleton technology adoption is accelerating as a result of recent advancements in material technologies, electronic and electrical engineering, control technologies, and sensor and software development. Taken individually, many of these advancements have become ubiquitous in peoples&#8217; everyday lives. Supported by an industry-leading intellectual property portfolio, we believe that we have learned how to integrate these existing technologies; wrapping the result around a human being efficiently, elegantly and safely. We further believe that we can do so across a broad spectrum of applications, from persons with lower limb paralysis to able-bodied users.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For medical applications we have two primary products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">EksoNR is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. In June 2020, we received 501(k) clearance from the U.S. Food and Drug Administration, or FDA, to market our EksoNR for use with patients with ABI. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, EksoNR allows for the early mobilization of patients and, increased endurance during rehabilitation sessions through higher step counts and extended training durations. The intent is to allow the patient's central nervous system to take advantage of a patient's neuroplasticity to maximize recovery.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">EksoUE is a wearable upper body exoskeleton that assists patients with a broad range of upper extremity impairments and aims to provide a wider active range of motion, increased endurance, and heightened intensity during rehabilitation sessions.</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For able-bodied industrial workers, we built on the leading market position we achieved with EksoVest and EksoZeroG by introducing EVO, a new wearable exoskeleton for overhead work.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like EksoVest, EVO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an upper body exoskeleton that elevates and supports a worker's arms to assist them with tasks ranging from chest height to overhead. Based on extensive customer feedback, EVO was designed specifically to increase adoption of exoskeletons in the workplace. Compared to EksoVest, EVO is lighter weight, lower profile, lower cost, and has minimal contact with the body, making it comfortable to wear while enabling an even broader free range of motion. The goal is for workers using EVO to experience lower levels of fatigue and reduce on-site injuries</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while boosting productivity. In 2020, we introduced EVO into targeted vertical markets including food processing, specific construction trades, and manufacturing.</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EksoHealth - Rehabilitation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, we focus our healthcare business on rehabilitation robotics. We are leveraging our patented exoskeleton technology to develop and market products intended to enable patients with lower limb impairments to rehabilitate earlier and with better outcomes than the current standard of care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EksoNR</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our leading product, EksoNR, is a wearable bionic suit that allows our hospital and rehabilitation customers to provide in-patients and out-patients the ability to stand and walk over ground while the device makes real-time adjustments to correct issues with the patient&#8217;s reciprocal gait. Patients receive therapy in the device under the supervision of a physical therapist, and typically use an additional assistive device such as a cane, crutches or a walker.  Walking is achieved by a user shifting their weight, requiring the user to achieve balance thereby replicating and reinforcing the movements of a natural gait. If needed, some patients utilize sensors in the device which assist in step initiation. Battery-powered motors drive the legs, detecting the deficient neuromuscular function and providing the level of assistance necessary for a user to complete their step. Users can expect to walk, with aid from the device, the first time they put on the EksoNR exoskeleton (after passing an assessment). Physical therapists can transfer patients to or from their wheelchair and don or remove the EksoNR in less than ten minutes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EksoNR incorporates SmartAssist, our proprietary, adaptive software that allows a patient to perform to their capability but dynamically provides 0-100% power on either side of the body as needed for successful walking.  SmartAssist can promote a greater number of high-quality steps in a short time period and support the early re-learning of correct step patterns and weight shifts, potentially mitigating compensatory behaviors. SmartAssist also has allowed our customers to significantly expand the spectrum of patients that can potentially benefit from robotic rehabilitation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, SmartAssist can aid in promoting early mobility by training patients (PreGait) to walk in an exoskeleton.We believe this expands access of care to additional patients. SmartAssist also includes next generation Variable Assist technology. Variable Assist allows healthcare providers to adjust the level of assistance provided by the EksoNR as necessary, in some instances allowing patients to power themselves (FreeGait). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another important feature of our EksoNR is its EksoPulse Analytics, a real-time data capture program. EksoPulse gathers and transmits statistics and device information during EksoNR walking sessions. This information can be used to track patient progression and to monitor device utilization.&#160;The EksoNR records data such as steps, speed, step size, and other settings along with error logs and operating parameters.&#160;Data is sent securely to our servers where it is available for customers to view, filter, and export through a secure web portal.&#160;This feature enables more thorough patient care while reducing manual data entry.&#160;It also enables us to provide a higher level of service through early identification and thorough reporting of device errors, saving customers the time and expense of unnecessary on-site visits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The EksoNR is used by customers in both in-patient and out-patient settings. Our customers believe that for patients with some preserved motor ability (for example, after a stroke, a traumatic brain injury (TBI), or an incomplete SCI), the EksoNR exoskeleton offers unique benefits. It helps therapists teach proper step patterns and weight shifts, allowing patients potentially to mobilize earlier and ultimately to walk again. By allowing individuals to stand and walk in a full weight-bearing setting, early clinical evidence is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">beginning to show, that EksoNR may offer potential healthcare benefits (inclusive of patients with complete SCI). These benefits include a reduction in secondary complications such as pressure sores, urinary tract infections, bowel problems, pneumonia and other respiratory issues, bone loss/osteoporosis, cardiovascular disease and psychological disorders resulting in reduced post injury medical costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:0.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EksoGT</span></div><div style="margin-top:0.2pt;padding-left:9pt"><span><br/></span></div><div style="margin-top:0.2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EksoGT, previously our leading rehabilitation product, has been superseded by EksoNR.  We may still sell small quantities of EksoGT into certain foreign countries while awaiting regulatory clearance for our EksoNR.  For existing customers with one or more previously purchased EksoGT, we offer an upgrade package.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had shipped over 500 EksoGT and EksoNR units combined to over 400 rehabilitation facilities or customers worldwide. The number of units utilized at a facility varies from one to six, and is driven by the number of beds and rehabilitation sessions a hospital can offer and that hospital&#8217;s adoption of robotics within its rehabilitation protocols.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EksoUE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered the market for upper extremity rehabilitation devices with EksoUE.  EksoUE is a wearable assistive device that helps to reduce the effect of gravity on the wearer&#8217;s shoulders and arms.  While worn, EksoUE allows longer, more intense rehabilitation sessions by reducing fatigue, while also allowing the patient to achieve a larger active range of motion.  Similar to EksoNR, EksoUE is a tool for use by trained clinicians, primarily physical and occupational therapists, during rehabilitation sessions.  Based on the same technology that is used in our industrial products, EksoUE uses a passive (non-motorized) design which avoids the need to charge or manage batteries and other electrical systems.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Market Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rehabilitation clinics with significant stroke, TBI, and SCI populations comprise the primary market for our medical products. Due to their chronic nature, we believe that these conditions have an enormous clinical and economic impact on both people with the conditions and the healthcare system. According to the Centers for Disease Control, there are approximately 800,000 strokes suffered per year in the U.S. and approximately 15 million worldwide, making stroke rehabilitation our largest target market. Likewise, according to the National Spinal Cord Injury Statistical Center, there are approximately 18,000 incidences of SCI per year in the U.S., and according to the World Health Organization, between 250,000 to 500,000 incidences worldwide. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the market opportunity for robotic exoskeleton rehabilitation may be large, we also recognize that the path for medical devices to become the standard of care is long and challenging. We believe that our ability to accelerate adoption will also be based, in part, on our ability to build on our partners&#8217; early efforts: (i) to expand clinical evidence and (ii) to drive toward </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standard of care. We are already seeing customers appreciate that one way for stroke patients at in-patient facilities to receive the recommended amount of rehabilitation per guidelines is by using an EksoNR, the only device currently in the market that has the versatility to provide an over-ground gait training intervention that is task-specific, high intensity and allows for a margin of error, across the continuum of care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Evidence</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our early clinical customers have participated in research focusing on safety and feasibility of exoskeletons and robotics in rehabilitation market development. These early studies were favorable and have further developed to focus on efficacy and outcomes. EksoNR technology is one of the most studied exoskeletons in the market. World-renowned institutions are leading the charge in research focused on acquired brain injury, stroke, spinal cord injury, multiple sclerosis and others. EksoNR is involved in over 115 investigator-initiated studies with greater than 2000 enrolled patient participants. Notable gains have been observed with increased heart rate, rating of perceived exertion and metabolic responses when walking in EksoNR. Also discussed is improved gait speed, walking distance and standing balance out of EksoNR demonstrating improvements in motor activity and functional mobility independence. Our latest company sponsored WISE (Walking Improvement for SCI with Exoskeleton) study demonstrates clinically meaningful improvement in independent walking speed, functional gains in shorter timeframe and influence of factors that may modify gait recovery. The data is currently being submitted to journals for publication. </span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union also requires a two-track approach to market penetration and subsequent coverage, requiring separate claims for purchasing the device and for requests for reimbursement. We are well represented in clinics run by German and Austrian accident insurers, with four out of nine rehabilitation sites in Germany and four out of four rehabilitation sites in Austria. We operate out-patient rehabilitation sessions paid by an accident insurer, where a patient trains using our EksoGT or EksoNR device twice a week. We are using these examples to integrate exoskeletal therapy in existing care pathways. In the United Kingdom, the National Institute for Health and Care Excellence, or NICE, has selected us as the first exoskeleton company to produce a Medtech Innovation Briefing, or MIB, which are designed to support National Health Services, or NHS, and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies. The MIB highlighted the innovative aspect of our proprietary SmartAssist software, which differentiates our EksoNR and EksoGT from other available exoskeletons.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Economic Value Proposition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We&#160;believe&#160;that&#160;our&#160;EksoNR allows our customers to benefit economically without modifying the reimbursement model or reimbursement codes. First, many of our customers have reported that utilizing the EksoNR promotes continuous patient improvement beginning sooner than with traditional rehabilitation methods, potentially leading to a commensurate increase in insurance reimbursements. Second, many of our customers report that facilities equipped with EksoNR as part of their rehabilitation programs attract more patients, thereby driving positive economic benefits.  Lastly, we believe that improvements in patient outcomes, such as those seen with the use of EksoNR, translate positively to other metrics including discharge to community, staffing efficiency in the rehabilitation unit, and reductions in readmission rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Sales and Marketing Efforts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key marketing goal today is the broad-based commercial adoption of our EksoNR in the rehabilitation setting. We are focusing our go-to-market protocols and collateral on our three target audiences: medical administrators, medical directors/ therapists, and patients. Working closely with thought leaders, we will continue to build upon our early user-group exchanges, develop clinical education programs, and grow our medical advisory council.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There continues to be high market interest in expanding neurosciences service lines. In alignment with this interest, our sales priority involves the education of clinical and executive stakeholders on the economic and clinical value of our EksoNR Robotics Neuro Rehabilitation Program under our FDA indications of Stroke, Acquired Brain Injury, and Spinal Cord Injury. In tandem, we continue to leverage our EksoNR customer base to educate and mentor strategic target centers that specialize in Stroke, ABI and SCI rehabilitation in key market service areas across the US and Canada. Geographically, the priorities have been Canada, the U.S., and Mexico in the Americas, Germany in EMEA (the Europe, the Middle East, and Africa region), and Singapore, Hong Kong, and Australia in APAC (the Asia Pacific region). Currently, we utilize a direct sales force for the U.S., Canada, Singapore, Hong Kong, Germany and Switzerland. We also have an expanding distributor network in EMEA and Asia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales and marketing team is principally based in the U.S., Germany, and Singapore, and is structured as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One commercial leader each for the Americas, EMEA, and APAC;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Americas, EMEA, and APAC sales professionals that pursue new prospects and organize demonstrations;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical professionals and physical therapists that provide peer-to-peer demonstrations and trainings;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Marketing professionals and consultants to build awareness and generate demand;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ambassadors, who are stroke and SCI survivors, that provide demonstrations and personal experiences.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales cycle for the EksoNR averages approximately eight to 12 months for a first device and six to eight months for subsequent devices. Our typical sale is our EksoNR complete package, which includes the device and all relevant components, two sets of batteries for continuous run-time, training through two levels of certification, and SmartAssist software. Customers also typically purchase Ekso Care, which is our one- to four-year after-sales service package.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Services and Customer Success</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed leading clinical capability in robotic rehabilitation, and we provide extensive training and support to our customers to ensure they are successful.  All rentals or sales include customer training. This is comprised of both on-line and in-person training of our customers&#8217; physical therapists. We have made this a high priority as we recognize getting customers comfortable using our product is a prerequisite to them successfully implementing a robotic rehabilitation program. In addition to the training that is included with each sale or rental, we also offer additional training services for customers who are interested in more advanced uses of the product or who desire more supervised experiences.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">After Sales Service</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We provide direct service for the EksoNR at our facilities in Richmond, California, and Germany.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we utilize third-party service providers for some customers in EMEA and APAC. When maintenance or service is required, a customer schedules service by contacting us directly. We then arrange for the appropriate service, depending on the level of Ekso Care the customer has purchased and the nature of the service required. In some cases, we may decide it is appropriate to send an Ekso field technician onsite to service the device. However, many service issues are diagnosable remotely with the use of EksoPulse.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Ekso Care service programs we provide a Fee-for-Service option. In this program, EksoNR repair is fulfilled per quote on demand of the customer and as per our repair price list.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Manufacturing and Supply Chain </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We produce the EksoNR at our facilities in Richmond, California for worldwide sales. We currently run one line for one shift per day and believe we have the capacity to eventually run additional lines and shifts should we deem it appropriate. The EksoNR uses over 700 purchased parts, which we source globally from over 70 suppliers. Whenever possible, we seek to secure dual source suppliers for our components.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to the philosophy of continuous improvement has continued to increase product performance and reliability over the past year. As a result, we expect our cost of field service will continue to decline over the next 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EksoWorks - Able-Bodied Industrial Applications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue market and product development opportunities for the industrial market.  Our initial efforts have included EksoZeroG Arm, a mobile arm mount that makes heavy tools feel weightless and enables workers to be more productive and safe, and EksoVest, </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an upper body exoskeleton that elevates and supports a worker's arms to assist them with tasks ranging from chest height to overhead. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on our existing EksoVest technology, in August of 2020 we introduced EVO, an endurance-boosting assistive upper body exoskeleton that alleviates the burden of repetitive work. EVO&#8217;s innovative design is our latest product for able-bodied applications. EVO is a passive, spring-loaded assistive upper-body exoskeleton that aids workers with overhead work. It is designed to reduce fatigue and shoulder and back muscle strain, with the goal of eliminating work-related injuries to the neck, shoulder, and back. EVO offers 5-15 pounds of lift assistance in each arm to elevate and alleviate the day-to-day strain on workers across all industries. Shoulder injuries caused by overhead work, repetitive tasks, and overexertion is the leading cause of lost work days due to workplace injuries. Ekso Bionics is striving to alleviate the burden on skilled workers, drastically reducing the number of workplace injuries and cutting down on worker fatigue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market feedback continues to indicate a growing imperative among construction and manufacturing companies to drive adoption of improved safety and health practices. Furthermore, based on initial field-testing and market research, we believe that industrial&#160;exoskeletons&#160;have the potential to help prevent workforce injuries, improve productivity and over time reduce </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">workers&#8217; compensation and related costs. In the U.S. alone, our target manufacturing and construction verticals employ a total of 18.4 million workers (according to U.S. Bureau of Labor Statistics), many of whom can potentially benefit from our assistive technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, human augmentation technology is being viewed by senior managers of companies that have participated in field-testing as an opportunity to extend the careers of experienced and skilled workers while also changing the work environment to attract future workers to these careers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that the evidence clearly demonstrates that there is significant demand for human augmentation in industrial applications, adoption rates remain a challenge due to the nascent nature of the technology.  That said, we believe that there is significant mid-to-long-term potential in the industrial markets, and accordingly, we will continue our product development efforts to expand our EksoWorks product offerings. Given the fragmented nature of the industrial market we believe that the best approach in this market involves collaboration with established strategic partners that can help us target applications tailored for specific use cases. We believe that leveraging our extensive exoskeleton expertise and intellectual property portfolio with the established channel and applying the expertise of one or more strategic partners unlocks the highest value for us and our stockholders. We continue to engage with multiple potential industrial partners, and plan to continue this approach going forward.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">China Joint Venture</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a joint venture, or the China JV, to develop and serve the exoskeleton market in China and certain other Asian markets and to create a global exoskeleton manufacturing center. The Equity Joint Venture Contract, dated January 30, 2019, between us, Zhejiang Youchuang Venture Capital Investment Co., Ltd., and another partner, collectively referred to as, the JV Partners, as amended by the Amendment to the Joint Venture Contract, dated April 30, 2019, or the JV Agreement, provided for the establishment of the China JV as a limited liability company pursuant to the Law on Sino-foreign Equity Joint Ventures and the Regulations for the Implementation of the Law on Sino-foreign Equity Joint Ventures. In May 2020, the Company, and the JV Partners received notice from the Committee on Foreign Investment in the United States, or CFIUS, in connection with its review of the Company&#8217;s and the JV Partners&#8217; investment in the China JV. The notice stated that CFIUS&#8217;s prior national security concerns regarding the China JV could not be mitigated. In connection with such determination, on July 13, 2020, the Company and the JV Partners entered into a National Security Agreement, or NSA, which, among other things, required the termination of the Company&#8217;s agreements and role with the China JV. On August 12, 2020, the Company and the JV Partners agreed to terminate the agreements underlying the China JV. As of December 31, 2020, all agreements related to the China JV had been terminated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established an extensive intellectual property portfolio that includes various U.S. patents and patent applications. The table below provides a summary of U.S. patents by issuing status and ownership status.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:62.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuing&#160;Status</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">License&#160;Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued<br/>Patents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending<br/>Applications</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensed to the Company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exclusively licensed to the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-owned with Regents of the University of California, exclusively licensed to the Company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-owned with the Regents of the University of California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sole ownership by the Company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total: 65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pending applications mean a complete application has been filed with the applicable patent authority and additional action is pending. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these applications have also been filed internationally as appropriate for their respective subject matter. As of December 31, 2020, 203 applications have issued or have been allowed as patents internationally. Our patent portfolio contains 227 cases that have issued or are in prosecution in 21 countries outside the U.S.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio includes product and method type claims, since the devices that we produce and the processes performed by those devices are patentable. Our patents encompass technologies relevant to our devices, including medical exoskeletons, commercial exoskeletons, actuators, and strength-enhancing exoskeletons. The earliest priority date of the portfolio reaches back to 2003, and new applications may continue to be filed from time-to-time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensors include the Regents of the University of California, or UC Berkeley, and Garrett Brown (as a result of our acquisition of technology of Equipois, LLC, or Equipois).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license with UC Berkeley consists of two agreements and one amendment to the agreement covering ten patent cases exclusively licensed to us, nine of which have issued and one of which remains in prosecution or the UC Berkeley License Agreements. Inventions covered by a further three patent applications are co-owned by us and UC Berkeley, with no license agreement between us and UC Berkeley. As a result, UC Berkeley may license its rights in these patents to a third party. With respect to two of these co-owned patent applications, UC Berkeley has licensed their rights in the U.S. to an unrelated third party. The third patent application will need to be fully prosecuted before it can be determined which claims are exclusive to us (through a previous license) and which claims UC Berkeley may license to other entities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the UC Berkeley License Agreements, Ekso Bionics initially paid UC Berkeley consideration consisting of $5,000 in cash and 310,400 common shares of Ekso Bionics, and committed to pay a 1% royalty on sales, including sales generated by sublicenses. In addition, the UC Berkeley License Agreements call for minimum annual payments of $50,000. We do not pay royalties to UC Berkeley on products sold or to be resold to the U.S. government.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, as a result of government funding we receive, the patents have a government use license, granting the U.S. government a non-exclusive, non-transferable, irrevocable, paid-up license for use of the inventions for or on behalf of the U.S. government, as is typical in the case of government sponsored research.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of assets of Equipois, we assumed the rights and obligations of Equipois under a license agreement with Garrett Brown, the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants us an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, we will be required to pay Mr. Brown a single-digit royalty on net receipts, subject to a $50,000 annual minimum royalty requirement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Out-Licensing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the breadth of the coverage across various bionic systems and technologies, together with our freedom to grant sub-licenses under the UC Berkeley License Agreements gives us the potential to generate licensing revenue in fields outside our present areas of commercialization. Since 2009, we have generated approximately $1.8 million in such licensing revenue from our two licensees: Lockheed Martin Corporation or Lockheed and OttoBock Healthcare Product GmbH or OttoBock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive revenue pursuant to a Government Field Cross License Agreement dated as of July 1, 2013 between Ekso Bionics, Inc. and Lockheed and a Cross License Agreement dated as of July 1, 2013 between Ekso Bionics, Inc. and Lockheed. Pursuant to these agreements, we have licensed to Lockheed certain rights with respect to our anthropomorphic exoskeleton technology for which Lockheed is obligated to pay us a royalty on sales of products incorporating such technology.  Royalty fees from Lockheed were either de minimus or nil for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to OttoBock, we received exclusivity payments pursuant to the License and Services Agreement dated October 27, 2014. The License and Services Agreement grants OttoBock exclusive rights in order to develop a semi-active prosthetic knee prototype for use in medical prosthetics and provides that OttoBock will pay us a royalty based on sales by OttoBock of products incorporating the licensed technology. We did not receive any royalty fees from Ottobock during the years ended December 31, 2020 and 2019, respectively. In November of 2019, OttoBock informed us that they will not be pursuing commercialization of products based on our intellectual property.  As a result, we do not expect additional royalty revenue from OttoBock in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into a set of agreements with Daydo Co, Ltd., or Daydo, related to distribution and cross-licensing of EksoVest.  Under these agreements, Daydo has exclusive distribution rights for EksoVest within Japan and rights to modify EksoVest as needed to address the Japanese market in exchange for royalty payments to us. We also have rights to use any improvements made by Daydo. Daydo released its localized version of EksoVest (called Task AR) in January of 2019.  Revenue from related royalty payments was de minimis in 2020 and 2019.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In June 2020, we entered into a non-exclusive license agreement with HAWE Hydraulik of Germany for rights to develop hydraulic pumps covered by a family of our patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The agreement additionally includes an exclusivity option. We did not receive any royalty revenue from this license in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical technology and industrial robotics industries are characterized by intense competition and rapid technological change. We believe that a number of other companies are developing competitive technology and devices for both the able-bodied and medical fields of use and many of these competitors have significantly more financial and other resources than we possess.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the medical field, we face competition from companies that are focused on technology for rehabilitation of patients suffering from stroke and related neurological disabilities as well as from companies that are focused on SCI. In stroke, Cyberdyne, Parker Hannafin&#8217;s Indego, and ReWalk all now offer ambulatory exoskeletons for rehabilitation use in various markets where we operate. While not functionally equivalent, Hocoma, AlterG, Aretech and Reha Technology are selling treadmill-based gait therapies. In SCI, ReWalk Robotics and Parker Hannafin also sell ambulatory exoskeletons. Other companies who have announced plans to commercialize robotic exoskeletons include: Bionik Laboratories and SuitX.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technologies developed by competitors in the areas of stroke rehabilitation and SCI represent therapeutic interventions with utility at varying points of the continuum of care. Clinically, the EksoNR is unique in its broad ability to mobilize pre- or even non-ambulatory patients using a full weight bearing, over ground, task-based platform. From a practice management perspective, the EksoNR is less expensive than many other systems, has a smaller footprint, the ability to move around the hospital, and uses standard power requirements that make it easy to integrate into existing infrastructure. Other over-ground exoskeletons were initially designed for an individual to achieve ambulation reliant on the device. By contrast, the EksoNR&#8217;s design accommodates patients with complete paraplegia and additionally includes features that are optimized to assist therapists in helping patients with some motor ability learn to walk again in a clinical setting, treating several patients and indications in a single day.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the most pressing challenges we face are not necessarily competitive technologies, but rather achieving rapid market awareness and adoption of this emerging technology while acclimating prospects to a fundamentally new paradigm in neuro-rehabilitation and mobility. In addition, it may be difficult for the rehabilitation department of a hospital or clinic to secure the funds for acquisition of an Ekso device in an environment where capital expenditures of this magnitude are not commonly incurred by those rehabilitation departments.</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the able-bodied field, Lockheed Martin, Raytheon, BAE Systems, Panasonic, Honda, Daewoo, Noonee, Revision Military, SuitX, Skel-ex, Levitate and Cyberdyne - among others - are each developing or commercializing some form of exoskeleton for military and/or industrial applications.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The field of robotic exoskeleton technology remains in its infancy. As this field develops, we believe that we will face increased competition on the basis of product features, clinical outcomes, price, services and other factors. Our competitive position will depend on multiple, complex factors, including our ability to achieve market acceptance for our products, develop new products, implement production and marketing plans, secure regulatory approvals for products under development and protect our intellectual property. In some instances, competitors may also offer, or may attempt to develop, alternative therapies for disease states that may be delivered without a medical device.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Regulation and Product Approval</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government regulates the medical device industry through various agencies, including but not limited to the FDA, which administers the Federal Food, Drug and Cosmetic Act, or FDCA. The design, testing, manufacturing, storage, labeling, distribution, advertising, and marketing of medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the United States, including the FDA, and by similar agencies in other countries. Any medical device product that we develop must receive all requisite regulatory approvals or clearances, as the case may be, before it may be marketed in a particular country. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Device Development, Marketing Clearance and Approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be associated with a device and the extent of control deemed necessary to ensure the device&#8217;s safety and effectiveness. Devices requiring fewer controls because they are deemed to pose </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lower risk are placed in Class I or II. Class I devices are deemed to pose the least risk and are subject only to general controls applicable to all devices, such as requirements for device labeling, premarket notification, and adherence to the FDA&#8217;s current good manufacturing practice requirements, as reflected in its Quality System Regulation, or QSR. Class II devices are intermediate risk devices that are subject to general controls and may also be subject to special controls such as performance standards, product-specific guidance documents, special labeling requirements, patient registries or post-market surveillance. Class III devices are those for which insufficient information exists to assure safety and effectiveness solely through general or special controls, and include life- sustaining, life-supporting, or implantable devices, and devices not &#8220;substantially equivalent&#8221; to a device that is already legally marketed. Most Class I devices, and some Class II devices are exempted by regulation from the 510(k) clearance requirement and can be marketed without prior authorization from the FDA. Class I and Class II devices that have not been so exempted are eligible for marketing through the 510(k) clearance pathway. By contrast, devices placed in Class III generally require premarket approval, or PMA, prior to commercial marketing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain 510(k) clearance for a medical device, an applicant must submit a premarket notification application to the FDA demonstrating that the device is &#8220;substantially equivalent&#8221; to a predicate device, which is typically a Class II device that is legally marketed in the United States. A device is substantially equivalent to a predicate device if it has the same intended use and (i) the same technological characteristics, or (ii) has different technological characteristics and the information submitted demonstrates that the device is as safe and effective as a legally marketed device and does not raise different questions of safety or effectiveness. A showing of substantial equivalence sometimes, but not always, requires clinical data. Generally, the 510(k) clearance process can exceed 90 days and may extend to a year or more. After a device has received 510(k) clearance for a specific intended use, any modification that could significantly affect its safety or effectiveness, such as a significant change in the design, materials, method of manufacture or intended use, will require a new 510(k) clearance or if the device as modified is not substantially equivalent to a legally marketed predicate device PMA. While the determination as to whether new authorization is needed is initially left to the manufacturer, the FDA may review this determination and evaluate the regulatory status of the modified product at any time and may request the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA is obtained. The manufacturer may also be subject to significant regulatory fines or penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second, more comprehensive, approval process applies to a new device that is not substantially equivalent to a predicate device or that is to be used in supporting or sustaining life or preventing impairment. These devices are normally Class III devices requiring PMA. The FDA will approve the PMA application if it finds there is reasonable assurance that the device is safe and effective for its intended use. The PMA process takes substantially longer than the 510(k) process, approximately one to two years or more.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some instances, the FDA may find that a device is new and not substantially equivalent to a predicate device but is also not a high-risk device as is generally the case with Class III PMA devices. In these instances, the FDA may allow a device to be reclassified from Class III to Class I or II. The de novo reclassification option is an alternate pathway to classify novel devices of low to moderate risk that had automatically been placed in Class III after receiving a &#8220;not substantially equivalent&#8221; (NSE) determination in response to a 510(k) notification. The FDCA also allows a sponsor to submit a de novo reclassification request to the FDA for novel low to moderate risk devices without first being required to submit a 510(k) application. These types of applications are referred to as &#8220;Evaluation of Automatic Class III Designation&#8221; or &#8220;de novo.&#8221; In instances where a device is deemed not substantially equivalent to a Class II predicate device, the candidate device may be filed as a de novo application which may lead to delays in regulatory decisions by the FDA. FDA review of a de novo application may lead the FDA to identify the device as either a Class I or II device and subject to or exempt from 510(k) premarket notification.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are generally required to support a PMA or de novo reclassification application and are sometimes required for 510(k) clearance. Clinical trials generally require an investigational device exemption application, or IDE, approved in advance by the FDA for a specified number of patients and study sites, unless the product is deemed a non-significant risk device eligible for more abbreviated IDE requirements. Clinical trials are subject to extensive monitoring, recordkeeping and reporting requirements. Clinical trials must be conducted under the oversight of an institutional review board or an IRB, for the relevant clinical trial sites and must comply with FDA regulations, including but not limited to those relating to good clinical practices. Conducting a clinical trial also requires obtaining the patients' informed consent in form and substance compliant with both FDA requirements and state and federal privacy and human subject protection regulations. The FDA or the IRB could suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA approval to market the product in the U.S. To date, the EksoGT has been the subject of several clinical studies, some sponsored by us, as well as non-Ekso-sponsored independent studies conducted by rehabilitation institutions. In addition, we are currently conducting several studies to investigate additional indications for use for the EksoGT, as well as to evaluate clinical and non-clinical outcomes of using the device.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Our current indication for use, or IFU, clearance for stroke, SCI, and ABI. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On April 4, 2016, we received clearance from the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">FDA to market our EksoGT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with SCI at levels T4 to L5, and individuals with SCI at levels of T3 to C7 (ASIA D), in accordance with the device&#8217;s labeling. On July 19, 2016, we received clearance from the FDA to expand/clarify the indications and labeling to expressly include individuals with hemiplegia due to stroke who have upper extremity function of at least 4 out of 5 strength in at least one arm. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On June 15, 2020, we received clearance from FDA to expand the indications for use, or IFU, and labeling to expressly include individuals with acquired brain injury, including traumatic brain injury and stroke who have upper extremity function of at least 4 out of 5 strength in at least one arm.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device is placed on the market, numerous regulatory requirements apply. These&#160;include:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:434.25pt"><tr><td style="width:1.0pt"></td><td style="width:22.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:408.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">labeling regulations and FDA prohibitions against the promotion of products for un-cleared, unapproved or off-label use or indication;</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510(k) clearance of product modifications that could significantly affect safety or efficacy or that would constitute a major change in intended use of one of our cleared devices;</span></td></tr><tr style="height:41pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">post-approval restrictions or conditions, including post-approval study commitments;</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the FDA's recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">regulations pertaining to voluntary recalls; and</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">notices provision regarding corrections or removals.</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising and promotion of medical devices, in addition to being regulated by the FDA, are also regulated by the Federal Trade Commission and by state regulatory and enforcement authorities. Recently, promotional activities for FDA-regulated products of other companies have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. In addition, under the federal Lanham Act and similar state laws, competitors and others can initiate litigation relating to advertising claims. If the FDA determines that promotional or training material related to an approved device constitute the promotion of an un-cleared or unapproved use, the FDA could request that the promotional or training materials related to such device be modified or it could subject the manufacturer to regulatory or enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged and adoption of the products would be impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA to determine our compliance with the QSR and other regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since January 2020, there has been one report of an adverse event relating to our EksoNR and none related to our EksoGT devices reported to the FDA under the Manufacturer and User Facility Device Experience Database.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to regulations in the U.S., we are subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products in foreign countries. Regardless of the FDA&#8217;s approval requirements for a particular product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA and foreign regulatory authorities may change, and additional government regulations may be enacted which could prevent or delay regulatory approval of our products and could also increase the cost of regulatory compliance. We </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the U.S. or abroad.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources and Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;19, 2021, we had 40 employees, including 39 full time employees and one part-time employee. Seven employees reside in Europe and two in Singapore. None of our employees are covered by a collective bargaining agreement and we consider our relationship with our employees to be good.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We endeavor to maintain a workplace that is free from discrimination or harassment on the basis of color, race, sex, national origin, ethnicity, religion, age, disability, sexual orientation, gender identification or expression or any other status protected by applicable law. We conduct annual training to prevent harassment and discrimination and monitor employee conduct year-round, including by providing employees with access to an anonymous whistleblower hotline to report any violations. The basis for recruitment, hiring, development, training, compensation and advancement at the Company is qualifications, performance, skills and experience. Our employees are fairly compensated, without regard to gender, race and ethnicity, and routinely recognized for outstanding performance and provided with training and professional development opportunities. Our compensation program is designed to attract and retain talent. We continually assess and strive to enhance employee satisfaction and engagement. Our employees, many of whom have been employed by us for the majority of our existence, frequently express satisfaction with management including by responding positively about our management in anonymous surveys. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated as PN Med Group Inc. in Nevada on January 30, 2012. Prior to the Merger and Split-Off (each as defined below), our business was to distribute medical supplies and equipment in Chile.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 15, 2014, we consummated the Merger, in which our wholly-owned subsidiary, Ekso Acquisition Corp., a corporation formed in the State of Delaware on January 3, 2014, merged with and into Ekso Bionics, Inc., a corporation incorporated in the State of Delaware on January 19, 2005. Ekso Bionics&#160;was the surviving corporation in the Merger and became our wholly-owned subsidiary. All of the outstanding Ekso Bionics' capital stock was converted into shares of our common stock in the Merger.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger and pursuant to a split-off agreement and general release, we transferred our pre-Merger assets and liabilities to our pre-Merger majority stockholders, in exchange for the surrender by them and cancellation of 2,497,586 shares of our common stock, or the Split-Off, after adjusting to give effect to the 1-for-7 reverse stock split, which occurred on May 4, 2016 and the subsequent 1-for-15 reverse stock split, which occurred on March 24, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Merger and Split-Off, we discontinued our pre-Merger business and acquired the business of Ekso Bionics, and have continued the existing business operations of Ekso Bionics as a publicly-traded company under the name Ekso Bionics Holdings, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive office is located at 1414 Harbour Way South, Suite&#160;1201, Richmond, California, and our telephone number is (510) 984-1761.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge on or through our website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Our internet address is www.eksobionics.com. This website address is intended to be an inactive, textual reference only; none of the material on this website is part of this Annual Report. Copies of our annual reports on Form 10-K will be furnished without charge to any person who submits a written request directed to the attention of our Secretary, at our offices located at 1414 Harbour Way South, Suite&#160;1201, Richmond, California, 94804. The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our securities is highly speculative and involves a high degree of risk.&#160;&#160;We face a variety of risks that may affect our operations or financial results and many of those risks are driven by factors that we cannot control or predict.&#160;&#160;Before investing in our securities, you should carefully consider the following risks, together with the financial and other information contained in this prospectus.&#160;&#160;If any of the following risks actually occurs, our business, prospects, financial condition and results of operations could be materially adversely affected.&#160;&#160;In that case, the trading price of our common stock would likely decline and investors may lose all or a part of their investment.&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report contains certain statements relating to future events or our future financial performance. Readers are cautioned that such forward-looking statements are only predictions and involve risks and uncertainties, and that actual events or results may differ materially. In evaluating such statements, readers should specifically consider the various factors identified in this Annual Report, including the matters set forth below, which could cause actual results to differ materially from those indicated by such forward-looking statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks described below do not purport to be all the risks to which we could be exposed. This section is a summary of certain risks and is not set out in any particular order of priority. They are the risks that we presently believe are material to our operations. Additional risks of which we are not presently aware or which we presently deem immaterial may also impair our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business and Operational Risks <br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic has adversely affected our financial condition and there is little future certainty. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted our business, including our employees, suppliers, customers and other business partners. We have seen demand for our exoskeleton products decrease in the current business environment, as many inpatient rehabilitation facilities temporarily shift priorities and delay capital expenditures. Many of our customers are not able to access their facilities, are not performing elective surgeries and are sending patients home sooner than they otherwise would, all of which may reduce their need for our products and impact their decisions as to leasing or acquiring our products. It is also harder for us to drive growth when our sales teams cannot visit rehabilitation facilities and demonstrate our products in person and given difficulties in presenting new data to the public and attending professional conferences.  In addition, there could be a potential effect of a slowdown at FDA, which could result in delays of regulatory correspondence that are necessary for us to maintain or advance our product candidates in clinical studies. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other risks applicable to business operating in the current environment. For example, our business insurance may not provide coverage against economic loss or claims specifically tied to COVID-19. A greater number of our employees are working remotely, which exposes us to a greater risk of cybersecurity breaches. The COVID-19 outbreak may also adversely impact our ability to make requisite filings under federal securities laws on a routine and timely basis. In addition, any deterioration in economic conditions due to the COVID-19 pandemic or any related market volatility may impact our ability to access the capital markets or ability to obtain financing on favorable terms or at all, which may affect our liquidity. The situation is constantly evolving, however, so the extent to which the COVID-19 outbreak will impact business and the economy is uncertain. Accordingly, consequences stemming from the ongoing COVID-19 pandemic could have a material adverse effect on our business, financial condition, results of operations and cash flows.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history upon which investors can evaluate our future prospects. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we were incorporated in 2005, we did not sell our first Ekso medical device until 2012 and did not sell our first industrial unit until 2016. Therefore, we have limited operating history upon which an evaluation of our business plan or performance and prospects can be made. Our business and prospects must be considered in light of the potential problems, delays, uncertainties and complications encountered in connection with a newly established business and creating a new industry. The risks include, but are not limited to, the possibility that we will not be able to develop functional and scalable products and services, or that although functional and scalable, our products and services will not be economical to market; that our competitors hold proprietary rights that preclude us from marketing such products; that our competitors market a superior or equivalent product; that we are not able to upgrade and enhance our technologies and products to accommodate new features and expanded service offerings; or that we fail to receive necessary regulatory clearances for our products. To successfully introduce and market our products at a profit, we must establish brand name recognition and competitive advantages for our products. There are no assurances that we can successfully address these challenges. If we are unsuccessful, we and our business, financial condition and operating results could be materially and adversely affected.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The markets in which our products are sold are highly competitive. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face competition within the medical devices and industrial robotics markets on the basis of product features, clinical outcomes, price, services and other factors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position will depend on multiple, complex factors, including our ability to achieve market acceptance for our products, develop new products, implement production and marketing plans, secure regulatory approvals for products under development and protect our intellectual property. Competitors may offer, or may attempt to develop, more efficacious, safer, cheaper, or more convenient alternatives to our products, including alternatives that could make the need for robotic exoskeletons obsolete. The entry into the market of manufacturers located in low-cost manufacturing locations may also create pricing pressure, particularly in developing markets. Our future success depends, among other things, upon our ability to compete effectively against current technology, as well as to respond effectively to technological advances, and upon our ability to successfully implement our marketing strategies and execute our research and development plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market for our products is new and unproven, and susceptible to technological change and scientific developments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for medical and industrial exoskeletons is new and unproven. We cannot be certain that the market for robotic exoskeletons will continue to develop, or that robotic exoskeletons for medical or industrial use will achieve market acceptance. Additionally, the development of new or improved products, processes or technologies by other companies may render our products or proposed products obsolete or less competitive. Furthermore, the use of robotic devices is not universally accepted in the rehabilitation community. The exoskeleton market may fail to develop, or may develop more slowly than we anticipate, or we may be unable to respond effectively to technological changes or fail to gain acceptance of our product in our target markets. Current or future clinical trials and studies may not provide sufficient data that the rehabilitation community interprets to support the use of exoskeletons in rehabilitation, or such trials and studies may actually prove the opposite. Any of these outcomes could materially and adversely affect our business, financial condition and operating results. <br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage policies and reimbursement levels of third-party payers may impact sales of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the adoption of our product by our customers becomes dependent in the future on their ability to obtain adequate reimbursement for treatments provided using our product from third-party payers, the coverage policies and reimbursement levels of these third-party payers may impact the decisions of healthcare providers and facilities to purchase our products or the prices they would be willing to pay for those products. Reimbursement rates could also affect the acceptance rates of new technologies. We have no control over these factors.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will experience long and variable sales cycles. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EksoNR has a lengthy sale and purchase order cycle because it is a major capital expenditure item and generally requires the approval of senior management at purchasing institutions, which may contribute to substantial fluctuations in our quarterly operating results. <br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International sales of our products are subject to factors outside of our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business currently depends in part on our activities in the EMEA, APAC, and other foreign markets. Our international activities are subject to a number of risks inherent in selling and operating abroad, including failure of local laws to provide the same degree of protection against infringement of our intellectual property rights; protectionist laws and business practices that favor local competitors, which could slow our growth in international markets; the expense of establishing facilities and operations in new foreign markets; building an organization capable of supporting geographically dispersed operations, challenges caused by distance, language and cultural differences; challenges caused by differences in legal regulations, markets, and customer preferences, which may limit our ability to adapt our products or succeed in other regions; multiple, conflicting, and changing laws and regulations, including complications due to unexpected changes in regulatory requirements, foreign laws, tax schemes, international import and export legislation, trading and investment policies, exchange controls and tariff and other trade barriers; foreign tax consequences; fluctuations in currency exchange rates and foreign currency translation adjustments; foreign exchange controls that might prevent us from repatriating income earned outside the United States; imposition of public sector controls; differing payer reimbursement regimes, governmental payers or patient self-pay systems and price controls; political, economic and social instability; and restrictions on the export or import of technology.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on independent distributors for the sale and marketing of our products in certain geographies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In non-German-speaking European countries, other EMEA countries and Central and South American countries, we rely on independent distributors to distribute and assist us with the marketing and sale of our products. These distributors are our principal customers, and revenue growth will depend in large part on our success in establishing and maintaining this sales and distribution channel. However, there can be no assurance that our distributors will be successful in selling our products to end users, or will focus adequate resources on selling them, and they may not continue to purchase or market our products for a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of reasons.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may suffer if we are not able to attract and retain key employees. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on our ability to identify, hire, train and retain highly qualified managerial, technical and sales and marketing personnel. In addition, as we introduce new products or services, we will need to hire additional personnel. Currently, competition for personnel with the required knowledge, skill and experiences is intense, particularly in the San Francisco Bay area, where we are headquartered, and we may not be able to attract, assimilate or retain such personnel. The inability to attract and retain the necessary managerial, technical and sales and marketing personnel could have a material adverse effect on our business, results of operations and financial condition.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The acquisition of other companies, businesses, or technologies could result in operating difficulties, dilution, and other harmful consequences.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may selectively pursue strategic acquisitions, any of which could be material to our business, operating results, and financial condition. Future acquisitions could divert management&#8217;s time and focus from operating our business. In addition, integrating an acquired company, business or technology is risky and may result in unforeseen operating difficulties and expenditures associated with integrating employees from the acquired company into our organization and integrating each company&#8217;s accounting, management information, human resources and other administrative systems to permit effective management. The anticipated benefits of future acquisitions may not materialize. Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses, or write-offs of goodwill, any of which could harm our financial condition. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Natural or other disasters could disrupt our business and result in loss of revenue or in higher expenses. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural disasters, terrorist activities, military conflict and other business disruptions could seriously harm our revenue and financial condition and increase our costs and expenses. Our corporate headquarters are located in California, a seismically active region. A natural disaster in any of our major markets in North America or Europe could have a material adverse impact on our operations, operating results and financial condition. Further, any unanticipated business disruption caused by Internet security threats, damage to global communication networks or otherwise could have a material adverse impact on our operating results.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial &amp; Accounting Risks <br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses to date and anticipate continuing to incur losses in the future, and we may not achieve or maintain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have thus far been largely dependent on capital raised through the sale of equity securities in various public and private offerings, and we have incurred losses in each fiscal year since our incorporation in 2005. Our net losses were $15.8 million and $12.1 million for the years ended December 31, 2020 and 2019, respectively (with losses from an increase in common stock purchase warrant liabilities due to an increase in our stock price accounting for a $3.1 million increase in net losses in 2020). As of December 31, 2020 and 2019, we had an accumulated deficit of $199.1 million and $183.3 million, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The operation of our business and our growth efforts will require significant cash outlays and advance capital equipment expenditures and commitments. We believe we have sufficient resources to operate for the foreseeable future based upon our current cash resources, the recent rate of using cash for operations and investment, and assuming modest increases in current revenue offset by incremental increases in expenses related to increased sales and marketing and research and development, and a potential increase in rental activity from our medical device business. However, unless we are able to generate significant revenues from sales and rentals of our products, we will not be able to achieve or maintain profitability in the near future or at all, and we will remain largely dependent on capital raised from past and future financings to implement our business plan, support our operations and service our debt obligations, which totaled $3.1 million as of January 31, 2021. Our lack of profitability may depress our stock price, and if we are unable become profitable, we may be required to reduce the scope of our business development activities, which could harm our business plans, financial condition and operating results, or to cease our operations entirely.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our loan agreement imposes certain financial, and operational restrictions on us, limiting the discretion of our management in operating our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our loan agreement with Pacific Western Bank, which we entered into in August 2020, or our PWB Loan Agreement, contains, subject to certain carve-outs, various restrictive covenants that limit our management's discretion in operating our business. In particular, these instruments limit our ability to, among other things incur additional debt, grant liens on assets, sell or acquire </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">assets outside the ordinary course of business, pay dividends and make certain fundamental business changes. Our obligations are also secured by a security interest in all of our assets, exclusive of intellectual property. As a result, we may need to use our capital resources to repay the PWB Loan in order to undertake certain financing or strategic transactions. <br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Management will have broad discretion as to our use of capital resources.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, we had $12.9 million in cash and cash equivalents, and our recently completed public offering in February 2021 resulted in our receiving an additional $36.4&#160;million in estimated net proceeds. Our management will have broad discretion in the application of these capital resources, including for working capital and other general corporate purposes, which may include repayment of debt, acquisitions and other business opportunities. The amounts and timing of our use of proceeds will vary depending on a number of factors, including the amount of cash generated or used by our operations, and the rate of growth, if any, of our business. In addition, while we have not entered into any agreements, commitments or understandings relating to any significant transaction as of the date of this Annual Report, we may use a portion of the net proceeds to pursue acquisitions of other businesses, products or technologies that are complementary to our business, joint ventures and licensing arrangements, and other strategic transactions and business opportunities. Our broad use of these funds may not always align with the focus of our investors, and our investors may not have the opportunity as part of their investment decision in any such offering to assess whether the net proceeds of such offering are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from any offering, their ultimate use may vary from the intended use as may be stated in the relevant prospectus related to such offering. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from any offering in a variety of capital preservation investments. These investments may not yield a favorable return to our securityholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to reduce the cost to manufacture or service our products as planned. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business plan assumes that exoskeletons can be manufactured more inexpensively than they are currently being manufactured. However, we have not yet found a way to significantly reduce the manufacturing cost of our products and doing so may prove more difficult than expected or even impossible. For example, if expectations for greater functionality of the products drive costs up as other factors drive costs down, the result may be that the overall cost of manufacturing the product stays the same or even increases. Likewise, we currently provide service and support of our products for our customers at a high standard (both in and out of warranty), and plan on continuing to do so. Our business plan also assumes that as we continue to improve our product, we achieve improved levels of product reliability and decreased service cost and frequency, which also may prove more difficult than expected.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to leverage our cost structure or achieve better margins. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the early stage of our commercial efforts, and particularly the early stage of customer adoption of our products, our current sales and marketing, research and development, and general and administrative expenses are each a higher percentage of sales than they will need to be for us to reach profitability. While we do expect these expenses to grow as our business grows, we also expect these expenses to decline as a percentage of revenues over time. If we are unable to leverage these costs and grow revenues at a greater pace than these operating expenses as we expect, we will not be able to achieve viable operating margins and profitability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could fail to maintain effective internal control over our financial reporting. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 404 of the Sarbanes-Oxley Act of 2002 requires us to include in our annual reports on Form 10-K and quarterly reports on Form 10-Q an assessment by management of the effectiveness of our internal control over financial reporting. While we believe that the policies, processes and procedures we have put in place will be sufficient to render our internal controls over financial reporting effective, our initiatives may not prove successful. If so, management may not be able to conclude that our internal control over financial reporting is effective. This could result in a loss of investor confidence in the reliability of our financial statements, which in turn could negatively affect the price of our common stock. In addition, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404. Our compliance with Section 404 may require that we incur substantial accounting expense and expend significant management efforts. <br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Risks<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protecting our intellectual proprietary rights can be costly, and our success in doing so is not certain. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success largely depends on our ability to market technologically competitive products. Failure to protect or to obtain, maintain or extend adequate patent and other intellectual property rights could materially adversely impact our competitive advantage and impair our business. Our issued patents may not be sufficient to protect our intellectual property and our patent applications may not result in issued patents. Even if our patent applications issue as patents, they may not issue in a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner or may challenge the validity of our patents. Our attempts to prevent third parties from circumventing our intellectual property and other rights ultimately may be unsuccessful. We may also fail to take the required actions or pay the necessary fees to maintain any of our patents that issue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we have not filed applications for all of our inventions internationally and may not be able to prevent third parties from using our proprietary technologies or may lose access to technologies critical to our products in other countries. These include, in some cases, countries in which we are currently selling products and countries in which we intend to sell products in the future.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The industries in which we operate, including, in particular, the medical device industry, are characterized by extensive intellectual property litigation and, from time to time, we might be the subject of claims by third parties of potential infringement or misappropriation. Regardless of outcome, such claims are expensive to defend and divert the time and effort of our management and operating personnel from other business issues. A successful claim or claims of patent or other intellectual property infringement against us could result in our payment of significant monetary damages and/or royalty payments or negatively impact our ability to sell current or future products in the affected category and could have a material adverse effect on our business, cash flows, financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because competition in our industry is intense, competitors may infringe or otherwise violate our issued patents, patents of our licensors or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly, or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. We may also elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes prior to litigation, and any such license agreements may require us to pay royalties and other fees that could be significant. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of the patents and patent applications in the intellectual property portfolio are not within our complete control, which could reduce the value of such patents. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our U.S. patents (which have associated international patents and applications) are co-owned by UC Berkeley. UC Berkeley has exclusively licensed its rights under many of these patents to us, but we do not have an exclusive license to UC Berkeley&#8217;s rights under three of these patents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UC Berkeley has licensed their U.S. rights in two of these three co-owned patents to an unrelated third-party.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third patent is a continuation-in-part of a patent that UC Berkeley has licensed to us. Under the terms of the relevant license agreement between us and UC Berkeley, we have exclusive rights to any claims that are fully supported by the specification in the parent application. However, any claims that are not based on the specification in the parent application are co-owned by UC Berkeley and us, and UC Berkeley&#8217;s rights in respect of such claims are not exclusively licensed to us. There is no assurance that we will be able to obtain a license to UC Berkeley&#8217;s rights in any such claims on commercially reasonable terms or at all, and UC Berkeley may choose to license its rights to third parties instead of us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with our acquisition of certain assets from Equipois, we assumed the rights and obligations of Equipois with respect to certain patents and patent applications under an in-license of intellectual property from a third-party and subject to an out-license of that intellectual property to an unrelated third-party for use in a particular field. We do not have complete control over the prosecution of these patent applications. As well, the license of intellectual property rights under these patents to third parties could reduce the value of our patent portfolio and limit any income or license fees that we might receive if we were to attempt to transfer or license our rights under any of our co-owned or licensed patents.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third-parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to two exclusive license agreements and one amendment to the license agreement with UC Berkeley, covering ten patents exclusively licensed to us. In addition, in connection with our acquisition of certain assets from Equipois, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumed the rights and obligations of Equipois with respect to certain patents and patent applications under an in-license of intellectual property from a third-party and subject to an out-license of that intellectual property to an unrelated third-party for use in a particular field. We may also need to obtain additional licenses from others to advance our research and development activities or allow the commercialization of our devices or any other devices we may identify and pursue. Our license agreements with UC Berkeley and the rights and obligations that we assumed in connection with the Equipois acquisition impose various development, diligence, commercialization, and other obligations on us, and any future license agreements may impose similar or other obligations on us. For example, under our license agreements with UC Berkeley we are required to submit a commercialization plan with performance milestones and progress report to UC Berkeley, and must satisfy specified minimum annual royalty payment obligations. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If our license agreements with UC Berkeley are terminated, or if our agreements granting us intellectual property rights in connection with the Equipois acquisition or any future agreements granting us material intellectual property rights are terminated or impeded in a material way, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products that may be identical or functionally similar to our devices and we may be required to cease our development and commercialization of such devices. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise between us and our counterparties regarding intellectual property subject to a licensing agreement, including the scope of rights granted under the license agreement and other interpretation-related issues; the extent to which our devices, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; the sublicensing of patent and other rights under our collaborative research and development relationships; our diligence obligations under the license agreement and what activities satisfy those diligence obligations; the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and the priority of invention of patented or patentable technology. In addition, certain provisions in our license agreement with UC Berkeley may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected devices, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our devices for an adequate amount of time. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our devices are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new devices, patents protecting such devices might expire before or shortly after such devices are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Regulatory Compliance Risks<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain or maintain necessary regulatory clearances or approvals for our medical device products, or if clearances or approvals for future products or modifications to existing products are delayed or not issued, our commercial operations would be harmed. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our EksoGT, EksoNR and EksoUE products are medical devices and are regulated by the FDA, the European Union and other governmental authorities both inside and outside of the United States. These agencies enforce laws and regulations that govern the development, testing, manufacturing, labeling, advertising, marketing and distribution, and market surveillance of our medical products. Our failure to comply with these complex laws and regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, before we can market a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive either clearance under Section 510(k) of the FDCA or approval of a premarket approval or PMA application from the FDA, unless an exemption applies. Both the PMA and the 510(k) clearance process can be expensive, lengthy and uncertain. The FDA&#8217;s 510(k) clearance process may take anywhere from several months to over a year. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from one to three years, or even longer, from the time the application is filed with the FDA. In addition, PMA generally requires the performance of one or more clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also has substantial discretion in the medical device review process. Despite the time, effort and cost, we cannot assure you that any particular device will be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory approvals could harm our business. Failure can occur at any stage, and we could encounter problems that cause us to repeat or perform additional development, standardized testing, pre-clinical studies and clinical trials. Any delay or failure to obtain necessary regulatory approvals could harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other non-U.S. regulatory authorities can delay, limit or deny clearance or approval of a medical device candidate for many reasons, including a medical device candidate may not be deemed to be substantially equivalent to a device lawfully marketed either as a grandfathered device or one that was cleared through the 510(k) premarket notification process; a medical device candidate may not be deemed to be substantially equivalent to a device lawfully marketed either as a grandfathered device or one that was cleared through the 510(k) premarket notification process; a medical device candidate may not be deemed to be in conformance with applicable standards and regulations; FDA or other regulatory officials may not find the data from pre-clinical studies and clinical trials or other product testing date to be sufficient; other non-U.S. regulatory authorities may not approve our processes or facilities or those of any of our third-party manufacturers, thereby restricting export; or the FDA or other non-U.S. regulatory authorities may change clearance or approval policies or adopt new regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after regulatory clearance or approval has been granted, a cleared or approved product and its manufacturer are subject to extensive regulatory requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising and promotion for the product. If we fail to comply with the regulatory requirements of the FDA or other non-U.S. regulatory authorities, or if previously unknown problems with our products or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions, including restrictions on the products, manufacturers or manufacturing process; adverse inspectional observations (Form 483), warning letters, non-warning letters incorporating inspectional observations; civil or criminal penalties or fines; injunctions; product seizures, detentions or import bans; voluntary or mandatory product recalls and publicity requirements; suspension or withdrawal of regulatory clearances or approvals; total or partial suspension of production; imposition of restrictions on operations, including costly new manufacturing requirements; refusal to clear or approve pending applications or premarket notifications; and import and export restrictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If imposed on us, any of these sanctions could have a material adverse effect on our reputation, business, results of operations and financial condition.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modifications to our EksoNR and our future products may require new 510(k) clearances or premarket approvals, or may require us to cease marketing or recall the modified products until clearances are obtained </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2016, we received clearance from the FDA to market our EksoGT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with SCI at levels T4 to L5, and individuals with SCI at levels of T3 to C7 (ASIA D), in accordance with the device&#8217;s labeling. On July 19, 2016, we received clearance from the FDA to expand/clarify the indications and labeling to expressly include individuals with hemiplegia due to stroke who have upper extremity function of at least four-fifths in only one arm. Our prior cleared indications for use statement required that individuals with hemiplegia due to stroke have upper extremity function of at least four-fifths in both arms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An element of our strategy is to continue to upgrade our robotic exoskeleton platform to incorporate new software and hardware enhancements. Any modification to a 510(k)-cleared device, including our EksoGT, that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design, or manufacture, requires a new 510(k) clearance or, possibly, a PMA. The FDA requires every manufacturer to make this determination in the first instance based on the final guidance document issued by the FDA in October 2017 addressing when to submit a new 510(k) application due to modifications to 510(k)-cleared devices and a separate guidance document on when to submit a new 510(k) application due to software changes to 510(k)-cleared devices. Although largely aligned with the FDA&#8217;s longstanding guidance document issued in 1997, the 2017 guidance includes targeted changes intended to provide additional clarity on when a new 510(k) application is needed. The FDA may review our determinations regarding whether new clearances or approvals are necessary, and may not agree with our decisions. If the FDA disagrees with our determinations for any future changes, or prior changes to previously marketed products, as the case may be, we may be required to cease marketing or to recall the modified products until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may introduce new products with enhanced features and extended capabilities from time to time. The products may be subject to various regulatory processes, and we may need to obtain and maintain regulatory approvals in order to sell our new products. If a potential purchaser of our products believes that we plan to introduce a new product in the near future or if a potential purchaser is located in a country where a new product that we have introduced has not yet received regulatory approval, planned purchases may be deferred or delayed. As a result, new product introductions may adversely impact our financial results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to meet strict post-market regulatory requirements with respect to our products could require us to pay fines, incur other costs or even close our facilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with the FDA&#8217;s Quality System Regulation, or QSR, which is a complex regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing and shipping of our marketed products. These regulatory requirements may significantly increase our production costs and may even prevent us from making our products in amounts sufficient to meet market demand. If we change our approved manufacturing process, the FDA may need to review the process before it may be used. The FDA enforces the QSR through periodic announced and unannounced inspections of manufacturing facilities. Failure to comply with regulatory requirements such as QSR may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and non-U.S. regulations regarding the manufacture and sale of medical devices are subject to future changes. The complexity, timeframes and costs associated with obtaining marketing clearances are unknown. Although we cannot predict the impact, if any, these changes might have on our business, the impact could be material.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to fines, penalties or injunctions if we are determined to be promoting the use of our products for unapproved or &#8220;off-label&#8221; uses. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any cleared or approved product may be promoted only for its indicated uses and our promotional materials must comply with FDA and other applicable laws and regulations. We believe that the specific use for which our products are marketed fall within the scope of the indications for use that have been cleared by the FDA. However, if the FDA determines that our promotional materials or training constitutes promotion of an unapproved use, it could request that we modify our promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged and adoption of the products would be impaired.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to adverse medical device reporting obligations, voluntary corrective actions or agency enforcement actions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDA&#8217;s medical device reporting or MDR regulations, we are required to report to the FDA any incident in which our product may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. For example, we have been informed of a limited number of events with respect to our EksoNR or EksoGT devices that have been determined to be reportable pursuant to the MDR regulations. In each case, the required MDR report was filed with the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers bringing medical devices to market in the European Economic Area are legally bound to report any incident that led or might have led to the death or serious deterioration in the state of health of a patient, user or other person, and which the manufacturer&#8217;s device is suspected to have caused, to the competent authority in whose jurisdiction the incident occurred. In such case, the manufacturer must file an initial report with the relevant competent authority, which would be followed by further evaluation or investigation of the incident and a final report indicating whether further action is required. The events described above that were reported to the FDA were also reported to the relevant EU regulatory authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also required to follow detailed recordkeeping requirements for all Company-initiated medical device corrections and removals, and to report such corrective and removal actions to the FDA if they are carried out in response to a risk to health and have not otherwise been reported under the MDR regulations. Any adverse event involving our products could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Recalls of our products, or agency actions relating to our failure to comply with our reporting or recordkeeping obligations, could harm our reputation and financial results.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with anti-kickback and fraud regulations could result in substantial penalties and changes in our business operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not provide healthcare services, submit claims for third-party reimbursement, or receive payments directly from Medicare, Medicaid or other third-party payers for our products, we are subject to healthcare fraud and abuse regulation and enforcement by federal, state and foreign governments, which could significantly impact our business. These laws may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">constrain the business and financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future. The principal U.S. federal laws implicated include, but are not limited to, those that prohibit, among other things, (i) filing, or causing to be filed, false or improper claims for federal payment, known as the false claims laws, (ii) payment, solicitation or receipt of unlawful inducements, directly or indirectly, for the referral of business reimbursable under federally-funded health care programs, known as the anti-kickback laws, and (iii) health care service providers from seeking reimbursement for providing certain services to a patient who was referred by a physician who has certain types of direct or indirect financial relationships with the service provider, known as the Stark law. Many states have similar laws that apply to reimbursement by state Medicaid and other government funded programs as well as in some cases to all payers. In addition, we may be subject to federal and state data privacy laws that govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws and regulations will involve substantial costs. We are subject to the risk that a person or government could allege we have engaged in fraud or other misconduct, even if none occurred. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us now or in the future, we may be subject to penalties, including civil and criminal penalties, damages, fines, disgorgement, exclusion from governmental health care programs, additional integrity oversight and reporting obligations, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in law or regulation could make it more difficult and costly for us to manufacture, market and distribute our products or obtain or maintain regulatory approval of new or modified products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated devices. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of future products. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. Elections could result in significant changes in, and uncertainty with respect to, legislation, regulation and government policy that could significantly impact our business and the health care industry. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in the laws or regulations that govern the clearance and approval processes relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market, and distribute existing products. Significant delays in receiving clearance or approval, or the failure to receive clearance or approval, for any new products would have an adverse effect on our ability to expand our business.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare changes in the U.S. and other countries, including recently enacted legislation reforming the U.S. healthcare system, could have a negative impact on our future operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our ability to sell our products profitably. For example, in 2010, the Patient Protection and Affordable Care Act, or ACA, was enacted into law. The legislation seeks to reform the United States healthcare system. It is far-reaching and is intended to expand access to health insurance coverage, improve quality and reduce costs over time. We expect the law will have a significant impact upon various aspects of our business operations. The ACA reduces Medicare and Medicaid payments to hospitals, clinical laboratories and pharmaceutical companies, and could otherwise reduce the volume of medical procedures. These factors, in turn, could result in reduced demand for our products and increased downward pricing pressure. It is also possible that the ACA will result in lower reimbursements. While the ACA is intended to expand health insurance coverage to uninsured persons in the United States, the impact of any overall increase in access to healthcare on sales of our products remains uncertain. The current U.S. Presidential administration and the majority party in both Houses of U.S. Congress have indicated their desire to repeal all or certain provisions of the ACA. It is unclear whether, when and how that repeal could be effectuated and what the effect on the healthcare sector might be. A number of lawsuits have been filed challenging various aspects of the ACA and related regulations. In addition, the efficacy of the ACA is the subject of much debate among members of Congress and the public. On December 14, 2018, the U.S. District Court for the Northern District of Texas held the individual mandate provisions, and therefore the entirety of ACA, unconstitutional. The impact of the ruling is stayed as it is appealed to the Fifth Circuit Court of Appeals. Our business may be materially and adversely impacted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the event that the ACA in part, or in its entirety, is ruled unconstitutional. Furthermore, the uncertainty regarding the constitutionality of the ACA, or specific provisions therein, may negatively affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Jobs Act was enacted and signed into law, one part of which repeals the &#8220;individual mandate&#8221; introduced by the ACA starting in 2019. The repeal of the &#8220;individual mandate&#8221; may have an adverse effect on ACA insurance markets and lead to further legislative changes. In addition, the new law imposes a 2.3% excise tax on medical devices that will apply to U.S. sales of our medical device products. In January 2018, President Trump signed into law a spending package that included a two-year moratorium on the medical device excise tax, which lapsed on December 31, 2019. This tax has had, and may continue to have, a negative impact on our gross margin. There have been other changes to the ACA since the enactment of the Tax Cuts and Jobs Act, and Congress could still consider additional legislation to repeal or replace all or certain elements of the ACA. In addition, other reform legislation has been passed subsequent to the enactment of the ACA, including measures that reduced reimbursement for certain providers and entities under federal health care programs. The outlook for the healthcare sector is unclear, and we are unable to predict the future course of federal or state healthcare legislation and regulations. Changes in the law or regulatory framework that reduce our revenues or increase our costs could also harm our business, financial condition and results of operations and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future elections in the United States could result in significant changes in, and uncertainty with respect to, legislation, regulation, implementation of Medicare and/or Medicaid, and government policy that could significantly impact our business and the healthcare industry. In the event that legal challenges are successful, or the ACA, is repealed or materially amended, particularly any elements of the ACA that are beneficial to our business or that cause changes in the health insurance industry, including reimbursement and coverage by private payers or, Medicare or Medicaid payers, our business, operating results and financial condition could be harmed. While it is not possible to predict whether and when any such changes may occur, certain proposals, including a repeal or material amendment of the ACA, could harm our business, operating results and financial condition. In addition, even if the ACA is not amended or repealed, the President and the executive branch of the federal government have a significant impact on the implementation of the provisions of the ACA, and the current or future administrations could make changes impacting the implementation and enforcement of the ACA, which could harm our business, operating results and financial</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Risks<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may become subject to voluntary or involuntary recall. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture or in the event that a product poses an unacceptable risk to health. In addition, manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. To date, we have initiated only one field action in which we voluntarily accelerated our maintenance schedule based on field usage.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a medical human exoskeleton is used by a paralyzed individual to walk, the individual relies completely on the exoskeleton to hold them upright. There are many exoskeleton components that, if they were to fail catastrophically, could cause a fall resulting in severe injury or death of the patient. Certain of our competitors have reported injuries caused by the malfunction of human exoskeleton devices (in at least one case to the FDA). Injuries caused by the malfunction or misuse of human exoskeleton devices, even where such malfunction or misuse occurs with respect to one of our competitor&#8217;s products, could cause regulatory agencies to implement more conservative regulations on the medical human exoskeleton industry, which could significantly increase our operating costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, when an industrial exoskeleton is used by a healthy individual - for example to operate heavy machinery overhead - malfunction of the device at an inopportune moment could result in severe injury or death of the person using the device. Such occurrences could result in regulatory action on the part of OSHA or its foreign counterparts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future recalls of any of our products could divert managerial and financial resources, impair our ability to manufacture our products in a cost-effective and timely manner, and have an adverse effect on our reputation, results of operations and financial condition. In some circumstances, such adverse events could also cause delays in new product approvals. We may also be required to bear other costs or take other actions that may have a negative impact on our future sales and our ability to generate profits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, personal injuries relating to the use of our products could also result in product liability claims being brought against us. Any product liability claim brought against us, with or without merit, could result in substantial damages, be costly and time-consuming to defend and could increase our insurance rates or prevent us from securing insurance coverage in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product liability insurance may not adequately cover potential claims or recalls. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing, manufacture, marketing and sale of medical devices and industrial products entail the inherent risk of liability claims or product recalls. Although we maintain product liability insurance, the coverage is subject to deductibles and limitations, and may not be adequate to cover future claims. A successful product liability claim or product recall could inhibit or prevent the successful commercialization of our products, cause a significant financial burden on us, or both, which in either case could have a material adverse effect on our business and financial condition.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty claims and our accelerated maintenance program results in additional operating costs to us.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our EksoNR and EksoGT generally include a one-year warranty for parts and services in the U.S. and a two-year warranty in Europe, the Middle East and Africa. We also generally provide customers with an option to purchase an extended warranty for up to an additional three years. The costs associated with such warranties, including any warranty-related legal proceedings, could have a material adverse effect on our results of operations, cash flows and liquidity. As we enhance our product and in an effort to build our brand and drive adoption, we have elected to incur increased service expenses related to an accelerated maintenance program, field corrections and the implementation of technological improvements developed subsequent to many of our units being placed into service, sometimes outside of its warranty and contractual obligations. Continuation of these activities could have a material adverse effect on our results of operations, cash flows and liquidity.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Common Stock<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">You may be diluted from future issuances of our equity securities, including from compensatory equity awards, exercise of outstanding warrants, or issuances of securities in financing or strategic transactions, and such issuances, or perception that such issuances may occur, could depress the market price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future operating or business decisions may cause dilution to our stockholders. For example, we may sell equity securities or issue securities exercisable or convertible into shares of our common stock in connection with strategic transactions or for financing purposes, including under an At The Market Offering Agreement we entered into in October 2020 with H.C. Wainwright &amp; Co., LLC or our &#8220;shelf&#8221; registration statement on Form S-3 (File No. 333-239203) which was declared effective by the SEC on June 26, 2020. While in 2020, we sold no shares of common stock under our &#8220;at the market offering&#8221; program, but from year-end to February&#160;25, 2021, we sold $0.8 million of common stock under the program, leaving $6.7 million available for future offerings under our current prospectus for the offering. After giving effect to our public offering in February 2021, registered warrant transactions and potential sales under our prospectus for the &#8220;at the market offering&#8221; program, approximately $16.7 million of registered securities are available for issuance under our shelf registration statement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also registered all of the shares of common stock that we may issue pursuant to the exercise of 0.5 million stock options and settlement of 0.1 million restricted stock units outstanding as of December 31, 2020 and granted under our Amended and Restated 2014 Incentive Plan (the &#8220;Incentive Plan&#8221;), the 1.1 million shares reserved for future issuance under the Incentive Plan, and all of the 0.5 million shares of common stock that we may issue in the future under our Employee Stock Purchase Plan. You may also be subject to dilution from the exercise or settlement of outstanding options or restricted stock units under the Incentive Plan, and from the exercise of warrants, with respect to which as of February&#160;25, 2021, 1.0 million were exercisable at a weighted average exercise price of $6.63 per share. In addition, sales or issuances of a substantial number of shares of our common stock, or other equity-related securities in the public markets, or the perception that such sales or issuances could occur, could depress the market price of our common stock. <br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ability of our Board of Directors to issue additional stock may prevent us from making more difficult transactions, including a sale or merger. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors is authorized to issue up to 10 million shares of preferred stock with powers, rights and preferences designated by it. Shares of voting or convertible preferred stock could be issued, or rights to purchase such shares could be issued, to create voting impediments or to frustrate persons seeking to effect a takeover or otherwise gain control of us. The ability of the Board of Directors to issue such additional shares of preferred stock, with rights and preferences it deems advisable, could discourage an attempt by a party to acquire control of us by tender offer or other means. Such issuances could therefore deprive stockholders of benefits that could result from such an attempt, such as the realization of a premium over the market price for their shares in a tender offer or the temporary increase in market price that such an attempt could cause. Moreover, the issuance of such additional shares of preferred stock to persons friendly to the Board of Directors could make it more difficult to remove incumbent officers and directors from office even if such change were to be favorable to stockholders generally.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid and do not intend to pay cash dividends.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends have never been declared or paid on our common stock, and we do not anticipate such a declaration or payment for the foreseeable future. We expect to use future earnings, if any, to fund business growth. Therefore, stockholders will not receive any funds absent a sale of their shares of common stock. If we do not pay dividends, our common stock may be less valuable because a return on investment will only occur if our stock price appreciates<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been, and may continue to be, highly volatile.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from our initial listing on Nasdaq on August 9, 2016 through December 31, 2020, the closing price of our common stock fluctuated from a high of $93.15 per share to a low of $2.54 per share (on a split-adjusted basis), and our stock price continues to fluctuate. The market price of our common stock may continue to fluctuate significantly in response to numerous factors, some of which are beyond our control, such as our ability to grow our revenue and customer base; the announcement of new products or product enhancements by us or our competitors; developments concerning regulatory oversight and approvals; variations in our and our competitors&#8217; results of operations; changes in earnings estimates or recommendations by securities analysts, if our common stock is covered by analysts; successes or challenges in our collaborative arrangements or alternative funding sources; developments in the rehabilitation and industrial robotics markets; the results of product liability or intellectual property lawsuits; future issuances of common stock or other securities; the addition or departure of key personnel; announcements by us or our competitors of acquisitions, investments or strategic alliances; and general market conditions and other factors, including factors unrelated to our operating performance.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trading of our common stock is limited, which may affect our stock price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading of our common stock is currently conducted on Nasdaq. The liquidity of our common stock is limited, not only in terms of the number of shares that can be bought and sold at a given price, but also as it may be adversely affected by delays in the timing of transactions and low coverage by research analysts&#8217; the media, if at all. These factors may result in different prices for our common stock than might otherwise be obtained in a more liquid market and could also result in a larger spread between the bid and asked prices for our common stock. In addition, without a large public float, our common stock is less liquid than the stock of companies with broader public ownership, and, as a result, the trading prices of our common stock may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate his or her investment in our common stock. Trading of a relatively small volume of our common stock may have a greater impact on the trading price of our stock than would be the case if our public float were larger. Additionally, sales by stockholders of substantial amounts of our shares of common stock, the issuance of new shares of common stock by us or the perception that these sales may occur in the future could materially and adversely affect the market price of our common stock, and you may lose all or a portion of your investment in our common stock.</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_22"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are currently located at 1414 Harbour Way South, Suite 1201, Richmond, CA 94804, where we leased approximately 45,000 square feet. The Richmond office serves as headquarters for our medical device and industrial device sales segments. In addition, we lease approximately 1,400 square feet of office space at Friesenweg 4, House 13, 4th floor, 22763 Hamburg, Germany for our European headquarters. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own any real property.</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_28"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="padding-right:6.75pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we may be involved in litigation that we believe is of the type common to companies engaged in our line of business, including intellectual property and employment issues. While the outcome of these other claims cannot be predicted with certainty, we do not believe that the outcome of any of these other legal matters will have a material adverse effect on our results of operations, financial condition or cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information and Dividend Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been traded on the Nasdaq Capital Market under the symbol &#8220;EKSO&#8221; since August 9, 2016. Prior to August 9, 2016, our common stock was eligible for quotation and traded on the OTC Market. The quotation of our common stock on the OTC market began on or about January 16, 2014. The closing price of EKSO stock as of February&#160;19, 2021 was $9.22.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;19, 2021, we had approximately 185 stockholders of record of our common stock. This number does not include stockholders whose shares are held in investment accounts by other entities.&#160;We believe that the actual number of stockholders is greater than the number of holders of record.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock and do not intend to pay cash dividends in the foreseeable future. Payment of future dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, restrictions imposed by financing arrangements, if any, legal and regulatory restrictions on the payment of dividends, current and anticipated cash needs and other factors the board of directors deems relevant.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;12, &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; of this Annual Report on Form 10-K for information regarding securities authorized for issuance under equity compensation plans.</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_1655"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SELECTED FINANCIAL DATA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements. Actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause future results to differ materially from those projected in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" and elsewhere in this Annual Report. See also "Cautionary Note Regarding Forward-Looking Statements."</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2020, we effected a one-for-fifteen reverse stock split, or the Reverse Stock Split, reducing the number of our common shares outstanding on that date from 87.4 million shares to approximately 5.8 million shares. Additionally, the exercise price and number of all outstanding options and warrants, and the number of shares reserved for future issuance pursuant to our equity compensation plan were all adjusted proportionately. All such amounts presented herein have been adjusted retroactively to reflect these changes. The number of the Company&#8217;s authorized shares were not proportionately reduced in the Reverse Stock Split and remain at 141,428,571 shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion highlights the results of our operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of our financial condition and results of operations presented herein. The following discussion and analysis is based on our audited consolidated financial statements contained in this Annual Report on Form 10-K, which have been prepared in accordance with generally accepted accounting principles in the United States. You should read the discussion and analysis together with such financial statements and the related notes thereto.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the COVID-19 outbreak to be a global pandemic. In response to this pandemic, public health officials and governments across the world have recommended and mandated actions to curb the spread of the SARS-COV-2 virus, the pathogen that causes COVID-19. The COVID-19 pandemic and the related responses to the pandemic have caused a significant adverse impact on the global economy, including disruptions to supply chains, sharp increases in unemployment and overall economic uncertainty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This pandemic has negatively impacted our business, including our employees, suppliers, customers and other business partners, resulting in our terminating 23 employees in 2020. We have seen demand for our exoskeleton products decrease in the current business environment, as many inpatient rehabilitation facilities temporarily shift priorities and delay capital expenditures, resulting in 61 units booked (non-cancellable customer orders) in 2020 compared to 98 in 2019, a decrease of 38%. We have seen that the clinical need has not diminished as more data is coming out about the increase prevalence of strokes during this pandemic. As such, we continue to engage with our current and prospective customers through video conferencing, virtual training events and online education demos to offer our support and showcase the value of our Ekso devices. Although market uncertainties related to the pandemic make it difficult for us to project the full impact on our business and customers, we believe that we are well-positioned to serve our customers when business conditions begin to normalize.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to instruct the majority of our employees to work from home, restrict non-critical business travel and have enhanced the use of personal protective equipment in our facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are hopeful that COVID cases and hospitalizations will continue to decrease, and now that our clinical team is fully vaccinated and are active onsite at rehab centers, we expect to see an uptick in live in-person interactions going forward. In fact, we are now close to the number of onsite demos in the first quarter of 2021 compared to the previous three quarters combined.  While we are cautiously optimistic about the current COVID outlook, the successful completion of our first virtual training sessions leave us well-positioned to address existing pipeline opportunities, mitigating the effects of future COVID-related lock downs or travel restrictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continues to actively monitor the global situation and its effects on our financial position and operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design, develop, sell, and rent exoskeleton products that augment human strength, endurance and mobility. Our exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities. We have sold or leased devices that (i) enable individuals with neurological conditions affecting gait (acquired brain injury and spinal cord injury) to rehabilitate, and in some cases, to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the commercial opportunity for exoskeleton technology adoption is accelerating as a result of recent advancements in material technologies, electronic and electrical engineering, control technologies, and sensor and software development. Taken individually, many of these advancements have become ubiquitous in peoples&#8217; everyday lives. We believe that we have learned how to integrate these existing technologies and wrap the result around a human being efficiently, elegantly and safely, supported by an industry leading intellectual property portfolio. We further believe that we can do so across a broad spectrum of applications, from persons with lower limb paralysis to able-bodied users.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EksoHealth</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EksoHealth is our business unit focused on developing, marketing, and selling exoskeletons for medical applications. Our leading product in EksoHealth, the EksoNR, is a robotic exoskeleton used to provide physical therapy for patients with lower extremity impairment. EksoNR, which in 2019 superseded our EksoGT product in this segment, includes unique features designed specifically to assist physical therapists and other clinicians to teach patients to walk again after suffering a neurological impairment. Typical conditions that can be treated with the assistance of EksoNR include acquired brain injuries, such as stroke and traumatic brain injuries, as well as spinal cord injuries and others. The benefits of using EksoNR for rehabilitation can include earlier mobilization of patients, longer and more intense rehab sessions, and better quality of sessions compared to alternative therapies. The product is most typically used in a clinical setting, with the most common among those being inpatient rehab facilities and stroke centers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EksoUE is a wearable upper body exoskeleton that is also used as a tool during rehabilitation. EksoUE is designed to assists patients with a broad range of upper extremity impairments and aims to provide them with a wider active range of motion and increased endurance for rehabilitation sessions of higher intensity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EksoWorks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EksoWorks is our business unit focused on developing, marketing, and selling exoskeletons and other assistive tools for industrial applications. The target users for these devices are generally able-bodied, and as such the goal of these products is to reduce fatigue for workers. The benefits of fatigue reduction can include reduced rates of injuries, higher productivity, higher worker morale, and lower turnover. Currently, we sell these products primarily directly to companies that deploy them for use in their operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within EksoWorks we have two main categories of products. Our wearable exoskeleton products include EksoVest and the new EVO, both of which support the weight of a worker&#8217;s arms and tools, reducing the fatigue associated with working at or above shoulder height for extended periods. These products are currently targeted at end markets in Manufacturing, Aerospace, Construction, and Food Processing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EksoZeroG is a tool holder that can mount on aerial lift platform or scaffolding. This effectively reduces the weight of heavy tools as felt by the operator. EksoZeroG has been sold primarily through rental companies into the construction market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operational Highlights</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In 2020, we booked a total of 61 EksoGT and EksoNR units, 19 of which were subscription units and 9 of which were previously rented units that were converted to sales. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recorded annual gross margins of approximately 57% in 2020, compared to 49% in 2019.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2020, we announced the worldwide launch of our upgraded EksoPulse platform, an innovative cloud-based information technology platform that measures and analyzes progress using the EksoNR robotic exoskeleton. The improved analytics system provides an easy-to-use dashboard to chart activity in rehabilitation sessions, enhancing the clinician, institutional, and patient experience of the most clinically used exoskeleton.&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2020, we received FDA clearance to market our EksoNR robotic exoskeleton for use with acquired brain injury patients</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Also in June 2020, we were named &#8220;Best Healthcare Robotics Company&#8221; in 2020 MedTech Breakthrough Awards Program</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2020, we launched EVO, an endurance-boosting assistive upper body exoskeleton designed for industrial use.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Financing Activities</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2020, we received proceeds of a $1.1 million unsecured loan under the Paycheck Protection Program, or the PPP. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2020, we sold&#160;1,747,704&#160;shares of our common stock and warrants to purchase up to&#160;873,852&#160;shares of our common stock, or June 2020 Investor Warrants, at a combined public offering price of&#160;$4.51&#160;per share for proceeds, net of&#160;expenses and underwriting discount and commission, of $7.1&#160;million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2020, we paid off the entire amount of $1.5 million of the Company's indebtedness to Western Alliance Bank with proceeds from a new loan of $2.0 million from Pacific Western Bank. The terms of the new loan agreement include monthly interest-only payments over the next three years.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the year ended December 31, 2020, we received $3.3 million in proceeds from the exercise of 723,426 warrants.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsequent to year end, we received estimated net proceeds of $36.4 million from an underwritten public offering, $1.4&#160;million from warrant exercises, and $0.7 million from sales under our "at the market offering" program. Refer to Note. 18 in the notes to our consolidated financial statements under the caption Subsequent Events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Estimates, and Judgments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. Besides the estimates identified below that are considered critical, we make many other accounting estimates in preparing our financial statements and related disclosures. All estimates, whether or not deemed critical, affect reported amounts of assets, liabilities, revenues and expenses, as well as disclosures of contingent liabilities. These estimates and judgments are also based on historical experience and other factors that are believed to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known, even for estimates and judgments that are not deemed critical.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our EksoHealth segment revenue is primarily generated through the sale and rental of our EksoNR and associated software (SmartAssist and VariableAssist), EksoUE, sale of accessories, and support and maintenance contracts (Ekso Care). Revenue from EksoHealth sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from our facility for sales of our EksoNR, software, and accessories. Ekso Care support and maintenance contracts extend coverage beyond our standard warranty agreements. The separately priced Ekso Care contracts range from&#160;12&#160;to&#160;48 months. We receive payment at the inception of the contract and recognize revenue over the term of the agreement. Revenue from medical device rentals is recognized over the lease term, typically over 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our EksoWorks segment revenue is generated by the sales of our EksoVest, EksoZeroG and EVO. Revenue from EksoWorks device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from our facility.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory valuation</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress, or WIP. Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. We periodically evaluate the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge to the consolidated statements of operations and comprehensive loss. Our estimate of write-downs for excess and obsolete inventory is based on a detailed analysis of on-hand inventory and purchase commitments in excess of forecasted demand.&#160; Subsequent disposals of inventories are recorded as a reduction of an inventory reserve.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure stock-based compensation expense for certain stock-based awards made to employees and directors based on the estimated fair value of the award on the date of grant using the Black-Scholes option-pricing model, or the&#160;Black-Scholes Model, and recognize the fair value on a straight-line basis over the requisite service periods of the awards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the fair value of stock options on the date of grant using the Black-Scholes Model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. We adopted the simplified method of estimating the expected term pursuant to SEC Staff Accounting Bulletin Topic 14. On this basis, we estimate the expected term of options granted by taking the average of the vesting term and the contractual term of the option.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, from time to time, modified the terms of stock options granted to our employees. We account for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value based measure of the modified award on the date of modification over the fair value of the original award immediately before the modification.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally account for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where there is a possibility that we may have to settle warrants in cash, we estimate the fair value of the issued warrants as a liability at each reporting date and record changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants have been determined using the Black-Scholes option-pricing model (the &#8220;Black-Scholes Model&#8221;) and the Binomial Lattice model (the &#8220;Lattice Model&#8221;). The Black-Scholes Model requires inputs, such as the expected volatility, expected term, exercise price, risk-free interest rate, and the value of the underlying security. The Lattice Model provides for assumptions regarding expected volatility, expected term, exercise price, risk-free interest rates, the value of the underlying security, and the probability of and likely timing of a specific event within the period to maturity. These values are subject to a significant degree of judgment on our part. Our common stock price represents a significant input that affects the valuation of our warrants.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess our ability to continue as a going concern at every interim and annual period in accordance with Accounting Standards Codification ("ASC") 205-40,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements &#8211; Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the year ended December 31, 2020 to the year ended December 31, 2019 (dollars in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:48.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,035)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,694)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross profit %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,042)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance cost associated with warrant issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on warrant liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,056)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on modification of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,534)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,041)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,825)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,132)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,693)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Not meaningful</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue decreased $5.0 million, or 36%, for the year ended December 31, 2020, compared to the same period of 2019. This decrease was comprised of a&#160;$3.9 million&#160;decrease in EksoHealth and a&#160;$1.1 million&#160;decrease in EksoWorks primarily due to a decrease in volume of medical device sales driven by the impact of the COVID-19 pandemic, as our customers shifted their priorities to prepare for and manage their business during the pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit decreased $1.7 million, or 25%, for the year ended December 31, 2020, compared to the same period of&#160;2019, primarily attributable to a decreased volume of device sales. Gross margin was approximately 57% for the year ended December 31, 2020, compared to a gross margin of 49% for the same period in 2019. Gross margins increased primarily due to higher average selling prices for EksoNR, an increased proportion of medical device sales in overall revenue composition, lower unit production costs, the introduction of EVO, and higher service margins. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses decreased $3.6 million, or 32%, for the year ended December 31, 2020, compared to the same period of 2019, primarily due to a decrease in employee compensation expenses as a result of a furlough and a reduction in force in March and May 2020, respectively, lower selling expense as we shifted to video conferencing, virtual training events and online education demonstrations, lower general marketing and trade show activities, and the absence of clinical trials expense due to the completion of our main clinical trial in the first quarter of 2019.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased $2.1 million, or 46%, for the year ended December 31, 2020, compared to the same period of 2019, primarily due to a decrease in employee compensation expenses as a result of a furlough and a reduction in force in March and May 2020, respectively, and a decrease in patent and licensing costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $0.3 million, or 4%, for the year ended December 31, 2020, compared to the same period of 2019, primarily due to an increase in legal expense.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment charge of $0.2 million was recorded in the year ended December 31, 2020, reducing the goodwill balance to zero. No goodwill impairment charge was recorded in 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring expense of $0.2 million was recorded in the year ended December 31, 2020, and related to the completion of a restructuring plan in May of 2020. We streamlined our operations and reduced our workforce by approximately 35% to lower operating expenses and reduce cash burn. The restructuring expense consisted of employee severance payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reduction in operating expenses reflects the continuation of the company-wide initiatives we implemented last year, the restructuring completed in May 2020, as well as improving overall operational efficiencies. Our focus remains on optimizing the cost structure of our organization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased $0.2 million, or 64% for the year ended December 31, 2020, compared to the same period of 2019, primarily due to lower effective interest rates on our term loans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on revaluation of warrant liabilities of $3.1 million for the year ended December 31, 2020, was associated with the revaluation of warrants issued in 2015, 2019 and 2020. Gain on revaluation of warrant liabilities of $6.4 million for the year ended December 31, 2019, related to warrants issued in 2015 and 2019. Gains and losses on revaluation of warrants are primarily driven by changes in our stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on modification of warrants of $0.3 million for the year ended December 31, 2019, was due to the reduction of the exercise price of the 2015 Warrants from $56.10 per share to $41.25 per share, in connection with an amendment of the 2015 Warrant Agreement, which retroactively removed a provision from such securities purchase agreement that prohibited the Company from effecting or entering into an agreement to effect any issuance by the Company of its common stock at a price determined based on the trading price of the Company&#8217;s common stock or otherwise at a future determined price.&#160;There was no comparable amount during the same period in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant issuance expense of&#160;$0.3 million&#160;for the&#160;year ended December 31, 2020&#160;was recorded in connection with our private placement offerings of warrants to purchase common stock concurrently with a registered direct offering of our common stock in June 2020. We incurred $1.1 million in direct financing costs, which were allocated on a relative fair value basis between the common stock and warrant issuances, of which $0.3 million was allocated to warrants and expensed immediately. Warrant issuance expense of $1.1 million for the year ended December 31, 2019 was recorded in connection with our May 2019 and December 2019 financings. We incurred&#160;$1.7 million&#160;in direct financing costs, which were allocated on a relative fair value basis between the common stock and warrant issuances, of which&#160;$1.1 million&#160;was allocated to warrants and expensed immediately. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net was $1.0 million&#160;for the&#160;year ended December 31, 2020, compared to other expense, net of  $0.1 million the same period of&#160;2019, due to unrealized gains and losses on foreign currency revaluations of our inter-company monetary assets and liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have devoted substantially all of our efforts toward the development of exoskeletons for the medical and industrial markets, toward the commercialization of medical exoskeletons to rehabilitation centers and toward raising capital.&#160;We have financed our operations primarily through the issuance and sale of equity securities for cash consideration and through bank debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At&#160;December 31, 2020, we had working capital of&#160;$13.4 million, compared to working capital of&#160;$11.0 million at&#160;December 31, 2019.&#160;&#160;The increase in working capital&#160;is primarily due to higher cash balance from equity financings, warrants exercises, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the reduction of notes payable, current as a result of retiring our WAB Term Loan. Our cash and cash equivalents as of&#160;December 31, 2020&#160;consisted of bank deposits with third party financial institutions.&#160;&#160;As of&#160;December 31, 2020, of our&#160;$12.9 million&#160;of cash,&#160;$12.3 million&#160;was held domestically while&#160;$0.6 million&#160;was held by foreign subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had an accumulated deficit of $199.1 million and cash on hand of $12.9 million.&#160; Largely as a result of significant research and development activities related to our advanced technology and commercialization of such technology into our medical device business, we have incurred significant operating losses and negative cash flows from operations since inception. We have incurred net losses of $15.8 million and $12.1 million for the years ended December 31, 2020 and 2019, respectively. In the year ended December 31, 2020, we received net proceeds of $7.1 million from a registered direct offering and $3.3 million from warrant exercises, and used $8.8 million of cash in our operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to year-end through February&#160;25, 2021, we received estimated net proceeds of $36.4 million from an underwritten public offering, $1.4&#160;million from warrant exercises, and $0.7 million from sales under our "at the market offering" program. Refer to Note. 18 in the notes to our consolidated financial statements under the caption Subsequent Events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, management took several actions to alleviate the substantial doubt about the our ability to continue as a going concern that existed as of the date of issuance of the December 31, 2019 consolidated financial statements, including, but not limited to, the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;streamlined our operations and reduced our workforce by approximately 35% to lower operating expenses and reduce cash burn;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;conducted a registered direct offering of 1,747,704 shares of our common stock for net proceeds of $7.1 million;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;paid off the entire amount of $1.5 million of our indebtedness to Western Alliance Bank with proceeds from a new loan of $2.0 million from Pacific Western Bank. The terms of the new loan agreement include monthly interest-only payments over the next three years.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;invested in the development and reliability of our products;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;restructured our commercial organization and strategy which has been gaining traction;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;received FDA clearance for ABI to market our product to a larger patient population increasing the value proposition to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 9 in the notes to our consolidated financial statements under the caption&#160;Notes Payable, net, borrowings under our new secured term loan agreement with Pacific Western Bank have a requirement of minimum cash on hand equivalent to the current outstanding principal balance. As of&#160;December 31, 2020, $2.0 million&#160;of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of&#160;December 31, 2020&#160;is estimated to be $10.9 million. With this unrestricted cash balance and the impact of management's actions described above, and additional cash received after year-end, we believe that we currently have sufficient cash to fund our operations beyond the look forward period of one year from the issuance of these consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our actual capital requirements may vary significantly and will depend on many factors. We plan to continue our investments in our (i) sales initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation market, (ii) research, development and commercialization activities with respect to exoskeletons for rehabilitation, and (iii) development and commercialization of able-bodied exoskeletons for industrial use. Consequently, we may require significant additional financing in the future, which we intend to raise through corporate collaborations, public or private equity offerings, debt financings, or warrant solicitations. Sales of additional equity securities by us could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, we may be required to further reduce our discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the sources and uses of cash for the periods stated (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:62.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,862&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations decreased $7.0 million, or&#160;44%, for the&#160;year ended December 31, 2020, compared to the same period of&#160;2019,&#160;primarily due to the reduction in operating expenses by improving overall operational efficiencies, including but not limited to, the reduction of employee headcount. In addition, increased collection efforts resulted in higher ratio of accounts receivable collections to sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities decreased $0.1 million, or 100%, during the year ended December 31, 2020, compared to the same period of&#160;2019, primarily due to lower hardware and software purchases due to lower headcount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $10.7 million&#160;for the&#160;year ended December 31, 2020&#160;was from the sale of our common stock for net proceeds of $7.1 million in connection with the equity financing in June 2020, proceeds of $1.1 million from our PPP loan, and proceeds of $3.3 million from the exercise of June 2020 Warrants and May 2019 Warrants, partially offset by aggregate principal payments of $1.3 million against our term loan and the $1.5 million payoff of our loan with Western Alliance Bank.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $19.0 million for the year ended December 31, 2019 was from the sale of common stock and warrants for net proceeds of&#160;$9.0 million&#160;in connection with the equity financing in May 2019, net proceeds of $4.2 million with the equity financing in December 2019, net proceeds of $2.8 million from our &#8220;at the market offering&#8221; program, net proceeds of $5.0 million from equity investors associated with the JV Agreement, and proceeds of $0.2 million from the exercise of stock options, partially offset by aggregate principal payments of&#160;$2.4 million&#160;against our term loan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity is not dependent on the use of off-balance sheet financing arrangements (as that term is defined in Item 303(a) (4) (ii) of Regulation S-K) and as of December 31, 2020, we had no such arrangements. There has been no material change in our contractual obligations other than in the ordinary course of business since our fiscal year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding contractual obligations, including interest payments, as of December 31, 2020 and the effect those obligations are expected to have on our liquidity and cash flows in future periods (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:35.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments Due By Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-3 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the table above, which reflects only fixed payment obligations, we have two license agreements to maintain exclusive rights to certain patents. Under these license agreements, we are required to pay 1% of net sales of products sold to entities other than the U.S. government. In the event of a sublicense, we will owe 21% of license fees and must pass through 1% of the sub-licensee&#8217;s net sales of products sold to entities other than the U.S. government. The license agreements also stipulate minimum annual royalties of $50,000 per year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Equipois in December 2015, we assumed the rights and obligations of Equipois under a license agreement with the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants us an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, we will be required to pay a single-digit royalty on net receipts, subject to a $50,000 annual minimum royalty requirement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. We had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling&#160;$0.4 million&#160;as of&#160;December 31, 2020, which is expected to be paid within a year. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 in the notes to our consolidated financial statements under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of new accounting pronouncements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our financial results in U.S. dollars; however, we conduct business in foreign countries. For U.S. reporting purposes, we translate all assets and liabilities of our non-U.S. subsidiaries at the period-end exchange rate, equity at historical exchange rates, and revenue and expenses at the average exchange rates in effect during the periods. The net effect of these translation adjustments is shown in the accompanying consolidated financial statements as a component of stockholders&#8217; equity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate a portion of our revenue and collect receivables in foreign currencies outside of the U.S. and, as such, we have foreign currency exposure. Currently, we sell our products mainly in United States dollars, Euros, and Singapore dollars although we may in the future transact business in other currencies. Future fluctuations in the foreign exchange rates of these currencies can result in foreign exchange gains and losses which may impact our financial results. In the past, we have not hedged our exposures to foreign currencies or entered into any other derivative instruments and we have no current plans to do so. For the year ended December 31, 2020, sales denominated in foreign currencies were approximately 33% of total revenue. A hypothetical 10% increase in the United&#160;States dollar exchange rate used would have resulted in a $0.3 million decrease to revenues for 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market rate risk for changes in interest rates relates primarily to our term loan. The variable interest rate related to our long-term debt is charged at the greater of 0.50% above the variable rate of interest announced by the lender as its &#8220;prime rate&#8221; then in effect or 4.50.&#160; A hypothetical 10% change in the lender's prime rate would have an immaterial impact on our annualized interest expense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial statements are filed as part of this Annual Report on Form 10-K</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page<br/>Number</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_52">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_52">38</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_55">Consolidated Balance Sheets as of December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_55">40</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_61">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_61">41</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_64">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_64">42</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_70">Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_70">43</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_73">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_73">45</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders and Board of Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richmond, California</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Consolidated Financial Statements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Ekso Bionics Holdings, Inc. as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described in Note 2 to the consolidated financial statements, the Company&#8217;s contracts with customers sometimes contain multiple performance obligations, which are accounted for separately if they are distinct. In such cases, the transaction price is then allocated to the distinct performance obligations on a relative standalone selling price basis and revenue is recognized when the distinct performance obligation is satisfied. For example, device revenue is recognized at the point in time that the customer takes control of the device, generally upon shipment, and subscription and service revenues are recognized over time as the services are performed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing the Company&#8217;s revenue recognition was challenging, specifically related to the identification and determination of the distinct performance obligations, the allocation of the transaction price to the identified performance obligations and the timing of revenue recognition. For example, certain arrangements required judgment to determine the distinct performance obligations, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">how the transaction price is allocated to the identified performance obligations, and the appropriate timing of revenue recognition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding and evaluated the design of the Company&#8217;s process and controls to determine the distinct performance obligations, allocation of the transaction price to the identified performance obligations and the timing of revenue recognition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Among the procedures we performed to test the determination of the distinct performance obligations, allocations of the transaction price to the identified performance obligations and the timing of revenue recognition, we read executed contracts and purchase orders to understand the rights and obligations conveyed in the contractual arrangement, evaluated management&#8217;s assessment of the performance obligations and whether they were distinct, determined the reasonableness of the standalone selling price used by management in the allocation of the transaction price to the performance obligations, and tested the timing of revenue recognition for a sample of individual sales transactions. We evaluated the accuracy of the Company&#8217;s accounting conclusions, specifically related to the identification and determination of distinct performance obligations, allocation of the transaction price to the identified performance obligations, and the timing of revenue recognition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.479%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ OUM &amp; CO. LLP</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Francisco, California</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2010.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNC0xLTEtMS0w_33a9b785-454a-4d89-b85b-44cc86cd965f">12,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNC0zLTEtMS0w_394209fe-22fa-4a32-9256-79905ebb4499">10,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of $<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNS0wLTEtMS0wL3RleHRyZWdpb246ZjI2MmNkNjczZGU3NDU5MDkzYTBjN2JmNGMyNTkyNmZfMzg0ODI5MDY5NzI5Mw_b7409031-8ad1-45ee-9283-4026945b6491">42</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNS0wLTEtMS0wL3RleHRyZWdpb246ZjI2MmNkNjczZGU3NDU5MDkzYTBjN2JmNGMyNTkyNmZfMzg0ODI5MDY5NzI5OQ_5c2bae69-e2a9-48e9-8a40-a6b4e83aff2d">121</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNS0xLTEtMS0w_12f2f072-ad8a-40b1-bb9f-d2b4c5adec88">3,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNS0zLTEtMS0w_291f195a-0d9e-4d28-a57e-489888221f03">5,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNi0xLTEtMS0w_f95fa37b-7926-4b4d-abbf-34c0d71267b9">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNi0zLTEtMS0w_e9626257-2643-4fcd-b5c2-2bc4abdac886">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNy0xLTEtMS0w_3e1e79ed-d427-486c-b3cc-8863fb3ae2c4">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNy0zLTEtMS0w_da529cce-37a3-483b-9d9c-b754f90ffa1e">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfOC0xLTEtMS0w_ad1e96d8-3f2f-49c6-90c4-eea8781b0bd0">18,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfOC0zLTEtMS0w_4d45a202-16df-4d4c-995b-cc6df6a38724">18,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfOS0xLTEtMS0w_41e38bf4-ab14-49c1-83b1-de7bc8f5b20f">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfOS0zLTEtMS0w_85853ef2-ef7a-416d-97c2-0dacd3ac1539">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTAtMS0xLTEtMA_32a035de-71f3-40a5-b5e3-b560ff45a72b">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTAtMy0xLTEtMA_08a9a8d9-b822-40e2-b3e4-aa39ee5467cf">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTEtMS0xLTEtMA_e1a00c5d-2279-4545-a259-6b1a91e49b44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTEtMy0xLTEtMA_5d7fd432-c953-4427-a108-8527b698485f">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTItMS0xLTEtMA_756220c6-5064-45f5-9fda-5d3639e5e2b6">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTItMy0xLTEtMA_fbd07a9e-721f-4235-9bdf-2de529b13e94">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTMtMS0xLTEtMA_dcea8347-ba52-43fd-a0f8-2be5235d6546">20,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTMtMy0xLTEtMA_44159b9f-63dc-4262-bc49-64303169cb8b">21,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTctMS0xLTEtMA_6a2f3f8c-55e1-4846-b05a-84804ca5d21c">1,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTctMy0xLTEtMA_5bc980b1-82e2-49d0-b1e6-15ec41736001">1,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTgtMS0xLTEtMA_1d8f03b6-670b-4d10-9437-bef992135a72">1,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTgtMy0xLTEtMA_72efe25c-4bca-4f0f-842f-ad4721540e7e">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTktMS0xLTEtMA_8c9792d4-8a11-4040-bde7-6cd8887e3062">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTktMy0xLTEtMA_759f3ac2-4102-482b-b580-49cc9fae65a9">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjAtMS0xLTEtMA_b19c0f46-9893-4395-a2df-1099245a9f24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjAtMy0xLTEtMA_f86513f7-6100-4b81-9936-f48a6f37e531">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjEtMS0xLTEtMA_cc8ec08e-dfdf-4405-aa2c-b6e2af90c274">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjEtMy0xLTEtMA_ed34d6a6-cffb-4652-8d6c-92467b3b594b">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjItMS0xLTEtMA_a88af7fd-62e7-4436-bd6b-a755601e1712">4,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjItMy0xLTEtMA_54d67616-7b81-4527-beed-398e11e59296">7,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjMtMS0xLTEtMA_132f5c0d-c9ef-43c9-8f00-4daa43d7b437">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjMtMy0xLTEtMA_030aa669-3bc9-435b-a115-384e388c0316">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjQtMS0xLTEtMA_7ea2dea8-6e57-4a47-a9ff-bee2f069cad6">3,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjQtMy0xLTEtMA_91019969-6d4d-4f83-8a81-c0b168e84fa9">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjUtMS0xLTEtMA_311c26d3-9b5b-4080-8ce4-7f2fd2a0daa0">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjUtMy0xLTEtMA_4f55ecd0-e3b5-4442-8b0c-175602965ba6">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjYtMS0xLTEtMA_741b9dd4-db5f-419f-9a5a-4e1efda8c6bc">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjYtMy0xLTEtMA_f9175da9-a4ce-463e-93bc-40e5179b5ba4">4,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjctMS0xLTEtMA_5f666808-9530-440c-9287-c4c9d5003a7a">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjctMy0xLTEtMA_f25cf985-4c25-4b21-ac63-95c4f422eaa0">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjgtMS0xLTEtMA_82ef0b54-4f28-460b-abc0-8663a8fef61a">16,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjgtMy0xLTEtMA_5b7c690c-3a9c-4eea-b548-7800d322d9e1">15,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 16)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjktMS0xLTEtMA_8bd794ff-e580-43fd-86d8-7885d366a320"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjktMy0xLTEtMA_5c23561b-292e-4c43-a91b-8b0e7895344b"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNjE_63d57617-22f3-43e7-8b7c-283c7f66eddb"><ix:nonFraction unitRef="usdPerShare" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNjE_b3eac00f-d729-4118-8389-c71cd14189cf">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNjk_5ea5a736-41b3-48f6-9b22-d553f61fdab4"><ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNjk_d3410503-17cc-44b2-b7bc-a590ec8e6536">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNzM_200f7ab6-e51b-485d-b52d-c3e428c27bab"><ix:nonFraction unitRef="shares" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNzM_585d170b-7885-4f0c-a159-57c30ff7d0fb"><ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNzM_6e5ce7f2-0a6b-4c7c-ab6c-0e8d80bbf711"><ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNzM_d58d88a6-119b-421a-bfb7-88786fc1d0c3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2020 and 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMS0xLTEtMA_d92dabd5-d0f2-4eb0-b000-3df03f98be68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMy0xLTEtMA_6055d5a1-6e67-4931-85f7-f5d2b5109c4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczNzY_088339d4-7331-4619-9b97-77ee25509fb7"><ix:nonFraction unitRef="usdPerShare" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczNzY_e6f30c55-db9a-43f8-9a28-33eb5cea64fb">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczODU_9a37a21f-e031-4bf6-8600-f2b24fba70ab"><ix:nonFraction unitRef="shares" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczODU_b98c2567-b8c6-4b56-9130-cc81b20a75a9">141,429</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczOTM_00907bf2-4b71-40d8-a54a-dacd61e0165d"><ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczOTM_7fe2d3cb-f36d-48fd-bffc-dd309b7daa4f">8,349</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTc0MDE_85c48f05-0aee-4a49-b2d8-ddf303412407"><ix:nonFraction unitRef="shares" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTc0MDE_979f0a4d-198f-450e-92f5-b85f65968410">5,795</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMS0xLTEtMA_2611835e-276d-489b-ad2d-fb2c1c85bf49">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMy0xLTEtMA_8f03763f-fa57-43b9-ae59-6b3fc00b0582">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzMtMS0xLTEtMA_acf135b0-b245-4593-a736-a5a53b427ebf">204,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzMtMy0xLTEtMA_58c4005b-98bc-4018-aeeb-43c58797892f">190,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzQtMS0xLTEtMA_ea7cb5b3-34e5-4283-b111-a7adee3b22cd">847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzQtMy0xLTEtMA_bdaded1b-4968-443e-acb4-74aaf96142c2">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzUtMS0xLTEtMA_0e8f253b-9d39-44ff-bf4a-fb0e7437071f">199,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzUtMy0xLTEtMA_39ee348a-27ff-41e1-b70b-cd74f1e524cc">183,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzYtMS0xLTEtMA_31a4b939-59ae-416b-9282-04792d3b4cae">4,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzYtMy0xLTEtMA_4ec4d7a9-196b-491c-99b4-1353f686e43c">6,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzctMS0xLTEtMA_f47f42b9-de71-418b-9666-fdc219111fdb">20,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzctMy0xLTEtMA_6fbad5e6-0a36-4b59-928c-29b49d3868f6">21,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:22.5pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:64.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMi0xLTEtMS0w_947a65d4-2248-467d-b31b-948a6ff3a438">8,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMi0zLTEtMS0w_c7e3dfd2-1220-4111-8008-e1b348e591c4">13,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMy0xLTEtMS0w_b6c31977-8df2-4b98-ae1b-4597036626cc">3,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMy0zLTEtMS0w_c8fde8f7-fd42-4793-b447-f54007b6060f">7,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfNC0xLTEtMS0w_347e842f-2244-4826-a34d-5258f5450fe1">5,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfNC0zLTEtMS0w_c07b4cd2-d885-4337-a6d2-0c973f73c789">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfNy0xLTEtMS0w_a5e1155a-7fbd-471f-a316-0ed306a0cc7c">7,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfNy0zLTEtMS0w_8b4f3555-9ee3-4eea-a84f-de1ba6e5235c">11,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfOC0xLTEtMS0w_528a750c-396d-4261-abad-70ffeb186458">2,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfOC0zLTEtMS0w_c65db4f3-f6ed-410b-9187-308fe88293fd">4,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfOS0xLTEtMS0w_47ca9f18-20c7-4434-8944-2389d2910f9d">7,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfOS0zLTEtMS0w_ca4c7e6d-d473-48f1-9b2f-5c6c9fdb5e99">7,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTAtMS0xLTEtMTI5MQ_be47497a-766c-43c0-a5d7-21fb657b8a39">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTAtMy0xLTEtMTI5MQ_074bed6d-f5de-495a-8e87-392b108c4c5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTAtMS0xLTEtMA_2dead2d9-1e48-4fd0-994f-b909d6073602">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTAtMy0xLTEtMA_d8b9bd00-2f1b-4957-adfb-993476ce9183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTEtMS0xLTEtMA_ac0daf5a-95d3-450d-ba11-3f0242448b1c">18,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTEtMy0xLTEtMA_78852f12-1c21-416c-ab76-1f9a94c8a6af">23,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTMtMS0xLTEtMA_dd51f210-7599-43e2-aa00-f7a803781fba">13,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTMtMy0xLTEtMA_0f46eb92-ed7a-4b2c-8eeb-b6759d2757cd">16,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTYtMS0xLTEtMA_1c9763d3-eb6d-4b0a-8cbb-5fc2eb5588f8">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTYtMy0xLTEtMA_7cfc18a6-0d9a-454f-b9f9-d01006ba0eea">384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance cost associated with warrant issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="ekso:WarrantIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTctMS0xLTEtMA_16f82520-66f8-48f1-baaa-e6d5eb09634c">329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="ekso:WarrantIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTctMy0xLTEtMA_d1260515-45f8-4a79-b420-197f7e796c0f">1,096</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ekso:GainLossOnWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTgtMS0xLTEtMA_00fc8be0-c19d-47e8-a788-473db1607eda">3,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="ekso:GainLossOnWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTgtMy0xLTEtMA_b0344c95-ded8-4d73-8c8b-833dbf462390">6,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on modification of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:GainLossOnWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTktMS0xLTEtMA_9dd93e56-e233-41fd-9994-2c1c43547e04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" name="ekso:GainLossOnWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTktMy0xLTEtMA_2d70313d-21f0-47e6-a03f-075865445849">257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjAtMS0xLTEtMA_f8d464a4-bf9c-41be-af42-893ca61e850d">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjAtMy0xLTEtMA_2268df54-369a-45a1-81fb-fe7e14655c79">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjEtMS0xLTEtMA_fb7df25b-aed8-4e6d-8f6c-e64f7f7faafd">2,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjEtMy0xLTEtMA_588754f0-ba82-49e4-ae85-f5558a15d841">4,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjYtMS0xLTEtMA_4217ac9f-a393-47f6-97c7-031b188c89f0">15,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjYtMy0xLTEtMA_89b0ab3b-4647-4871-86d6-04f2e7670322">12,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjctMS0xLTEtMA_28bbde32-61e4-4417-9a59-f7d3bdad8b2d">897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjctMy0xLTEtMA_f7e72932-d9e1-4600-b8af-f75105d1c812">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjgtMS0xLTEtMA_06df7129-8bf5-4261-bd35-a0aeff00c751">16,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjgtMy0xLTEtMA_a7f62284-d8c6-435e-9894-b000efd3991e">11,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share applicable to common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMzAtMS0xLTEtMA_545fcf49-82b4-430e-825d-f1f9bb1c8a97">2.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMzAtMy0xLTEtMA_c4b476c2-7907-4018-be4f-1c5a29ccf867">2.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMzItMS0xLTEtMA_55bb4a46-4459-4449-9efa-1ea856afc4b7">7,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMzItMy0xLTEtMA_22f1d12a-091e-48f8-97da-407abab44e60">4,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_64"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.687%"><tr><td style="width:1.0%"></td><td style="width:34.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.417%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i846dd5585ada4e0498b73873e27cdcdc_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi0xLTEtMS0w_67796140-0ec2-42f5-a1b7-4c42a0fa8017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846dd5585ada4e0498b73873e27cdcdc_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi0zLTEtMS0w_7f5d01db-e807-4040-ad06-17ffdee2648f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i771c5968601e4ebbaee595d0efedc2df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi01LTEtMS0w_b1ae72da-3922-41c2-b458-efdad8c4c33e">4,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771c5968601e4ebbaee595d0efedc2df_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi03LTEtMS0w_9fc27227-df2e-41fc-b62d-25c0e4f007e8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001a198ae0ad4ccaabceb0a88f0757da_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi05LTEtMS0w_8f0e4f4d-d5db-46bd-be36-005e92e58b84">173,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b330504326e4a9bbc4d3e4b7244e5fb_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi0xMS0xLTEtMA_763d3a49-4cb4-472e-be14-b8a50b783611">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ed408484abc4ce88899f293e7cfe8ad_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi0xMy0xLTEtMA_0f073f3a-600f-4f4d-b612-e55ad53eceaa">171,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd59b28ca904e409d6a180ec9f55846_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi0xNS0xLTEtMA_c530f71c-2e23-499d-b1f1-b48991606dcd">2,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0c5a8bcf1214cdea5e114d7188288c6_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMy0xMy0xLTEtMA_a4299af9-abc7-40a1-9aca-b118eb622d9f">12,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMy0xNS0xLTEtMA_89851fe9-f069-4a5e-b9c6-c3584c465565">12,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity financing, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNS01LTEtMS0w_d33982d7-1089-4df1-8b61-85f88c5bb4e7">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNS03LTEtMS0w_296f2f4a-52a3-4873-8387-c5788cab3c16">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNS05LTEtMS0w_c3c75f05-8554-488c-921c-fed827c873ac">12,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNS0xNS0xLTEtMA_bacbbe2b-7476-4210-a714-d10ca757fa83">12,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipois sales earn-out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231" decimals="-3" name="ekso:StockIssuedDuringPeriodShareEquiposisSalesEarnOut" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNi01LTEtMS0w_0f1a5483-c4ae-4a13-b3b0-3ea11c011294">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231" decimals="-3" name="ekso:StockIssuedDuringPeriodValueEquiposisSalesEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNi05LTEtMS0w_bccba06d-75ae-4637-94cd-6e389324ff76">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="ekso:StockIssuedDuringPeriodValueEquiposisSalesEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNi0xNS0xLTEtMA_d8ff72f5-8f68-4c9d-96d7-8541cb4e64a4">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity incentive plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNy01LTEtMS0w_2aaa9de6-a07d-4fc0-af51-a7f63b6a2d22">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNy05LTEtMS0w_b6fcf445-fbde-493e-9d26-e564035f9079">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNy0xNS0xLTEtMA_e68b6a2d-825f-4cd1-a4ef-164aa17760c2">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matching contribution to 401(k) plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOC01LTEtMS0w_43b1218f-10bc-481d-887e-488a03451b0e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOC05LTEtMS0w_1d1d1391-dff1-49d9-a72f-2b48b6564061">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOC0xNS0xLTEtMA_3e437c76-b018-4c59-a6c0-8c3193f3892c">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In lieu of employee cash bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOS01LTEtMS0w_5864a038-506e-4a78-8e24-c565a27af2e0">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOS05LTEtMS0w_1a883a29-9c99-46cc-bcbd-fe4cab050eaa">919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOS0xNS0xLTEtMA_4280fac9-c4ab-489d-97b6-baca93414cb0">919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTAtOS0xLTEtMA_4820aefe-f284-464f-b01e-9fe1517f96af">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTAtMTUtMS0xLTA_9095f546-1655-474c-a939-93a60ce078cd">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9f045d0163b47d080fcc09d4ec9b298_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTEtMTEtMS0xLTA_b9a4e882-45d2-4824-8bd0-7477e23bfcc4">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTEtMTUtMS0xLTA_983db78e-3da1-4ad5-b274-4b7fb2156926">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fdf493d0b2b4110824781819eb0a66c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItMS0xLTEtMA_6da0a78e-de7f-4fa3-946c-7ec86faf5e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fdf493d0b2b4110824781819eb0a66c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItMy0xLTEtMA_115a14d1-0b81-4e94-bbd1-7a86c26440e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0387f9eb02e44e3b6ba26b31874ce98_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItNS0xLTEtMA_41ed3135-0ef7-4a89-b312-f369fe53dbc5">5,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0387f9eb02e44e3b6ba26b31874ce98_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItNy0xLTEtMA_31b78397-0735-4966-a28d-664f19b41a5f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355702e247f64033a0ce80c82800d085_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItOS0xLTEtMA_8a17c095-f7e9-4c83-9d5c-8fa70509a3e1">190,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164b98fab8ca484db400c50acb2bde32_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItMTEtMS0xLTA_5e8ffb75-77fe-42cb-b3f2-c911af22dbcc">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id633f108918a485b94dd3575f357c6d1_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItMTMtMS0xLTA_c62744bb-7721-48c4-a9e7-fccc09d04e30">183,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItMTUtMS0xLTA_21a9a99b-7469-4744-ab39-41ec42356d84">6,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8437b75fb864b51a8daec69829e7ede_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTMtMTMtMS0xLTA_fab51601-ae0f-4fab-a928-b79b27cdea2c">15,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTMtMTUtMS0xLTA_365743c0-8025-4ea3-b610-4910c2808d20">15,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity financing, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTUtNS0xLTEtMA_f8826d42-06eb-4e7d-a0f3-8648c289e299">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTUtNy0xLTEtMA_28ef0c61-1b93-47a8-8728-a412b5445bac">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTUtOS0xLTEtMA_ce85c8ec-8391-4176-8e04-0375c7a3e208">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTUtMTUtMS0xLTA_52257cef-8eba-4019-983b-4cc88de8d82f">7,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity incentive plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTYtNS0xLTEtMA_58804c85-f09b-465d-bac4-b0307bf95759">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231" decimals="-3" name="ekso:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctNS0xLTEtMTY0NA_852b1e08-15e4-4b5d-a077-59c88a4fa38e">723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ekso:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctOS0xLTEtMTY0NA_2d49e278-1d49-40de-996e-ad87f2b4f999">7,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ekso:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctMTUtMS0xLTI1Njg_9dab0fac-763b-4ad9-86ff-13620e29b76a">7,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matching contribution to 401(k) plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctNS0xLTEtMA_5989cd11-0868-42fc-813e-00d87117317a">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctOS0xLTEtMA_3392a6f4-adb7-41cd-849d-9015a6c3cc02">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctMTUtMS0xLTA_b0c0ebfa-bf1c-44dc-9fcb-153a8b6dd6d8">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In lieu of cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTgtNS0xLTEtMA_73cf29da-d2ae-47f7-bfbd-cdadab0b7df1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTgtOS0xLTEtMA_906806d7-e25b-4dae-a5d8-a8e788bf6d8d">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTgtMTUtMS0xLTA_cbc6cc8d-13fd-4f7f-b9d6-bd1c0bef73d0">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued as a result of rounding due to reverse-stock split</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTktNS0xLTEtMA_26a4cd75-d04d-42e3-932a-1cef52f47918">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ekso:AdjustmentsToAdditionalPaidInCapitalWarrantIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjEtOS0xLTEtMTY1MA_4b6d832c-5aa9-4da2-9bc8-19e2a44b6691">2,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ekso:AdjustmentsToAdditionalPaidInCapitalWarrantIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjEtMTUtMS0xLTI1NzM_1629fc5c-fef0-4bd3-8a85-b3fe381265a9">2,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjAtOS0xLTEtMA_e4999154-8b4a-4b14-a35e-a1c326ef7643">2,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjAtMTUtMS0xLTA_571b8ef4-9ad8-4e69-8f25-4d407c3719e5">2,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1244662c4107454f9abedb0d2c7dd95a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjEtMTEtMS0xLTA_fc85725c-bd81-4386-90d0-3c5fa85f3ac7">897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjEtMTUtMS0xLTA_bb1f3234-265f-411d-a992-2f7d4c0d97ac">897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fb8ef54637c4de2a9b1091027aa5962_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItMS0xLTEtMA_2b8fbafe-ed89-44ba-913c-791d5c7027a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb8ef54637c4de2a9b1091027aa5962_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItMy0xLTEtMA_67ab5e5e-0fec-4c2c-82da-5a0867f68337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56dbcebcd6d641bdb0fa75661fc45501_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItNS0xLTEtMA_51c6f5aa-8f36-47b0-9e8e-be4ed444b301">8,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56dbcebcd6d641bdb0fa75661fc45501_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItNy0xLTEtMA_d7904ad3-053f-4cdd-a7d6-ef877651b8a6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b0ba326b044c5d8a0bb299a3ec93ef_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItOS0xLTEtMA_ebcad8a6-c446-4247-bd1a-fcc2e1a0312a">204,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic126d0c0305a496bb377ee4b4e95f356_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItMTEtMS0xLTA_fd93cbce-009e-45e3-bd36-51c53e884965">847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7fef623934b4bd19b22ecc59a17e7ca_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItMTMtMS0xLTA_d8597d08-2a2f-431b-bee9-1667c74eba04">199,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItMTUtMS0xLTA_0241f623-edaf-4c02-8981-556ee4c93849">4,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:62.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.555%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMy0xLTEtMS0w_a6baf523-4dc3-4a56-b840-4747b405395f">15,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMy0zLTEtMS0w_efe1a95a-5406-4ba3-b9c6-71adcaeba45f">12,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNS0xLTEtMS0w_c0bc7627-e083-44e8-98a4-9e9f1b755a86">620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNS0zLTEtMS0w_7b782da0-7953-49de-9cdb-151828c9e81c">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNy0xLTEtMS0w_137d4ca6-a0b7-4acd-996d-1f1f1b5c6739">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNy0zLTEtMS0w_c76f65eb-cda1-49e3-b8b2-f7426966e6cd">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfOC0xLTEtMS0w_132a52a1-a4f4-4e94-9728-60f0c047e6c8">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfOC0zLTEtMS0w_24c9fec1-e927-41b8-9eab-b41fa0022750">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount, change in contingent liability and accretion of final payment fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfOS0xLTEtMS0w_1820dc7e-eea9-4633-a8e4-6fb512d54552">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfOS0zLTEtMS0w_831b2b2d-ba4e-442c-8639-bb41cc115e00">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on modification of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="ekso:GainLossOnModificationOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTAtMS0xLTEtMTMxMA_d19415bc-6299-43d5-b37c-db283ad49a05">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="ekso:GainLossOnModificationOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTAtMy0xLTEtMTMxMA_538eca0b-62e6-4302-ab84-2fe0c2181da3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on investment of unconsolidated affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTAtMS0xLTEtMA_f46adc45-2621-4a67-8524-56163d9d8700">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTAtMy0xLTEtMA_b297fb21-175c-4955-b52a-f1d1be178cff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock contribution to 401(k) plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="ekso:CommonStockContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTEtMS0xLTEtMA_f44f7e1a-4720-4472-a502-bf6ccee40e93">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="ekso:CommonStockContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTEtMy0xLTEtMA_3d27e3ef-f7a8-466e-be3a-e35db47706c2">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTItMS0xLTEtMA_5c843d2d-7090-452c-8c47-8d733f03f84f">2,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTItMy0xLTEtMA_33558296-143f-43be-b4ef-2d45c79ff0d9">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance cost attributable to issuance of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTMtMS0xLTEtMA_937b11b4-92a3-4bd5-8f56-f3f792ccb6ef">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTMtMy0xLTEtMA_af1eadb8-13c4-467f-bd92-a7544d4ab700">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on revaluation of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ekso:GainLossOnWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTQtMS0xLTEtMA_083f5999-22dc-4f2f-aad6-672308b7eb8f">3,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="ekso:GainLossOnWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTQtMy0xLTEtMA_aefafe11-e4d5-4aba-a622-587bf88ee5d1">6,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on modification of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:GainLossOnWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTUtMS0xLTEtMA_a9d19c7a-41ea-4c2f-a2ee-c5279238c64e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" name="ekso:GainLossOnWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTUtMy0xLTEtMA_1fc93fc1-bb7e-4844-84aa-88319fd8d58f">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (gain) loss on foreign currency transactions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTYtMS0xLTEtMA_fad4f9a3-8aa2-47e9-a54d-3561e9adc290">947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTYtMy0xLTEtMA_159479f2-8331-42d4-a561-21e08b3695e5">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTgtMS0xLTEtMA_95908f4b-0d7b-41b1-bd87-29a5bda01e4d">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTgtMy0xLTEtMA_8a35f31e-e5cb-463a-b959-d992b6ff21e4">1,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTktMS0xLTEtMA_369f10eb-b91a-46a1-9666-9c703f45db2e">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTktMy0xLTEtMA_2cc88e6c-4c0c-4cca-b3c8-e2013b0112d0">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense, operating lease right-of-use assets, and other assets, current and noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjAtMS0xLTEtMA_b46cb848-55eb-440d-8ae6-9cfeee4b0aa0">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjAtMy0xLTEtMA_ee7067fb-ea24-47e0-9fb4-d485022149f9">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjEtMS0xLTEtMA_18dd3aac-3708-4631-8871-dff511dee753">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjEtMy0xLTEtMA_7160a865-2124-4077-9760-0f1eefe5ddd5">1,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjItMS0xLTEtMA_f702b2ec-6b90-484d-9e7d-568521b8ce11">876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjItMy0xLTEtMA_5f97f340-0b1d-403d-8c29-5fc93a706901">1,135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjMtMS0xLTEtMA_692cdd67-8bb7-4431-a4a6-92042cee190f">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjMtMy0xLTEtMA_7552e3a7-f08d-490c-8f22-fbf5583dfd08">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjQtMS0xLTEtMA_23cc5010-f1c7-49be-8af1-ebab4ef8c92d">8,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjQtMy0xLTEtMA_bb251584-a6d9-4caa-9a19-8c4899afa45c">15,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjYtMS0xLTEtMA_be16a42d-cab7-43b5-9774-a028983faf82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjYtMy0xLTEtMA_77310611-72dc-4923-89df-996db0ffb3d7">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjctMS0xLTEtMA_372addc7-f0d0-40ea-981d-b6b347e963e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjctMy0xLTEtMA_7dd62ece-2c46-4e96-982f-b12de0186d60">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock and warrants, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjktMS0xLTEtMA_b8af9fb8-e08f-461e-b519-be241704153b">7,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjktMy0xLTEtMA_e4d3cc54-9d85-4c1f-a1b5-ad7e6869ea04">21,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzAtMS0xLTEtMA_ddf2b2c3-c65b-49f5-90f9-22d43f787f02">1,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzAtMy0xLTEtMA_e0a9d4be-c844-4afc-88d5-b345fa08109f">2,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of remaining balance on long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzMtMS0xLTEtMTMyNw_47c92a85-9cc2-4647-9d82-c739690cc5b0">1,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzMtMy0xLTEtMTMyNw_e3b5cde3-7d92-411f-959f-ddf0a10ba230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzMtMS0xLTEtMA_5f06204f-0195-4ca8-8cb4-b422f22cfc1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzMtMy0xLTEtMA_752a8137-33e2-4a0d-8358-40dcb1ffc7ab">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzQtMS0xLTEtMA_2dfd1c69-c6e5-45fa-9706-10be1ec78367">3,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzQtMy0xLTEtMA_13aebf50-7dab-4190-999d-1b39200a7399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzUtMS0xLTEtMA_d5c21c66-40c1-410c-8dc6-e8fe970b771c">3,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzUtMy0xLTEtMA_782c797c-25cb-4de5-bb6c-88df78cab7a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzYtMS0xLTEtMA_5816c625-858d-4bad-acc9-9a91cf45d7a4">10,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzYtMy0xLTEtMA_9f34fdc5-8d6b-4a55-9c6d-b9687fd5b382">19,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzctMS0xLTEtMA_043d3555-d19e-488e-8360-7dd4d22a8b63">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzctMy0xLTEtMA_d6ba313d-73d2-47ba-8a98-5bd226be5deb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzgtMS0xLTEtMA_5deabd53-0997-41da-8718-6e1766be7326">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzgtMy0xLTEtMA_382267b2-2cc2-49c8-a656-017d420f7a4d">3,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash at beginning of the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzktMS0xLTEtMA_e6d01a33-c040-4701-9cc1-7b13f5581d28">10,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd59b28ca904e409d6a180ec9f55846_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzktMy0xLTEtMA_cb58e6a4-7606-45a5-a9a7-a9aee36b8972">7,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash at end of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDAtMS0xLTEtMA_eb659a77-9be6-4f8a-a278-ee7ec03a4d19">12,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDAtMy0xLTEtMA_0bdd7c47-e392-4ad4-982a-ef2de757d61e">10,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDMtMS0xLTEtMA_e511a144-a3df-4b76-94c5-171d04883d3b">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDMtMy0xLTEtMA_6a2dcbf1-4f6b-4ca9-9150-fc2dba1252f6">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:62.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.555%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDQtMS0xLTEtMA_0537e91a-398a-416f-8332-d7f4c2605d0c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDQtMy0xLTEtMA_d92a5542-f178-44e2-abb2-5bb19deb724d">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liability to equity upon exercise of warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDYtMS0xLTEtNjIzNQ_741dcbde-2a8f-40ab-b47c-6542fdb47277">3,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDYtMy0xLTEtNjIzNQ_97970b7b-cc86-455c-b6e0-9c5ff52be7a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issuance for common stock contribution to 401(k) plan</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="ekso:SharesIssuedCapitalContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDctMS0xLTEtNjIxMg_968dd601-d54f-472d-b0ee-14041cdfa368">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="ekso:SharesIssuedCapitalContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDctMy0xLTEtNjIxMg_cf1ce975-338e-41d6-a569-39525c7ff681">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer of inventory to (from) property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="ekso:TransferOfPropertyAndEquipmentFromInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDgtMS0xLTEtNjIxOQ_e1708b52-5bc5-44a1-aa22-638f82bfce03">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="ekso:TransferOfPropertyAndEquipmentFromInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDgtMy0xLTEtNjIxOQ_6707352b-9356-4591-ae5b-5720134582fb">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issuance in lieu of cash compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDktMS0xLTEtNjIyNA_40c46423-41f4-436b-95c0-ff42c03447b4">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDktMy0xLTEtNjIyNA_404dd797-def2-43d4-b710-b266f80bf8d0">919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition of operating right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:OperatingLeasesRightOfUseAssetInitialRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDctMS0xLTEtMA_a29cf048-7797-4ceb-b427-15caf1e77db9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="ekso:OperatingLeasesRightOfUseAssetInitialRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDctMy0xLTEtMA_fcbadcf9-cbb4-40cd-a697-176ce6f95649">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition of operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:OperatingLeasesLiabilityInitialRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDgtMS0xLTEtMA_fab5cf26-1f7d-4e2a-8220-7e76dcbe867f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="ekso:OperatingLeasesLiabilityInitialRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDgtMy0xLTEtMA_51abdad3-f42f-49e1-9466-d496ec5b9be9">1,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issuance for vesting of restricted stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:RestrictedStockIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNTItMS0xLTEtNjIzNw_6a0362b5-c83f-416a-a21f-a81acee1f2b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="ekso:RestrictedStockIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNTItMy0xLTEtNjIzNw_e84b1ef5-c0fe-46ba-872e-e165e5e6f479">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred rent associated with ASC 842</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:OperatingLeasesIncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDktMS0xLTEtMA_3997e902-c8c6-4fb4-b659-07108d3ea3ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="ekso:OperatingLeasesIncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDktMy0xLTEtMA_b1d46981-a76d-49a3-a95a-34753dd12b46">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipois sales earn-out</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:SalesEarnout" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNTMtMS0xLTEtMA_42b39990-cf94-4694-b590-4e3aa87785f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="ekso:SalesEarnout" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNTMtMy0xLTEtMA_2bf2a2bf-fdad-4cc0-ad0a-70bcc1f23dfc">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:700;line-height:120%"> </span></div><div id="i3e979bd8812343be80d8bde3987d68dd_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNTM5OQ_597686fc-9f2f-421e-93de-2058796d25b6" continuedAt="i3cc3b0ff42e0447bb560781d0b41420b" escape="true">Organization</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3cc3b0ff42e0447bb560781d0b41420b" continuedAt="i20cd78e6082141bfb57d0aefd9317062"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ekso Bionics Holdings, Inc. (the "Company"), designs, develops, sells, and rents exoskeleton products to augment human strength, endurance and mobility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and persons with physical disabilities. The Company has sold and rented devices that (i) enable individuals with neurological conditions affecting gait (acquired brain injury and spinal cord injury) to rehabilitate and to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Founded in 2005, the Company is headquartered in the San Francisco Bay area and listed on the Nasdaq Capital Market under the symbol &#8220;EKSO&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all dollar and share amounts included in these notes to the consolidated financial statements are in thousands.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfOTIx_0e8f253b-9d39-44ff-bf4a-fb0e7437071f">199,103</ix:nonFraction>.&#160; Largely as a result of significant research and development activities related to the development of the Company&#8217;s advanced technology and commercialization of such technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. In the year ended December 31, 2020, the Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3a01f618e3f9488cb29bae5e918482c6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM1OTQ3Nw_22215f2e-b27b-4b11-b0ca-1db240deaf15">7,082</ix:nonFraction> from a registered direct offering and of $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM1OTE0NA_e17d4a37-9565-4649-95b3-26a8bcbfb0d9">3,334</ix:nonFraction> from warrant exercises, and used $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfMTI4Ng_ddc751e2-487b-4da4-bafd-47f4baf6e4d4">8,755</ix:nonFraction> of cash in its operations. Cash on hand at&#160;December 31, 2020&#160;was $<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjMzNzk1MQ_33a9b785-454a-4d89-b85b-44cc86cd965f">12,862</ix:nonFraction>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to year-end through February&#160;25, 2021 the Company received estimated net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3ef9cf6430ff4f8e9422f488739fa849_D20210201-20210228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM1OTU1OQ_acf060bc-ce84-46df-98a2-0080b834cf6b">36,404</ix:nonFraction> from an underwritten public offering, $<ix:nonFraction unitRef="usd" contextRef="i92564e533c5b46fca6e27927910f77db_D20210101-20210225" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM1ODk0NQ_02923e06-1ed9-4951-956b-a4c4b7314153">1,416</ix:nonFraction> from warrant exercises, and $<ix:nonFraction unitRef="usd" contextRef="idb89bd35b9ca4d7680abe71e8e1cb17e_D20210101-20210225" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM1ODk3Mw_77403403-dce3-424b-908d-29fb4b21bf1a">664</ix:nonFraction> from ATM sales. Refer to Note. 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, management took several actions to alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern that existed as of the date of issuance of the December 31, 2019 consolidated financial statements, including, but not limited to, the following:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">streamlined the Company's operations and reduced its workforce by approximately <ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfMzI5ODUzNDkwMjIzNA_e1d33b3f-f3c3-4d31-9b66-860b2553725b">35</ix:nonFraction>% to lower operating expenses and reduce cash burn;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducted a registered direct offering for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3a01f618e3f9488cb29bae5e918482c6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfMzI5ODUzNDkwMjIzOQ_22215f2e-b27b-4b11-b0ca-1db240deaf15">7,082</ix:nonFraction>;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">paid off the entire amount of $<ix:nonFraction unitRef="usd" contextRef="i7b032681769845018b20e932f7d48c5b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfMzI5ODUzNDkwMjI1MA_306db6a9-9316-471c-8f92-b10dc982ab57">1,512</ix:nonFraction> of the Company's indebtedness to Western Alliance Bank with proceeds from a new loan of $<ix:nonFraction unitRef="usd" contextRef="ic845df26b7574c9688eaf63d2b286340_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfMzI5ODUzNDkwMjI2MQ_d687d6db-a63b-482c-9e43-e2dbaaba7b7a">2,000</ix:nonFraction> from Pacific Western Bank. The terms of the new loan agreement include monthly interest-only payments until August 2023.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">invested in the development and reliability of its products;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restructured the Company's commercial organization and strategy which has been gaining traction; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">received clearance from the U.S. Food and Drug Administration ("FDA") for Acquired Brain Injury ("ABI") to market the Company's product to a larger patient population increasing the value proposition to its customers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes payable, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, borrowings under the Company&#8217;s new secured term loan agreement with Pacific Western Bank have a liquidity covenant requiring minimum cash on hand equivalent to the current outstanding principal balance. As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ekso:DebtCovenantCovenantComplianceUnrestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM0MDIxMA_de0797ea-9cc4-4ebe-8e85-db45423b2060">2,000</ix:nonFraction> of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of December 31, 2020 is approximately $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ekso:UnrestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM0MDIyMQ_ef49b286-e7e5-4bd3-865e-e6f965455110">10,862</ix:nonFraction>. With this unrestricted cash balance, the impact of management's actions described above, and additional cash received after year-end, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of one year from the issuance of these consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s actual capital requirements may vary significantly and will depend on many factors. The Company plans to continue its investments in its (i) sales initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i20cd78e6082141bfb57d0aefd9317062">market, (ii) research, development and commercialization activities with respect to exoskeletons for rehabilitation, and (iii) development and commercialization of able-bodied exoskeletons for industrial use. Consequently, the Company may require significant additional financing in the future, which the Company intends to raise through corporate collaborations, public or private equity offerings, debt financings, or warrant solicitations. Sales of additional equity securities by the Company could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, the Company may be required to further reduce its discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NjE_0fd52eec-018a-4d89-a7aa-388bf8295a92" continuedAt="i7f18fc724bb0424eb61e3a95920448c0" escape="true">Summary of Significant Accounting Policies and Estimates</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i7f18fc724bb0424eb61e3a95920448c0" continuedAt="i88b4a4e9a04045c48e3ed7a9e22c558b"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NDk_4206e0e2-b3eb-4e69-9457-c60c499df95e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation and Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States or U.S. GAAP. In the opinion of management, all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented have been included and are normal and recurring in nature. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year&#8217;s presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All common share and per share amounts have been adjusted to reflect the one-for-fifteen reverse stock split completed on March 24, 2020. See Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalization and Equity Structure &#8211; Reverse Stock Split</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MzE_16c28cc8-220d-4cfc-8f41-c4d86e61442c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2Nzc_f37a024e-3d11-47da-a321-706f3e25bc8b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive (loss) income as a component of stockholders&#8217; equity.  Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNjU5NzA2OTc5OTI2MA_cdc096c2-8d6c-4938-b628-81b0ad756a66" continuedAt="ia02bfbd52f1948ecb87eb65b0ed002d4" escape="true">Accumulated Other Comprehensive (Loss) Income </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia02bfbd52f1948ecb87eb65b0ed002d4">The Company's accumulated other comprehensive (loss) income consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments.</ix:continuation> <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MjQ_2b852cb1-6915-4fc9-a364-894c9727dfcd" continuedAt="i5f1fe274bf4d40b8b5e4c191b2f8e8ff" escape="true">The change in accumulated other comprehensive (loss) income presented on the consolidated balance sheets for the year ended December 31, 2020, is reflected in the table below net of tax:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i88b4a4e9a04045c48e3ed7a9e22c558b" continuedAt="i9e0deb70df2f494c90877a360718d003"><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i5f1fe274bf4d40b8b5e4c191b2f8e8ff"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164b98fab8ca484db400c50acb2bde32_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjhmNjQ4YWFjODMzZjQ3MjhhNTFlNjA4MjE3Yjk2NjIzL3RhYmxlcmFuZ2U6OGY2NDhhYWM4MzNmNDcyOGE1MWU2MDgyMTdiOTY2MjNfMS0xLTEtMS0w_bc18ad46-29da-4ea3-8d29-ddcd5e0f6b52">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on foreign currency translation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1244662c4107454f9abedb0d2c7dd95a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjhmNjQ4YWFjODMzZjQ3MjhhNTFlNjA4MjE3Yjk2NjIzL3RhYmxlcmFuZ2U6OGY2NDhhYWM4MzNmNDcyOGE1MWU2MDgyMTdiOTY2MjNfMi0xLTEtMS0w_354c7fc7-0e78-4b35-9885-4f82433b29aa">897</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic126d0c0305a496bb377ee4b4e95f356_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjhmNjQ4YWFjODMzZjQ3MjhhNTFlNjA4MjE3Yjk2NjIzL3RhYmxlcmFuZ2U6OGY2NDhhYWM4MzNmNDcyOGE1MWU2MDgyMTdiOTY2MjNfMy0xLTEtMS0w_b93fe107-6c7e-4e1a-9a57-c91616249f98">847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNjU5NzA2OTc5OTI2MQ_b8ebf334-ff16-4f9f-be20-4fcefb7be01c" continuedAt="i360bc339010f4db0b9bba71a69a8c1bb" escape="true">Cash</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i360bc339010f4db0b9bba71a69a8c1bb">The Company places its cash in the custody of, financial institutions with high credit ratings. The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents.</ix:continuation> The Company did not have any cash equivalents or investments in money market funds as of December 31, 2020 and 2019.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MTA_1588cfa8-05de-428a-9c61-318e0af0339d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &#160;The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia.  Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2020 and 2019. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company had two customers with an accounts receivable balance totaling 10% or more of the Company&#8217;s total accounts receivable (<ix:nonFraction unitRef="number" contextRef="i6806a66d666343109c438a29d2361243_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNDk0NzgwMjM2OTY2OQ_84fe885f-f3b4-401e-abb0-a1edda3a865d">13</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6634dcaf84414ad4a2238d4e3b472d60_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNDk0NzgwMjM2OTY2Mg_b05f9832-1b4c-428a-b6ff-ee4463bc609e">10</ix:nonFraction>%, respectively), as compared with one customer at December 31, 2019 (<ix:nonFraction unitRef="number" contextRef="i4c852fde248a46429a59913a353fcd78_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfODkwMw_db0982e2-9dba-419d-8e6f-56af5a91baa0">11</ix:nonFraction>%). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no customers with sales of 10% or more of the Company&#8217;s total revenue for the year ended December 31, 2020, as compared with one for the year ended December 31, 2019 (<ix:nonFraction unitRef="number" contextRef="i5526a54efe4b4f308ec50b4abcc4ccc1_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNDk0NzgwMjM2OTYzOA_5686c814-fe34-4469-a7e0-157e65ed2982">15</ix:nonFraction>%). Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 17. Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MTc_aed58e4b-16e0-4a9a-9519-803cdff2f1f1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand.&#160; Subsequent disposals of inventories are recorded as a reduction of inventory.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NDY_290d6c50-5a47-48fe-8bf7-875461267665" continuedAt="i1a5465a5efd34b94b6349f3880cf4e89" escape="true">Inventories consisted of the following:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i9e0deb70df2f494c90877a360718d003" continuedAt="ia59db41658d74299ace7f77fd5fd2464"><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i1a5465a5efd34b94b6349f3880cf4e89"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfMi0xLTEtMS0w_57673630-16f3-4935-a212-9d57f31a0687">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfMi0zLTEtMS0w_55120f6a-0d55-4811-a633-56f10d40328e">2,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfMy0xLTEtMS0w_c065dfd5-95a1-413d-918c-dddaf482e6d8">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfMy0zLTEtMS0w_c61724c6-fdee-441b-94a5-359f75fc4b47">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfNC0xLTEtMS0w_cf1ef81b-9cd9-42aa-a33e-64289bd4f96a">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfNC0zLTEtMS0w_6f76049c-7a7f-475c-89a5-9d979b3ca78a">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfNS0xLTEtMS0w_5dc19b99-0ed7-49ee-ad2f-dea3b3918791">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfNS0zLTEtMS0w_f9436c4e-7502-4295-859a-606936cb9bbd">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NjM_06fce9f9-e1d2-4e43-a6e9-9d8d1b94d7fe" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board ("FASB")&#160;issued Accounting Standard Update (&#8220;ASU&#8221;), No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. The Company adopted the standard effective January 1, 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. As a result, the Company no longer recognizes deferred rent on the balance sheet.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May of 2020, the Company streamlined its operations and reduced its workforce by approximately <ix:nonFraction unitRef="number" contextRef="i425546ef7c404c1fb5e6ce43069f77b8_D20200501-20200531" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNDk0NzgwMjM2MzMxMg_685bc993-33f4-4a0d-95ac-399586bed4e1">35</ix:nonFraction>% to lower operating expenses and reduce cash burn. The restructuring plan was completed by the end of the second quarter of 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded restructuring expense of $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNDk0NzgwMjM2MzQwMg_2dead2d9-1e48-4fd0-994f-b909d6073602">244</ix:nonFraction> for the year ended December 31, 2020 comprised of termination benefit costs. As of December 31, 2020, there was no accrued restructuring cost remaining on the Company&#8217;s consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2Mzg_3475652c-1d53-4fac-ba61-2ef0e54521f1" continuedAt="i068690d6e0694e16a17111d25f33b385" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i068690d6e0694e16a17111d25f33b385">Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTIxNDU_cd4dc075-4b7e-413d-b6dc-6727130d268c">three</span> to <ix:nonNumeric contextRef="i81b4652764f7496fae43691e5665e11e_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTIxNTE_317e4afa-a072-4f9a-bbb0-65ae1432e415">ten years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the estimated useful life or the related term of the lease. The costs of repairs and maintenance are expensed when incurred, while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized.</ix:continuation>&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MTk_907eb87c-9c6c-4e3e-bb8a-ecde13723907" continuedAt="ie8c7e7f0de82457bb3e8342db56f8dee" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie8c7e7f0de82457bb3e8342db56f8dee">The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not be recoverable from the estimated future cash flows expected to result from the Company&#8217;s use or eventual disposition. If estimates of future undiscounted net cash flows are insufficient to recover the carrying value of the assets, the Company will record an impairment loss in the amount by which the carrying value of the assets exceeds the fair value. If the assets are determined to be recoverable, but the useful lives are shorter than originally estimated, the Company will depreciate or amortize the net book value of the assets over the newly determined remaining useful lives.</ix:continuation> None of the Company&#8217;s property and equipment or intangible assets were impaired as of December 31, 2020 and 2019. <ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTMzNjU_26389453-d83f-4370-bbef-e53a91001083"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTMzNjU_b144119d-4e34-4183-9c8f-aceb3574f7a8">No</ix:nonFraction></ix:nonFraction> impairment loss has been recognized in the years ended December 31, 2020 and 2019.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="ia59db41658d74299ace7f77fd5fd2464" continuedAt="i85106610d15b440f8eead1aaa89702f9"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MTg_9d777e59-a512-4bcf-a419-65794939510d" continuedAt="i10583d49a77843c387f351cbd92d5a45" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. The Company performs an annual impairment assessment, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill. The Company performs impairment tests using a fair value approach when necessary. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously maintained a goodwill balance as a result of a prior acquisition of intangible assets from Equipois, LLC in December 2015 consisting of mechanical balance and support arms technologies, including the rights to the ZeroG product.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i10583d49a77843c387f351cbd92d5a45">As a result of declining sales and gross margin, combined with the overall uncertainty about the future of the ZeroG product line, the Company performed an impairment assessment of goodwill utilizing the simplified method, which resulted in an impairment of goodwill of $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMzI5ODUzNDk1NDg1OQ_8103fbef-20ae-4d15-afab-bff29ddb8b04">189</ix:nonFraction> reducing the goodwill balance to zero. In estimating the fair value, the Company utilized a discounted cash flow model, which is dependent on a number of assumptions, including forecasted revenues and profit margins.</ix:continuation> <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNjU5NzA2OTgxNjYwNA_67205cb6-a6da-449f-9c13-137c8e25af53" continuedAt="iad25f3c1af9d45718de6c79d79052699" escape="true">The following table sets forth the changes to goodwill for the year ended December 31, 2020:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="iad25f3c1af9d45718de6c79d79052699"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:82.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjZlZTA0OTYzODc3ODQ1NzQ5YWZhMTdmZjhmZTFiMWQzL3RhYmxlcmFuZ2U6NmVlMDQ5NjM4Nzc4NDU3NDlhZmExN2ZmOGZlMWIxZDNfMS0xLTEtMS0xNTUx_e864b302-2d64-4324-8431-c35499f6a408">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjZlZTA0OTYzODc3ODQ1NzQ5YWZhMTdmZjhmZTFiMWQzL3RhYmxlcmFuZ2U6NmVlMDQ5NjM4Nzc4NDU3NDlhZmExN2ZmOGZlMWIxZDNfMi0xLTEtMS0yNTk5_97357a3e-3a76-4080-8e41-a5509708f43c">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjZlZTA0OTYzODc3ODQ1NzQ5YWZhMTdmZjhmZTFiMWQzL3RhYmxlcmFuZ2U6NmVlMDQ5NjM4Nzc4NDU3NDlhZmExN2ZmOGZlMWIxZDNfMy0xLTEtMS0xNTUx_2772b294-d3eb-403d-9616-b63f110e2727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="ekso:WarrantPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NTM_4d365010-9b20-4dd4-a354-a7e4c078b5a1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that it may need to settle the warrants in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where there is a possibility that the Company may have to settle warrants in cash, it estimates the fair value of the issued warrants as a liability at each reporting date and record changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants have been determined using the Black-Scholes option-pricing model (the &#8220;Black-Scholes Model&#8221;) and the Binomial Lattice model (the &#8220;Lattice Model&#8221;). The Black-Scholes Model requires inputs, such as the expected volatility, expected term, exercise price, risk-free interest rate, and the value of the underlying security. The Lattice Model provides for assumptions regarding expected volatility, expected term, exercise price, risk-free interest rates, the value of the underlying security, and the probability of and likely timing of a specific event within the period to maturity. These values are subject to a significant degree of the Company&#8217;s judgment. The Company&#8217;s common stock price represents a significant input that affects the valuation of the warrants.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="ekso:GoingConcernPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MDc_e3940851-9f99-4a29-a9e7-fb6d39668d4e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements &#8211; Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NDE_4a5fd3a8-048c-4d78-bc17-707cdbfbd4b5" continuedAt="i9711df0eb88346f9b42cb961dc096da5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i85106610d15b440f8eead1aaa89702f9" continuedAt="ie0bd820fcf224c4ab4438a2aa0b12ff3"><ix:continuation id="i9711df0eb88346f9b42cb961dc096da5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical device segment (EksoHealth) revenue is primarily generated through the sale and rental of the EksoNR and EksoGT, associated software (SmartAssist and VariableAssist), the sale and rental of the EksoUE, the sale of accessories, and the sale of support and maintenance contracts (Ekso Care). Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company&#8217;s facility for sales of the EksoNR or EksoGT, software and accessories. Ekso Care support and maintenance contracts extend coverage beyond the Company&#8217;s standard warranty agreements. The separately priced Ekso Care contracts range from&#160;<ix:nonNumeric contextRef="ibc2375e404df4bee8066cbe643660925_D20200101-20201231" format="ixt-sec:durmonth" name="ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTgxMzU_c60e148d-218f-463b-bf5d-e3a1fb8d536d">12</ix:nonNumeric>&#160;to&#160;<ix:nonNumeric contextRef="i6fdcba7194b1415db1370657080e8199_D20200101-20201231" format="ixt-sec:durmonth" name="ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTgxNDE_1bd9a57a-86e1-4a2c-ab5c-f7b68e127819">48</ix:nonNumeric> months. The Company receives payment at the inception of the contract and recognizes revenue over the term of the agreement. Revenue from medical device rentals is recognized over the rental term, typically <ix:nonNumeric contextRef="ibc2375e404df4bee8066cbe643660925_D20200101-20201231" format="ixt-sec:durmonth" name="ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMzI5ODUzNDk1NDgyNg_f0c49c4c-0082-467f-8d2d-0840b0a42a93">12</ix:nonNumeric> months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s industrial device segment (EksoWorks) revenue is generated through the sale and rental of the upper body exoskeletons (EksoVest and the recently introduced EVO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company&#8217;s facility. Revenue from industrial device rentals is recognized over the rental term, typically 12 months.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="ekso:GovernmentGrantPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MjE_f473efec-769e-4d38-abe7-4b70f7cb5ef8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Grants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for nonreciprocal government grants by applying the contributions received in accordance with guidance in ASC Topic 958-605. To determine if a grant is non-reciprocal or reciprocal and whether the application of ASC 606 is required, the Company considers whether the transfer of resources is one in which commensurate value is exchanged. If commensurate value is not exchanged for the goods or services provided, the Company assesses whether the grant is conditional or unconditional.&#160; Grants that contain both a barrier and right to return are considered conditional and revenue is deferred until such conditions are satisfied. In January 2019, the Company received a government grant from the Singapore Economic Development Board (&#8220;SEDB&#8221;) in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i55263caaaf314901a8c536dda2b3d628_I20190131" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTk1MzY_1fe21faa-89ba-4b45-b434-44650ca29323">1,500</ix:nonFraction>. The receipt of the funds is conditional upon certain operational milestones that must be met and maintained through December 31, 2021. Therefore, the Company has not recognized revenue related to the government grant from the SEBD nor received cash from the SEBD.  The Company expects to recognize revenue related to this grant in 2021.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2ODI_2722ffdf-385a-4533-bfb9-085eb1eb3208" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist of costs incurred for internal research and development activities. These costs primarily include salaries and other personnel-related expenses, contractor fees, legal fees associated with developing and maintaining intellectual property, prototype materials, facility costs, supplies, and depreciation of equipment associated with the design and development of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NTY_915b3e7b-8ec9-4811-99a5-1b1f6d2a9b0c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. Under this method, income tax expense or benefit is recognized for the amount of taxes payable or refundable for the current year and for deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company's consolidated financial statements or tax returns. The Company accounts for any income tax contingencies in accordance with accounting guidance for income taxes. The measurement of current and deferred tax assets and liabilities is based on provisions of currently enacted tax laws. The effects of any future changes in tax laws or rates have not been considered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the preparation of the Company's consolidated financial statements included herein, the Company estimates its income taxes and tax contingencies in each of the tax jurisdictions in which it operates prior to the completion and filing of its tax returns. This process involves estimating actual current tax expense together with assessing temporary differences resulting from differing treatment of items, such as deferred revenue, for tax and accounting purposes. These differences result in net deferred tax assets and liabilities. The Company must then assess the likelihood that the deferred tax assets will be realizable, and to the extent they believe that realizability is not likely, the Company must establish a valuation allowance. In assessing the need for any additional valuation allowance, the Company considers all the evidence available to it, both positive and negative, including historical levels of income, legislative developments, expectations and risks associated with estimates of future taxable income, and ongoing prudent and feasible tax planning strategies.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="ie0bd820fcf224c4ab4438a2aa0b12ff3" continuedAt="i38fbcc411ca84bcb887db37091294431"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2OTM_74fd0d54-a406-4a38-aba6-45cac69c0581" continuedAt="id2b723666bad43b0b22fba58b9a105c4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock-based compensation expense for certain stock-based awards made to employees and directors based on the estimated fair value of the award on the date of grant using the Black-Scholes Model and recognizes the fair value on a straight-line basis over the requisite service periods of the awards. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s determination of the fair value of stock options on the date of grant using the Black-Scholes Model is affected by the Company&#8217;s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company&#8217;s stock price, volatility over the term of the awards, and actual and projected employee stock option exercise behaviors (expected term). Due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the Company adopted the simplified method of estimating the expected term pursuant to SEC Staff Accounting Bulletin Topic 14. On this basis, the Company estimated the expected term of options granted by taking the average of the vesting term and the contractual term of the option.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of restricted stock units (&#8220;RSUs&#8221;) is determined at the date of grant using the Company&#8217;s closing stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. For awards with performance-based conditions, at the point that it becomes probable that the performance conditions will be met, the Company records a cumulative catch-up of the expense from the grant date to the current date, and then amortizes the remainder of the expense over the remaining service period. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id2b723666bad43b0b22fba58b9a105c4">The Company has, from time to time, modified the terms of its stock options to employees. The Company accounts for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification.</ix:continuation>&#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NzA_44f513bb-084f-4f16-846f-1c5a1bdaa1b9" continuedAt="idd7b903a47be484998e2577e669dbcd8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2022 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i38fbcc411ca84bcb887db37091294431"><ix:continuation id="idd7b903a47be484998e2577e669dbcd8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Adopted in 2020</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates the computation of the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will record a goodwill impairment charge based on the excess of a reporting unit&#8217;s carrying amount over its fair value. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company adopted the new guidance as of January 1, 2020, which reduced the complexity surrounding the evaluation of goodwill for impairment. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard modifies the disclosure requirements on fair value measurements in Topic 820 by removing the requirement to disclose the reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The standard expands the disclosure requirements for Level 3 fair value measurement, primarily focused on changes in unrealized gains and losses included in other comprehensive income. The amendments in this update became effective for the Company in the first quarter of 2020. The Company adopted ASU 2018-03 as of January 1, 2020. The adoption of this ASU did not have a material impact on the Company's consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RleHRyZWdpb246YjkwMDRlMTJmNzI3NDA1N2JmNzQ1ZWU0ODU0YWEzMmNfNjk2_6efb1862-4c69-4a4f-aec3-c907e26d86f6" continuedAt="ib172c09649454b3083058a7c2e5b98a3" escape="true">Net Loss Per Share of Common Stock</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib172c09649454b3083058a7c2e5b98a3"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RleHRyZWdpb246YjkwMDRlMTJmNzI3NDA1N2JmNzQ1ZWU0ODU0YWEzMmNfNjg2_020a897d-7b14-4a9b-ab84-1dccb001d1ec" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted average number of shares of common stock, adjusted to include conversion of certain stock options and warrants for common stock and release of common stock in connection with restricted stock units during the period, as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:62.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfNC0xLTEtMS0w_383019d5-2761-4830-b715-a8357741c73f">15,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfNC0zLTEtMS0w_adc2759a-32ff-4c3b-b85a-73574bad9aec">12,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net loss used for dilution calculation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfNi0xLTEtMS0w_c75e7705-b00e-430a-b406-56dad67a8886">15,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfNi0zLTEtMS0w_20f81ac9-81a2-47eb-bde1-e7f91edb82be">12,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfOS0xLTEtMS0w_39b1c99a-2f8d-419c-b927-32ebd2a481df">7,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfOS0zLTEtMS0w_e964b4fc-e7e5-4655-bf47-67678077b3f3">4,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive weighted-average number of shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTEtMS0xLTEtMA_44736574-82a7-4565-8e63-81447ed457ab">7,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTEtMy0xLTEtMA_8759a9e4-6071-44a5-871d-feaa3b47e984">4,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTQtMS0xLTEtMA_da305846-77bd-496d-ad34-55df221c747b">2.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTQtMy0xLTEtMA_785ecd17-3bd7-4567-a1b4-27c53e0a8530">2.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTUtMS0xLTEtMA_05142841-a021-4fc2-8277-b82b982bf3b1">2.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTUtMy0xLTEtMA_a6cc46e7-86c4-43af-89a7-17c932bd6f86">2.53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RleHRyZWdpb246YjkwMDRlMTJmNzI3NDA1N2JmNzQ1ZWU0ODU0YWEzMmNfNjg5_40497b68-1081-4144-90b7-dacee5b17441" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:62.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67594e576125433d9c1e6603131224a3_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfMi0xLTEtMS0w_928df115-fe2a-4143-870f-8b3fed993e29">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibde6413b3f484fbb82f25ef7d5c4d24b_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfMi0zLTEtMS0w_9218cf5d-a490-43ba-a261-892ebae484c5">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c51e051811a48169af92a76d27be60a_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfMy0xLTEtMS0w_f031cdd0-3687-45dc-936f-22fd827dc0ed">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bd0c434eb694450b138a39e7717b97d_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfMy0zLTEtMS0w_7776d8e6-96fe-4457-81f5-0beedf95f67d">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants for common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40711bfb573748f5b097264402445a5e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfNC0xLTEtMS0w_16ad3b0a-1d08-4af2-9e92-17e8ecaa266d">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8fcc63d43e042fb816a4a8bb922bd22_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfNC0zLTEtMS0w_52f7407b-6a9d-4fbd-b851-b016fa9b7e5f">1,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfNS0xLTEtMS0w_e3617710-9d55-4d34-956f-ca4d5157fb56">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfNS0zLTEtMS0w_192e6a60-56e9-44b4-a11a-940900567f10">1,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84OC9mcmFnOjMwMTk1MmRlNjJhOTQxNDg5YzU5YmNhNzU4OTExM2MwL3RleHRyZWdpb246MzAxOTUyZGU2MmE5NDE0ODljNTliY2E3NTg5MTEzYzBfNjU3OA_71e896cc-f11e-48b4-bde0-52b082cce146" continuedAt="i0a06327aadd74319841d6ba73a6d1f88" escape="true">Investment in Unconsolidated Affiliate</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i0a06327aadd74319841d6ba73a6d1f88"><div style="padding-right:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company, Zhejiang Youchuang Venture Capital Investment Co., Ltd and another partner (collectively, the &#8220;JV Partners&#8221;) received notice from the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) in connection with its review of the Company&#8217;s and the JV Partners&#8217; investment in Exoskeleton Intelligent Robotics Co. Limited (the &#8220;China JV&#8221;). The notice stated that CFIUS&#8217;s prior national security concerns regarding the China JV could not be mitigated. In connection with such determination, on July 13, 2020, the Company and the JV Partners entered into a National Security Agreement (&#8220;NSA&#8221;), which, among other things, requires the termination of the Company&#8217;s agreements and role with the China JV. The Company intends to work cooperatively with the JV Partners and CFIUS to implement the terms of the NSA. On August 12, 2020, the Company and the JV Partners agreed to terminate the agreements underlying the China JV. As of December 31, 2020, all agreements related to the China JV had been terminated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the above, during the year ended December 31, 2020, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84OC9mcmFnOjMwMTk1MmRlNjJhOTQxNDg5YzU5YmNhNzU4OTExM2MwL3RleHRyZWdpb246MzAxOTUyZGU2MmE5NDE0ODljNTliY2E3NTg5MTEzYzBfNDk0NzgwMjMzOTQxMA_f46adc45-2621-4a67-8524-56163d9d8700">66</ix:nonFraction> loss on investment in unconsolidated affiliate in the consolidated statements of operations and comprehensive loss related to the write-off of previously recorded direct costs related to establishing the China JV.</span></div></ix:continuation><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RleHRyZWdpb246YmYwYTg1ZjRkYmNjNGI4YThjYTY0MGIzNTgyMTk5MzFfMjMyNQ_79d5cd0a-4138-4f24-ba88-14d18d468245" continuedAt="ibcf5a2c20e864935a6c14b8ff330d378" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ibcf5a2c20e864935a6c14b8ff330d378" continuedAt="ia482fee877cf4f9cadcc84d8f539f62e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RleHRyZWdpb246YmYwYTg1ZjRkYmNjNGI4YThjYTY0MGIzNTgyMTk5MzFfMjMzMw_02c13c34-4e84-4a5e-8184-012c78d62799" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s fair value hierarchies for its financial assets and liabilities which require fair value measurement on a recurring basis are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50bf1458d43243298850ecebb3a893ff_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfMy0xLTEtMS0w_569b7440-28a5-4b83-83a0-9e0caeeb46a5">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bdafc8b87643a8940a27e6b36684f3_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfMy0zLTEtMS0w_02d7bab8-99eb-4dd0-ba46-438c1699bc62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb140a2a8bd1427c8038bc9cc6fc4ddd_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfMy01LTEtMS0w_a2d5c20e-38d1-49c2-982f-566fe65686b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e30bf53c5f4d90befcffe3dcd462ba_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfMy03LTEtMS0w_54ad188c-2ada-442e-a30b-5d2e534f27e8">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a48682c16b4e88b27b2fa322d058d3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOC0xLTEtMS0w_5eb37cd1-6fb5-47ba-9205-683950153db4">4,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i649dad9fb14749e9996c2dc8928958e1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOC0zLTEtMS0w_7dab36f1-b98d-4753-ab6b-a3a31a0ac1c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84a84e7d32604e62861e794eea7d7ca1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOC01LTEtMS0w_0010e944-c987-4c57-9d04-b7ecf273fb82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab6a2c45f8a47ecba7fe4b30e1dda70_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOC03LTEtMS0w_2977e45c-3109-43ea-8889-dc73f9207b20">4,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent success fee liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a48682c16b4e88b27b2fa322d058d3_I20191231" decimals="-3" name="ekso:ContingentSuccessFeeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOS0xLTEtMS0w_98ae85b4-3c02-479e-a725-6741f7591d3b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i649dad9fb14749e9996c2dc8928958e1_I20191231" decimals="-3" format="ixt:zerodash" name="ekso:ContingentSuccessFeeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOS0zLTEtMS0w_1e518a50-71fd-4634-9f75-9ac1a3c199ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84a84e7d32604e62861e794eea7d7ca1_I20191231" decimals="-3" format="ixt:zerodash" name="ekso:ContingentSuccessFeeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOS01LTEtMS0w_255eed5f-6c24-4583-a38c-fa38152efe4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab6a2c45f8a47ecba7fe4b30e1dda70_I20191231" decimals="-3" name="ekso:ContingentSuccessFeeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOS03LTEtMS0w_e39ed620-be88-4fae-8dad-f2295302e2b8">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020 and 2019, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and the valuation techniques used did not change compared to the Company&#8217;s established practice.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="ia482fee877cf4f9cadcc84d8f539f62e"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RleHRyZWdpb246YmYwYTg1ZjRkYmNjNGI4YThjYTY0MGIzNTgyMTk5MzFfMjMyOA_336c9964-6d78-4fb2-a32b-221cb33f7131" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of Company&#8217;s Level 3 financial liabilities during the year ended December 31, 2020,&#160;which were measured at fair value on a recurring basis:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:68.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant<br/>Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent<br/>Success&#160;Fee<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9396d4559e45441f873fc24b5a39358d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfMS0xLTEtMS0w_d3185aef-a6da-477a-9211-473eee0ded61">4,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411cf8f5b27a4e37a9f9854d5abc3f48_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfMS0zLTEtMS0w_38b12ece-b9fd-4112-8fea-5569a3afd8ac">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial fair value of warrants in connection with June 2020 financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfMi0xLTEtMS0w_ff014dee-bac3-4310-bbbc-106aaf4d171f">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42740a38dd614cefb84f83af69916e8d_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfMi0zLTEtMS0w_44f2c1dd-85dc-4f97-aeb4-ada7ef6b7d56">0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of warrants issued in June 2020, December 2019, May 2019 financing, and December 2015 equity financings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ekso:GainLossOnWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNC0xLTEtMS0w_9b41725e-7c3e-49fd-8a46-e1020e844dd2">3,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42740a38dd614cefb84f83af69916e8d_D20200101-20201231" decimals="-3" name="ekso:GainLossOnWarrantLiability" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNC0zLTEtMS0w_05d244d8-9e73-4ae5-b105-b7a774ca719b">0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liability to equity upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNS0xLTEtMS0w_3aeee738-d9bd-4651-a094-7935711c13fb">3,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42740a38dd614cefb84f83af69916e8d_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNS0zLTEtMS0w_c7deedeb-47ed-4f10-a9a3-a377818a3050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on revaluation of contingent liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNi0xLTEtMS0w_dab7fe14-4f36-4aa7-9a31-67018563b22a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42740a38dd614cefb84f83af69916e8d_D20200101-20201231" decimals="-3" name="ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNi0zLTEtMS0w_bb7ac942-fc58-49ed-9e81-498b4ac8bd46">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0440a5ac3cb444bf8c87c1ca6ea5f57a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNy0xLTEtMS0w_418a828e-db81-428f-bc94-2c159fa255c7">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2871a384ac049ccbda9e8abc03f027c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNy0zLTEtMS0w_c559e316-dc65-4bac-b95e-1e2dd8318646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13 in the notes to consolidated financial statements under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalization and Equity Structure &#8211; Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a description of the warrants accounted for as a liability, including the method and inputs used to estimate their fair value.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzg3NA_40af4978-1237-429f-801e-d5611f8933f6" continuedAt="i612f0d6df55d4cba8ee85f6ca938a4de" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i612f0d6df55d4cba8ee85f6ca938a4de" continuedAt="i8a5cb47e454b42fb824bdba5d7f9deba"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the following five steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not directly observable, the Company estimates the selling price based on market conditions and entity-specific factors including features and functionality of the product and/or services, the geography of the Company&#8217;s customers, type of the Company&#8217;s markets. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Timing of revenue recognition may differ from the timing of invoicing to customers and receipt of payment. For the sale of its products, the Company generally recognizes revenue at a point in time through the ship-and-bill performance obligations. For the rental of its products, the Company generally recognizes revenue over the rental term commencing upon the completion of customer training.  For service agreements, the Company generally invoices customers at the beginning of the coverage period and records revenue related to the billed amounts over time, equivalent to the coverage period of the maintenance and support contract.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts (Ekso Care), but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i8a5cb47e454b42fb824bdba5d7f9deba" continuedAt="if677981aea0d436992a91dbcea8cfd94"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzg4Mg_cbdd93f5-6dd3-4c56-a52d-9cc8135ff21a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred extended maintenance and support</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ekso:DeferredExtendedMaintenanceAndSupport" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMS0xLTEtMS0w_082a1fc3-d1a5-436f-80a7-1e13635d903f">2,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ekso:DeferredExtendedMaintenanceAndSupport" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMS0zLTEtMS0w_6a72cc71-816c-4a15-ace5-9745023b2d5a">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="ekso:DeferredRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMi0xLTEtMS0w_ff084765-42ee-4786-8279-b9af112b851d">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="ekso:DeferredRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMi0zLTEtMS0w_ab2dba7b-1709-4b31-a400-75ad873bf658">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred device, rental revenues and advances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="ekso:DeferredDeviceRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMy0xLTEtMS0w_f543715d-37b4-4273-b188-09d2b54e9870">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="ekso:DeferredDeviceRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMy0zLTEtMS0w_bf979378-04b8-414c-bcb5-d7a50f46cd06">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfNi0xLTEtMS0w_63fee3c2-6b51-417f-85b8-3ff641071bb4">3,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfNi0zLTEtMS0w_508dde89-05f7-4acd-adb2-5e4789cd08f0">3,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfNy0xLTEtMS0w_8ea3f63f-c517-4af0-9ca8-3db038ad1fa2">1,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfNy0zLTEtMS0w_ddb6f955-3b65-4eca-9792-5a5f86b07653">1,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues, non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfOC0xLTEtMS0w_33ea7eb0-446d-44e3-b65d-37617de9df2d">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfOC0zLTEtMS0w_1fc6e116-1fbf-4920-985f-4141d57cb18c">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue activity consisted of the following for the year ended December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjdkNTYxNjcxOWEzODQ4NmQ5ZmM3MmIwNTY5YjczNDM2L3RhYmxlcmFuZ2U6N2Q1NjE2NzE5YTM4NDg2ZDlmYzcyYjA1NjliNzM0MzZfMC0xLTEtMS0w_30f6976b-4ad1-4a87-9f92-b441be4ee4f2">3,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferral of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ekso:ContractWithCustomerLiabilityDeferralOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjdkNTYxNjcxOWEzODQ4NmQ5ZmM3MmIwNTY5YjczNDM2L3RhYmxlcmFuZ2U6N2Q1NjE2NzE5YTM4NDg2ZDlmYzcyYjA1NjliNzM0MzZfMS0xLTEtMS0w_d0f2faac-a2d4-4234-bf98-a9350371544f">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjdkNTYxNjcxOWEzODQ4NmQ5ZmM3MmIwNTY5YjczNDM2L3RhYmxlcmFuZ2U6N2Q1NjE2NzE5YTM4NDg2ZDlmYzcyYjA1NjliNzM0MzZfMi0xLTEtMS0w_1a0cf02c-9fa2-434d-aca5-15bfc99795db">1,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjdkNTYxNjcxOWEzODQ4NmQ5ZmM3MmIwNTY5YjczNDM2L3RhYmxlcmFuZ2U6N2Q1NjE2NzE5YTM4NDg2ZDlmYzcyYjA1NjliNzM0MzZfMy0xLTEtMS0w_4b1797d6-3bec-450b-b9ad-8c859ad17d12">3,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company&#8217;s deferred revenue was&#160;$<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMjY2Mg_277a4b54-ad10-4eed-8197-0b9034eb6af7">3,302</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company expects to recognize approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i63834f56293d4e708f774c76a532f46f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMjc0Mg_e97be50a-7667-4be1-9606-da1de15b6a00">1,496</ix:nonFraction>&#160;of the deferred revenue during&#160;2021,&#160;$<ix:nonFraction unitRef="usd" contextRef="i3036960b630e4dc68acd1c3ce4478d07_I20201231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMjc4MA_de72f2a6-5548-41fa-8715-108938b5b093">908</ix:nonFraction>&#160;in&#160;2022, and&#160;$<ix:nonFraction unitRef="usd" contextRef="i1189ad224a9542f99ef6b9177be8258c_I20201231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMjc5NA_b989ce52-53b4-4ed8-a19b-8913e7db806a">898</ix:nonFraction> thereafter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to deferred revenue, the Company has non-cancellable backlog of $<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="ekso:ContractwithCustomerLiabilityNonCancellableBacklog" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMjg4OA_f021633a-4c7c-446e-9c03-23c29e8a4a6a">515</ix:nonFraction>&#160;related to its contracts for rental units with its customers. These rental contracts typically have <ix:nonNumeric contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" format="ixt-sec:durmonth" name="us-gaap:LessorOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzg0ODI5MDcwMTU0OA_0a905909-b824-4ddb-b3ba-b0a82fffa9cc">12</ix:nonNumeric>-month lease terms and rental income is recognized on a straight-line basis over the lease term.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, accounts receivable, net of allowance for doubtful accounts, were $<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzEzNA_87aae2a8-c0ec-420e-89d1-4d557594bcf1">3,389</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzE0MQ_9a124a3a-d835-4142-a221-e02b87efa0d6">5,208</ix:nonFraction>, respectively, and are included in current assets on the Company&#8217;s consolidated balance sheets. The allowance for doubtful accounts reflects the Company&#8217;s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within <ix:nonNumeric contextRef="id643b591bbe442ff89d7f6fedbd8777a_D20200101-20201231" format="ixt-sec:durday" name="ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzYzMA_e9947f89-3171-493b-b130-db1cb3cd7019">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i81b4652764f7496fae43691e5665e11e_D20200101-20201231" format="ixt-sec:durday" name="ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzYzNg_a1fb4866-1444-495c-98bb-6000a66bb29b">90</ix:nonNumeric> days.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzg3MQ_9d0470bd-4d77-49cb-9c25-1a8fe5bd027a" continuedAt="i9bc3192a07454310a1ac55575d224891" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company&#8217;s revenue by major source for the year ended December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:35.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoHealth</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoWorks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8795be88184c80b93b87063b29336c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMS0xLTEtMS0w_7f132c05-f0a1-4738-8120-8e1a556b6b62">5,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d78b1f57364d88a58dd74bda2ee22e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMS0zLTEtMS0w_d9f72d45-15f2-4e13-b376-2b8ea486d7d1">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a856fa0deb4f4bbebb18b45f3772fe_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMS01LTEtMS0w_d84f6af7-4533-47cd-bda4-ab9dcae2063e">5,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b6f83daf3c4c15b23e671334f13579_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMi0xLTEtMS0w_0759d28c-9940-446d-ae9b-4bf7c6fb7d58">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i889b78375c774b5687a5747a1b43cb23_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMi0zLTEtMS0w_e7288587-b1a4-4504-8f12-998dd0141141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c6f90a20b044e3acc886642e9c1309_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMi01LTEtMS0w_9886f2c7-f2c4-4a88-8a9a-26d1689bd3e0">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38da83df0b94a2b83b0d1f8a9f1dc30_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy0xLTEtMS0yOTUx_ab5776e5-8db6-4061-9b35-7ca73c2d66be">782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e574a2fabc1499f884fcd1b5951b4e7_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy0zLTEtMS0yOTUx_01ff501d-f1eb-4bbd-9dfd-ae3704980ee3">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i033d5839f04849bfb1ee07ea7dc6b0f4_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy01LTEtMS0zMTEz_a243872f-7152-40e5-9a0f-9d5783891873">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd34bb1047b430b85a6b141bc79a7c9_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy0xLTEtMS0w_1a6b9078-71cb-44dc-a501-933bfaec3883">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia43ebf9f36cf41eba45fa05244dc8ac4_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy0zLTEtMS0w_26f3df6e-f624-4ce4-86b2-f132612cbd2a">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i322cf066e9f44f9cbb3ec118a91e904c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy01LTEtMS0w_7943710f-0862-4327-8d7a-620912c55e8b">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8235348a80e487c9f3e8030b4d8ce9a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNC0xLTEtMS0w_82eba04f-ba95-493d-bac4-602ace196fb5">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3162a8935b1c4ff380fbdae542396c82_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNC0zLTEtMS0w_2031e06a-2b46-4e6a-8b61-68b5ddfacaac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14005e4eb1146e986a9ef76f055084d_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNC01LTEtMS0w_72c73446-82f0-4864-9c4a-4ba258508d11">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib881b817aa7445709d8070f5fe391132_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNS0xLTEtMS0w_15829b8b-a5e8-4cd2-9ae4-d1a37d0f0a10">8,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a7edc5f16340378382788c4c0dc691_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNS0zLTEtMS0w_b1567f0a-8614-4a7e-a768-2bb87557ea64">816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNS01LTEtMS0w_d0dea0f2-7777-4405-97f0-b9fcdbe5de9e">8,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="if677981aea0d436992a91dbcea8cfd94"><ix:continuation id="i9bc3192a07454310a1ac55575d224891"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company&#8217;s revenue by major source for the year ended December 31, 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:35.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoHealth</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoWorks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27aec484daea4c1dbfd941c2654431bb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMS0xLTEtMS0w_5f4e419b-b361-43db-a9e8-58aeec28402a">9,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26d674e4b5d49679bf4f50fdb4b6c18_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMS0zLTEtMS0w_53a3d216-4b4c-4aab-a476-826910262015">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95975cc540d54a198ad22e25ed0dcb73_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMS01LTEtMS0w_d0a94322-3d1b-4668-ba44-cc9f100f74bf">10,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5078e9375e6b4702909ac2925b30c4bc_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMi0xLTEtMS0w_f4592a6c-1e2e-4077-9fb3-35ea8e6454f7">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f73b9d15a3b46ef9fe037af79d4534d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMi0zLTEtMS0w_b770b406-7711-469e-862b-bfacf3806987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e152e2c14f448a681c80c12f29fa109_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMi01LTEtMS0w_c0e190c5-1214-45a0-8525-aebce4a59ada">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6c52ce74dc42cc9138e832cd3dd672_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy0xLTEtMS0yOTY1_bef47798-43dc-40c9-9c62-9b7da69fd3ac">913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1098ca438a48cd9e106e5843d6cd36_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy0zLTEtMS0yOTY1_9c2803bf-b022-44fb-b1d6-725d14e8f3b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6d3ffd252aa43aa8bf3e178360945c2_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy01LTEtMS0zMTE1_5caa8a44-a197-4357-ab55-2e8d6ae91b31">913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28c029fe6658433091f9348fc9d54912_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy0xLTEtMS0w_0cb4665d-e392-4f4f-9bab-3f51f5f43df6">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f6ebc39e4f40b78d40104fb7855d08_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy0zLTEtMS0w_28c7e021-7fe6-4c3a-a080-01ec9ef439ba">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f7abf2a1ea34998ba75e15db09892c4_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy01LTEtMS0w_dda063eb-f53d-4a2d-abf2-e752e9c471a3">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2cedde1fd8d4e13817c08df4f3817d1_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNC0xLTEtMS0w_106f23c9-2f0e-4e5a-b475-80a825eb8fbf">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ed2b595380454aa4357b1f8bbc92f8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNC0zLTEtMS0w_d2204d0c-1d14-43ba-bc3d-923d5f5dc972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41bb0fad4e647a688e43967bb0bb7be_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNC01LTEtMS0w_7916db0a-c099-4915-85fd-4fa207419c4a">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb99287795245cead94469bb0004c47_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNS0xLTEtMS0w_9b6389bc-4b77-4f75-87aa-52eca0f67a08">11,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015e0abf22814adbb2132f59a1724e19_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNS0zLTEtMS0w_4bf05e00-3869-4112-9337-79bf67bea512">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNS01LTEtMS0w_ed0f88a6-6403-4bef-a6b1-f134193f9845">13,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90ZXh0cmVnaW9uOjI3NTE0MTM0ODkyMTQ0MGFiZDIwNTI0NzBjODc2Y2FjXzIzMw_bfd77f8e-f313-4bfb-8c26-18ebf5798835" continuedAt="i3d9a28b65f16435193b27584503b49a6" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3d9a28b65f16435193b27584503b49a6"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90ZXh0cmVnaW9uOjI3NTE0MTM0ODkyMTQ0MGFiZDIwNTI0NzBjODc2Y2FjXzIyOQ_09059d90-1637-4c42-8df2-b4b4f8600f2d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company-owned fleet</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f70fd4ec65c4972b421c5aa5b36941b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzItMS0xLTEtMC90ZXh0cmVnaW9uOjgwZmM0NjJkYjMxMDQ2ODk4YTllNDAzNTRmM2E2ODUzXzM4NDgyOTA2OTcyMjQ_4593408e-e32c-4924-b7e1-642deda25740">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i660e36a98e0746cf8a42c3b13e52a56b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzItMS0xLTEtMC90ZXh0cmVnaW9uOjgwZmM0NjJkYjMxMDQ2ODk4YTllNDAzNTRmM2E2ODUzXzM4NDgyOTA2OTcyMjg_6c48a665-2781-4fcf-966d-13fdd7173ccc">4</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id479e8c373654ebbb87b0a250bcc1e8c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzItMy0xLTEtMA_ecd0cc31-fc2b-4fb9-9775-72dee03b24e2">3,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd0c5c2bb3c4768abec83b24e2a64d3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzItNS0xLTEtMA_29595bda-c449-4295-ba6c-8eff31ef176b">3,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f923f15e82d409bac227a17e3701888_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjM3NzE4MzA2NmZmNjQwNGM4MDU2Y2I2YjdhZjcwY2RmXzM4NDgyOTA2OTcyMjQ_cc343b0a-ff95-48b8-92d0-8b69cd11693f">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i3d2e914eb0a5485b9d8820fc1baacc8d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjM3NzE4MzA2NmZmNjQwNGM4MDU2Y2I2YjdhZjcwY2RmXzM4NDgyOTA2OTcyMjc_e83587bd-8f60-402f-a85b-d3afb259f6cb">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658969b097ae4314a93b0abea1d13868_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzMtMy0xLTEtMA_564ddd53-bcda-468e-9c8e-ce936ad59338">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763c0e7c9c9d44dcb6a9636b86af9d12_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzMtNS0xLTEtMA_57237fc8-9bf6-4a86-a85f-fecce3b12002">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i130b8496b8734097b3481b467f0807f8_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjljNjI0YzI5ODIwNzRjYzg5M2Q0ZDEyNTlmZTM2ZTQ0XzM4NDgyOTA2OTcyMjU_0c567219-c96a-4aa7-8523-c3e937619431">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i03553d669ad34441ba31a9b58507f565_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjljNjI0YzI5ODIwNzRjYzg5M2Q0ZDEyNTlmZTM2ZTQ0XzM4NDgyOTA2OTcyMjk_1f95921e-577a-4903-8a3d-5b07a8231872">10</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54e4f7da48f45918ff0109be65c5330_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzQtMy0xLTEtMA_e0d28394-f470-4f9e-9bba-5a181e7fd1c8">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abecebb024344bea34c7c37ce810974_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzQtNS0xLTEtMA_4299b1f6-1109-4e6c-a8a1-6a6647168c22">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, office and leased equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ec4203661dc40138fda63b48b530a85_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjJhY2I4OTBmOTdlYjQ5ZjVhYTJiMjQwNzNhY2U2OTEyXzM4NDgyOTA2OTcyMjQ_b81b5032-1b7e-40f1-8ca4-028ec533e381">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i049203243d424699b4e0dd6029b0888a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjJhY2I4OTBmOTdlYjQ5ZjVhYTJiMjQwNzNhY2U2OTEyXzM4NDgyOTA2OTcyMjc_4c4922d0-824e-4c13-8cda-3c59eb3d9910">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165ec35cb06746f8ab56f69fe0d5c964_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzUtMy0xLTEtMA_e810fed8-f059-4034-b428-0bedb6de0d57">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f933f335564a9fac29ff916331aa4e_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzUtNS0xLTEtMA_f5a2df08-1a39-4f6c-acae-e2380d1cda2d">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d35bea06791470faea4c0d59dbb1e5a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzYtMS0xLTEtMC90ZXh0cmVnaW9uOmE0ZDQ3NTJjZjhjMDQzYjI4YWI4M2I0ZDdmNWFjNzk1XzM4NDgyOTA2OTcyMjQ_45c33203-4917-47df-ad0a-af97bb8da8ad">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i2005fc6b0f7943b3ba42ed850a5c303e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzYtMS0xLTEtMC90ZXh0cmVnaW9uOmE0ZDQ3NTJjZjhjMDQzYjI4YWI4M2I0ZDdmNWFjNzk1XzM4NDgyOTA2OTcyMjc_c28d481e-cc90-4723-ae51-f28399042a81">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9feb071f8b40bfbfab0e7da695b5dd_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzYtMy0xLTEtMA_ba7e0e69-5f8c-4cbc-b828-f090b60bea03">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd9eb144ecd423dade80dac3f927d7c_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzYtNS0xLTEtMA_5c7a04f7-5bc2-453d-9c1f-b7f21af222a7">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tools, molds, dies and jigs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i56395207f3fa42a797c5ba80cfdfc6b8_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzctMS0xLTEtMC90ZXh0cmVnaW9uOmZiMTY2MTQ4ZGJhNzQzNjliN2ZhMmRjMDYyZDE0Zjk3XzM4NDgyOTA2OTcyMjI_2d30487a-c0f9-4669-aad1-4684ff06ac0c">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18e0975d5f84534ac0b1db267f24d9b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzctMy0xLTEtMA_fee51f66-9384-408c-9e20-f174a169f82f">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d7b8be94cd47d2b55ddb60df657ed4_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzctNS0xLTEtMA_f255ad44-bb4b-43f9-84ad-3734f6eb3e70">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and peripherals</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09b4c0d4a24e49a0a8ffd3a7005294c4_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzgtMS0xLTEtMC90ZXh0cmVnaW9uOjg1N2RlZGUwNGI2ZDRlZDQ4NjExZjY4OTBiZjdhYTNlXzM4NDgyOTA2OTcyMjQ_0fb67738-7a68-4021-99f5-817f85430b02">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i27ca24a6e01a4c5e818349f32894630b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzgtMS0xLTEtMC90ZXh0cmVnaW9uOjg1N2RlZGUwNGI2ZDRlZDQ4NjExZjY4OTBiZjdhYTNlXzM4NDgyOTA2OTcyMjc_7572353a-c7f7-4e20-af2e-e3a86135a9b1">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac816c78ecee495db3e143bd5054df3a_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzgtMy0xLTEtMA_d5f74204-e841-4765-a0a7-bda63e6bc21e">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a91e8c1fb344769e0f47516a30046c_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzgtNS0xLTEtMA_6c951f07-7ff2-44c1-9ff9-594e9206e010">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzktMy0xLTEtMA_11521650-5187-4aba-84ed-ba3b98b66e15">5,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzktNS0xLTEtMA_d77bcf36-8834-4e8a-a680-1210d269ef33">5,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzEwLTMtMS0xLTA_6a173559-7579-4917-88a8-48dd115a4cb1">4,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzEwLTUtMS0xLTA_b21cb91b-7792-42cb-b8c9-c718b19901fd">4,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzExLTMtMS0xLTA_b5fb0d59-1cc2-4d49-9f78-3b9728816866">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzExLTUtMS0xLTA_fe713a99-3554-47a0-bb66-eed6528ec5d6">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense of property and equipment, net totaled $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90ZXh0cmVnaW9uOjI3NTE0MTM0ODkyMTQ0MGFiZDIwNTI0NzBjODc2Y2FjXzE3NA_520da64f-dd8a-4501-9684-29394193d7e6">620</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90ZXh0cmVnaW9uOjI3NTE0MTM0ODkyMTQ0MGFiZDIwNTI0NzBjODc2Y2FjXzE4MQ_d53a5ae6-84ea-47aa-b8f7-badab7119424">690</ix:nonFraction> for the years ended December 31, 2020 and 2019, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90ZXh0cmVnaW9uOjI1NjA3NTU5MDBmMDQzMWFiNzk1OWYwMTI4MjM3ZGRjXzExNDM_16816a8c-a3db-4df0-af0a-041084b0877a" continuedAt="ic8d9d1634e544682ab53182a2068d45f" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic8d9d1634e544682ab53182a2068d45f" continuedAt="i94cd643d4b164db89413e0f697e65809"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90ZXh0cmVnaW9uOjI1NjA3NTU5MDBmMDQzMWFiNzk1OWYwMTI4MjM3ZGRjXzExNDY_341991d1-1683-4e8d-aa0e-7af9befbb350" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzItMS0xLTEtMA_70e32b79-0d4e-4fc3-8934-1a5ff83f3d3a">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzItMy0xLTEtMA_029edc62-1bb3-409d-9b06-d464c9aceacc">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzMtMS0xLTEtMA_bb9cb3ce-0e0b-4840-bb9a-071aff066658">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzMtMy0xLTEtMA_f138427b-bc3f-4f1a-88fc-fe7b60481c33">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="ekso:AccruedClinicalCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzQtMS0xLTEtMA_82667039-4894-4459-91b7-fec7b26d7d7c">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="ekso:AccruedClinicalCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzQtMy0xLTEtMA_c41ec4bf-c4e9-4cad-b31d-8050d0fa524e">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzgtMS0xLTEtMA_7bda3e64-07bd-4514-8667-2659dc0914d6">1,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzgtMy0xLTEtMA_3c6d2712-5738-409b-a6d4-b83c9928131e">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warranty</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:StandardProductWarrantyDescription" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90ZXh0cmVnaW9uOjI1NjA3NTU5MDBmMDQzMWFiNzk1OWYwMTI4MjM3ZGRjXzMyOTg1MzQ4ODQ1Mjg_8f165068-93cb-4f4a-b744-5b9f70b3d12c">Sales of devices generally include an initial warranty for parts and services for one year in the Americas, two years in Europe, the Middle East, Africa, and one or two years in the Asia Pacific region.</ix:nonNumeric>  A liability for the estimated cost of product warranty is established at the time revenue is recognized based on the historical experience of known product failure rates and expected material and labor costs to provide warranty services. Specific additional warranty accruals may be made if unforeseen technical problems arise. Alternatively, if estimates are determined to be greater than the actual amounts necessary, a portion of the liability may be reversed in future periods.&#160;Warranty costs are reflected in the consolidated statements of operations and comprehensive loss as a component of costs of revenue. The current portion of the warranty liability is classified as a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i94cd643d4b164db89413e0f697e65809"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of accrued liabilities, while the long-term portion of the warranty liability is classified as a component of other non-current liabilities in the consolidated balance sheets.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="ekso:ProductMaintenanceAndWarrantyTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90ZXh0cmVnaW9uOjI1NjA3NTU5MDBmMDQzMWFiNzk1OWYwMTI4MjM3ZGRjXzExNDA_6dc6a87d-aee2-4c51-b6e6-ab48ca1c542c" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.544%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warranty</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231" decimals="-3" name="ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzItMS0xLTEtMA_0d823766-6000-46a7-b789-6b52bd61661a">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e076985ae14c239cf28cb82308d69e_I20181231" decimals="-3" name="ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzItMy0xLTEtMA_d3a7bfc9-5d46-4104-9c7c-28a4e05213ea">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for estimated future expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663e54f1b87347028c8829a7b346f7be_D20200101-20201231" decimals="-3" name="ekso:ProductMaintenanceWarrantyAddition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzMtMS0xLTEtMA_f925e301-c674-47ec-add1-0a98acafdbb8">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc8ff9bb9094f2ca094767c70c3d73f_D20190101-20191231" decimals="-3" name="ekso:ProductMaintenanceWarrantyAddition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzMtMy0xLTEtMA_76918272-6396-4242-9f26-f0c2864b6b14">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i663e54f1b87347028c8829a7b346f7be_D20200101-20201231" decimals="-3" name="ekso:ProductMaintenanceWarrantyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzQtMS0xLTEtMA_9a496cd0-3868-4e9d-88b4-1e7c58a5d46c">343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccc8ff9bb9094f2ca094767c70c3d73f_D20190101-20191231" decimals="-3" name="ekso:ProductMaintenanceWarrantyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzQtMy0xLTEtMA_50738ea1-287a-4ef3-9233-6ff4224595d0">385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2406d983ae408d82890348c4593fe2_I20201231" decimals="-3" name="ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzUtMS0xLTEtMA_13939482-c80e-4185-843a-fe43f5e14b2f">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231" decimals="-3" name="ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzUtMy0xLTEtMA_86cd3b68-7694-4475-87b9-e0d6c75c87aa">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2406d983ae408d82890348c4593fe2_I20201231" decimals="-3" name="ekso:ProductMaintenanceWarrantyLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzctMS0xLTEtMA_1514ffa2-b5f7-41ef-afce-713ada91e934">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231" decimals="-3" name="ekso:ProductMaintenanceWarrantyLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzctMy0xLTEtMA_a3230c97-5dcc-4582-8c45-1308bbcc61d5">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2406d983ae408d82890348c4593fe2_I20201231" decimals="-3" name="ekso:ProductMaintenanceWarrantyLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzgtMS0xLTEtMA_95cb0f82-7951-4a12-b8ea-dc7fcf9dd24e">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231" decimals="-3" name="ekso:ProductMaintenanceWarrantyLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzgtMy0xLTEtMA_2d5c9218-8cec-409b-b72a-7ae80d87e9c2">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2406d983ae408d82890348c4593fe2_I20201231" decimals="-3" name="ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzktMS0xLTEtMA_1a59588c-56e8-4a73-bc4e-9a8e810f712e">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231" decimals="-3" name="ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzktMy0xLTEtMA_b15964a0-4a6e-47a2-ba34-1651fa69e117">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzQwMjA_f696d2e5-1292-4e3c-9267-aa25bfd6f36d" continuedAt="i5308a030da614ddc83b521d609787299" escape="true">Notes payable, net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5308a030da614ddc83b521d609787299" continuedAt="i698cef49e0804f69b0b68d46d08f8813"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WAB and PWB Term Loans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WAB Term Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company entered into a loan agreement with Western Alliance Bank ("WAB loan") and received a loan in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="i7b6df24c948e48979ba8b93b03bc8282_I20161231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzk3_be2f2f00-da7c-407d-9fa1-19232f61185d">7,000</ix:nonFraction> that&#160;bore interest on the outstanding daily balance at a floating per annum rate equal to the 30-day U.S. LIBOR plus <ix:nonFraction unitRef="number" contextRef="ia26aaae57e1a4c82bb8d24f30b52abe8_D20161201-20161231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzIxOA_fe540437-050c-4a30-aa80-1ed0905ce229">5.41</ix:nonFraction>%. The Company was required to pay accrued interest on the WAB loan on the first day of each month through and including January 1, 2018. Commencing on February 1, 2018, the Company was required to make equal monthly payments of principal, together with accrued and unpaid interest maturing on January 1, 2021. On April 29, 2020 the Company entered into a second amendment to the December 2016 WAB loan agreement to defer principal payments for <ix:nonNumeric contextRef="i75e32a08cd3c442a9b9ba9304b50179b_D20200429-20200429" format="ixt-sec:durwordsen" name="ekso:DebtInstrumentDeferralPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk1NDg_87f3850d-d727-4b14-a142-c4be4ce55a50">three months</ix:nonNumeric> beginning in May 2020, with adjustments when the principal payments resumed on August 1, 2020. During the three-month deferral period the Company was required to make interest only payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final payment fee, debt issuance costs, and the initial fair value of the success fee combined with the stated interest resulted in an effective interest rate for the WAB loan of <ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzQ5NDc4MDIzMzE1Mjg_69d1e36a-281c-4ec8-8869-838ae05e4f36">8.49</ix:nonFraction>% for the year ended December 31, 2020. The final payment fee, initial fair value of the success fee, and debt issuance costs were accreted/amortized to interest expense using the effective interest method over the life of the loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PWB Term Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into a new loan agreement (the "PWB Loan Agreement") with a different lender, Pacific Western Bank, and received a loan in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="i820fe364817646f793de1bd99129025e_I20200831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk1NzE_080b37dd-3ce9-414f-bd7b-86138a491105">2,000</ix:nonFraction> (the "PWB Term Loan") that bears interest on the outstanding daily balance at a rate equal to the greater of: (a) <ix:nonFraction unitRef="number" contextRef="i414af477b5eb412594fd4faab7f47ca1_D20200801-20200830" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk1Nzk_f23f29cd-b37b-44c9-aad1-ce53a96fcc6c">0.50</ix:nonFraction>% above the variable rate of interest announced by the lender as its &#8220;prime rate&#8221; then in effect; or (b) <ix:nonFraction unitRef="number" contextRef="i820fe364817646f793de1bd99129025e_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk1ODU_a3339108-9557-4453-8b35-871da4c72d98">4.50</ix:nonFraction>%. The PWB Loan Agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the PWB Term Loan were used to pay off the entire amount of the Company's indebtedness on the WAB loan which amounted to $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk1OTY_ad9a7b0b-d1f3-4f2b-bf94-22bb58e9974c">1,512</ix:nonFraction>. Pursuant to the PWB Loan Agreement, the remainder of the PWB Term Loan proceeds may be used for general corporate purposes which totaled $<ix:nonFraction unitRef="usd" contextRef="ic845df26b7574c9688eaf63d2b286340_I20201231" decimals="-3" name="ekso:LineOfCreditFacilityCapacityAvailableForSpecificPurpose" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk2MDQ_5a7d98f1-3a59-4d39-9772-e34324035a37">480</ix:nonFraction>, net of debt discounts and issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay accrued interest on the current loan on the 13th day of each month through and including August 13, 2023. The principal balance of the PWB Term Loan matures on August 13, 2023, at which time all unpaid principal and accrued and unpaid interest shall be due and payable in full. The interest rate of the PWB Term Loan is subject to increase in the event of late payments and after occurrence of and during the continuation of an event of default. Upon maturity, all unpaid principal and accrued and unpaid interest shall be due and payable in full. The Company may elect to prepay the PWB Term Loan at any time, in whole or in part, without penalty or premium.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i698cef49e0804f69b0b68d46d08f8813" continuedAt="ibd7eb5c1de1d48cfa5cc501d8c2d70f6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $<ix:nonFraction unitRef="usd" contextRef="ic845df26b7574c9688eaf63d2b286340_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk2MTA_b7f10f4c-0437-4525-b56d-384f9d3306ef">2,000</ix:nonFraction> as of December 31, 2020. On December 31, 2020, with cash on hand of $<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzQ5NDc4MDIzMzQyNjA_cee3d033-eb4b-4330-a554-fc4d6706678f">12,862</ix:nonFraction>, the Company was compliant with this liquidity covenant and all other covenants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of <ix:nonFraction unitRef="number" contextRef="i5f6e46cb0a00471f82de8d8582d4cbe4_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzQ5NDc4MDIzNDcyMjU_eb597e63-6242-4ac9-bfb1-2dc52a8830ae">4.64</ix:nonFraction>% for the year ended December 31, 2020. The debt issuance costs will be amortized to interest expense using the effective interest method over the life of the loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzQwMjI_81720038-5624-4d2a-a863-68e3206a76f9" continuedAt="i7255e4493164444882c38fbbb691047b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents scheduled principal payments of the Company's note payable as of December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:87.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 - 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:zerodash" name="ekso:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzEtMS0xLTEtMA_e0346f97-0118-4ede-b699-bb4bd214f2b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzItMS0xLTEtMA_60f51d83-df3b-4d7d-9167-f0717c49bf15">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzMtMS0xLTEtMA_5588d336-83b9-43f1-9a6f-0c7f8193809f">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less final payment fee, discount and issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzQtMS0xLTEtMA_de3a0a71-0bd5-46f6-861e-82f5da45603c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzUtMS0xLTEtMA_40fe3a08-23e9-4cb1-a8de-766b3d371239">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzctMS0xLTEtMA_abadc16d-a40b-4c25-9001-a808ce9d671e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzgtMS0xLTEtMA_63b860d2-0e9c-436d-ac85-63e46defc888">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzktMS0xLTEtMA_8771a292-a673-414b-9b11-e2d4e77b2370">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program Loan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 20, 2020, the Company received an unsecured loan in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="ied25b6065fd04927890a9579112ce304_I20200420" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk2MTg_1d8a6178-401a-44a8-834c-fff66d5e3178">1,086</ix:nonFraction> under the Paycheck Protection Program (the &#8220;PPP&#8221;) administered by the U.S. Small Business Administration, or the SBA, pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;), or the PPP loan.  The PPP loan provides for an interest rate of <ix:nonFraction unitRef="number" contextRef="ied25b6065fd04927890a9579112ce304_I20200420" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzkzNDU4NDg4NTkxNjA_494fc0eb-a53f-4797-afdf-a20b183c21a4">1.00</ix:nonFraction>% per year, and matures <ix:nonNumeric contextRef="id59142af679b474d9606680f4928a206_D20200420-20200420" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzkzNDU4NDg4NTkxODY_b8759057-4051-4209-bb08-3389c73afce1">two years</ix:nonNumeric> after the date of initial disbursement. The terms of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, or the PPP Flexibility Act, which was enacted on June 5, 2020.  Based on management's interpretation of the the PPP Flexibility Act, the Company expects to begin making principal and interest payments on the PPP loan beginning in 2022. The overall timing of payments with respect to the amounts of principal and interest due could change based on the ultimate determination of what may or may not be forgiven.  The PPP loan may be used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments, mortgage interest payments and interest payments on any other debt obligation that were incurred before February 15, 2020. Under the terms of the CARES Act and the PPP Flexibility Act, the Company may apply for and be granted forgiveness for all or a portion of loan granted under the PPP loan, with such forgiveness to be determined, subject to limitations (including where employees of the Company have been terminated and not re-hired by a certain date), based on the use of the loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness may also be subject to further requirements in regulations and guidelines adopted by the SBA. While the Company currently believes that the majority of the use of the PPP loan proceeds will meet the conditions for forgiveness under the PPP, no assurance is provided that the Company will obtain partial forgiveness of the loan.  Terms of the loan may change subject to future enactments relating to the PPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7255e4493164444882c38fbbb691047b" continuedAt="i9503bbf8d1c7494aa2bbc1e3c186b4a3">The follow table presents the scheduled principal payments of the Company's PPP loan note payable as of December 31, 2020, shown if the loan is not forgiven:</ix:continuation></span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><div style="margin-bottom:6pt"><ix:continuation id="ibd7eb5c1de1d48cfa5cc501d8c2d70f6"><ix:continuation id="i9503bbf8d1c7494aa2bbc1e3c186b4a3"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:87.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzEtMS0xLTEtMTQ5Ng_1d9a02a3-5650-4399-baef-20876751d9a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzItMS0xLTEtMTQ5Ng_7cf3abbf-81ad-4b4e-b9dd-3c9aaa87b8c8">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzQtMS0xLTEtMjYwNQ_3368ebd5-ca25-4289-b438-69127af0be3b">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzYtMS0xLTEtMTUwMQ_e052fcdd-3b46-4c8c-9b09-fba35b44d9f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzctMS0xLTEtMTUwMQ_86c3ca4d-9089-4438-b5c6-da20e900b7b0">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzgtMS0xLTEtMjYwOA_7475edb5-cc5a-45e1-a618-2abd8364d5cf">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzMwMDM_3ae7ad1d-df84-402d-ba66-b3b81876acde" continuedAt="i4f35a145c8044f709d566efafa89367c" escape="true">Lease Obligations</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4f35a145c8044f709d566efafa89367c" continuedAt="i7d2feaea6c92433abd35c540816fd3dd"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a <ix:nonNumeric contextRef="ie41cddf1a88a4eeab4f0e94b552e1cad_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzMyOTg1MzQ4OTU5Nzk_2966d644-d95d-4d58-ad94-b9500f1bf069">five-year</ix:nonNumeric> operating lease agreement for its headquarters and manufacturing facility in Richmond, California, or the Richmond Lease, which expires in May 2022, with no further options to extend or terminate. The lease includes non-lease components (i.e. common area maintenance costs) that are paid separately from rent based on actual costs incurred. In June 2020, the Company entered into an amendment to the Richmond Lease to make a one-time payment of $<ix:nonFraction unitRef="usd" contextRef="i4013c40327cb4b46bc304ebb13174011_D20200601-20200630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzY1OTcwNjk3NzYzMzE_46daf4cf-615b-4b8f-98ea-3456b352fdc8">300</ix:nonFraction> to cover its remaining lease obligations for the remainder of 2020, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i4013c40327cb4b46bc304ebb13174011_D20200601-20200630" decimals="-3" name="ekso:OperatingLeaseAbatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzY1OTcwNjk3NzYzMzc_980c93df-6bf6-4d35-bccb-fd106ecf4071">48</ix:nonFraction> abatement and a lease payment deferral of $<ix:nonFraction unitRef="usd" contextRef="ie41cddf1a88a4eeab4f0e94b552e1cad_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzY1OTcwNjk3NzYzNDI_149129ae-2a56-4489-ada5-af8ae93b7557">79</ix:nonFraction> to be paid in equal monthly installments in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's <ix:nonNumeric contextRef="iae9cf36b522d452a848dfea8122fdd50_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzMyOTg1MzQ4OTU5ODA_4cf72021-4d90-4319-be47-64885cf8808b">five-year</ix:nonNumeric> operating lease agreement for its European operations office in Hamburg, Germany expires in July 2022. It has an option to extend for another <ix:nonNumeric contextRef="iae9cf36b522d452a848dfea8122fdd50_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzMyOTg1MzQ4OTU5ODE_d5797a75-6967-426a-a171-688da56792a7">five-year</ix:nonNumeric> term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through April 2019, the Company had an unoccupied leased sales office in Freiburg, Germany, which had a lease term that expired in December 2020. In April 2019, the Company entered an agreement with the lessor of the Freiburg office releasing the Company from future lease payments after April 30, 2019.  </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzMwMDk_d22d139b-1c6b-499d-a481-83b76d30071a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future lease payments as of December 31, 2020 are as follows, which are presented as lease liabilities on the Company&#8217;s consolidated balance sheets:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.497%"><tr><td style="width:1.0%"></td><td style="width:62.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzEtMi0xLTEtMA_d06f837c-eaae-4c40-b52a-e59ef817993b">599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzItMi0xLTEtMA_9b016623-a691-4ca2-a65d-64446160bb1e">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzYtMi0xLTEtMA_b75de322-e353-4585-8968-2d83c5710f3f">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzctMi0xLTEtMA_84b8553b-0bcd-4cd9-b286-eb9d8702a1ee">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzgtMi0xLTEtMA_89180c9b-8199-4f96-834b-3ba80f380ee8">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzEwLTItMS0xLTA_c5e51635-b7f4-4522-8824-5ef04b07bad6">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzExLTItMS0xLTA_7be92f25-3a9b-4186-ab2e-b7ec75af583d">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzEyLTItMS0xLTA_0566b4c3-5608-4067-ab09-dd3ccd1b8f0c">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzE0LTItMS0xLTA_5f75e109-ab75-422e-9dab-b209240d01d0">1.44</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzE1LTItMS0xLTA_a5e28b9d-6fd8-4e6b-bb3e-ca03582e2295">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense under the Company&#8217;s operating leases was $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzE5MzU_af255846-320d-4130-827e-0650c6505368">537</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzE5NDI_cb8e1cf6-bf40-41f7-a347-8225f441a46e">551</ix:nonFraction>, for the years ended December 31, 2020 and 2019, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Practical Expedients</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7d2feaea6c92433abd35c540816fd3dd">As part of the transition to ASC 842, the Company elected to use the modified retrospective transition method with the new standard being applied as of the January 1, 2019 adoption date. Additionally, the Company has elected, as of the adoption date, not to reassess whether expired or existing contracts contain leases under the new definition of a lease; the lease classification for expired or existing leases; or whether previously capitalized initial direct costs would qualify for capitalization under ASC 842.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTgvZnJhZzo5YjNhNmY0Nzk1OTQ0OTNjYTAyNGNmNGRjZDlmNTEyZC90ZXh0cmVnaW9uOjliM2E2ZjQ3OTU5NDQ5M2NhMDI0Y2Y0ZGNkOWY1MTJkXzUzOA_265a037b-065f-4346-b59c-497965ed74ce" continuedAt="if2809ec80c07474890ef9aac690f4d64" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if2809ec80c07474890ef9aac690f4d64">The Company administers a 401(k) retirement plan, or the 401(k) Plan, in which all employees are eligible to participate. Each eligible employee may elect to contribute to the 401(k) Plan. The Company has made matching contributions in the form of shares of the Company's common stock to the 401(k) Plan in an amount equal to <ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTgvZnJhZzo5YjNhNmY0Nzk1OTQ0OTNjYTAyNGNmNGRjZDlmNTEyZC90ZXh0cmVnaW9uOjliM2E2ZjQ3OTU5NDQ5M2NhMDI0Y2Y0ZGNkOWY1MTJkXzM1Ng_c3cff4f7-2e0d-4c63-8905-b10fc8040e9b">50</ix:nonFraction>% of employee contributions (up to the statutory limit), subsequent to year-end. The expense related to the contribution was $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTgvZnJhZzo5YjNhNmY0Nzk1OTQ0OTNjYTAyNGNmNGRjZDlmNTEyZC90ZXh0cmVnaW9uOjliM2E2ZjQ3OTU5NDQ5M2NhMDI0Y2Y0ZGNkOWY1MTJkXzQ4Mg_769bd413-deff-49f1-8192-96b7ccf3fdf3">169</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTgvZnJhZzo5YjNhNmY0Nzk1OTQ0OTNjYTAyNGNmNGRjZDlmNTEyZC90ZXh0cmVnaW9uOjliM2E2ZjQ3OTU5NDQ5M2NhMDI0Y2Y0ZGNkOWY1MTJkXzQ4OQ_c73639bb-c9ef-4a77-8ec9-a6450828a291">142</ix:nonFraction> for the years ended December 31, 2020 and 2019, respectively.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjEvZnJhZzozNDMzM2RjMDQ2Nzk0NDU0ODIwMDg3OWE2YmFhMDMwNi90ZXh0cmVnaW9uOjM0MzMzZGMwNDY3OTQ0NTQ4MjAwODc5YTZiYWEwMzA2XzE5ODk_b3d746db-4928-4e55-bc26-ad2ecd7f313a" continuedAt="i49f6652048154a2b9c1ad526135c3dea" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i49f6652048154a2b9c1ad526135c3dea"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the Company&#8217;s directors, Dr. Ted Wang, is the founder, general partner and Chief Investment Officer of Puissance Capital Management LP, or Puissance Capital, which is an affiliate of Puissance Cross-Border Opportunities II LLC, one of the Company&#8217;s largest stockholders until November 2020. Prior to Dr. Wang&#8217;s appointment to the Board in connection with the Rights Offering in September 2017, the Company entered into a <ix:nonNumeric contextRef="iff102119cd6a456596f0197f90723327_D20170901-20170930" format="ixt-sec:durwordsen" name="ekso:RelatedPartyTransactionConsultingAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjEvZnJhZzozNDMzM2RjMDQ2Nzk0NDU0ODIwMDg3OWE2YmFhMDMwNi90ZXh0cmVnaW9uOjM0MzMzZGMwNDY3OTQ0NTQ4MjAwODc5YTZiYWEwMzA2XzM4NDgyOTA2OTkyMDY_e0a7209a-e700-4e53-9835-96018a00fe51">one-year</ix:nonNumeric> consulting agreement with Angel Pond Capital LLC, or Angel Pond, an entity solely owned and managed by Dr. Wang and affiliated with Puissance Capital. Angel Pond provides consulting services to the Company with respect to strategic positioning in the Asia Pacific region, including introduction to potential strategic partners and the development of strategic partnerships for the sale and manufacture of the Company&#8217;s products in that market. During the year ended December&#160;31, 2019, Angel Pond provided consulting services amounting to $<ix:nonFraction unitRef="usd" contextRef="i66089c57ef3447548266d31fba65e3f3_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjEvZnJhZzozNDMzM2RjMDQ2Nzk0NDU0ODIwMDg3OWE2YmFhMDMwNi90ZXh0cmVnaW9uOjM0MzMzZGMwNDY3OTQ0NTQ4MjAwODc5YTZiYWEwMzA2XzEzMjg_389eacc6-49e1-4e20-8310-f1585d227eba">30</ix:nonFraction> during, which was expensed in the consolidated statement of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company sold EksoVest raw material inventory and tooling to the China JV for</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjEvZnJhZzozNDMzM2RjMDQ2Nzk0NDU0ODIwMDg3OWE2YmFhMDMwNi90ZXh0cmVnaW9uOjM0MzMzZGMwNDY3OTQ0NTQ4MjAwODc5YTZiYWEwMzA2XzE5ODM_dc6ad137-6c49-4587-afe9-a47d993645d5">45</ix:nonFraction>.</span></div></ix:continuation><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_124"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE4MTI4_4445454d-5a42-47ae-af5d-be80bc3a340f" continuedAt="iec64658afb2a46178a2c3ef06277e6ff" escape="true">Capitalization and Equity Structure</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iec64658afb2a46178a2c3ef06277e6ff" continuedAt="i5932a217c17e4346a045ceec87f5fbb2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the close of the stock market on March 24, 2020, the Company effected a 1-for-15 reverse split of its common stock (the "Reverse Stock Split"). As a result, all common stock share amounts included in this filing have been retroactively reduced by a factor of fifteen, rounded up to the nearest whole share, and all common stock per share amounts have been increased by a factor of fifteen, with the exception of the Company's common stock par value and the Company's authorized shares. Amounts affected include common stock outstanding, restricted stock units, common stock underlying stock options and warrants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on September 16, 2019, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) informing the Company that because the closing bid price for the Company&#8217;s common stock listed on the Nasdaq Capital Market was below $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b7783a67c59429aa5c50cce7d3f36a4_I20190916" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzU0OTc1NTgyMTE1NTI_10669845-4ebd-470a-b462-1630f663ce0a">1.00</ix:nonFraction> per share for <ix:nonFraction unitRef="days" contextRef="i5b7783a67c59429aa5c50cce7d3f36a4_I20190916" decimals="0" name="ekso:NumberOfConsecutiveBusinessDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzU0OTc1NTgyMTE1NTY_8bcb11a8-32f3-44ba-b199-50109588e91f">30</ix:nonFraction> consecutive business days, the Company did not meet the minimum closing bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split was effected in order to raise the per share trading price of its common stock above $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b7783a67c59429aa5c50cce7d3f36a4_I20190916" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzU0OTc1NTgyMTE1NjA_6f3129ef-0a99-43b9-a9f9-623a423998f9">1.00</ix:nonFraction> and regain compliance with Nasdaq&#8217;s listing requirements. On April 7, 2020, the Company regained compliance with the minimum bid price requirement required by the Nasdaq listing rules.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s authorized capital stock at December 31, 2020 consisted of <ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzExMw_077ccceb-2bcd-4a15-b099-564b5fb216ba">141,429</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE0Mw_fe9cc4d6-4237-4a95-b1c5-e080b261d1ea">10,000</ix:nonFraction> shares of preferred stock. The authorized capital was not reduced in connection with the Reverse Stock Split. At December 31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE4MA_1aee757d-75f8-4070-99b2-2700e0f7a387"><ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE4MA_5e077c3c-a5ff-4229-b175-85092f9c3146">8,349</ix:nonFraction></ix:nonFraction> shares of common stock issued and outstanding and <ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzIzOA_d7b08877-812c-43c8-a13c-0af90faef24f"><ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzIzOA_dfd34515-ec47-4d33-873d-ae9a40066415">no</ix:nonFraction></ix:nonFraction> shares of preferred stock issued and outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i5932a217c17e4346a045ceec87f5fbb2" continuedAt="i5def2ddd00864f97be0aefa387e872cb"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of outstanding shares of common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the Board of Directors may determine. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting for the election of directors. The common stock is not entitled to preemptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of the Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of the common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. Each outstanding share of common stock is duly and validly issued, fully paid, and non-assessable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2020 Common Stock and Warrants to Purchase Common Stock Offering</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a securities purchase agreement, or the June 2020 Purchase Agreement, with certain purchasers. Pursuant to the June 2020 Purchase Agreement, the Company sold in a registered direct offering, or the June 2020 Offering, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1332f3e466ea4d9886d520016e1fe9a9_D20200601-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwMjQ_d5580eeb-f828-4f57-a0a0-241a68f7cf72">1,748</ix:nonFraction> shares of its common stock. Pursuant to such agreement, the Company also sold, in a concurrent private placement offering, warrants to purchase <ix:nonFraction unitRef="shares" contextRef="icdfb6150e11040dbbad6a66db73b4fdb_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwMTk_e3fcdcd8-6617-400a-844a-7dec9b510b11">874</ix:nonFraction> shares of its common stock, or the June 2020 Investor Warrants. The gross proceeds of the June 2020 Offering and the concurrent private placement offering were $<ix:nonFraction unitRef="usd" contextRef="i4cc3408bdfbe4b5f8276263fd666f8e1_D20200601-20200630" decimals="-3" format="ixt:numdotdecimal" name="ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwMzE_9990020d-7a3a-4baf-a12a-b03eb0e02913">7,890</ix:nonFraction>, the June 2020 Gross Proceeds. Each June 2020 Investor Warrant has an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i20c3fa9143d1494f9fa80ba4773d37c2_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwMzk_32cf2810-8f27-4c76-8aa0-56d420f21b51">5.18</ix:nonFraction> per share, subject to adjustment in certain circumstances, and is exercisable immediately and will expire five and one-half years from issuance, or on December 10, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As compensation for services provided by the placement agent for the June 2020 Offering, or the Placement Agent, the Company paid a cash fee equal to <ix:nonFraction unitRef="number" contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630" decimals="INF" name="ekso:ClassOfWarrantOrRightCashFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNDY_d7775492-564d-452e-bc30-723804e15d36">7.0</ix:nonFraction>% of the June 2020 Gross Proceeds ($<ix:nonFraction unitRef="usd" contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630" decimals="-3" name="ekso:ClassOfWarrantOrRightCashFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNTI_f63d10d7-01d1-4c70-ba48-5c3f792bc93b">552</ix:nonFraction>) and a management fee equal to <ix:nonFraction unitRef="number" contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630" decimals="INF" name="ekso:ClassOfWarrantOrRightManagementFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNjM_caa15189-d1a4-456f-a93f-7e9dd19b3c8b">1.0</ix:nonFraction>% of the June 2020 Gross Proceeds ($<ix:nonFraction unitRef="usd" contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630" decimals="-3" name="ekso:ClassOfWarrantOrRightManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNTg_b6262a51-5fe6-49e1-a765-3073410fdac6">79</ix:nonFraction>), and issued, in a concurrent private placement offering, warrants to purchase shares of the Company's common stock, or the June 2020 Placement Agent Warrants, in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630" decimals="INF" name="ekso:ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNjk_6fd68c9d-81d6-4e66-9c88-ce064c2508d9">7.0</ix:nonFraction>% of the aggregate number of shares of common stock sold in the June 2020 Offering, or <ix:nonFraction unitRef="shares" contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630" decimals="-3" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNzU_4a166417-7603-45fe-bce8-fad9ed110cc2">122</ix:nonFraction> shares in the aggregate, in substantially the same form as the June 2020 Investor Warrants, except that the June 2020 Placement Agent Warrants will expire <ix:nonNumeric contextRef="i8146ef51059a4e8588f8cfa2a49cc7c6_D20200101-20201231" format="ixt-sec:durwordsen" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwOTE_dc3463f6-fada-474e-8c76-a78cdf86aee2">five years</ix:nonNumeric> from the effective date of the June 2020 Offering, or on June 7, 2025, and have an exercise price per share equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i35f4d4c9162e4396a697be5d9061262e_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwODA_18113ef5-f06d-474c-99c9-5b2c17746869">5.64</ix:nonFraction>. In connection with the June 2020 Offering, the Company also incurred $<ix:nonFraction unitRef="usd" contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630" decimals="-3" name="ekso:WarrantIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwODc_fd94449f-3946-4d07-b76c-6cb54310459b">98</ix:nonFraction> in other expenses of the Placement Agent paid for or reimbursed by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the $<ix:nonFraction unitRef="usd" contextRef="i4cc3408bdfbe4b5f8276263fd666f8e1_D20200601-20200630" decimals="-3" format="ixt:numdotdecimal" name="ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxMDk_b2d6640f-721d-450a-a942-6b6bbe687cfe">7,890</ix:nonFraction> in proceeds, $<ix:nonFraction unitRef="usd" contextRef="iae50490cbb4b480698dbb2b1ea92f87e_D20200601-20200630" decimals="-3" format="ixt:numdotdecimal" name="ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxMTc_89ec4104-3916-4a39-afb1-fa478dee9caf">2,650</ix:nonFraction> was allocated to the June 2020 Investor Warrants and June 2020 Placement Agent Warrants, or, collectively, the June 2020 Warrants, based on the fair value method, with the remaining proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1332f3e466ea4d9886d520016e1fe9a9_D20200601-20200630" decimals="-3" format="ixt:numdotdecimal" name="ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxMjU_07c1584e-e884-4352-85af-c31e9ac5531b">5,240</ix:nonFraction> allocated to the common stock shares sold in the June 2020 Offering. In connection with the June 2020 Offering and concurrent private placement offerings, the Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i4cc3408bdfbe4b5f8276263fd666f8e1_D20200601-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxMzM_1e6f6601-4814-4266-87c5-1f09a753ded4">1,117</ix:nonFraction> in direct financing costs, including a fair value of $<ix:nonFraction unitRef="usd" contextRef="i6260ae69ccdc47afb974156191ec17ed_I20200630" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxOTQ_1da98a1b-3484-4eab-b979-cb1a28295d04">309</ix:nonFraction> of June 2020 Placement Agent Warrants. Financing costs of $<ix:nonFraction unitRef="usd" contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNDE_17d54966-96fb-4670-99e7-515c9b1fcc1f">808</ix:nonFraction>, excluding the fair value of the June 2020 Placement Agents Warrants, were allocated on the fair value basis between the common stock shares sold in the June 2020 Offering and the June 2020 Warrants, as follows: $<ix:nonFraction unitRef="usd" contextRef="iae50490cbb4b480698dbb2b1ea92f87e_D20200601-20200630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNDc_735f9ad2-b5e5-44b3-a848-876460ca1b4a">329</ix:nonFraction> was allocated to the June 2020 Warrants and expensed immediately in other income (expense), net in the accompanying consolidated statements of operations and comprehensive income (loss) and $<ix:nonFraction unitRef="usd" contextRef="i1332f3e466ea4d9886d520016e1fe9a9_D20200601-20200630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNTM_1fb365d8-9fbe-45b4-93ce-c707ed4d1da4">479</ix:nonFraction> was allocated to the common stock shares sold in the June 2020 Offering and recorded as a reduction to additional paid in capital. The direct financing cost of $<ix:nonFraction unitRef="usd" contextRef="i6260ae69ccdc47afb974156191ec17ed_I20200630" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNTk_f781b15b-0af8-4f4e-90bc-36ee6bc8abe8">309</ix:nonFraction> associated with the June 2020 Placement Agent warrants was also allocated to the common stock shares sold in the June 2020 Offering and recorded as a reduction to additional paid in capital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At the Market Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright &amp; Co., LLC (the "Agent"), under which the Company may issue and sell shares of its common stock, from time to time, to or through the Agent. Offers and sales of shares of common stock by the Company through the Agent may be made by any method deemed to be an &#8220;at the market offering&#8221; as defined under SEC Rule 415 or in privately negotiated transactions, subject to certain conditions. Such shares may be offered pursuant to the registration statement on Form S-3 (File No. 333-239203) (the &#8220;Registration Statement&#8221;), which was declared effective by the SEC on June 26, 2020, and a related prospectus supplement filed with the SEC on October 9, 2020 (the &#8220;ATM Prospectus&#8221;). Pursuant to the Registration Statement and the ATM Prospectus, shares having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i656a19543c2446298336599b639f4ed9_D20201001-20201031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNjU_07ff2d7b-60e0-4094-b273-6b4c999d257b">7,500</ix:nonFraction> may be offered and sold, subject to certain SEC rules limiting the amount of shares of the Company&#8217;s common stock that may be sold by the Company under the Registration Statement. Under the ATM Agreement, shares of the Company's common stock may not be sold for a price lower than $<ix:nonFraction unitRef="usdPerShare" contextRef="i60337cf454184d3fab3c487c42a73b04_I20201031" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNzM_04bc2f9c-646c-4113-b590-77977a119885">6.75</ix:nonFraction> per share.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i5def2ddd00864f97be0aefa387e872cb" continuedAt="ic7335580811140c2b4c0f7c092a7e637"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement with Cantor Fitzgerald &amp; Co. (the "Cantor Agreement"). Prior to entering into the ATM Agreement, the Company terminated the Cantor Agreement in September 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not sell any shares of common stock under the Cantor Agreement or the ATM Agreement during the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may issue shares of preferred stock from time to time in one or more series, each of which will have such distinctive designation or title as shall be determined by its Board of Directors and will have such voting powers, full or limited, or no voting powers, and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated in such resolution or resolutions providing for the issue of such class or series of preferred stock as may be adopted from time to time by the Board of Directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="ekso:ScheduleOfWarrantsOutstandingTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE4MTMw_99e25bcb-1598-49c0-8dff-36bc955458b1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant shares outstanding as of December 31, 2019 and December 31, 2020 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020 Investor Warrants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia03e27ee3b474253a9b6b29d30ad3245_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMS0xLTEtNzU1_23499abd-4348-4c03-bba9-81bea71c41d6">5.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16884269eeb946c9a8d814ed9a37da17_D20200101-20201231" format="ixt-sec:duryear" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMy0xLTEtNzU1_86aae4b4-381b-4b1a-ab4b-5a7ec69b3d5e">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic069febcd575454ba36115614e1e67f4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtNS0xLTEtNzU1_1b55eb8d-208e-4ea0-bb75-7c719ed21c40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16884269eeb946c9a8d814ed9a37da17_D20200101-20201231" decimals="-3" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtNy0xLTEtNzU1_b0afe565-ef03-4518-ab9a-4518d7aed62c">874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16884269eeb946c9a8d814ed9a37da17_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtOS0xLTEtNzU1_3386393f-f648-4485-bedb-db25be2881fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i16884269eeb946c9a8d814ed9a37da17_D20200101-20201231" decimals="-3" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMTEtMS0xLTc1NQ_0a7d3e5e-5a6a-48f4-897c-23a71e7a3299">477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia03e27ee3b474253a9b6b29d30ad3245_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMTMtMS0xLTkyMQ_1f48b382-b7d8-4987-b75b-7f87d4c0ce2b">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020 Placement Agent Warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c7551fdba7443329e59bdddaaf0a8c4_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMS0xLTEtNzU1_f219b129-5083-4d4e-b7e9-d70f4019232c">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i18a8a6dd04bb4af0a97b953a6edf6367_D20200101-20201231" format="ixt-sec:duryear" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMy0xLTEtNzU1_b348b780-79f4-4b0b-b0eb-b72af72dd641">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ecc4c18109a4778a6436d117e42e20d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItNS0xLTEtNzU1_d0528bbe-188e-45c4-b543-b155755a631e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18a8a6dd04bb4af0a97b953a6edf6367_D20200101-20201231" decimals="-3" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItNy0xLTEtNzU1_7ffa4dc1-5b06-4d62-84fd-161d6dabbbc3">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18a8a6dd04bb4af0a97b953a6edf6367_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItOS0xLTEtNzY0_600c6923-5e13-454e-98d1-566f77ae76bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18a8a6dd04bb4af0a97b953a6edf6367_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMTEtMS0xLTc2NA_d604951f-533f-414b-ae83-81fbb01ad0cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c7551fdba7443329e59bdddaaf0a8c4_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMTMtMS0xLTkxNw_edc7ef22-0020-4ae2-9eac-688bea672bc9">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06d98523cf3c41fc9f81c5db24a92b70_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMS0xLTEtMA_64a2de84-d78a-485e-b6bb-3a453c9218b7">8.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i43dcca06f1114b118c295c1360b5597c_D20200101-20201231" format="ixt-sec:duryear" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMy0xLTEtMA_8b8882ee-f75a-4d3d-8c73-222885fc07f1">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib21914757ec84913b068b738154fc31c_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtNS0xLTEtMA_39accf70-c053-4cc5-94fd-7a551f343106">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43dcca06f1114b118c295c1360b5597c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtNy0xLTEtMA_dadb5d99-45ab-4716-9739-a9f0717bd9bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43dcca06f1114b118c295c1360b5597c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtOS0xLTEtMA_6359bebd-5ddc-4b14-a2d5-e1519fa0d905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43dcca06f1114b118c295c1360b5597c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMTEtMS0xLTA_aeed7847-d889-4c3a-9f8f-e38af69824a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06d98523cf3c41fc9f81c5db24a92b70_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMTMtMS0xLTA_5b38ed18-5f51-45b6-b73e-88db5115650a">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Placement Agent Warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8eab057d5354f54a6a1f4b6e697e1fe_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMS0xLTEtMA_f39020d0-53d1-464b-8a70-acd9fe5f31bb">8.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i883563dff2a0452fb06639ade8f1ec83_D20200101-20201231" format="ixt-sec:duryear" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMy0xLTEtMA_06bfc019-a72f-410e-8808-d2f78f9f688f">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8eab057d5354f54a6a1f4b6e697e1fe_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItNS0xLTEtMA_df17d954-1d32-49e4-8541-13d12baf5d84">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i883563dff2a0452fb06639ade8f1ec83_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItNy0xLTEtMA_02a08ca5-3af8-4122-b9ca-e1c480bd0037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i883563dff2a0452fb06639ade8f1ec83_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItOS0xLTEtMA_272e47a4-782d-423a-aa41-e2c5a2f95b31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i883563dff2a0452fb06639ade8f1ec83_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMTEtMS0xLTA_3b678f50-e062-4046-9e24-b087600d44b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ae106f6d2ac4c01ae9d3275ad51c856_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMTMtMS0xLTA_8bbd4bec-27eb-4cf8-a88e-48b1c4edcc45">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2019 Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtMS0xLTEtMA_92256575-2bd5-4328-82b6-06acc88d8926">3.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231" format="ixt-sec:duryear" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtMy0xLTEtMA_839d6967-8d14-4439-a9c2-3a95ecc111fd">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16f2fc5bc8324b9c95780543103873be_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtNS0xLTEtMA_87cd5ab0-a206-45a7-a348-0f008af7ac54">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtNy0xLTEtMA_0a1c5fe0-ed2e-425f-8351-36c023ee97ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtOS0xLTEtMA_20cb7a50-aa73-46cc-b7a0-02b5dbd7b64a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231" decimals="-3" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtMTEtMS0xLTA_5d86e237-9bf4-4202-a855-765b3c23fe14">246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtMTMtMS0xLTA_4f36708a-bfb3-4a37-9582-866d4b2c3320">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Information Agent Warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i425ea3e27fe44ae8ababe62ca6a2566d_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtMS0xLTEtMA_b6ae65dc-d8e5-4968-8b3b-d0f8195d84f4">22.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i474fb265033b492d99eef7003d923965_D20200101-20201231" format="ixt-sec:duryear" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtMy0xLTEtMA_7dd28113-d855-4675-b913-6141d52fc426">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e758452b88142cebe39df57428e5d23_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtNS0xLTEtMA_4db65f83-df31-4fc7-8eb4-81d777130254">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i474fb265033b492d99eef7003d923965_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtNy0xLTEtMA_e63fb9f4-f74c-45c7-9782-72aa15a6824f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i474fb265033b492d99eef7003d923965_D20200101-20201231" decimals="-3" name="ekso:ClassOfWarrantOrRightExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtOS0xLTEtMA_32d09607-07d7-4cee-8172-2cddd9bb1c74">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i474fb265033b492d99eef7003d923965_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtMTEtMS0xLTA_54236238-c233-4e3d-b053-18223c45552b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i425ea3e27fe44ae8ababe62ca6a2566d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtMTMtMS0xLTA_669fbc83-6f6d-434f-b799-0e353072d3cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic67e632c480a4a389d734d7b66ce5c48_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtMS0xLTEtMA_aae4a846-df3b-466f-af12-fddf3f61d248">41.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie460538640c64e2cba78df79c4755d79_D20200101-20201231" format="ixt-sec:duryear" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtMy0xLTEtMA_17c17e11-0038-4d8e-b165-3b10fe360562">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7c1742f015b49289941792b99828fec_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtNS0xLTEtMA_ae435599-70a2-4d15-bcc6-9e62ff5aeeaf">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie460538640c64e2cba78df79c4755d79_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtNy0xLTEtMA_4c2300c3-9ee9-4a2b-b559-5ea6bc8cadd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie460538640c64e2cba78df79c4755d79_D20200101-20201231" decimals="-3" name="ekso:ClassOfWarrantOrRightExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtOS0xLTEtMA_3f223b1b-23e6-452f-b57d-01646f45ebea">107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie460538640c64e2cba78df79c4755d79_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtMTEtMS0xLTA_80ba99d6-0b66-44df-98b7-e3759ca8d49a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic67e632c480a4a389d734d7b66ce5c48_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtMTMtMS0xLTA_2993791d-4803-418b-89e9-bc6da6fee151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-2014 warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0318eadd0412421d9ab7a16182414edb_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktMS0xLTEtMA_d14cf5b8-4ec5-46fa-b38f-e825cb8e9f52">144.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i493d79f55e7241dc9784879e595c2d55_D20200101-20201231" format="ixt-sec:duryear" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktMy0xLTEtMC90ZXh0cmVnaW9uOjlmNWJjMTkyOWE1MzQxZjlhZjU4YjZhZTFkZGNhMGM0XzMyOTg1MzQ4ODMzMzc_a54a9358-cdaf-4ba2-a081-2efca50a4e35">9</ix:nonNumeric>-<ix:nonNumeric contextRef="i32847a63786c4c40911455a3c40434a8_D20200101-20201231" format="ixt-sec:duryear" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktMy0xLTEtMC90ZXh0cmVnaW9uOjlmNWJjMTkyOWE1MzQxZjlhZjU4YjZhZTFkZGNhMGM0XzMyOTg1MzQ4ODMzNDI_02ec6a09-5746-4634-bfe7-c82294dfaefc">10</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e9a44a009bc4cff8921788207667b9b_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktNS0xLTEtMA_b6ce4a53-10b7-4dbd-8dc4-5b4ab3e4b9fa">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66dedf87145f4fc990355ef06fe907ce_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktNy0xLTEtMA_2947b0cd-1920-468f-bb83-cfea667411ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i66dedf87145f4fc990355ef06fe907ce_D20200101-20201231" decimals="-3" name="ekso:ClassOfWarrantOrRightExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktOS0xLTEtMA_537b20be-aa3c-4c85-bbea-46860e9dae4f">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66dedf87145f4fc990355ef06fe907ce_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktMTEtMS0xLTA_52842053-c68e-4acb-aef1-64b63c52c1ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0318eadd0412421d9ab7a16182414edb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktMTMtMS0xLTA_4d06edfc-54e5-4274-88d3-15bfafd841f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEwLTUtMS0xLTA_07b36b69-8538-4c74-8b3d-0632eda89d27">1,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEwLTctMS0xLTA_fc68fe33-bafe-4159-b7b8-e545c966027b">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="ekso:ClassOfWarrantOrRightExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEwLTktMS0xLTA_12d21e68-11ba-417d-b1de-23fa07db2309">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEwLTExLTEtMS0w_b45df1a2-af68-4497-9304-e97bdff410e0">723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEwLTEzLTEtMS0w_fe555839-4b9e-4d91-972a-a4460bf626ff">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2020 Investor Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company issued the June 2020 Investor Warrants, exercisable for up to <ix:nonFraction unitRef="shares" contextRef="ia73bddff44ca4b2f9d2a82edae8e117f_I20200630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxODI_33a8cefc-1c30-453e-9392-ac58af470076">874</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b04630ec1374a39bd730200d9ce743a_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxODc_894d2eed-626b-4633-964e-fa4dae6b49c7">5.18</ix:nonFraction> per share. The June 2020 Warrants were issued as exercisable immediately, and will expire five and one-half years from the date of issuance, or on December 10, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the June 2020 Investor Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its June 2020 Investor Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the June 2020 Investor Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company&#8217;s common stock determined according to a formula set forth in the June 2020 Investor Warrant. The June 2020 Investor Warrants will be automatically exercised on a cashless basis on their expiration date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2020 Investor Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants. During the year ended December 31, 2020, <ix:nonFraction unitRef="shares" contextRef="ia50fed56d7e846008e27b2faa05cf892_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzMyOTg1MzQ5NTU0Mzk_a3aa562e-bcbe-4aee-95f2-820954121d23">477</ix:nonFraction> shares of the June 2020 Warrants were exercised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2020 Investor Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the June 2020 Investor Warrants, as defined in the June 2020 Investor Warrants, the holders of the June 2020 Investor Warrants will be entitled to receive upon exercise of the June 2020 Investor Warrants the kind and amount </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="ic7335580811140c2b4c0f7c092a7e637" continuedAt="i0a30070eeeb240c091058c935e63faf1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of securities, cash or other property that the holders would have received had they exercised the June 2020 Investor Warrants immediately prior to such fundamental transaction. Alternatively, the Company or any successor entity will, at the option of a holder of a June 2020 Investor Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder&#8217;s June 2020 Investor Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder&#8217;s June 2020 Investor Warrant. Because of this put-option provision, the June 2020 Investor Warrants are classified as a liability and are marked to market at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant liability related to the June 2020 Investor Warrants is measured at fair value upon issuance and at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzY1OTcwNjk4MTEyNDE_3dab62c0-2792-45d2-8ca3-aa5b39d87922" continuedAt="i8fc03068c8c04351a991fbfdcc926c6c" escape="true">The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Investor Warrants:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i8fc03068c8c04351a991fbfdcc926c6c" continuedAt="i18037582775f46d4978d5c982d294bde"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:62.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 10, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a3cb75354a8437c97c6a048fbb71d72_I20201231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzEtMS0xLTEtOTMx_795e4ce9-6fe0-47ea-94b6-a69541101e3d">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i606b7f43b71a44adb687cff9e4202f75_I20200610" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzEtMi0xLTEtOTI4_38525e4a-3819-44ff-bf02-154da3869027">3.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15042960a2014c12aeb3b609cd137087_D20200101-20201231" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzItMS0xLTEtOTMx_4c1e076b-0619-4266-a53c-041a0c246c25">5.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93802bef0c2445c789f2445d0a127497_D20200610-20200610" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzItMi0xLTEtOTI4_002ac6fe-394e-4b0d-b959-706b6d8d41fe">5.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba22e1721af04a2e9319870ded4bd2de_I20201231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzMtMS0xLTEtOTMx_fe660513-f88a-42a0-8bce-f91e558bb6a3">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia3aa1cf0746c4b5baceaeb908424df8d_I20200610" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzMtMi0xLTEtOTI4_d3780150-ce6b-4d85-92ab-17f668fac278">0.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i084accc9ec374285be3b0a73a7a1090a_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzQtMS0xLTEtOTMx_a4c9fe2a-ffdf-435c-be0c-ba50ff614b8e">4.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b12218955364d9da56354373add4e0a_I20200610" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzQtMi0xLTEtOTI4_1979b29e-42d2-412e-b41d-00879c6fb7a0">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd9481bf7e0140ac800169b45355f91d_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzUtMS0xLTEtOTMx_6f37a1d7-262f-42a6-97fc-35db56ac8ec0">105.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5038cfc88eee4338ae569f8f794e2d53_I20200610" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzUtMi0xLTEtOTI4_d56b8c18-16a1-44b6-8d94-0d8612595b80">96.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2020 Placement Agent Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company issued the June 2020 Placement Agent Warrants, exercisable for up to <ix:nonFraction unitRef="shares" contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630" decimals="-3" name="ekso:ClassOfWarrantOrRightIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NDk5OTc_55a92a3c-55f2-42c4-b636-1366a5619857">122</ix:nonFraction> shares of the Company&#8217;s common stock, to the placement agent for such offering. The June 2020 Placement Agent Warrants have substantially the same form as the June 2020 Investor Warrants, including the put option described above, except that they have an exercise price per share equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i6260ae69ccdc47afb974156191ec17ed_I20200630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NTAwMDU_06a38da2-907c-4230-a295-ed59c24da681">5.64</ix:nonFraction>, subject to adjustment in certain circumstances, and will expire on June 7, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the put-option provision in the June 2020 Placement Agent Warrants, these warrants are classified as a liability and are marked to market at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant liability related to the June 2020 Placement Agent Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. <ix:continuation id="i18037582775f46d4978d5c982d294bde" continuedAt="i07a5f90384f049cabb3560f6a7a6cf60">The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Placement Agent Warrants:</ix:continuation></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><ix:continuation id="i07a5f90384f049cabb3560f6a7a6cf60" continuedAt="ibcff2226e638400795e1f7aabc332b29"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:62.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 10, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c0e3631de7946a9b5dd656a12e3ee57_I20201231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzEtMS0xLTEtOTA2_e0bc7571-b03a-494e-a281-ebf05d628f2e">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i917d2e433bec4af6a5015a89dffd0ec1_I20200610" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzEtMi0xLTEtOTI2_01b022fb-65cd-4b12-93c6-a1f1f66c6968">3.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic719e6ce8263469b8620118bde4798db_D20200101-20201231" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzItMS0xLTEtOTA2_acc648e9-5371-4602-9d4b-87bf04a39683">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87826571264a49058ae7d9ecedc374f7_D20200610-20200610" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzItMi0xLTEtOTI2_5d39bb16-ba3a-4460-b068-49c887a2e28c">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i970ae68e19f845e0a61ab8293e716384_I20201231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzMtMS0xLTEtOTA2_bf5586ea-890a-4bde-b87f-ab942fdc167c">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b14b8e6815740a780625da52773615e_I20200610" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzMtMi0xLTEtOTI2_2eb99684-6fa0-44d5-a87d-de0da4c5ba16">0.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i265b24fe236d4a33a086749d8f3bc1d0_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzQtMS0xLTEtOTA2_636cc6fc-e435-4804-bf8c-a3f53848351d">4.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ffd06e2b41643a5851058ccd43c25f4_I20200610" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzQtMi0xLTEtOTI2_d3656905-3611-4b8e-875a-65f9d05bc537">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i885b3e5d68a84f4e90e8c7922cef7995_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzUtMS0xLTEtOTA2_9aebf5a6-fff1-4b46-a601-bbda8eacc1e3">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51a2440d2a3b4d3d84b38c26002ea3ff_I20200610" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzUtMi0xLTEtOTI2_6cbff034-1cda-416c-a940-8c383f5ca86e">96.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2019 Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pursuant to a securities purchase agreement (the "December 2019 Offering") the Company issued warrants (the "December 2019 Warrants") to purchase <ix:nonFraction unitRef="shares" contextRef="i6e10eafaaf69412a980b03f834b1e6dd_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc3MjE_f11e6dd4-9138-4f77-b01a-56aa16691076">556</ix:nonFraction> shares of common stock. The December 2019 Warrants are currently exercisable have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i49b5955b1efd4de9a0856fc1539f6432_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc4MDU_ebdd3a1d-738e-4bb4-80b7-648872e3480c">8.10</ix:nonFraction> per share, and will expire <ix:nonNumeric contextRef="i3687529f69424becaeceedf73f6828ec_D20191201-20191231" format="ixt-sec:durwordsen" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc5OTU_ca274b0f-3855-4206-beee-799b28fdcc6c">five years</ix:nonNumeric> from the date they initially became exercisable, or on June 21, 2025. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the December 2019 Warrants, the Company or any successor entity will, at the option of a holder of a December 2019 Warrant, exercisable concurrently with or at any time within <ix:nonNumeric contextRef="id396d3085bb24e85baf89441852a463a_D20190101-20191231" format="ixt-sec:durday" name="ekso:ClassOfWarrantOrRightDurationOfPutOption" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NTAwMjA_6ff89f19-36f9-4051-b148-324e2066eeb8">30</ix:nonNumeric> days after the consummation of such Fundamental Transaction, purchase such holder&#8217;s December 2019 Warrant by paying to such holder an amount of cash equal to the Black-</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i0a30070eeeb240c091058c935e63faf1" continuedAt="i0eadef54a03f45318372b0530cea11a4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scholes value of the remaining unexercised portion of such holder&#8217;s December 2019 Warrant within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NTAwMTE_96686e94-4d73-4fcb-ac01-69c8e1bec88a">five</span> trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the December 2019 Warrants are classified as a liability and are marked to market at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant liability related to the December 2019 Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. <ix:continuation id="ibcff2226e638400795e1f7aabc332b29" continuedAt="ieeaa8ecce55f46aaa98cbb0594877df4">The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Warrants:</ix:continuation></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="ieeaa8ecce55f46aaa98cbb0594877df4" continuedAt="i20bc4c3a6c944e66a02f3aa25b3e32d7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:503.25pt"><tr><td style="width:1.0pt"></td><td style="width:318.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:90.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide46f57c594c4d7e8de120bbe04cf45a_I20201231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzEtMS0xLTEtMA_51c4185b-57bb-4285-81ab-705ea92ecf62">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bc70242a8314a19af7cff0da761421c_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzEtMi0xLTEtMA_a4996259-77be-4509-b30a-b2389eab50ea">5.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0145713900c94e918e32d701921d1975_D20200101-20201231" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzItMS0xLTEtMA_aa451fad-ddb7-4b41-a142-fce84f16b938">8.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0b034ea5e3e4dc5851a3ccb19e99abf_D20190101-20191231" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzItMi0xLTEtMA_b224a5a3-4c23-4c1b-a098-2b51fa54e206">8.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5aecd5d37d3b4bb4b4adf7077dc24cde_I20201231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzMtMS0xLTEtMA_862f344f-304c-428e-84ce-c3f3acbeb004">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6293a6a35cfd4251acaaf9a8e93b0369_I20191231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzMtMi0xLTEtMA_252a6dd1-9295-4456-91bd-9f73c87a8642">1.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib7f8299a4e214d92957aee41ce77fb46_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzQtMS0xLTEtMA_f2771989-38f8-4a69-b00c-2c86b3e0fc33">4.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iea7e5c100ba04f8687538cfb181146ee_I20191231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzQtMi0xLTEtMA_87e811a1-7d2e-491a-9462-a032761b97e7">5.47</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6df92243b17458caf062b597eca0bb0_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzUtMS0xLTEtMA_24015082-ed17-4a4b-a1dd-aa49411fa864">107.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c6706df2ef4faca8ee7e3eab8da237_I20191231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzUtMi0xLTEtMA_cb192809-fc43-41f0-ae2e-e3e1be682fed">95.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2019 Placement Agent Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, in connection with the December 2019 Offering, the Company issued warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ia8eab057d5354f54a6a1f4b6e697e1fe_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzQ5NDc4MDIzNjUyMzM_df17d954-1d32-49e4-8541-13d12baf5d84">52</ix:nonFraction> shares of the Company&#8217;s common stock to the placement agent for such offering (the "December 2019 Placement Agent Warrants"). The December 2019 Placement Agent Warrants have substantially the same form as the December 2019 Warrants, except that they have an exercise price per share equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8eab057d5354f54a6a1f4b6e697e1fe_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzk4NjE_f39020d0-53d1-464b-8a70-acd9fe5f31bb">8.44</ix:nonFraction>, subject to adjustment in certain circumstances, and will expire on December 18, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant liability related to the December 2019 Placement Agent Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Placement Agent Warrants:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="i20bc4c3a6c944e66a02f3aa25b3e32d7" continuedAt="i7fadb24fd93c4494850fcb05ef4947ea"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:503.25pt"><tr><td style="width:1.0pt"></td><td style="width:318.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:90.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia91c98835d204cc08859c956d9414520_I20201231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzEtMS0xLTEtMA_7402236d-cc48-4973-9e6d-9d53d98e0302">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3215b84b357a450a985217089ba29281_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzEtMi0xLTEtMA_f7473966-da88-4892-8ea6-b9dcabb8424f">5.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i069a96fbc276471e994ddb6c40a43503_D20200101-20201231" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzItMS0xLTEtMA_748dd0bb-4e5a-46ac-a591-89a362e78b96">8.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1857924bad947049734ec580f40b921_D20190101-20191231" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzItMi0xLTEtMA_023e8aa2-d457-4658-8544-2d892e60e878">8.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e863bdfa06a4bdda07cfb2cdc16b526_I20201231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzMtMS0xLTEtMA_28575205-0bb5-42f8-8d54-1fc094feb4df">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i054e3c8419c84d5cbbdb1d4f07127102_I20191231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzMtMi0xLTEtMA_31031e5d-aab0-48d9-946d-44fab06cea49">1.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4998d0b3b84c4399a118546128a7647b_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzQtMS0xLTEtMA_ac14eb54-6f56-47a7-ab83-9e34abdd30f1">3.97</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i38e0af14fe5042aa8dc04877b3a4299a_I20191231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzQtMi0xLTEtMA_66aa1a25-6c79-4a19-b335-c8ada8db5075">4.97</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e2f59b7ba4641e584ab2ac68b96fe24_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzUtMS0xLTEtMA_243c40ca-7309-42a6-b196-db3e9eef6bb2">109.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d99f049683342dab1c5c4e16251a30b_I20191231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzUtMi0xLTEtMA_b0fde918-beef-439d-b4a5-92ba94abd558">93.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has assessed that the likelihood of a Change of Control (as defined in the December 2019 Placement Agent Warrants), occurring during the term of the December 2019 Placement Agent Warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the warrants fair value is nominal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2019 Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, pursuant to an underwriting agreement, (the "May 2019 Offering"), the Company issued warrants (the "May 2019 Warrants") to purchase <ix:nonFraction unitRef="shares" contextRef="ic650ec13b1084703a7916113f5898f77_I20200630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzMyOTg1MzQ5NTU0MzE_4555f5be-608c-4f13-8264-028a6f23b731">444</ix:nonFraction> shares of common stock. The May 2019 Warrants are currently exercisable and have a current exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia0e15a98c6ae4762a3a129475340835f_D20200101-20201231" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzQ5NDc4MDIzOTcyNjU_0b3ea96c-683f-4cea-8ddd-61cdc5ef8f04">3.52</ix:nonFraction> per share, and will expire <ix:nonNumeric contextRef="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231" format="ixt-sec:durwordsen" name="ekso:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzEwNDc3_839d6967-8d14-4439-a9c2-3a95ecc111fd">five years</ix:nonNumeric> from the date of their issuance, or on May 24, 2024. The May 2019 Warrants contain a price protection feature, pursuant to which, subject to certain exceptions, if shares of common stock are sold or issued in the future, or securities convertible or exercisable for shares of the Company&#8217;s common stock are sold or issued in the future, for consideration, or with an exercise price or conversion price, as applicable, per share less than the exercise price per share then in effect for the May 2019 Warrants, the exercise price of the May 2019 Warrants is reduced to the consideration paid for, or the exercise price or conversion price of, as the case may be, the securities issued in such offering. Pursuant to this provision, in connection with the June 2020 Offering, the exercise price of the May 2019 Warrants was reduced to $<ix:nonFraction unitRef="usdPerShare" contextRef="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzExMzIx_92256575-2bd5-4328-82b6-06acc88d8926">3.52</ix:nonFraction> per share, being the amount that is equal to the lower of (x) the consideration paid for the securities issued in the June 2020 Offering, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzQ5NDc4MDIzODY3Njc_d7b17e3f-b9ad-45db-999b-a489793031ec">4.51</ix:nonFraction> per share, (y) the lowest exercise price of the June 2020 Warrants, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ia03e27ee3b474253a9b6b29d30ad3245_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzQ5NDc4MDIzODY3NzE_23499abd-4348-4c03-bba9-81bea71c41d6">5.18</ix:nonFraction>, and (z) the lowest one-day volume-weighted average price of the Company&#8217;s Common Stock on the Nasdaq Capital Market as measured each day during </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i0eadef54a03f45318372b0530cea11a4" continuedAt="i0518029b619f49d1a4d6b14d3716189a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the five trading day period starting on June 8, 2020, rounded to the nearest share, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzExNzg3_92256575-2bd5-4328-82b6-06acc88d8926">3.52</ix:nonFraction>. During the year ended December 31, 2020, <ix:nonFraction unitRef="shares" contextRef="ie223919cfb0644d4b99679da636b322e_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzMyOTg1MzQ5NTU0MjM_5464040c-ebe0-4bff-82a1-04b08445c066">246</ix:nonFraction> shares of the May 2019 warrants were exercised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the Company effects or enters into any issuance of common stock or options or convertible securities exercisable for or convertible into common stock at a price which varies or may vary with the market price of the shares of the Company's common stock, subject to certain exceptions, a May 2019 Warrant holder may, at the time of exercise of the holder&#8217;s warrant, elect to exercise the warrant at such variable price. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The May 2019 Warrants include a put option, whereby while the May 2019 Warrants are outstanding, if the Company enters into a Change of Control, as defined in the May 2019 Warrants, the Company or any successor entity will, at the option of a 2019 Warrant holder exercise within 90 days after the public disclosure of the Change of Control transaction, purchase such holder&#8217;s May 2019 Warrants by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such warrants on the later date of consummation of the Change of Control transaction or two trading days after the notice of such request. Because of this put option provision, the May 2019 Warrants are classified as a liability and are marked to market at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant liability related to the May 2019 Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. <ix:continuation id="i7fadb24fd93c4494850fcb05ef4947ea" continuedAt="i0138d90907804edf9ecf6c51db84036b">The following assumptions were used in a combination of the Black-Scholes Model and the Lattice Model to measure the fair value of the May 2019 Warrants:</ix:continuation></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="i0138d90907804edf9ecf6c51db84036b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:318.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:90.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:98.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i84041bbc80d94707bdd1c71475762b9b_I20201231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzEtMS0xLTEtMA_eee32525-1b84-418c-820c-c689500fba06">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i78706eee04a546a7a74922c746e3304a_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzEtMi0xLTEtMA_53f2d48a-e740-40ab-b2a7-e1a83ed412db">5.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0e15a98c6ae4762a3a129475340835f_D20200101-20201231" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzItMS0xLTEtMA_0b3ea96c-683f-4cea-8ddd-61cdc5ef8f04">3.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c63f0a4b66643c095e667bc8734eabc_D20190101-20191231" decimals="INF" name="ekso:StockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzItMi0xLTEtMA_3da87899-b512-4b60-a295-df67d58a4873">5.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i460359c10d04485b8f24e8e8000ce638_I20201231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzMtMS0xLTEtMA_054fc5c1-37f9-4e61-8432-ce30fb80c93c">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie74af6c07ea14138ab2b4641dd046986_I20191231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzMtMi0xLTEtMA_1bb03e07-357f-4245-88a6-c1bf7943ac20">1.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i283ae8fe845b4608857dda0e19da19e4_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzQtMS0xLTEtMA_f2e840c2-4a4e-47e9-bb39-be2bf937d5b4">3.40</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i584a64da65b8465189421614a29d1307_I20191231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzQtMi0xLTEtMA_859ab6f9-77ff-4437-83db-360e28c6d9bc">4.40</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i163a45d096374a6caa35072e4bb91628_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzUtMS0xLTEtMA_1a3426b3-01ae-4f9b-81e0-5f33aa12b5d9">107.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f9096b4594d4ef887154e71f8bc2cfd_I20191231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzUtMi0xLTEtMA_77791fa9-f2c3-4366-8343-be08537fb3b3">93.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has assessed that the likelihood of a Change of Control occurring during the term of the warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the May 2019 Warrants fair value is nominal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Information Agent Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, in connection with a rights offering in August 2017, the Company issued warrants (the "2017 Information Agents Warrants") to purchase <ix:nonFraction unitRef="shares" contextRef="icdf0c791c34846d7948b3a5350feab73_I20170930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzEzOTkz_9c28c313-d2d9-4b4e-a8c8-2f07027b5435">13</ix:nonFraction> shares of the Company&#8217;s common stock to an information agent. The 2017 Information Agent Warrants had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icdf0c791c34846d7948b3a5350feab73_I20170930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzQ5NDc4MDIzODcyMzk_768cf236-ef48-4116-bf39-e9c14a85de5f">22.50</ix:nonFraction> per share and became exercisable immediately upon issuance and remained exercisable until September 13, 2020. These warrants were recorded in stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet. These warrants expired during the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, the Company issued warrants (the "2015 Warrants") to purchase <ix:nonFraction unitRef="shares" contextRef="i7d2869ade03c4be1a192746ea93a57ed_I20151231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE0NDQ0_154e5f7c-ae8f-486d-a763-1cec20eaedc6">141</ix:nonFraction>&#160;shares which are currently exercisable with a current exercise price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i67dc8fa5926e44009110a64d1f17ab86_I20151231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE0NDgw_95b245da-6052-4659-8d28-441b8822923f">41.25</ix:nonFraction>&#160;per share. The 2015 Warrants contained a put-option provision. Under this provision, while the 2015 Warrants were outstanding, if the Company entered into a Fundamental Transaction, as defined in the 2015 Warrants, the Company or any successor entity shall, at the option of each warrant holder, exercisable at any time concurrently with or within 30 days after the consummation of the Fundamental Transaction, purchase the warrant from the holder exercising such option by paying to the holder an amount of cash equal to the Black-Scholes Model value of the remaining unexercised portion of such holder&#8217;s warrant on the date of the consummation of the Fundamental Transaction. Because of this put-option provision, the 2015 Warrants were classified as a liability and are marked to market at each reporting date. Through December 31, 2019,&#160;<ix:nonFraction unitRef="shares" contextRef="i8ef49a5dee2d41ff9b68a844e92232cd_D20190101-20191231" decimals="-3" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE1MzI2_52a079f7-4a9d-446a-9463-d1eec9df8c36">35</ix:nonFraction>&#160;shares of the 2015 Warrants were exercised. During the year ended December 31, 2020, <ix:nonFraction unitRef="shares" contextRef="i579155917cc84c16b497230e8d059707_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="ekso:ClassOfWarrantOrRightExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE1Mzk5_1269d837-c0b7-4964-bb9f-b6e59de9796b">none</ix:nonFraction> of the 2015 Warrants were exercised. In the year ended December 31, 2019, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i8ef49a5dee2d41ff9b68a844e92232cd_D20190101-20191231" decimals="-3" sign="-" name="ekso:GainLossOnWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE2Mzc3_75a90828-1b8d-4339-b0d8-9f0143196cd9">257</ix:nonFraction> loss on the modification of these warrants related to an amendment which reduced the exercise price of the warrants. These warrants expired during the year ended December 31, 2020. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i0518029b619f49d1a4d6b14d3716189a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-2014 Merger Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase preferred stock of Ekso Bionics Inc. outstanding prior to the Merger were converted into warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i918faac37d3648509a88395256f45bfe_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE3NTAw_c3a72389-c367-48f5-86e5-ad9c76252a66">6</ix:nonFraction> shares of common stock of the Company in connection with the Merger (the "Merger Warrants"). As a result of the May 2019 Offering, which was a firm commitment underwritten public offering, the Merger Warrants expired, in accordance with their terms.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMjM_3cc324ed-1b03-4c20-a880-91f3586ce20b" continuedAt="id1b1676502e8475f91f6bcd21d245fe4" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="id1b1676502e8475f91f6bcd21d245fe4" continuedAt="ia72935830c714a0da558c0f3e7dfc1e0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, prior to the Merger, the Board of Directors and a majority of the stockholders adopted the 2014 Equity Incentive Plan, or the 2014 Plan, allowing for the issuance of <ix:nonFraction unitRef="shares" contextRef="icb64e100a4ea46aeaf2e021efaf9fc23_I20141231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzIzOA_177b76d2-feb3-4f8e-ba37-b5a2c5e621c7">137</ix:nonFraction> shares of common stock. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMTE_9c6b1cac-50e6-4f73-8f23-753101fc9d49" continuedAt="i7c520849d0f74b05af41613c0dc0ff9e" escape="true">The 2014 Plan has since been amended and restated with approval by the stockholders to increase the maximum number of shares issuable, as shown in the table below:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="i7c520849d0f74b05af41613c0dc0ff9e" continuedAt="ia55849c58ab94ef598bfdf5b535cad2d"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:422.25pt"><tr><td style="width:1.0pt"></td><td style="width:298.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original share pool</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i877dabd6d9f1456b80f4388fc9919198_I20141231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzAtMS0xLTEtMA_c2ab6761-a1ac-47c9-86a3-d15391d07f44">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15b635d7791d4729a41246f37fdd5040_D20150101-20151231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzEtMS0xLTEtMA_02d44910-8074-4348-9989-cc44907e9ea0">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2017 increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fba51ad7cb8481bae70c35bf580f079_D20170601-20170630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzItMS0xLTEtMA_48a7e659-3408-477a-baad-a50657ae32ad">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2017 increase (ratified in June 2018)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5fa56f65ff31460b927499357c824471_D20171201-20171231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzMtMS0xLTEtMA_e359f984-6a21-4ce3-85f3-7077c1bcd076">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzQtMS0xLTEtMA_959d53f2-de2c-4b56-b3ff-cfd74f15929b">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020 increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66f66be5e4ca4a3fbef0430494cb2a38_D20200301-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzUtMS0xLTEtMjY5Ng_73d571ea-a1ed-4b93-9fd0-003d038cffcc">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2020 increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzYtMS0xLTEtMjY5Ng_e605a39b-7451-4757-901c-ca2f33715d8b">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share authorized for grant as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8347ac776ecd461e8415e7b0e8c4a7fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzUtMS0xLTEtMA_039e00e6-4a94-465b-aec9-3ca0ff476a4d">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the total shares authorized for grant under the 2014 Plan was&#160;<ix:nonFraction unitRef="shares" contextRef="i8347ac776ecd461e8415e7b0e8c4a7fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzQ5NDc4MDIzMzE5NzU_039e00e6-4a94-465b-aec9-3ca0ff476a4d">1,974</ix:nonFraction>, of which <ix:nonFraction unitRef="shares" contextRef="i8347ac776ecd461e8415e7b0e8c4a7fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzUxOA_06040db0-4aca-4852-a201-d0b2152f4c50">1,113</ix:nonFraction> were available for future grants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2014 Plan, the Board of Directors may award stock options, restricted stock, restricted stock units, stock appreciation rights and dividend equivalent rights having either a fixed or variable price related to the fair market value of the shares and with an exercise or conversion privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions or any other security with the value derived from the value of the shares.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia55849c58ab94ef598bfdf5b535cad2d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant under the 2014 Plan was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:422.25pt"><tr><td style="width:1.0pt"></td><td style="width:298.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares Available For Grant</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i607f7ac1d3694172a81a41007edb3395_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzEtMS0xLTEtMA_78c39955-f346-48ba-ab80-5c59688ac67b">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie4579f566e42442e9e3dc9eb88d2d447_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzItMS0xLTEtMA_72580e9e-f2b3-49bc-995f-611bb0af34ee">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4579f566e42442e9e3dc9eb88d2d447_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzMtMS0xLTEtMA_2576f717-0701-46f5-99e3-8345481b7a0d">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4579f566e42442e9e3dc9eb88d2d447_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzQtMS0xLTEtMA_e7a7da2a-9e8f-4019-87e1-b390ff796b5c">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share pool increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10a66b0cab964a889263784aee1901fe_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzUtMS0xLTEtMA_a4a5df65-2e52-4d21-a5b2-dca516954220">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8347ac776ecd461e8415e7b0e8c4a7fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzYtMS0xLTEtMA_f355cb53-28b3-496b-99f0-9942fc0c6763">1,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors may grant stock options under the 2014 Plan at a price of not less than <ix:nonFraction unitRef="number" contextRef="iec71a31edf584b3fbbe26a8ef6da1b57_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzEzMTg_78f4b48e-0f90-43dd-aab1-23ee7206a379">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the date the option is granted. The maximum term of an incentive stock option granted to participants may not exceed <ix:nonNumeric contextRef="i8724e49e7c1c44f9ae22762caedea6d7_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzE0OTY_2a977823-67fd-4a16-ba75-6ae655f3d7e6">ten years</ix:nonNumeric>. Subject to the limitations discussed above, the Board of Directors determines the term and exercise or purchase price of other awards granted under the 2014 Plan. The Board of Directors also determines the terms and conditions of awards, including the vesting schedule and any forfeiture provisions. Options granted under the 2014 Plan vest upon the passage of time, generally <ix:nonNumeric contextRef="iec71a31edf584b3fbbe26a8ef6da1b57_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzE5MzI_1a3a1b14-a8c1-42ea-99f4-94001a7caa32">four years</ix:nonNumeric>, or upon the attainment of certain performance criteria established by the Board of Directors. The Company may grant options to purchase common stock to non-employees for advisory and consulting services. Upon exercise of a stock option, the Company issues new shares of common stock.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="ia72935830c714a0da558c0f3e7dfc1e0" continuedAt="i132e77e20dc648cfb46ed36aec5f3230"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMjA_3cb3d7c3-01da-44f3-bbe9-070bbbfb2486" continuedAt="ibdfef964ab6b49d4b147472f4aae5ee4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity during the year ended December 31, 2020 is presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4eccbe0a4d6f46a7beb0bc1fe08e5bab_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzEtMS0xLTEtMA_70a214cb-ee0f-4c60-add2-981d54a29a3e">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4eccbe0a4d6f46a7beb0bc1fe08e5bab_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzEtMy0xLTEtMA_4f3ca69d-9619-4e6d-b542-d9926d9f3f22">36.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzItMS0xLTEtMA_18279bda-6781-4072-82fe-37719c050f2f">90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzItMy0xLTEtMA_73810e98-ca75-4f1e-84df-c8a754b8b369">5.65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzMtMS0xLTEtMA_fce2ca96-4d55-4b76-834f-e18304014716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzMtMy0xLTEtMA_65fce8e3-0017-4f1b-a36b-e62e896043b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzQtMS0xLTEtMA_4fa48975-6912-4883-8c02-1f990ce4946f">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzQtMy0xLTEtMA_61062a9b-2efa-4c71-a677-693967994f78">26.59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzUtMS0xLTEtMA_3f1b230b-d36a-4c67-91e5-dfe6bfc4f792">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzUtMy0xLTEtMA_07ff523c-0720-44dd-ad68-f5e01c480bfc">41.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzYtMS0xLTEtMA_67277f92-167b-41fd-a9cc-3182c55f6eef">529</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzYtMy0xLTEtMA_5d2d7c0a-d170-4656-b9bb-0db0bbe275ec">31.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzYtNS0xLTEtMA_85e78d91-0d6b-4403-93c9-32e6c12bef0e">7.35</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzYtNy0xLTEtMA_4be34d43-de78-4680-9863-f0e3550c632b">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzctMS0xLTEtMA_1dde5fea-2d11-4975-b5e0-bc5da9269395">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzctMy0xLTEtMA_8dc84b1c-5423-49a1-8d4e-65ffe845e534">31.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzctNS0xLTEtMA_0b598580-dadc-4e8b-9993-5beccc32fcda">7.35</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzctNy0xLTEtMA_024fb673-81a9-42d9-872b-9492e76e296a">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at year end</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzgtMS0xLTEtMA_6d994b06-b20a-4c1f-b43f-52ad0386429f">342</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzgtMy0xLTEtMA_88d7b32c-e810-4134-8653-5eb37fbf4ade">40.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzgtNS0xLTEtMA_2fabf7b5-d2a7-41f7-bfd0-d038fffbb632">6.71</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzgtNy0xLTEtMA_f9f927fb-6df9-4957-a926-ad9dbd589e0e">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzIzMzc_3dd16f8a-613b-44a7-9784-55c1e7820ff9">0</ix:nonFraction> in cash from exercised stock options. The intrinsic value of the options exercised totaled $<ix:nonFraction unitRef="usd" contextRef="ic57345e588804cfe860c750737f00dd8_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI0MzE_799c13c5-1091-4948-a493-e9c267ad162b">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id37bd0dc0daa4fb7b83159c71d2bfa17_I20191231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI0Mzg_892e5334-76b2-469d-953d-9bc494aa1349">233</ix:nonFraction>, for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted for the years ended&#160;December 31, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI1OTA_2520be33-cb37-44b2-9b0b-b20debd4d6d3">4.42</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i311beee139874abaaa623022d8afd3cd_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI1OTc_dc5ecf21-ab61-4ca7-bd4a-4b0f79e76b87">10.20</ix:nonFraction>, respectively. The total grant date fair value of stock option vested during the years ended December 31, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI3MDc_38c86f03-91a5-486a-a3b1-4c87a97eb62b">1,900</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i311beee139874abaaa623022d8afd3cd_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI3MTQ_2a9dfcb9-0d5e-413c-bbb3-acefc19ab203">2,602</ix:nonFraction>, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, total unrecognized compensation cost related to unvested stock options was $<ix:nonFraction unitRef="usd" contextRef="ic57345e588804cfe860c750737f00dd8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI4MTg_67cd3935-34df-4fda-9c5f-a27ab82ab1c8">2,203</ix:nonFraction>. This amount is expected to be recognized as stock-based compensation expense in the Company&#8217;s consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of <ix:nonNumeric contextRef="i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzMwMzE_5806e9b1-f3e4-411a-97b7-94f5c1360667">2.0</ix:nonNumeric> years.</span></div><div><span><br/></span></div><ix:continuation id="ibdfef964ab6b49d4b147472f4aae5ee4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding as of December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:15.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of<br/>Exercise<br/>Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if0686788f1e24c1290b7f0d92818a8ed_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItMC0xLTEtMC90ZXh0cmVnaW9uOmFjMTEwYjAzODE3ZjQwM2M4NmYyYTYwMTJiMDQ1NWMwXzMyOTg1MzQ4ODMzNTA_57d2dbc0-2d14-4177-984b-f11f90e42889">5.55</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="if0686788f1e24c1290b7f0d92818a8ed_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItMC0xLTEtMC90ZXh0cmVnaW9uOmFjMTEwYjAzODE3ZjQwM2M4NmYyYTYwMTJiMDQ1NWMwXzMyOTg1MzQ4ODMzNTc_3f8b0574-1eb7-4b07-baa4-4938b9f49485">9.15</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32119daf61d74b55a3c8238a0cb3d15b_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItMi0xLTEtMA_f49394d4-41ca-431f-ba1a-3e57aeb41c0a">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0686788f1e24c1290b7f0d92818a8ed_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItNC0xLTEtMA_fb73c14a-05c3-483b-9222-aba62f84dce3">8.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32119daf61d74b55a3c8238a0cb3d15b_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItNi0xLTEtMA_01d4fa5e-5e34-4125-be6f-05eb546b4bac">7.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32119daf61d74b55a3c8238a0cb3d15b_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItOC0xLTEtMA_fec89668-98e0-4a8e-b430-f8151805d6d8">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32119daf61d74b55a3c8238a0cb3d15b_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItMTAtMS0xLTA_3ccfd9b7-3bc3-413c-85ce-0d31101d4bc7">6.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i87e27b2516f148d697ece33f11777fc4_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI3MWYwYjRiMjE2MDRiOTZhMmIyOGQ4ODQ0ZmM0NDc4XzMyOTg1MzQ4ODMzNTA_1c2596ff-0180-4e51-b427-c21d915c65a4">16.95</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i87e27b2516f148d697ece33f11777fc4_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI3MWYwYjRiMjE2MDRiOTZhMmIyOGQ4ODQ0ZmM0NDc4XzMyOTg1MzQ4ODMzNTc_9902f768-9a71-460d-a53f-0a17f1cd4db1">26.85</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i082ff8dadd2c49fa8fbb80b8ffef3976_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtMi0xLTEtMA_fa87e768-beed-4bea-aa74-02a4662a2688">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87e27b2516f148d697ece33f11777fc4_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtNC0xLTEtMA_d27bd56f-0dd1-4977-b7dd-c4c6a5c3da08">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i082ff8dadd2c49fa8fbb80b8ffef3976_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtNi0xLTEtMA_f1937142-7e90-4fc1-84fc-275fadd3bc76">22.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i082ff8dadd2c49fa8fbb80b8ffef3976_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtOC0xLTEtMA_226e8d40-b3d2-4017-b75d-648e0c0ec045">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i082ff8dadd2c49fa8fbb80b8ffef3976_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtMTAtMS0xLTA_200749a9-a2dd-4638-a380-ed3c4c05ecdd">22.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6e851d50c5564e38abf2c0a93b86475f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjJiN2NlYTMyMzZhNDRiZWFhMjlhOThhMmVlZDc1MDIxXzMyOTg1MzQ4ODMzNTA_20dfad9c-2fd5-42dc-a606-fbb4c132b2d9">27.30</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i6e851d50c5564e38abf2c0a93b86475f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjJiN2NlYTMyMzZhNDRiZWFhMjlhOThhMmVlZDc1MDIxXzMyOTg1MzQ4ODMzNTc_ed40d56c-7a7b-4988-b96e-a389e3a8bd1f">56.70</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2948b44d394340328fd63500766a8e47_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtMi0xLTEtMA_88ee6541-b159-445a-86dd-5ac75d84f586">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e851d50c5564e38abf2c0a93b86475f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtNC0xLTEtMA_123a84d5-6c90-49c7-8e6a-0747f3d0ea96">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2948b44d394340328fd63500766a8e47_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtNi0xLTEtMA_2360c664-4cbe-4d32-ba56-1a1baae506b4">34.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2948b44d394340328fd63500766a8e47_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtOC0xLTEtMA_a31fdfbd-0217-47d4-b2a5-58948e51799d">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2948b44d394340328fd63500766a8e47_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtMTAtMS0xLTA_ab6505f7-44b5-474f-8426-bd55d301c6c4">35.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6df990af732247609512a586b14ed964_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjk2ZTEwZGM4NWM2ZjQ2OWI4ZGVjMWU1NjVhNTEyZDQwXzMyOTg1MzQ4ODMzNTE_a571efe9-8402-45a8-b32d-8eb58e1e33ef">60.00</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i6df990af732247609512a586b14ed964_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjk2ZTEwZGM4NWM2ZjQ2OWI4ZGVjMWU1NjVhNTEyZDQwXzMyOTg1MzQ4ODMzNTk_4003f1e6-6082-4f7b-928f-74bed42face5">229.95</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9584796b78247a691fb1d74e4e04c73_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtMi0xLTEtMA_2d5cfc05-ee1b-4674-8045-e3b5d5cf56bb">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6df990af732247609512a586b14ed964_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtNC0xLTEtMA_4c46187d-69dd-44e7-882f-4acc08c6f4e1">4.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9584796b78247a691fb1d74e4e04c73_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtNi0xLTEtMA_2d986d91-5005-4a6f-99e4-ebbfdeaccd0e">119.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9584796b78247a691fb1d74e4e04c73_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtOC0xLTEtMA_511fa40d-a023-4679-b723-3ed9e668c92e">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9584796b78247a691fb1d74e4e04c73_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtMTAtMS0xLTA_c1851f9b-80b9-4ce9-b488-9a47f856db09">119.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzYtMi0xLTEtMA_c6f341b2-fb67-41cc-89b0-6460de630455">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzYtNC0xLTEtMA_d3385170-9e4a-4a5c-aaf5-66616cd394c5">7.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzYtNi0xLTEtMA_d34811b1-7943-47f0-9efb-dde87ba5566d">31.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzYtOC0xLTEtMA_fcd2a77f-2e99-4886-9d69-1ddb8d564744">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzYtMTAtMS0xLTA_e0ca2a93-0d6b-4cd5-901e-250cc639653e">40.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense using the straight-line method over the requisite service period. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMjY_568b1169-0850-469c-8d63-922c084b93fc" continuedAt="i1482a96faa1e4250927f22b7d5fbc954" escape="true">The share fair value of each stock option was determined on the date of grant using the Black-Scholes Model under the following assumptions:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i1482a96faa1e4250927f22b7d5fbc954"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:62.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzItMS0xLTEtMA_904fa8a7-be84-4431-9c27-1a0dfd7d5660">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzItMy0xLTEtMA_caad1ce4-af13-4df6-9eb5-6987655e19f1">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjA0M2Y1ZDMzZGY1NzRlMjY5ZDQwNWI3ZjhmMzc4YmViXzMyOTg1MzQ4ODMzNTA_d1d0ac84-d592-495b-a895-43ef6a6ff520">1.44</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjA0M2Y1ZDMzZGY1NzRlMjY5ZDQwNWI3ZjhmMzc4YmViXzMyOTg1MzQ4ODMzNTc_986881bc-1e95-43a6-9f23-bd3ef27ec3d7">1.65</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjI5OGFjZDUzYTc4MTRhNjBhMjliYTJjZjcwOGMwNjE5XzMyOTg1MzQ4ODMzNDk_83cfafba-b67d-4fa9-84d5-5f7af8cca73f">1.67</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjI5OGFjZDUzYTc4MTRhNjBhMjliYTJjZjcwOGMwNjE5XzMyOTg1MzQ4ODMzNTU_ea31f6e2-054f-44a4-ac35-784b9ff37bd8">2.5</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id643b591bbe442ff89d7f6fedbd8777a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjc1Yjc3NDI1MGNlZTQ2OGJiNTcwNjFiMmNhYjA1MmI1XzMyOTg1MzQ4ODMzNjU_30139aec-a33c-43b5-94d7-a75e40617fa0">5.27</ix:nonNumeric> - <ix:nonNumeric contextRef="i81b4652764f7496fae43691e5665e11e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjc1Yjc3NDI1MGNlZTQ2OGJiNTcwNjFiMmNhYjA1MmI1XzMyOTg1MzQ4ODMzNzY_53512267-698a-4c33-ae82-c5ba4d7f3aa9">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzQtMy0xLTEtMC90ZXh0cmVnaW9uOjM1ZDU4OTA1MjdiZTRkODBiMmFhYjI4M2EwMDIyYzUyXzMyOTg1MzQ4ODMzNDM_9406524f-2e15-4841-8e40-9d3ae5507785">6.08</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjBhMzhhY2QwYjNkNzRkMjBiODA3Njk1Yjk3ODBhZjc4XzMyOTg1MzQ4ODMzNDU_b3561502-923a-47f4-ab02-589020f2ed94">100</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjBhMzhhY2QwYjNkNzRkMjBiODA3Njk1Yjk3ODBhZjc4XzMyOTg1MzQ4ODMzNTE_27f968f9-cd68-46ca-b81e-39e5dd292d6f">102</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjk2YTY2MWU3ZGNmNTQ4MTY5NThiYTgzZmU0ZWZlNWE3XzMyOTg1MzQ4ODMzNDM_ad2d62c1-ee4c-48cd-96ef-dcb6fccd8fb4">100</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjk2YTY2MWU3ZGNmNTQ4MTY5NThiYTgzZmU0ZWZlNWE3XzMyOTg1MzQ4ODMzNDk_2455be6f-6701-4493-921b-fb6b29287a8e">103</ix:nonFraction>%</span></div></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i132e77e20dc648cfb46ed36aec5f3230"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues RSUs to employees and non-employee service providers. Each RSU represents the right to receive <ix:nonFraction unitRef="shares" contextRef="iafd5100ca7f64a00831c51a479b855ff_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="ekso:ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzMyOTg1MzQ4OTE5Njg_4e3e25b2-8507-4b91-a18a-85ed483ac4a3">one</ix:nonFraction> share of the Company&#8217;s common stock upon vesting and subsequent settlement. The fair value of RSUs is determined based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMjE_1bc857cb-e308-46c9-aa7e-bc237376df80" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity for the year ended December 31, 2020 is summarized below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Grant-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i214faac982094d0986fd63789ae5cc48_I20191231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzEtMS0xLTEtMA_0b61128a-c419-4eb8-ad0f-6a47bb15e187">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i214faac982094d0986fd63789ae5cc48_I20191231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzEtMy0xLTEtMA_011d25a2-39f6-43c7-a23a-6726b0f0e4da">10.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzItMS0xLTEtMA_2d816758-e917-4001-90d5-5756633b3dc6">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzItMy0xLTEtMA_2383686c-ad18-4db2-80a6-ccbd96108f97">4.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzMtMS0xLTEtMA_a5eace08-7b20-4256-ba60-b7c56a755d8f">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzMtMy0xLTEtMA_790f9d18-b711-4a4d-92c4-fdf2bf4c9b49">6.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzQtMS0xLTEtMA_8c8c29f6-daff-4902-b52d-7c7389478c07">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzQtMy0xLTEtMA_8091d1a1-397b-45ca-ab29-27a60dc4330c">10.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafd5100ca7f64a00831c51a479b855ff_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzUtMS0xLTEtMA_59b8005a-b77a-4a6b-b3e3-c51622b29909">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iafd5100ca7f64a00831c51a479b855ff_I20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzUtMy0xLTEtMA_d0c2aed9-e4bd-424a-8b73-09f0672060ca">6.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant-date fair value of RSUs&#160;that vested during the year ended December 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzM4NjY_76ddc2f9-f158-4339-a340-1991f9c68a4b">251</ix:nonFraction>. As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="iafd5100ca7f64a00831c51a479b855ff_I20201231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzM4ODA_2d19a27d-3d8c-45d9-ac51-1a9e1981b25e">741</ix:nonFraction> of total unrecognized compensation expense related to unvested RSUs was expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzQwMTU_d574bd30-c720-478c-b0a0-b71d9ad42746">2.20</ix:nonNumeric> years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is included in the consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending upon the nature of services provided. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMjc_61809ae5-d2a2-4db8-bc92-6eda18742a47" continuedAt="i96fa0b1527934c0ba75f984e6f82be04" escape="true">Stock-based compensation expense related to stock options and RSUs granted to employees and non-employees was as follows:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i96fa0b1527934c0ba75f984e6f82be04"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:66.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2cb1ee725d64b848c8abc9e90945dbb_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzItMS0xLTEtMA_3295196c-067f-437a-806e-926a264acfd1">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3cd9b4295544ce39f97760979ddef45_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzItMy0xLTEtMA_f476b6e0-2bbd-492b-a78c-76a215aaa080">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983c680de266493eb3b87d6e84973e71_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzMtMS0xLTEtMA_ca43e7c6-baf7-4b9d-8af3-e16e05f03b96">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e43a3b8d704169bc941d426832f568_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzMtMy0xLTEtMA_c0712d6f-7422-4066-836b-7b4fbbec6152">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0580d79d27744dfa79750de680b753e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzQtMS0xLTEtMA_c07cdbed-1469-459c-a81e-aa1bb9ffbd67">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9bf3c95d404943b8b37bf228a87293_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzQtMy0xLTEtMA_726893b8-37ed-4723-b239-9e3ecf8c5ade">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzUtMS0xLTEtMA_a9795200-ae7f-4168-a8ce-7f4aa9d6a3ae">2,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzUtMy0xLTEtMA_fd271407-adf5-4e1d-81da-75d4d413e38b">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an Employee Stock Purchase Plan, or ESPP. Under the ESPP, the Company has <ix:nonFraction unitRef="shares" contextRef="ie50e530344ba4276bb503495928f0afe_I20201231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzUzNzU_bb9b8776-929b-4659-a875-498109e2a5bc">500</ix:nonFraction> shares of common stock reserved for issuance, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i5f8787b85d56465398b389abe5c50313_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzU2Nzc_331018ef-d515-4fc4-a8cb-fbb2b3e5167f">25</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The ESPP provides for <ix:nonNumeric contextRef="i5f8787b85d56465398b389abe5c50313_D20200101-20201231" format="ixt-sec:durwordsen" name="ekso:DefinedContributionPlanOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzMyOTg1MzQ4OTE5ODk_58c90ea0-df29-4c25-87f4-7905d347ccb9">six-month</ix:nonNumeric> offering periods. At the end of each offering period, employees can purchase shares at <ix:nonFraction unitRef="number" contextRef="i5f8787b85d56465398b389abe5c50313_D20200101-20201231" decimals="INF" name="ekso:DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzU4NjQ_26bd2f66-9e6e-4d0b-8fea-99f542f239aa">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of December 31, 2020, the Company had not initiated employee enrollment to the plan.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzQ5MTE_d608ce29-fa56-49c7-b326-1bff82bbaf49" continuedAt="i5f077ae3dfbe4b0f921a276c18ba9951" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i5f077ae3dfbe4b0f921a276c18ba9951" continuedAt="i04c6baacf6374edb97cdac32dc1a79f8"><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzQ5MTc_8a71c4af-e5a0-413f-874a-f0d2b593b418" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of pre-tax loss for the years ended December 31, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:66.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzItMS0xLTEtMA_4088c7de-7ca3-4bb0-abce-ce91fe23ea9e">14,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzItMy0xLTEtMA_9111692d-af94-4837-b279-913443d4ff3f">10,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzMtMS0xLTEtMA_f0b12e9a-3f70-4f7b-b308-ea28c59d268c">871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzMtMy0xLTEtMA_67176ab8-67e8-44f4-8a64-52eb3c693f4f">1,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzQtMS0xLTEtMA_8fd66ce3-8e18-4fd5-8fbe-dc90fb936fbb">15,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzQtMy0xLTEtMA_cb0e9f7b-3c0c-4bd5-8f44-97ef34428c54">12,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><div><span><br/></span></div><ix:continuation id="i04c6baacf6374edb97cdac32dc1a79f8" continuedAt="id5412f9a660b4038bced243609483435"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE0Mg_0708dd20-5529-4794-8578-c862f0216b4c"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE0Mg_6446b5e1-e56b-479c-bc90-fb3d6f436bb5"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE0Mg_b929c218-1320-4031-a801-7904b5bf46d2"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE0Mg_f31d6cb6-af84-42dd-9e44-d5a53570a290">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> current or deferred federal and state income tax expense or benefit for the years ended December 31, 2020 and 2019 because the Company generated net operating losses, and currently management does not believe it is more likely than not that the net operating losses will be realized. The Company&#8217;s non-U.S. tax obligation is primarily for business activities conducted through Germany and Singapore for which taxes were included in other expense, net for the years ended December 31, 2020 and 2019 and determined to be immaterial and accordingly, such amounts were excluded from the following tables.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzQ5MjE_7065878a-6686-4384-8f1c-7ac926c1b631" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) for the years ended December 31, 2020 and 2019 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:65.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzItMS0xLTEtMA_9e997d25-cbb0-447a-956c-b31e7bc7c8ea">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzItMy0xLTEtMA_4376561f-99c6-4928-aee7-32faed269562">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzMtMS0xLTEtMA_470d8388-5ec1-4940-9fda-1d560b5f76ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzMtMy0xLTEtMA_58aab1b3-31d7-4ba9-a15c-f97f72560bc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzQtMS0xLTEtMA_f3677a28-a6d9-4e60-adbb-6c65b9997199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzQtMy0xLTEtMA_5b818fd8-4326-4445-b061-f6e5b921b16e">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzUtMS0xLTEtMA_4bf1c4c4-7102-426b-b2fc-e8969ac7ff24">16.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzUtMy0xLTEtMA_1711a4f6-0d14-4755-93b4-74a4e4c6b078">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on warrant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="3" sign="-" name="ekso:EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzYtMS0xLTEtMA_84c6e881-a37a-4652-ab9b-7c108e00255f">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="3" name="ekso:EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzYtMy0xLTEtMA_7d22a7cc-607d-43ae-aae3-4f07c58edb1d">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzctMS0xLTEtMA_b622fbb6-c67a-4b84-89bd-2991812e83fc">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzctMy0xLTEtMA_23241dec-012e-4a20-846a-f01ac7d5d887">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzgtMS0xLTEtMA_4bd914d5-2602-4537-a107-4192179dee7a">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzgtMy0xLTEtMA_e60ff5d8-a628-49bd-8150-d091ca9c6eb1">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzktMS0xLTEtMA_bc27e308-5702-4af2-9d97-d35e630e4540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzktMy0xLTEtMA_d2a8f93a-5f65-48e8-b1f3-1dc672e56e70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzQ5MTg_04d845e4-15dd-4775-84ca-5b4b1418b7a4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences and related deferred tax assets and liabilities as of December 31, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzMtMS0xLTEtMA_73a3a1cf-f890-492e-9b68-aef1d0638288">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzMtMy0xLTEtMA_8070133d-48f3-4bd1-8fc8-45b62078a94d">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzQtMS0xLTEtMA_32d30999-01c5-4318-8ece-2cd9e73f4529">43,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzQtMy0xLTEtMA_9f90119c-e7fe-419c-aa39-e0da4969aff5">40,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzUtMS0xLTEtMA_37d75969-b838-454d-9d29-b8939d056cb0">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzUtMy0xLTEtMA_57bccd7a-5148-4acc-baa6-f1b5274d57c7">1,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzYtMS0xLTEtMA_325fa649-a123-475c-9545-51c0751ca311">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzYtMy0xLTEtMA_f29c77d3-b3d0-449d-a418-98e88e8804b0">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzctMS0xLTEtMA_79389b31-4cc5-4c64-870a-629a5b786e1c">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzctMy0xLTEtMA_731e48d7-1454-4784-8569-0563f95cd414">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzgtMS0xLTEtMA_182ef686-55d7-43ea-8355-faa15f6a818f">2,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzgtMy0xLTEtMA_4cf0a4ce-4feb-4fe3-969a-0f4ce4230f6b">2,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="ekso:DeferredTaxAssetsOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzktMS0xLTEtMA_817b1425-2a3c-4e41-8dd6-836899d713ed">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="ekso:DeferredTaxAssetsOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzktMy0xLTEtMA_a824e671-412f-43ef-a382-74a20873360b">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzEwLTEtMS0xLTA_a75b3351-4f54-48c3-bacb-0ea2de00aef0">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzEwLTMtMS0xLTA_6656d29e-3fc8-4b72-aae6-812841ae93da">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="ekso:DeferredTaxLiabilitiesOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzEzLTEtMS0xLTA_ac1d4264-7112-477d-b7ef-2f969b3977be">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="ekso:DeferredTaxLiabilitiesOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzEzLTMtMS0xLTA_49c8abfc-c143-4943-b85e-4fafb2cdc75e">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE0LTEtMS0xLTA_1a991055-90e0-4c52-a671-cd8c2f5cd51f">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE0LTMtMS0xLTA_59ab9797-4294-4549-b55a-28b80cc11e02">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE1LTEtMS0xLTA_6dc17df1-8ebd-4767-be00-c5ac90f0ff3a">48,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE1LTMtMS0xLTA_05178494-d6e8-49df-a79f-3db62675ea37">45,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE2LTEtMS0xLTA_06c6706e-590d-4d3d-9bff-25a8516bee33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE2LTMtMS0xLTA_6104d6d0-453d-409f-a69c-d0a17b698b47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of the Company&#8217;s net deferred tax assets. The Company primarily considered such factors as the Company&#8217;s history of operating losses, the nature of the Company&#8217;s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. The Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance was established and no deferred tax assets were shown in the accompanying consolidated balance sheets. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE3OTY_b21cb845-e3c0-4604-8656-db01b5852a98">3,192</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE4MDM_56691309-c2d9-4273-808f-dfc1a4fa559c">3,899</ix:nonFraction> in the years ended December 31, 2020 and December 31, 2019, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="id5412f9a660b4038bced243609483435" continuedAt="ic80f95f6dbd1463ba23fb61f22001644"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For tax years beginning after December 31, 2018, the Global Intangible Low-taxed Income ("GILTI") took effect.  Due to the aggregated losses of the foreign subsidiaries, there was no GILTI inclusion for the years ended December 31, 2020 and December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020 the U.S. enacted the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). On December 21, 2020, The U.S. Congress passed the Consolidation Appropriations Act, 2021 (the CAA Act).  We have evaluated the provisions of the CARES Act and CCA Act and determined that it did not result in a significant impact on our tax provision.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 29, 2020 California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of California net operating losses and limits the use of California research tax credits for tax years beginning in 2020 and before 2023.  The suspension of net operating losses and the restriction of research tax credits  did not result in a significant impact on the value of our deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 the Company had federal net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i8bb6a31fa69b42789b1e10282b4ace5b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzIxNTI_0b7b9dcd-8747-4d90-8016-8a2c9b39c1ae">164,296</ix:nonFraction>. The federal net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i10c35f66e6034eec83024df6ac610e24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzIyMDQ_389cf95a-c2bb-4b72-ace4-5a2167251191">120,792</ix:nonFraction> generated before January 1, 2018 will begin to expire in 2027, and $<ix:nonFraction unitRef="usd" contextRef="i8a5e4922e5c349469514d98ce6786b33_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzIyNzI_46388f77-1dac-43bd-bb9e-8b1184978684">43,503</ix:nonFraction> will carryforward indefinitely but are subject to the 80% taxable income limitation. The Company also had federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i319319b8233c4303ad3523ef6efcc360_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzI0NDI_c59bcf1e-87d1-41fe-8b38-9c2719d815c7">1,943</ix:nonFraction> that will expire beginning in 2031, if not utilized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had state net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i7df6497f41704a339bcb35d3d532dc6b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzI1NjY_fe518427-3740-4289-aaeb-c412db893859">106,955</ix:nonFraction>, which will begin to expire in 2028. The Company also had state research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ib6b25f2478684c8396497673025f1b5f_I20201231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzI2ODQ_c36e8179-5c6e-4053-8a57-ee77d5574e85">641</ix:nonFraction>, which have no expiration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had foreign net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ia06204e374c64847aa8ca39f1c059324_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzI3ODU_7178a507-6148-4a14-a9a6-e08c88eff9da">9,655</ix:nonFraction>. The foreign net operating loss carryforwards do not expire.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the Company&#8217;s net operating losses and credit carryforwards may be subject to annual limitations in the event of a Section 382 ownership change. Such future limitations could result in the expiration of net operating losses and credit carryforwards before utilization as a result of such an ownership change.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzQ5MDc_1f82ef2d-4f0d-4835-9e2d-f68a3bd26278" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:87.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c7032c4140109d9f983f53b19765_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTpmN2Y0MDJhZjYxZTg0MDBkODA1ODUwNWE3ZjE3Njc1YS90YWJsZXJhbmdlOmY3ZjQwMmFmNjFlODQwMGQ4MDU4NTA1YTdmMTc2NzVhXzMtMS0xLTEtMA_18cb8be4-fdaa-44c6-9dd0-681f08639fe2">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase of unrecognized tax benefits taken in prior years</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTpmN2Y0MDJhZjYxZTg0MDBkODA1ODUwNWE3ZjE3Njc1YS90YWJsZXJhbmdlOmY3ZjQwMmFmNjFlODQwMGQ4MDU4NTA1YTdmMTc2NzVhXzQtMS0xLTEtMA_1c2015e5-ff89-4029-b41c-2d3874a2d9b2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase of unrecognized tax benefits related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTpmN2Y0MDJhZjYxZTg0MDBkODA1ODUwNWE3ZjE3Njc1YS90YWJsZXJhbmdlOmY3ZjQwMmFmNjFlODQwMGQ4MDU4NTA1YTdmMTc2NzVhXzUtMS0xLTEtMA_05477bab-fbf3-4495-826a-86d966bbabef">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTpmN2Y0MDJhZjYxZTg0MDBkODA1ODUwNWE3ZjE3Njc1YS90YWJsZXJhbmdlOmY3ZjQwMmFmNjFlODQwMGQ4MDU4NTA1YTdmMTc2NzVhXzYtMS0xLTEtMA_c771e5f8-63e3-4bd7-890d-56ea698cc060">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is able to recognize these uncertain tax positions, the unrecognized tax benefits would not impact the effective tax rate if the Company applies a full valuation allowance against the deferred tax assets, as provided in the Company&#8217;s current policy.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic80f95f6dbd1463ba23fb61f22001644">The Company had not incurred any material tax interest or penalties as of December 31, 2020. The Company does not anticipate any significant change within 12&#160;months of this reporting date of its uncertain tax positions. The Company is subject to taxation in the United States and various state jurisdictions, Germany, and Singapore. There are no ongoing examinations by taxing authorities at this time. The Company&#8217;s tax years 2007 through 2020 will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss credits. The Company&#8217;s 2016 to 2020 tax years will remain open for examination by the German tax authority for four years from the end of the year in which the applicable return was filed. The Company&#8217;s 2018 to 2020 tax years will remain open for examination by the Singapore tax authority for four years from the date of  the applicable assessment.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzIzMzg_05e3f4e0-f433-4541-a31e-990c5cd3ebd1" continuedAt="i2532ba2439ae4622b2545bfab6dc5cb0" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i2532ba2439ae4622b2545bfab6dc5cb0" continuedAt="i9849bd41f33f4510ba1b133c45bc6bcb"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Contracts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="license_agreement" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="ekso:NumberOfLicenseAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzkw_dbea2522-5430-41d6-949f-22091529ca54">two</ix:nonFraction> license agreements with the Regents of the University of California to maintain exclusive rights to patents. The Company is required to pay <ix:nonFraction unitRef="number" contextRef="i8c8907ba268e43a890f1228c1a43a77e_D20200101-20201231" decimals="INF" name="ekso:RoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzIzMw_9ad8719c-cad6-428b-b90f-6cacc780fab3">1</ix:nonFraction>% of net sales of licensed medical devices sold to entities other than the U.S. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><ix:continuation id="i9849bd41f33f4510ba1b133c45bc6bcb"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government. In addition, the Company is required to pay <ix:nonFraction unitRef="number" contextRef="if2504c7ec30a492e9cc1f890fccd8252_D20200101-20201231" decimals="INF" name="ekso:RoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzM3MA_6cbd286b-63ae-4316-a117-a47cc6ba1930">21</ix:nonFraction>% of consideration collected from any sub-licensee for the grant of the sub-license. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with acquisition of Equipois, LLC ("Equipois"), the Company assumed the rights and obligations of Equipois under a license agreement with the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants the Company an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, the Company is required to pay the developer a single-digit royalty on net receipts, subject to a $<ix:nonFraction unitRef="usd" contextRef="i4123648869a94d87948d26689a8190ad_I20201231" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzk4NQ_8731a193-0b65-427f-9dd5-0dff477b4a9c">50</ix:nonFraction> annual minimum royalty requirement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling&#160;$<ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:PurchaseObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzE1OTQ_6caf32a7-147c-4e0f-add6-a7957f57ec8c">396</ix:nonFraction>&#160;as of&#160;December 31, 2020, which is expected to be paid within a year. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Obligations</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzIzMzQ_f86d1984-a0cb-4f5c-a8d9-a51a6af7fba2" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's outstanding contractual obligations, including interest payments, as of December 31, 2020 and the effect those obligations are expected to have on its liquidity and cash flows in future periods:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payments Due By Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than<br/>one year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3-5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b339ba80adf48a59e5a09a23f722e4b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzItMS0xLTEtMA_5a8939c8-ed94-43c9-9e21-4876cd6d88bd">3,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b339ba80adf48a59e5a09a23f722e4b_I20201231" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzItMy0xLTEtMA_3468a9a0-07c2-4ff0-97e2-6ca5c7f345f9">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b339ba80adf48a59e5a09a23f722e4b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzItNS0xLTEtMA_895e085e-5293-48d3-9191-a98efcfe4d4f">3,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b339ba80adf48a59e5a09a23f722e4b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFifthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzItNy0xLTEtMA_b5d60d8d-29c2-4504-a9e4-c31c58f52db6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility operating lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d1eb01e13aa4edd802e72c1ca0af002_I20201231" decimals="-3" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzMtMS0xLTEtMA_79450c5f-08fe-4bbb-9a32-938eb236c832">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d1eb01e13aa4edd802e72c1ca0af002_I20201231" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzMtMy0xLTEtMA_a586cfc5-c149-44c0-9d5b-7252f53f681e">599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d1eb01e13aa4edd802e72c1ca0af002_I20201231" decimals="-3" name="us-gaap:ContractualObligationDueInThirdYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzMtNS0xLTEtMA_78954be9-a56c-4526-b642-4013796ea6fb">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d1eb01e13aa4edd802e72c1ca0af002_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFifthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzMtNy0xLTEtMA_6492abb5-e08c-46b3-a5f7-e62ab4fbcd23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzUtMS0xLTEtMA_735e2735-8733-48c6-a073-d90f8321ee3e">4,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzUtMy0xLTEtMA_d2921b07-8c8d-4f4d-84e7-16c624fb3ecc">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzUtNS0xLTEtMA_9a96610f-1728-4c43-9603-6a3f9ac765ec">3,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFifthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzUtNy0xLTEtMA_6b63f4d7-d73d-48c0-8095-439e30ad631b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company&#8217;s consolidated financial statements.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ekso Bionics Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90ZXh0cmVnaW9uOmRiY2EyOGU4YzU3NTRmOTdiYzY5ZjM3NjdlMjI5OTMyXzk1MA_51c8b5ea-7ea8-48af-adad-c7305ab6085d" continuedAt="i8311c864a1514a679a92e6d70136daca" escape="true">Segment Disclosures</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i8311c864a1514a679a92e6d70136daca"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90ZXh0cmVnaW9uOmRiY2EyOGU4YzU3NTRmOTdiYzY5ZjM3NjdlMjI5OTMyXzQ2_811deeb8-e4ee-4206-9aa0-06785ef8c6f6">two</ix:nonFraction> reportable segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, sells and rents exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, sells, and rents exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The reportable segments are each managed separately because they serve distinct markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates performance and allocates resources based on segment gross profit margin.  The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90ZXh0cmVnaW9uOmRiY2EyOGU4YzU3NTRmOTdiYzY5ZjM3NjdlMjI5OTMyXzk0NA_c5b9f196-41cf-4094-a34a-9a9353e70b7a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment reporting information is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:39.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoHealth</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoWorks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib881b817aa7445709d8070f5fe391132_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzItMS0xLTEtMA_541e140f-e516-4edd-bb4c-bc38752afcc3">8,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a7edc5f16340378382788c4c0dc691_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzItMy0xLTEtMA_7671e91e-3b5e-431b-99c4-6132fe5d022f">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzItNS0xLTEtMA_bd283b73-64f8-4a76-8281-b3b0333fbf1b">8,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib881b817aa7445709d8070f5fe391132_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzMtMS0xLTEtMA_1761e712-40a6-4c0e-9d7c-4e215d153584">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a7edc5f16340378382788c4c0dc691_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzMtMy0xLTEtMA_b00d6f4f-71ed-4303-a55e-17c4ed1a7144">593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzMtNS0xLTEtMA_81ce7b85-ef5d-400d-a97a-29cf7a297cd5">3,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib881b817aa7445709d8070f5fe391132_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzQtMS0xLTEtMA_a756c640-723e-46b8-a9a8-011ac9732a79">4,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a7edc5f16340378382788c4c0dc691_D20200101-20201231" decimals="-3" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzQtMy0xLTEtMA_a3ec3d37-8193-4e21-bc91-96a562c22189">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzQtNS0xLTEtMA_6691ff51-d382-4923-8a92-a17ea635263f">5,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb99287795245cead94469bb0004c47_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzctMS0xLTEtMA_1f132644-48c4-4d13-b8b8-a34a5266de3c">11,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015e0abf22814adbb2132f59a1724e19_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzctMy0xLTEtMA_bf99d906-e431-4347-8618-bc70e7fafd1b">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzctNS0xLTEtMA_54c07c62-21af-4fec-b5be-a24b5381529e">13,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb99287795245cead94469bb0004c47_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzgtMS0xLTEtMA_b436a538-bcd7-41d0-8aab-2b313982367f">5,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015e0abf22814adbb2132f59a1724e19_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzgtMy0xLTEtMA_6a577025-6cb4-45c9-9935-1ba47c5bca9d">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzgtNS0xLTEtMA_91d74ce4-a39a-49a0-893c-132258406da1">7,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb99287795245cead94469bb0004c47_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzktMS0xLTEtMA_45e78c44-b7c2-4834-ac6a-ab6628aa0ef1">6,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015e0abf22814adbb2132f59a1724e19_D20190101-20191231" decimals="-3" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzktMy0xLTEtMA_e4e13b6e-4175-42b5-baa4-d9e2d69a6c6e">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzktNS0xLTEtMA_6aceaf1e-d6b2-4b8a-9367-e6c5a70149dd">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from one customer of the Company&#8217;s EksoHealth segment represented approximately $<ix:nonFraction unitRef="usd" contextRef="i3cb3927a9fbf4e13a0140f4d17c94c07_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90ZXh0cmVnaW9uOmRiY2EyOGU4YzU3NTRmOTdiYzY5ZjM3NjdlMjI5OTMyXzgyMQ_fac2a138-9ddf-4e22-807d-1114b727bd8f">2,138</ix:nonFraction> of the Company&#8217;s consolidated revenues for the year ended December 31, 2019.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90ZXh0cmVnaW9uOmRiY2EyOGU4YzU3NTRmOTdiYzY5ZjM3NjdlMjI5OTMyXzk1Mw_8bcd785d-80db-4606-83e5-03215ccb24e2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geographic revenue information based on location of customer is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:65.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie155c69f21734a16917958178e1f51a1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzItMS0xLTEtMA_b07fb71a-5e6d-4900-b16d-cc2229c84d54">5,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6cdf8903fd44d7852fe7584e4e99cd_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzItMy0xLTEtMA_f4e9c6b0-d6c7-4853-9c0f-1116ed49c70b">9,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0989d807f24270a4bd9f5c3d8d8d32_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzMtMS0xLTEtMA_c22dd587-9be1-45a9-9dd1-1a17384897a6">2,937</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3552c786c174ef89dfaa1c2526fc4e1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzMtMy0xLTEtMA_15a6fcf3-1267-465c-84fa-27ed794a00e0">4,846</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzQtMS0xLTEtMA_ef4eff3d-2552-4ff4-8d58-4267d9f15292">8,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzQtMy0xLTEtMA_486810e6-eece-4cf6-ab3a-8157c8583445">13,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzY2OA_17d8db89-8273-4594-a31c-131dc79f98df" continuedAt="i3fde6d39dc814510b5d525ba9820a6ee" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3fde6d39dc814510b5d525ba9820a6ee"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into an amended and restated underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright &amp; Co., LLC ("Wainwright"), to sell <ix:nonFraction unitRef="shares" contextRef="i632f81a051354fdf864a43648798ddbe_D20210201-20210226" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQ2OTk_e66b59fa-22bd-4a7e-987c-58fe764dfcee">3,902</ix:nonFraction> shares of the Company's common stock for public price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaad6ab00ad864f69a9e847781dc8db64_I20210226" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQ3MTQ_e021a9a0-bcb8-4e9a-81c8-dd6c84fd7b86">10.25</ix:nonFraction> per share, for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i632f81a051354fdf864a43648798ddbe_D20210201-20210226" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQ2NzM_541fb296-1c7a-4a99-b811-c1af1d3783a0">40,000</ix:nonFraction> (the "February 2021 Offering").  The Company estimates that the net proceeds from the February 2021 Offering will be approximately $<ix:nonFraction unitRef="usd" contextRef="i3ef9cf6430ff4f8e9422f488739fa849_D20210201-20210228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQ3MzE_acf060bc-ce84-46df-98a2-0080b834cf6b">36,404</ix:nonFraction> after deducting underwriting discounts and commissions and estimated offering expenses. Pursuant to the Underwriting Agreement, the Company issued to certain designees of Wainwright <ix:nonNumeric contextRef="iaad6ab00ad864f69a9e847781dc8db64_I20210226" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzMyOTg1MzQ4OTU4Mzg_b96364d3-d17d-44c5-beb7-9278a877dc16">5</ix:nonNumeric>-year warrants (the &#8220;2021 Warrants&#8221;) to purchase shares of Common Stock in an amount equal to <ix:nonFraction unitRef="number" contextRef="i9b5c460bf8c84b56a0349fb3c3d0e654_D20210201-20210228" decimals="INF" name="ekso:ClassOfWarrantOrRightPercentageOfAggregateSharesSold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzY1OTcwNjk3NzgxMDI_4047e477-6c4d-439c-baa3-8226954e8dbc">7.0</ix:nonFraction>% of the aggregate number of shares sold in the February 2021 Offering at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i16bf31763ef74fad820cf6aed9bb0918_I20210226" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzY1OTcwNjk3NzgxMTA_ac5dbde2-adb3-4a5b-bb05-e5e64cb6a843">12.8125</ix:nonFraction> per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021 through February&#160;25, 2021, the Company received proceeds of $<ix:nonFraction unitRef="usd" contextRef="i92564e533c5b46fca6e27927910f77db_D20210101-20210225" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzA1ODI_02923e06-1ed9-4951-956b-a4c4b7314153">1,416</ix:nonFraction> from the exercise of <ix:nonFraction unitRef="shares" contextRef="i0cb8fcd93e684118ad89bca6e3dc19c7_D20210101-20210225" decimals="-3" name="ekso:ClassOfWarrantOrRightExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzA1ODg_7b374414-4566-44cc-810c-9974f99912f6">275</ix:nonFraction> warrants and sold <ix:nonFraction unitRef="shares" contextRef="idb89bd35b9ca4d7680abe71e8e1cb17e_D20210101-20210225" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQyNjQ_b77e3b17-062e-4b4f-baff-e797911bf614">78</ix:nonFraction> shares of the Company's common stock under the ATM Agreement at an average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i226916c19ca6463c961b406e024eca43_I20210226" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQyNzA_87dbfeb8-c4d9-4bb2-954f-f02569c48286">10.72</ix:nonFraction> for proceeds of $<ix:nonFraction unitRef="usd" contextRef="idb89bd35b9ca4d7680abe71e8e1cb17e_D20210101-20210225" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQ0MjM_77403403-dce3-424b-908d-29fb4b21bf1a">664</ix:nonFraction>, net of commission and issuance costs. As of February 25, 2021, the Company has $<ix:nonFraction unitRef="usd" contextRef="ic513e7ac66894d34b00b95cd51300460_D20210225-20210225" decimals="-3" format="ixt:numdotdecimal" name="ekso:SaleOfStockValueOfSharesAvailableForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzc2OTU_ad364a1c-0f71-4063-bd7b-677b084db6e9">6,668</ix:nonFraction> available for future offerings under the prospectus filed with respect to the ATM Agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_154"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Controls and Procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of December 31, 2020. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures&#160;were&#160;effective&#160;to ensure&#160;that information required to be disclosed in reports filed by us under the Securities Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It should be noted that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment and makes assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. Management believes that the financial statements included in this Annual Report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the U.S. Securities Exchange Act, Rules 13a-15(f) and 15d-15(f). Our internal control system was designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our management believes that based on this criteria, as of December 31, 2020, our internal control over financial reporting is effective.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our registered public accounting firm regarding our internal control over financial reporting. Our report was not subject to attestation by our registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permits us to provide only management&#8217;s report in this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control Over Financial Reporting:</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other changes in our internal control over financial reporting identified in connection with the evaluation required by (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_157"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference from our Proxy Statement, relating to our&#160;2021&#160;Annual Meeting of Shareholders, under the heading &#8220;Corporate Governance,&#8221; to be filed with the SEC within 120 days of&#160;December 31, 2020.</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference from our Proxy Statement, relating to our&#160;2021 Annual Meeting of Shareholders, under the headings &#8220;Executive Compensation&#8221; and &#8220;Director Compensation,&#8221; to be filed with the SEC within 120 days of December 31, 2020.</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGERS AND RELATED STOCKHOLDER MATTERS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference from our Proxy Statement, relating to our&#160;2021&#160;Annual Meeting of Shareholders, under the heading &#8220;Common Stock Ownership of Certain Beneficial Owners and Management,&#8221; to be filed with the SEC within 120 days of&#160;December 31, 2020.</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_172"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference from our Proxy Statement, relating to our&#160;2021&#160;Annual Meeting of Shareholders, under the heading &#8220;Certain Relationships and Related Party Transactions,&#8221; to be filed with the SEC within 120 days of December 31, 2020.</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein&#160;by reference from our Proxy Statement, relating to our&#160;2021&#160;Annual Meeting of Shareholders, under the headings &#8220;Audit Committee Report&#8221; and &#8220;Audit Fees and Services,&#8221; to be filed with the SEC within 120 days of December 31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:42.91pt">Financial Statements and Schedules:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following financial statement documents are included as part of Item&#160;8 to this Form 10-K:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-54pt"><span><br/></span></div><div style="padding-left:108pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reports of Independent Registered Public Accounting Firm</span></div><div style="padding-left:108pt;text-align:justify"><span><br/></span></div><div style="padding-left:108pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets as of December 31, 2020 and 2019 </span></div><div style="padding-left:108pt;text-align:justify"><span><br/></span></div><div style="padding-left:108pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations and Comprehensive loss for the years ended December 31, 2020 and 2019 </span></div><div style="padding-left:108pt;text-align:justify"><span><br/></span></div><div style="padding-left:108pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2020 and 2019 </span></div><div style="padding-left:108pt;text-align:justify"><span><br/></span></div><div style="padding-left:108pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019 </span></div><div style="padding-left:108pt;text-align:justify"><span><br/></span></div><div style="padding-left:108pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="padding-left:108pt;text-align:justify"><span><br/></span></div><div style="padding-left:76.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-54pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:42.34pt">Exhibits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The exhibits filed with this Annual Report are set forth in the Exhibit Index.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.967%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex2-1.htm">Agreement and Plan of Merger and Reorganization, dated as of January 15, 2014, by and among the Registrant, Acquisition Sub and Ekso Bionics, Inc. (incorporated by reference from Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420415017256/v403902_ex3-1.htm">Articles of Incorporation of the Registrant (incorporated by reference from Exhibit 3.1 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 19, 2015)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex3-3.htm">Certificate of Merger of Ekso Bionics, Inc., with and into Acquisition Sub, filed January 15, 2014 (incorporated by reference from Exhibit 3.3 to the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex3-4.htm">By-Laws of the Registrant (incorporated by reference from Exhibit 3.4 to the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420415072702/v427793_ex3-1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed on December 23, 2015 (incorporated by reference from Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on December 24, 2015)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420416093290/v436201_ex3-1.htm">Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock, filed on April 4, 2016 (incorporated by reference from Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on April 7, 2016)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420416099014/v438965_ex3-1.htm">Certificate of Change of Ekso Bionics Holdings, Inc. effective May 4, 2016 (incorporated by reference from Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on May 5, 2016)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420417065493/tv482098_ex3-1.htm">Certificate of Amendment of Certificate of Incorporation of Ekso Bionics Holdings, Inc. (incorporated by reference from Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on December 27, 2017)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465920037753/tm2013624d1_ex3-1.htm">Certificate of Amendment of Certificate of Incorporation of Ekso Bionics Holdings, Inc. (incorporated by reference from Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on March 24, 2020)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420415038664/v413845_ex4-4.htm">Form of specimen certificate (incorporated by reference from Exhibit 4.4 to the Registrant&#8217;s Registration Statement on Form S-3 filed on June 23, 2015)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-24.htm">Form of Ekso Bionics&#8217; Warrant to purchase shares of its common stock (converted under the Merger Agreement into warrants to purchase shares of the Registrant&#8217;s Common Stock) (incorporated by reference from Exhibit 10.24 to the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2014)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420415072702/v427793_ex4-1.htm">Form of Warrant to purchase shares of the Registrant&#8217;s common stock (incorporated by reference from Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed December 24, 2015)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420419013306/tv515959_ex99-2.htm">Form of Amendment to Common Stock Purchase Warrant (incorporated by reference from Exhibit 99.2 to the Registrant&#8217;s Current Report on Form 8-K filed March 11, 2019)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465919074976/tm1926727d1_ex4-1.htm">Form of Common Stock Purchase Warrant (incorporated by reference from Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed December 20, 2019)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465919074976/tm1926727d1_ex4-2.htm">Form of Placement Agent Common Stock Purchase Warrant (incorporated by reference from Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed December 20, 2019)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.967%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465919076558/tm1928279d2_ex4-1.htm">Form of Warrant (incorporated by reference from Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed December 30, 2019)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex4-1.htm">Form of Warrant (incorporated by reference from Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex4-1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex4-1.htm">10, 2020)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex4-2.htm">Form of Placement Agent Warrant (incorporated by reference from Exhibit 4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex4-2.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex4-2.htm"> to the Registrant&#8217;s Current Report on Form 8-K filed June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex4-2.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex4-2.htm">10, 2020)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit410.htm">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Underwriter Common Stock Purchase Warrant (incorporated by reference from Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed February 11, 2021)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000033/ekso-hcwatmofferingagr.htm">At The Market Offering Agreement, by and among Ekso Bionics Holdings, Inc., and H.C. Wainwright &amp; Co., LLC (incorporated by reference from Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000033/ekso-hcwatmofferingagr.htm">1.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000033/ekso-hcwatmofferingagr.htm"> to the Registrant&#8217;s Current Report on Form 8-K filed on October 9, 2020)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-10.htm">Form of Registration Rights Agreement (incorporated by reference from Exhibit 10.10 of the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114036119008051/nc10001374x1_def14a.htm#tAPPA">Amended and Restated 2014 Equity Incentive Plan (incorporated by reference from Appendix A to the Registrant&#8217;s Proxy Statement on Schedule 14A filed on April 30, 2019)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-13.htm">Form of Director Option Agreement under 2014 Equity Incentive Plan (incorporated by reference from Exhibit 10.13 to the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-14.htm">Form of Employee Option Agreement under 2014 Equity Incentive Plan (incorporated by reference from Exhibit 10.14 to the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420417040909/v471408_ex10-46.htm">Form of Employee Restricted Stock Unit Award under 2014 Equity Incentive Plan (incorporated by reference from Exhibit 10.46 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed August 7, 2017)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420417022835/v465227_def14a.htm#a_015">2017 Employee Stock Purchase Plan (incorporated by reference from Appendix A to Registrant&#8217;s Proxy Statement on Schedule 14 filed on April 28, 2017)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420418043722/tv500802_ex10-1.htm">Jack Glenn Offer Letter dated July 24, 2018 (incorporated by reference from Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed August 13, 2018)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:9pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420418043722/tv500802_ex10-2.htm">Jack Glenn Employment Agreement effective August 13, 2018 (incorporated by reference from Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed August 13, 2018)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420418057183/tv506199_ex10-1.htm">Steven Sherman Offer Letter dated October 30, 2018 (incorporated by reference from Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed November 5, 2018)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000162828018013896/ekso-093018xex103.htm">Jack Peurach Employment Agreement dated August 7, 2018 (incorporated by reference from Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed November 7, 2018)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#8224;**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000005/exhibit1011.htm">Jason Jones Offer Letter dated September 19, 2018 (incorporated by reference from Exhibit 10.11 to the Registrant's Annual Report on Form 10-K filed February 27, 2020)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420419023745/tv520694_ex10-1.htm">William Shaw Offer Letter dated April 2, 2019 (incorporated by reference from Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed May 6, 2019)</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.967%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-19.htm">Exclusive License Agreement, dated as of November 15, 2005, by and between The Regents of the University of California and Berkeley ExoTech, Inc., d/b/a Berkeley ExoWorks (incorporated by reference from Exhibit 10.19 to the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-20.htm">Exclusive License Agreement, dated as of July 14, 2008, by and between The Regents of the University of California and Berkeley ExoTech, Inc., d/b/a/ Berkeley Bionics and formerly d/b/a Berkeley ExoWorks (as amended by Amendment #1 to Exclusive License Agreement, dated as of May 20, 2009, by and between The Regents of the University of California and Berkeley Bionics) (incorporated by reference from Exhibit 10.20 to the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414019450/v373064_ex10-25.htm">Government Field Cross License Agreement dated as of July 1, 2013 between Ekso Bionics and Lockheed Martin Corporation (incorporated by reference from Exhibit 10.25 to the Amendment No. 2 to the Registrations&#8217; Current Report on Form 8-K filed March 31, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414019450/v373064_ex10-26.htm">Medical License Agreement dated as of July 1, 2013 between Ekso Bionics and Lockheed Martin Corporation (incorporated by reference from Exhibit 10.26 to the Amendment No. 2 to the Registrations&#8217; Current Report on Form 8-K filed March 31, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414019450/v373064_ex10-27.htm">Cross License Agreement dated as of July 1, 2013 between Ekso Bionics and Lockheed Martin Corporation (incorporated by reference from Exhibit 10.27 to the Amendment No. 2 to the Registrations&#8217; Current Report on Form 8-K filed March 31, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414029944/v377217_ex10-20.htm">Form of Non-Employee Director Indemnification Agreement (incorporated by reference from Exhibit 10.20 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 13, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414029944/v377217_ex10-21.htm">Form of Executive Officer Indemnification Agreement (incorporated by reference from Exhibit 10.21 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 13, 2014)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420415072702/v427793_ex10-1.htm">Securities Purchase Agreement dated December 23, 2015, between Ekso Bionics Holdings, Inc. and each purchaser thereto (incorporated by reference from Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed December 24, 2015)</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420416093290/v436201_ex10-1.htm">Form of Amendment to Securities Purchase Agreement&#160;(incorporated by reference from Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed April 7, 2016)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420419013306/tv515959_ex99-1.htm">Form of Amendment to Purchase Agreement (incorporated by reference from Exhibit 99.1 to the Registrant&#8217;s Current Report on Form 8-K filed March 11, 2019)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420418045684/tv501341_ex99-1.htm">Form of Waiver of Subsequent Equity Sale Prohibition (incorporated by reference from Exhibit 99.1 to the Registrant&#8217;s Current Report on Form 8-K filed August 21, 2018)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000091957417005581/d7575979_ex10-1.htm">Purchase Agreement, dated as of July 19, 2017, by and between Ekso Bionics Holdings, Inc. and Puissance Cross-Border Opportunities II LLC&#160;(incorporated by reference from Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed July 25, 2017)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000091957417005581/d7575979_ex10-2.htm">Registration Rights Agreement, dated as of July 19, 2017, by and between Ekso Bionics Holdings, Inc. and Puissance Cross-Border Opportunities II LLC (incorporated by reference from Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed July 25, 2017)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000110465919074976/tm1926727d1_ex10-1.htm">Form of Securities Purchase Agreement (incorporated by reference from Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed December 20, 2019)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-21.htm">Lease, dated November 29, 2011, between FPOC, LLC and Berkeley Bionics, Inc dba Ekso Bionics (incorporated by reference from Exhibit 10.21 to the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2014)</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.967%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000005/exhibit1028.htm">First Amendment to Lease Agreement, dated March 28, 2012, between FPOC LLC and Berkeley Bionics, Inc. DBA Ekso Bionics, Inc. (incorporated by reference from Exhibit 10.28 to the Registrant's Annual Report on Form 10-K filed February 27, 2020)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420416132829/v451418_ex10-38.htm">Second Amendment to Lease Agreement dated November 5, 2016, between FPOC, LLC and Ekso Bionics, Inc. (incorporated by reference from Exhibit 10.38 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1030.htm">Third Amendment to Lease Agreement dated June 16, 2020 between FPOC, LLC and Ekso Bionics, Inc.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000016/ekso-3312020xex101.htm">Second Amendment to Loan and Security Agreement, dated April 29, 2020, by and between Western Alliance Bank, Ekso Bionics Holdings, Inc. and Ekso Bionics, Inc. (incorporated by reference from </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000016/ekso-3312020xex101.htm">Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000016/ekso-3312020xex101.htm"> 10.1 to the Registrant's Quarterly Report on Form 10-Q filed April 30, 2020)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000114420417001005/v456407_ex10-2.htm">Success Fee Agreement dated as of December 30, 2016 by and among the Registrant, Ekso Bionics, Inc. and Western Alliance Bank (incorporated by reference from Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed January 6, 2017)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000027/exhibit101.htm">Loan and Security Agreement dated as of August 17, 2020 by and among the Registrant, EKSO Bionics Holdings, Inc., EKSO Bionics, Inc. and Pacific Western Bank (incorporated by reference from Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed August 21, 2020)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908419000002/exhibit103612312018.htm">Agreement for Consulting Services between Ekso Bionics Holdings, Inc and Angel Pond Capital, LLC, dated July 2017 (incorporated by reference from Exhibit 10.36 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2018)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000008/ex101.htm">Unsecured Paycheck Protection Program Note, dated April 18, 2020, by and between the Registrant, EKSO Bionics, Inc., and Western Alliance Bank, under the U.S. Small Business Administration (incorporated by reference from Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed April 24, 2020)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21112312020.htm">Subsidiaries of the Registrant</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23112312020.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31112312020.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31212312020.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32112312020.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32212312020.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 &#167;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files of Financial Statements and Notes.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.ins &#167;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instant Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.sch &#167;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.cal &#167;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.def &#167;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.lab &#167;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.pre &#167;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Presentation Linkbase Document</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Confidential Treatment portions of this exhibit have been omitted as permitted by applicable regulations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement</span></div><div><span><br/></span></div><div id="i3e979bd8812343be80d8bde3987d68dd_1662"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to include summary information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i3e979bd8812343be80d8bde3987d68dd_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e979bd8812343be80d8bde3987d68dd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ Jack Peurach</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWERS OF ATTORNEY</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and Jack Peurach and John F. Glenn, and each of them, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their substitutes may lawfully do or cause to be done by virtue hereof.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:32.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ Jack Peurach</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jack Peurach</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ John F. Glenn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John F. Glenn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting and Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ Steven Sherman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Steven Sherman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ Mary Ann Cloyd</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mary Ann Cloyd</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ Charles Li</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Charles Li</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ Rhonda A. Wallen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rhonda A. Wallen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ Stanley Stern</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stanley Stern</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ Ted Wang</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ted Wang</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>2
<FILENAME>exhibit410.htm
<DESCRIPTION>EX-4.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iceb7358674a5418b866ba540d68dd213_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.10</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES  <br>REGISTERED PURSUANT TO SECTION 12 OF  <br>THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary description of common stock of Ekso Bionics Holdings, Inc. (the &#8220;Company&#8221; or &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;), which the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The following summary does not purport to be complete and is subject to and qualified in its entirety by reference to the applicable provisions of Nevada law, our articles of incorporation, as amended (&#8220;charter&#8221;) and our bylaws (&#8220;bylaws&#8221;).  For a complete description of our common stock, we refer you to our charter and our bylaws, which are included as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2020.&#160; The summary below is also qualified by provisions of applicable law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF COMMON STOCK</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our charter, we are authorized to issue 141,428,571 shares of common stock, par value $0.001 per share.&#160;</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of outstanding shares of common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times and in such amounts as the board from time to time may determine. </font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting of the election of directors then standing for election. </font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-emptive Rights, Redemption, Conversion and Sinking Fund Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The common stock is not entitled to pre-emptive rights and is not subject to conversion, redemption or sinking fund provisions. </font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon liquidation, dissolution or winding up of our Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of the common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. Each outstanding share of common stock is duly and validly issued, fully paid and non-assessable.&#160;</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There are no restrictions on the transfer of our common stock except such restrictions as may be imposed by applicable securities laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Listing</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;EKSO.&#8221;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>3
<FILENAME>exhibit1030.htm
<DESCRIPTION>EX-10.30
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id07768eb4eb743c4ae95cd87d6dfcdc0_1"></div><div style="min-height:69pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.30</font></div></div><div style="margin-top:3.2pt;padding-left:96.15pt;padding-right:96.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">THIRD AMENDMENT TO LEASE AGREEMENT</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">THIS THIRD AMENDMENT TO LEASE AGREEMENT (this &#8220;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:118%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Amendment&#8221;) is made as of June 16, 2020, between FPOC, LLC, a California limited liability company (hereinafter called &#34;Landlord&#34;), and Ekso Bionics, Inc., a Delaware corporation (hereinafter called &#34;Tenant&#34;), having a place of business at 1414 Harbour Way So., Suite 1201, Richmond, California 94804 (the &#8220;Premises&#8221;).</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:96.12pt;padding-right:96.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41.95pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;padding-left:24.34pt">Landlord is the owner of the office building located at 1414 Harbour Way So., Richmond, California 94804, and commonly known as The Ford Building (the &#8220;Building&#8221;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:44.95pt;padding-right:5.85pt;text-align:justify;text-indent:-39pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;padding-left:28pt">Tenant occupies the Premises pursuant to a Lease dated as of November 29, 2011, as amended by a First Amendment to Lease Agreement dated as of March 28, 2012, and a Second Amendment to Lease Agreement dated as of November 5, 2016 (collectively, the &#8220;Lease&#8221;).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41.95pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;padding-left:25pt">Tenant is delinquent in the payment of the Base Rent (as described in Paragraph 3 of the Second Amendment to Lease) and Tenant&#8217;s Operating Cost Share for April and May, 2020 (being $68,274.26 and $25,026.96, respectively) and desires to modify said rent payments to provide for a lump sum (being paid herewith), to amortize (for payment during 2021) certain sums, and to be provided an abatement of certain sums, all of which Landlord is prepare to accommodate and agree to, as set forth and subject to the terms and conditions set forth herein.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:96.15pt;padding-right:96.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AGREEMENT&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:21pt;text-decoration:underline">Capitalized Terms&#59; Incorporation of Recitals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Capitalized terms used but not defined in this 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:117%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%"> Amendment shall have the meanings ascribed to them in the Lease. The recitals set forth above are incorporated by reference in this 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:117%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%"> Amendment with the same force and effect as if repeated at length.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:20.33pt;text-decoration:underline">Rent Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Tenant pays herewith to Landlord the sum of Three Hundred Thousand and 00&#47;100 Dollars ($300,000.00) (the &#8220;Lump Sum&#8221;). Said sum shall be applied as follows&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:78pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">First&#58;&#160;&#160;&#160;&#160;To the Base Rent due for April and May, 2020 (in the amount of</font></div><div style="margin-top:0.25pt;padding-left:60pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">$68,274.26) and to the Tenant&#8217;s Operating Cost Share for April and May, 2020 (in the amount of $25,026.96), being the combined amount of $93,301.22&#59;</font></div><div><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:7%">1</font></div><div><font><br></font></div></div></div><div id="id07768eb4eb743c4ae95cd87d6dfcdc0_4"></div><hr style="page-break-after:always"><div style="min-height:69pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.2pt;padding-left:59.95pt;padding-right:5.8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Second&#58; The balance thereof (being $ $206,698.78) shall be accepted by Landlord as payment in full for the Base Rent otherwise due for the period of June 1 through December 31, 2020 (being $246,128.68, being $35,161.24 x seven months) and for the Tenant&#8217;s Operating Cost Share (paid as a monthly estimate) for the period of June 1 through December 31, 2020 (being $87,594.36, being</font></div><div style="margin-top:0.25pt;padding-left:60pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">$12,513.48 x seven months), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%"> that Tenant pays monthly, timely and in full (due the same day as the payment of Base Rent) from and after January 1, 2021 and for twelve (12) monthly payments thereafter, the sum of $6,612.46 (being a total of such payments of $79,349.54 (the &#8220;Deferred Payment Amount&#8221;)). For clarity of understanding in the preceding, the parties acknowledge that the aggregate sum of Base Rent otherwise due for the period of April through December, 2020, is $314,402.94, and Tenant&#8217;s Operating Cost Share for the same period is $112,621.32, for an aggregate sum of $427,024.26. Upon application of the Lump Sum, a balance owing remains of $127,024.26. Upon payment of the Deferred Payment Amount ($79,349.54), said balance remaining would be</font></div><div style="margin-top:0.7pt;padding-left:60pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$47,674.72.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:60pt;padding-right:5.8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Provided and conditioned upon no event of default having occurred or then existing under the Lease (beyond any applicable cure period), then Landlord shall credit to Tenant, on December 31, 2020, the sum of $47,674.72 (being abated rent otherwise due under the Lease), which credit shall be an inducement. The preceding inducement is conditioned upon Tenant&#8217;s full and faithful performance of all of the terms, covenants and conditions of this Lease. In the event of default (beyond any applicable cure period) said inducement shall automatically be deemed deleted from this Lease and of no further force or effect, and any credit&#47;abatement given or paid by Landlord shall be immediately due and payable by Tenant to Landlord.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:60pt;padding-right:5.75pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">Landlord expressly waives its right to any late fees otherwise provided for under the Lease, as to the payment delinquency for April and May, 2020. The provisions of Paragraph 5.4 of the Lease (setting forth the process for the annual accounting and reconciliation of Tenant&#8217;s Operating Cost Share) shall continue to apply and, as to calendar year 2020, Tenant&#8217;s payments thereto shall be deemed to be in the amount of $150,161.76.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60pt;padding-right:5.7pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Tenant&#8217;s payment obligations for Base Rent as of January 1, 2021 shall be as otherwise stated in the Lease and specifically in Paragraph 3 of the Second Amendment to Lease. Notwithstanding anything to the contrary set forth in the Lease, all payments by Tenant as of January 1, 2021 shall first be applied to the monthly payment due towards the Deferred Payment Amount, and thereafter to all other sums due under the Lease. The Lump Sum paid herewith is deemed and agreed to be &#8220;earned&#8221; immediately by Landlord, and not subject to proration or allocation to any specific or subsequent period(s) of time, and is paid in consideration of Landlord entering into this 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:117%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%"> Amendment, including waiving of certain late fees and providing for the potential abatement described herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:7%">2</font></div><div><font><br></font></div></div></div><div id="id07768eb4eb743c4ae95cd87d6dfcdc0_7"></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%;padding-left:21pt;text-decoration:underline">Continued Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. The parties acknowledge and agree that the Lease remains in full force and effect, unchanged except as expressly provided for in this 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:118%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Amendment. This 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:118%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Amendment and the Lease shall be read together as one document. In the event of any conflict between the terms of this 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:118%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Amendment and the terms of the Lease, the terms of this 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:118%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Amendment shall govern.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:6pt;padding-right:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%;padding-left:20.33pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. This 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:118%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Amendment shall be governed by and construed and enforced in accordance with the laws of the State of California.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%;padding-left:21.68pt;text-decoration:underline">Further Modifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. This 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:118%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Amendment may only be modified pursuant to a written agreement signed by all of the parties hereto.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:20.33pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">. This 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:117%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%"> Amendment and the documents described herein contain the entire agreement between the parties hereto with respect to the matters described herein and supersede all prior agreements, oral or written, between the parties hereto with respect to such matters.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%;padding-left:21.68pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. This 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:118%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Amendment may be executed in several counterparts and all so executed shall constitute one agreement, binding upon all of the parties hereto, notwithstanding that all of the parties are not signatories to the same counterpart.</font></div><div><font><br></font></div><div style="padding-left:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">IN WITNESS WHEREOF, the parties have executed this 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:118%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Amendment as of the date first written above.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LANDLORD&#58;&#160;&#160;&#160;&#160;TENANT&#58;</font></div><div style="margin-top:0.25pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FPOC, LLC&#160;&#160;&#160;&#160;EKSO BIONICS, INC.</font></div><div style="margin-top:0.1pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A California limited liability company&#160;&#160;&#160;&#160;A Delaware corporation</font></div><div><font><br></font></div><div style="padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;text-decoration:underline">&#47;s&#47; J.R. Orton, III</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        J.R. Orton, III</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        Manager</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; John F. Glenn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">John F. Glenn&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.1pt;padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CFO&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:222pt;padding-right:72.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:7%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>exhibit21112312020.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i821ff8a196614ba8bc6a2f29e596605c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF THE REGISTRANT</font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ekso Bionics, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ekso Bionics GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ekso Bionics (Asia) Pte. Ltd. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exhibit23112312020.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia13fef0b4d1c40bf8b7e449c07072aec_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-198357, No. 333-207131, No. 333-220808, No. 333-222663, No. 333-226037, No. 333-230404, No. 333-232512, No. 333-236412 and No. 333-237527), Form S-3 (No. 333-195783, No. 333-220807 and No. 333-239203) and Form S-1 (No. 333-239679) of Ekso Bionics Holdings, Inc. of our report dated February&#160;25, 2021, relating to the consolidated financial statements of Ekso Bionics Holdings, Inc. which appears in this Annual Report on Form 10-K.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; OUM &#38; CO. LLP</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Francisco, California</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exhibit31112312020.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id5a4adbc3c144efca189a0b4923aad3b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jack Peurach, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">I have reviewed this annual report on Form 10-K of Ekso Bionics Holdings, Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021 </font></div><div style="margin-bottom:17pt;margin-top:5pt;padding-left:54pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jack Peurach</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jack Peurach</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exhibit31212312020.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i41d1de5242564e76af627c1e0bb1ce8e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John F. Glenn, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">I have reviewed this annual report on Form 10-K of Ekso Bionics Holdings, Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021 </font></div><div style="margin-bottom:17pt;margin-top:5pt;padding-left:54pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John F. Glenn</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John F. Glenn</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exhibit32112312020.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia2248b7175a54a6a92148a9a62993530_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Ekso Bionics Holdings, Inc. (the &#8220;Company&#8221;), for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Jack Peurach, Chief Executive Officer and President and principal executive officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;25, 2021 </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:252pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jack Peurach</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jack Peurach</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>exhibit32212312020.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icfe936dab9b447799aad53648e1a1b9a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Ekso Bionics Holdings, Inc. (the &#8220;Company&#8221;), for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, John F. Glenn, Chief Financial Officer and principal financial officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;25, 2021 </font></div><div style="margin-bottom:17pt;margin-top:5pt;padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John F. Glenn</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John F. Glenn</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>ekso-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:019e24a5-8506-4b4f-a6ec-39d6306edf95,g:9d00d04a-17f2-484e-b0d0-858320403c94-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ekso="http://www.eksobionics.com/20201231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eksobionics.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ekso-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ekso-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ekso-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ekso-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.eksobionics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.eksobionics.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlows" roleURI="http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows">
        <link:definition>1005006 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.eksobionics.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.eksobionics.com/role/OrganizationDetails">
        <link:definition>2402401 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandEstimates" roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies and Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandEstimatesPolicies" roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies and Estimates (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandEstimatesTables" roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies and Estimates (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails" roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies and Estimates - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails" roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails" roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStock" roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStock">
        <link:definition>2110103 - Disclosure - Net Loss Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockTables" roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables">
        <link:definition>2311302 - Disclosure - Net Loss Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>2412406 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>2413407 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinUnconsolidatedAffiliate" roleURI="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate">
        <link:definition>2114104 - Disclosure - Investment in Unconsolidated Affiliate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinUnconsolidatedAffiliateDetails" roleURI="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliateDetails">
        <link:definition>2415408 - Disclosure - Investment in Unconsolidated Affiliate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.eksobionics.com/role/FairValueMeasurement">
        <link:definition>2116105 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.eksobionics.com/role/FairValueMeasurementTables">
        <link:definition>2317303 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>2418409 - Disclosure - Fair Value Measurement - Schedule of Fair Value Hierarchies for Financial Assets and Liabilities on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails" roleURI="http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails">
        <link:definition>2419410 - Disclosure - Fair Value Measurement - Summary of Changes in Fair Value of Level 3 Financial Liabilities on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.eksobionics.com/role/RevenueRecognition">
        <link:definition>2120106 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.eksobionics.com/role/RevenueRecognitionTables">
        <link:definition>2321304 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionSummaryofDeferredRevenueDetails" roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails">
        <link:definition>2422411 - Disclosure - Revenue Recognition - Summary of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionSummaryofDeferredRevenueDetails_1" roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails_1">
        <link:definition>2422411 - Disclosure - Revenue Recognition - Summary of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionSummaryofDeferredRevenueActivityDetails" roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails">
        <link:definition>2423412 - Disclosure - Revenue Recognition - Summary of Deferred Revenue Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionAdditionalInformationDetails" roleURI="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails">
        <link:definition>2424413 - Disclosure - Revenue Recognition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionAdditionalInformationDetails_1" roleURI="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails_1">
        <link:definition>2424413 - Disclosure - Revenue Recognition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionSummaryofDisaggregationofRevenueDetails" roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails">
        <link:definition>2425414 - Disclosure - Revenue Recognition - Summary of Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnet">
        <link:definition>2126107 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetTables">
        <link:definition>2327305 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>2428415 - Disclosure - Property and Equipment, net - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetNarrativeDetails" roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetNarrativeDetails">
        <link:definition>2429416 - Disclosure - Property and Equipment, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.eksobionics.com/role/AccruedLiabilities">
        <link:definition>2130108 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesTables">
        <link:definition>2331306 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails">
        <link:definition>2432417 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesScheduleofWarrantyCostsDetails" roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails">
        <link:definition>2433418 - Disclosure - Accrued Liabilities - Schedule of Warranty Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Notespayablenet" roleURI="http://www.eksobionics.com/role/Notespayablenet">
        <link:definition>2134109 - Disclosure - Notes payable, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotespayablenetTables" roleURI="http://www.eksobionics.com/role/NotespayablenetTables">
        <link:definition>2335307 - Disclosure - Notes payable, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotespayablenetAdditionalInformationDetails" roleURI="http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails">
        <link:definition>2436419 - Disclosure - Notes payable, net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotespayablenetDebtRepaymentDetails" roleURI="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails">
        <link:definition>2437420 - Disclosure - Notes payable, net - Debt Repayment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotespayablenetDebtRepaymentDetails_1" roleURI="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails_1">
        <link:definition>2437420 - Disclosure - Notes payable, net - Debt Repayment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotespayablenetPrincipalRepaymentDetails" roleURI="http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails">
        <link:definition>2438421 - Disclosure - Notes payable, net - Principal Repayment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligations" roleURI="http://www.eksobionics.com/role/LeaseObligations">
        <link:definition>2139110 - Disclosure - Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsTables" roleURI="http://www.eksobionics.com/role/LeaseObligationsTables">
        <link:definition>2340308 - Disclosure - Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsNarrativeDetails" roleURI="http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails">
        <link:definition>2441422 - Disclosure - Lease Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsFutureMinimumPaymentsDetails" roleURI="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails">
        <link:definition>2442423 - Disclosure - Lease Obligations - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsFutureMinimumPaymentsDetails_1" roleURI="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails_1">
        <link:definition>2442423 - Disclosure - Lease Obligations - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.eksobionics.com/role/EmployeeBenefitPlan">
        <link:definition>2143111 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.eksobionics.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2444424 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.eksobionics.com/role/RelatedPartyTransactions">
        <link:definition>2145112 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.eksobionics.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2446425 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationandEquityStructure" roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructure">
        <link:definition>2147113 - Disclosure - Capitalization and Equity Structure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationandEquityStructureTables" roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureTables">
        <link:definition>2348309 - Disclosure - Capitalization and Equity Structure (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationandEquityStructureNarrativeDetails" roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails">
        <link:definition>2449426 - Disclosure - Capitalization and Equity Structure - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails" roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails">
        <link:definition>2450427 - Disclosure - Capitalization and Equity Structure - Schedule of Warrant Share Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails" roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails">
        <link:definition>2451428 - Disclosure - Capitalization and Equity Structure - Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.eksobionics.com/role/StockbasedCompensation">
        <link:definition>2152114 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.eksobionics.com/role/StockbasedCompensationTables">
        <link:definition>2353310 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation2014EquityIncentivePlanDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails">
        <link:definition>2454429 - Disclosure - Stock-based Compensation - 2014 Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails">
        <link:definition>2455430 - Disclosure - Stock-based Compensation - Summary of Increase in Maximum Number of Shares Issuable to Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails">
        <link:definition>2456431 - Disclosure - Stock-based Compensation - Summary of Shares Available for Future Grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionsNarrativeDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails">
        <link:definition>2457432 - Disclosure - Stock-based Compensation - Stock Options Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>2458433 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationExercisedOptionsNarrativeDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails">
        <link:definition>2459434 - Disclosure - Stock-based Compensation - Exercised Options Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationSummaryofStockOptionsOutstandingDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails">
        <link:definition>2460435 - Disclosure - Stock-based Compensation - Summary of Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails">
        <link:definition>2461436 - Disclosure - Stock-based Compensation - Summary of Share Fair Value of Each Stock Option on Date of Grant using Black-Scholes Model Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails">
        <link:definition>2462437 - Disclosure - Stock-based Compensation - Schedule of Unvested Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails">
        <link:definition>2463438 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense Related to Stock Options and RSUs Granted to Employees and Non-employees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>2464439 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.eksobionics.com/role/IncomeTaxes">
        <link:definition>2165115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.eksobionics.com/role/IncomeTaxesTables">
        <link:definition>2366311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails" roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails">
        <link:definition>2467440 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Pre-tax Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2468441 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails" roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails">
        <link:definition>2469442 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) Differed from Amounts Computed by Applying Statutory Federal Income Tax Rate to Pretax Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2470443 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences and Related Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>2471444 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.eksobionics.com/role/CommitmentsandContingencies">
        <link:definition>2172116 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesTables">
        <link:definition>2373312 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2474445 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails" roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails">
        <link:definition>2475446 - Disclosure - Commitments and Contingencies - Summary of Outstanding Contractual Obligations Including Interest Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentDisclosures" roleURI="http://www.eksobionics.com/role/SegmentDisclosures">
        <link:definition>2176117 - Disclosure - Segment Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentDisclosuresTables" roleURI="http://www.eksobionics.com/role/SegmentDisclosuresTables">
        <link:definition>2377313 - Disclosure - Segment Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentDisclosuresScheduleofSegmentReportingInformationDetails" roleURI="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails">
        <link:definition>2478447 - Disclosure - Segment Disclosures - Schedule of Segment Reporting Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentDisclosuresScheduleofGeographicRevenueInformationDetails" roleURI="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails">
        <link:definition>2479448 - Disclosure - Segment Disclosures - Schedule of Geographic Revenue Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.eksobionics.com/role/SubsequentEvents">
        <link:definition>2180118 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.eksobionics.com/role/SubsequentEventsDetails">
        <link:definition>2481449 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ekso_AccruedLiabilitiesTable" abstract="true" name="AccruedLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ekso_OtherLiabilitiesDomain" abstract="true" name="OtherLiabilitiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_OperatingLeasesRightOfUseAssetInitialRecognition" abstract="false" name="OperatingLeasesRightOfUseAssetInitialRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_DirectOfferingMember" abstract="true" name="DirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_December2019WarrantsMember" abstract="true" name="December2019WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ScheduleOfSignificantAccountingPoliciesTable" abstract="true" name="ScheduleOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ekso_NumberOfLicenseAgreements" abstract="false" name="NumberOfLicenseAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ekso_EksoHealthMember" abstract="true" name="EksoHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_GainLossOnModificationOfOperatingLeaseLiabilities" abstract="false" name="GainLossOnModificationOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_OtherliabilitiesAxis" abstract="true" name="OtherliabilitiesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ekso_SharesIssuedCapitalContribution" abstract="false" name="SharesIssuedCapitalContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_CollaborativeArrangementsMember" abstract="true" name="CollaborativeArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear" abstract="false" name="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_WarrantIssuanceExpense" abstract="false" name="WarrantIssuanceExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_DefinedContributionPlanOfferingPeriod" abstract="false" name="DefinedContributionPlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ekso_StockConversionPrice" abstract="false" name="StockConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ekso_CommonStockContribution" abstract="false" name="CommonStockContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_TwothousandFifteenWarrantsMember" abstract="true" name="TwothousandFifteenWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_Pre2014WarrantsMember" abstract="true" name="Pre2014WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_DeferredExtendedMaintenanceAndSupport" abstract="false" name="DeferredExtendedMaintenanceAndSupport" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_RelatedPartyTransactionConsultingAgreement" abstract="false" name="RelatedPartyTransactionConsultingAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock" abstract="false" name="ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ekso_ProductMaintenanceWarrantyLiabilitiesCurrent" abstract="false" name="ProductMaintenanceWarrantyLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant" abstract="false" name="EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ekso_ProductMaintenanceAndWarrantyTableTextBlock" abstract="false" name="ProductMaintenanceAndWarrantyTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ekso_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" abstract="false" name="ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_OperatingLeasesIncreaseDecreaseInDeferredRent" abstract="false" name="OperatingLeasesIncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter" abstract="false" name="DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightCashFeePercentage" abstract="false" name="ClassOfWarrantOrRightCashFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ekso_JuneTwentyTwentyInvestorWarrantsMember" abstract="true" name="JuneTwentyTwentyInvestorWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_A2017InformationAgentWarrantsMember" abstract="true" name="A2017InformationAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightIssued" abstract="false" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ekso_WarrantPolicyTextBlock" abstract="false" name="WarrantPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ekso_GainLossOnWarrantModification" abstract="false" name="GainLossOnWarrantModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_GainLossOnWarrantLiability" abstract="false" name="GainLossOnWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember" abstract="true" name="JuneTwentyTwentyPlacementAgentsWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_EksoWorksMember" abstract="true" name="EksoWorksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_IssuanceOfCommonStockUnderAbstract" abstract="true" name="IssuanceOfCommonStockUnderAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ekso_ProductMaintenanceWarrantyExpense" abstract="false" name="ProductMaintenanceWarrantyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut" abstract="false" name="StockIssuedDuringPeriodShareEquiposisSalesEarnOut" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ekso_RichmondCaliforniaMember" abstract="true" name="RichmondCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_AngelPondCapitalLlcMember" abstract="true" name="AngelPondCapitalLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightExpirationPeriod" abstract="false" name="ClassOfWarrantOrRightExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ekso_ScheduleOfWarrantsOutstandingTableTextBlock" abstract="false" name="ScheduleOfWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ekso_GovernmentGrantPolicyPolicyTextBlock" abstract="false" name="GovernmentGrantPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ekso_DeferredDeviceRevenue" abstract="false" name="DeferredDeviceRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_OperatingLeasesLiabilityInitialRecognition" abstract="false" name="OperatingLeasesLiabilityInitialRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_NumberOfConsecutiveBusinessDays" abstract="false" name="NumberOfConsecutiveBusinessDays" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod" abstract="false" name="ClassOfWarrantOrRightPutOptionDurationOfPayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightDurationOfPutOption" abstract="false" name="ClassOfWarrantOrRightDurationOfPutOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightOutstandingRollForward" abstract="true" name="ClassOfWarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ekso_GoingConcernPolicyTextBlock" abstract="false" name="GoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ekso_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ContingentSuccessFeeMember" abstract="true" name="ContingentSuccessFeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_HamburgGermanyMember" abstract="true" name="HamburgGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_AccruedClinicalCostCurrent" abstract="false" name="AccruedClinicalCostCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance" abstract="false" name="SaleOfStockValueOfSharesAvailableForFutureIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_December2015WarrantsMember" abstract="true" name="December2015WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_InformationAgentWarrantsMember" abstract="true" name="InformationAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold" abstract="false" name="ClassOfWarrantOrRightPercentageOfAggregateSharesSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ekso_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalWarrantIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_DebtCovenantCovenantComplianceUnrestrictedCash" abstract="false" name="DebtCovenantCovenantComplianceUnrestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightCashFee" abstract="false" name="ClassOfWarrantOrRightCashFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_AccruedLiabilitiesRollforwardRollForward" abstract="true" name="AccruedLiabilitiesRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightManagementFeePercentage" abstract="false" name="ClassOfWarrantOrRightManagementFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ekso_TransferOfPropertyAndEquipmentFromInventory" abstract="false" name="TransferOfPropertyAndEquipmentFromInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_RentalsMember" abstract="true" name="RentalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_FacilityOperatingLeaseMember" abstract="true" name="FacilityOperatingLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_SalesEarnout" abstract="false" name="SalesEarnout" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts" abstract="false" name="StockIssuedDuringPeriodValueEquiposisSalesEarnOuts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_June2020PlacementAgentWarrantsMember" abstract="true" name="June2020PlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightExpired" abstract="false" name="ClassOfWarrantOrRightExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ekso_LoanAgreementMember" abstract="true" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ContractWithCustomerLiabilityDeferralOfRevenue" abstract="false" name="ContractWithCustomerLiabilityDeferralOfRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_ProductMaintenanceWarrantyAddition" abstract="false" name="ProductMaintenanceWarrantyAddition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_December2019PlacementAgentWarrantsMember" abstract="true" name="December2019PlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration" abstract="false" name="ContractsWithCustomerAccountsReceivablePaymentTermsDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" abstract="false" name="ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_ContingentSuccessFeeLiability" abstract="false" name="ContingentSuccessFeeLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightExercised" abstract="false" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ekso_May2019WarrantsMember" abstract="true" name="May2019WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose" abstract="false" name="LineOfCreditFacilityCapacityAvailableForSpecificPurpose" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_UnrestrictedCash" abstract="false" name="UnrestrictedCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember" abstract="true" name="SalesRevenueGoodsNetExcludingGovernmentSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent" abstract="false" name="ProductMaintenanceWarrantyLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_RoyaltyPercentage" abstract="false" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ekso_EquityIncentivePlan2014Member" abstract="true" name="EquityIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ClassOfWarrantOrRightManagementFeeExpense" abstract="false" name="ClassOfWarrantOrRightManagementFeeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_RestrictedStockIssued" abstract="false" name="RestrictedStockIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ekso_OperatingLeaseAbatement" abstract="false" name="OperatingLeaseAbatement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_A2019WarrantsMember" abstract="true" name="A2019WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_PWBLoanAgreementMember" abstract="true" name="PWBLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxAssetsOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_JuneTwentyTwentyPlacementAgentWarrantsMember" abstract="true" name="JuneTwentyTwentyPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward" abstract="false" name="ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ekso_ContractwithCustomerLiabilityNonCancellableBacklog" abstract="false" name="ContractwithCustomerLiabilityNonCancellableBacklog" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_GeneratedBefore2018Expire2027Member" abstract="true" name="GeneratedBefore2018Expire2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_AccruedLiabilitiesLineItems" abstract="true" name="AccruedLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ekso_DebtInstrumentDeferralPeriod" abstract="false" name="DebtInstrumentDeferralPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ekso_LicenseRevenueMember" abstract="true" name="LicenseRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_DeferredRoyalties" abstract="false" name="DeferredRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_June2020InvestorWarrantsMember" abstract="true" name="June2020InvestorWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_StockIssuedDuringPeriodValueExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ekso_June2020WarrantsMember" abstract="true" name="June2020WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_WarrantyMember" abstract="true" name="WarrantyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_GeneratedBefore2018CarryforwardIndefinitelyMember" abstract="true" name="GeneratedBefore2018CarryforwardIndefinitelyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ekso_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ekso_DeferredTaxLiabilitiesOperatingLeaseLiability" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>ekso-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:019e24a5-8506-4b4f-a6ec-39d6306edf95,g:9d00d04a-17f2-484e-b0d0-858320403c94-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eksobionics.com/role/CoverPage" xlink:type="simple" xlink:href="ekso-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9d84a7c6-f234-41d3-9875-94b2c9c85761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7778343d-9d8b-484c-a5c4-8e4d08eb770a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9d84a7c6-f234-41d3-9875-94b2c9c85761" xlink:to="loc_us-gaap_Liabilities_7778343d-9d8b-484c-a5c4-8e4d08eb770a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fbef8126-e482-4a0c-a3fd-12c85c38d297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9d84a7c6-f234-41d3-9875-94b2c9c85761" xlink:to="loc_us-gaap_StockholdersEquity_fbef8126-e482-4a0c-a3fd-12c85c38d297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_af7c406d-564b-42ce-bedc-2851ca458f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6fe892dc-3a90-4cd0-8157-44090fa21e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af7c406d-564b-42ce-bedc-2851ca458f27" xlink:to="loc_us-gaap_PreferredStockValue_6fe892dc-3a90-4cd0-8157-44090fa21e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3e75ffab-5963-4217-9967-d6f7bd313e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af7c406d-564b-42ce-bedc-2851ca458f27" xlink:to="loc_us-gaap_CommonStockValue_3e75ffab-5963-4217-9967-d6f7bd313e33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8998c1ed-7739-4320-8dbc-1efc26b28e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af7c406d-564b-42ce-bedc-2851ca458f27" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8998c1ed-7739-4320-8dbc-1efc26b28e42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b7a3978-833f-42cc-a5ca-8836e3aca7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af7c406d-564b-42ce-bedc-2851ca458f27" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b7a3978-833f-42cc-a5ca-8836e3aca7bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd5dcfa6-bcc1-4ec7-8f8f-af12caa5b678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af7c406d-564b-42ce-bedc-2851ca458f27" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd5dcfa6-bcc1-4ec7-8f8f-af12caa5b678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9b7b2b4-3e6b-4446-8a99-8aaca1262847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23e85601-a53e-490f-9724-fe91f28eb14e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9b7b2b4-3e6b-4446-8a99-8aaca1262847" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23e85601-a53e-490f-9724-fe91f28eb14e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1dae720e-365c-490f-9a69-582d5a98a10f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9b7b2b4-3e6b-4446-8a99-8aaca1262847" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1dae720e-365c-490f-9a69-582d5a98a10f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1058243e-fb98-43e0-996e-73096ae41f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9b7b2b4-3e6b-4446-8a99-8aaca1262847" xlink:to="loc_us-gaap_InventoryNet_1058243e-fb98-43e0-996e-73096ae41f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a29c46cd-cc69-437a-8483-edac1238d1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9b7b2b4-3e6b-4446-8a99-8aaca1262847" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a29c46cd-cc69-437a-8483-edac1238d1bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b0281d2d-f3ed-46b0-9915-199b008ff948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_772b5724-dc6d-4eff-9158-9bde84f07111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0281d2d-f3ed-46b0-9915-199b008ff948" xlink:to="loc_us-gaap_LiabilitiesCurrent_772b5724-dc6d-4eff-9158-9bde84f07111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b7104c04-e214-4583-860c-5028afb9c7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0281d2d-f3ed-46b0-9915-199b008ff948" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b7104c04-e214-4583-860c-5028afb9c7fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_69d66b9e-754c-4fc1-8478-c785e4121693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0281d2d-f3ed-46b0-9915-199b008ff948" xlink:to="loc_us-gaap_LongTermNotesPayable_69d66b9e-754c-4fc1-8478-c785e4121693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a672d612-0976-40cc-8b39-c84d235a987e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0281d2d-f3ed-46b0-9915-199b008ff948" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a672d612-0976-40cc-8b39-c84d235a987e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1528b388-99ee-4b25-b984-c03ddecab895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0281d2d-f3ed-46b0-9915-199b008ff948" xlink:to="loc_us-gaap_DerivativeLiabilities_1528b388-99ee-4b25-b984-c03ddecab895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9453a409-68ee-47bc-a999-13fd97cb1758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0281d2d-f3ed-46b0-9915-199b008ff948" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9453a409-68ee-47bc-a999-13fd97cb1758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_84b1b352-44a2-43b3-a89b-ac2c24b09a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d38648ed-689e-49d9-a3bf-60f25917c057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_84b1b352-44a2-43b3-a89b-ac2c24b09a8f" xlink:to="loc_us-gaap_AssetsCurrent_d38648ed-689e-49d9-a3bf-60f25917c057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cca73f1c-e554-4b00-9c38-e6f73fd439f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_84b1b352-44a2-43b3-a89b-ac2c24b09a8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cca73f1c-e554-4b00-9c38-e6f73fd439f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d2e09ccb-abc3-4c47-b9af-bba6f59d906f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_84b1b352-44a2-43b3-a89b-ac2c24b09a8f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d2e09ccb-abc3-4c47-b9af-bba6f59d906f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_14feef81-b2a0-416f-8743-56b48a6cc4f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_84b1b352-44a2-43b3-a89b-ac2c24b09a8f" xlink:to="loc_us-gaap_Goodwill_14feef81-b2a0-416f-8743-56b48a6cc4f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9d190d61-6ccb-449a-94e4-3488f35a43be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_84b1b352-44a2-43b3-a89b-ac2c24b09a8f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9d190d61-6ccb-449a-94e4-3488f35a43be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1e17a64b-f575-415a-b280-71eaf05e7685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_25eb6004-951e-432a-ad4a-874bc8c55d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1e17a64b-f575-415a-b280-71eaf05e7685" xlink:to="loc_us-gaap_AccountsPayableCurrent_25eb6004-951e-432a-ad4a-874bc8c55d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2c02c15a-c86f-4f15-9c51-1de2f0ca0286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1e17a64b-f575-415a-b280-71eaf05e7685" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2c02c15a-c86f-4f15-9c51-1de2f0ca0286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6fd02d14-a7a0-4d9f-b953-b382090f3279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1e17a64b-f575-415a-b280-71eaf05e7685" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6fd02d14-a7a0-4d9f-b953-b382090f3279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_de3f2eda-d5eb-4ace-9862-79a21d9ed829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1e17a64b-f575-415a-b280-71eaf05e7685" xlink:to="loc_us-gaap_NotesPayableCurrent_de3f2eda-d5eb-4ace-9862-79a21d9ed829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5efb10c2-7598-4e31-a91a-56638756607e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1e17a64b-f575-415a-b280-71eaf05e7685" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5efb10c2-7598-4e31-a91a-56638756607e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e37c824d-5957-4308-b5f0-49de5d516255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f7b4860f-d25b-457d-b152-8108c2787f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e37c824d-5957-4308-b5f0-49de5d516255" xlink:to="loc_us-gaap_OperatingIncomeLoss_f7b4860f-d25b-457d-b152-8108c2787f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a385bd2a-6513-4e4c-a679-a6270c6c8252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e37c824d-5957-4308-b5f0-49de5d516255" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a385bd2a-6513-4e4c-a679-a6270c6c8252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ae008053-9bc8-4aaa-9216-a2782828f77d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_919b89b4-840c-45ce-a3c4-a9ec49ad8ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ae008053-9bc8-4aaa-9216-a2782828f77d" xlink:to="loc_us-gaap_InterestExpense_919b89b4-840c-45ce-a3c4-a9ec49ad8ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_WarrantIssuanceExpense_ce438a77-1692-4b81-af5a-804836cd9536" xlink:href="ekso-20201231.xsd#ekso_WarrantIssuanceExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ae008053-9bc8-4aaa-9216-a2782828f77d" xlink:to="loc_ekso_WarrantIssuanceExpense_ce438a77-1692-4b81-af5a-804836cd9536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantLiability_7f32c99f-2ae7-438b-9ebb-4bc0227a8d8f" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ae008053-9bc8-4aaa-9216-a2782828f77d" xlink:to="loc_ekso_GainLossOnWarrantLiability_7f32c99f-2ae7-438b-9ebb-4bc0227a8d8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantModification_dc881b31-4b04-4855-af03-b96bc3bbb5e3" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantModification"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ae008053-9bc8-4aaa-9216-a2782828f77d" xlink:to="loc_ekso_GainLossOnWarrantModification_dc881b31-4b04-4855-af03-b96bc3bbb5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_765973f4-9507-4811-8a5e-8b4add943862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ae008053-9bc8-4aaa-9216-a2782828f77d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_765973f4-9507-4811-8a5e-8b4add943862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0c78e96e-6077-4f5b-81f7-eb82aebb24d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e1b335e4-6305-4e30-876e-d02809db98a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0c78e96e-6077-4f5b-81f7-eb82aebb24d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e1b335e4-6305-4e30-876e-d02809db98a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_3e3370ff-ac4e-4c43-9efb-5bf88093c927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0c78e96e-6077-4f5b-81f7-eb82aebb24d9" xlink:to="loc_us-gaap_SellingAndMarketingExpense_3e3370ff-ac4e-4c43-9efb-5bf88093c927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2cd28052-eaeb-47e6-a74c-1eb5313eeb26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0c78e96e-6077-4f5b-81f7-eb82aebb24d9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2cd28052-eaeb-47e6-a74c-1eb5313eeb26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3d5f0fab-edee-41ab-aa46-1a95f94f569f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0c78e96e-6077-4f5b-81f7-eb82aebb24d9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3d5f0fab-edee-41ab-aa46-1a95f94f569f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3ef7a0a1-0fd1-4b6c-ac3a-7117d0e4b87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0c78e96e-6077-4f5b-81f7-eb82aebb24d9" xlink:to="loc_us-gaap_RestructuringCharges_3ef7a0a1-0fd1-4b6c-ac3a-7117d0e4b87a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0885aad3-939b-41e8-a620-f34b750d244e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_17235099-2ab9-4b1e-ac52-c35a8df94d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0885aad3-939b-41e8-a620-f34b750d244e" xlink:to="loc_us-gaap_GrossProfit_17235099-2ab9-4b1e-ac52-c35a8df94d20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3e9ac003-8d9e-4da8-b889-59f749119c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0885aad3-939b-41e8-a620-f34b750d244e" xlink:to="loc_us-gaap_OperatingExpenses_3e9ac003-8d9e-4da8-b889-59f749119c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_dc743569-c688-405c-b5ab-87f5a50804e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_12b816d4-528e-40b8-800a-935d7232c1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_dc743569-c688-405c-b5ab-87f5a50804e2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_12b816d4-528e-40b8-800a-935d7232c1b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d6143e17-0b59-47c6-bc1e-9cea506439e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_dc743569-c688-405c-b5ab-87f5a50804e2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d6143e17-0b59-47c6-bc1e-9cea506439e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4f84fe64-c91f-4bfc-9852-c54ab954e56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6f1cf1a-ab4c-47f1-88bd-387e85b37745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4f84fe64-c91f-4bfc-9852-c54ab954e56f" xlink:to="loc_us-gaap_NetIncomeLoss_b6f1cf1a-ab4c-47f1-88bd-387e85b37745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1a0a4a2f-e9ec-41e4-a711-a773fc527f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4f84fe64-c91f-4bfc-9852-c54ab954e56f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1a0a4a2f-e9ec-41e4-a711-a773fc527f1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7ecc56c0-3544-43a7-b07f-b8054ac13107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7ecc56c0-3544-43a7-b07f-b8054ac13107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a7a534e2-2292-453f-8ae8-1f588619d7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a7a534e2-2292-453f-8ae8-1f588619d7bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantModification_d6dac193-52f2-4229-93be-b242044b8db8" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantModification"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_ekso_GainLossOnWarrantModification_d6dac193-52f2-4229-93be-b242044b8db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_04025b6b-f8cd-4327-94cb-e51f48cee2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_04025b6b-f8cd-4327-94cb-e51f48cee2c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c07c06f3-2b77-4a38-8289-1519af7e261c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c07c06f3-2b77-4a38-8289-1519af7e261c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bbb6b75b-ed39-488f-80e1-46b55622624b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_NetIncomeLoss_bbb6b75b-ed39-488f-80e1-46b55622624b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8458c451-eac5-4450-863c-5dc24405564f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8458c451-eac5-4450-863c-5dc24405564f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7c1e47d8-627d-4553-b9d2-d33347f5fa52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7c1e47d8-627d-4553-b9d2-d33347f5fa52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_160d59a9-f4a7-420e-b08e-f1656b9e1395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_ShareBasedCompensation_160d59a9-f4a7-420e-b08e-f1656b9e1395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CommonStockContribution_7624968c-cbaf-4bcf-b2be-2189b8e80938" xlink:href="ekso-20201231.xsd#ekso_CommonStockContribution"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_ekso_CommonStockContribution_7624968c-cbaf-4bcf-b2be-2189b8e80938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e5587ed0-df69-4351-96de-defaaf2b9c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e5587ed0-df69-4351-96de-defaaf2b9c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantLiability_f2ca7d55-44ed-41c0-95b6-9946521f70dc" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantLiability"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_ekso_GainLossOnWarrantLiability_f2ca7d55-44ed-41c0-95b6-9946521f70dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnModificationOfOperatingLeaseLiabilities_6ed6bd31-b548-4345-bacb-abd76ef319fc" xlink:href="ekso-20201231.xsd#ekso_GainLossOnModificationOfOperatingLeaseLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_ekso_GainLossOnModificationOfOperatingLeaseLiabilities_6ed6bd31-b548-4345-bacb-abd76ef319fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d71e3263-3ad3-413c-aa69-afd19f56eeae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d71e3263-3ad3-413c-aa69-afd19f56eeae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7efac907-d15a-4c45-86c2-cf1c0cd1f1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7efac907-d15a-4c45-86c2-cf1c0cd1f1cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_77666815-19b2-4548-af3a-113afa3329cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_77666815-19b2-4548-af3a-113afa3329cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_02bb7636-20db-49da-9842-3b8001c69bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_02bb7636-20db-49da-9842-3b8001c69bcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_66a29456-43a1-4f95-a895-7b14bba5a246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_Depreciation_66a29456-43a1-4f95-a895-7b14bba5a246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_3169da31-56df-42fb-87ec-53dfe065737f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89776c79-c5ff-49f6-94e4-de5c3a7dcc7d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_3169da31-56df-42fb-87ec-53dfe065737f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36ff641a-b12b-47c8-8ef3-f29885d04b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_61a04553-d1f0-4eed-b021-a04661b3c757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36ff641a-b12b-47c8-8ef3-f29885d04b77" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_61a04553-d1f0-4eed-b021-a04661b3c757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_2d7f48b3-9cf1-4917-97f2-2c258d2f5d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36ff641a-b12b-47c8-8ef3-f29885d04b77" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_2d7f48b3-9cf1-4917-97f2-2c258d2f5d2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_41b446aa-5d52-47e4-9281-dcded895e2ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36ff641a-b12b-47c8-8ef3-f29885d04b77" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_41b446aa-5d52-47e4-9281-dcded895e2ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_30c3bbc0-40f7-44fd-b102-4034cc5a9607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36ff641a-b12b-47c8-8ef3-f29885d04b77" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_30c3bbc0-40f7-44fd-b102-4034cc5a9607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c36955c1-3a58-4c7b-a407-1c5413ceb7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36ff641a-b12b-47c8-8ef3-f29885d04b77" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c36955c1-3a58-4c7b-a407-1c5413ceb7bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_87412da2-c004-4b4a-b8bb-fcfc1e0799e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36ff641a-b12b-47c8-8ef3-f29885d04b77" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_87412da2-c004-4b4a-b8bb-fcfc1e0799e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a1202011-f7de-49bd-9a12-ea6b3a8da969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c07a580f-b119-4a44-ac8d-d0ad811a2e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a1202011-f7de-49bd-9a12-ea6b3a8da969" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c07a580f-b119-4a44-ac8d-d0ad811a2e1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_58d4f0c6-a506-4ca7-b798-4847870952c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a1202011-f7de-49bd-9a12-ea6b3a8da969" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_58d4f0c6-a506-4ca7-b798-4847870952c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0147023-ca35-450f-bb11-8650cdba3013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a1202011-f7de-49bd-9a12-ea6b3a8da969" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0147023-ca35-450f-bb11-8650cdba3013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4466df9-f8c2-401a-ab8b-3c8c740d2a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a1202011-f7de-49bd-9a12-ea6b3a8da969" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4466df9-f8c2-401a-ab8b-3c8c740d2a05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd23e240-5615-457a-9676-9bf0113b0b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f814be9-d52c-4a65-93c5-850093a3088a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd23e240-5615-457a-9676-9bf0113b0b00" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f814be9-d52c-4a65-93c5-850093a3088a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/Organization" xlink:type="simple" xlink:href="ekso-20201231.xsd#Organization"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/Organization" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/OrganizationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#OrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/OrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimates"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesPolicies"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_088d373e-7e45-4794-8df4-bc65d67a0089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c58af7f0-93e7-4cb9-91dd-df51daa64887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_088d373e-7e45-4794-8df4-bc65d67a0089" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c58af7f0-93e7-4cb9-91dd-df51daa64887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9e3e4ae5-b674-48cf-a9a4-6b1c3ac940e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_088d373e-7e45-4794-8df4-bc65d67a0089" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9e3e4ae5-b674-48cf-a9a4-6b1c3ac940e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5c17d714-6f5c-42b8-a683-cb4a8ee239b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_088d373e-7e45-4794-8df4-bc65d67a0089" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5c17d714-6f5c-42b8-a683-cb4a8ee239b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStock" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStock"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStockTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90ff3c89-e29d-4b10-a8e8-61f8f59d864b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_03eb5dbe-f5fd-4663-861c-d1c436345850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90ff3c89-e29d-4b10-a8e8-61f8f59d864b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_03eb5dbe-f5fd-4663-861c-d1c436345850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_4148235b-aa44-4395-8254-e3178739fa51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f07a73db-c764-43fa-9dbc-3e256158c526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_4148235b-aa44-4395-8254-e3178739fa51" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f07a73db-c764-43fa-9dbc-3e256158c526" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate" xlink:type="simple" xlink:href="ekso-20201231.xsd#InvestmentinUnconsolidatedAffiliate"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliateDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#InvestmentinUnconsolidatedAffiliateDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliateDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurement"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurementTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurementTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognition"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognition" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDeferredRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_36e2c819-3063-4579-9b65-87865d7753e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredDeviceRevenue_e5a6968d-5d7d-486a-b184-08e1517b3773" xlink:href="ekso-20201231.xsd#ekso_DeferredDeviceRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_36e2c819-3063-4579-9b65-87865d7753e4" xlink:to="loc_ekso_DeferredDeviceRevenue_e5a6968d-5d7d-486a-b184-08e1517b3773" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredExtendedMaintenanceAndSupport_82ea7eaa-10a9-47c0-9f01-b8c977ca6216" xlink:href="ekso-20201231.xsd#ekso_DeferredExtendedMaintenanceAndSupport"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_36e2c819-3063-4579-9b65-87865d7753e4" xlink:to="loc_ekso_DeferredExtendedMaintenanceAndSupport_82ea7eaa-10a9-47c0-9f01-b8c977ca6216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredRoyalties_a2e88e55-1da6-43c9-a416-87d27a739d0c" xlink:href="ekso-20201231.xsd#ekso_DeferredRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_36e2c819-3063-4579-9b65-87865d7753e4" xlink:to="loc_ekso_DeferredRoyalties_a2e88e55-1da6-43c9-a416-87d27a739d0c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails_1" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDeferredRevenueDetails_1"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_09a7c074-dcec-47f7-85d6-802518b14553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f82617a0-27e6-4582-b32f-7d72c37eea3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_09a7c074-dcec-47f7-85d6-802518b14553" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f82617a0-27e6-4582-b32f-7d72c37eea3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9e2c9454-9090-4a8e-8269-4257c1a46fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_09a7c074-dcec-47f7-85d6-802518b14553" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9e2c9454-9090-4a8e-8269-4257c1a46fa6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDeferredRevenueActivityDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails_1" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionAdditionalInformationDetails_1"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDisaggregationofRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnet"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnetTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_86506a58-2c82-405e-a775-c623b2abaee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_68f89703-a68e-4451-835f-99b7a344a297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_86506a58-2c82-405e-a775-c623b2abaee2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_68f89703-a68e-4451-835f-99b7a344a297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14993a9b-8753-4e8d-89ae-ce91e93e4acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_86506a58-2c82-405e-a775-c623b2abaee2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14993a9b-8753-4e8d-89ae-ce91e93e4acc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnetNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilities"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0b9ae7a5-47ed-4472-85bf-a0337002e85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedClinicalCostCurrent_2c0d7fc5-56ba-427a-a1ff-7ce67a28591c" xlink:href="ekso-20201231.xsd#ekso_AccruedClinicalCostCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0b9ae7a5-47ed-4472-85bf-a0337002e85a" xlink:to="loc_ekso_AccruedClinicalCostCurrent_2c0d7fc5-56ba-427a-a1ff-7ce67a28591c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5efdde84-4b58-4f46-b1be-d60da57f3637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0b9ae7a5-47ed-4472-85bf-a0337002e85a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5efdde84-4b58-4f46-b1be-d60da57f3637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_9717ce7d-899f-4dd3-8eba-452840bf7727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0b9ae7a5-47ed-4472-85bf-a0337002e85a" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_9717ce7d-899f-4dd3-8eba-452840bf7727" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilitiesScheduleofWarrantyCostsDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_23c15807-6df7-464a-83cd-6f134f5d3e10" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent_18071750-1681-4eb3-baf3-8d98d42f7e59" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_23c15807-6df7-464a-83cd-6f134f5d3e10" xlink:to="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent_18071750-1681-4eb3-baf3-8d98d42f7e59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent_e1007619-0545-4f56-ae52-d31c77ad0413" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_23c15807-6df7-464a-83cd-6f134f5d3e10" xlink:to="loc_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent_e1007619-0545-4f56-ae52-d31c77ad0413" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/Notespayablenet" xlink:type="simple" xlink:href="ekso-20201231.xsd#Notespayablenet"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/Notespayablenet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/NotespayablenetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetDebtRepaymentDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e765bce0-ef06-4106-83b0-8d2e18a0a274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear_4502ff2a-acdb-4a7a-a5d7-1d162a3ae735" xlink:href="ekso-20201231.xsd#ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_e765bce0-ef06-4106-83b0-8d2e18a0a274" xlink:to="loc_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear_4502ff2a-acdb-4a7a-a5d7-1d162a3ae735" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cfd51118-8afd-42ed-b7d4-e18acd649d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_e765bce0-ef06-4106-83b0-8d2e18a0a274" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cfd51118-8afd-42ed-b7d4-e18acd649d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fbc72fb2-eba6-468f-9a46-b390668a87c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b25d4ecb-3954-4dae-98d5-26052481c714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_fbc72fb2-eba6-468f-9a46-b390668a87c5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b25d4ecb-3954-4dae-98d5-26052481c714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b576c235-4e76-4d54-9588-7709e1de6934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_fbc72fb2-eba6-468f-9a46-b390668a87c5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b576c235-4e76-4d54-9588-7709e1de6934" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails_1" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetDebtRepaymentDetails_1"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ac1e4e8f-0f60-4de5-90e4-9148c8895d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_06258ec2-082d-40d9-85ac-623660299a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ac1e4e8f-0f60-4de5-90e4-9148c8895d77" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_06258ec2-082d-40d9-85ac-623660299a4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_cde6e885-4927-4d2a-8c81-8dcc0717f1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ac1e4e8f-0f60-4de5-90e4-9148c8895d77" xlink:to="loc_us-gaap_LongTermDebtCurrent_cde6e885-4927-4d2a-8c81-8dcc0717f1d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetPrincipalRepaymentDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_921330d8-8b8d-4fa0-9224-bff2d124d1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5148a116-5480-45a5-9081-d789f4d12c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_921330d8-8b8d-4fa0-9224-bff2d124d1c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5148a116-5480-45a5-9081-d789f4d12c9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fc802630-8bd5-41f5-b7d6-56015042b473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_921330d8-8b8d-4fa0-9224-bff2d124d1c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fc802630-8bd5-41f5-b7d6-56015042b473" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligations" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligations"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/LeaseObligations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3423f6d6-47f1-4a7e-91bb-5df3ce5dfe59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ac1fec67-8502-4426-990b-b19cf6b0f89b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3423f6d6-47f1-4a7e-91bb-5df3ce5dfe59" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ac1fec67-8502-4426-990b-b19cf6b0f89b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2e6989a3-ddb7-4e21-9b84-86ca163acb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3423f6d6-47f1-4a7e-91bb-5df3ce5dfe59" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2e6989a3-ddb7-4e21-9b84-86ca163acb53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_462f8b94-c7af-4949-8897-dc847d8d2d07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_82cc5979-0da6-4569-bc18-cc2d298fcb6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_462f8b94-c7af-4949-8897-dc847d8d2d07" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_82cc5979-0da6-4569-bc18-cc2d298fcb6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9cb0b425-21df-4cc7-8941-9a42e598368b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_462f8b94-c7af-4949-8897-dc847d8d2d07" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9cb0b425-21df-4cc7-8941-9a42e598368b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails_1" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsFutureMinimumPaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f7f09985-1f34-43be-8a87-7b2ee87f4dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_97e5efbc-d26b-461d-9cb0-b67f534b839c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f7f09985-1f34-43be-8a87-7b2ee87f4dbe" xlink:to="loc_us-gaap_OperatingLeaseLiability_97e5efbc-d26b-461d-9cb0-b67f534b839c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_208e6ca2-a325-4a22-a994-602d98e0dcf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f7f09985-1f34-43be-8a87-7b2ee87f4dbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_208e6ca2-a325-4a22-a994-602d98e0dcf1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="ekso-20201231.xsd#EmployeeBenefitPlan"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/EmployeeBenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ekso-20201231.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructure" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructure"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructure" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensation"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensation2014EquityIncentivePlanDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationStockOptionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationExercisedOptionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofStockOptionsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3af9d9ca-1154-491c-a5ce-4d3d49904b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7239e3fa-6adf-447a-8d89-33864f13d417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3af9d9ca-1154-491c-a5ce-4d3d49904b0c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7239e3fa-6adf-447a-8d89-33864f13d417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_af103bae-033c-48eb-b797-5013ce261f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3af9d9ca-1154-491c-a5ce-4d3d49904b0c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_af103bae-033c-48eb-b797-5013ce261f27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_271e80b5-ba52-45a1-9f6c-202e2e7ab3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_364a7853-601f-4a9d-b9da-9c3c2eda2a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_271e80b5-ba52-45a1-9f6c-202e2e7ab3ea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_364a7853-601f-4a9d-b9da-9c3c2eda2a6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_65c5693d-5bf9-47a6-8192-7476c6c60407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_271e80b5-ba52-45a1-9f6c-202e2e7ab3ea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_65c5693d-5bf9-47a6-8192-7476c6c60407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_93520cef-6c1e-4856-83ad-cb99ddc70f99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_271e80b5-ba52-45a1-9f6c-202e2e7ab3ea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_93520cef-6c1e-4856-83ad-cb99ddc70f99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b30a8dca-62fd-4289-b116-1efcb2ce8a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_271e80b5-ba52-45a1-9f6c-202e2e7ab3ea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b30a8dca-62fd-4289-b116-1efcb2ce8a07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant_f73a9bd0-ca21-4203-982b-5830037d2240" xlink:href="ekso-20201231.xsd#ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_271e80b5-ba52-45a1-9f6c-202e2e7ab3ea" xlink:to="loc_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant_f73a9bd0-ca21-4203-982b-5830037d2240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2301763f-7b80-4485-933b-b83f231752ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_271e80b5-ba52-45a1-9f6c-202e2e7ab3ea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2301763f-7b80-4485-933b-b83f231752ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4f205319-c1f1-429e-aa0a-4a699517c417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_271e80b5-ba52-45a1-9f6c-202e2e7ab3ea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4f205319-c1f1-429e-aa0a-4a699517c417" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_46182d0c-9654-4e2c-9a6a-bd5854bc3eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_46182d0c-9654-4e2c-9a6a-bd5854bc3eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d1701b7f-3274-42d5-afd3-9421973512d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d1701b7f-3274-42d5-afd3-9421973512d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_80bdfe1d-5c5b-461b-86c7-b437d7e996d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_80bdfe1d-5c5b-461b-86c7-b437d7e996d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_00865dc7-cfa2-4f92-b57d-ef542be7a774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_00865dc7-cfa2-4f92-b57d-ef542be7a774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_4fae2527-cbbd-460d-8d20-43de97e2d927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_4fae2527-cbbd-460d-8d20-43de97e2d927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1c8998fd-c3fd-4d9d-b09a-29e4c1bf9b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1c8998fd-c3fd-4d9d-b09a-29e4c1bf9b78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_abcc4dc9-7043-4f4c-b61d-8df7d2399582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_abcc4dc9-7043-4f4c-b61d-8df7d2399582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b618e266-7119-413c-95d1-e04cbabead6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b618e266-7119-413c-95d1-e04cbabead6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability_52f6ed09-56e4-4304-b2fd-f327ab2bbb75" xlink:href="ekso-20201231.xsd#ekso_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability_52f6ed09-56e4-4304-b2fd-f327ab2bbb75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_2f9e53b3-e425-4be7-b188-70372e55c35f" xlink:href="ekso-20201231.xsd#ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_2f9e53b3-e425-4be7-b188-70372e55c35f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8785f902-9c46-4447-88b8-2612902a0b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ad106157-ff93-4040-9dcc-2bc4aba44597" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8785f902-9c46-4447-88b8-2612902a0b80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_87cf1132-1cc5-4c48-b056-47438bbdfd32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_3ad568d5-48cc-464d-adab-c7412bf204e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_87cf1132-1cc5-4c48-b056-47438bbdfd32" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_3ad568d5-48cc-464d-adab-c7412bf204e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_bd86d823-4de0-42f7-bda4-2929ad74fddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_87cf1132-1cc5-4c48-b056-47438bbdfd32" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_bd86d823-4de0-42f7-bda4-2929ad74fddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_d72976e8-25d1-47b2-8c4b-b7f2d66b124f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_87cf1132-1cc5-4c48-b056-47438bbdfd32" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_d72976e8-25d1-47b2-8c4b-b7f2d66b124f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosures" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosures"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosuresTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosuresTables"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosuresTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosuresScheduleofSegmentReportingInformationDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosuresScheduleofGeographicRevenueInformationDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ekso-20201231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.eksobionics.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>ekso-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:019e24a5-8506-4b4f-a6ec-39d6306edf95,g:9d00d04a-17f2-484e-b0d0-858320403c94-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CoverPage" xlink:type="simple" xlink:href="ekso-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/CoverPage" xlink:type="extended" id="i07df6b632b7b43af91a68ad9ef312615_CoverPage"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="ie24e489c546f4874b1ba96a91a22e179_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ie0586a5f0f6e4ae8bf79b55ba66343e4_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i0fdb2c1a5785421e9a577a4aade568e3_ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i77d477b4e5914b20b53b13adcafdfed9_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1a2976ab-af18-4f77-92bf-2e9b6a4b205f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1a2976ab-af18-4f77-92bf-2e9b6a4b205f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_937bf8d4-b5c3-490f-aea9-dd01234e58dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_StockholdersEquity_937bf8d4-b5c3-490f-aea9-dd01234e58dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1c169e33-282b-4543-b102-499be17e0d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_SharesOutstanding_1c169e33-282b-4543-b102-499be17e0d09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_360072a4-94d5-455d-a14a-148bc495efb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_NetIncomeLoss_360072a4-94d5-455d-a14a-148bc495efb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:href="ekso-20201231.xsd#ekso_IssuanceOfCommonStockUnderAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5e599025-5b56-43ca-aaee-3e3a0e08c0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5e599025-5b56-43ca-aaee-3e3a0e08c0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8eedf6c2-a567-4836-acce-615a4c3353f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8eedf6c2-a567-4836-acce-615a4c3353f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts_dae494ad-98d4-4461-ae06-fe343b2a39ce" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts_dae494ad-98d4-4461-ae06-fe343b2a39ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut_bedf4527-9e69-456d-8af5-cffbd037eeab" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut_bedf4527-9e69-456d-8af5-cffbd037eeab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_59175a13-069d-4c41-8724-289b7372054a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_59175a13-069d-4c41-8724-289b7372054a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_aecf99a1-7cbf-4222-b72a-19eabed08ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_aecf99a1-7cbf-4222-b72a-19eabed08ef3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants_ec63be5e-4f9b-4e74-a0ad-7dcdb041b0ef" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants_ec63be5e-4f9b-4e74-a0ad-7dcdb041b0ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants_557423c9-64dc-42ed-b364-f158da7de247" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants_557423c9-64dc-42ed-b364-f158da7de247" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_fe6dcadc-46b7-4ea6-9382-6675a4e495be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_fe6dcadc-46b7-4ea6-9382-6675a4e495be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_6bbffb73-aa26-493a-8a1b-c52dcbe8442c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_6bbffb73-aa26-493a-8a1b-c52dcbe8442c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_21b2a6ab-6add-4047-bbb6-f09cc0cbb807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_21b2a6ab-6add-4047-bbb6-f09cc0cbb807" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4b98bd3f-705e-4494-afee-18c950ee59f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4b98bd3f-705e-4494-afee-18c950ee59f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_f9958daf-5ce0-4974-8894-8d78ed94fbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_f9958daf-5ce0-4974-8894-8d78ed94fbac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance_fbd91cf4-ae9d-46cd-85d7-6ab2333e7a69" xlink:href="ekso-20201231.xsd#ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance_fbd91cf4-ae9d-46cd-85d7-6ab2333e7a69" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_6f24b9e2-813b-4fab-91bf-e55bf72c1465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_6f24b9e2-813b-4fab-91bf-e55bf72c1465" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ffa4c715-ae9b-4337-95cd-606429d56bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ffa4c715-ae9b-4337-95cd-606429d56bfb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_433c39da-aa1b-4fa4-a6eb-477eb012a1ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_70b6e2db-593e-4453-9cd5-f0750be64650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_61128415-a222-40f5-99c7-61b3329ccb15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1a2976ab-af18-4f77-92bf-2e9b6a4b205f" xlink:to="loc_us-gaap_StatementTable_61128415-a222-40f5-99c7-61b3329ccb15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_49648fab-caed-4068-bfeb-88b2cc6146b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_61128415-a222-40f5-99c7-61b3329ccb15" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_49648fab-caed-4068-bfeb-88b2cc6146b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_49648fab-caed-4068-bfeb-88b2cc6146b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_49648fab-caed-4068-bfeb-88b2cc6146b9" xlink:to="loc_us-gaap_EquityComponentDomain_49648fab-caed-4068-bfeb-88b2cc6146b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_49648fab-caed-4068-bfeb-88b2cc6146b9" xlink:to="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1ca4d8a1-7ff8-4d8b-b1cb-2618bc5c64d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:to="loc_us-gaap_PreferredStockMember_1ca4d8a1-7ff8-4d8b-b1cb-2618bc5c64d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_387c1a45-075d-45e4-b052-7cfe092fc127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:to="loc_us-gaap_CommonStockMember_387c1a45-075d-45e4-b052-7cfe092fc127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fc4617bf-318c-4dd2-ba0f-79cc6247175e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fc4617bf-318c-4dd2-ba0f-79cc6247175e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1deffc1b-1393-462b-a118-18d7cf0e7e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1deffc1b-1393-462b-a118-18d7cf0e7e00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e6c63024-1182-49b9-929f-9f06a6f63bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:to="loc_us-gaap_RetainedEarningsMember_e6c63024-1182-49b9-929f-9f06a6f63bc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5c31c42a-8af4-4576-9506-47ec9a7839b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_61128415-a222-40f5-99c7-61b3329ccb15" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5c31c42a-8af4-4576-9506-47ec9a7839b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5c31c42a-8af4-4576-9506-47ec9a7839b0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5c31c42a-8af4-4576-9506-47ec9a7839b0" xlink:to="loc_us-gaap_ClassOfStockDomain_5c31c42a-8af4-4576-9506-47ec9a7839b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dca57835-8b58-4e2a-997f-c61a38212c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5c31c42a-8af4-4576-9506-47ec9a7839b0" xlink:to="loc_us-gaap_ClassOfStockDomain_dca57835-8b58-4e2a-997f-c61a38212c45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_07782998-8ab4-4c19-bd62-b8c3fdbfa56d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dca57835-8b58-4e2a-997f-c61a38212c45" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_07782998-8ab4-4c19-bd62-b8c3fdbfa56d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended" id="i9291fd92fa9e41648c64f1d10c4061fb_ConsolidatedStatementofCashFlows"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/Organization" xlink:type="simple" xlink:href="ekso-20201231.xsd#Organization"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/Organization" xlink:type="extended" id="i14681b624d0247ce834486060ea03705_Organization"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/OrganizationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#OrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/OrganizationDetails" xlink:type="extended" id="i91ad9bc81d444397aabbeaf712ea2e91_OrganizationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a91608f-adb8-4190-8007-ac580cf7a0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a91608f-adb8-4190-8007-ac580cf7a0e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08000f29-befb-46ef-8a6a-38fad030cf6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08000f29-befb-46ef-8a6a-38fad030cf6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b3118fe-fdcf-4fb2-8fad-a23e4b4814b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b3118fe-fdcf-4fb2-8fad-a23e4b4814b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_168e1685-8f4a-4cfd-a864-b2eb4efff016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_168e1685-8f4a-4cfd-a864-b2eb4efff016" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_e0745a90-332c-46cd-a283-a4c000ba952e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_e0745a90-332c-46cd-a283-a4c000ba952e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_30a3bd10-0b96-4fa7-8de8-44791b6493ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_30a3bd10-0b96-4fa7-8de8-44791b6493ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2159685d-c544-4938-8417-70102eed127d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2159685d-c544-4938-8417-70102eed127d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_37554cf9-fa4f-49b5-8aa0-089ef714b199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_37554cf9-fa4f-49b5-8aa0-089ef714b199" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DebtCovenantCovenantComplianceUnrestrictedCash_3f17f4e2-460b-466d-99d4-dc37c891ec74" xlink:href="ekso-20201231.xsd#ekso_DebtCovenantCovenantComplianceUnrestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_ekso_DebtCovenantCovenantComplianceUnrestrictedCash_3f17f4e2-460b-466d-99d4-dc37c891ec74" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_UnrestrictedCash_78b9fb43-e9e0-47a8-8bfb-73577cdf2b8b" xlink:href="ekso-20201231.xsd#ekso_UnrestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_ekso_UnrestrictedCash_78b9fb43-e9e0-47a8-8bfb-73577cdf2b8b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_01971405-b129-4861-8a57-7f98e2e8be79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_01971405-b129-4861-8a57-7f98e2e8be79" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bb4d59d1-722d-437d-968d-31c8c3bccf39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bb4d59d1-722d-437d-968d-31c8c3bccf39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb4d59d1-722d-437d-968d-31c8c3bccf39_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bb4d59d1-722d-437d-968d-31c8c3bccf39" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb4d59d1-722d-437d-968d-31c8c3bccf39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f96ca0a-d22c-470c-b56b-3eacff9504d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bb4d59d1-722d-437d-968d-31c8c3bccf39" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f96ca0a-d22c-470c-b56b-3eacff9504d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DirectOfferingMember_c5a2da29-a8d3-4288-a800-e4c1c8596464" xlink:href="ekso-20201231.xsd#ekso_DirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f96ca0a-d22c-470c-b56b-3eacff9504d1" xlink:to="loc_ekso_DirectOfferingMember_c5a2da29-a8d3-4288-a800-e4c1c8596464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c813fbdd-7ff7-479f-9643-24b132650ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:to="loc_us-gaap_DebtInstrumentAxis_c813fbdd-7ff7-479f-9643-24b132650ceb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c813fbdd-7ff7-479f-9643-24b132650ceb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c813fbdd-7ff7-479f-9643-24b132650ceb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c813fbdd-7ff7-479f-9643-24b132650ceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1bee06d7-2e88-4a2c-8bd0-48fdcb26875c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c813fbdd-7ff7-479f-9643-24b132650ceb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1bee06d7-2e88-4a2c-8bd0-48fdcb26875c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LoanAgreementMember_1f39300d-9d66-436a-8ccc-df59bebbd00c" xlink:href="ekso-20201231.xsd#ekso_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1bee06d7-2e88-4a2c-8bd0-48fdcb26875c" xlink:to="loc_ekso_LoanAgreementMember_1f39300d-9d66-436a-8ccc-df59bebbd00c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_PWBLoanAgreementMember_47bc6d54-b4f4-44fb-b760-e086406f3fd1" xlink:href="ekso-20201231.xsd#ekso_PWBLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1bee06d7-2e88-4a2c-8bd0-48fdcb26875c" xlink:to="loc_ekso_PWBLoanAgreementMember_47bc6d54-b4f4-44fb-b760-e086406f3fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7ccbfa1b-ab1f-4711-b6a1-1b1162e19fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7ccbfa1b-ab1f-4711-b6a1-1b1162e19fde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7ccbfa1b-ab1f-4711-b6a1-1b1162e19fde_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7ccbfa1b-ab1f-4711-b6a1-1b1162e19fde" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7ccbfa1b-ab1f-4711-b6a1-1b1162e19fde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_032df56a-7998-416b-9f9b-b1f47cb6cdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7ccbfa1b-ab1f-4711-b6a1-1b1162e19fde" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_032df56a-7998-416b-9f9b-b1f47cb6cdb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TermLoanMember_282b124a-5b0d-416b-b34c-004c1639ca97" xlink:href="ekso-20201231.xsd#ekso_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_032df56a-7998-416b-9f9b-b1f47cb6cdb8" xlink:to="loc_ekso_TermLoanMember_282b124a-5b0d-416b-b34c-004c1639ca97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7fa9ca20-aef9-4f76-b76f-87d58225dd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7fa9ca20-aef9-4f76-b76f-87d58225dd46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7fa9ca20-aef9-4f76-b76f-87d58225dd46_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7fa9ca20-aef9-4f76-b76f-87d58225dd46" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7fa9ca20-aef9-4f76-b76f-87d58225dd46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_746b5910-4862-48bd-b2de-738d793ce6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7fa9ca20-aef9-4f76-b76f-87d58225dd46" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_746b5910-4862-48bd-b2de-738d793ce6a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6f6e34f7-1110-4c7f-aea7-cd5d9bf02f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_746b5910-4862-48bd-b2de-738d793ce6a2" xlink:to="loc_us-gaap_SubsequentEventMember_6f6e34f7-1110-4c7f-aea7-cd5d9bf02f5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimates"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates" xlink:type="extended" id="ib95cc2f0eb2f4452b75ecc759b18a58a_SummaryofSignificantAccountingPoliciesandEstimates"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesPolicies"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies" xlink:type="extended" id="i6ab3101aae3a45b394248a6ed29e6f68_SummaryofSignificantAccountingPoliciesandEstimatesPolicies"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables" xlink:type="extended" id="i059fd2980f524046bf2470f24b6378fb_SummaryofSignificantAccountingPoliciesandEstimatesTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails" xlink:type="extended" id="i973af8ed289a4f6b90091768d35aeead_SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:href="ekso-20201231.xsd#ekso_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_b90f6913-9297-420e-94ce-42cd7fc87cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_b90f6913-9297-420e-94ce-42cd7fc87cfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0a1e9bd9-e3f3-4e6a-86a4-ea002746f235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0a1e9bd9-e3f3-4e6a-86a4-ea002746f235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3a5ca78d-45cc-4ea4-9bb9-5bb42e772b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3a5ca78d-45cc-4ea4-9bb9-5bb42e772b90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_cdcf4d29-63fc-41c1-bcce-cc5d1a7a45bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_RestructuringCharges_cdcf4d29-63fc-41c1-bcce-cc5d1a7a45bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0c5ce52a-7ca2-43b3-a131-07c493d68b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0c5ce52a-7ca2-43b3-a131-07c493d68b12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_756af44c-00cf-4d23-bb75-3a3542843196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_756af44c-00cf-4d23-bb75-3a3542843196" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_db0a6cfd-d298-404d-80a8-b5505c55f0e3" xlink:href="ekso-20201231.xsd#ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_db0a6cfd-d298-404d-80a8-b5505c55f0e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6251551c-4b85-4212-8a05-d645800e4c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6251551c-4b85-4212-8a05-d645800e4c79" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_99598a12-ceec-4f9e-9359-98bbb6ed4e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_GrantsReceivable_99598a12-ceec-4f9e-9359-98bbb6ed4e59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:href="ekso-20201231.xsd#ekso_ScheduleOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ca0856f9-afb8-449a-8a9b-682336c3d394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ca0856f9-afb8-449a-8a9b-682336c3d394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ca0856f9-afb8-449a-8a9b-682336c3d394_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ca0856f9-afb8-449a-8a9b-682336c3d394" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ca0856f9-afb8-449a-8a9b-682336c3d394_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_db72cda3-5f65-49fe-9bf5-f90b8a7fdaf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ca0856f9-afb8-449a-8a9b-682336c3d394" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_db72cda3-5f65-49fe-9bf5-f90b8a7fdaf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1b2525c3-c9c4-407e-9fe3-862654cdd52b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_db72cda3-5f65-49fe-9bf5-f90b8a7fdaf9" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1b2525c3-c9c4-407e-9fe3-862654cdd52b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4a1289-1f8c-4ea2-b40d-972ff9c63846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4a1289-1f8c-4ea2-b40d-972ff9c63846" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c4a1289-1f8c-4ea2-b40d-972ff9c63846_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4a1289-1f8c-4ea2-b40d-972ff9c63846" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c4a1289-1f8c-4ea2-b40d-972ff9c63846_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5b859bb8-10ef-4241-b5eb-93c360ae21d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4a1289-1f8c-4ea2-b40d-972ff9c63846" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5b859bb8-10ef-4241-b5eb-93c360ae21d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_9694c558-d78a-4e03-8a3d-8ff2275f5177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5b859bb8-10ef-4241-b5eb-93c360ae21d8" xlink:to="loc_us-gaap_AccountsReceivableMember_9694c558-d78a-4e03-8a3d-8ff2275f5177" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_958fb583-30e9-44ba-b695-c1f9040a4499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5b859bb8-10ef-4241-b5eb-93c360ae21d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_958fb583-30e9-44ba-b695-c1f9040a4499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a6a7027-2987-4f00-8311-610dc7cb747e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_srt_RangeAxis_9a6a7027-2987-4f00-8311-610dc7cb747e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a6a7027-2987-4f00-8311-610dc7cb747e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9a6a7027-2987-4f00-8311-610dc7cb747e" xlink:to="loc_srt_RangeMember_9a6a7027-2987-4f00-8311-610dc7cb747e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b33e3f6-4345-4d8e-b581-217431da725e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9a6a7027-2987-4f00-8311-610dc7cb747e" xlink:to="loc_srt_RangeMember_2b33e3f6-4345-4d8e-b581-217431da725e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_01a898a5-fa09-4f7b-b2b2-7a1135d4ada3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2b33e3f6-4345-4d8e-b581-217431da725e" xlink:to="loc_srt_MinimumMember_01a898a5-fa09-4f7b-b2b2-7a1135d4ada3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1009fc5f-b595-442b-92e0-37bae1693dad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2b33e3f6-4345-4d8e-b581-217431da725e" xlink:to="loc_srt_MaximumMember_1009fc5f-b595-442b-92e0-37bae1693dad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b1d0dd09-8624-4868-a4c5-964f19ff1026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b1d0dd09-8624-4868-a4c5-964f19ff1026" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b1d0dd09-8624-4868-a4c5-964f19ff1026_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b1d0dd09-8624-4868-a4c5-964f19ff1026" xlink:to="loc_us-gaap_SegmentDomain_b1d0dd09-8624-4868-a4c5-964f19ff1026_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_91466a83-6980-40a4-b4da-df7b50c7f818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b1d0dd09-8624-4868-a4c5-964f19ff1026" xlink:to="loc_us-gaap_SegmentDomain_91466a83-6980-40a4-b4da-df7b50c7f818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoHealthMember_eed4b1da-af7c-44a6-aa68-d2bf4eb78a86" xlink:href="ekso-20201231.xsd#ekso_EksoHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_91466a83-6980-40a4-b4da-df7b50c7f818" xlink:to="loc_ekso_EksoHealthMember_eed4b1da-af7c-44a6-aa68-d2bf4eb78a86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dda67a62-1f27-4cce-9063-900f1e049b58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_srt_MajorCustomersAxis_dda67a62-1f27-4cce-9063-900f1e049b58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_dda67a62-1f27-4cce-9063-900f1e049b58_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_dda67a62-1f27-4cce-9063-900f1e049b58" xlink:to="loc_srt_NameOfMajorCustomerDomain_dda67a62-1f27-4cce-9063-900f1e049b58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3d7d151f-2ae4-434b-8d32-366a53be10ed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_dda67a62-1f27-4cce-9063-900f1e049b58" xlink:to="loc_srt_NameOfMajorCustomerDomain_3d7d151f-2ae4-434b-8d32-366a53be10ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CustomerAMember_9d4f5a79-fd35-4f8f-88df-0b099a41a2a7" xlink:href="ekso-20201231.xsd#ekso_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3d7d151f-2ae4-434b-8d32-366a53be10ed" xlink:to="loc_ekso_CustomerAMember_9d4f5a79-fd35-4f8f-88df-0b099a41a2a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CustomerBMember_fbc93b38-e0bc-4941-aa71-a8483425e893" xlink:href="ekso-20201231.xsd#ekso_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3d7d151f-2ae4-434b-8d32-366a53be10ed" xlink:to="loc_ekso_CustomerBMember_fbc93b38-e0bc-4941-aa71-a8483425e893" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="ibea22bf2ec784fc7bcda18d39a4d51f0_SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c6ecdc52-e961-4c26-bf59-b46e943f4839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_07a65e7c-c241-4552-9efc-ad02f592a26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c6ecdc52-e961-4c26-bf59-b46e943f4839" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_07a65e7c-c241-4552-9efc-ad02f592a26c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3dd77456-02b4-4f2e-a824-90147b8aa107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_07a65e7c-c241-4552-9efc-ad02f592a26c" xlink:to="loc_us-gaap_StockholdersEquity_3dd77456-02b4-4f2e-a824-90147b8aa107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0a08521d-bf24-41cd-b612-ec902428f24f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_07a65e7c-c241-4552-9efc-ad02f592a26c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0a08521d-bf24-41cd-b612-ec902428f24f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c0f85bd-356f-46ca-b382-bf03c784b3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac07a228-5ab1-445e-a637-53382346d538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c6ecdc52-e961-4c26-bf59-b46e943f4839" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac07a228-5ab1-445e-a637-53382346d538" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_132be21e-4d91-470b-9382-743eadc2414a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac07a228-5ab1-445e-a637-53382346d538" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_132be21e-4d91-470b-9382-743eadc2414a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_132be21e-4d91-470b-9382-743eadc2414a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_132be21e-4d91-470b-9382-743eadc2414a" xlink:to="loc_us-gaap_EquityComponentDomain_132be21e-4d91-470b-9382-743eadc2414a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_203b835a-d7dc-41fd-82a4-4d9f282b5ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_132be21e-4d91-470b-9382-743eadc2414a" xlink:to="loc_us-gaap_EquityComponentDomain_203b835a-d7dc-41fd-82a4-4d9f282b5ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_18608d47-eb4e-4482-a743-0dfdfd160e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_203b835a-d7dc-41fd-82a4-4d9f282b5ddd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_18608d47-eb4e-4482-a743-0dfdfd160e83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails" xlink:type="extended" id="i82df1bdcc4764aabb0e74d1bbc9afe1f_SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails" xlink:type="extended" id="ia03b9bbcf1da4e598d1dbe97a323620d_SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStock" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStock"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStock" xlink:type="extended" id="i956a7a1d0f47483088058097ad3ea4ce_NetLossPerShareofCommonStock"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStockTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables" xlink:type="extended" id="ief37cb190b4c44bc9b2550388ea0e7e8_NetLossPerShareofCommonStockTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended" id="iab09c9bc05014ee28a752a09e3b28edd_NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i78c5a7829c3e49ada25f1eb139aa9dee_NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ec73b738-4401-4d4b-8ba4-dc8a121cd5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f0e65170-2e53-4ffc-88d8-749c5310add5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ec73b738-4401-4d4b-8ba4-dc8a121cd5fc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f0e65170-2e53-4ffc-88d8-749c5310add5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14d2960e-15e5-4504-b834-653defaad178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ec73b738-4401-4d4b-8ba4-dc8a121cd5fc" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14d2960e-15e5-4504-b834-653defaad178" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6f42344-2ba3-43b2-9a7f-efdf5801b5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14d2960e-15e5-4504-b834-653defaad178" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6f42344-2ba3-43b2-9a7f-efdf5801b5c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6f42344-2ba3-43b2-9a7f-efdf5801b5c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6f42344-2ba3-43b2-9a7f-efdf5801b5c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6f42344-2ba3-43b2-9a7f-efdf5801b5c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8695226c-4270-464d-ad1a-a62ede8038f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6f42344-2ba3-43b2-9a7f-efdf5801b5c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8695226c-4270-464d-ad1a-a62ede8038f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bb0bdc80-1686-401b-8c02-dc450a58fd94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8695226c-4270-464d-ad1a-a62ede8038f7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bb0bdc80-1686-401b-8c02-dc450a58fd94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2858654b-061f-4782-b806-0e6cf103bf2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8695226c-4270-464d-ad1a-a62ede8038f7" xlink:to="loc_us-gaap_RestrictedStockMember_2858654b-061f-4782-b806-0e6cf103bf2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a58f3625-2761-43e1-a8ed-0ea14c40a23c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8695226c-4270-464d-ad1a-a62ede8038f7" xlink:to="loc_us-gaap_WarrantMember_a58f3625-2761-43e1-a8ed-0ea14c40a23c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate" xlink:type="simple" xlink:href="ekso-20201231.xsd#InvestmentinUnconsolidatedAffiliate"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate" xlink:type="extended" id="ia6237f7e0e474f4d981f732894a48fb8_InvestmentinUnconsolidatedAffiliate"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliateDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#InvestmentinUnconsolidatedAffiliateDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliateDetails" xlink:type="extended" id="i54a35dfbb554425787e8df8ea05c621e_InvestmentinUnconsolidatedAffiliateDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurement"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurement" xlink:type="extended" id="i58da971b36cb4d8db9a8fb3999b4cd71_FairValueMeasurement"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurementTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurementTables" xlink:type="extended" id="i4d43e476115f48698a6e9e7e1994f1e6_FairValueMeasurementTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="if1f495e72f0847d7af3a1006793b53c4_FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c0b3bb8f-345c-4940-ad4a-10fb7e42f95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6c5629d9-e8cf-42df-8007-ab5062912c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c0b3bb8f-345c-4940-ad4a-10fb7e42f95c" xlink:to="loc_us-gaap_DerivativeLiabilities_6c5629d9-e8cf-42df-8007-ab5062912c53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContingentSuccessFeeLiability_2aa7ad4f-e9fd-44ac-ba01-2bcfbf5d8dca" xlink:href="ekso-20201231.xsd#ekso_ContingentSuccessFeeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c0b3bb8f-345c-4940-ad4a-10fb7e42f95c" xlink:to="loc_ekso_ContingentSuccessFeeLiability_2aa7ad4f-e9fd-44ac-ba01-2bcfbf5d8dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d628bc9f-c295-4d38-8224-d18c5a95ffdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c0b3bb8f-345c-4940-ad4a-10fb7e42f95c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d628bc9f-c295-4d38-8224-d18c5a95ffdb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85250bae-4012-4e35-98a9-648966bfef14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d628bc9f-c295-4d38-8224-d18c5a95ffdb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85250bae-4012-4e35-98a9-648966bfef14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85250bae-4012-4e35-98a9-648966bfef14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85250bae-4012-4e35-98a9-648966bfef14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85250bae-4012-4e35-98a9-648966bfef14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cfa2e1f-76b3-475c-8677-cb870a31ce0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85250bae-4012-4e35-98a9-648966bfef14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cfa2e1f-76b3-475c-8677-cb870a31ce0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cc6ed798-c2ed-43a5-acdc-a4698e78f96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cfa2e1f-76b3-475c-8677-cb870a31ce0e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cc6ed798-c2ed-43a5-acdc-a4698e78f96e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d8cbd164-b691-4506-8c2f-df9f79b8c611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cfa2e1f-76b3-475c-8677-cb870a31ce0e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d8cbd164-b691-4506-8c2f-df9f79b8c611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d177f20d-11ee-482d-a3d2-f9b836b77e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cfa2e1f-76b3-475c-8677-cb870a31ce0e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d177f20d-11ee-482d-a3d2-f9b836b77e8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_57191d2f-a89d-4a65-8a31-984c67d88a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d628bc9f-c295-4d38-8224-d18c5a95ffdb" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_57191d2f-a89d-4a65-8a31-984c67d88a9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_57191d2f-a89d-4a65-8a31-984c67d88a9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_57191d2f-a89d-4a65-8a31-984c67d88a9e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_57191d2f-a89d-4a65-8a31-984c67d88a9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c40fc00e-312b-4dc5-bb9e-4affa49f3c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_57191d2f-a89d-4a65-8a31-984c67d88a9e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c40fc00e-312b-4dc5-bb9e-4affa49f3c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_86effe75-2e68-4882-a91c-6eb0359471b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c40fc00e-312b-4dc5-bb9e-4affa49f3c0c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_86effe75-2e68-4882-a91c-6eb0359471b9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="i71cf8f38f4774cf386dd4d9bf468fc80_FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51e76719-28bc-41e6-b962-1122f0e9017f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51e76719-28bc-41e6-b962-1122f0e9017f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_443f31ec-e392-4e50-bf39-f9235fbc2bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_443f31ec-e392-4e50-bf39-f9235fbc2bcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_beeeb623-eb64-410c-9af2-dd505e919ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_beeeb623-eb64-410c-9af2-dd505e919ef6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantLiability_f13da25e-a466-43e0-98ea-cdd2ebcea73a" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_ekso_GainLossOnWarrantLiability_f13da25e-a466-43e0-98ea-cdd2ebcea73a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification_d84a9ea0-9fc6-4813-b4a4-a94f9931e20c" xlink:href="ekso-20201231.xsd#ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification_d84a9ea0-9fc6-4813-b4a4-a94f9931e20c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement_079492e2-b852-4915-9cdf-2941379e4e38" xlink:href="ekso-20201231.xsd#ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement_079492e2-b852-4915-9cdf-2941379e4e38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3ae35239-b20c-4dc9-9aa3-bebb25deb32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9580b338-2451-47ab-8f71-0520e2f8b836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51e76719-28bc-41e6-b962-1122f0e9017f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9580b338-2451-47ab-8f71-0520e2f8b836" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_320a41e6-e282-4b57-b539-a67082c1e45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9580b338-2451-47ab-8f71-0520e2f8b836" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_320a41e6-e282-4b57-b539-a67082c1e45a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_320a41e6-e282-4b57-b539-a67082c1e45a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_320a41e6-e282-4b57-b539-a67082c1e45a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_320a41e6-e282-4b57-b539-a67082c1e45a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ebea96d8-eece-4e8b-a0e8-c9894d9dc5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_320a41e6-e282-4b57-b539-a67082c1e45a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ebea96d8-eece-4e8b-a0e8-c9894d9dc5b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_81f61d56-67de-4f98-aa1e-a72ad5645b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ebea96d8-eece-4e8b-a0e8-c9894d9dc5b7" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_81f61d56-67de-4f98-aa1e-a72ad5645b2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContingentSuccessFeeMember_6c02c921-bd81-4896-b3de-189375fd6ef8" xlink:href="ekso-20201231.xsd#ekso_ContingentSuccessFeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ebea96d8-eece-4e8b-a0e8-c9894d9dc5b7" xlink:to="loc_ekso_ContingentSuccessFeeMember_6c02c921-bd81-4896-b3de-189375fd6ef8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognition"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/RevenueRecognition" xlink:type="extended" id="id35a9eccfb7342129eb95db9a63eb614_RevenueRecognition"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionTables" xlink:type="extended" id="ie94b56d6ea2645d9b4c3606f47e1bceb_RevenueRecognitionTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails" xlink:type="extended" id="i4a6c0e47187e497e9192a019ea9b12a2_RevenueRecognitionSummaryofDeferredRevenueDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDeferredRevenueActivityDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails" xlink:type="extended" id="i952e1f27b8d248c7add47eae05ccf01e_RevenueRecognitionSummaryofDeferredRevenueActivityDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="extended" id="i29cbead353954df8abefc7e6516aabfe_RevenueRecognitionAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_14ccb76d-dc54-4111-ab57-c0079a27a05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_14ccb76d-dc54-4111-ab57-c0079a27a05d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f5fc8c4f-2e79-4070-9f50-440204469dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f5fc8c4f-2e79-4070-9f50-440204469dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractwithCustomerLiabilityNonCancellableBacklog_df570161-a7b1-4f3e-8705-76dd96d27d1a" xlink:href="ekso-20201231.xsd#ekso_ContractwithCustomerLiabilityNonCancellableBacklog"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_ekso_ContractwithCustomerLiabilityNonCancellableBacklog_df570161-a7b1-4f3e-8705-76dd96d27d1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f97f77da-3bc0-48a5-b89a-308ffc9214b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f97f77da-3bc0-48a5-b89a-308ffc9214b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_c7f1adfb-c72f-4710-8511-a8748c5fed57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_c7f1adfb-c72f-4710-8511-a8748c5fed57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d4fbd472-87ba-40f4-b350-fa354159faad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d4fbd472-87ba-40f4-b350-fa354159faad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_8a0ffbc1-78a2-4c73-a931-90e3b0d4202b" xlink:href="ekso-20201231.xsd#ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_8a0ffbc1-78a2-4c73-a931-90e3b0d4202b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:to="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7226606-e8f9-4c93-8ad5-d0ae244b5a39_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:to="loc_srt_RangeMember_e7226606-e8f9-4c93-8ad5-d0ae244b5a39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:to="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aba3d3b0-122d-4af2-ad35-38aac859882b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:to="loc_srt_MinimumMember_aba3d3b0-122d-4af2-ad35-38aac859882b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05d241da-a531-442a-b25b-f065d7381f44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:to="loc_srt_MaximumMember_05d241da-a531-442a-b25b-f065d7381f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_31e1f47f-0181-48eb-b95a-199229b24ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_31e1f47f-0181-48eb-b95a-199229b24ac2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails_1" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionAdditionalInformationDetails_1"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails_1" xlink:type="extended" id="id874b100ebd54c63ad8cca3ca06a8fca_RevenueRecognitionAdditionalInformationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_14ccb76d-dc54-4111-ab57-c0079a27a05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_14ccb76d-dc54-4111-ab57-c0079a27a05d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f5fc8c4f-2e79-4070-9f50-440204469dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f5fc8c4f-2e79-4070-9f50-440204469dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractwithCustomerLiabilityNonCancellableBacklog_df570161-a7b1-4f3e-8705-76dd96d27d1a" xlink:href="ekso-20201231.xsd#ekso_ContractwithCustomerLiabilityNonCancellableBacklog"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_ekso_ContractwithCustomerLiabilityNonCancellableBacklog_df570161-a7b1-4f3e-8705-76dd96d27d1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f97f77da-3bc0-48a5-b89a-308ffc9214b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f97f77da-3bc0-48a5-b89a-308ffc9214b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_c7f1adfb-c72f-4710-8511-a8748c5fed57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_c7f1adfb-c72f-4710-8511-a8748c5fed57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d4fbd472-87ba-40f4-b350-fa354159faad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d4fbd472-87ba-40f4-b350-fa354159faad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_8a0ffbc1-78a2-4c73-a931-90e3b0d4202b" xlink:href="ekso-20201231.xsd#ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_8a0ffbc1-78a2-4c73-a931-90e3b0d4202b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:to="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7226606-e8f9-4c93-8ad5-d0ae244b5a39_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:to="loc_srt_RangeMember_e7226606-e8f9-4c93-8ad5-d0ae244b5a39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:to="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aba3d3b0-122d-4af2-ad35-38aac859882b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:to="loc_srt_MinimumMember_aba3d3b0-122d-4af2-ad35-38aac859882b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05d241da-a531-442a-b25b-f065d7381f44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:to="loc_srt_MaximumMember_05d241da-a531-442a-b25b-f065d7381f44" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails" xlink:type="extended" id="ia8fc70d691f648218052b41dbdcaee7f_RevenueRecognitionSummaryofDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_db4d7d74-23a1-4f08-9685-a47adbe88279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3ca6722e-5f75-44bb-ac45-3e12d0c13c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_db4d7d74-23a1-4f08-9685-a47adbe88279" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3ca6722e-5f75-44bb-ac45-3e12d0c13c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_81abf56e-8f33-4886-bd3a-bca80b9c5241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_db4d7d74-23a1-4f08-9685-a47adbe88279" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_81abf56e-8f33-4886-bd3a-bca80b9c5241" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7d230d34-b5a6-4797-a6da-9ec4e4833ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_81abf56e-8f33-4886-bd3a-bca80b9c5241" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7d230d34-b5a6-4797-a6da-9ec4e4833ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7d230d34-b5a6-4797-a6da-9ec4e4833ca4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d230d34-b5a6-4797-a6da-9ec4e4833ca4" xlink:to="loc_us-gaap_SegmentDomain_7d230d34-b5a6-4797-a6da-9ec4e4833ca4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0e91de4b-5a90-4e4a-934b-056ba636b3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d230d34-b5a6-4797-a6da-9ec4e4833ca4" xlink:to="loc_us-gaap_SegmentDomain_0e91de4b-5a90-4e4a-934b-056ba636b3f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoHealthMember_51774fcc-eb19-48b3-9948-74b50b2d665d" xlink:href="ekso-20201231.xsd#ekso_EksoHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0e91de4b-5a90-4e4a-934b-056ba636b3f7" xlink:to="loc_ekso_EksoHealthMember_51774fcc-eb19-48b3-9948-74b50b2d665d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoWorksMember_6557f4ea-32a1-428d-8453-11770cbfcec2" xlink:href="ekso-20201231.xsd#ekso_EksoWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0e91de4b-5a90-4e4a-934b-056ba636b3f7" xlink:to="loc_ekso_EksoWorksMember_6557f4ea-32a1-428d-8453-11770cbfcec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8df6a42e-8954-45a6-92ab-d9c019b77847" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_81abf56e-8f33-4886-bd3a-bca80b9c5241" xlink:to="loc_srt_ProductOrServiceAxis_8df6a42e-8954-45a6-92ab-d9c019b77847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8df6a42e-8954-45a6-92ab-d9c019b77847_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8df6a42e-8954-45a6-92ab-d9c019b77847" xlink:to="loc_srt_ProductsAndServicesDomain_8df6a42e-8954-45a6-92ab-d9c019b77847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8df6a42e-8954-45a6-92ab-d9c019b77847" xlink:to="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f3de26ad-87fe-4a03-96fa-9ac708a1c436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:to="loc_us-gaap_ProductMember_f3de26ad-87fe-4a03-96fa-9ac708a1c436" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_f262e99f-024d-4c26-bebd-8959239b7da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:to="loc_us-gaap_ServiceMember_f262e99f-024d-4c26-bebd-8959239b7da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RentalsMember_cf5dcfd1-7be8-45de-a0d8-ad52ad4a7193" xlink:href="ekso-20201231.xsd#ekso_RentalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:to="loc_ekso_RentalsMember_cf5dcfd1-7be8-45de-a0d8-ad52ad4a7193" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_32d5f197-fca9-49d2-81a3-1e84e9ce2a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_32d5f197-fca9-49d2-81a3-1e84e9ce2a59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CollaborativeArrangementsMember_e0af2db7-120f-4f3b-adde-229e9ee64c50" xlink:href="ekso-20201231.xsd#ekso_CollaborativeArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:to="loc_ekso_CollaborativeArrangementsMember_e0af2db7-120f-4f3b-adde-229e9ee64c50" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnet"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnet" xlink:type="extended" id="i78e9a4dc896443638be804db9bc972db_PropertyandEquipmentnet"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnetTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnetTables" xlink:type="extended" id="if958c30b086c4aba8ab9cc475d083ef2_PropertyandEquipmentnetTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="if5d8aac9797b4768b26a1c08c6f0773e_PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bb82f2a3-2adc-4ccc-8c97-87b14530d6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bb82f2a3-2adc-4ccc-8c97-87b14530d6bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_33a4194d-0804-4e79-9f55-201290670ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_33a4194d-0804-4e79-9f55-201290670ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f850d66f-dd92-4ce0-94d1-36cdbce19acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f850d66f-dd92-4ce0-94d1-36cdbce19acf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e635b4e7-4c5b-471b-80f6-a3fd928ae419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e635b4e7-4c5b-471b-80f6-a3fd928ae419" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c5a6e90-ce26-4aa3-b9f9-c92c8cf62638" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c5a6e90-ce26-4aa3-b9f9-c92c8cf62638" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4455be37-9bda-4966-97b2-abad7f3b2f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c5a6e90-ce26-4aa3-b9f9-c92c8cf62638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4455be37-9bda-4966-97b2-abad7f3b2f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4455be37-9bda-4966-97b2-abad7f3b2f12_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4455be37-9bda-4966-97b2-abad7f3b2f12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4455be37-9bda-4966-97b2-abad7f3b2f12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4455be37-9bda-4966-97b2-abad7f3b2f12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransportationEquipmentMember_571d5d12-3391-49ad-a82e-b529566160e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransportationEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_TransportationEquipmentMember_571d5d12-3391-49ad-a82e-b529566160e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_bb0a06d8-a062-46b9-92d5-2768205d029f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_bb0a06d8-a062-46b9-92d5-2768205d029f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1039126f-4f37-4f2b-834e-26d9be74ab53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1039126f-4f37-4f2b-834e-26d9be74ab53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_c078bef7-532e-4746-8ae0-4772ea7df78b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_OfficeEquipmentMember_c078bef7-532e-4746-8ae0-4772ea7df78b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_33c8fffe-0bfc-4aec-a7ee-9adcebbdb451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_33c8fffe-0bfc-4aec-a7ee-9adcebbdb451" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_b6c96cd0-c008-4e60-a6e6-f0950c6cb30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_b6c96cd0-c008-4e60-a6e6-f0950c6cb30a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d525d9e5-3498-451a-bfdc-084b233855f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_ComputerEquipmentMember_d525d9e5-3498-451a-bfdc-084b233855f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1313277d-0040-43cd-a27a-e640bb2a4438" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c5a6e90-ce26-4aa3-b9f9-c92c8cf62638" xlink:to="loc_srt_RangeAxis_1313277d-0040-43cd-a27a-e640bb2a4438" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1313277d-0040-43cd-a27a-e640bb2a4438_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1313277d-0040-43cd-a27a-e640bb2a4438" xlink:to="loc_srt_RangeMember_1313277d-0040-43cd-a27a-e640bb2a4438_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64252bca-1cad-4808-a34b-2c4a7474b804" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1313277d-0040-43cd-a27a-e640bb2a4438" xlink:to="loc_srt_RangeMember_64252bca-1cad-4808-a34b-2c4a7474b804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b8451a7a-d56a-4e84-b8a2-6a238ff19868" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_64252bca-1cad-4808-a34b-2c4a7474b804" xlink:to="loc_srt_MinimumMember_b8451a7a-d56a-4e84-b8a2-6a238ff19868" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b581cd98-5cbe-4635-8c9b-9de1b9cc91db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_64252bca-1cad-4808-a34b-2c4a7474b804" xlink:to="loc_srt_MaximumMember_b581cd98-5cbe-4635-8c9b-9de1b9cc91db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="extended" id="i5e2cc99c74b9457fb6bddd17b4b4acfd_PropertyandEquipmentnetNarrativeDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilities"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilities" xlink:type="extended" id="i501474c6e3ef4a0298afb641bf523f95_AccruedLiabilities"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilitiesTables" xlink:type="extended" id="i938e8fb162c648df8b142980527622aa_AccruedLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended" id="i2f875d7661c74291bf5ab666d37e702f_AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilitiesScheduleofWarrantyCostsDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails" xlink:type="extended" id="ia98ac498530348c0b42432f15bc78892_AccruedLiabilitiesScheduleofWarrantyCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:href="ekso-20201231.xsd#ekso_AccruedLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:href="ekso-20201231.xsd#ekso_AccruedLiabilitiesRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:to="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_580bc711-f35d-4d4c-8414-d5dac6059c79" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:to="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_580bc711-f35d-4d4c-8414-d5dac6059c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyAddition_edca58cf-768f-4dcd-af51-6f0c6402a6d7" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyAddition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:to="loc_ekso_ProductMaintenanceWarrantyAddition_edca58cf-768f-4dcd-af51-6f0c6402a6d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyExpense_51324c84-1942-4d09-a4f9-2621329f040d" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:to="loc_ekso_ProductMaintenanceWarrantyExpense_51324c84-1942-4d09-a4f9-2621329f040d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_c1002568-912b-415b-8436-8e3e470f0a57" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent_95edc066-f688-490d-bd4a-ac106b2988ba" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:to="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent_95edc066-f688-490d-bd4a-ac106b2988ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent_149eca51-cde1-45fe-ab3e-f8b309716f1d" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:to="loc_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent_149eca51-cde1-45fe-ab3e-f8b309716f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_b9b75cdb-9859-4c31-a1dc-28aa420e7555" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyDescription_4495ba5c-c456-4e19-90a0-df801b317c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:to="loc_us-gaap_StandardProductWarrantyDescription_4495ba5c-c456-4e19-90a0-df801b317c2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedLiabilitiesTable_d150541f-24e0-49c5-84a5-b055c2835a71" xlink:href="ekso-20201231.xsd#ekso_AccruedLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:to="loc_ekso_AccruedLiabilitiesTable_d150541f-24e0-49c5-84a5-b055c2835a71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OtherliabilitiesAxis_994de724-3b77-4aa7-a512-8ef9e91728ca" xlink:href="ekso-20201231.xsd#ekso_OtherliabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ekso_AccruedLiabilitiesTable_d150541f-24e0-49c5-84a5-b055c2835a71" xlink:to="loc_ekso_OtherliabilitiesAxis_994de724-3b77-4aa7-a512-8ef9e91728ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OtherLiabilitiesDomain_994de724-3b77-4aa7-a512-8ef9e91728ca_default" xlink:href="ekso-20201231.xsd#ekso_OtherLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ekso_OtherliabilitiesAxis_994de724-3b77-4aa7-a512-8ef9e91728ca" xlink:to="loc_ekso_OtherLiabilitiesDomain_994de724-3b77-4aa7-a512-8ef9e91728ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OtherLiabilitiesDomain_22d3a8e8-e639-441e-9e1a-283e3331542a" xlink:href="ekso-20201231.xsd#ekso_OtherLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ekso_OtherliabilitiesAxis_994de724-3b77-4aa7-a512-8ef9e91728ca" xlink:to="loc_ekso_OtherLiabilitiesDomain_22d3a8e8-e639-441e-9e1a-283e3331542a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_WarrantyMember_4555e117-84f5-4749-9b80-627bb2d1f0aa" xlink:href="ekso-20201231.xsd#ekso_WarrantyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_OtherLiabilitiesDomain_22d3a8e8-e639-441e-9e1a-283e3331542a" xlink:to="loc_ekso_WarrantyMember_4555e117-84f5-4749-9b80-627bb2d1f0aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/Notespayablenet" xlink:type="simple" xlink:href="ekso-20201231.xsd#Notespayablenet"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/Notespayablenet" xlink:type="extended" id="iddf62881ec624d498d929962f7296266_Notespayablenet"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/NotespayablenetTables" xlink:type="extended" id="i9673d0a123034883a45256696e34c5b7_NotespayablenetTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails" xlink:type="extended" id="i335657e7141546b4bcfd00b1cf7bbc99_NotespayablenetAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_82e2b2e2-1887-42c3-8179-44d163aef45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_82e2b2e2-1887-42c3-8179-44d163aef45e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8db1f55d-f72e-4fe3-9c28-a21ab0ac5b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8db1f55d-f72e-4fe3-9c28-a21ab0ac5b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DebtInstrumentDeferralPeriod_b66fc256-16b5-4f99-9ca0-1bbe1ebdd533" xlink:href="ekso-20201231.xsd#ekso_DebtInstrumentDeferralPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_ekso_DebtInstrumentDeferralPeriod_b66fc256-16b5-4f99-9ca0-1bbe1ebdd533" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_c5a7e045-15b9-4676-bde9-c846d8b1c748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_c5a7e045-15b9-4676-bde9-c846d8b1c748" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_94f5a341-0772-40e9-8820-e8585ecf26ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_94f5a341-0772-40e9-8820-e8585ecf26ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_9d9dda82-1b6c-40f4-a1b1-8d37fa7572b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_9d9dda82-1b6c-40f4-a1b1-8d37fa7572b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose_0849cc51-ecd9-41ca-811e-fa458e0486a4" xlink:href="ekso-20201231.xsd#ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose_0849cc51-ecd9-41ca-811e-fa458e0486a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ddde3004-b5a1-47f3-843f-bfc9a9cae3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_LongTermDebt_ddde3004-b5a1-47f3-843f-bfc9a9cae3fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ee391fd-98cb-4464-9fe0-fc22aa7674f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ee391fd-98cb-4464-9fe0-fc22aa7674f2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c009de02-18e7-4282-b356-700a519f76f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c009de02-18e7-4282-b356-700a519f76f8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_392eb517-07ff-49f8-8540-32a8e205fcbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentTerm_392eb517-07ff-49f8-8540-32a8e205fcbc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0b419841-ba6b-464a-b9f3-3985f4fb504c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:to="loc_us-gaap_DebtInstrumentAxis_0b419841-ba6b-464a-b9f3-3985f4fb504c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0b419841-ba6b-464a-b9f3-3985f4fb504c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0b419841-ba6b-464a-b9f3-3985f4fb504c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0b419841-ba6b-464a-b9f3-3985f4fb504c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6d510f8-3b69-46e6-9dc9-74de920cff1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0b419841-ba6b-464a-b9f3-3985f4fb504c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6d510f8-3b69-46e6-9dc9-74de920cff1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LoanAgreementMember_1429a4f2-ccd6-40b7-87ed-0bf84204b55c" xlink:href="ekso-20201231.xsd#ekso_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6d510f8-3b69-46e6-9dc9-74de920cff1e" xlink:to="loc_ekso_LoanAgreementMember_1429a4f2-ccd6-40b7-87ed-0bf84204b55c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_PWBLoanAgreementMember_4c0fddba-e812-4482-8005-de1d45cb9e13" xlink:href="ekso-20201231.xsd#ekso_PWBLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6d510f8-3b69-46e6-9dc9-74de920cff1e" xlink:to="loc_ekso_PWBLoanAgreementMember_4c0fddba-e812-4482-8005-de1d45cb9e13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_43d110e1-b588-4f95-b5ea-9e34a5dc16a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:to="loc_us-gaap_VariableRateAxis_43d110e1-b588-4f95-b5ea-9e34a5dc16a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_43d110e1-b588-4f95-b5ea-9e34a5dc16a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_43d110e1-b588-4f95-b5ea-9e34a5dc16a5" xlink:to="loc_us-gaap_VariableRateDomain_43d110e1-b588-4f95-b5ea-9e34a5dc16a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e7110000-49a1-466a-b571-20b5cd63783c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_43d110e1-b588-4f95-b5ea-9e34a5dc16a5" xlink:to="loc_us-gaap_VariableRateDomain_e7110000-49a1-466a-b571-20b5cd63783c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_b9af1963-4ee7-49c1-91ac-ca630192d95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e7110000-49a1-466a-b571-20b5cd63783c" xlink:to="loc_us-gaap_PrimeRateMember_b9af1963-4ee7-49c1-91ac-ca630192d95f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_29de0b48-ddec-4d95-a693-bdbf6c964afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_29de0b48-ddec-4d95-a693-bdbf6c964afe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_29de0b48-ddec-4d95-a693-bdbf6c964afe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_29de0b48-ddec-4d95-a693-bdbf6c964afe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_29de0b48-ddec-4d95-a693-bdbf6c964afe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_071d0159-f494-4358-9701-100438f6a4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_29de0b48-ddec-4d95-a693-bdbf6c964afe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_071d0159-f494-4358-9701-100438f6a4c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TermLoanMember_f69dcb19-c041-4090-a15f-490591b8a843" xlink:href="ekso-20201231.xsd#ekso_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_071d0159-f494-4358-9701-100438f6a4c2" xlink:to="loc_ekso_TermLoanMember_f69dcb19-c041-4090-a15f-490591b8a843" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_83eb8699-fbf0-49ad-adf3-59ee56e31805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_071d0159-f494-4358-9701-100438f6a4c2" xlink:to="loc_us-gaap_UnsecuredDebtMember_83eb8699-fbf0-49ad-adf3-59ee56e31805" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetDebtRepaymentDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails" xlink:type="extended" id="i02369c03a4fa4f76ab58b48c49fe0b30_NotespayablenetDebtRepaymentDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetPrincipalRepaymentDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails" xlink:type="extended" id="iebe9318f710046dc9cec5c309e614004_NotespayablenetPrincipalRepaymentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5d66dc72-8197-4207-b2c4-77abb32edacd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5d66dc72-8197-4207-b2c4-77abb32edacd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_68fb3f6f-bde8-419a-9145-0e4c45a5f266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_68fb3f6f-bde8-419a-9145-0e4c45a5f266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ae85dda6-fbc0-4144-916c-6553a9e8d793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ae85dda6-fbc0-4144-916c-6553a9e8d793" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0ae057b2-88ad-4b95-991a-2a64248d38af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_LongTermDebtCurrent_0ae057b2-88ad-4b95-991a-2a64248d38af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8cd0ac7b-5fcc-4738-a0d7-39a29298e902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8cd0ac7b-5fcc-4738-a0d7-39a29298e902" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_04ee8724-7e5e-490f-a3d8-4be5be897f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_LongTermDebt_04ee8724-7e5e-490f-a3d8-4be5be897f6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6ac40201-7523-4cac-9c26-892d0b45f35b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_DebtInstrumentTable_6ac40201-7523-4cac-9c26-892d0b45f35b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7c71f767-bd72-404d-b4b3-9bb1eeb9e211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ac40201-7523-4cac-9c26-892d0b45f35b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7c71f767-bd72-404d-b4b3-9bb1eeb9e211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7c71f767-bd72-404d-b4b3-9bb1eeb9e211_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7c71f767-bd72-404d-b4b3-9bb1eeb9e211" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7c71f767-bd72-404d-b4b3-9bb1eeb9e211_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_47176de6-664d-48a0-921c-907be707bb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7c71f767-bd72-404d-b4b3-9bb1eeb9e211" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_47176de6-664d-48a0-921c-907be707bb6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_e735b961-79d0-4a3c-ad60-0e8a2fff728b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_47176de6-664d-48a0-921c-907be707bb6a" xlink:to="loc_us-gaap_UnsecuredDebtMember_e735b961-79d0-4a3c-ad60-0e8a2fff728b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligations" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligations"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/LeaseObligations" xlink:type="extended" id="iefbe1559eed04eb599715c2855bf95cf_LeaseObligations"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsTables" xlink:type="extended" id="ic9ce19d4cce34ce68a6e2c6f0f272f21_LeaseObligationsTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails" xlink:type="extended" id="id85d8b740e694fa5838f5ae5f2d240c7_LeaseObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_eaca3759-95b6-487e-8afb-dc1daa6059a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_eaca3759-95b6-487e-8afb-dc1daa6059a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_431c8721-313f-461a-93d8-9d4f921a6f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_OperatingLeasePayments_431c8721-313f-461a-93d8-9d4f921a6f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OperatingLeaseAbatement_1518c034-3722-479e-907e-a5a6c541b1ae" xlink:href="ekso-20201231.xsd#ekso_OperatingLeaseAbatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_ekso_OperatingLeaseAbatement_1518c034-3722-479e-907e-a5a6c541b1ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6edcd4a1-63e0-40bf-a219-7871baf9d729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_OperatingLeaseLiability_6edcd4a1-63e0-40bf-a219-7871baf9d729" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_373cb5e5-e59a-4ab6-bda8-5e0a3d0b7172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_373cb5e5-e59a-4ab6-bda8-5e0a3d0b7172" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_577a7697-bd99-4365-8eef-14f10e5c34ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_OperatingLeaseExpense_577a7697-bd99-4365-8eef-14f10e5c34ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4d49fd4e-a3bf-4717-84bd-b0f6e2720ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_DebtInstrumentTable_4d49fd4e-a3bf-4717-84bd-b0f6e2720ee5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_99a723fc-c675-4c4c-86e2-15f39dfb7847" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4d49fd4e-a3bf-4717-84bd-b0f6e2720ee5" xlink:to="loc_srt_StatementGeographicalAxis_99a723fc-c675-4c4c-86e2-15f39dfb7847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_99a723fc-c675-4c4c-86e2-15f39dfb7847_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_99a723fc-c675-4c4c-86e2-15f39dfb7847" xlink:to="loc_srt_SegmentGeographicalDomain_99a723fc-c675-4c4c-86e2-15f39dfb7847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d4a80ce3-ab90-459b-be69-b0f961266718" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_99a723fc-c675-4c4c-86e2-15f39dfb7847" xlink:to="loc_srt_SegmentGeographicalDomain_d4a80ce3-ab90-459b-be69-b0f961266718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RichmondCaliforniaMember_bec908bb-2b18-492b-9c6d-a677397cc045" xlink:href="ekso-20201231.xsd#ekso_RichmondCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d4a80ce3-ab90-459b-be69-b0f961266718" xlink:to="loc_ekso_RichmondCaliforniaMember_bec908bb-2b18-492b-9c6d-a677397cc045" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_HamburgGermanyMember_5084e6fa-4579-4d69-af63-e212742f3874" xlink:href="ekso-20201231.xsd#ekso_HamburgGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d4a80ce3-ab90-459b-be69-b0f961266718" xlink:to="loc_ekso_HamburgGermanyMember_5084e6fa-4579-4d69-af63-e212742f3874" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsFutureMinimumPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails" xlink:type="extended" id="i396db8ec42694a238a03ec9cf591e3c1_LeaseObligationsFutureMinimumPaymentsDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="ekso-20201231.xsd#EmployeeBenefitPlan"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/EmployeeBenefitPlan" xlink:type="extended" id="i3146983eb66d4fdea954c0208452677a_EmployeeBenefitPlan"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" id="i95ae5e1e13c6463584a91d16c6993202_EmployeeBenefitPlanDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ekso-20201231.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/RelatedPartyTransactions" xlink:type="extended" id="i437167c612204547bb6c1bdb1c116037_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i9f5b663c989f4b91889fed4c71fa0dc1_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_357902c2-9f51-4447-95f1-e606c1722c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RelatedPartyTransactionConsultingAgreement_b3ccd109-55a9-4aa3-a0ba-9fc52e7a0f5c" xlink:href="ekso-20201231.xsd#ekso_RelatedPartyTransactionConsultingAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_357902c2-9f51-4447-95f1-e606c1722c70" xlink:to="loc_ekso_RelatedPartyTransactionConsultingAgreement_b3ccd109-55a9-4aa3-a0ba-9fc52e7a0f5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_8a82a797-6d87-48ed-a7ec-b797367e703e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_357902c2-9f51-4447-95f1-e606c1722c70" xlink:to="loc_us-gaap_PaymentsForFees_8a82a797-6d87-48ed-a7ec-b797367e703e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_538f5bbd-50aa-4745-8156-dc02b04e1fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_357902c2-9f51-4447-95f1-e606c1722c70" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_538f5bbd-50aa-4745-8156-dc02b04e1fd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2cc2ad7e-9212-4f03-ad56-6506adcfce04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_357902c2-9f51-4447-95f1-e606c1722c70" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2cc2ad7e-9212-4f03-ad56-6506adcfce04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0d53b10d-d594-4d8e-9a72-61438e508ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2cc2ad7e-9212-4f03-ad56-6506adcfce04" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0d53b10d-d594-4d8e-9a72-61438e508ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0d53b10d-d594-4d8e-9a72-61438e508ac8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0d53b10d-d594-4d8e-9a72-61438e508ac8" xlink:to="loc_us-gaap_RelatedPartyDomain_0d53b10d-d594-4d8e-9a72-61438e508ac8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fb68da45-f244-4180-90cc-ed1f355b4c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0d53b10d-d594-4d8e-9a72-61438e508ac8" xlink:to="loc_us-gaap_RelatedPartyDomain_fb68da45-f244-4180-90cc-ed1f355b4c68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AngelPondCapitalLlcMember_82454696-f4ee-4672-ae88-aa1b90b4c09d" xlink:href="ekso-20201231.xsd#ekso_AngelPondCapitalLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_fb68da45-f244-4180-90cc-ed1f355b4c68" xlink:to="loc_ekso_AngelPondCapitalLlcMember_82454696-f4ee-4672-ae88-aa1b90b4c09d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructure" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructure"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructure" xlink:type="extended" id="i4499218415da41e7a2b49c1f1ffee27f_CapitalizationandEquityStructure"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureTables" xlink:type="extended" id="i9c0505dda4794ab0bd359c057dca4cd0_CapitalizationandEquityStructureTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails" xlink:type="extended" id="i5ff29d67b617461996e833bab02a6ce1_CapitalizationandEquityStructureNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_03e1b65f-8436-4e43-8c7d-f9fb32314b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_03e1b65f-8436-4e43-8c7d-f9fb32314b5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_NumberOfConsecutiveBusinessDays_42d328e5-e1a0-41ff-82e8-77f618d0bf17" xlink:href="ekso-20201231.xsd#ekso_NumberOfConsecutiveBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_NumberOfConsecutiveBusinessDays_42d328e5-e1a0-41ff-82e8-77f618d0bf17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_02a057fa-44d0-4daf-8b60-88eca2bc6fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_02a057fa-44d0-4daf-8b60-88eca2bc6fb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a27a21be-d78c-4c14-8dbb-22bfc27f0512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a27a21be-d78c-4c14-8dbb-22bfc27f0512" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5712f66d-253d-4759-9f34-f4d654454fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_CommonStockSharesIssued_5712f66d-253d-4759-9f34-f4d654454fcb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6a55de91-af26-438b-b811-3c36add16a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6a55de91-af26-438b-b811-3c36add16a6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a4d2a284-3c14-4a64-b547-d72ea57f6b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a4d2a284-3c14-4a64-b547-d72ea57f6b04" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ed33b179-4c42-4082-8299-752686df0110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ed33b179-4c42-4082-8299-752686df0110" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79a0a492-1977-4598-a63c-ac7863dc6c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79a0a492-1977-4598-a63c-ac7863dc6c4d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2a3a098b-75e0-49e6-b101-6cc6999f5df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2a3a098b-75e0-49e6-b101-6cc6999f5df4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants_767cfba3-8947-41ae-9aa8-fecd63a5316c" xlink:href="ekso-20201231.xsd#ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants_767cfba3-8947-41ae-9aa8-fecd63a5316c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_03bf9a70-80ca-4262-81d4-bd659bd4ae9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_03bf9a70-80ca-4262-81d4-bd659bd4ae9e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightCashFeePercentage_6d8ccd2b-1eb4-4b98-8f27-33f28779e0d1" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightCashFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightCashFeePercentage_6d8ccd2b-1eb4-4b98-8f27-33f28779e0d1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightCashFee_6d0e8706-595d-4da0-9271-f9a445dc549d" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightCashFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightCashFee_6d0e8706-595d-4da0-9271-f9a445dc549d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightManagementFeePercentage_c19a181e-0272-4d33-8891-f6a7ffa02d17" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightManagementFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightManagementFeePercentage_c19a181e-0272-4d33-8891-f6a7ffa02d17" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightManagementFeeExpense_6eb9020c-6f20-4ac1-ac0d-f015529602af" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightManagementFeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightManagementFeeExpense_6eb9020c-6f20-4ac1-ac0d-f015529602af" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock_d2f76d39-b938-4604-93be-16c79425b00a" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock_d2f76d39-b938-4604-93be-16c79425b00a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightIssued_1339d36b-a428-4e48-80b7-35c595734a5e" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightIssued_1339d36b-a428-4e48-80b7-35c595734a5e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExpirationPeriod_30a765c6-ca70-46c2-a87f-a768f30f694a" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightExpirationPeriod_30a765c6-ca70-46c2-a87f-a768f30f694a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockConversionPrice_01e8d11a-e1f2-4d0f-83b7-73f751cc3114" xlink:href="ekso-20201231.xsd#ekso_StockConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_StockConversionPrice_01e8d11a-e1f2-4d0f-83b7-73f751cc3114" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_37c4c7f1-df4b-43c0-afc4-df74a723d410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_37c4c7f1-df4b-43c0-afc4-df74a723d410" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_WarrantIssuanceExpense_01f32295-0c28-49fa-819b-31c0d12074fa" xlink:href="ekso-20201231.xsd#ekso_WarrantIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_WarrantIssuanceExpense_01f32295-0c28-49fa-819b-31c0d12074fa" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_663badb6-685c-4e84-87a3-b514d6eec334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_663badb6-685c-4e84-87a3-b514d6eec334" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_60bdfd65-8fb3-4349-b58f-cd923d55c740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_60bdfd65-8fb3-4349-b58f-cd923d55c740" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f8b1d031-e695-48c1-82e2-f5d4e088dbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f8b1d031-e695-48c1-82e2-f5d4e088dbe6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightDurationOfPutOption_f2afac60-8d89-4109-9336-066b7af6ed1d" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightDurationOfPutOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightDurationOfPutOption_f2afac60-8d89-4109-9336-066b7af6ed1d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod_0248d723-b77e-4ba5-a627-0d1c614a9e16" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod_0248d723-b77e-4ba5-a627-0d1c614a9e16" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExercised_5f04a6d2-fce4-421c-8432-514a306835ee" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightExercised_5f04a6d2-fce4-421c-8432-514a306835ee" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantModification_14206753-0892-4c49-821e-9c3ce59116f5" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantModification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_GainLossOnWarrantModification_14206753-0892-4c49-821e-9c3ce59116f5" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_13d42b54-5bdc-4097-864d-43b7592753df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_13d42b54-5bdc-4097-864d-43b7592753df" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_45d44e91-73bc-4b72-bc26-f2fb488387d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_45d44e91-73bc-4b72-bc26-f2fb488387d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45d44e91-73bc-4b72-bc26-f2fb488387d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45d44e91-73bc-4b72-bc26-f2fb488387d9" xlink:to="loc_us-gaap_EquityComponentDomain_45d44e91-73bc-4b72-bc26-f2fb488387d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ab8d661b-1c98-438d-905e-c3f0b860d40f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45d44e91-73bc-4b72-bc26-f2fb488387d9" xlink:to="loc_us-gaap_EquityComponentDomain_ab8d661b-1c98-438d-905e-c3f0b860d40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_18abe2ce-bd32-4fb7-bd6e-1dce62e4dca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ab8d661b-1c98-438d-905e-c3f0b860d40f" xlink:to="loc_us-gaap_CommonStockMember_18abe2ce-bd32-4fb7-bd6e-1dce62e4dca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_953f7c6b-4720-47f7-bad2-6ea37f170ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ab8d661b-1c98-438d-905e-c3f0b860d40f" xlink:to="loc_us-gaap_WarrantMember_953f7c6b-4720-47f7-bad2-6ea37f170ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c8003f76-ea11-4ca5-9214-91552d73009f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c8003f76-ea11-4ca5-9214-91552d73009f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8003f76-ea11-4ca5-9214-91552d73009f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c8003f76-ea11-4ca5-9214-91552d73009f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8003f76-ea11-4ca5-9214-91552d73009f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b974f1a1-b693-4ef2-a1f2-3d87ce344ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c8003f76-ea11-4ca5-9214-91552d73009f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b974f1a1-b693-4ef2-a1f2-3d87ce344ecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DirectOfferingMember_66959632-c2de-435b-8259-856be0db1574" xlink:href="ekso-20201231.xsd#ekso_DirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b974f1a1-b693-4ef2-a1f2-3d87ce344ecb" xlink:to="loc_ekso_DirectOfferingMember_66959632-c2de-435b-8259-856be0db1574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AtTheMarketOfferingMember_e97d0d5c-b3ce-4670-9f91-4cef7207238e" xlink:href="ekso-20201231.xsd#ekso_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b974f1a1-b693-4ef2-a1f2-3d87ce344ecb" xlink:to="loc_ekso_AtTheMarketOfferingMember_e97d0d5c-b3ce-4670-9f91-4cef7207238e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4162946b-f2e1-47a3-bfeb-2bc97f0d94a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4162946b-f2e1-47a3-bfeb-2bc97f0d94a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4162946b-f2e1-47a3-bfeb-2bc97f0d94a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4162946b-f2e1-47a3-bfeb-2bc97f0d94a3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4162946b-f2e1-47a3-bfeb-2bc97f0d94a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4162946b-f2e1-47a3-bfeb-2bc97f0d94a3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020WarrantsMember_dc2f8035-63e0-435c-839c-f37e0c7bbe2e" xlink:href="ekso-20201231.xsd#ekso_June2020WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_June2020WarrantsMember_dc2f8035-63e0-435c-839c-f37e0c7bbe2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020InvestorWarrantsMember_45a85ded-ee00-4523-be26-912fe6569538" xlink:href="ekso-20201231.xsd#ekso_June2020InvestorWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_June2020WarrantsMember_dc2f8035-63e0-435c-839c-f37e0c7bbe2e" xlink:to="loc_ekso_June2020InvestorWarrantsMember_45a85ded-ee00-4523-be26-912fe6569538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020PlacementAgentWarrantsMember_57d67ad5-3469-4070-bc2a-c44030e4758a" xlink:href="ekso-20201231.xsd#ekso_June2020PlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_June2020WarrantsMember_dc2f8035-63e0-435c-839c-f37e0c7bbe2e" xlink:to="loc_ekso_June2020PlacementAgentWarrantsMember_57d67ad5-3469-4070-bc2a-c44030e4758a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_A2019WarrantsMember_c81f059b-5ef9-432a-bef0-e19e40e4658b" xlink:href="ekso-20201231.xsd#ekso_A2019WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_A2019WarrantsMember_c81f059b-5ef9-432a-bef0-e19e40e4658b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019PlacementAgentWarrantsMember_64059269-13ee-468e-8d43-426a8a052551" xlink:href="ekso-20201231.xsd#ekso_December2019PlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_December2019PlacementAgentWarrantsMember_64059269-13ee-468e-8d43-426a8a052551" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_May2019WarrantsMember_611024a2-ca09-400a-a3cf-ecc3a41153eb" xlink:href="ekso-20201231.xsd#ekso_May2019WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_May2019WarrantsMember_611024a2-ca09-400a-a3cf-ecc3a41153eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_InformationAgentWarrantsMember_7da7c35b-9e62-4959-ae6a-f61e5c50b9a4" xlink:href="ekso-20201231.xsd#ekso_InformationAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_InformationAgentWarrantsMember_7da7c35b-9e62-4959-ae6a-f61e5c50b9a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TwothousandFifteenWarrantsMember_5155e107-9d5f-476f-a07c-b774458af278" xlink:href="ekso-20201231.xsd#ekso_TwothousandFifteenWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_TwothousandFifteenWarrantsMember_5155e107-9d5f-476f-a07c-b774458af278" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d21ef0b6-3913-48da-b86a-c6813775e115" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_srt_RangeAxis_d21ef0b6-3913-48da-b86a-c6813775e115" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d21ef0b6-3913-48da-b86a-c6813775e115_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d21ef0b6-3913-48da-b86a-c6813775e115" xlink:to="loc_srt_RangeMember_d21ef0b6-3913-48da-b86a-c6813775e115_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09e30bf1-9c65-43f7-8e46-3796a7556dfe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d21ef0b6-3913-48da-b86a-c6813775e115" xlink:to="loc_srt_RangeMember_09e30bf1-9c65-43f7-8e46-3796a7556dfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_84b119ec-8e85-467c-a75a-17aebd429258" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_09e30bf1-9c65-43f7-8e46-3796a7556dfe" xlink:to="loc_srt_MinimumMember_84b119ec-8e85-467c-a75a-17aebd429258" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_dc318f7f-02a8-4c03-aed1-967e5c64c4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_dc318f7f-02a8-4c03-aed1-967e5c64c4c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_dc318f7f-02a8-4c03-aed1-967e5c64c4c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_dc318f7f-02a8-4c03-aed1-967e5c64c4c6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_dc318f7f-02a8-4c03-aed1-967e5c64c4c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4acd100d-cdd3-4927-95c9-e0b9ea427120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_dc318f7f-02a8-4c03-aed1-967e5c64c4c6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4acd100d-cdd3-4927-95c9-e0b9ea427120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputConversionPriceMember_a25d1ea7-67c5-4ef1-bc9f-006fae03c693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4acd100d-cdd3-4927-95c9-e0b9ea427120" xlink:to="loc_us-gaap_MeasurementInputConversionPriceMember_a25d1ea7-67c5-4ef1-bc9f-006fae03c693" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails" xlink:type="extended" id="ie125b819f7e04ec39e2b121687639c3b_CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_677abfd8-5c15-459c-ab80-59cc66d5f4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0fd03a5b-6438-495b-bec1-0633125464f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_677abfd8-5c15-459c-ab80-59cc66d5f4bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0fd03a5b-6438-495b-bec1-0633125464f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExpirationPeriod_20f3d96f-1ff2-4ec9-be12-e0abd4ae5b8c" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_677abfd8-5c15-459c-ab80-59cc66d5f4bb" xlink:to="loc_ekso_ClassOfWarrantOrRightExpirationPeriod_20f3d96f-1ff2-4ec9-be12-e0abd4ae5b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_677abfd8-5c15-459c-ab80-59cc66d5f4bb" xlink:to="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7c65373b-a69c-44d1-b8d5-b6a6da5c7349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7c65373b-a69c-44d1-b8d5-b6a6da5c7349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightIssued_9ea16fde-377b-4654-9315-dba5064b9a7a" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:to="loc_ekso_ClassOfWarrantOrRightIssued_9ea16fde-377b-4654-9315-dba5064b9a7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExpired_866dbdfc-d615-4bda-a589-4859395994d8" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:to="loc_ekso_ClassOfWarrantOrRightExpired_866dbdfc-d615-4bda-a589-4859395994d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExercised_c2b54909-9090-4763-a799-04f5f0080fe3" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:to="loc_ekso_ClassOfWarrantOrRightExercised_c2b54909-9090-4763-a799-04f5f0080fe3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6280a423-d6c2-44a6-886d-e392823d7692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_857ca993-9ebd-4969-9f2e-6b87fc793fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_677abfd8-5c15-459c-ab80-59cc66d5f4bb" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_857ca993-9ebd-4969-9f2e-6b87fc793fa2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5d1adf17-6b12-47bf-8271-a66e6b456a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_857ca993-9ebd-4969-9f2e-6b87fc793fa2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5d1adf17-6b12-47bf-8271-a66e6b456a98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5d1adf17-6b12-47bf-8271-a66e6b456a98_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5d1adf17-6b12-47bf-8271-a66e6b456a98" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5d1adf17-6b12-47bf-8271-a66e6b456a98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5d1adf17-6b12-47bf-8271-a66e6b456a98" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyInvestorWarrantsMember_0e2b09a3-86af-4be4-b611-a422a17d655b" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyInvestorWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_JuneTwentyTwentyInvestorWarrantsMember_0e2b09a3-86af-4be4-b611-a422a17d655b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember_e8613266-f1c4-4016-ac95-f9cd166af99e" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember_e8613266-f1c4-4016-ac95-f9cd166af99e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019WarrantsMember_ff9e6453-17a2-45cd-8346-d7730a748149" xlink:href="ekso-20201231.xsd#ekso_December2019WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_December2019WarrantsMember_ff9e6453-17a2-45cd-8346-d7730a748149" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019PlacementAgentWarrantsMember_57680f9e-8382-42bf-8599-68e8839695c3" xlink:href="ekso-20201231.xsd#ekso_December2019PlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_December2019PlacementAgentWarrantsMember_57680f9e-8382-42bf-8599-68e8839695c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_May2019WarrantsMember_4ffb4008-b91a-43c8-900f-379af2c391a0" xlink:href="ekso-20201231.xsd#ekso_May2019WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_May2019WarrantsMember_4ffb4008-b91a-43c8-900f-379af2c391a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_A2017InformationAgentWarrantsMember_9846ce9d-aa3b-464a-afd4-6bbcd44652c2" xlink:href="ekso-20201231.xsd#ekso_A2017InformationAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_A2017InformationAgentWarrantsMember_9846ce9d-aa3b-464a-afd4-6bbcd44652c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2015WarrantsMember_796bc6d6-f723-4044-b26c-4ba8e8cb42fb" xlink:href="ekso-20201231.xsd#ekso_December2015WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_December2015WarrantsMember_796bc6d6-f723-4044-b26c-4ba8e8cb42fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_Pre2014WarrantsMember_18156b8f-3c48-4c36-8519-9287279cac94" xlink:href="ekso-20201231.xsd#ekso_Pre2014WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_Pre2014WarrantsMember_18156b8f-3c48-4c36-8519-9287279cac94" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0cc32906-4168-4138-bf55-e6537e9bbb9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_857ca993-9ebd-4969-9f2e-6b87fc793fa2" xlink:to="loc_srt_RangeAxis_0cc32906-4168-4138-bf55-e6537e9bbb9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0cc32906-4168-4138-bf55-e6537e9bbb9a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0cc32906-4168-4138-bf55-e6537e9bbb9a" xlink:to="loc_srt_RangeMember_0cc32906-4168-4138-bf55-e6537e9bbb9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df2ff5ec-f79c-4be6-81ee-0283bbe1f1cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0cc32906-4168-4138-bf55-e6537e9bbb9a" xlink:to="loc_srt_RangeMember_df2ff5ec-f79c-4be6-81ee-0283bbe1f1cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_34b0443c-8eae-47ef-bff8-8ff0897f45f6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_df2ff5ec-f79c-4be6-81ee-0283bbe1f1cd" xlink:to="loc_srt_MinimumMember_34b0443c-8eae-47ef-bff8-8ff0897f45f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_52a3528a-99a4-40da-bc6e-2619fc995c90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_df2ff5ec-f79c-4be6-81ee-0283bbe1f1cd" xlink:to="loc_srt_MaximumMember_52a3528a-99a4-40da-bc6e-2619fc995c90" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails" xlink:type="extended" id="i140f7ac4ffca4ac8a52bf15385c24d62_CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3fa2d68f-1f44-4bf3-ae00-1aa0cc6bb182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:to="loc_us-gaap_SharePrice_3fa2d68f-1f44-4bf3-ae00-1aa0cc6bb182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockConversionPrice_87945eb0-c99c-42bd-abf6-d0a0742aa447" xlink:href="ekso-20201231.xsd#ekso_StockConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:to="loc_ekso_StockConversionPrice_87945eb0-c99c-42bd-abf6-d0a0742aa447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_8bf260ed-e453-4222-afa8-78bed9527686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_8bf260ed-e453-4222-afa8-78bed9527686" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_08a20a6f-bc03-45a2-a730-ef0381bae7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_08a20a6f-bc03-45a2-a730-ef0381bae7e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_17530f2e-2ee0-4d97-ad96-022ba52a7b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_17530f2e-2ee0-4d97-ad96-022ba52a7b00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_50cdc6f6-d05d-4553-9c42-7c183d10262c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_17530f2e-2ee0-4d97-ad96-022ba52a7b00" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_50cdc6f6-d05d-4553-9c42-7c183d10262c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_50cdc6f6-d05d-4553-9c42-7c183d10262c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_50cdc6f6-d05d-4553-9c42-7c183d10262c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_50cdc6f6-d05d-4553-9c42-7c183d10262c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_50cdc6f6-d05d-4553-9c42-7c183d10262c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_0159e9ab-0c4b-431c-8f14-5eaffe3be670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_0159e9ab-0c4b-431c-8f14-5eaffe3be670" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputConversionPriceMember_59c5c48e-5b73-4970-8370-9d404a922e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:to="loc_us-gaap_MeasurementInputConversionPriceMember_59c5c48e-5b73-4970-8370-9d404a922e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f9d6fba4-2422-4670-8c52-20986fad6cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f9d6fba4-2422-4670-8c52-20986fad6cd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_eb093396-fa99-417e-8dd8-0cadbd0c4942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_eb093396-fa99-417e-8dd8-0cadbd0c4942" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_6f99d060-37a0-4a48-b9af-62ce8d2ecc40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_6f99d060-37a0-4a48-b9af-62ce8d2ecc40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_09535eb7-a92b-4697-a9e9-50c11e4a40a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_17530f2e-2ee0-4d97-ad96-022ba52a7b00" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_09535eb7-a92b-4697-a9e9-50c11e4a40a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_09535eb7-a92b-4697-a9e9-50c11e4a40a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_09535eb7-a92b-4697-a9e9-50c11e4a40a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_09535eb7-a92b-4697-a9e9-50c11e4a40a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_09535eb7-a92b-4697-a9e9-50c11e4a40a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyInvestorWarrantsMember_5468bd02-e3fa-4057-b3c0-4f45789a61d4" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyInvestorWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:to="loc_ekso_JuneTwentyTwentyInvestorWarrantsMember_5468bd02-e3fa-4057-b3c0-4f45789a61d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember_83637074-dd50-4bbc-bf68-f76c6b1dfdd6" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyPlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:to="loc_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember_83637074-dd50-4bbc-bf68-f76c6b1dfdd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019WarrantsMember_a09d7bfc-93f6-4182-9eca-17346f205c93" xlink:href="ekso-20201231.xsd#ekso_December2019WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:to="loc_ekso_December2019WarrantsMember_a09d7bfc-93f6-4182-9eca-17346f205c93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019PlacementAgentWarrantsMember_38ac5aea-6f0d-4951-b575-e7a8f9099e21" xlink:href="ekso-20201231.xsd#ekso_December2019PlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:to="loc_ekso_December2019PlacementAgentWarrantsMember_38ac5aea-6f0d-4951-b575-e7a8f9099e21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_May2019WarrantsMember_66f7b282-d7d3-4b39-8c1e-f2df90cbc7bb" xlink:href="ekso-20201231.xsd#ekso_May2019WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:to="loc_ekso_May2019WarrantsMember_66f7b282-d7d3-4b39-8c1e-f2df90cbc7bb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensation"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensation" xlink:type="extended" id="i0b7b1a2ef68b47f383a11ed14bf261a8_StockbasedCompensation"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationTables" xlink:type="extended" id="ib06a66f5f5e84a678097873bb56c609f_StockbasedCompensationTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensation2014EquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails" xlink:type="extended" id="i02a5d9aa292e4afd90e12cbbb45a6082_StockbasedCompensation2014EquityIncentivePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3177d738-23e3-4148-bf34-dd105e4416db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc3c08b0-d310-4089-995c-ba9ddbe5ce9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3177d738-23e3-4148-bf34-dd105e4416db" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc3c08b0-d310-4089-995c-ba9ddbe5ce9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6f7bf761-b2c2-44e4-a4b7-9cc48223e05f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3177d738-23e3-4148-bf34-dd105e4416db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6f7bf761-b2c2-44e4-a4b7-9cc48223e05f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e0df2de2-4fba-4310-8a6d-39482c316aff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3177d738-23e3-4148-bf34-dd105e4416db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e0df2de2-4fba-4310-8a6d-39482c316aff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_025bfbdc-fa52-4684-a006-8135a8056cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3177d738-23e3-4148-bf34-dd105e4416db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_025bfbdc-fa52-4684-a006-8135a8056cef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e7194151-7a90-4336-97e1-5e0b194fe35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_025bfbdc-fa52-4684-a006-8135a8056cef" xlink:to="loc_us-gaap_PlanNameAxis_e7194151-7a90-4336-97e1-5e0b194fe35e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e7194151-7a90-4336-97e1-5e0b194fe35e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e7194151-7a90-4336-97e1-5e0b194fe35e" xlink:to="loc_us-gaap_PlanNameDomain_e7194151-7a90-4336-97e1-5e0b194fe35e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c66f9bab-cf48-40c8-ac65-1d52a904c955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e7194151-7a90-4336-97e1-5e0b194fe35e" xlink:to="loc_us-gaap_PlanNameDomain_c66f9bab-cf48-40c8-ac65-1d52a904c955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member_3829a1d1-2ad0-4b97-880b-01f8a31c3bcd" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c66f9bab-cf48-40c8-ac65-1d52a904c955" xlink:to="loc_ekso_EquityIncentivePlan2014Member_3829a1d1-2ad0-4b97-880b-01f8a31c3bcd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails" xlink:type="extended" id="i5be39d3d61d641cdb5b9538b99693771_StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba9fec73-3e28-4c67-bfe2-87f007b43906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a6dce4e7-0ee1-4841-ac53-521c5573c4de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba9fec73-3e28-4c67-bfe2-87f007b43906" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a6dce4e7-0ee1-4841-ac53-521c5573c4de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3be2645e-1bdb-477e-8403-355c60991688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba9fec73-3e28-4c67-bfe2-87f007b43906" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3be2645e-1bdb-477e-8403-355c60991688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9b3efff5-fe28-407d-9aea-6468f4fafba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba9fec73-3e28-4c67-bfe2-87f007b43906" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9b3efff5-fe28-407d-9aea-6468f4fafba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fb555d2-9783-4d80-82e4-0339ab5559ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba9fec73-3e28-4c67-bfe2-87f007b43906" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fb555d2-9783-4d80-82e4-0339ab5559ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_af5079ee-4e57-45b5-96eb-20d2944546d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fb555d2-9783-4d80-82e4-0339ab5559ae" xlink:to="loc_us-gaap_PlanNameAxis_af5079ee-4e57-45b5-96eb-20d2944546d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_af5079ee-4e57-45b5-96eb-20d2944546d4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_af5079ee-4e57-45b5-96eb-20d2944546d4" xlink:to="loc_us-gaap_PlanNameDomain_af5079ee-4e57-45b5-96eb-20d2944546d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_df530f62-2354-40e0-9d78-7e9bd85735af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_af5079ee-4e57-45b5-96eb-20d2944546d4" xlink:to="loc_us-gaap_PlanNameDomain_df530f62-2354-40e0-9d78-7e9bd85735af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member_5f27bf4f-9255-4404-ac80-02a1bb4fb14d" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_df530f62-2354-40e0-9d78-7e9bd85735af" xlink:to="loc_ekso_EquityIncentivePlan2014Member_5f27bf4f-9255-4404-ac80-02a1bb4fb14d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails" xlink:type="extended" id="iec3cb4f834a84bb0b632c4cc83fad074_StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1fd3079-64b5-4864-9455-ebabf9f39696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1fd3079-64b5-4864-9455-ebabf9f39696" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_85a610ae-d699-4114-a502-1c41a8dfc02d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_85a610ae-d699-4114-a502-1c41a8dfc02d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_668b1324-1ed2-49fb-92b8-354f90265c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_668b1324-1ed2-49fb-92b8-354f90265c93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2fe2a737-bd85-4c0d-a8f7-c810e2574c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2fe2a737-bd85-4c0d-a8f7-c810e2574c15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_49c7a912-bedd-48b5-a2b8-d7776afefc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_49c7a912-bedd-48b5-a2b8-d7776afefc4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2f8332c2-a981-4b6e-bd6f-405a27e1e85f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2f8332c2-a981-4b6e-bd6f-405a27e1e85f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5094654-9d3d-46b7-8a6e-34f9fedba067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8cdea8c4-075a-4851-9c7c-74fe6803f09e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1fd3079-64b5-4864-9455-ebabf9f39696" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8cdea8c4-075a-4851-9c7c-74fe6803f09e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_49eb6a0a-ad67-4df6-92e4-1cbd64a8f6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8cdea8c4-075a-4851-9c7c-74fe6803f09e" xlink:to="loc_us-gaap_PlanNameAxis_49eb6a0a-ad67-4df6-92e4-1cbd64a8f6e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_49eb6a0a-ad67-4df6-92e4-1cbd64a8f6e4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_49eb6a0a-ad67-4df6-92e4-1cbd64a8f6e4" xlink:to="loc_us-gaap_PlanNameDomain_49eb6a0a-ad67-4df6-92e4-1cbd64a8f6e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7b92c0e2-72f5-45d0-98ae-3eb51125ca38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_49eb6a0a-ad67-4df6-92e4-1cbd64a8f6e4" xlink:to="loc_us-gaap_PlanNameDomain_7b92c0e2-72f5-45d0-98ae-3eb51125ca38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member_bad0a9ee-bc7a-4bc4-b961-1a2f15224458" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7b92c0e2-72f5-45d0-98ae-3eb51125ca38" xlink:to="loc_ekso_EquityIncentivePlan2014Member_bad0a9ee-bc7a-4bc4-b961-1a2f15224458" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationStockOptionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails" xlink:type="extended" id="i3312c0e30ee44893958a5b763cd7acc1_StockbasedCompensationStockOptionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc21c5b-5984-479a-b06a-cd9825fec54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4b8f1ebb-3427-4801-b50d-ab45313c4181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc21c5b-5984-479a-b06a-cd9825fec54b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4b8f1ebb-3427-4801-b50d-ab45313c4181" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_806e6053-9ce5-4ba0-b63b-54976f98d731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc21c5b-5984-479a-b06a-cd9825fec54b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_806e6053-9ce5-4ba0-b63b-54976f98d731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a179b68f-2e53-4eb2-846a-87d0dfd53fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc21c5b-5984-479a-b06a-cd9825fec54b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a179b68f-2e53-4eb2-846a-87d0dfd53fce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1a38be85-5a7e-4416-8e9b-b1219cc4ed17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a179b68f-2e53-4eb2-846a-87d0dfd53fce" xlink:to="loc_us-gaap_PlanNameAxis_1a38be85-5a7e-4416-8e9b-b1219cc4ed17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1a38be85-5a7e-4416-8e9b-b1219cc4ed17_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1a38be85-5a7e-4416-8e9b-b1219cc4ed17" xlink:to="loc_us-gaap_PlanNameDomain_1a38be85-5a7e-4416-8e9b-b1219cc4ed17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a5763ed9-43f3-48d6-a0a2-ad7b77c212a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1a38be85-5a7e-4416-8e9b-b1219cc4ed17" xlink:to="loc_us-gaap_PlanNameDomain_a5763ed9-43f3-48d6-a0a2-ad7b77c212a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member_3c72bc8e-b9d8-4ad2-b2e7-1ea9f7d08b0b" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a5763ed9-43f3-48d6-a0a2-ad7b77c212a3" xlink:to="loc_ekso_EquityIncentivePlan2014Member_3c72bc8e-b9d8-4ad2-b2e7-1ea9f7d08b0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76149361-06e8-42bb-96e2-7ac14bc41d32" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a179b68f-2e53-4eb2-846a-87d0dfd53fce" xlink:to="loc_srt_RangeAxis_76149361-06e8-42bb-96e2-7ac14bc41d32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76149361-06e8-42bb-96e2-7ac14bc41d32_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_76149361-06e8-42bb-96e2-7ac14bc41d32" xlink:to="loc_srt_RangeMember_76149361-06e8-42bb-96e2-7ac14bc41d32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b9aedb5-56ab-4687-ab60-9ad2dc811ef7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_76149361-06e8-42bb-96e2-7ac14bc41d32" xlink:to="loc_srt_RangeMember_0b9aedb5-56ab-4687-ab60-9ad2dc811ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_48987d4c-f781-4dec-acec-e53727f7124c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b9aedb5-56ab-4687-ab60-9ad2dc811ef7" xlink:to="loc_srt_MinimumMember_48987d4c-f781-4dec-acec-e53727f7124c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f5bbf0f9-f0c5-4fc5-952e-7ce2dc058ad9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b9aedb5-56ab-4687-ab60-9ad2dc811ef7" xlink:to="loc_srt_MaximumMember_f5bbf0f9-f0c5-4fc5-952e-7ce2dc058ad9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended" id="i05d6373680a141429c6f8cd1fce3fc09_StockbasedCompensationSummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8286a2b9-54ba-4357-bf8f-d56e4d2c0a67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8286a2b9-54ba-4357-bf8f-d56e4d2c0a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e260bf4d-af38-4d87-a32c-58aa374de964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e260bf4d-af38-4d87-a32c-58aa374de964" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_acf9f626-5e1d-47bd-9a2c-5a7032de9fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_acf9f626-5e1d-47bd-9a2c-5a7032de9fc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_df38abba-e8c8-43c0-9a1c-15d0b788017a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_df38abba-e8c8-43c0-9a1c-15d0b788017a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c979d622-6a53-4058-8ed3-85361b79ed8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c979d622-6a53-4058-8ed3-85361b79ed8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_df6879e6-21a8-484d-b875-e92efdbfdd25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_03de9ade-a14a-4345-8cc0-0e8b8dea5926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_03de9ade-a14a-4345-8cc0-0e8b8dea5926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_24d86156-f250-43b5-8f72-e9c190538738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_24d86156-f250-43b5-8f72-e9c190538738" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3d4bfe83-e3ea-4eed-800d-94949cea98f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3d4bfe83-e3ea-4eed-800d-94949cea98f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5bcf4aad-5c0f-461b-9129-11aa6b1a0c60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5bcf4aad-5c0f-461b-9129-11aa6b1a0c60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4fdb096d-a77b-4fdb-843e-a4019524e922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4fdb096d-a77b-4fdb-843e-a4019524e922" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3e6ee85a-33a0-4847-99a6-cb65e975020c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3e6ee85a-33a0-4847-99a6-cb65e975020c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef2848bb-5738-48ad-881e-f73a15945f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef2848bb-5738-48ad-881e-f73a15945f2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d455f641-d133-4302-98d7-175744d2d5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cdaa19ef-f7d4-49ca-95aa-129287e4f53b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cdaa19ef-f7d4-49ca-95aa-129287e4f53b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9477be1d-30d1-4462-a77a-27a55d2793b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9477be1d-30d1-4462-a77a-27a55d2793b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17bac7c7-6741-4635-805b-600c7772d813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17bac7c7-6741-4635-805b-600c7772d813" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_68500da2-5567-4c5a-be18-0e3bf2fd1607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_68500da2-5567-4c5a-be18-0e3bf2fd1607" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b32fd047-bb9b-43e5-a278-7aee48f14d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b32fd047-bb9b-43e5-a278-7aee48f14d83" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b438b262-4672-4c02-916a-3aeaa7a80528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b438b262-4672-4c02-916a-3aeaa7a80528" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_248bc19f-cef5-4d94-a1ea-248088a1610f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_248bc19f-cef5-4d94-a1ea-248088a1610f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_09aa3df4-ac6c-418f-ab0d-8fd222685b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_09aa3df4-ac6c-418f-ab0d-8fd222685b79" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6d2fad2-9e23-4f19-8648-5e764d62b1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6d2fad2-9e23-4f19-8648-5e764d62b1f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0b9cb71d-788a-4cd1-b930-a351a5057b87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6d2fad2-9e23-4f19-8648-5e764d62b1f4" xlink:to="loc_us-gaap_AwardTypeAxis_0b9cb71d-788a-4cd1-b930-a351a5057b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b9cb71d-788a-4cd1-b930-a351a5057b87_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0b9cb71d-788a-4cd1-b930-a351a5057b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b9cb71d-788a-4cd1-b930-a351a5057b87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c020eed-44b5-496b-8df5-d5103aa4e9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0b9cb71d-788a-4cd1-b930-a351a5057b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c020eed-44b5-496b-8df5-d5103aa4e9aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member_960f835b-1805-4240-b6ce-2595add8b2df" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c020eed-44b5-496b-8df5-d5103aa4e9aa" xlink:to="loc_ekso_EquityIncentivePlan2014Member_960f835b-1805-4240-b6ce-2595add8b2df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationExercisedOptionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails" xlink:type="extended" id="i1b63d2eef6e94ace876f30d8c1d7be41_StockbasedCompensationExercisedOptionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8804d289-3de8-4d1e-9b9e-020e961cc48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8804d289-3de8-4d1e-9b9e-020e961cc48c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1211d9ed-f829-41e5-92df-7bf63a018ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1211d9ed-f829-41e5-92df-7bf63a018ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e10e91d6-f2a2-432b-a39f-0110bafc34ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e10e91d6-f2a2-432b-a39f-0110bafc34ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_34ef34a7-f0fc-4c8a-bb9e-22e0fde82507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_34ef34a7-f0fc-4c8a-bb9e-22e0fde82507" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d2529dad-2352-425b-aa8d-ccf0b6cba7d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d2529dad-2352-425b-aa8d-ccf0b6cba7d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cba25abd-5c2f-4045-8300-98d585a7c384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cba25abd-5c2f-4045-8300-98d585a7c384" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d934af1f-14ae-4ad1-9672-8d68946b04c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d934af1f-14ae-4ad1-9672-8d68946b04c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4d19cb28-814b-4e85-943e-b0f3085259a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d934af1f-14ae-4ad1-9672-8d68946b04c3" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4d19cb28-814b-4e85-943e-b0f3085259a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4d19cb28-814b-4e85-943e-b0f3085259a4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4d19cb28-814b-4e85-943e-b0f3085259a4" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4d19cb28-814b-4e85-943e-b0f3085259a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4117746c-d37d-4c99-8b5b-ab08c8e63839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4d19cb28-814b-4e85-943e-b0f3085259a4" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4117746c-d37d-4c99-8b5b-ab08c8e63839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_46ea06e2-b2bb-4b4c-9b57-f11a50f18a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4117746c-d37d-4c99-8b5b-ab08c8e63839" xlink:to="loc_us-gaap_EmployeeStockOptionMember_46ea06e2-b2bb-4b4c-9b57-f11a50f18a3e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofStockOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails" xlink:type="extended" id="i3d5646e07d1641a69e846960047b4553_StockbasedCompensationSummaryofStockOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_5c364c09-dae9-4faa-ba8d-baecfe018654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_5c364c09-dae9-4faa-ba8d-baecfe018654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4cdb8b96-2ab7-420c-a2d8-f7bcde6ec850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4cdb8b96-2ab7-420c-a2d8-f7bcde6ec850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f09dcc5f-430f-4924-bed0-253fc79ec5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f09dcc5f-430f-4924-bed0-253fc79ec5e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_557be4c1-6044-4297-a8ec-760e14895144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_557be4c1-6044-4297-a8ec-760e14895144" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_04cd3a02-e972-481b-b4d2-8db1566ce18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_04cd3a02-e972-481b-b4d2-8db1566ce18f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_3f43926c-3c68-4b48-a740-0aadd6057c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_3f43926c-3c68-4b48-a740-0aadd6057c97" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8443ba22-57a1-497d-bb63-cac982db65a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8443ba22-57a1-497d-bb63-cac982db65a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ceccacff-ff0f-4fa5-89e6-ba5db4e4c526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ceccacff-ff0f-4fa5-89e6-ba5db4e4c526" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e9c4504f-d7a8-444a-b5d7-2b6426c29df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ceccacff-ff0f-4fa5-89e6-ba5db4e4c526" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e9c4504f-d7a8-444a-b5d7-2b6426c29df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e9c4504f-d7a8-444a-b5d7-2b6426c29df9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e9c4504f-d7a8-444a-b5d7-2b6426c29df9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e9c4504f-d7a8-444a-b5d7-2b6426c29df9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e9c4504f-d7a8-444a-b5d7-2b6426c29df9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeOneMember_6822b112-1d5e-4173-b530-3d9f5956e768" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:to="loc_ekso_ExercisePriceRangeOneMember_6822b112-1d5e-4173-b530-3d9f5956e768" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeTwoMember_9ab6ffbb-dad5-4756-9a3c-dad920d080bb" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:to="loc_ekso_ExercisePriceRangeTwoMember_9ab6ffbb-dad5-4756-9a3c-dad920d080bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeThreeMember_38e439b1-a766-4a03-9a58-ae0002901e0b" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:to="loc_ekso_ExercisePriceRangeThreeMember_38e439b1-a766-4a03-9a58-ae0002901e0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeFourMember_93588acb-74a0-4884-8f53-3dac1a763530" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:to="loc_ekso_ExercisePriceRangeFourMember_93588acb-74a0-4884-8f53-3dac1a763530" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails" xlink:type="extended" id="id9c4ffb7ede048ec8ef8a7b5c6c734de_StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0218498f-1ff0-4ac4-9374-566367c7c431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0218498f-1ff0-4ac4-9374-566367c7c431" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_393bcf85-b09e-4ff3-bd27-679c0db4e46d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_393bcf85-b09e-4ff3-bd27-679c0db4e46d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b6fd85bd-bc15-47ad-aa63-1a96b9f1c51e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b6fd85bd-bc15-47ad-aa63-1a96b9f1c51e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2f9169e-da2d-41f6-ae0a-745840c08766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2f9169e-da2d-41f6-ae0a-745840c08766" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_231613ee-4e81-4178-ac46-d1e74d21ab0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_231613ee-4e81-4178-ac46-d1e74d21ab0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_658c2609-df03-40b2-aeb7-da0c96b3fdf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_658c2609-df03-40b2-aeb7-da0c96b3fdf8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8af35f18-5e17-44c4-8b5d-b807dfe52e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8af35f18-5e17-44c4-8b5d-b807dfe52e2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_443519e6-4636-4123-988b-3d7d6bf5c0a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8af35f18-5e17-44c4-8b5d-b807dfe52e2c" xlink:to="loc_srt_RangeAxis_443519e6-4636-4123-988b-3d7d6bf5c0a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_443519e6-4636-4123-988b-3d7d6bf5c0a9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_443519e6-4636-4123-988b-3d7d6bf5c0a9" xlink:to="loc_srt_RangeMember_443519e6-4636-4123-988b-3d7d6bf5c0a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4149986a-5fc9-4094-8e3e-5a65ef8dbd2e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_443519e6-4636-4123-988b-3d7d6bf5c0a9" xlink:to="loc_srt_RangeMember_4149986a-5fc9-4094-8e3e-5a65ef8dbd2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2f8384cf-e07d-44ec-947e-f94a75b783c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4149986a-5fc9-4094-8e3e-5a65ef8dbd2e" xlink:to="loc_srt_MinimumMember_2f8384cf-e07d-44ec-947e-f94a75b783c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4b562aca-0dd7-4e45-a75f-30a86c9058fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4149986a-5fc9-4094-8e3e-5a65ef8dbd2e" xlink:to="loc_srt_MaximumMember_4b562aca-0dd7-4e45-a75f-30a86c9058fa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails" xlink:type="extended" id="idef8bde81f174382b257d272a6dc5233_StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward_4da42657-83c5-4774-8d3a-bc180c75c6f7" xlink:href="ekso-20201231.xsd#ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward_4da42657-83c5-4774-8d3a-bc180c75c6f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2805e991-03ac-4511-80e0-5e5e53bb5313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2805e991-03ac-4511-80e0-5e5e53bb5313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a5bdfa5d-fb5c-483d-b301-82a4b1f4bfb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a5bdfa5d-fb5c-483d-b301-82a4b1f4bfb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_768878a0-2322-4989-b826-c6194e26b85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_768878a0-2322-4989-b826-c6194e26b85d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0c8e9f7b-4f65-472d-9f54-e931715e0fba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0c8e9f7b-4f65-472d-9f54-e931715e0fba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_f4942b7c-9aaa-494d-88ea-134a7bc6ada3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_fa20eff6-43eb-4fee-9d1a-ec8aad10889a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_fa20eff6-43eb-4fee-9d1a-ec8aad10889a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6b2683a-1cd2-44bb-a46b-6b879b008d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6b2683a-1cd2-44bb-a46b-6b879b008d41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_890568e1-f668-4a78-b8f4-c1680672a56d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_890568e1-f668-4a78-b8f4-c1680672a56d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_e496ff94-df3c-43bf-a59f-09845278219f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_e496ff94-df3c-43bf-a59f-09845278219f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_162fd417-adaf-48a3-be79-584de55c7ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_29e8e3ac-22ba-4811-b97b-c46ceb60a9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_29e8e3ac-22ba-4811-b97b-c46ceb60a9e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_77dce076-b097-43e4-a86d-c34f652b946a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_77dce076-b097-43e4-a86d-c34f652b946a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bcb04ff9-ea98-4f9a-a552-c3d41aec887f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bcb04ff9-ea98-4f9a-a552-c3d41aec887f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_acd6b14d-3acc-40c0-adc2-ad3a6b9ec9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_acd6b14d-3acc-40c0-adc2-ad3a6b9ec9f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_00f22f1f-31fc-40ab-b737-6c29c9a02e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_acd6b14d-3acc-40c0-adc2-ad3a6b9ec9f4" xlink:to="loc_us-gaap_AwardTypeAxis_00f22f1f-31fc-40ab-b737-6c29c9a02e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00f22f1f-31fc-40ab-b737-6c29c9a02e7d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_00f22f1f-31fc-40ab-b737-6c29c9a02e7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00f22f1f-31fc-40ab-b737-6c29c9a02e7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc52512b-3884-4bbf-b12a-30c372e09a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_00f22f1f-31fc-40ab-b737-6c29c9a02e7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc52512b-3884-4bbf-b12a-30c372e09a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9361c0f1-fad1-44e5-946e-29fdeeec3f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc52512b-3884-4bbf-b12a-30c372e09a3f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9361c0f1-fad1-44e5-946e-29fdeeec3f51" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails" xlink:type="extended" id="i6691fee4df034fb9b331cec20db52c08_StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76e0c5af-196d-4709-982e-a40891cf5015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9842bda6-1e15-4233-9e6c-3b2fc88abe50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76e0c5af-196d-4709-982e-a40891cf5015" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9842bda6-1e15-4233-9e6c-3b2fc88abe50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9efc978-e386-41dc-9592-df0c7f1ee54a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76e0c5af-196d-4709-982e-a40891cf5015" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9efc978-e386-41dc-9592-df0c7f1ee54a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_41c4f757-d482-4f1e-bced-47fa009ff269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9efc978-e386-41dc-9592-df0c7f1ee54a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_41c4f757-d482-4f1e-bced-47fa009ff269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_41c4f757-d482-4f1e-bced-47fa009ff269_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41c4f757-d482-4f1e-bced-47fa009ff269" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_41c4f757-d482-4f1e-bced-47fa009ff269_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1c02483a-0ee8-4118-b980-0b7f694370c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41c4f757-d482-4f1e-bced-47fa009ff269" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1c02483a-0ee8-4118-b980-0b7f694370c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_7f29cdd1-8bf3-481f-8f12-8b089b02722e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1c02483a-0ee8-4118-b980-0b7f694370c6" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_7f29cdd1-8bf3-481f-8f12-8b089b02722e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fadbea30-0879-44b0-97c7-d3ae1668451a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1c02483a-0ee8-4118-b980-0b7f694370c6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fadbea30-0879-44b0-97c7-d3ae1668451a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4fe2cbb5-ee8c-4451-9c6f-2cc906408075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1c02483a-0ee8-4118-b980-0b7f694370c6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4fe2cbb5-ee8c-4451-9c6f-2cc906408075" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="i68004a612f7d4a9a9ab633a98353b7cd_StockbasedCompensationEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0dfeb1a2-775a-449c-9acd-3f7cb6c7ee57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0dfeb1a2-775a-449c-9acd-3f7cb6c7ee57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_61e09a88-abce-4fe1-beeb-887471348b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_61e09a88-abce-4fe1-beeb-887471348b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DefinedContributionPlanOfferingPeriod_3bbcaf17-2bef-4864-a51f-7fa21bf7a4fd" xlink:href="ekso-20201231.xsd#ekso_DefinedContributionPlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:to="loc_ekso_DefinedContributionPlanOfferingPeriod_3bbcaf17-2bef-4864-a51f-7fa21bf7a4fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter_16a2a9ca-c577-4951-a811-83463bfe6eef" xlink:href="ekso-20201231.xsd#ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:to="loc_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter_16a2a9ca-c577-4951-a811-83463bfe6eef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16653acd-3980-46d8-b52b-9d3c72b4caee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16653acd-3980-46d8-b52b-9d3c72b4caee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f9fb637f-85b1-434c-9328-5128731d5213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16653acd-3980-46d8-b52b-9d3c72b4caee" xlink:to="loc_us-gaap_PlanNameAxis_f9fb637f-85b1-434c-9328-5128731d5213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f9fb637f-85b1-434c-9328-5128731d5213_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f9fb637f-85b1-434c-9328-5128731d5213" xlink:to="loc_us-gaap_PlanNameDomain_f9fb637f-85b1-434c-9328-5128731d5213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ae8a8e6f-30e0-4899-952d-b069bf038fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f9fb637f-85b1-434c-9328-5128731d5213" xlink:to="loc_us-gaap_PlanNameDomain_ae8a8e6f-30e0-4899-952d-b069bf038fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EmployeeStockPurchasePlanMember_12a6dec2-6eaf-4e77-ab97-0656477a8679" xlink:href="ekso-20201231.xsd#ekso_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ae8a8e6f-30e0-4899-952d-b069bf038fa3" xlink:to="loc_ekso_EmployeeStockPurchasePlanMember_12a6dec2-6eaf-4e77-ab97-0656477a8679" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/IncomeTaxes" xlink:type="extended" id="i37c297ef1d4546d78eccf271ffcf2afc_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesTables" xlink:type="extended" id="ied7da754d8964b499e6b79ae10e79924_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails" xlink:type="extended" id="i326c2fc3db114194b17a1a0de3d03dde_IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i978ada26a0994d729985067587d3c26e_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_8fc82cfd-eade-4e88-b1ea-524eb9c7d1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_8fc82cfd-eade-4e88-b1ea-524eb9c7d1aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_dc91fb9c-5cc8-407c-a4a1-7e7b226edb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_dc91fb9c-5cc8-407c-a4a1-7e7b226edb9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1743b43f-ef93-443d-85eb-4b767f0d3ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1743b43f-ef93-443d-85eb-4b767f0d3ac9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_82cb377f-b15b-48ff-bb42-1ad3da01e987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_82cb377f-b15b-48ff-bb42-1ad3da01e987" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_b9c0ab3e-6480-4f66-8a72-8b2aca205d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:to="loc_us-gaap_TaxPeriodAxis_b9c0ab3e-6480-4f66-8a72-8b2aca205d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_b9c0ab3e-6480-4f66-8a72-8b2aca205d3a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_b9c0ab3e-6480-4f66-8a72-8b2aca205d3a" xlink:to="loc_us-gaap_TaxPeriodDomain_b9c0ab3e-6480-4f66-8a72-8b2aca205d3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_cc07336b-75b8-40c4-ba4d-723981bc5313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_b9c0ab3e-6480-4f66-8a72-8b2aca205d3a" xlink:to="loc_us-gaap_TaxPeriodDomain_cc07336b-75b8-40c4-ba4d-723981bc5313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GeneratedBefore2018Expire2027Member_6f4f3c1c-8637-4c91-8aef-29a970302845" xlink:href="ekso-20201231.xsd#ekso_GeneratedBefore2018Expire2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_cc07336b-75b8-40c4-ba4d-723981bc5313" xlink:to="loc_ekso_GeneratedBefore2018Expire2027Member_6f4f3c1c-8637-4c91-8aef-29a970302845" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember_d5bc1507-7dcf-4e17-a896-7c00f2fdcb54" xlink:href="ekso-20201231.xsd#ekso_GeneratedBefore2018CarryforwardIndefinitelyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_cc07336b-75b8-40c4-ba4d-723981bc5313" xlink:to="loc_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember_d5bc1507-7dcf-4e17-a896-7c00f2fdcb54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2112ca3c-d9c4-465b-bc8b-774ff300f8e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2112ca3c-d9c4-465b-bc8b-774ff300f8e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2112ca3c-d9c4-465b-bc8b-774ff300f8e4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2112ca3c-d9c4-465b-bc8b-774ff300f8e4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2112ca3c-d9c4-465b-bc8b-774ff300f8e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_88849315-70c9-4824-bac0-4d0628717f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2112ca3c-d9c4-465b-bc8b-774ff300f8e4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_88849315-70c9-4824-bac0-4d0628717f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_1502b4fc-0cee-442f-a931-7a324d8d6065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_88849315-70c9-4824-bac0-4d0628717f97" xlink:to="loc_us-gaap_DomesticCountryMember_1502b4fc-0cee-442f-a931-7a324d8d6065" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_457d1906-dbf2-43b7-86fb-c2b3a79add4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_88849315-70c9-4824-bac0-4d0628717f97" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_457d1906-dbf2-43b7-86fb-c2b3a79add4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_459d1673-237f-4b3a-b952-9e306a51fe3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_88849315-70c9-4824-bac0-4d0628717f97" xlink:to="loc_us-gaap_ForeignCountryMember_459d1673-237f-4b3a-b952-9e306a51fe3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2d94829d-ce5d-4040-8552-65ac01485df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2d94829d-ce5d-4040-8552-65ac01485df6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2d94829d-ce5d-4040-8552-65ac01485df6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2d94829d-ce5d-4040-8552-65ac01485df6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2d94829d-ce5d-4040-8552-65ac01485df6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_54ff7b71-e5b1-4525-a9cb-2758b9e50d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2d94829d-ce5d-4040-8552-65ac01485df6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_54ff7b71-e5b1-4525-a9cb-2758b9e50d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_4ded6634-39de-4199-ac1c-1c50655f0712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_54ff7b71-e5b1-4525-a9cb-2758b9e50d13" xlink:to="loc_us-gaap_ResearchMember_4ded6634-39de-4199-ac1c-1c50655f0712" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails" xlink:type="extended" id="i6a84c8b3870b411fb2b09d52987769d6_IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="if3181a689db740f5b2d0d9bb658d33a7_IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="icc8c6b94db094baeb6329846951a0e1e_IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingencies" xlink:type="extended" id="i08886e0345ca420e8325df6a305fe82d_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="i805be5186c3f4935a120c96bc671c214_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i93fbc96214a24892a77adee540a04297_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_NumberOfLicenseAgreements_18295268-fb36-4fd9-ad1e-f1e3066da4a8" xlink:href="ekso-20201231.xsd#ekso_NumberOfLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:to="loc_ekso_NumberOfLicenseAgreements_18295268-fb36-4fd9-ad1e-f1e3066da4a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RoyaltyPercentage_206b5b1f-7271-492e-8abc-4e0806953493" xlink:href="ekso-20201231.xsd#ekso_RoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:to="loc_ekso_RoyaltyPercentage_206b5b1f-7271-492e-8abc-4e0806953493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_83fb2dbd-63a6-46fc-871f-1fefd190b825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_83fb2dbd-63a6-46fc-871f-1fefd190b825" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_a512150a-1f7d-4ce0-af3d-f1808844f9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:to="loc_us-gaap_PurchaseObligation_a512150a-1f7d-4ce0-af3d-f1808844f9af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_62977cc5-0e7a-487e-9d2e-c9e1907ff9a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_62977cc5-0e7a-487e-9d2e-c9e1907ff9a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9f88a54d-a1af-4a17-b2a3-c66134e1bbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_62977cc5-0e7a-487e-9d2e-c9e1907ff9a5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9f88a54d-a1af-4a17-b2a3-c66134e1bbcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9f88a54d-a1af-4a17-b2a3-c66134e1bbcd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9f88a54d-a1af-4a17-b2a3-c66134e1bbcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9f88a54d-a1af-4a17-b2a3-c66134e1bbcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c93c5935-5f60-4504-a9eb-35a612641d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9f88a54d-a1af-4a17-b2a3-c66134e1bbcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c93c5935-5f60-4504-a9eb-35a612641d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_5ea12320-19e0-48bc-9072-abfdf83d4370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c93c5935-5f60-4504-a9eb-35a612641d10" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_5ea12320-19e0-48bc-9072-abfdf83d4370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fc11b7ce-4fad-4981-b0d0-72d870965d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_62977cc5-0e7a-487e-9d2e-c9e1907ff9a5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fc11b7ce-4fad-4981-b0d0-72d870965d29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fc11b7ce-4fad-4981-b0d0-72d870965d29_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc11b7ce-4fad-4981-b0d0-72d870965d29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fc11b7ce-4fad-4981-b0d0-72d870965d29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77a6b658-5ee8-4e8f-9ea2-c0a86754e85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc11b7ce-4fad-4981-b0d0-72d870965d29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77a6b658-5ee8-4e8f-9ea2-c0a86754e85e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember_ccb94bd5-fe24-4430-8db1-3b25c75449a8" xlink:href="ekso-20201231.xsd#ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77a6b658-5ee8-4e8f-9ea2-c0a86754e85e" xlink:to="loc_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember_ccb94bd5-fe24-4430-8db1-3b25c75449a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LicenseRevenueMember_a1d1a21c-4996-40f1-8526-a0210213cdba" xlink:href="ekso-20201231.xsd#ekso_LicenseRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77a6b658-5ee8-4e8f-9ea2-c0a86754e85e" xlink:to="loc_ekso_LicenseRevenueMember_a1d1a21c-4996-40f1-8526-a0210213cdba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails" xlink:type="extended" id="i0793871353ba4edd9c0d98b8a5a57bd8_CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_2ce045b0-4d27-4cf5-93dd-ade58d80e375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:to="loc_us-gaap_ContractualObligation_2ce045b0-4d27-4cf5-93dd-ade58d80e375" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_beb900c1-a4d9-4d08-9767-e656585debf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_beb900c1-a4d9-4d08-9767-e656585debf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_726988d4-223b-4118-97eb-06dc9017c777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_726988d4-223b-4118-97eb-06dc9017c777" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_2f2dcf7f-79eb-46ed-8c3b-0beaf334479c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_2f2dcf7f-79eb-46ed-8c3b-0beaf334479c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_6e804c04-e1f8-4977-8925-a8f90d6fe42f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:to="loc_us-gaap_OtherCommitmentsTable_6e804c04-e1f8-4977-8925-a8f90d6fe42f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c5605c6e-bf41-4b58-95b0-bc668ab6666a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_6e804c04-e1f8-4977-8925-a8f90d6fe42f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c5605c6e-bf41-4b58-95b0-bc668ab6666a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c5605c6e-bf41-4b58-95b0-bc668ab6666a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c5605c6e-bf41-4b58-95b0-bc668ab6666a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c5605c6e-bf41-4b58-95b0-bc668ab6666a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ba63ccb-b47a-44a7-8315-2c3b2021d5f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c5605c6e-bf41-4b58-95b0-bc668ab6666a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ba63ccb-b47a-44a7-8315-2c3b2021d5f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TermLoanMember_b93a0b44-be2c-45e6-8b0d-38b475ac4864" xlink:href="ekso-20201231.xsd#ekso_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9ba63ccb-b47a-44a7-8315-2c3b2021d5f6" xlink:to="loc_ekso_TermLoanMember_b93a0b44-be2c-45e6-8b0d-38b475ac4864" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8412a4dd-b202-43f0-bee8-020b408afe29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_6e804c04-e1f8-4977-8925-a8f90d6fe42f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8412a4dd-b202-43f0-bee8-020b408afe29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8412a4dd-b202-43f0-bee8-020b408afe29_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8412a4dd-b202-43f0-bee8-020b408afe29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8412a4dd-b202-43f0-bee8-020b408afe29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844aba0f-128e-4351-a936-e53686a3af14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8412a4dd-b202-43f0-bee8-020b408afe29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844aba0f-128e-4351-a936-e53686a3af14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_FacilityOperatingLeaseMember_091d09e2-3ea8-480e-b659-f87d47937050" xlink:href="ekso-20201231.xsd#ekso_FacilityOperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844aba0f-128e-4351-a936-e53686a3af14" xlink:to="loc_ekso_FacilityOperatingLeaseMember_091d09e2-3ea8-480e-b659-f87d47937050" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosures" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosures"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosures" xlink:type="extended" id="i0d919a5f40074de297f0c36278488f5c_SegmentDisclosures"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosuresTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosuresTables"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosuresTables" xlink:type="extended" id="i530cc3f472874b03939db84a9ac352b0_SegmentDisclosuresTables"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosuresScheduleofSegmentReportingInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails" xlink:type="extended" id="i8e5331a1131143fbb704eef3b775cfdf_SegmentDisclosuresScheduleofSegmentReportingInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_9ef9baab-81bb-4838-aa6d-f9f5004b6d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:to="loc_us-gaap_NumberOfReportableSegments_9ef9baab-81bb-4838-aa6d-f9f5004b6d11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0d3bb191-1ada-4382-8ec5-673311ddf238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0d3bb191-1ada-4382-8ec5-673311ddf238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e4600e6b-6c81-4928-abc6-36c230d2baa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e4600e6b-6c81-4928-abc6-36c230d2baa5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_965dadbc-e986-4fb0-931d-cf80edbcb46d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:to="loc_us-gaap_GrossProfit_965dadbc-e986-4fb0-931d-cf80edbcb46d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e8a094ec-7b81-4450-849a-c101ae9ef0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e8a094ec-7b81-4450-849a-c101ae9ef0d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d8abb198-84de-41cd-bdea-bdfb891f14c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e8a094ec-7b81-4450-849a-c101ae9ef0d7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d8abb198-84de-41cd-bdea-bdfb891f14c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d8abb198-84de-41cd-bdea-bdfb891f14c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d8abb198-84de-41cd-bdea-bdfb891f14c9" xlink:to="loc_us-gaap_SegmentDomain_d8abb198-84de-41cd-bdea-bdfb891f14c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_34bb038a-ac15-4474-8d1f-18809fced4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d8abb198-84de-41cd-bdea-bdfb891f14c9" xlink:to="loc_us-gaap_SegmentDomain_34bb038a-ac15-4474-8d1f-18809fced4ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoHealthMember_44ecd566-ed1c-48f7-b5ff-02bf5240af7f" xlink:href="ekso-20201231.xsd#ekso_EksoHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_34bb038a-ac15-4474-8d1f-18809fced4ef" xlink:to="loc_ekso_EksoHealthMember_44ecd566-ed1c-48f7-b5ff-02bf5240af7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoWorksMember_feb682da-e154-49a0-adcb-bbec7ef5ae95" xlink:href="ekso-20201231.xsd#ekso_EksoWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_34bb038a-ac15-4474-8d1f-18809fced4ef" xlink:to="loc_ekso_EksoWorksMember_feb682da-e154-49a0-adcb-bbec7ef5ae95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_25111206-03a4-403f-9a55-e533dcc465f9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e8a094ec-7b81-4450-849a-c101ae9ef0d7" xlink:to="loc_srt_MajorCustomersAxis_25111206-03a4-403f-9a55-e533dcc465f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_25111206-03a4-403f-9a55-e533dcc465f9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_25111206-03a4-403f-9a55-e533dcc465f9" xlink:to="loc_srt_NameOfMajorCustomerDomain_25111206-03a4-403f-9a55-e533dcc465f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_59e29edd-a75f-4338-8003-f4f45eeba675" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_25111206-03a4-403f-9a55-e533dcc465f9" xlink:to="loc_srt_NameOfMajorCustomerDomain_59e29edd-a75f-4338-8003-f4f45eeba675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CustomerOneMember_0b104ba7-2ac6-41dd-834f-0dca4e35dceb" xlink:href="ekso-20201231.xsd#ekso_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_59e29edd-a75f-4338-8003-f4f45eeba675" xlink:to="loc_ekso_CustomerOneMember_0b104ba7-2ac6-41dd-834f-0dca4e35dceb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosuresScheduleofGeographicRevenueInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails" xlink:type="extended" id="i8b7b90421e14459494593c170f9e4172_SegmentDisclosuresScheduleofGeographicRevenueInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6ee83cc8-33d7-41af-a2c3-2d7674e865a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a9bc6396-e6e0-4a94-98bf-393bbf6f92c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6ee83cc8-33d7-41af-a2c3-2d7674e865a9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a9bc6396-e6e0-4a94-98bf-393bbf6f92c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_744073f4-2842-41c2-a160-1e7a4cfdf5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6ee83cc8-33d7-41af-a2c3-2d7674e865a9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_744073f4-2842-41c2-a160-1e7a4cfdf5a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a674e541-4154-4c9d-a4cc-68159af415e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_744073f4-2842-41c2-a160-1e7a4cfdf5a3" xlink:to="loc_srt_StatementGeographicalAxis_a674e541-4154-4c9d-a4cc-68159af415e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a674e541-4154-4c9d-a4cc-68159af415e6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a674e541-4154-4c9d-a4cc-68159af415e6" xlink:to="loc_srt_SegmentGeographicalDomain_a674e541-4154-4c9d-a4cc-68159af415e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_63062746-01c0-4ba5-b0f8-f2a2c073eb04" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a674e541-4154-4c9d-a4cc-68159af415e6" xlink:to="loc_srt_SegmentGeographicalDomain_63062746-01c0-4ba5-b0f8-f2a2c073eb04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_adf55521-55e1-4cf0-94e0-d4f800d726c8" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_63062746-01c0-4ba5-b0f8-f2a2c073eb04" xlink:to="loc_country_US_adf55521-55e1-4cf0-94e0-d4f800d726c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1c595c71-3743-468f-9d73-b71dcfd3dc1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_63062746-01c0-4ba5-b0f8-f2a2c073eb04" xlink:to="loc_us-gaap_NonUsMember_1c595c71-3743-468f-9d73-b71dcfd3dc1a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ekso-20201231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SubsequentEvents" xlink:type="extended" id="i7f12c110281d43e0bd106d097f958bad_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.eksobionics.com/role/SubsequentEventsDetails" xlink:type="extended" id="i47c5d78831914f41a1d8fe699f4f4d33_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_82316ebe-76ce-4992-adb5-e30462364ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_82316ebe-76ce-4992-adb5-e30462364ee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_15bf4e62-1cf1-49ef-aaa4-59e1f9f9700a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_15bf4e62-1cf1-49ef-aaa4-59e1f9f9700a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8dea877a-cf35-4acc-a6a6-67a2e3c904a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8dea877a-cf35-4acc-a6a6-67a2e3c904a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_009518ce-ce4b-48c8-90b8-11ebda24e1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_009518ce-ce4b-48c8-90b8-11ebda24e1d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1128181e-794f-4434-9502-61873b6a148c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1128181e-794f-4434-9502-61873b6a148c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold_86f357b8-9ac7-4e99-8355-7df81280beab" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold_86f357b8-9ac7-4e99-8355-7df81280beab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71234371-ab15-4fbe-8e69-8f3bc8663a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71234371-ab15-4fbe-8e69-8f3bc8663a54" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExercised_a68a01df-f946-46bc-b4d2-ba7666309c3c" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_ekso_ClassOfWarrantOrRightExercised_a68a01df-f946-46bc-b4d2-ba7666309c3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance_a810437a-ea90-4c46-9969-ee0f12231b83" xlink:href="ekso-20201231.xsd#ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance_a810437a-ea90-4c46-9969-ee0f12231b83" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f3242a17-0056-43d2-a66b-7e4628ec5272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f3242a17-0056-43d2-a66b-7e4628ec5272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f3242a17-0056-43d2-a66b-7e4628ec5272_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f3242a17-0056-43d2-a66b-7e4628ec5272" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f3242a17-0056-43d2-a66b-7e4628ec5272_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c635ee62-b01e-4d5b-8144-afe85c4cbd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f3242a17-0056-43d2-a66b-7e4628ec5272" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c635ee62-b01e-4d5b-8144-afe85c4cbd8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_085f7bc8-1e8e-4cac-a2ea-88104c1df6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c635ee62-b01e-4d5b-8144-afe85c4cbd8b" xlink:to="loc_us-gaap_SubsequentEventMember_085f7bc8-1e8e-4cac-a2ea-88104c1df6d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_61d27152-932f-4f02-b7c9-6a0db2f33b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_61d27152-932f-4f02-b7c9-6a0db2f33b2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_61d27152-932f-4f02-b7c9-6a0db2f33b2a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_61d27152-932f-4f02-b7c9-6a0db2f33b2a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_61d27152-932f-4f02-b7c9-6a0db2f33b2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4c38da42-4264-4f51-8138-120f591c796a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_61d27152-932f-4f02-b7c9-6a0db2f33b2a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4c38da42-4264-4f51-8138-120f591c796a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020WarrantsMember_fddb3c54-8daf-4d0d-a57a-5b276f3dc229" xlink:href="ekso-20201231.xsd#ekso_June2020WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4c38da42-4264-4f51-8138-120f591c796a" xlink:to="loc_ekso_June2020WarrantsMember_fddb3c54-8daf-4d0d-a57a-5b276f3dc229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_81ce28b9-b1c3-4fe6-830a-c444934cb532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_81ce28b9-b1c3-4fe6-830a-c444934cb532" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81ce28b9-b1c3-4fe6-830a-c444934cb532_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_81ce28b9-b1c3-4fe6-830a-c444934cb532" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81ce28b9-b1c3-4fe6-830a-c444934cb532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c6f3e10-8d63-4805-bda4-ad727908a0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_81ce28b9-b1c3-4fe6-830a-c444934cb532" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c6f3e10-8d63-4805-bda4-ad727908a0c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_78ae79b6-05a1-4e57-a8ba-9da4dedc8449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c6f3e10-8d63-4805-bda4-ad727908a0c6" xlink:to="loc_us-gaap_OverAllotmentOptionMember_78ae79b6-05a1-4e57-a8ba-9da4dedc8449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AtTheMarketOfferingMember_4f06fa84-9dfb-4754-9200-b6eb7817a24e" xlink:href="ekso-20201231.xsd#ekso_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c6f3e10-8d63-4805-bda4-ad727908a0c6" xlink:to="loc_ekso_AtTheMarketOfferingMember_4f06fa84-9dfb-4754-9200-b6eb7817a24e" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>ekso-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:019e24a5-8506-4b4f-a6ec-39d6306edf95,g:9d00d04a-17f2-484e-b0d0-858320403c94-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ekso_GeneratedBefore2018Expire2027Member_c4f402d2-2e16-452b-b4a9-eab91a851ce8_terseLabel_en-US" xlink:label="lab_ekso_GeneratedBefore2018Expire2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generated before 2018, expire 2027</link:label>
    <link:label id="lab_ekso_GeneratedBefore2018Expire2027Member_label_en-US" xlink:label="lab_ekso_GeneratedBefore2018Expire2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generated Before 2018, Expire 2027 [Member]</link:label>
    <link:label id="lab_ekso_GeneratedBefore2018Expire2027Member_documentation_en-US" xlink:label="lab_ekso_GeneratedBefore2018Expire2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generated Before 2018, Expire2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GeneratedBefore2018Expire2027Member" xlink:href="ekso-20201231.xsd#ekso_GeneratedBefore2018Expire2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_GeneratedBefore2018Expire2027Member" xlink:to="lab_ekso_GeneratedBefore2018Expire2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInFifthYear_824423df-10a6-49e7-b94a-8e37c470de8e_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3-5 Years</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4eb8e14c-d886-46ee-9cc7-a84431324624_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ProductMaintenanceAndWarrantyTableTextBlock_ef32f54d-547a-46ed-b657-117ba06eac54_verboseLabel_en-US" xlink:label="lab_ekso_ProductMaintenanceAndWarrantyTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warranty Costs</link:label>
    <link:label id="lab_ekso_ProductMaintenanceAndWarrantyTableTextBlock_label_en-US" xlink:label="lab_ekso_ProductMaintenanceAndWarrantyTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Maintenance And Warranty [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceAndWarrantyTableTextBlock" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceAndWarrantyTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ProductMaintenanceAndWarrantyTableTextBlock" xlink:to="lab_ekso_ProductMaintenanceAndWarrantyTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_96d389ff-1417-4bda-a18a-986231f483e7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_AccruedLiabilitiesRollforwardRollForward_da3ca3da-4d3b-4c74-8583-64c77854b6eb_terseLabel_en-US" xlink:label="lab_ekso_AccruedLiabilitiesRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ekso_AccruedLiabilitiesRollforwardRollForward_label_en-US" xlink:label="lab_ekso_AccruedLiabilitiesRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ekso_AccruedLiabilitiesRollforwardRollForward_documentation_en-US" xlink:label="lab_ekso_AccruedLiabilitiesRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Rollforward [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedLiabilitiesRollforwardRollForward" xlink:href="ekso-20201231.xsd#ekso_AccruedLiabilitiesRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_AccruedLiabilitiesRollforwardRollForward" xlink:to="lab_ekso_AccruedLiabilitiesRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_SignificantAccountingPoliciesLineItems_57152d0a-4d93-4ffa-82d3-a1abaac49a3f_terseLabel_en-US" xlink:label="lab_ekso_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ekso_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_ekso_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SignificantAccountingPoliciesLineItems" xlink:href="ekso-20201231.xsd#ekso_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems" xlink:to="lab_ekso_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_964a1298-3d61-4d05-94b4-da6cb4d2add8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbd51e72-4ee7-457c-b0c8-c7ac57c2b02a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_94e01afd-cd05-4cb1-8007-8b5a02097a77_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent_02c20cd0-d413-4ce5-8dac-c093f32407fb_terseLabel_en-US" xlink:label="lab_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred rent associated with ASC 842</link:label>
    <link:label id="lab_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Increase (Decrease) In Deferred Rent</link:label>
    <link:label id="lab_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent_documentation_en-US" xlink:label="lab_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Increase (Decrease) In Deferred Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent" xlink:href="ekso-20201231.xsd#ekso_OperatingLeasesIncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent" xlink:to="lab_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_a7a73af7-d790-45af-aa35-6b72f2fc9776_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and support</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_a52902ed-4e5f-440e-aa5f-adbb5df7ed72_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_682fc5e6-0c19-4d38-9f9d-0cd88a03e54b_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c8222120-efd6-4f93-8cf4-d121ead5c6f8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4460be3e-ecf1-493a-92fe-5ffeab47eb8b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d65906f4-86c8-43be-b446-e2cb9a83c2f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share pool increase (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4a8cf0e3-8b3c-45a9-a84d-d1c8bd2400c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_NumberOfLicenseAgreements_dc61e2cf-4a3c-4113-9450-0cbe0d8df967_terseLabel_en-US" xlink:label="lab_ekso_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of license agreements</link:label>
    <link:label id="lab_ekso_NumberOfLicenseAgreements_label_en-US" xlink:label="lab_ekso_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of License Agreements</link:label>
    <link:label id="lab_ekso_NumberOfLicenseAgreements_documentation_en-US" xlink:label="lab_ekso_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_NumberOfLicenseAgreements" xlink:href="ekso-20201231.xsd#ekso_NumberOfLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_NumberOfLicenseAgreements" xlink:to="lab_ekso_NumberOfLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_53cbfe4c-a27a-444f-bdaa-a4f95654ab4f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_65249191-19a5-4b36-b84b-03e9b7f1d7c0_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_a8429d1a-051d-4ea9-8d58-0305616df344_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b4c8c9e2-f5e5-4e6e-ae62-d6dfda63a2bc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_df89b0f3-045e-44a7-97d2-daf814fbdd4c_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c105a45-def3-4cd6-b484-8260befb1700_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_2ecb4106-37bc-4aec-a2c2-1495b77fd5c2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device warranty</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_3007fc3b-6de2-46cb-b831-91abaf4ef75a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0564a742-aec1-413b-a5e6-7b5b4072582e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_SharesIssuedCapitalContribution_dee90675-2d91-458f-902d-de34b852170a_terseLabel_en-US" xlink:label="lab_ekso_SharesIssuedCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issuance for common stock contribution to 401(k) plan</link:label>
    <link:label id="lab_ekso_SharesIssuedCapitalContribution_label_en-US" xlink:label="lab_ekso_SharesIssuedCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued ,Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SharesIssuedCapitalContribution" xlink:href="ekso-20201231.xsd#ekso_SharesIssuedCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_SharesIssuedCapitalContribution" xlink:to="lab_ekso_SharesIssuedCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_NumberOfConsecutiveBusinessDays_10d054ef-1dc6-46e7-b41f-251517e68a43_terseLabel_en-US" xlink:label="lab_ekso_NumberOfConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consecutive Business days</link:label>
    <link:label id="lab_ekso_NumberOfConsecutiveBusinessDays_label_en-US" xlink:label="lab_ekso_NumberOfConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consecutive Business days</link:label>
    <link:label id="lab_ekso_NumberOfConsecutiveBusinessDays_documentation_en-US" xlink:label="lab_ekso_NumberOfConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consecutive Business days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_NumberOfConsecutiveBusinessDays" xlink:href="ekso-20201231.xsd#ekso_NumberOfConsecutiveBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_NumberOfConsecutiveBusinessDays" xlink:to="lab_ekso_NumberOfConsecutiveBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_8cd236ea-8dc8-4608-b867-22e2229f48e5_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_bd1d8f95-6fcd-494f-ba4e-cccc9ea0586e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember_6835d6ff-7825-4837-a832-72aa3dfb2854_terseLabel_en-US" xlink:label="lab_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Placement Agent Warrants</link:label>
    <link:label id="lab_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember_label_en-US" xlink:label="lab_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June Twenty Twenty Placement Agents Warrants [Member]</link:label>
    <link:label id="lab_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember_documentation_en-US" xlink:label="lab_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June Twenty Twenty Placement Agents Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember" xlink:to="lab_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d45b67f1-2b1a-4d0d-864f-d209e7d645e2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt, net of financing costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c68bb3b8-0324-4d1c-800c-a40401c1922c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_918c82b7-39bd-4050-8c33-f39cd36e4f95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_415c879f-364f-4753-b3a6-668959172668_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Weighted Average Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a14faeee-c81b-4323-8aa1-cf40869db709_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightManagementFeePercentage_b513813c-b76f-4386-a36f-b2adc9fc0f9a_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightManagementFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right management fee percentage</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightManagementFeePercentage_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightManagementFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Management Fee Percentage</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightManagementFeePercentage_documentation_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightManagementFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Management Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightManagementFeePercentage" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightManagementFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightManagementFeePercentage" xlink:to="lab_ekso_ClassOfWarrantOrRightManagementFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7c0334ee-b4c0-4536-969a-224768f1100b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Revenue Activity</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_55137f93-ccf6-461c-b4f2-1e18d833e180_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_1c5805a9-7402-4e32-9ba1-bddf777a6d53_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_91f393f9-749c-4f55-9f98-1507702d3907_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_934f4a9c-4f87-4447-91de-de62c7270f23_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_42819a63-8d00-402f-8d0d-2419e880b632_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_A2019WarrantsMember_6c375437-39ab-468f-994a-41b0fce188d0_terseLabel_en-US" xlink:label="lab_ekso_A2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 warrants</link:label>
    <link:label id="lab_ekso_A2019WarrantsMember_label_en-US" xlink:label="lab_ekso_A2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Warrants [Member]</link:label>
    <link:label id="lab_ekso_A2019WarrantsMember_documentation_en-US" xlink:label="lab_ekso_A2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_A2019WarrantsMember" xlink:href="ekso-20201231.xsd#ekso_A2019WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_A2019WarrantsMember" xlink:to="lab_ekso_A2019WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_765c2995-fca5-4158-b3a5-84fc63afd11c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a9de5b7a-05b9-4c63-9c96-2947a5c56dbf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c3edc703-e15f-4e91-a655-18d74fdd0cc8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e0e5d34d-9f37-4c08-8397-a1158c2f419e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity incentive plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_be361634-23d8-46b2-bbe7-4985b43d2bb9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0566c889-4e78-4314-b74f-96ada28de5a6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4c7189f6-11e3-409d-92bf-61b2d86da294_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a2e4484c-f032-46f8-96c3-cb60f9af3316_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_CommonStockContribution_60387223-9200-40d7-a8b6-7fd8798747f7_terseLabel_en-US" xlink:label="lab_ekso_CommonStockContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock contribution to 401(k) plan</link:label>
    <link:label id="lab_ekso_CommonStockContribution_label_en-US" xlink:label="lab_ekso_CommonStockContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CommonStockContribution" xlink:href="ekso-20201231.xsd#ekso_CommonStockContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_CommonStockContribution" xlink:to="lab_ekso_CommonStockContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_68c5b04f-5293-4bb6-980d-3a4b145028a1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_a216c1f8-300c-4881-84f9-17b74cc78a36_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_eb008767-9121-44ae-a241-7febb333e199_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5f84ba2e-157d-4b23-8ee3-154b9bf0a2d0_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1b4dbee7-e6a1-4a2b-bc16-68a11a751c8f_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2c05dc0b-4c27-497e-9a5b-aa1302db9cfc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_EquityIncentivePlan2014Member_085ee37d-c530-4df8-9c63-8ddf6986960a_verboseLabel_en-US" xlink:label="lab_ekso_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity incentive plan</link:label>
    <link:label id="lab_ekso_EquityIncentivePlan2014Member_8c779865-4fe5-486f-9e1d-ef318e5e3fc4_terseLabel_en-US" xlink:label="lab_ekso_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity incentive plan</link:label>
    <link:label id="lab_ekso_EquityIncentivePlan2014Member_label_en-US" xlink:label="lab_ekso_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_EquityIncentivePlan2014Member" xlink:to="lab_ekso_EquityIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_382958fd-fdff-4bb1-8507-91a8c8b3007b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold_6aab9a97-34d3-4ab4-aadb-21710a96f05e_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock, percent</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant Or Right, Percentage Of Aggregate Shares Sold</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold_documentation_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant Or Right, Percentage Of Aggregate Shares Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold" xlink:to="lab_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_f6b6fa2e-8139-4afb-a854-7b4b80ac6d87_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_WarrantIssuanceExpense_04c2ff73-2864-4e6b-92ae-9f5ba116646e_negatedTerseLabel_en-US" xlink:label="lab_ekso_WarrantIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance cost associated with warrant issuance</link:label>
    <link:label id="lab_ekso_WarrantIssuanceExpense_86165ed0-6219-4c61-b520-467201a0ae7f_terseLabel_en-US" xlink:label="lab_ekso_WarrantIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expense</link:label>
    <link:label id="lab_ekso_WarrantIssuanceExpense_label_en-US" xlink:label="lab_ekso_WarrantIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issuance Expense</link:label>
    <link:label id="lab_ekso_WarrantIssuanceExpense_documentation_en-US" xlink:label="lab_ekso_WarrantIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Amount of expense incurred on issuance of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_WarrantIssuanceExpense" xlink:href="ekso-20201231.xsd#ekso_WarrantIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_WarrantIssuanceExpense" xlink:to="lab_ekso_WarrantIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_824f315f-a3bc-4f7a-98f8-3a476dbeb37d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e88258a3-2407-437d-ad79-4629d602f513_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_23d4d8db-3a62-43f1-9d98-40a09e79931b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hierarchies for Financial Assets and Liabilities on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e517b828-f47e-46e5-8d85-450a05217175_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_8e63099e-2169-4bfb-bfbd-8f380094e9c9_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b3996c14-4ab2-4fe0-b956-f7c89726fb83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_1c5afdc2-2925-4d5e-b8be-d230587ea8d2_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_63d5ed7e-299e-4c32-a99f-6cd84b7cc088_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_806ca06d-cfd9-457b-8b15-ff51bf9d5876_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_e1b42c2a-bfd6-4be2-93ce-695c494e266f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices, Lower (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_55ab53b9-d1d9-44d7-aa61-24fe73c39bd4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_1508060d-efe4-4aef-8a05-dc2705ff5ff7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ef408c47-ad56-4960-b9bf-a0f05efcc92c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at year end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_656685a9-71e9-49b9-9fd4-7a3eb3b4ef24_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_86d141d6-9afd-45f4-829e-5298b41e28a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of remaining balance on long-term debt</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_13691090-7c49-4c39-a766-4f2013b76aa8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of remaining balance of long-term debt</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_43d41ffb-047b-4e91-96de-ec0cf6356cf1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_65699045-8bc7-4f41-8d0a-7d269c3913a9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contribution to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1a78f99d-dffc-49e8-ac02-4919270d19c5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of vested shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_June2020WarrantsMember_e86b865a-10bf-46e1-932a-a7dd2828d056_terseLabel_en-US" xlink:label="lab_ekso_June2020WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Warrants</link:label>
    <link:label id="lab_ekso_June2020WarrantsMember_label_en-US" xlink:label="lab_ekso_June2020WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Warrants [Member]</link:label>
    <link:label id="lab_ekso_June2020WarrantsMember_documentation_en-US" xlink:label="lab_ekso_June2020WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020WarrantsMember" xlink:href="ekso-20201231.xsd#ekso_June2020WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_June2020WarrantsMember" xlink:to="lab_ekso_June2020WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_087858ed-06c1-43ac-af80-84253d11b3b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ExercisePriceRangeThreeMember_015b4565-6163-4b63-805c-0282460ab12e_terseLabel_en-US" xlink:label="lab_ekso_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$27.30 - $56.70</link:label>
    <link:label id="lab_ekso_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_ekso_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeThreeMember" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ExercisePriceRangeThreeMember" xlink:to="lab_ekso_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_854d7864-49e0-4d69-8234-a42077019c72_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37e69d69-e2b3-4530-b4a3-5ce0b97b9a0e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_74225a86-32be-4ac2-a837-ceded9fb204e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_7e2ef1fb-300d-474c-99a2-606bd6a68204_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6e1c4a01-b75d-422a-9478-3572971ee975_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_9a6be920-f08a-429b-b556-5b155b2dea2b_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_295839f8-02d5-49dd-a419-a291a3796a31_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ae81fbd5-d117-49e2-9f86-b4ea7806293b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a14db23c-0d97-413b-a204-b098fe1664cc_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_74bbeb53-f431-4775-ac5e-44afb816c183_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b11abb72-3612-44b1-8a81-7eedf8ee2980_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_55632511-7ced-4dd6-a7f3-cab3e98fa8a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_d9d97c6a-9255-4895-a574-e193f5978845_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_09b2f9b5-76df-43af-8505-6b5ec5b84fe0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_3ce64fe6-7f06-449f-8bfb-7e7f65fa7aeb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForFees_c74d28b9-1b3b-4f92-adc3-2b5c66a6b86b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_540c61c6-4b9b-43d8-94b6-96fd7677fdaa_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and peripherals</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_b860613e-6563-4a04-8be9-6acb91b387e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0563f2ca-b2aa-4c76-8e23-ae396fc7d888_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_GainLossOnWarrantLiability_1b9d221c-e09a-4136-a136-31857015d85d_verboseLabel_en-US" xlink:label="lab_ekso_GainLossOnWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) gain on warrant liabilities</link:label>
    <link:label id="lab_ekso_GainLossOnWarrantLiability_313ea90e-96dc-4ba5-b114-ad5ae2b7c056_negatedLabel_en-US" xlink:label="lab_ekso_GainLossOnWarrantLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on revaluation of warrant liabilities</link:label>
    <link:label id="lab_ekso_GainLossOnWarrantLiability_929fdb7e-03b0-452d-ae61-e093d58f43ee_negatedTerseLabel_en-US" xlink:label="lab_ekso_GainLossOnWarrantLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of warrants issued in June 2020, December 2019, May 2019 financing, and December 2015 equity financings</link:label>
    <link:label id="lab_ekso_GainLossOnWarrantLiability_label_en-US" xlink:label="lab_ekso_GainLossOnWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Warrant Liability</link:label>
    <link:label id="lab_ekso_GainLossOnWarrantLiability_documentation_en-US" xlink:label="lab_ekso_GainLossOnWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantLiability" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_GainLossOnWarrantLiability" xlink:to="lab_ekso_GainLossOnWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightManagementFeeExpense_9ffdc61b-22f1-4bd9-8b8d-d1ab221d17bf_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right management fee</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightManagementFeeExpense_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Management Fee Expense</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightManagementFeeExpense_documentation_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Management Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightManagementFeeExpense" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightManagementFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightManagementFeeExpense" xlink:to="lab_ekso_ClassOfWarrantOrRightManagementFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c0c84d84-270b-44d6-b868-3254f9693ab6_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_d863a489-d98a-41c7-accb-da5d7a02a587_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_cb7d3fa0-80ff-4055-b589-1fe3109830bd_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_96c59bad-f478-4341-996a-cdcd9075a7f0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightDurationOfPutOption_b9c414d6-b077-4225-b3cc-44046418ec61_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightDurationOfPutOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of put option</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightDurationOfPutOption_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightDurationOfPutOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Duration Of Put Option</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightDurationOfPutOption_documentation_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightDurationOfPutOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Duration Of Put Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightDurationOfPutOption" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightDurationOfPutOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightDurationOfPutOption" xlink:to="lab_ekso_ClassOfWarrantOrRightDurationOfPutOption" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_af4b1900-ebea-42ff-a757-5dd2605232e0_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightCashFee_054a472b-2810-4da1-8443-23625c10b12a_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightCashFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right cash fee</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightCashFee_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightCashFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Cash Fee</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightCashFee_documentation_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightCashFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Cash Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightCashFee" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightCashFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightCashFee" xlink:to="lab_ekso_ClassOfWarrantOrRightCashFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d7457431-e448-4177-b0ee-b2afc0c14a5b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_37d194ef-c19b-4dff-b667-0cf87488fb50_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c0160388-0e15-41ea-818b-e9f0191f7238_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c0dc112-8f7c-4ba5-89a0-83d52a812cbd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_78eb56f2-a837-4ef0-87e4-54e6c9538ba4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_855efd09-f64f-4aa0-a157-955191a09375_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5a8d90da-8740-414f-8df6-4dc1093c4748_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputConversionPriceMember_c878f817-5031-4bdf-9aa1-320b08e5c838_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputConversionPriceMember_bc6448c4-cbc2-49ec-9d45-c0a93be20b14_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputConversionPriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputConversionPriceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputConversionPriceMember" xlink:to="lab_us-gaap_MeasurementInputConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_June2020PlacementAgentWarrantsMember_ecc5b091-5d2a-433d-8c83-ee761f57a6ba_terseLabel_en-US" xlink:label="lab_ekso_June2020PlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Placement Agent Warrants</link:label>
    <link:label id="lab_ekso_June2020PlacementAgentWarrantsMember_label_en-US" xlink:label="lab_ekso_June2020PlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Placement Agent Warrants [Member]</link:label>
    <link:label id="lab_ekso_June2020PlacementAgentWarrantsMember_documentation_en-US" xlink:label="lab_ekso_June2020PlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020PlacementAgentWarrantsMember" xlink:href="ekso-20201231.xsd#ekso_June2020PlacementAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_June2020PlacementAgentWarrantsMember" xlink:to="lab_ekso_June2020PlacementAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_53d6ccc4-7435-42dd-9dcf-ca12718a8a5e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per share applicable to common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8e92625b-ff59-4d53-b96e-3752d899c6df_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a435464-e515-4ca2-b8a2-793ed6a754cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightExpirationPeriod_ed70f2f6-7892-4459-9514-d4235b66643e_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right expiration period</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightExpirationPeriod_6f7bc415-1263-4d1f-874f-f3008f7a36ec_verboseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term (Years)</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightExpirationPeriod_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExpirationPeriod" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightExpirationPeriod" xlink:to="lab_ekso_ClassOfWarrantOrRightExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_DebtInstrumentDeferralPeriod_e522c544-0d65-4a78-8f67-9059e08c8770_terseLabel_en-US" xlink:label="lab_ekso_DebtInstrumentDeferralPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferral principal payment period</link:label>
    <link:label id="lab_ekso_DebtInstrumentDeferralPeriod_label_en-US" xlink:label="lab_ekso_DebtInstrumentDeferralPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Deferral Period</link:label>
    <link:label id="lab_ekso_DebtInstrumentDeferralPeriod_documentation_en-US" xlink:label="lab_ekso_DebtInstrumentDeferralPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Deferral Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DebtInstrumentDeferralPeriod" xlink:href="ekso-20201231.xsd#ekso_DebtInstrumentDeferralPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_DebtInstrumentDeferralPeriod" xlink:to="lab_ekso_DebtInstrumentDeferralPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ca3c9ac8-bdde-4ffa-bb85-7ad7b62975ba_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_LicenseRevenueMember_ea93181a-0d13-456c-9575-4316dcc09da4_verboseLabel_en-US" xlink:label="lab_ekso_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees</link:label>
    <link:label id="lab_ekso_LicenseRevenueMember_label_en-US" xlink:label="lab_ekso_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LicenseRevenueMember" xlink:href="ekso-20201231.xsd#ekso_LicenseRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_LicenseRevenueMember" xlink:to="lab_ekso_LicenseRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_5d8b6c53-4acc-4ebb-84bf-2a2163bc67ea_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty agreement terms</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:to="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1e4fc262-0c01-4f60-8dd8-c440a272b1c8_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligations</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd6352a8-154c-4330-925a-89eca3126ed6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_afcddeb4-68d6-4998-b494-385929caedf1_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_84517da0-38d1-476e-9a30-9cbabdef422c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember_8f00a715-ccc2-46fc-ad96-6cce525e1d79_terseLabel_en-US" xlink:label="lab_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generated before 2018, carryforward indefinitely</link:label>
    <link:label id="lab_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember_label_en-US" xlink:label="lab_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generated Before 2018, Carryforward Indefinitely [Member]</link:label>
    <link:label id="lab_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember_documentation_en-US" xlink:label="lab_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generated Before 2018, Carryforward Indefinitely [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember" xlink:href="ekso-20201231.xsd#ekso_GeneratedBefore2018CarryforwardIndefinitelyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember" xlink:to="lab_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a672c082-80cb-4705-9914-c4fdbf4b3e6f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_GoingConcernPolicyTextBlock_156bb7f3-e2fd-471e-826f-f61489439115_verboseLabel_en-US" xlink:label="lab_ekso_GoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_ekso_GoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_ekso_GoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GoingConcernPolicyTextBlock" xlink:href="ekso-20201231.xsd#ekso_GoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_GoingConcernPolicyTextBlock" xlink:to="lab_ekso_GoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_02fc4b81-975a-4e35-bf4c-81b21f9e988f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_44352b44-2225-49c9-92f5-440849ce0c68_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6de6c800-c87f-4e15-9145-9889b3885021_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_PWBLoanAgreementMember_65f429a0-2f75-465c-8517-6a34b2704bbe_terseLabel_en-US" xlink:label="lab_ekso_PWBLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PWB loan agreement</link:label>
    <link:label id="lab_ekso_PWBLoanAgreementMember_label_en-US" xlink:label="lab_ekso_PWBLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PWB Loan Agreement [Member]</link:label>
    <link:label id="lab_ekso_PWBLoanAgreementMember_documentation_en-US" xlink:label="lab_ekso_PWBLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PWB Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_PWBLoanAgreementMember" xlink:href="ekso-20201231.xsd#ekso_PWBLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_PWBLoanAgreementMember" xlink:to="lab_ekso_PWBLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bb22c7e-44a7-41c5-953b-f18cd292f6be_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_63aaa757-ebf5-47b9-aabb-6c2dace8edaf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share authorized for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_d4c24616-d631-4e43-b539-3b0c6ca8a916_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts_8f46afa6-eba2-4996-93d7-b4f953af157c_terseLabel_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipois sales earn-out</link:label>
    <link:label id="lab_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts_label_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Equiposis Sales Earn Outs</link:label>
    <link:label id="lab_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts_documentation_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Equiposis Sales Earn Out</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts" xlink:to="lab_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ce2d4037-3fa7-4504-a27f-750b170d683f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_01d052b9-f7bb-427c-90d6-d55a923587ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c4bd9c70-7a0f-451c-be21-0b5cf667b45b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ecf06608-e417-4243-9fd3-f2e47df6c9f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_Pre2014WarrantsMember_e7a34cd0-9a72-4379-85fd-9e6d9aaa4b09_terseLabel_en-US" xlink:label="lab_ekso_Pre2014WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-2014 warrants</link:label>
    <link:label id="lab_ekso_Pre2014WarrantsMember_label_en-US" xlink:label="lab_ekso_Pre2014WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre 2014 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_Pre2014WarrantsMember" xlink:href="ekso-20201231.xsd#ekso_Pre2014WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_Pre2014WarrantsMember" xlink:to="lab_ekso_Pre2014WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc17c099-2553-4da7-a439-62cb2a164d23_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7ff1aa83-e7b5-4c19-ac3a-f7597259b1eb_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_6ca24786-3170-4cf3-8549-018d611e84a1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6802ccfd-6ef5-4b10-8e58-8cab81cdfb29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_DirectOfferingMember_b90f788b-b133-4c97-b3d1-1574df1fd25e_terseLabel_en-US" xlink:label="lab_ekso_DirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct offering</link:label>
    <link:label id="lab_ekso_DirectOfferingMember_label_en-US" xlink:label="lab_ekso_DirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Offering [Member]</link:label>
    <link:label id="lab_ekso_DirectOfferingMember_documentation_en-US" xlink:label="lab_ekso_DirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DirectOfferingMember" xlink:href="ekso-20201231.xsd#ekso_DirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_DirectOfferingMember" xlink:to="lab_ekso_DirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_d89ef9f6-a8be-4878-912d-2a45a9219ebe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_0644f17b-384c-44be-b8f7-d367f22008e8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contribution to 401(k) plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember_197f8b35-63c4-482c-8c9e-8ed5fba60d77_terseLabel_en-US" xlink:label="lab_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 placement agent warrants</link:label>
    <link:label id="lab_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember_label_en-US" xlink:label="lab_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June Twenty Twenty Placement Agent Warrants [Member]</link:label>
    <link:label id="lab_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember_documentation_en-US" xlink:label="lab_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June Twenty Twenty Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyPlacementAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember" xlink:to="lab_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_3bc4dbac-525e-4396-a814-08b04f8af3d1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_26d976f3-5bcc-4f05-89a1-4eccee24baba_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_08302fa0-aade-408d-9d51-eb47e32c2224_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f54b5e65-e8a3-4aef-bd96-c84157d1f353_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_654b611b-7df4-49fd-ae4d-59384c5d0895_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_827cfc2d-6656-4785-b3dc-91241cdfb541_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_3d5a7567-e3cd-42a1-b0e5-88b46d38b824_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_06392f2b-888c-42af-b74d-d8bcf217da55_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_3786a0ee-3b11-4762-9dee-a240c3cd088f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term of lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_bc1448d7-bbdf-4662-96ca-b5d883fb796b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_a5f99dd5-fa29-49a5-82cf-a366f749dac2_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-3 Years</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:to="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_08f0d9cc-9015-49af-9b75-4471f7383419_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160;Weighted Average Grant- Date Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22c721ed-29b0-423b-8399-56381a5bbf8c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_2d94d577-988d-41de-b7bd-e7784a0164f2_periodStartLabel_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of the period</link:label>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_aabc9403-ea3f-4377-b2bb-5ae3a7b32c22_periodEndLabel_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of the period</link:label>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_fa39bdeb-744a-415c-85c8-ec9d1c350919_totalLabel_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_label_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Maintenance Warranty Liabilities Current Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" xlink:to="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent_41dc0777-6095-4724-8212-ae63be682fad_verboseLabel_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent_label_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Maintenance Warranty Liabilities Noncurrent</link:label>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying value of noncurrent portion of product maintenance and warranty liabilities as on the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent" xlink:to="lab_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fed68477-c568-4bb4-832b-acff4bd6af15_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0d7fc0c5-385b-4944-a069-5eeab2b276af_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dc63f575-4c26-4a2b-8713-9f82c7b82e99_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Weighted-Average Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a90aa7f4-e2b1-4897-87d0-6c2d22120a4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_07362398-390d-47ac-815e-5bd599594c9f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f1365079-155f-4eb1-b080-31550711664e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_81688f9e-8d1a-4182-80ea-b22653eb137e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_73bb77a3-71bd-4d03-98ac-4ffc2e5d09e0_verboseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4f90dcb2-bfd1-4e5d-add9-7e853dee2dd5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants_72e86470-2449-4cff-862d-b419f026e65b_terseLabel_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:label id="lab_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_4e7fdd32-f0fa-4baf-9fc4-8a096aebb822_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6fb02a7f-4100-418d-b9ca-3c0ee6a1b71c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7b7b95cb-ff6d-4da0-af99-5afd75836f5b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ExercisePriceRangeFourMember_24af02cf-f6cf-457e-b9ff-a55dd67a3fc1_terseLabel_en-US" xlink:label="lab_ekso_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$60.00 - $229.95</link:label>
    <link:label id="lab_ekso_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_ekso_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeFourMember" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ExercisePriceRangeFourMember" xlink:to="lab_ekso_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f5bbe0f0-a7ce-4764-8d9d-f3c0a32acd36_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_d2528188-0a96-4032-83bc-355c3548ce6d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Unconsolidated Affiliate</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_9c3e3ff6-0237-499c-99e6-618faad46707_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Disclosures</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_693173f4-231c-4263-b2e9-7e54dc38f7fe_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity financing, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3ec56df9-3233-4f75-837a-9bf4f3e2c649_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_fb388df8-91ac-46ae-9fb6-c9dd3e605b5b_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_GainLossOnWarrantModification_1a5dfcce-1bd5-4dd5-967f-bc58d5811c10_terseLabel_en-US" xlink:label="lab_ekso_GainLossOnWarrantModification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on modification of warrants</link:label>
    <link:label id="lab_ekso_GainLossOnWarrantModification_15184978-9b1d-4a39-a259-45749374ac0e_negatedNetLabel_en-US" xlink:label="lab_ekso_GainLossOnWarrantModification" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on modification of warrants</link:label>
    <link:label id="lab_ekso_GainLossOnWarrantModification_30eb479c-58d2-4098-960b-5240e86a7528_negatedTerseLabel_en-US" xlink:label="lab_ekso_GainLossOnWarrantModification" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on modification of warrants</link:label>
    <link:label id="lab_ekso_GainLossOnWarrantModification_label_en-US" xlink:label="lab_ekso_GainLossOnWarrantModification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Warrant Modification</link:label>
    <link:label id="lab_ekso_GainLossOnWarrantModification_documentation_en-US" xlink:label="lab_ekso_GainLossOnWarrantModification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Warrant Modification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantModification" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantModification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_GainLossOnWarrantModification" xlink:to="lab_ekso_GainLossOnWarrantModification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b96b8363-113f-4f26-a444-dfeb4c6e0068_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial fair value of warrants in connection with June 2020 financing</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_2d1c22e7-4210-43af-b4ac-58d4b06fe0f5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_7307af2b-4a11-4448-af4b-1df0cd09598d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_GainLossOnModificationOfOperatingLeaseLiabilities_c0431f38-8ea5-4ebd-8931-621e60d2b9ca_terseLabel_en-US" xlink:label="lab_ekso_GainLossOnModificationOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on modification of operating lease liabilities</link:label>
    <link:label id="lab_ekso_GainLossOnModificationOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_ekso_GainLossOnModificationOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Modification Of Operating Lease Liabilities</link:label>
    <link:label id="lab_ekso_GainLossOnModificationOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_ekso_GainLossOnModificationOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Modification Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnModificationOfOperatingLeaseLiabilities" xlink:href="ekso-20201231.xsd#ekso_GainLossOnModificationOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_GainLossOnModificationOfOperatingLeaseLiabilities" xlink:to="lab_ekso_GainLossOnModificationOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6adeb146-4143-4325-814e-9266f26eba11_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5b172da3-60d6-4a50-bb35-5fe00ceec193_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_457511d1-67c1-4289-831a-e9b8b1e4136e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_03af71ee-b589-426f-bf39-b5d0504567a0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_74f16da7-50e5-429f-a0ea-254de931e774_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0660c132-2eff-4d3f-8beb-6200854a0350_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_52994245-8ecd-46f4-947f-b488f58376b7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current share price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_76ab3f45-06d5-46c1-86ab-93de061797cf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_3f38c77b-4ed2-4e46-8159-91cb04878276_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_eebce726-80ff-41f0-a183-4407b21cb8ec_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation due in less than one year</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_72e3f997-f7da-4a88-ab20-95e724e97a12_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_1e062676-536b-4496-b248-5e1ac0263291_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_db41d74e-405c-40b7-8f08-ca2ff85bfb4b_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_CustomerAMember_a1c7e36e-7360-40c4-815a-0cf7366de6ad_terseLabel_en-US" xlink:label="lab_ekso_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_ekso_CustomerAMember_label_en-US" xlink:label="lab_ekso_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_ekso_CustomerAMember_documentation_en-US" xlink:label="lab_ekso_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CustomerAMember" xlink:href="ekso-20201231.xsd#ekso_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_CustomerAMember" xlink:to="lab_ekso_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_47ae8e62-1c3f-4430-9fe5-2ae68ea3a49f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6d54ac82-99ea-4d2c-8ac0-90583d03b961_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares sold</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_768da3b0-3a35-415e-a35a-8c9b3b1c8cac_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fa67d4cf-c7d3-4e1d-aa2e-0df01c4dcafd_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_37dc6f23-7f34-43a3-8bb4-506a21d31397_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable, Weighted Average Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_51181ea4-9b81-4ad5-906e-2923143f4862_verboseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Outstanding Contractual Obligations Including Interest Payments</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_16c2b933-51e8-46a4-8ca4-c7503cfed27d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of inventory parts and tooling</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_29fdb0c8-6af7-4a5a-8200-a00161198826_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_62723fb8-aa2d-4130-b852-7f9783d03493_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b3d223b3-3cfc-45e0-a671-55ae6ba4aabc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_4d7cad38-8fbb-4db5-9633-8a4bfde6a623_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dd8d7fca-c783-400d-84bf-60591c33a338_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_9b6cf141-71a7-4034-9533-cd0bc3d271ea_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_92a55d66-7e97-4bd5-bdae-eb261d329802_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_920f6864-fee9-4fde-9780-f669728b7b7d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b2e79acd-a389-45c0-91fb-726e67605e35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_DeferredDeviceRevenue_d17fcc30-77b5-4af7-a399-387dbd7cf12c_terseLabel_en-US" xlink:label="lab_ekso_DeferredDeviceRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred device, rental revenues and advances</link:label>
    <link:label id="lab_ekso_DeferredDeviceRevenue_label_en-US" xlink:label="lab_ekso_DeferredDeviceRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Device Revenue</link:label>
    <link:label id="lab_ekso_DeferredDeviceRevenue_documentation_en-US" xlink:label="lab_ekso_DeferredDeviceRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Device Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredDeviceRevenue" xlink:href="ekso-20201231.xsd#ekso_DeferredDeviceRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_DeferredDeviceRevenue" xlink:to="lab_ekso_DeferredDeviceRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c376c2b3-f197-4a50-a262-3809964aa51e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f400bf59-1b82-49b5-904a-4c11a64abb79_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a3d55462-390d-46d4-a41a-c04e16a7fcff_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e77f8e84-7335-4b83-ae17-842aea5fac0c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_873d1f41-e4e5-460f-9a7c-dcf1adbdad3c_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years), Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_0afad655-4264-4f8a-ace9-6c4648f66d8a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9ff3e180-5a68-4a3c-b430-ee53a2c4950b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_JuneTwentyTwentyInvestorWarrantsMember_e1a5de65-66ed-40f8-87fa-62b4dcefc7c1_terseLabel_en-US" xlink:label="lab_ekso_JuneTwentyTwentyInvestorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Investor Warrants</link:label>
    <link:label id="lab_ekso_JuneTwentyTwentyInvestorWarrantsMember_label_en-US" xlink:label="lab_ekso_JuneTwentyTwentyInvestorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June Twenty Twenty Investor Warrants [Member]</link:label>
    <link:label id="lab_ekso_JuneTwentyTwentyInvestorWarrantsMember_documentation_en-US" xlink:label="lab_ekso_JuneTwentyTwentyInvestorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June Twenty Twenty Investor Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyInvestorWarrantsMember" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyInvestorWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_JuneTwentyTwentyInvestorWarrantsMember" xlink:to="lab_ekso_JuneTwentyTwentyInvestorWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6784977e-9fd9-4eec-a9d5-5d18ae2bafd1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_f116b260-2e65-497b-887b-a4053dfb1e98_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_4a385cc0-f54c-4e1f-b91c-4943ecb2ad24_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7bfa32c3-47cc-4b2c-8d28-eae8decb535e_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_71b8cb5b-8370-4319-a9f8-34978de43b64_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_EksoHealthMember_ac965542-b7b7-43d3-a5b7-c7c94c6367b2_terseLabel_en-US" xlink:label="lab_ekso_EksoHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EksoHealth</link:label>
    <link:label id="lab_ekso_EksoHealthMember_272644e4-a262-4d56-ad9e-c1e89fe07e0a_verboseLabel_en-US" xlink:label="lab_ekso_EksoHealthMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EksoHealth</link:label>
    <link:label id="lab_ekso_EksoHealthMember_label_en-US" xlink:label="lab_ekso_EksoHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EksoHealth [Member]</link:label>
    <link:label id="lab_ekso_EksoHealthMember_documentation_en-US" xlink:label="lab_ekso_EksoHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EksoHealth [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoHealthMember" xlink:href="ekso-20201231.xsd#ekso_EksoHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_EksoHealthMember" xlink:to="lab_ekso_EksoHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0f9ba6be-a6db-4828-a010-73e7145c9cef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8343e420-9a4c-4555-b23d-64354dcdbfc5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_5f63ab9a-e857-44ca-adcc-e43fae0f41ff_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3179a636-24e6-4d3f-acff-5bbceee4a356_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_39565cac-f5ea-4f33-852c-439e1030e6d0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_36a5be3b-39af-422c-9e6f-c353c4b306b2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_dfbc367d-6d70-4345-9126-5ce00b064eb0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement_511d46dd-e261-4b82-964e-11d23d4662b3_negatedLabel_en-US" xlink:label="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on revaluation of contingent liability</link:label>
    <link:label id="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement_label_en-US" xlink:label="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Changes Due To Re-measurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement" xlink:href="ekso-20201231.xsd#ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement" xlink:to="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_OtherLiabilitiesDomain_7c02bc38-ba1d-4d7c-97d5-b7efc848fa46_terseLabel_en-US" xlink:label="lab_ekso_OtherLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Domain]</link:label>
    <link:label id="lab_ekso_OtherLiabilitiesDomain_label_en-US" xlink:label="lab_ekso_OtherLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OtherLiabilitiesDomain" xlink:href="ekso-20201231.xsd#ekso_OtherLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_OtherLiabilitiesDomain" xlink:to="lab_ekso_OtherLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ec5b9596-bc6f-4648-a9f8-4d6e56b4d3dd_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_564cb07e-e324-4b30-946e-458409c426be_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a238e217-8c8a-4c96-bc91-204c0d987689_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_543fc74f-2df7-45e5-b5af-3d26fcac852c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_9e030a7f-8593-42ed-93ae-049acf13c1c1_verboseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a4651af1-a0ab-45ca-93e9-0011d2535288_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1d7b5f76-ff08-4e0f-9b35-c70c75e6111c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_EksoWorksMember_40b78c58-766c-4399-9a06-a8c9e25b9a14_verboseLabel_en-US" xlink:label="lab_ekso_EksoWorksMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EksoWorks</link:label>
    <link:label id="lab_ekso_EksoWorksMember_9d0a2187-496a-49d4-b994-2e8d10015f17_terseLabel_en-US" xlink:label="lab_ekso_EksoWorksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EksoWorks</link:label>
    <link:label id="lab_ekso_EksoWorksMember_label_en-US" xlink:label="lab_ekso_EksoWorksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EksoWorks [Member]</link:label>
    <link:label id="lab_ekso_EksoWorksMember_documentation_en-US" xlink:label="lab_ekso_EksoWorksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EksoWorks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoWorksMember" xlink:href="ekso-20201231.xsd#ekso_EksoWorksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_EksoWorksMember" xlink:to="lab_ekso_EksoWorksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_9d985038-0791-451c-bd97-2b36e0d4e2d1_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable, Number of Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5b789442-2acc-48d4-911d-9dba34077251_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d571d0d1-70ad-41ec-b4f3-c0f8bcad4840_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_4fd7bdf6-7e7d-47b4-a594-6e59397e4554_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear_555cc603-8d35-4726-ab0a-57fae40e47fa_terseLabel_en-US" xlink:label="lab_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 - 2022</link:label>
    <link:label id="lab_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear_label_en-US" xlink:label="lab_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Maturities Repayments Of Principal Remainder to Two Year</link:label>
    <link:label id="lab_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear_documentation_en-US" xlink:label="lab_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Maturities Repayments Of Principal Remainder to Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear" xlink:href="ekso-20201231.xsd#ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear" xlink:to="lab_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_449d4845-a309-4ca3-bf36-94dc6af72816_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_04ed13a5-5efe-42da-8b5e-f48d7baf7dde_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0b4ccbd6-7552-4d2a-977c-7c6ca636f166_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_89578c0b-00d6-45ee-877c-8c744c4e5eeb_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_UnrestrictedCash_ca776512-9c09-4ed1-9375-e71954c854ad_terseLabel_en-US" xlink:label="lab_ekso_UnrestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted cash</link:label>
    <link:label id="lab_ekso_UnrestrictedCash_label_en-US" xlink:label="lab_ekso_UnrestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_UnrestrictedCash" xlink:href="ekso-20201231.xsd#ekso_UnrestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_UnrestrictedCash" xlink:to="lab_ekso_UnrestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4e354acf-b4a4-4cca-8699-ec36314bd0b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_bc2022de-84ee-4c2f-9019-163e6339fe10_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_050d8ca5-7073-40fa-82c7-a83c57a0681d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Geographic Revenue Information</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e178a32f-0f4a-4537-aaf6-96f333c9608d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, Gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_010e2ccf-8c00-4223-a3bf-81ceaaa5ae4f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_9783df82-bfcc-4ab0-bede-509b15a9a962_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_76e8c97f-4531-4d3d-8bb4-41f4fb876201_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_87bbf331-e401-40f8-9a10-44bd64194d9c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6a4bb4ae-5a13-432a-84bb-6aa16a136c99_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d41316cf-3baa-4549-af88-8eae3c7aa40f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e93a5252-1aab-476b-b035-20a6fe70b1dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_324158d0-6f54-48e0-a4c1-ce703997fd9d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_AccruedClinicalCostCurrent_3f22702c-daf9-4af3-99d4-92141b6a2bbc_verboseLabel_en-US" xlink:label="lab_ekso_AccruedClinicalCostCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ekso_AccruedClinicalCostCurrent_label_en-US" xlink:label="lab_ekso_AccruedClinicalCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Cost Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedClinicalCostCurrent" xlink:href="ekso-20201231.xsd#ekso_AccruedClinicalCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_AccruedClinicalCostCurrent" xlink:to="lab_ekso_AccruedClinicalCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_d9b4d266-da31-4be4-a6a5-77e4182916c7_terseLabel_en-US" xlink:label="lab_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease assets</link:label>
    <link:label id="lab_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Right Of Use Asset</link:label>
    <link:label id="lab_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:href="ekso-20201231.xsd#ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:to="lab_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_dfa1a335-17ad-4cd1-9acd-6b124f83522d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6025fd8c-50c1-4917-8f3a-8236acb7bdfb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11ef4229-314b-48d8-8aac-0638ccebef29_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense, operating lease right-of-use assets, and other assets, current and noncurrent</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_6a367704-610b-44c1-80ca-a5ad1309b51e_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-allotment option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_29e93b3d-6a9d-4ebb-875f-c010b5be29f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightCashFeePercentage_b21bb76f-30ed-48ad-878b-6e290f3d877d_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightCashFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right cash fee percentage</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightCashFeePercentage_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightCashFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Cash Fee Percentage</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightCashFeePercentage_documentation_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightCashFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Cash Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightCashFeePercentage" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightCashFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightCashFeePercentage" xlink:to="lab_ekso_ClassOfWarrantOrRightCashFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ed387850-baed-4e62-9e1c-d233d9ae748a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less final payment fee, discount and issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8f782b4c-abaf-4145-b890-5f3be3166574_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_eb1f7c2e-6b36-4396-b8d8-278c15bb86dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6056cdd2-40b6-46fe-a30b-83a374ebf8c9_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_f7abaecd-e91c-4af6-a3c5-390cb6cc845b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_StockConversionPrice_e9009201-dba0-404e-97f2-a02c26a95804_terseLabel_en-US" xlink:label="lab_ekso_StockConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_ekso_StockConversionPrice_label_en-US" xlink:label="lab_ekso_StockConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockConversionPrice" xlink:href="ekso-20201231.xsd#ekso_StockConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_StockConversionPrice" xlink:to="lab_ekso_StockConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_6df18e36-dd46-4a08-b860-af48e44fc3f7_verboseLabel_en-US" xlink:label="lab_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable payment terms</link:label>
    <link:label id="lab_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_6d334e22-2b3f-4fc2-b307-1328c78106db_terseLabel_en-US" xlink:label="lab_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_label_en-US" xlink:label="lab_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracts With Customer, Accounts Receivable, Payment Terms, Duration</link:label>
    <link:label id="lab_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_documentation_en-US" xlink:label="lab_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracts With Customer, Accounts Receivable, Payment Terms, Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration" xlink:href="ekso-20201231.xsd#ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration" xlink:to="lab_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a6a333f4-3150-4429-892e-4b5d0b6ddf9b_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_RoyaltyPercentage_48c68a27-38b0-4a44-887d-1d465c586297_terseLabel_en-US" xlink:label="lab_ekso_RoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage</link:label>
    <link:label id="lab_ekso_RoyaltyPercentage_label_en-US" xlink:label="lab_ekso_RoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RoyaltyPercentage" xlink:href="ekso-20201231.xsd#ekso_RoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_RoyaltyPercentage" xlink:to="lab_ekso_RoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e962cee4-52e9-4b7d-a09f-77ae69dcded6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bbf549ad-28e8-4725-8360-7966c545c0ac_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_52f3c702-feb0-443c-bb8a-4303e0c96533_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_88a33d1e-9437-4127-b657-b79f818e9d20_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2dfabd63-f60b-4fd2-8b47-41be02017b53_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Expense (Benefit) Differed from Amounts Computed by Applying Statutory Federal Income Tax Rate to Pretax Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e0575489-0ef3-44d5-a91d-115699b9539f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_33aa98a9-a632-4be0-836d-32c48eaa7e59_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3332ba1e-3f4c-45af-b849-71c9920897f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_429f5473-bb14-48e0-a97d-4d5e6baaca4e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_e334356f-d406-4445-b998-1ec853b5f4eb_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_792f90b9-e23d-4741-9b8a-3f47ed30511f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3ca9774b-a5f0-49aa-8c89-ed63c13f56ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4a23e8ca-2be3-46c3-9ded-cd099528d4f4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original share pool (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_b14bb4fc-af34-4192-a7e4-5a0799163658_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on investment of unconsolidated affiliate</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_dc1e6ba6-ef80-4f1d-8235-cec79b6c41eb_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1d019573-f4ac-4c66-8f5b-cb9e3b8f9160_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d2e92ce2-51d5-4cb1-84da-cc14122390a2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_74ac1577-88b8-4367-afe9-c925b2befecf_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_16d8d618-7ed5-4189-a4d0-c4e4650a9e44_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7d0bdaf9-2c57-48ae-80ff-396833907c3a_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants_5795a7e7-3c4f-4328-b726-6ee18dd1c401_terseLabel_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants_label_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Exercise Of Warrants</link:label>
    <link:label id="lab_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants_documentation_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="lab_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_e724c8da-263f-4a45-b278-42a5c3f19add_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ContingentSuccessFeeLiability_00559e54-fd46-4ca8-ac3f-864f29f32a37_verboseLabel_en-US" xlink:label="lab_ekso_ContingentSuccessFeeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent success fee liability</link:label>
    <link:label id="lab_ekso_ContingentSuccessFeeLiability_label_en-US" xlink:label="lab_ekso_ContingentSuccessFeeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Success Fee Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContingentSuccessFeeLiability" xlink:href="ekso-20201231.xsd#ekso_ContingentSuccessFeeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ContingentSuccessFeeLiability" xlink:to="lab_ekso_ContingentSuccessFeeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_32f8a850-4fd6-4281-be0f-7dd27fd98383_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_DeferredRoyalties_82bbbb77-0678-4bcd-a0ac-b97e1d56b083_terseLabel_en-US" xlink:label="lab_ekso_DeferredRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred royalties</link:label>
    <link:label id="lab_ekso_DeferredRoyalties_label_en-US" xlink:label="lab_ekso_DeferredRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalties</link:label>
    <link:label id="lab_ekso_DeferredRoyalties_documentation_en-US" xlink:label="lab_ekso_DeferredRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredRoyalties" xlink:href="ekso-20201231.xsd#ekso_DeferredRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_DeferredRoyalties" xlink:to="lab_ekso_DeferredRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_36df8ab3-857b-4b0e-b058-183cf4a7d4ac_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ea3c43b9-4040-4e4d-990e-cd35a167eae7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3e3ec9d7-0c75-45ed-8a95-59cecd1c18e3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_184c4b1d-2835-427d-98ba-5f64bf72212c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_TermLoanMember_df194723-a941-44ca-ab91-9ae95905cb8b_terseLabel_en-US" xlink:label="lab_ekso_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loans</link:label>
    <link:label id="lab_ekso_TermLoanMember_label_en-US" xlink:label="lab_ekso_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TermLoanMember" xlink:href="ekso-20201231.xsd#ekso_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_TermLoanMember" xlink:to="lab_ekso_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_9116e842-d4c8-4a0f-941e-8ac139314be5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightExpired_6d9ead1b-88bd-4666-b894-4221ca48cd7c_negatedLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired (in shares)</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightExpired_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExpired" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightExpired" xlink:to="lab_ekso_ClassOfWarrantOrRightExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember_1b4a9e54-5195-4374-9e66-6da975dccf23_verboseLabel_en-US" xlink:label="lab_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember_label_en-US" xlink:label="lab_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue Goods Net Excluding Government Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember" xlink:href="ekso-20201231.xsd#ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember" xlink:to="lab_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_363ba848-e45f-4478-bfe0-9f5d3297f8a4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_HamburgGermanyMember_61fc651f-8567-4478-8981-f75810eebc49_terseLabel_en-US" xlink:label="lab_ekso_HamburgGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hamburg, Germany</link:label>
    <link:label id="lab_ekso_HamburgGermanyMember_label_en-US" xlink:label="lab_ekso_HamburgGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hamburg, Germany [Member]</link:label>
    <link:label id="lab_ekso_HamburgGermanyMember_documentation_en-US" xlink:label="lab_ekso_HamburgGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hamburg, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_HamburgGermanyMember" xlink:href="ekso-20201231.xsd#ekso_HamburgGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_HamburgGermanyMember" xlink:to="lab_ekso_HamburgGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyExpense_e98fb99d-6fa9-4cd7-af62-0838444213cc_negatedLabel_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs</link:label>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyExpense_label_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Maintenance Warranty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyExpense" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ProductMaintenanceWarrantyExpense" xlink:to="lab_ekso_ProductMaintenanceWarrantyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_08113fad-7a5e-41b0-ae7e-c83717188e94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_339e8f00-2214-497b-a504-5dd6f1851ddd_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Domestic and Foreign Components of Pre-tax Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ScheduleOfWarrantsOutstandingTableTextBlock_f3f8f1cc-3c21-42a2-a874-a437bdf3349b_terseLabel_en-US" xlink:label="lab_ekso_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrant Share Activity</link:label>
    <link:label id="lab_ekso_ScheduleOfWarrantsOutstandingTableTextBlock_label_en-US" xlink:label="lab_ekso_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants Outstanding [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:href="ekso-20201231.xsd#ekso_ScheduleOfWarrantsOutstandingTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:to="lab_ekso_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1d7f4969-57a4-44b3-b4a1-e54bdef10c5e_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_c8bc63cc-8177-4f57-b8b6-e6356d2f6bf1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_a84dc901-4f26-48fd-9239-b83e75cc7d3b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_80967d37-eba1-478c-bb7d-645ed6a6e038_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5765eafd-f4aa-41bd-be61-93046a0ad031_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_CollaborativeArrangementsMember_e4c82d2c-62fc-4df7-9572-d219479d1523_terseLabel_en-US" xlink:label="lab_ekso_CollaborativeArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements</link:label>
    <link:label id="lab_ekso_CollaborativeArrangementsMember_label_en-US" xlink:label="lab_ekso_CollaborativeArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Member]</link:label>
    <link:label id="lab_ekso_CollaborativeArrangementsMember_documentation_en-US" xlink:label="lab_ekso_CollaborativeArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CollaborativeArrangementsMember" xlink:href="ekso-20201231.xsd#ekso_CollaborativeArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_CollaborativeArrangementsMember" xlink:to="lab_ekso_CollaborativeArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut_a8ec7eb5-f1c6-484e-86b4-c6b80fdaeb9a_terseLabel_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipois sales earn-out (in shares)</link:label>
    <link:label id="lab_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut_label_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Share Equiposis Sales Earn Out</link:label>
    <link:label id="lab_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut_documentation_en-US" xlink:label="lab_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Share Equiposis Sales Earn Out</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut" xlink:to="lab_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bcc615b7-adba-4a0d-90ee-9f39230bab79_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_3331ce5a-8b19-4b9d-bf34-477f81cc4bbb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset (liability)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_19e7548c-29ac-434b-85f8-1fdec469350c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f582006b-7a31-4a48-bebf-0968b6920a9f_netLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_961965e8-feba-4012-b9d1-2577c5c14fe4_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a51efc12-4606-4e53-bfa6-051741b8cb22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4c3b2d54-462e-4d46-94fd-29fc5e387399_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Shares Available for Future Grant</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_97167357-7748-41cf-8f30-875c0a5f5c10_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from direct offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a4537aef-cff6-43b7-8d75-a9e37ad8e63f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b4249473-7ac4-4d29-bfc2-152297a1ff85_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_2c1d7605-72a1-4611-9e26-d9a07e2cf411_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_758bcb23-babf-40c9-a0f1-a0e15e04b88f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dfd010f1-ffa1-4f8d-b80e-fce4a6f32f50_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_bf405e1b-3e72-4381-b84c-7b6652c383a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_CustomerOneMember_56144ddb-cab0-486b-9275-516259d3043f_terseLabel_en-US" xlink:label="lab_ekso_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer one</link:label>
    <link:label id="lab_ekso_CustomerOneMember_label_en-US" xlink:label="lab_ekso_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_ekso_CustomerOneMember_documentation_en-US" xlink:label="lab_ekso_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CustomerOneMember" xlink:href="ekso-20201231.xsd#ekso_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_CustomerOneMember" xlink:to="lab_ekso_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4bf84733-5748-4298-bd9c-fd08d3383bea_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_37ecb028-524c-47f5-9212-530c7c8e966b_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_bc831e71-b7a7-4f29-bbc6-711d7b2285fe_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_1b5cc5ca-4d7c-482e-8e5a-8a9711d1d48f_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_4349416a-3efe-4344-acc7-5aaba42e0640_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward_d8164d68-9829-4cfc-8045-9f3afa83d0ce_terseLabel_en-US" xlink:label="lab_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right to receive per award</link:label>
    <link:label id="lab_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward_label_en-US" xlink:label="lab_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement By Share-Based Payment Award, Right To Receive Per Award</link:label>
    <link:label id="lab_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward_documentation_en-US" xlink:label="lab_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement By Share-Based Payment Award, Right To Receive Per Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward" xlink:href="ekso-20201231.xsd#ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward" xlink:to="lab_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants_8e1569ee-d474-4352-a28c-35b8423cdde0_terseLabel_en-US" xlink:label="lab_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate proceeds</link:label>
    <link:label id="lab_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants_label_en-US" xlink:label="lab_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock Preference Stock And Warrants</link:label>
    <link:label id="lab_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants_documentation_en-US" xlink:label="lab_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and from issuance of rights to purchase common shares at a predetermined price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" xlink:href="ekso-20201231.xsd#ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" xlink:to="lab_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_ae651a6d-c37d-424f-b3aa-3126fa631e7e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fa0bf41a-7e34-4c6d-91cf-2d507d85a7ec_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share Fair Value of Each Stock Option on Date of Grant using Black-Scholes Model Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_be90ffc7-4336-484c-8e2d-0b645bb2772f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_ce67553b-9dcc-4f0a-90f5-e7d649321e98_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9b919cf1-3aaa-4b1e-b614-693de6282267_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ExercisePriceRangeOneMember_70f289c3-b136-468b-95c3-47980b81c6e1_terseLabel_en-US" xlink:label="lab_ekso_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$5.55 - $9.15</link:label>
    <link:label id="lab_ekso_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_ekso_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeOneMember" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ExercisePriceRangeOneMember" xlink:to="lab_ekso_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d294c695-8090-4fee-982e-8b5e9e9ba297_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86c3675a-9bda-4c0d-99c8-83522a6a27a2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5008e802-244d-44b6-bf76-3c954df95399_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization and Equity Structure</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_0b79df95-d597-4b0b-9626-a3d557ceedd3_verboseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5aed8aad-416b-4c59-882b-cb8517cdf3df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_7b504e9b-415a-4b9a-ac96-97dea8c0b41d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_87c5d7bd-0118-4fd7-bebf-6b0473c8dbe8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_46d1a867-bcd9-4823-9040-b67768481887_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant_80abc79e-14fc-44d0-a9df-3b73d4b84bab_verboseLabel_en-US" xlink:label="lab_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on warrant</link:label>
    <link:label id="lab_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant_label_en-US" xlink:label="lab_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Unrealized Gain Loss on Warrant</link:label>
    <link:label id="lab_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant_documentation_en-US" xlink:label="lab_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrealized gain/loss on warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant" xlink:href="ekso-20201231.xsd#ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant" xlink:to="lab_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_4c24c224-84e6-4072-8073-ff28d2651606_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount, change in contingent liability and accretion of final payment fee</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_AccruedLiabilitiesTable_0665e8a4-c9d8-412b-abbe-9de01cd4bdd6_terseLabel_en-US" xlink:label="lab_ekso_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Table]</link:label>
    <link:label id="lab_ekso_AccruedLiabilitiesTable_label_en-US" xlink:label="lab_ekso_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedLiabilitiesTable" xlink:href="ekso-20201231.xsd#ekso_AccruedLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_AccruedLiabilitiesTable" xlink:to="lab_ekso_AccruedLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_360c2473-cafe-4e5e-80f0-486857562d8e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_92337c78-04f3-4d64-9867-88617e314667_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0616732d-9035-4b33-8503-cfd0174e7c8b_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_c0e20fc1-61f1-4144-8537-102eeae1f4e7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c0469bdc-79ff-4cd2-84a0-e5ab87308a91_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5f05a7bb-1aff-457c-8ffd-171cd33387c4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_9abe75e1-4837-42ff-af70-1a37ae175267_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1b45aec3-42df-4727-a845-12ca0572408d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_35bc3b3a-7e86-454e-a86b-6498bd8de754_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_900dfa58-18a7-41f8-952d-34729c72d41a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_8bd666aa-f38f-495f-89af-f23b546835ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_fa7ae481-1dcc-4497-be55-08a3a374783a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyAddition_1f2fb232-92f7-438b-b390-f753f509a5c4_verboseLabel_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyAddition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for estimated future expense</link:label>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyAddition_label_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyAddition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Maintenance Warranty Addition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyAddition" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyAddition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ProductMaintenanceWarrantyAddition" xlink:to="lab_ekso_ProductMaintenanceWarrantyAddition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_22bafd75-2a53-4085-af22-1257764391a8_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_ea75886f-d6cb-4e81-b414-46bd8a273353_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_69464197-3cde-4dc6-9582-8390fee0fc5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4c3ddbf2-866a-4e13-959f-cd8eaea83b8e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $42 and $121, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c4991bd1-ac08-45f0-9e0e-29e665506b52_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_ed8eb9d3-b083-4ffb-afb5-679424fbb72f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f96ca7d1-bdb9-4486-9c8d-e058a674a526_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5e3d8fa1-e02a-477e-b61b-b305e5bc71fc_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_27821be9-8579-422e-9cf1-4d16d9b6ee6e_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0cfffed6-24a7-4bfe-b466-c7dc76655c86_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e776d64b-8da6-4003-8083-507afc4d810f_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod_a35b37fa-7bc6-4081-9537-b5f8ccd0882b_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put option pay period</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Put Option, Duration Of Pay Period</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod_documentation_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Put Option, Duration Of Pay Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod" xlink:to="lab_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_fe7e469b-cb2b-48ef-97d4-180b3c8bdf59_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_December2019WarrantsMember_3dae6f0c-2657-4eb2-b772-1c4f3f76c1fc_terseLabel_en-US" xlink:label="lab_ekso_December2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Warrants</link:label>
    <link:label id="lab_ekso_December2019WarrantsMember_b630794e-42e1-48c0-a5c5-248e66ad199c_verboseLabel_en-US" xlink:label="lab_ekso_December2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Warrants</link:label>
    <link:label id="lab_ekso_December2019WarrantsMember_label_en-US" xlink:label="lab_ekso_December2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Warrants [Member]</link:label>
    <link:label id="lab_ekso_December2019WarrantsMember_documentation_en-US" xlink:label="lab_ekso_December2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019WarrantsMember" xlink:href="ekso-20201231.xsd#ekso_December2019WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_December2019WarrantsMember" xlink:to="lab_ekso_December2019WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_d4045c28-715e-47e0-ad6b-beeb81d988ee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e5d639dc-fe6c-4f60-8c25-223f3483035c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0aeb5195-1665-47e9-bca3-df7be746e85b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_beab71f9-64e2-410d-9c0c-bde79a0f4cc1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_1cd67ab1-29f3-45e5-b068-6f198b6d082b_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_0a9bd24f-bb18-4e00-b617-fc824fadf655_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_ad0253d3-4175-4a72-b30c-c407e0cd3439_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5c7f0b73-4cba-43b8-a0f1-6984e8cc87fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_WarrantPolicyTextBlock_01ffaf54-c43a-4590-b9fa-a5ec04a510bf_terseLabel_en-US" xlink:label="lab_ekso_WarrantPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Valuation</link:label>
    <link:label id="lab_ekso_WarrantPolicyTextBlock_label_en-US" xlink:label="lab_ekso_WarrantPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
    <link:label id="lab_ekso_WarrantPolicyTextBlock_documentation_en-US" xlink:label="lab_ekso_WarrantPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for warrant liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_WarrantPolicyTextBlock" xlink:href="ekso-20201231.xsd#ekso_WarrantPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_WarrantPolicyTextBlock" xlink:to="lab_ekso_WarrantPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_69ee1d39-41b8-45a0-8087-45b094eadb47_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2c07cf8f-8f4c-4184-8a7a-fd5d849b1a3e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7976efae-4251-4272-abde-d31fd7c078f4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_d4bec5a4-bcfa-4af9-820d-4fa81d026fb6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_8c6a8daf-4107-41d0-81d7-a7a6483b4e4c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants for common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_d9f04f63-e451-44ca-8438-12614a346d04_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants for common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1711d7f4-a43f-44ef-b2e6-3aa0f97afb22_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_InformationAgentWarrantsMember_de3aeb15-741a-4a46-9848-cec83edddd45_terseLabel_en-US" xlink:label="lab_ekso_InformationAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information agent warrants</link:label>
    <link:label id="lab_ekso_InformationAgentWarrantsMember_label_en-US" xlink:label="lab_ekso_InformationAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_InformationAgentWarrantsMember" xlink:href="ekso-20201231.xsd#ekso_InformationAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_InformationAgentWarrantsMember" xlink:to="lab_ekso_InformationAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_7707d98b-be35-4194-b014-5934a4d0d7d1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_DebtCovenantCovenantComplianceUnrestrictedCash_9d64e9ba-e2cb-4833-999f-35869b15a977_terseLabel_en-US" xlink:label="lab_ekso_DebtCovenantCovenantComplianceUnrestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, unrestricted cash</link:label>
    <link:label id="lab_ekso_DebtCovenantCovenantComplianceUnrestrictedCash_label_en-US" xlink:label="lab_ekso_DebtCovenantCovenantComplianceUnrestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Covenant Compliance, Unrestricted Cash</link:label>
    <link:label id="lab_ekso_DebtCovenantCovenantComplianceUnrestrictedCash_documentation_en-US" xlink:label="lab_ekso_DebtCovenantCovenantComplianceUnrestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Covenant Compliance, Unrestricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DebtCovenantCovenantComplianceUnrestrictedCash" xlink:href="ekso-20201231.xsd#ekso_DebtCovenantCovenantComplianceUnrestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_DebtCovenantCovenantComplianceUnrestrictedCash" xlink:to="lab_ekso_DebtCovenantCovenantComplianceUnrestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_f462c79d-cade-4254-ae6c-db7bdc68ae77_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_570e7938-40c7-41b6-89a3-33f25f6bd95d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_09e1b424-2cda-49c8-a875-19d3c76f766c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3143c914-ca4d-4b60-a348-bc58a91e0c25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_66d5945a-5c29-43e8-885a-f897ef329aaf_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_CustomerBMember_8849d754-15c0-4aff-978f-8878cb82eb6c_terseLabel_en-US" xlink:label="lab_ekso_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_ekso_CustomerBMember_label_en-US" xlink:label="lab_ekso_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_ekso_CustomerBMember_documentation_en-US" xlink:label="lab_ekso_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CustomerBMember" xlink:href="ekso-20201231.xsd#ekso_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_CustomerBMember" xlink:to="lab_ekso_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6066be84-1a3c-4a84-95c9-26b3703cb753_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c60c1e95-8f80-458d-9bcc-4741af81e01c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e0868bb9-0e3a-4129-9273-33183ecdc8eb_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7c977288-f23c-42e6-95b0-117ff454435a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9210df32-cb49-46a4-8e4f-2c7d2feb0f21_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d7b2f4dd-c1be-4539-8d00-a40cbad36d39_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_55a45b7a-d3e1-4b05-b70e-5fd66b8b3adf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_f9a2f0b3-1484-4495-82e0-b7f368fce34b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_f70b62e7-ed8e-4b31-bc92-e114e4ad015d_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e93f20a2-75a1-4747-afd7-126de538ed37_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_67de50a2-af85-430c-b08b-2c9d59f8c9a1_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_feeebad7-4c10-4112-a70e-4dbc6c3c0bf1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e4539aa2-4a7b-41db-9ff8-eb510faccac4_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive weighted-average number of shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_10b5db2c-be64-4310-a22b-3db04236245e_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_fc4357c2-e5c7-4be3-ad28-64cf32e77795_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_44a2dfb6-a36a-45ee-8a3c-834956b378e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_9496546b-eab1-4a4e-a9ae-1602f04bd77f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f4c83bea-2bb4-4d07-9bab-c0d02945018d_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_bc2f36ee-1721-4474-96fe-19677f2144f4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_07454e16-780f-4dd2-bff7-8f08a1e8d4be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c834898e-6f62-49ea-913e-f7611f41e24e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_cd54f0cb-2f75-445a-bad6-78eff2133d4f_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_f88840c2-1d7a-48f4-bf58-405d559fd694_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_09a81b7f-9f12-4499-bbd0-9ec1ccd1808e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_IssuanceOfCommonStockUnderAbstract_e720f784-6878-49a9-856e-e5eb3bce4056_terseLabel_en-US" xlink:label="lab_ekso_IssuanceOfCommonStockUnderAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under:</link:label>
    <link:label id="lab_ekso_IssuanceOfCommonStockUnderAbstract_label_en-US" xlink:label="lab_ekso_IssuanceOfCommonStockUnderAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Common Stock Under [Abstract]</link:label>
    <link:label id="lab_ekso_IssuanceOfCommonStockUnderAbstract_documentation_en-US" xlink:label="lab_ekso_IssuanceOfCommonStockUnderAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Common Stock Under</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_IssuanceOfCommonStockUnderAbstract" xlink:href="ekso-20201231.xsd#ekso_IssuanceOfCommonStockUnderAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract" xlink:to="lab_ekso_IssuanceOfCommonStockUnderAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_04f24362-138d-415f-9e38-b72b9f5d86bc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_41a46587-0cd0-407a-9517-0bbd92296c6d_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_FacilityOperatingLeaseMember_159a8d64-b1ef-470f-b1f2-0cd1df252591_terseLabel_en-US" xlink:label="lab_ekso_FacilityOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility operating lease</link:label>
    <link:label id="lab_ekso_FacilityOperatingLeaseMember_label_en-US" xlink:label="lab_ekso_FacilityOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility operating lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_FacilityOperatingLeaseMember" xlink:href="ekso-20201231.xsd#ekso_FacilityOperatingLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_FacilityOperatingLeaseMember" xlink:to="lab_ekso_FacilityOperatingLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_64f3658d-414b-4cbb-8b13-207365af8a4a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_683a9e89-bdf3-4888-9caf-77b38097fe97_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a180b88a-1d6c-4138-96e4-6a3973c37f43_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_982cb178-3372-460b-b578-a1b90de0e206_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_43d8b3b8-5579-4c23-be6e-faa02d234989_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_60ce72f8-a70b-4515-b1f7-92f26bcc63c0_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_021998bd-1de6-48c3-bf51-be4ce7ca15bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 141,429 shares authorized; 8,349 and 5,795 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ToolsDiesAndMoldsMember_609c0e43-6593-4d01-b60f-4b3227a0c851_verboseLabel_en-US" xlink:label="lab_us-gaap_ToolsDiesAndMoldsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tools, molds, dies and jigs</link:label>
    <link:label id="lab_us-gaap_ToolsDiesAndMoldsMember_label_en-US" xlink:label="lab_us-gaap_ToolsDiesAndMoldsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tools, Dies and Molds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ToolsDiesAndMoldsMember" xlink:to="lab_us-gaap_ToolsDiesAndMoldsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a59114a8-7c9d-46d8-8d32-6075acc5b33b_netLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b2d8f5f8-9a57-40da-9eee-2f9d2130ab3c_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_8a76dc56-b938-45da-ad58-b2f9df30d27a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_179b48bc-46b5-4328-968a-216f68307561_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_ffebf8e5-f280-4ea7-b739-aff5498e33e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_1292368b-23f2-4da1-85ed-90b0817ffd88_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility of stock</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_December2019PlacementAgentWarrantsMember_26e149d7-baf2-41bd-b5f6-85e42bae0b64_terseLabel_en-US" xlink:label="lab_ekso_December2019PlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Placement Agent Warrants</link:label>
    <link:label id="lab_ekso_December2019PlacementAgentWarrantsMember_280b147e-6db9-4177-8d54-ff3e7e69edc1_verboseLabel_en-US" xlink:label="lab_ekso_December2019PlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Placement Agent Warrants</link:label>
    <link:label id="lab_ekso_December2019PlacementAgentWarrantsMember_label_en-US" xlink:label="lab_ekso_December2019PlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Placement Agent Warrants [Member]</link:label>
    <link:label id="lab_ekso_December2019PlacementAgentWarrantsMember_documentation_en-US" xlink:label="lab_ekso_December2019PlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Placement Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019PlacementAgentWarrantsMember" xlink:href="ekso-20201231.xsd#ekso_December2019PlacementAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_December2019PlacementAgentWarrantsMember" xlink:to="lab_ekso_December2019PlacementAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_66107feb-d313-4d83-912a-c6984971cb2e_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightOutstandingRollForward_d5a0b93e-2bcb-4887-abc0-db2b8f66640d_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="lab_ekso_ClassOfWarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_3d271766-5d6b-4a61-b4ea-fd768b71d7fc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_40a2ca0c-cd00-4869-b546-6c08607fc925_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity incentive plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_271bd1b7-70ee-42ad-ab8f-1c1877ea48f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_87d9fba6-14d3-4f3d-84ad-5a253bb1ae0c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715061c0-b5bb-45c2-a87d-7d989b6774b6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_de05aacd-bebb-4a4e-9499-cc8cff90a079_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c359eff-59f9-459e-8b55-3571a7301fdc_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_377e90e1-1876-48f1-b0e7-fbcd42a5a48d_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_4493d157-7c17-45ab-b634-e18d783588b5_verboseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance cost attributable to issuance of warrants</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_2289ec94-2e05-4b44-b155-89931d7b1b31_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Outstanding, Number of Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_AtTheMarketOfferingMember_9009a768-3976-4e4c-b0c6-e9a38eb7638b_terseLabel_en-US" xlink:label="lab_ekso_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market offering</link:label>
    <link:label id="lab_ekso_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ekso_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:label id="lab_ekso_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ekso_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AtTheMarketOfferingMember" xlink:href="ekso-20201231.xsd#ekso_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_AtTheMarketOfferingMember" xlink:to="lab_ekso_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8fefd08c-0b5c-4fe8-b1d6-45a57aaaf8df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_dd7a87b5-1139-46c3-aae7-94630d718215_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2f8d4e7b-5189-4106-af21-427a3cb4d22e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_OtherliabilitiesAxis_0558a6af-35cc-4a35-908a-a17641bdc4d9_terseLabel_en-US" xlink:label="lab_ekso_OtherliabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OtherLiabilities [Axis]</link:label>
    <link:label id="lab_ekso_OtherliabilitiesAxis_label_en-US" xlink:label="lab_ekso_OtherliabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OtherLiabilities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OtherliabilitiesAxis" xlink:href="ekso-20201231.xsd#ekso_OtherliabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_OtherliabilitiesAxis" xlink:to="lab_ekso_OtherliabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter_ddd1f21e-be4d-4b27-a179-55f8ac6dfd9a_terseLabel_en-US" xlink:label="lab_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contribution percentage</link:label>
    <link:label id="lab_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter_label_en-US" xlink:label="lab_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Percentage,Thereafter</link:label>
    <link:label id="lab_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter_documentation_en-US" xlink:label="lab_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Percentage,Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter" xlink:href="ekso-20201231.xsd#ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter" xlink:to="lab_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b6090f8a-b068-4e3a-9a7c-ec42fec5cc88_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_f44912a7-5509-4437-8512-5921d25a0f28_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of debt amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_445fffc7-0bb7-4bf7-8152-a9cd99c3ef8a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ef328720-9b3b-43f2-8654-462cbe8143df_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_RichmondCaliforniaMember_438eccd1-cb05-4158-ac4d-c91acd195275_terseLabel_en-US" xlink:label="lab_ekso_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:label id="lab_ekso_RichmondCaliforniaMember_label_en-US" xlink:label="lab_ekso_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California [Member]</link:label>
    <link:label id="lab_ekso_RichmondCaliforniaMember_documentation_en-US" xlink:label="lab_ekso_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RichmondCaliforniaMember" xlink:href="ekso-20201231.xsd#ekso_RichmondCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_RichmondCaliforniaMember" xlink:to="lab_ekso_RichmondCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_194cc17b-e23f-49c4-adec-14e0a2f96e88_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9905635e-5ee0-4395-afc0-6d4e01837bd6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f28ed8e5-5317-4dde-ad6a-6f819ab190e2_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3dd00aeb-1bf4-4fff-a204-7a71598c92b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_5a97b5da-50a0-4f4e-855f-204940435b72_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_RelatedPartyTransactionConsultingAgreement_011f8563-bb81-41d4-9230-4afcc54c329a_terseLabel_en-US" xlink:label="lab_ekso_RelatedPartyTransactionConsultingAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting agreement term</link:label>
    <link:label id="lab_ekso_RelatedPartyTransactionConsultingAgreement_label_en-US" xlink:label="lab_ekso_RelatedPartyTransactionConsultingAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Agreement</link:label>
    <link:label id="lab_ekso_RelatedPartyTransactionConsultingAgreement_documentation_en-US" xlink:label="lab_ekso_RelatedPartyTransactionConsultingAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RelatedPartyTransactionConsultingAgreement" xlink:href="ekso-20201231.xsd#ekso_RelatedPartyTransactionConsultingAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_RelatedPartyTransactionConsultingAgreement" xlink:to="lab_ekso_RelatedPartyTransactionConsultingAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_2f6612e1-82f2-4f25-98a0-a4258ce76a08_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_f181ba53-60f5-494a-a326-e63b05a0a1ef_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current federal and state income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d3cc4b7d-60e3-4b91-ba92-ecffa25b3cea_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_37a13a72-988f-4067-a0c7-2cbabbe97868_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_b417766e-38e2-4bbe-a58e-c1b547e2cab3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ContractwithCustomerLiabilityNonCancellableBacklog_50a19e2b-8f68-4e01-a341-dada5da47bfa_terseLabel_en-US" xlink:label="lab_ekso_ContractwithCustomerLiabilityNonCancellableBacklog" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancellable backlog</link:label>
    <link:label id="lab_ekso_ContractwithCustomerLiabilityNonCancellableBacklog_label_en-US" xlink:label="lab_ekso_ContractwithCustomerLiabilityNonCancellableBacklog" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Non-Cancellable Backlog</link:label>
    <link:label id="lab_ekso_ContractwithCustomerLiabilityNonCancellableBacklog_documentation_en-US" xlink:label="lab_ekso_ContractwithCustomerLiabilityNonCancellableBacklog" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Non-Cancellable Backlog</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractwithCustomerLiabilityNonCancellableBacklog" xlink:href="ekso-20201231.xsd#ekso_ContractwithCustomerLiabilityNonCancellableBacklog"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ContractwithCustomerLiabilityNonCancellableBacklog" xlink:to="lab_ekso_ContractwithCustomerLiabilityNonCancellableBacklog" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2effafe2-7985-4fba-99a7-1d96edfb66c8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries, benefits and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_91953efe-e951-44ab-90bd-4a63067e4a63_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_9f384d25-ee70-4ddc-a48a-b9250988128a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_c1808611-5223-4e47-b5c0-65c0148d1d87_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government grant</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7823df68-f876-4448-9951-e4f27a4e438b_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_840241be-b8dd-4df5-9f66-e3a4242ef907_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_3129fe9d-ec4d-47ac-b2dc-b01a3250e67a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_OperatingLeasesRightOfUseAssetInitialRecognition_55207572-b974-45b1-8013-6aee7701b980_terseLabel_en-US" xlink:label="lab_ekso_OperatingLeasesRightOfUseAssetInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of operating right-of-use assets</link:label>
    <link:label id="lab_ekso_OperatingLeasesRightOfUseAssetInitialRecognition_label_en-US" xlink:label="lab_ekso_OperatingLeasesRightOfUseAssetInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Right Of Use Asset, Initial Recognition</link:label>
    <link:label id="lab_ekso_OperatingLeasesRightOfUseAssetInitialRecognition_documentation_en-US" xlink:label="lab_ekso_OperatingLeasesRightOfUseAssetInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Right Of Use Asset, Initial Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OperatingLeasesRightOfUseAssetInitialRecognition" xlink:href="ekso-20201231.xsd#ekso_OperatingLeasesRightOfUseAssetInitialRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_OperatingLeasesRightOfUseAssetInitialRecognition" xlink:to="lab_ekso_OperatingLeasesRightOfUseAssetInitialRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_35daa486-9d5e-41b1-9aae-b03bbc806c3a_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase of unrecognized tax benefits related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a4bc4371-24db-45c1-868e-d91fc5c77d41_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase of unrecognized tax benefits taken in prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_adee276d-eccd-4008-a9c9-4d5190bc5ae0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizationLongtermDebtAndEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization, Long-term Debt and Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalizationLongtermDebtAndEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization, Long-term Debt and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizationLongtermDebtAndEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract" xlink:to="lab_us-gaap_CapitalizationLongtermDebtAndEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8a7dc964-58d5-4be0-923a-ee52e24d0288_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_WarrantyMember_ba25017f-74d0-47b4-a42e-8530d906e748_terseLabel_en-US" xlink:label="lab_ekso_WarrantyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty</link:label>
    <link:label id="lab_ekso_WarrantyMember_label_en-US" xlink:label="lab_ekso_WarrantyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_WarrantyMember" xlink:href="ekso-20201231.xsd#ekso_WarrantyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_WarrantyMember" xlink:to="lab_ekso_WarrantyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability_8a7bbd27-ac4a-4149-b944-4c74a06aace1_negatedTerseLabel_en-US" xlink:label="lab_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability_label_en-US" xlink:label="lab_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Liability</link:label>
    <link:label id="lab_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:href="ekso-20201231.xsd#ekso_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:to="lab_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ContractWithCustomerLiabilityDeferralOfRevenue_30188c49-62f0-4c98-944a-39de84d62117_terseLabel_en-US" xlink:label="lab_ekso_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferral of revenue</link:label>
    <link:label id="lab_ekso_ContractWithCustomerLiabilityDeferralOfRevenue_label_en-US" xlink:label="lab_ekso_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deferral Of Revenue</link:label>
    <link:label id="lab_ekso_ContractWithCustomerLiabilityDeferralOfRevenue_documentation_en-US" xlink:label="lab_ekso_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deferral Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:href="ekso-20201231.xsd#ekso_ContractWithCustomerLiabilityDeferralOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:to="lab_ekso_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_fd32a89e-a685-4f46-a63c-c53fe2ac4e91_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_69ea6969-9127-436b-9995-fe08463853ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_19f3813e-c2dd-4519-9e0c-6688c292d28c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_f5c8e0b4-2434-4a87-94ef-9bfe7a200b6c_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_d337d971-f54d-4e43-832d-262e2b127a38_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9c240aff-b81c-4251-958f-f181ae0f30a1_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5a79fb4e-e178-48ef-b307-f5fb32c9542a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_468e3313-2073-46b6-9f8a-ca9ce6d3185f_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_9290c5f5-2509-45d0-924d-0a357529a337_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_183697cc-fde1-4086-8842-3282fcb393c3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_78b9c000-a0b9-4e9f-9314-b9fad237cc83_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4d31687-39f3-414b-89fe-d6cbb0addd32_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_da443d57-d356-4857-b687-929d37439d84_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4938b35f-fcdc-4a47-acda-fa44da78aed3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36fe67a7-2cba-4852-8ab4-3ffb9477a8cd_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_48e9324c-1728-481e-a6ae-70c2342870ba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_139ed720-c93a-4aaa-b6db-12d618dfe55a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_129b8e9d-798a-4f88-8f1c-e55221d102ef_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f5f773ea-00fb-4dc6-a06d-857872e3b6be_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_438c5e20-cc5d-41ab-969b-190cee1d1abf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_50555ba2-5e41-48de-82a5-c3be69924197_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_7825d1d9-ebe9-43dc-bcca-0c511c587488_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b39eeece-8226-466e-a2c8-013c761be41e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_b1b8e9af-5077-4f16-95aa-00497b24a2bb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c6a54a87-396c-49e1-955a-c72238c7c2b4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Tax Effects of Temporary Differences and Related Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68496f57-ca18-4361-9a3c-e0e17ae6209f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5a0c601e-62a1-489f-876a-36e12619a542_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gain) loss on foreign currency transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_8ca6ca78-2ce2-4931-8b90-25d80e9d38d7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred federal and state income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f7dcf81b-195d-4132-9878-bc931c17b177_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax, net of federal tax effect</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_LoanAgreementMember_090750e2-7429-41e4-a858-1585b03cb54d_terseLabel_en-US" xlink:label="lab_ekso_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement</link:label>
    <link:label id="lab_ekso_LoanAgreementMember_label_en-US" xlink:label="lab_ekso_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LoanAgreementMember" xlink:href="ekso-20201231.xsd#ekso_LoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_LoanAgreementMember" xlink:to="lab_ekso_LoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_2f4d81d9-0998-4b9c-999b-d814f4a440ec_netLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available For Grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_63dbcc0f-01ae-43ce-8b02-b2b2ef580889_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent_328c7fe2-6304-4c02-8ce2-9ab36263b31d_verboseLabel_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent_label_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Maintenance Warranty Liabilities Current</link:label>
    <link:label id="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent_documentation_en-US" xlink:label="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying value of current portion of product maintenance and warranty liabilities as on the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent" xlink:to="lab_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f35f2a2f-d1dc-4d1b-8e21-a3ceed9369ca_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3263738f-e3e0-457e-84f8-7b8c074f0b33_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number warrants called (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2e2499f5-8ec1-410e-b560-bf1fc5013d36_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_3048cc5f-9b03-441f-8539-6dfc14aa5433_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6f984d82-dd61-4626-bfcf-6253abbed281_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5883bad7-0724-4736-a4d3-481541ac2de3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_80896293-ba02-4416-9e6f-9491f331d668_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_AngelPondCapitalLlcMember_3860d12b-fa75-49bb-a73a-faddbe5afd16_terseLabel_en-US" xlink:label="lab_ekso_AngelPondCapitalLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Angel Pond Capital LLC</link:label>
    <link:label id="lab_ekso_AngelPondCapitalLlcMember_label_en-US" xlink:label="lab_ekso_AngelPondCapitalLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Angel Pond Capital LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AngelPondCapitalLlcMember" xlink:href="ekso-20201231.xsd#ekso_AngelPondCapitalLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_AngelPondCapitalLlcMember" xlink:to="lab_ekso_AngelPondCapitalLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_ccbc8cab-23d9-45b2-981b-7476546314dd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as a result of rounding due to reverse-stock split</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_f8704b0d-e179-4f5f-8faf-09e4babc735c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ce217143-f799-4592-bd85-def74cae3579_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2462c049-059d-4a63-963e-c22f7c863b8a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted net loss used for dilution calculation</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9a2449e7-8bfa-4f08-915d-b75f25c6525f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In lieu of cash compensation / bonus (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_A2017InformationAgentWarrantsMember_2e7fea16-5c1a-4752-a0e7-01dfa6edf7e7_terseLabel_en-US" xlink:label="lab_ekso_A2017InformationAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Information Agent Warrants</link:label>
    <link:label id="lab_ekso_A2017InformationAgentWarrantsMember_label_en-US" xlink:label="lab_ekso_A2017InformationAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Information Agent Warrants [Member]</link:label>
    <link:label id="lab_ekso_A2017InformationAgentWarrantsMember_documentation_en-US" xlink:label="lab_ekso_A2017InformationAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Information Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_A2017InformationAgentWarrantsMember" xlink:href="ekso-20201231.xsd#ekso_A2017InformationAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_A2017InformationAgentWarrantsMember" xlink:to="lab_ekso_A2017InformationAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ff318d14-2514-4060-b2d5-e7dc84744326_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow activities</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_EmployeeStockPurchasePlanMember_a41c6d9a-a9b7-4ab7-9f47-c784ce9a0b84_terseLabel_en-US" xlink:label="lab_ekso_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_ekso_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ekso_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EmployeeStockPurchasePlanMember" xlink:href="ekso-20201231.xsd#ekso_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_EmployeeStockPurchasePlanMember" xlink:to="lab_ekso_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_da269d8a-7698-4fb5-b336-54c1ecd85503_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ca3f3377-7d52-4064-8820-0320d5d3e4b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense Related to Stock Options and RSUs Granted to Employees and Non-employees</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fb7d94f4-e611-4689-9946-31692259d614_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_a43afb67-e766-4a9e-87f3-467759f9cbec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0e74cd97-6000-4099-a291-ca62cb5913d1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_145df847-25cc-448a-8eda-b2c29cb935b1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_92e0aabd-c081-4d57-95ae-2d6fe9501573_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_942fc677-c0cb-41d9-9501-b3838d89e676_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1938fbbf-b86f-435f-b662-e51f382b2a82_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_5f2a1fe0-4a39-40b0-a17e-dbf413ab887a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution expense</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3788ec37-a10a-4593-8f3c-de3810df4924_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_DeferredExtendedMaintenanceAndSupport_369072c5-8beb-488c-a3e4-e42426d6913c_terseLabel_en-US" xlink:label="lab_ekso_DeferredExtendedMaintenanceAndSupport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred extended maintenance and support</link:label>
    <link:label id="lab_ekso_DeferredExtendedMaintenanceAndSupport_label_en-US" xlink:label="lab_ekso_DeferredExtendedMaintenanceAndSupport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Extended Maintenance And Support</link:label>
    <link:label id="lab_ekso_DeferredExtendedMaintenanceAndSupport_documentation_en-US" xlink:label="lab_ekso_DeferredExtendedMaintenanceAndSupport" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Extended Maintenance And Support</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredExtendedMaintenanceAndSupport" xlink:href="ekso-20201231.xsd#ekso_DeferredExtendedMaintenanceAndSupport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_DeferredExtendedMaintenanceAndSupport" xlink:to="lab_ekso_DeferredExtendedMaintenanceAndSupport" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_GovernmentGrantPolicyPolicyTextBlock_e58ccc53-9dd5-43b9-a315-268940b0a1d5_terseLabel_en-US" xlink:label="lab_ekso_GovernmentGrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants</link:label>
    <link:label id="lab_ekso_GovernmentGrantPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ekso_GovernmentGrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant, Policy [Policy Text Block]</link:label>
    <link:label id="lab_ekso_GovernmentGrantPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ekso_GovernmentGrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GovernmentGrantPolicyPolicyTextBlock" xlink:href="ekso-20201231.xsd#ekso_GovernmentGrantPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_GovernmentGrantPolicyPolicyTextBlock" xlink:to="lab_ekso_GovernmentGrantPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_OperatingLeasesLiabilityInitialRecognition_561392dc-c953-4fcd-9c3c-1d2b3564e189_terseLabel_en-US" xlink:label="lab_ekso_OperatingLeasesLiabilityInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of operating lease liabilities</link:label>
    <link:label id="lab_ekso_OperatingLeasesLiabilityInitialRecognition_label_en-US" xlink:label="lab_ekso_OperatingLeasesLiabilityInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Liability, Initial Recognition</link:label>
    <link:label id="lab_ekso_OperatingLeasesLiabilityInitialRecognition_documentation_en-US" xlink:label="lab_ekso_OperatingLeasesLiabilityInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Liability, Initial Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OperatingLeasesLiabilityInitialRecognition" xlink:href="ekso-20201231.xsd#ekso_OperatingLeasesLiabilityInitialRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_OperatingLeasesLiabilityInitialRecognition" xlink:to="lab_ekso_OperatingLeasesLiabilityInitialRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_20502f65-ef9f-4a38-8ebf-c93e30eb5dce_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_99fd526f-e8e5-4912-90f6-594fab8a0afc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity financing, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_22ebeff7-ff12-4ff5-9b85-a2a254ca6de4_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvement</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_5eac5358-4fc8-44ed-89e2-01a59aff40cc_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of warrant liability to equity upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_label_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward_9f837fe9-69bc-4649-b327-c31778947574_terseLabel_en-US" xlink:label="lab_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward_label_en-US" xlink:label="lab_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward_documentation_en-US" xlink:label="lab_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability Rollforward [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward" xlink:href="ekso-20201231.xsd#ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward" xlink:to="lab_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance_58c8d27f-1413-48dc-83f0-e27290b88dd6_negatedTerseLabel_en-US" xlink:label="lab_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants</link:label>
    <link:label id="lab_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance_label_en-US" xlink:label="lab_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Warrant Issuance</link:label>
    <link:label id="lab_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance_documentation_en-US" xlink:label="lab_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Warrant Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance" xlink:href="ekso-20201231.xsd#ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance" xlink:to="lab_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f646ec83-fb31-40a2-9389-767e8a1f8bc4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">prime rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f479148f-9207-4e12-befa-376e14fe650b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a2f3d8a4-d7ca-4890-b133-22c37ba53c3d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_70e193aa-9b56-4545-b7b3-b669f8880f49_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_6b4436c9-1a89-471e-919d-dba9ccfc1cb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_045cec61-cb7e-4b7f-8688-42588089035d_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_DefinedContributionPlanOfferingPeriod_add145a7-e221-4433-b651-30351b44409b_terseLabel_en-US" xlink:label="lab_ekso_DefinedContributionPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_ekso_DefinedContributionPlanOfferingPeriod_label_en-US" xlink:label="lab_ekso_DefinedContributionPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Offering Period</link:label>
    <link:label id="lab_ekso_DefinedContributionPlanOfferingPeriod_documentation_en-US" xlink:label="lab_ekso_DefinedContributionPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DefinedContributionPlanOfferingPeriod" xlink:href="ekso-20201231.xsd#ekso_DefinedContributionPlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_DefinedContributionPlanOfferingPeriod" xlink:to="lab_ekso_DefinedContributionPlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_OperatingLeaseAbatement_d5281db0-cc61-40ec-b9b2-07d9519fde07_terseLabel_en-US" xlink:label="lab_ekso_OperatingLeaseAbatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Abatement</link:label>
    <link:label id="lab_ekso_OperatingLeaseAbatement_label_en-US" xlink:label="lab_ekso_OperatingLeaseAbatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Abatement</link:label>
    <link:label id="lab_ekso_OperatingLeaseAbatement_documentation_en-US" xlink:label="lab_ekso_OperatingLeaseAbatement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Abatement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OperatingLeaseAbatement" xlink:href="ekso-20201231.xsd#ekso_OperatingLeaseAbatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_OperatingLeaseAbatement" xlink:to="lab_ekso_OperatingLeaseAbatement" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose_ec576f01-6a1f-4bc8-ba44-dad23627c386_terseLabel_en-US" xlink:label="lab_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for corporate purposes</link:label>
    <link:label id="lab_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose_label_en-US" xlink:label="lab_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Capacity Available For Specific Purpose</link:label>
    <link:label id="lab_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose_documentation_en-US" xlink:label="lab_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Capacity Available For Specific Purpose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose" xlink:href="ekso-20201231.xsd#ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose" xlink:to="lab_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_6533e24d-576f-4aed-bbfd-7bcfc3b13db8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parts and other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_95722454-900a-4302-812d-56243f06f162_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6a9cd527-30cd-49e5-8d0e-eba15e68aed6_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_9f0961f8-9183-41fe-b02e-3f1339af8635_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_96742616-34f0-4e75-9693-2f10ec7c7d5d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ScheduleOfSignificantAccountingPoliciesTable_6b3bc0d0-b80d-4b8b-a1f4-1d05ba973ccf_terseLabel_en-US" xlink:label="lab_ekso_ScheduleOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ekso_ScheduleOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_ekso_ScheduleOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable" xlink:href="ekso-20201231.xsd#ekso_ScheduleOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable" xlink:to="lab_ekso_ScheduleOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_64933d9e-bc7a-46b5-852d-652e9caa746a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_f72dae9f-d830-467c-9cbd-9a7523479abb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction on workforce</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_88abf27b-d41e-41a8-9e90-7c315e3bb796_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0cf63c1d-0305-4aaa-8119-efaa12ea26c2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cb2cc4de-4d09-4170-95e1-a9e255857e1d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_db12fd34-b6f1-44a2-82f7-fd75064c39ac_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_e55a11ee-e37e-4e29-b561-e84e05e803f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issuance in lieu of cash compensation</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_636f4c57-8dc9-4cdc-8eed-c5ed9be2a35a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightExercised_933aa49a-7e2f-4f18-a36e-e867cb6957a5_verboseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger/PPO warrant shares exercised (in shares)</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightExercised_1526c617-f9bc-44f1-96b4-c7a39ded146f_negatedLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightExercised_c8609f6b-5b44-4982-9e71-cb2328da934d_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightExercised_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Exercised</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightExercised_documentation_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants or rights exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExercised" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightExercised" xlink:to="lab_ekso_ClassOfWarrantOrRightExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_7942b1ab-f950-4f1c-bb4b-23806ca245ac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d7aee25a-98ab-4236-9123-320b645d75ec_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_50e401e1-7990-47c9-b176-5c3acf76ad33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_66e98c91-cee1-414b-b220-9045e1870e7f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_817f9446-b78d-423b-8060-4d319522dfc9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ContingentSuccessFeeMember_dc99bbe1-fca6-4167-a0fa-d794d47d1aea_terseLabel_en-US" xlink:label="lab_ekso_ContingentSuccessFeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Success&#160;Fee Liability</link:label>
    <link:label id="lab_ekso_ContingentSuccessFeeMember_label_en-US" xlink:label="lab_ekso_ContingentSuccessFeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Success Fee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContingentSuccessFeeMember" xlink:href="ekso-20201231.xsd#ekso_ContingentSuccessFeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ContingentSuccessFeeMember" xlink:to="lab_ekso_ContingentSuccessFeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d238e609-d195-4bf3-95b5-58a77e835793_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8cbe6286-d5a4-4e46-8572-d327a309092d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification_c7382226-d5ea-4f23-a5ff-2a79734c6f0c_negatedTerseLabel_en-US" xlink:label="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of warrant liability to equity upon exercise of warrants</link:label>
    <link:label id="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification_label_en-US" xlink:label="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Reclassification</link:label>
    <link:label id="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification_documentation_en-US" xlink:label="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Reclassification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification" xlink:href="ekso-20201231.xsd#ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification" xlink:to="lab_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_42acc83d-1f92-495a-8448-8d6d533453b3_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d1cf9a4d-9665-4597-a973-6bdf33f038b1_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_03c112c9-7d2f-4c03-88d0-0b1e1d3ec8d8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_44d6c0e4-8555-4aff-bcfa-be0ba8cbd98e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_b28e999d-d7f3-4f3d-b70a-9faa372fc301_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, net</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_b0a189d2-565f-4542-a707-cda62c9c6a59_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b9a0ac4c-5a11-46f0-a11f-407fb8c8675e_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ff5eabfb-84d4-4341-acdd-12d676eb1029_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_9c5396f6-530d-4d23-94b1-7512ad7fd480_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbbf8203-fdde-4a5a-939f-7826e7407c65_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash at beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_566081b3-46c9-49ec-a42b-2c65198c81a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash at end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c2e4b3a5-a46e-4cc7-aea1-953a96c06971_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a6aedb81-165a-4eac-844d-be9b23b5a786_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Principal Payments of Long-term Debt and Final Payment Fee</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b89d9a28-99d4-477c-984a-09ae5e34ec85_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3acba39e-99d6-493a-b3db-414faf06a1b8_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransportationEquipmentMember_12b0e5b6-bcac-4d1f-9877-3b829fbfae42_verboseLabel_en-US" xlink:label="lab_us-gaap_TransportationEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company-owned fleet</link:label>
    <link:label id="lab_us-gaap_TransportationEquipmentMember_label_en-US" xlink:label="lab_us-gaap_TransportationEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transportation Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransportationEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransportationEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransportationEquipmentMember" xlink:to="lab_us-gaap_TransportationEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6bee7fa8-047a-4741-80f2-0d74ee5a1677_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_087598a4-ffb4-4ee4-bd1d-966374e5d3d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyDescription_98b85e1c-5503-4a67-8641-440bcb789c9c_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Description</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyDescription_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyDescription" xlink:to="lab_us-gaap_StandardProductWarrantyDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_9db0ce33-3a8c-4ca0-8602-70e7cef9e82a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_71ee6475-8354-417d-af7c-f2fb6a1126a5_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input percentage</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_21ac66cc-3ce6-4a93-a669-853a2fbbb9b2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Fair Value of Level 3 Financial Liabilities on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_01504c8f-b038-4ae7-86e6-ef53fae35122_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices, Upper (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_May2019WarrantsMember_6c5627ea-a51e-43c8-a70f-a6709cdd8f14_terseLabel_en-US" xlink:label="lab_ekso_May2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2019 Warrants</link:label>
    <link:label id="lab_ekso_May2019WarrantsMember_1122e11c-977a-4f52-a57d-9f320d9987be_verboseLabel_en-US" xlink:label="lab_ekso_May2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2019 Warrants</link:label>
    <link:label id="lab_ekso_May2019WarrantsMember_label_en-US" xlink:label="lab_ekso_May2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2019 Warrants [Member]</link:label>
    <link:label id="lab_ekso_May2019WarrantsMember_documentation_en-US" xlink:label="lab_ekso_May2019WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2019 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_May2019WarrantsMember" xlink:href="ekso-20201231.xsd#ekso_May2019WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_May2019WarrantsMember" xlink:to="lab_ekso_May2019WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c973e556-7a07-4a52-bdcb-3d953f6d8ac0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25a62d14-246e-4525-a15d-62cf56836de7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_4bd6a356-5c33-41c4-aba3-52e828b53745_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_dce12164-0d4e-4a77-89f9-246892452fc7_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_96f6febd-919c-4df0-a344-b2c52f07c839_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_0e9a1fbb-d6a3-403a-a69b-d8c121fd6a8d_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_0b8d8100-f260-4aa3-895e-dd9427560a29_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_31b20639-e0ff-48b4-9d4d-07c91eae0995_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_2c8236e3-ed56-468d-a0a5-57bb2fddd4ef_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightIssued_2465089a-e862-4435-8f3c-5f17caa8d271_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightIssued_5fbd04a5-71ab-4d02-8f04-f12dcbb4b1a6_verboseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightIssued_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightIssued" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightIssued" xlink:to="lab_ekso_ClassOfWarrantOrRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_7e95d856-8830-40d3-97dc-a338caf6f93d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_June2020InvestorWarrantsMember_a53a6c7a-fa0c-4923-8fa0-720f838cbaa2_terseLabel_en-US" xlink:label="lab_ekso_June2020InvestorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Investor Warrants</link:label>
    <link:label id="lab_ekso_June2020InvestorWarrantsMember_label_en-US" xlink:label="lab_ekso_June2020InvestorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Investor Warrants [Member]</link:label>
    <link:label id="lab_ekso_June2020InvestorWarrantsMember_documentation_en-US" xlink:label="lab_ekso_June2020InvestorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Investor Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020InvestorWarrantsMember" xlink:href="ekso-20201231.xsd#ekso_June2020InvestorWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_June2020InvestorWarrantsMember" xlink:to="lab_ekso_June2020InvestorWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_8503be9f-47a1-43a0-8a71-d3c17a4ab318_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss on long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_58b46d78-2285-4b3a-8b7e-7150f42be0b3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7b45dfc6-51f1-45aa-8945-edf1fe067b31_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b243e60a-6bd5-4316-81a5-40bd7eb11dd1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_TwothousandFifteenWarrantsMember_febc3bb9-5a5c-4bd6-b0a2-2b89a5ea1578_verboseLabel_en-US" xlink:label="lab_ekso_TwothousandFifteenWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 warrants</link:label>
    <link:label id="lab_ekso_TwothousandFifteenWarrantsMember_label_en-US" xlink:label="lab_ekso_TwothousandFifteenWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousand Fifteen Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TwothousandFifteenWarrantsMember" xlink:href="ekso-20201231.xsd#ekso_TwothousandFifteenWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_TwothousandFifteenWarrantsMember" xlink:to="lab_ekso_TwothousandFifteenWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_December2015WarrantsMember_ae33790a-246a-4795-9ea3-8bf63507c3b9_terseLabel_en-US" xlink:label="lab_ekso_December2015WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Warrants</link:label>
    <link:label id="lab_ekso_December2015WarrantsMember_label_en-US" xlink:label="lab_ekso_December2015WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2015 Warrants [Member]</link:label>
    <link:label id="lab_ekso_December2015WarrantsMember_documentation_en-US" xlink:label="lab_ekso_December2015WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2015 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2015WarrantsMember" xlink:href="ekso-20201231.xsd#ekso_December2015WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_December2015WarrantsMember" xlink:to="lab_ekso_December2015WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_TransferOfPropertyAndEquipmentFromInventory_a9b51d64-0c56-4e31-96e7-40eaa32ee690_negatedLabel_en-US" xlink:label="lab_ekso_TransferOfPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of inventory to (from) property and equipment</link:label>
    <link:label id="lab_ekso_TransferOfPropertyAndEquipmentFromInventory_label_en-US" xlink:label="lab_ekso_TransferOfPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Property And Equipment From Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TransferOfPropertyAndEquipmentFromInventory" xlink:href="ekso-20201231.xsd#ekso_TransferOfPropertyAndEquipmentFromInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_TransferOfPropertyAndEquipmentFromInventory" xlink:to="lab_ekso_TransferOfPropertyAndEquipmentFromInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d2914c61-7c29-4e20-b38f-86042c41827f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_84417443-7302-4a69-a101-47b6c2d0d5fb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2b4c14b2-df4c-406d-8a27-68ad98b0279e_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5a892bf9-ebc0-4bb5-8269-3c3b04d39bee_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d5b05b67-9bb8-48f2-9c6c-350da6ceab71_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock_e90747b4-1127-4fad-88ef-d625e6ef425b_terseLabel_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of warrants issued to purchase shares of common stock</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock_label_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Percentage Of Warrants Issued To Purchase Shares Of Common Stock</link:label>
    <link:label id="lab_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock_documentation_en-US" xlink:label="lab_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Percentage Of Warrants Issued To Purchase Shares Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock" xlink:to="lab_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f15e13d9-55bf-40f1-82cb-ba98b0f73077_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a8fed080-64ce-44f2-8094-f399e9ed7f64_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_eaf0c0c6-4a48-479d-bfc6-30afbf0eb7f9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_SalesEarnout_537a62c7-6448-44d6-bae4-1b397377dc2c_terseLabel_en-US" xlink:label="lab_ekso_SalesEarnout" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipois sales earn-out</link:label>
    <link:label id="lab_ekso_SalesEarnout_label_en-US" xlink:label="lab_ekso_SalesEarnout" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales earn-out</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SalesEarnout" xlink:href="ekso-20201231.xsd#ekso_SalesEarnout"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_SalesEarnout" xlink:to="lab_ekso_SalesEarnout" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d60986dd-1457-40d9-857f-ad5c606e5042_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_b626ea27-4602-4b93-b2b3-b82b881cfdd3_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies and Estimates</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3ee22650-d178-4b68-93f3-209fb81f4284_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_ExercisePriceRangeTwoMember_3fee8194-dc44-4ce5-b625-96ad93a8323a_terseLabel_en-US" xlink:label="lab_ekso_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$16.95 - $26.85</link:label>
    <link:label id="lab_ekso_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_ekso_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeTwoMember" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_ExercisePriceRangeTwoMember" xlink:to="lab_ekso_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_832be872-491f-4dc3-b56c-05bd7ac27f57_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years), Ending Balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5fb24b4-066a-415a-9eff-5ad884bde000_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_afc1ea1b-5b1d-4c3a-8564-5037f19a7021_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88a707fe-2f8f-442e-868e-6de0b98a0899_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_845f70b2-db09-4836-8777-bedb8e9aafbf_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_dc3add82-d507-4c3e-a6aa-c6e37998efe1_terseLabel_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In lieu of employee cash bonus</link:label>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f743c9c8-1b62-4a39-b0cb-8e75989a7cc8_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at year end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_659937a6-75fa-49bd-9a02-1e27cbce2e01_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_87329455-535e-4ec7-afe6-9b14c7dad2d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_RentalsMember_8cf4afde-e212-4bde-a6cf-37fd2082aa61_terseLabel_en-US" xlink:label="lab_ekso_RentalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rentals</link:label>
    <link:label id="lab_ekso_RentalsMember_label_en-US" xlink:label="lab_ekso_RentalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rentals [Member]</link:label>
    <link:label id="lab_ekso_RentalsMember_documentation_en-US" xlink:label="lab_ekso_RentalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RentalsMember" xlink:href="ekso-20201231.xsd#ekso_RentalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_RentalsMember" xlink:to="lab_ekso_RentalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_df1b97ac-2b99-429e-9cd9-42e136d67253_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable, current</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b29e4953-a9ec-48b4-b006-fcf1330992fe_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_2c3e9785-83d4-4c7d-8a96-9a55f257962d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_a11b052c-edcf-412c-a1cc-3271d756d24d_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, office and leased equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_21470462-0f64-4e3d-a93e-c3e031885e5b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a1683c-e845-40d3-bcf5-cb614a75f70a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_720875e4-811c-47bc-abfe-cd4576808940_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_972f7c4f-9d53-42e8-8038-f77ead3edcdf_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5c4ea75e-1c2e-4d9c-8ae7-8b6d89892b23_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5f24fd91-188e-43b2-ae83-6a76776c21fc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_7bbacb2a-27a0-4e78-aa88-310f1652d0a7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_30e06228-e9e8-46dc-8e69-5273199ee826_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_60bda361-b5ce-4e16-aad4-912a0d9b0ee1_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance_f929414b-5c7b-4c60-8e61-04df4b2aedd2_terseLabel_en-US" xlink:label="lab_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for future offerings</link:label>
    <link:label id="lab_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance_label_en-US" xlink:label="lab_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Value Of Shares Available For Future Issuance</link:label>
    <link:label id="lab_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance_documentation_en-US" xlink:label="lab_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Value Of Shares Available For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance" xlink:href="ekso-20201231.xsd#ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance" xlink:to="lab_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3863ea5d-f3de-4b66-afbb-833022bad6cd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_RestrictedStockIssued_ca5e518d-4ebe-4304-9789-cf0d5534666b_terseLabel_en-US" xlink:label="lab_ekso_RestrictedStockIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issuance for vesting of restricted stock</link:label>
    <link:label id="lab_ekso_RestrictedStockIssued_label_en-US" xlink:label="lab_ekso_RestrictedStockIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Issued</link:label>
    <link:label id="lab_ekso_RestrictedStockIssued_documentation_en-US" xlink:label="lab_ekso_RestrictedStockIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RestrictedStockIssued" xlink:href="ekso-20201231.xsd#ekso_RestrictedStockIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_RestrictedStockIssued" xlink:to="lab_ekso_RestrictedStockIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e86946c9-c1ef-4ccf-93bd-ad935578fb6b_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements/Accounting Pronouncements Adopted in 2020</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1347268b-bf71-4b95-8f38-c158f55aae35_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ekso_AccruedLiabilitiesLineItems_31287a7e-e4e0-4c85-a0b0-fa30c82f9fc8_terseLabel_en-US" xlink:label="lab_ekso_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_ekso_AccruedLiabilitiesLineItems_label_en-US" xlink:label="lab_ekso_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedLiabilitiesLineItems" xlink:href="ekso-20201231.xsd#ekso_AccruedLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ekso_AccruedLiabilitiesLineItems" xlink:to="lab_ekso_AccruedLiabilitiesLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>ekso-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:019e24a5-8506-4b4f-a6ec-39d6306edf95,g:9d00d04a-17f2-484e-b0d0-858320403c94-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eksobionics.com/role/CoverPage" xlink:type="simple" xlink:href="ekso-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9c2fe6e6-3cfa-43f1-8227-d05c9b1fe806" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_DocumentType_9c2fe6e6-3cfa-43f1-8227-d05c9b1fe806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_8a4f853d-f555-40ac-a730-9fff88ed568f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_DocumentAnnualReport_8a4f853d-f555-40ac-a730-9fff88ed568f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1d1ce8a9-143c-452c-9954-409e0639431c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_DocumentPeriodEndDate_1d1ce8a9-143c-452c-9954-409e0639431c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_69a72f22-f1d3-48e9-8552-63c0ee27cace" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_CurrentFiscalYearEndDate_69a72f22-f1d3-48e9-8552-63c0ee27cace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1b64b231-f7d6-4e24-98fd-f7c4f87fae9c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_DocumentTransitionReport_1b64b231-f7d6-4e24-98fd-f7c4f87fae9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2a5f4760-eef8-46f4-9b6f-5873c80b8ad0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityFileNumber_2a5f4760-eef8-46f4-9b6f-5873c80b8ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e045107b-79e2-4796-b4ff-b8a0c723cf1d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityRegistrantName_e045107b-79e2-4796-b4ff-b8a0c723cf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_dc66e0d0-5fbc-4041-906f-f3ed1a7f1285" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_dc66e0d0-5fbc-4041-906f-f3ed1a7f1285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_de25a8fe-dd95-43f7-a413-98773f1734e8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityTaxIdentificationNumber_de25a8fe-dd95-43f7-a413-98773f1734e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fb6312f1-0cc4-4b22-b46d-243398695165" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityAddressAddressLine1_fb6312f1-0cc4-4b22-b46d-243398695165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_0650a4fb-98be-4177-a323-c6d48bbe78ca" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityAddressAddressLine2_0650a4fb-98be-4177-a323-c6d48bbe78ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_db081e04-62b9-406d-ace5-1d730ab5bde1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityAddressCityOrTown_db081e04-62b9-406d-ace5-1d730ab5bde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f3b8049f-cc83-4f39-b743-40f4f901a112" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityAddressStateOrProvince_f3b8049f-cc83-4f39-b743-40f4f901a112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_790611b1-e8dc-4a7b-bbad-7fea52b5aeec" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityAddressPostalZipCode_790611b1-e8dc-4a7b-bbad-7fea52b5aeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d8c09e4e-2833-45ab-a1ed-565b0c89cbf2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_CityAreaCode_d8c09e4e-2833-45ab-a1ed-565b0c89cbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b26d5d3e-da36-4449-a506-fe8dfb70ab86" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_LocalPhoneNumber_b26d5d3e-da36-4449-a506-fe8dfb70ab86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37bbdbdd-01e3-4ee5-9792-1a79a7b037d6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_Security12bTitle_37bbdbdd-01e3-4ee5-9792-1a79a7b037d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0e8f762e-d756-43d5-94d8-f20e867ccead" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_TradingSymbol_0e8f762e-d756-43d5-94d8-f20e867ccead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_17145bd3-c985-4f8d-9c99-63fa4910bedc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_SecurityExchangeName_17145bd3-c985-4f8d-9c99-63fa4910bedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_498eb382-1d11-44d7-b5b9-2a908b402448" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_498eb382-1d11-44d7-b5b9-2a908b402448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_3375d1db-3092-4378-a5de-440609735a37" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityVoluntaryFilers_3375d1db-3092-4378-a5de-440609735a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_606f4215-7077-4db5-8845-ae967947fdc8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityCurrentReportingStatus_606f4215-7077-4db5-8845-ae967947fdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9f4c6365-ddbc-48a9-8d27-8acef5a1aab2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityInteractiveDataCurrent_9f4c6365-ddbc-48a9-8d27-8acef5a1aab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_59ffd961-9e04-4220-970b-608daf29d527" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityFilerCategory_59ffd961-9e04-4220-970b-608daf29d527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e874b4fb-174c-428b-8bd6-324e00e412cf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntitySmallBusiness_e874b4fb-174c-428b-8bd6-324e00e412cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5b25605c-89bd-4a53-8a56-2bf3d4b07e0a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityEmergingGrowthCompany_5b25605c-89bd-4a53-8a56-2bf3d4b07e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c7ae6bdb-5af0-4888-b3a1-5ee0000a5fdc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityShellCompany_c7ae6bdb-5af0-4888-b3a1-5ee0000a5fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_9b1e2a29-0330-41a2-9c63-3e9eaeafb823" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityPublicFloat_9b1e2a29-0330-41a2-9c63-3e9eaeafb823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_87d0a996-6e58-40e8-a728-20222418962b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_87d0a996-6e58-40e8-a728-20222418962b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9341fe97-9388-4692-908b-9381cfc657a5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_AmendmentFlag_9341fe97-9388-4692-908b-9381cfc657a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_270c8394-dd1a-4da0-a8cd-558d5239a08f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_DocumentFiscalYearFocus_270c8394-dd1a-4da0-a8cd-558d5239a08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3dc12ba0-dc80-4c54-9106-b22360301a5e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3dc12ba0-dc80-4c54-9106-b22360301a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a1249a1e-8d07-4af2-b1f8-4a210c0e90c3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_EntityCentralIndexKey_a1249a1e-8d07-4af2-b1f8-4a210c0e90c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_661422f5-94c2-4434-bdfd-6f7bed3d3516" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3af62988-60cd-45e8-835b-2f1be91c7c4e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_661422f5-94c2-4434-bdfd-6f7bed3d3516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_92e04744-e6c7-4541-9e9b-0ae60773d7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_18bd7197-7879-4b2e-8980-3177b7b76f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_92e04744-e6c7-4541-9e9b-0ae60773d7e1" xlink:to="loc_us-gaap_AssetsAbstract_18bd7197-7879-4b2e-8980-3177b7b76f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_dba85bd4-fd8a-4394-ba1a-269837cd275d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18bd7197-7879-4b2e-8980-3177b7b76f83" xlink:to="loc_us-gaap_AssetsCurrentAbstract_dba85bd4-fd8a-4394-ba1a-269837cd275d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0709a3e5-7690-48cc-b494-3ab58c970656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dba85bd4-fd8a-4394-ba1a-269837cd275d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0709a3e5-7690-48cc-b494-3ab58c970656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4dffc3e6-bfe8-448b-85e6-09bdc0794855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dba85bd4-fd8a-4394-ba1a-269837cd275d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4dffc3e6-bfe8-448b-85e6-09bdc0794855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_079c69ae-6633-4cb7-84b3-6255cda27290" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dba85bd4-fd8a-4394-ba1a-269837cd275d" xlink:to="loc_us-gaap_InventoryNet_079c69ae-6633-4cb7-84b3-6255cda27290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d1ddf599-fe03-4aff-9dbc-088f930fbd67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dba85bd4-fd8a-4394-ba1a-269837cd275d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d1ddf599-fe03-4aff-9dbc-088f930fbd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2e101a19-47fc-49a4-8a5a-63558aa73cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dba85bd4-fd8a-4394-ba1a-269837cd275d" xlink:to="loc_us-gaap_AssetsCurrent_2e101a19-47fc-49a4-8a5a-63558aa73cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c2343090-84f7-4a4d-966f-d4f671a67b86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18bd7197-7879-4b2e-8980-3177b7b76f83" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c2343090-84f7-4a4d-966f-d4f671a67b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f8ccffc3-9b03-4db0-a755-31193ed6f764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18bd7197-7879-4b2e-8980-3177b7b76f83" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f8ccffc3-9b03-4db0-a755-31193ed6f764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8e30535a-0c95-4bce-9bd0-1fe7ed7f84dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18bd7197-7879-4b2e-8980-3177b7b76f83" xlink:to="loc_us-gaap_Goodwill_8e30535a-0c95-4bce-9bd0-1fe7ed7f84dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b604cf23-bfdb-4983-a20f-874a63cda6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18bd7197-7879-4b2e-8980-3177b7b76f83" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b604cf23-bfdb-4983-a20f-874a63cda6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e7727189-9f1a-4739-8ced-cb848690b9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18bd7197-7879-4b2e-8980-3177b7b76f83" xlink:to="loc_us-gaap_Assets_e7727189-9f1a-4739-8ced-cb848690b9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_92e04744-e6c7-4541-9e9b-0ae60773d7e1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9dc0305e-f397-48b3-8696-32309e912217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9dc0305e-f397-48b3-8696-32309e912217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a30afe30-594d-49a1-9a45-c1b01291a383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9dc0305e-f397-48b3-8696-32309e912217" xlink:to="loc_us-gaap_AccountsPayableCurrent_a30afe30-594d-49a1-9a45-c1b01291a383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2175f30f-555f-43e7-94c6-4077bb075f47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9dc0305e-f397-48b3-8696-32309e912217" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2175f30f-555f-43e7-94c6-4077bb075f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e5f34a2b-a614-4530-806e-a3684227739b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9dc0305e-f397-48b3-8696-32309e912217" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e5f34a2b-a614-4530-806e-a3684227739b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_494f5b32-dd29-410b-963c-16d9f6da32b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9dc0305e-f397-48b3-8696-32309e912217" xlink:to="loc_us-gaap_NotesPayableCurrent_494f5b32-dd29-410b-963c-16d9f6da32b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_001d930f-3804-4da7-9cdd-3887a4c198e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9dc0305e-f397-48b3-8696-32309e912217" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_001d930f-3804-4da7-9cdd-3887a4c198e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7047a4a0-6af1-4300-9a46-613a87acb9c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9dc0305e-f397-48b3-8696-32309e912217" xlink:to="loc_us-gaap_LiabilitiesCurrent_7047a4a0-6af1-4300-9a46-613a87acb9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9d2e2297-f37e-4958-8dbc-1a03eeebaaee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9d2e2297-f37e-4958-8dbc-1a03eeebaaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_7f4de0da-e2cd-42a3-9582-056a53389e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:to="loc_us-gaap_LongTermNotesPayable_7f4de0da-e2cd-42a3-9582-056a53389e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_05551be6-ddd7-405f-884b-02a6ce4f4497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_05551be6-ddd7-405f-884b-02a6ce4f4497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_7a21983a-54a7-4133-8193-a4083cab1ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:to="loc_us-gaap_DerivativeLiabilities_7a21983a-54a7-4133-8193-a4083cab1ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_672c9ecf-f41e-4ace-9b45-1482e0e7fa03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_672c9ecf-f41e-4ace-9b45-1482e0e7fa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_004b7a92-9d08-457f-964d-1ba241bba18d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:to="loc_us-gaap_Liabilities_004b7a92-9d08-457f-964d-1ba241bba18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cc5d8af5-bd26-4b32-bad8-93e757f37d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cc5d8af5-bd26-4b32-bad8-93e757f37d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8b6c94ab-c673-4591-a4cf-80746a38f209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8b6c94ab-c673-4591-a4cf-80746a38f209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a3f1651f-6c04-48a9-b180-4d6e53e6b7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b6c94ab-c673-4591-a4cf-80746a38f209" xlink:to="loc_us-gaap_PreferredStockValue_a3f1651f-6c04-48a9-b180-4d6e53e6b7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_85115fee-18bb-4260-a1da-6778bc268e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b6c94ab-c673-4591-a4cf-80746a38f209" xlink:to="loc_us-gaap_CommonStockValue_85115fee-18bb-4260-a1da-6778bc268e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1982dd1b-7871-4329-ab5f-d21112612984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b6c94ab-c673-4591-a4cf-80746a38f209" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1982dd1b-7871-4329-ab5f-d21112612984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e66f8d00-c5fa-4711-8b61-a4ccd08b0876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b6c94ab-c673-4591-a4cf-80746a38f209" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e66f8d00-c5fa-4711-8b61-a4ccd08b0876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ad5969a9-6ff0-4b84-8c0c-e6d582d4642a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b6c94ab-c673-4591-a4cf-80746a38f209" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ad5969a9-6ff0-4b84-8c0c-e6d582d4642a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7854c0a-cbd0-4bff-9720-616f4e25551a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b6c94ab-c673-4591-a4cf-80746a38f209" xlink:to="loc_us-gaap_StockholdersEquity_a7854c0a-cbd0-4bff-9720-616f4e25551a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3c52f67-f9b9-416d-870f-a32328633556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50a6d6ba-3576-471e-b9dd-a80cf07a008c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3c52f67-f9b9-416d-870f-a32328633556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f1228b88-8ce7-4ddc-88cb-342c9f684ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8cc6e1b9-ca84-4e09-83b3-9a11b772f469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1228b88-8ce7-4ddc-88cb-342c9f684ff3" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8cc6e1b9-ca84-4e09-83b3-9a11b772f469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bf5db05a-84a2-40a4-80b9-019db1038874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1228b88-8ce7-4ddc-88cb-342c9f684ff3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bf5db05a-84a2-40a4-80b9-019db1038874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a8b60f0b-633d-40a4-b302-d2379d782bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1228b88-8ce7-4ddc-88cb-342c9f684ff3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a8b60f0b-633d-40a4-b302-d2379d782bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4a717c7a-4d9f-41cd-9112-d5dd9ca00a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1228b88-8ce7-4ddc-88cb-342c9f684ff3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4a717c7a-4d9f-41cd-9112-d5dd9ca00a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cc5fe362-545b-4c7a-9e4b-c48a89ba8fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1228b88-8ce7-4ddc-88cb-342c9f684ff3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cc5fe362-545b-4c7a-9e4b-c48a89ba8fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_28fb84c2-eac8-47ce-9b5d-b2552ba88f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1228b88-8ce7-4ddc-88cb-342c9f684ff3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_28fb84c2-eac8-47ce-9b5d-b2552ba88f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_668730e5-97a1-4f64-906b-538cb5d8c9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1228b88-8ce7-4ddc-88cb-342c9f684ff3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_668730e5-97a1-4f64-906b-538cb5d8c9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f9ffda4e-aecd-4c75-8b99-fe9f7537e840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1228b88-8ce7-4ddc-88cb-342c9f684ff3" xlink:to="loc_us-gaap_CommonStockSharesIssued_f9ffda4e-aecd-4c75-8b99-fe9f7537e840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5114a565-75c7-4605-a6ac-6b89537615be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1228b88-8ce7-4ddc-88cb-342c9f684ff3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5114a565-75c7-4605-a6ac-6b89537615be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9c08058c-890e-4538-bc4a-b18374f5113e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9c08058c-890e-4538-bc4a-b18374f5113e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a44e253c-990a-44be-8ff5-f942eab1248b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a44e253c-990a-44be-8ff5-f942eab1248b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_8ade7bcd-99d1-4605-88cc-fb6de9c015fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_GrossProfit_8ade7bcd-99d1-4605-88cc-fb6de9c015fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7156d1d8-5e69-44b3-b921-c26ea238ee4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7156d1d8-5e69-44b3-b921-c26ea238ee4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_a479a96d-1803-49ca-bbbd-79cdd43001f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7156d1d8-5e69-44b3-b921-c26ea238ee4e" xlink:to="loc_us-gaap_SellingAndMarketingExpense_a479a96d-1803-49ca-bbbd-79cdd43001f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_58e15983-493e-4f35-b881-560b2eaf33cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7156d1d8-5e69-44b3-b921-c26ea238ee4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_58e15983-493e-4f35-b881-560b2eaf33cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_17f678f6-172e-4a56-970c-30208e3644d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7156d1d8-5e69-44b3-b921-c26ea238ee4e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_17f678f6-172e-4a56-970c-30208e3644d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5e6e2250-904a-4cb8-8561-4e5134dec88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7156d1d8-5e69-44b3-b921-c26ea238ee4e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5e6e2250-904a-4cb8-8561-4e5134dec88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c88db6e0-bea0-4f5a-bb73-d2c5d2b39c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7156d1d8-5e69-44b3-b921-c26ea238ee4e" xlink:to="loc_us-gaap_RestructuringCharges_c88db6e0-bea0-4f5a-bb73-d2c5d2b39c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2e977fb6-9da7-4f16-bd27-1ba700685aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7156d1d8-5e69-44b3-b921-c26ea238ee4e" xlink:to="loc_us-gaap_OperatingExpenses_2e977fb6-9da7-4f16-bd27-1ba700685aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dad01c93-ae52-42a6-94c9-14491c14c2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_OperatingIncomeLoss_dad01c93-ae52-42a6-94c9-14491c14c2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_2a64669f-1036-4947-957a-82503ca9a809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_2a64669f-1036-4947-957a-82503ca9a809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8b7db4c4-5e68-4879-a784-550d462d23a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2a64669f-1036-4947-957a-82503ca9a809" xlink:to="loc_us-gaap_InterestExpense_8b7db4c4-5e68-4879-a784-550d462d23a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_WarrantIssuanceExpense_7443d0f0-bb32-4b3b-a425-2561d4f47897" xlink:href="ekso-20201231.xsd#ekso_WarrantIssuanceExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2a64669f-1036-4947-957a-82503ca9a809" xlink:to="loc_ekso_WarrantIssuanceExpense_7443d0f0-bb32-4b3b-a425-2561d4f47897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantLiability_0f5c6216-1675-40eb-8ee3-9152ef8209fa" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2a64669f-1036-4947-957a-82503ca9a809" xlink:to="loc_ekso_GainLossOnWarrantLiability_0f5c6216-1675-40eb-8ee3-9152ef8209fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantModification_68ab0dd4-4d81-40e0-be0d-1c8682e5089d" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantModification"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2a64669f-1036-4947-957a-82503ca9a809" xlink:to="loc_ekso_GainLossOnWarrantModification_68ab0dd4-4d81-40e0-be0d-1c8682e5089d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8d32cbdd-a64c-475d-8c70-809e10e71069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2a64669f-1036-4947-957a-82503ca9a809" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8d32cbdd-a64c-475d-8c70-809e10e71069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a03d8c87-f69e-48a7-9b12-7331c430578b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2a64669f-1036-4947-957a-82503ca9a809" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a03d8c87-f69e-48a7-9b12-7331c430578b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cefbf796-2440-4e2e-af1f-31c42924f108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_NetIncomeLoss_cefbf796-2440-4e2e-af1f-31c42924f108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bf2875b9-9a8a-46ce-ac88-cfc3bd4b7d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bf2875b9-9a8a-46ce-ac88-cfc3bd4b7d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_58ada107-0eb1-4f73-9832-f37405a8b3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_58ada107-0eb1-4f73-9832-f37405a8b3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6fc66ada-e725-4be0-9add-3ca434adb366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_6fc66ada-e725-4be0-9add-3ca434adb366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e023adb1-8cca-48a4-b458-97f11bb9e5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ece8182f-dab9-425e-b219-2b4b47c80658" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e023adb1-8cca-48a4-b458-97f11bb9e5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_af635831-9ad7-4049-9921-8e2c46730fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_61128415-a222-40f5-99c7-61b3329ccb15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_af635831-9ad7-4049-9921-8e2c46730fd8" xlink:to="loc_us-gaap_StatementTable_61128415-a222-40f5-99c7-61b3329ccb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_49648fab-caed-4068-bfeb-88b2cc6146b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_61128415-a222-40f5-99c7-61b3329ccb15" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_49648fab-caed-4068-bfeb-88b2cc6146b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_49648fab-caed-4068-bfeb-88b2cc6146b9" xlink:to="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1ca4d8a1-7ff8-4d8b-b1cb-2618bc5c64d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:to="loc_us-gaap_PreferredStockMember_1ca4d8a1-7ff8-4d8b-b1cb-2618bc5c64d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_387c1a45-075d-45e4-b052-7cfe092fc127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:to="loc_us-gaap_CommonStockMember_387c1a45-075d-45e4-b052-7cfe092fc127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fc4617bf-318c-4dd2-ba0f-79cc6247175e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fc4617bf-318c-4dd2-ba0f-79cc6247175e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1deffc1b-1393-462b-a118-18d7cf0e7e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1deffc1b-1393-462b-a118-18d7cf0e7e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e6c63024-1182-49b9-929f-9f06a6f63bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6116af71-7b7e-46eb-86ab-fb9514eede96" xlink:to="loc_us-gaap_RetainedEarningsMember_e6c63024-1182-49b9-929f-9f06a6f63bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5c31c42a-8af4-4576-9506-47ec9a7839b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_61128415-a222-40f5-99c7-61b3329ccb15" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5c31c42a-8af4-4576-9506-47ec9a7839b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dca57835-8b58-4e2a-997f-c61a38212c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5c31c42a-8af4-4576-9506-47ec9a7839b0" xlink:to="loc_us-gaap_ClassOfStockDomain_dca57835-8b58-4e2a-997f-c61a38212c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_07782998-8ab4-4c19-bd62-b8c3fdbfa56d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dca57835-8b58-4e2a-997f-c61a38212c45" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_07782998-8ab4-4c19-bd62-b8c3fdbfa56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1a2976ab-af18-4f77-92bf-2e9b6a4b205f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_61128415-a222-40f5-99c7-61b3329ccb15" xlink:to="loc_us-gaap_StatementLineItems_1a2976ab-af18-4f77-92bf-2e9b6a4b205f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1a2976ab-af18-4f77-92bf-2e9b6a4b205f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_937bf8d4-b5c3-490f-aea9-dd01234e58dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_StockholdersEquity_937bf8d4-b5c3-490f-aea9-dd01234e58dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1c169e33-282b-4543-b102-499be17e0d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_SharesOutstanding_1c169e33-282b-4543-b102-499be17e0d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_360072a4-94d5-455d-a14a-148bc495efb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_NetIncomeLoss_360072a4-94d5-455d-a14a-148bc495efb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:href="ekso-20201231.xsd#ekso_IssuanceOfCommonStockUnderAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5e599025-5b56-43ca-aaee-3e3a0e08c0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5e599025-5b56-43ca-aaee-3e3a0e08c0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8eedf6c2-a567-4836-acce-615a4c3353f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8eedf6c2-a567-4836-acce-615a4c3353f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts_dae494ad-98d4-4461-ae06-fe343b2a39ce" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts_dae494ad-98d4-4461-ae06-fe343b2a39ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut_bedf4527-9e69-456d-8af5-cffbd037eeab" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut_bedf4527-9e69-456d-8af5-cffbd037eeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_59175a13-069d-4c41-8724-289b7372054a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_59175a13-069d-4c41-8724-289b7372054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_aecf99a1-7cbf-4222-b72a-19eabed08ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_aecf99a1-7cbf-4222-b72a-19eabed08ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants_ec63be5e-4f9b-4e74-a0ad-7dcdb041b0ef" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants_ec63be5e-4f9b-4e74-a0ad-7dcdb041b0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants_557423c9-64dc-42ed-b364-f158da7de247" xlink:href="ekso-20201231.xsd#ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants_557423c9-64dc-42ed-b364-f158da7de247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_fe6dcadc-46b7-4ea6-9382-6675a4e495be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_fe6dcadc-46b7-4ea6-9382-6675a4e495be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_6bbffb73-aa26-493a-8a1b-c52dcbe8442c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_6bbffb73-aa26-493a-8a1b-c52dcbe8442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_21b2a6ab-6add-4047-bbb6-f09cc0cbb807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_21b2a6ab-6add-4047-bbb6-f09cc0cbb807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4b98bd3f-705e-4494-afee-18c950ee59f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_IssuanceOfCommonStockUnderAbstract_b5a5d99d-a4e9-4e06-895b-333b30338237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4b98bd3f-705e-4494-afee-18c950ee59f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_f9958daf-5ce0-4974-8894-8d78ed94fbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_f9958daf-5ce0-4974-8894-8d78ed94fbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance_fbd91cf4-ae9d-46cd-85d7-6ab2333e7a69" xlink:href="ekso-20201231.xsd#ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance_fbd91cf4-ae9d-46cd-85d7-6ab2333e7a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_6f24b9e2-813b-4fab-91bf-e55bf72c1465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_6f24b9e2-813b-4fab-91bf-e55bf72c1465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ffa4c715-ae9b-4337-95cd-606429d56bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ffa4c715-ae9b-4337-95cd-606429d56bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_433c39da-aa1b-4fa4-a6eb-477eb012a1ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_StockholdersEquity_433c39da-aa1b-4fa4-a6eb-477eb012a1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_70b6e2db-593e-4453-9cd5-f0750be64650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c281c043-9f7c-43ec-8a7b-ee38c234b8fc" xlink:to="loc_us-gaap_SharesOutstanding_70b6e2db-593e-4453-9cd5-f0750be64650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="ekso-20201231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_cea2226e-3950-498b-955d-2a0c380200dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df1b41b5-6e5b-489a-bde5-272afbf9a8d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cea2226e-3950-498b-955d-2a0c380200dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df1b41b5-6e5b-489a-bde5-272afbf9a8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88faade8-fe77-4ddd-ad58-3f9e4f0f3dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df1b41b5-6e5b-489a-bde5-272afbf9a8d3" xlink:to="loc_us-gaap_NetIncomeLoss_88faade8-fe77-4ddd-ad58-3f9e4f0f3dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df1b41b5-6e5b-489a-bde5-272afbf9a8d3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bf4829c0-c8e9-4796-8437-b6988555662d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_us-gaap_Depreciation_bf4829c0-c8e9-4796-8437-b6988555662d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_61bd2e36-114b-4623-9a6f-91c27843401c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_61bd2e36-114b-4623-9a6f-91c27843401c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_56e8bfc2-c4ae-4279-a941-cf4a3f5ea9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_56e8bfc2-c4ae-4279-a941-cf4a3f5ea9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_d44be89d-6ea7-4d71-abb4-6a49040490b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_d44be89d-6ea7-4d71-abb4-6a49040490b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnModificationOfOperatingLeaseLiabilities_a18be573-8fc7-4ddb-a4bb-a12efc0e6d68" xlink:href="ekso-20201231.xsd#ekso_GainLossOnModificationOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_ekso_GainLossOnModificationOfOperatingLeaseLiabilities_a18be573-8fc7-4ddb-a4bb-a12efc0e6d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4b33a630-afe7-44be-8829-8d7ac389bc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4b33a630-afe7-44be-8829-8d7ac389bc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CommonStockContribution_94a12042-1d3c-425c-9d9d-cf99b0cc7aaf" xlink:href="ekso-20201231.xsd#ekso_CommonStockContribution"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_ekso_CommonStockContribution_94a12042-1d3c-425c-9d9d-cf99b0cc7aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_46049672-b351-432c-8d3a-bd3e9b554b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_us-gaap_ShareBasedCompensation_46049672-b351-432c-8d3a-bd3e9b554b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_df8656da-cd03-4233-b64c-02741f6348d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_df8656da-cd03-4233-b64c-02741f6348d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantLiability_54656484-4d0d-4484-b495-7662b6f77706" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_ekso_GainLossOnWarrantLiability_54656484-4d0d-4484-b495-7662b6f77706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantModification_fa70c392-4b05-48c4-bea4-8be6d1eb41b1" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantModification"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_ekso_GainLossOnWarrantModification_fa70c392-4b05-48c4-bea4-8be6d1eb41b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_60bb3e3b-161c-4245-ab6a-8471fdb28d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_60bb3e3b-161c-4245-ab6a-8471fdb28d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b3d23d1e-c420-41be-9517-441f787c4766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_000ef14a-cab9-4551-b0ad-42ef9ff32b83" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b3d23d1e-c420-41be-9517-441f787c4766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_56e8c086-1b13-4318-96d5-63802e08589c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b3d23d1e-c420-41be-9517-441f787c4766" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_56e8c086-1b13-4318-96d5-63802e08589c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_45d6a417-ced7-4fb6-9274-ac8e5d1f3db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b3d23d1e-c420-41be-9517-441f787c4766" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_45d6a417-ced7-4fb6-9274-ac8e5d1f3db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aabea125-1201-4db9-bc26-7cfe4e34be83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b3d23d1e-c420-41be-9517-441f787c4766" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aabea125-1201-4db9-bc26-7cfe4e34be83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10801bd9-fdbf-470f-a011-3a15aa54a161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b3d23d1e-c420-41be-9517-441f787c4766" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10801bd9-fdbf-470f-a011-3a15aa54a161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_49cad5b5-d5a2-45c3-ac1c-746c263ccf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b3d23d1e-c420-41be-9517-441f787c4766" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_49cad5b5-d5a2-45c3-ac1c-746c263ccf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7c71d3df-5cdb-4c3f-ba78-cef8e834c08d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b3d23d1e-c420-41be-9517-441f787c4766" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7c71d3df-5cdb-4c3f-ba78-cef8e834c08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ccd16e6e-44ba-4489-8e7b-055d43db7c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df1b41b5-6e5b-489a-bde5-272afbf9a8d3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ccd16e6e-44ba-4489-8e7b-055d43db7c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e966cf7-cbcb-4179-ad0e-483f93f81bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cea2226e-3950-498b-955d-2a0c380200dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e966cf7-cbcb-4179-ad0e-483f93f81bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efe23e31-6148-4d72-8aac-5aeeea796dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e966cf7-cbcb-4179-ad0e-483f93f81bf3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efe23e31-6148-4d72-8aac-5aeeea796dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_837b4c07-245a-4be9-8ff5-e41f600b8c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e966cf7-cbcb-4179-ad0e-483f93f81bf3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_837b4c07-245a-4be9-8ff5-e41f600b8c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50516d94-18e3-43a6-bdf3-4ba68c829c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cea2226e-3950-498b-955d-2a0c380200dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50516d94-18e3-43a6-bdf3-4ba68c829c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d553d29-1ec2-4d69-9645-01a2e4f8abfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50516d94-18e3-43a6-bdf3-4ba68c829c84" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d553d29-1ec2-4d69-9645-01a2e4f8abfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_10e5312d-b6fd-4cd5-bc87-d1482dd4983e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50516d94-18e3-43a6-bdf3-4ba68c829c84" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_10e5312d-b6fd-4cd5-bc87-d1482dd4983e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_182d20f6-0636-44af-aba0-ff38e058ed2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50516d94-18e3-43a6-bdf3-4ba68c829c84" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_182d20f6-0636-44af-aba0-ff38e058ed2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3b2ab9a3-1777-4093-b01a-b44f4930745d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50516d94-18e3-43a6-bdf3-4ba68c829c84" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3b2ab9a3-1777-4093-b01a-b44f4930745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_623dc2ca-5778-4604-b1e5-abe35f5afa51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50516d94-18e3-43a6-bdf3-4ba68c829c84" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_623dc2ca-5778-4604-b1e5-abe35f5afa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_70212eff-73e7-4cfb-bb08-35d5d792ed33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50516d94-18e3-43a6-bdf3-4ba68c829c84" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_70212eff-73e7-4cfb-bb08-35d5d792ed33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_97a3d90b-5df7-4de9-828c-93a056ab1056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50516d94-18e3-43a6-bdf3-4ba68c829c84" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_97a3d90b-5df7-4de9-828c-93a056ab1056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c4d0568-ba34-4595-85e9-c7a2a6b3e2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cea2226e-3950-498b-955d-2a0c380200dc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c4d0568-ba34-4595-85e9-c7a2a6b3e2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16c22a04-6aec-45ee-8174-dfc5b6742da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cea2226e-3950-498b-955d-2a0c380200dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16c22a04-6aec-45ee-8174-dfc5b6742da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12161604-51f7-4475-a31f-76fb0dd8a64f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cea2226e-3950-498b-955d-2a0c380200dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12161604-51f7-4475-a31f-76fb0dd8a64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9225bb63-7a01-474a-88de-6fdbe9a986d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cea2226e-3950-498b-955d-2a0c380200dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9225bb63-7a01-474a-88de-6fdbe9a986d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_24eb3e71-baec-4947-a8dd-2efba06eb0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cea2226e-3950-498b-955d-2a0c380200dc" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_24eb3e71-baec-4947-a8dd-2efba06eb0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_1c3054b4-2230-4b42-b860-6b20f0b522b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_24eb3e71-baec-4947-a8dd-2efba06eb0db" xlink:to="loc_us-gaap_IncomeTaxesPaid_1c3054b4-2230-4b42-b860-6b20f0b522b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1478687f-1697-4e1e-88ba-c601e8dc46c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_24eb3e71-baec-4947-a8dd-2efba06eb0db" xlink:to="loc_us-gaap_InterestPaidNet_1478687f-1697-4e1e-88ba-c601e8dc46c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cea2226e-3950-498b-955d-2a0c380200dc" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_22314a24-ac07-42f4-b2b9-fafb461a3b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_22314a24-ac07-42f4-b2b9-fafb461a3b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SharesIssuedCapitalContribution_39daf97c-6c12-42e7-9573-7155e91524b4" xlink:href="ekso-20201231.xsd#ekso_SharesIssuedCapitalContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:to="loc_ekso_SharesIssuedCapitalContribution_39daf97c-6c12-42e7-9573-7155e91524b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TransferOfPropertyAndEquipmentFromInventory_c9070624-4483-4550-abc9-d9b1a96fe508" xlink:href="ekso-20201231.xsd#ekso_TransferOfPropertyAndEquipmentFromInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:to="loc_ekso_TransferOfPropertyAndEquipmentFromInventory_c9070624-4483-4550-abc9-d9b1a96fe508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_d9c1b573-e0ff-4ae5-a291-d3f0fe4a5737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:to="loc_us-gaap_StockIssued1_d9c1b573-e0ff-4ae5-a291-d3f0fe4a5737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OperatingLeasesRightOfUseAssetInitialRecognition_fd39114a-4437-47d1-95b7-c50f3abbfa85" xlink:href="ekso-20201231.xsd#ekso_OperatingLeasesRightOfUseAssetInitialRecognition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:to="loc_ekso_OperatingLeasesRightOfUseAssetInitialRecognition_fd39114a-4437-47d1-95b7-c50f3abbfa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OperatingLeasesLiabilityInitialRecognition_33f85508-3c52-41f1-b029-0516d1afb318" xlink:href="ekso-20201231.xsd#ekso_OperatingLeasesLiabilityInitialRecognition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:to="loc_ekso_OperatingLeasesLiabilityInitialRecognition_33f85508-3c52-41f1-b029-0516d1afb318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RestrictedStockIssued_adb4e373-e884-44dc-96a8-bd45bb9e4625" xlink:href="ekso-20201231.xsd#ekso_RestrictedStockIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:to="loc_ekso_RestrictedStockIssued_adb4e373-e884-44dc-96a8-bd45bb9e4625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent_0889f159-2f1b-4fda-8c61-55e203407097" xlink:href="ekso-20201231.xsd#ekso_OperatingLeasesIncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:to="loc_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent_0889f159-2f1b-4fda-8c61-55e203407097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SalesEarnout_079e2389-c9cd-4493-95f4-ffe630497588" xlink:href="ekso-20201231.xsd#ekso_SalesEarnout"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e329e1a-0189-4e9f-a71c-be4117ac1e38" xlink:to="loc_ekso_SalesEarnout_079e2389-c9cd-4493-95f4-ffe630497588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/Organization" xlink:type="simple" xlink:href="ekso-20201231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acbdf2c7-792f-41db-bead-4685faa481d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_22c5a372-4000-486d-8792-25ab9396296c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acbdf2c7-792f-41db-bead-4685faa481d5" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_22c5a372-4000-486d-8792-25ab9396296c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/OrganizationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81e13bcb-2329-4c08-b9fc-c89ac0810500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81e13bcb-2329-4c08-b9fc-c89ac0810500" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bb4d59d1-722d-437d-968d-31c8c3bccf39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bb4d59d1-722d-437d-968d-31c8c3bccf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f96ca0a-d22c-470c-b56b-3eacff9504d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bb4d59d1-722d-437d-968d-31c8c3bccf39" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f96ca0a-d22c-470c-b56b-3eacff9504d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DirectOfferingMember_c5a2da29-a8d3-4288-a800-e4c1c8596464" xlink:href="ekso-20201231.xsd#ekso_DirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f96ca0a-d22c-470c-b56b-3eacff9504d1" xlink:to="loc_ekso_DirectOfferingMember_c5a2da29-a8d3-4288-a800-e4c1c8596464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c813fbdd-7ff7-479f-9643-24b132650ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:to="loc_us-gaap_DebtInstrumentAxis_c813fbdd-7ff7-479f-9643-24b132650ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1bee06d7-2e88-4a2c-8bd0-48fdcb26875c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c813fbdd-7ff7-479f-9643-24b132650ceb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1bee06d7-2e88-4a2c-8bd0-48fdcb26875c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LoanAgreementMember_1f39300d-9d66-436a-8ccc-df59bebbd00c" xlink:href="ekso-20201231.xsd#ekso_LoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1bee06d7-2e88-4a2c-8bd0-48fdcb26875c" xlink:to="loc_ekso_LoanAgreementMember_1f39300d-9d66-436a-8ccc-df59bebbd00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_PWBLoanAgreementMember_47bc6d54-b4f4-44fb-b760-e086406f3fd1" xlink:href="ekso-20201231.xsd#ekso_PWBLoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1bee06d7-2e88-4a2c-8bd0-48fdcb26875c" xlink:to="loc_ekso_PWBLoanAgreementMember_47bc6d54-b4f4-44fb-b760-e086406f3fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7ccbfa1b-ab1f-4711-b6a1-1b1162e19fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7ccbfa1b-ab1f-4711-b6a1-1b1162e19fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_032df56a-7998-416b-9f9b-b1f47cb6cdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7ccbfa1b-ab1f-4711-b6a1-1b1162e19fde" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_032df56a-7998-416b-9f9b-b1f47cb6cdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TermLoanMember_282b124a-5b0d-416b-b34c-004c1639ca97" xlink:href="ekso-20201231.xsd#ekso_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_032df56a-7998-416b-9f9b-b1f47cb6cdb8" xlink:to="loc_ekso_TermLoanMember_282b124a-5b0d-416b-b34c-004c1639ca97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7fa9ca20-aef9-4f76-b76f-87d58225dd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7fa9ca20-aef9-4f76-b76f-87d58225dd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_746b5910-4862-48bd-b2de-738d793ce6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7fa9ca20-aef9-4f76-b76f-87d58225dd46" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_746b5910-4862-48bd-b2de-738d793ce6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6f6e34f7-1110-4c7f-aea7-cd5d9bf02f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_746b5910-4862-48bd-b2de-738d793ce6a2" xlink:to="loc_us-gaap_SubsequentEventMember_6f6e34f7-1110-4c7f-aea7-cd5d9bf02f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d04a3c81-e718-4b86-a72d-c5b39c2c6cb3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a91608f-adb8-4190-8007-ac580cf7a0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a91608f-adb8-4190-8007-ac580cf7a0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08000f29-befb-46ef-8a6a-38fad030cf6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08000f29-befb-46ef-8a6a-38fad030cf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b3118fe-fdcf-4fb2-8fad-a23e4b4814b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b3118fe-fdcf-4fb2-8fad-a23e4b4814b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_168e1685-8f4a-4cfd-a864-b2eb4efff016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_168e1685-8f4a-4cfd-a864-b2eb4efff016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_e0745a90-332c-46cd-a283-a4c000ba952e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_e0745a90-332c-46cd-a283-a4c000ba952e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_30a3bd10-0b96-4fa7-8de8-44791b6493ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_30a3bd10-0b96-4fa7-8de8-44791b6493ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2159685d-c544-4938-8417-70102eed127d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2159685d-c544-4938-8417-70102eed127d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_37554cf9-fa4f-49b5-8aa0-089ef714b199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_37554cf9-fa4f-49b5-8aa0-089ef714b199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DebtCovenantCovenantComplianceUnrestrictedCash_3f17f4e2-460b-466d-99d4-dc37c891ec74" xlink:href="ekso-20201231.xsd#ekso_DebtCovenantCovenantComplianceUnrestrictedCash"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_ekso_DebtCovenantCovenantComplianceUnrestrictedCash_3f17f4e2-460b-466d-99d4-dc37c891ec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_UnrestrictedCash_78b9fb43-e9e0-47a8-8bfb-73577cdf2b8b" xlink:href="ekso-20201231.xsd#ekso_UnrestrictedCash"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_ekso_UnrestrictedCash_78b9fb43-e9e0-47a8-8bfb-73577cdf2b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_01971405-b129-4861-8a57-7f98e2e8be79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f6ab36e4-1aa1-48b0-8342-0b73714f855b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_01971405-b129-4861-8a57-7f98e2e8be79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimates"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ebb11091-a5c6-4e67-94e2-7b2b70a23604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fb45ef60-b76d-4c47-8e15-0c239a646249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ebb11091-a5c6-4e67-94e2-7b2b70a23604" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fb45ef60-b76d-4c47-8e15-0c239a646249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesPolicies"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_a46258ee-cebc-4b25-b022-642f770809d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_a46258ee-cebc-4b25-b022-642f770809d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f1d6ae11-3254-4e51-912d-a2f107a6693a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_UseOfEstimates_f1d6ae11-3254-4e51-912d-a2f107a6693a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a4cf1dd0-c191-49cd-a72f-e058c4a8ef21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a4cf1dd0-c191-49cd-a72f-e058c4a8ef21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_490ce380-7ed9-4b12-ab8b-eeaa6b39b60e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_490ce380-7ed9-4b12-ab8b-eeaa6b39b60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3b217ab2-195a-4ad9-a8f7-b237bd8b63bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3b217ab2-195a-4ad9-a8f7-b237bd8b63bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_79d4ac61-0280-4ba9-b1fc-ba45bba8f1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_79d4ac61-0280-4ba9-b1fc-ba45bba8f1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_586898ef-ae55-4065-8385-a54cfaaae32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_586898ef-ae55-4065-8385-a54cfaaae32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_0aaac04a-ca32-4709-883f-01da40567ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_0aaac04a-ca32-4709-883f-01da40567ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_369b8c5a-abd4-4510-8a4a-2a699ad10787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_369b8c5a-abd4-4510-8a4a-2a699ad10787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_02d7c28e-b2d1-4329-b8dc-7857907cf87e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_02d7c28e-b2d1-4329-b8dc-7857907cf87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33fa7bf6-d371-4073-ac6e-00d2c200575f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_33fa7bf6-d371-4073-ac6e-00d2c200575f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_WarrantPolicyTextBlock_a921a3c8-2007-41a0-9f39-2b557f1192a2" xlink:href="ekso-20201231.xsd#ekso_WarrantPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_ekso_WarrantPolicyTextBlock_a921a3c8-2007-41a0-9f39-2b557f1192a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GoingConcernPolicyTextBlock_90423fcd-530b-404e-af22-b5287f7ce53b" xlink:href="ekso-20201231.xsd#ekso_GoingConcernPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_ekso_GoingConcernPolicyTextBlock_90423fcd-530b-404e-af22-b5287f7ce53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4ed558fc-7879-4b60-ba5c-8a353fddd113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4ed558fc-7879-4b60-ba5c-8a353fddd113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GovernmentGrantPolicyPolicyTextBlock_76123a5d-3990-48fe-957f-3654bcdc098e" xlink:href="ekso-20201231.xsd#ekso_GovernmentGrantPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_ekso_GovernmentGrantPolicyPolicyTextBlock_76123a5d-3990-48fe-957f-3654bcdc098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_591fb7f4-1b85-44f6-824a-3b3ddb02d008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_591fb7f4-1b85-44f6-824a-3b3ddb02d008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_44decbe5-a994-44e6-9daa-aa1bbe0e9a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_44decbe5-a994-44e6-9daa-aa1bbe0e9a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b1d6fd69-27f3-4197-a2ff-3fdb9583c8a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b1d6fd69-27f3-4197-a2ff-3fdb9583c8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4519b0f9-25fd-452b-8c82-5d6c1f7d9949" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9fa3db-3bf0-410c-94e5-9939cc6c6ae5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4519b0f9-25fd-452b-8c82-5d6c1f7d9949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f3d487b5-0efb-456f-a751-6c0fe2bbb014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5c08b8a4-4d03-450f-be5b-79b189c9824a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3d487b5-0efb-456f-a751-6c0fe2bbb014" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5c08b8a4-4d03-450f-be5b-79b189c9824a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_90e51168-69fb-483a-8ccd-be60ac1db398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3d487b5-0efb-456f-a751-6c0fe2bbb014" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_90e51168-69fb-483a-8ccd-be60ac1db398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_ddaef6f3-3c42-4a57-ba6a-c72745e9a9b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3d487b5-0efb-456f-a751-6c0fe2bbb014" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_ddaef6f3-3c42-4a57-ba6a-c72745e9a9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ca58ba2b-c81a-4a0c-b32d-c95413f2ed7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:href="ekso-20201231.xsd#ekso_ScheduleOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca58ba2b-c81a-4a0c-b32d-c95413f2ed7b" xlink:to="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ca0856f9-afb8-449a-8a9b-682336c3d394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ca0856f9-afb8-449a-8a9b-682336c3d394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_db72cda3-5f65-49fe-9bf5-f90b8a7fdaf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ca0856f9-afb8-449a-8a9b-682336c3d394" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_db72cda3-5f65-49fe-9bf5-f90b8a7fdaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1b2525c3-c9c4-407e-9fe3-862654cdd52b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_db72cda3-5f65-49fe-9bf5-f90b8a7fdaf9" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1b2525c3-c9c4-407e-9fe3-862654cdd52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4a1289-1f8c-4ea2-b40d-972ff9c63846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4a1289-1f8c-4ea2-b40d-972ff9c63846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5b859bb8-10ef-4241-b5eb-93c360ae21d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4a1289-1f8c-4ea2-b40d-972ff9c63846" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5b859bb8-10ef-4241-b5eb-93c360ae21d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_9694c558-d78a-4e03-8a3d-8ff2275f5177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5b859bb8-10ef-4241-b5eb-93c360ae21d8" xlink:to="loc_us-gaap_AccountsReceivableMember_9694c558-d78a-4e03-8a3d-8ff2275f5177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_958fb583-30e9-44ba-b695-c1f9040a4499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5b859bb8-10ef-4241-b5eb-93c360ae21d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_958fb583-30e9-44ba-b695-c1f9040a4499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a6a7027-2987-4f00-8311-610dc7cb747e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_srt_RangeAxis_9a6a7027-2987-4f00-8311-610dc7cb747e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b33e3f6-4345-4d8e-b581-217431da725e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9a6a7027-2987-4f00-8311-610dc7cb747e" xlink:to="loc_srt_RangeMember_2b33e3f6-4345-4d8e-b581-217431da725e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_01a898a5-fa09-4f7b-b2b2-7a1135d4ada3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2b33e3f6-4345-4d8e-b581-217431da725e" xlink:to="loc_srt_MinimumMember_01a898a5-fa09-4f7b-b2b2-7a1135d4ada3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1009fc5f-b595-442b-92e0-37bae1693dad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2b33e3f6-4345-4d8e-b581-217431da725e" xlink:to="loc_srt_MaximumMember_1009fc5f-b595-442b-92e0-37bae1693dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b1d0dd09-8624-4868-a4c5-964f19ff1026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b1d0dd09-8624-4868-a4c5-964f19ff1026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_91466a83-6980-40a4-b4da-df7b50c7f818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b1d0dd09-8624-4868-a4c5-964f19ff1026" xlink:to="loc_us-gaap_SegmentDomain_91466a83-6980-40a4-b4da-df7b50c7f818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoHealthMember_eed4b1da-af7c-44a6-aa68-d2bf4eb78a86" xlink:href="ekso-20201231.xsd#ekso_EksoHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_91466a83-6980-40a4-b4da-df7b50c7f818" xlink:to="loc_ekso_EksoHealthMember_eed4b1da-af7c-44a6-aa68-d2bf4eb78a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dda67a62-1f27-4cce-9063-900f1e049b58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_srt_MajorCustomersAxis_dda67a62-1f27-4cce-9063-900f1e049b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3d7d151f-2ae4-434b-8d32-366a53be10ed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_dda67a62-1f27-4cce-9063-900f1e049b58" xlink:to="loc_srt_NameOfMajorCustomerDomain_3d7d151f-2ae4-434b-8d32-366a53be10ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CustomerAMember_9d4f5a79-fd35-4f8f-88df-0b099a41a2a7" xlink:href="ekso-20201231.xsd#ekso_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3d7d151f-2ae4-434b-8d32-366a53be10ed" xlink:to="loc_ekso_CustomerAMember_9d4f5a79-fd35-4f8f-88df-0b099a41a2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CustomerBMember_fbc93b38-e0bc-4941-aa71-a8483425e893" xlink:href="ekso-20201231.xsd#ekso_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3d7d151f-2ae4-434b-8d32-366a53be10ed" xlink:to="loc_ekso_CustomerBMember_fbc93b38-e0bc-4941-aa71-a8483425e893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:href="ekso-20201231.xsd#ekso_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ScheduleOfSignificantAccountingPoliciesTable_72e33ebc-37c6-4792-adb5-0a9c77ac9bbe" xlink:to="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_b90f6913-9297-420e-94ce-42cd7fc87cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_b90f6913-9297-420e-94ce-42cd7fc87cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0a1e9bd9-e3f3-4e6a-86a4-ea002746f235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0a1e9bd9-e3f3-4e6a-86a4-ea002746f235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3a5ca78d-45cc-4ea4-9bb9-5bb42e772b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3a5ca78d-45cc-4ea4-9bb9-5bb42e772b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_cdcf4d29-63fc-41c1-bcce-cc5d1a7a45bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_RestructuringCharges_cdcf4d29-63fc-41c1-bcce-cc5d1a7a45bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0c5ce52a-7ca2-43b3-a131-07c493d68b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0c5ce52a-7ca2-43b3-a131-07c493d68b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_756af44c-00cf-4d23-bb75-3a3542843196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_756af44c-00cf-4d23-bb75-3a3542843196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_db0a6cfd-d298-404d-80a8-b5505c55f0e3" xlink:href="ekso-20201231.xsd#ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_db0a6cfd-d298-404d-80a8-b5505c55f0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6251551c-4b85-4212-8a05-d645800e4c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6251551c-4b85-4212-8a05-d645800e4c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_99598a12-ceec-4f9e-9359-98bbb6ed4e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_SignificantAccountingPoliciesLineItems_8181b9dd-955a-4021-ad5a-8fdea63a3218" xlink:to="loc_us-gaap_GrantsReceivable_99598a12-ceec-4f9e-9359-98bbb6ed4e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_74ccc812-6242-496a-98bb-0f8b63c42712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac07a228-5ab1-445e-a637-53382346d538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74ccc812-6242-496a-98bb-0f8b63c42712" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac07a228-5ab1-445e-a637-53382346d538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_132be21e-4d91-470b-9382-743eadc2414a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac07a228-5ab1-445e-a637-53382346d538" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_132be21e-4d91-470b-9382-743eadc2414a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_203b835a-d7dc-41fd-82a4-4d9f282b5ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_132be21e-4d91-470b-9382-743eadc2414a" xlink:to="loc_us-gaap_EquityComponentDomain_203b835a-d7dc-41fd-82a4-4d9f282b5ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_18608d47-eb4e-4482-a743-0dfdfd160e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_203b835a-d7dc-41fd-82a4-4d9f282b5ddd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_18608d47-eb4e-4482-a743-0dfdfd160e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c6ecdc52-e961-4c26-bf59-b46e943f4839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac07a228-5ab1-445e-a637-53382346d538" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c6ecdc52-e961-4c26-bf59-b46e943f4839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_07a65e7c-c241-4552-9efc-ad02f592a26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c6ecdc52-e961-4c26-bf59-b46e943f4839" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_07a65e7c-c241-4552-9efc-ad02f592a26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3dd77456-02b4-4f2e-a824-90147b8aa107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_07a65e7c-c241-4552-9efc-ad02f592a26c" xlink:to="loc_us-gaap_StockholdersEquity_3dd77456-02b4-4f2e-a824-90147b8aa107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0a08521d-bf24-41cd-b612-ec902428f24f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_07a65e7c-c241-4552-9efc-ad02f592a26c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0a08521d-bf24-41cd-b612-ec902428f24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c0f85bd-356f-46ca-b382-bf03c784b3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_07a65e7c-c241-4552-9efc-ad02f592a26c" xlink:to="loc_us-gaap_StockholdersEquity_6c0f85bd-356f-46ca-b382-bf03c784b3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e6b19be6-3db1-4604-a9e9-4b77488a3c1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b82a380d-0519-4b53-a58d-6997d502fecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6b19be6-3db1-4604-a9e9-4b77488a3c1e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b82a380d-0519-4b53-a58d-6997d502fecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7224f0da-2664-4ba1-ba22-9c2378f39a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6b19be6-3db1-4604-a9e9-4b77488a3c1e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7224f0da-2664-4ba1-ba22-9c2378f39a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4ef41bbc-de75-4c6d-a603-8d8b1bef18c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6b19be6-3db1-4604-a9e9-4b77488a3c1e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4ef41bbc-de75-4c6d-a603-8d8b1bef18c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ba5442dc-b064-4849-ac47-5fd8be96399a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6b19be6-3db1-4604-a9e9-4b77488a3c1e" xlink:to="loc_us-gaap_InventoryNet_ba5442dc-b064-4849-ac47-5fd8be96399a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a32d3c59-4afd-4ab6-858a-85bcdfe19e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_169fa2b8-9626-4b83-99f2-178c5b5d2f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a32d3c59-4afd-4ab6-858a-85bcdfe19e88" xlink:to="loc_us-gaap_GoodwillRollForward_169fa2b8-9626-4b83-99f2-178c5b5d2f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f1b029b8-24cf-4340-a612-5579916e2608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_169fa2b8-9626-4b83-99f2-178c5b5d2f51" xlink:to="loc_us-gaap_Goodwill_f1b029b8-24cf-4340-a612-5579916e2608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_abe79831-8f24-4643-b005-3756d19f15d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_169fa2b8-9626-4b83-99f2-178c5b5d2f51" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_abe79831-8f24-4643-b005-3756d19f15d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_242c95e7-afc4-4316-b9e1-81062e2811ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_169fa2b8-9626-4b83-99f2-178c5b5d2f51" xlink:to="loc_us-gaap_Goodwill_242c95e7-afc4-4316-b9e1-81062e2811ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStock" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStock"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_470d794f-b63b-42ea-9a70-b0512617c767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3222c1ef-a9fa-4b10-ac63-38e856cd4f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_470d794f-b63b-42ea-9a70-b0512617c767" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3222c1ef-a9fa-4b10-ac63-38e856cd4f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStockTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5ae513e1-a474-445f-a128-ce0d79dc5eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6d19a503-a08a-4460-829a-8990b94a54ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5ae513e1-a474-445f-a128-ce0d79dc5eb9" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6d19a503-a08a-4460-829a-8990b94a54ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c3280063-cdb5-4083-8f63-bb8958327c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5ae513e1-a474-445f-a128-ce0d79dc5eb9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c3280063-cdb5-4083-8f63-bb8958327c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_85117702-162f-48fb-b0c8-c7623903243a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_68575f7c-2d78-434a-bf09-1964d69b1b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_85117702-162f-48fb-b0c8-c7623903243a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_68575f7c-2d78-434a-bf09-1964d69b1b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_70fba3ee-4218-4766-ac0b-8f4fc8786b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_68575f7c-2d78-434a-bf09-1964d69b1b58" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_70fba3ee-4218-4766-ac0b-8f4fc8786b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d19e5d8c-f791-4387-a39b-87d29635c31b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_68575f7c-2d78-434a-bf09-1964d69b1b58" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d19e5d8c-f791-4387-a39b-87d29635c31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4116bade-5d52-45f6-8165-a1db158b88b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_85117702-162f-48fb-b0c8-c7623903243a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4116bade-5d52-45f6-8165-a1db158b88b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f3be20b7-b170-4dc1-948d-3f1fb6530a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4116bade-5d52-45f6-8165-a1db158b88b1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f3be20b7-b170-4dc1-948d-3f1fb6530a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7a2258f6-d647-4901-8eba-368a1a3e13e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4116bade-5d52-45f6-8165-a1db158b88b1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7a2258f6-d647-4901-8eba-368a1a3e13e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8278a89f-8a60-41bb-82e7-ea2e0b312c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_85117702-162f-48fb-b0c8-c7623903243a" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8278a89f-8a60-41bb-82e7-ea2e0b312c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7f0e3126-1836-4b0d-9980-4c94e168dc17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8278a89f-8a60-41bb-82e7-ea2e0b312c80" xlink:to="loc_us-gaap_EarningsPerShareBasic_7f0e3126-1836-4b0d-9980-4c94e168dc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_26270a55-0c40-484b-b2d6-9e18fccde54a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8278a89f-8a60-41bb-82e7-ea2e0b312c80" xlink:to="loc_us-gaap_EarningsPerShareDiluted_26270a55-0c40-484b-b2d6-9e18fccde54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ef034901-0d76-44e5-b2f1-6f0c6291c816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14d2960e-15e5-4504-b834-653defaad178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ef034901-0d76-44e5-b2f1-6f0c6291c816" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14d2960e-15e5-4504-b834-653defaad178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6f42344-2ba3-43b2-9a7f-efdf5801b5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14d2960e-15e5-4504-b834-653defaad178" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6f42344-2ba3-43b2-9a7f-efdf5801b5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8695226c-4270-464d-ad1a-a62ede8038f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f6f42344-2ba3-43b2-9a7f-efdf5801b5c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8695226c-4270-464d-ad1a-a62ede8038f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bb0bdc80-1686-401b-8c02-dc450a58fd94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8695226c-4270-464d-ad1a-a62ede8038f7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bb0bdc80-1686-401b-8c02-dc450a58fd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2858654b-061f-4782-b806-0e6cf103bf2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8695226c-4270-464d-ad1a-a62ede8038f7" xlink:to="loc_us-gaap_RestrictedStockMember_2858654b-061f-4782-b806-0e6cf103bf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a58f3625-2761-43e1-a8ed-0ea14c40a23c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8695226c-4270-464d-ad1a-a62ede8038f7" xlink:to="loc_us-gaap_WarrantMember_a58f3625-2761-43e1-a8ed-0ea14c40a23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ec73b738-4401-4d4b-8ba4-dc8a121cd5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14d2960e-15e5-4504-b834-653defaad178" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ec73b738-4401-4d4b-8ba4-dc8a121cd5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f0e65170-2e53-4ffc-88d8-749c5310add5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ec73b738-4401-4d4b-8ba4-dc8a121cd5fc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f0e65170-2e53-4ffc-88d8-749c5310add5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate" xlink:type="simple" xlink:href="ekso-20201231.xsd#InvestmentinUnconsolidatedAffiliate"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c78e406e-c62c-49c3-8e75-e75fcf35c2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_2b380626-c2eb-4f00-8a9d-b14b685412b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c78e406e-c62c-49c3-8e75-e75fcf35c2a4" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_2b380626-c2eb-4f00-8a9d-b14b685412b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliateDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#InvestmentinUnconsolidatedAffiliateDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_56e76728-58cd-4fb8-8081-20365c527383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c369d1a0-e9ce-4beb-8812-2cc64d13661e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_56e76728-58cd-4fb8-8081-20365c527383" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c369d1a0-e9ce-4beb-8812-2cc64d13661e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eed71ac1-b7d9-4f73-94d2-001c2c86f37f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6f792641-c848-46f2-96f7-6614b7fc0913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eed71ac1-b7d9-4f73-94d2-001c2c86f37f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6f792641-c848-46f2-96f7-6614b7fc0913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_14bc5142-8b52-4dd7-8da2-7945eb8c104f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_922f479a-7c89-4b9e-ba0b-47841a666bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_14bc5142-8b52-4dd7-8da2-7945eb8c104f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_922f479a-7c89-4b9e-ba0b-47841a666bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e7997c5a-a597-400d-997d-818538b85f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_14bc5142-8b52-4dd7-8da2-7945eb8c104f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e7997c5a-a597-400d-997d-818538b85f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f78c6ca5-b032-4fbe-a47f-cdb532e1b419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d628bc9f-c295-4d38-8224-d18c5a95ffdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f78c6ca5-b032-4fbe-a47f-cdb532e1b419" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d628bc9f-c295-4d38-8224-d18c5a95ffdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85250bae-4012-4e35-98a9-648966bfef14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d628bc9f-c295-4d38-8224-d18c5a95ffdb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85250bae-4012-4e35-98a9-648966bfef14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cfa2e1f-76b3-475c-8677-cb870a31ce0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85250bae-4012-4e35-98a9-648966bfef14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cfa2e1f-76b3-475c-8677-cb870a31ce0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cc6ed798-c2ed-43a5-acdc-a4698e78f96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cfa2e1f-76b3-475c-8677-cb870a31ce0e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cc6ed798-c2ed-43a5-acdc-a4698e78f96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d8cbd164-b691-4506-8c2f-df9f79b8c611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cfa2e1f-76b3-475c-8677-cb870a31ce0e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d8cbd164-b691-4506-8c2f-df9f79b8c611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d177f20d-11ee-482d-a3d2-f9b836b77e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cfa2e1f-76b3-475c-8677-cb870a31ce0e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d177f20d-11ee-482d-a3d2-f9b836b77e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_57191d2f-a89d-4a65-8a31-984c67d88a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d628bc9f-c295-4d38-8224-d18c5a95ffdb" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_57191d2f-a89d-4a65-8a31-984c67d88a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c40fc00e-312b-4dc5-bb9e-4affa49f3c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_57191d2f-a89d-4a65-8a31-984c67d88a9e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c40fc00e-312b-4dc5-bb9e-4affa49f3c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_86effe75-2e68-4882-a91c-6eb0359471b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c40fc00e-312b-4dc5-bb9e-4affa49f3c0c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_86effe75-2e68-4882-a91c-6eb0359471b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c0b3bb8f-345c-4940-ad4a-10fb7e42f95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d628bc9f-c295-4d38-8224-d18c5a95ffdb" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c0b3bb8f-345c-4940-ad4a-10fb7e42f95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6c5629d9-e8cf-42df-8007-ab5062912c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c0b3bb8f-345c-4940-ad4a-10fb7e42f95c" xlink:to="loc_us-gaap_DerivativeLiabilities_6c5629d9-e8cf-42df-8007-ab5062912c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContingentSuccessFeeLiability_2aa7ad4f-e9fd-44ac-ba01-2bcfbf5d8dca" xlink:href="ekso-20201231.xsd#ekso_ContingentSuccessFeeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c0b3bb8f-345c-4940-ad4a-10fb7e42f95c" xlink:to="loc_ekso_ContingentSuccessFeeLiability_2aa7ad4f-e9fd-44ac-ba01-2bcfbf5d8dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3ae39f05-678d-4de8-92d9-01aed60ef0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9580b338-2451-47ab-8f71-0520e2f8b836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3ae39f05-678d-4de8-92d9-01aed60ef0e4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9580b338-2451-47ab-8f71-0520e2f8b836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_320a41e6-e282-4b57-b539-a67082c1e45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9580b338-2451-47ab-8f71-0520e2f8b836" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_320a41e6-e282-4b57-b539-a67082c1e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ebea96d8-eece-4e8b-a0e8-c9894d9dc5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_320a41e6-e282-4b57-b539-a67082c1e45a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ebea96d8-eece-4e8b-a0e8-c9894d9dc5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_81f61d56-67de-4f98-aa1e-a72ad5645b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ebea96d8-eece-4e8b-a0e8-c9894d9dc5b7" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_81f61d56-67de-4f98-aa1e-a72ad5645b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContingentSuccessFeeMember_6c02c921-bd81-4896-b3de-189375fd6ef8" xlink:href="ekso-20201231.xsd#ekso_ContingentSuccessFeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ebea96d8-eece-4e8b-a0e8-c9894d9dc5b7" xlink:to="loc_ekso_ContingentSuccessFeeMember_6c02c921-bd81-4896-b3de-189375fd6ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51e76719-28bc-41e6-b962-1122f0e9017f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9580b338-2451-47ab-8f71-0520e2f8b836" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51e76719-28bc-41e6-b962-1122f0e9017f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51e76719-28bc-41e6-b962-1122f0e9017f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_443f31ec-e392-4e50-bf39-f9235fbc2bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_443f31ec-e392-4e50-bf39-f9235fbc2bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_beeeb623-eb64-410c-9af2-dd505e919ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_beeeb623-eb64-410c-9af2-dd505e919ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantLiability_f13da25e-a466-43e0-98ea-cdd2ebcea73a" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_ekso_GainLossOnWarrantLiability_f13da25e-a466-43e0-98ea-cdd2ebcea73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification_d84a9ea0-9fc6-4813-b4a4-a94f9931e20c" xlink:href="ekso-20201231.xsd#ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification_d84a9ea0-9fc6-4813-b4a4-a94f9931e20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement_079492e2-b852-4915-9cdf-2941379e4e38" xlink:href="ekso-20201231.xsd#ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement_079492e2-b852-4915-9cdf-2941379e4e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3ae35239-b20c-4dc9-9aa3-bebb25deb32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b7f072a7-0732-45f1-b69e-dc3ea7afe609" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3ae35239-b20c-4dc9-9aa3-bebb25deb32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6fb843a2-acfb-4ceb-a2b5-299a2e7441be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_e0a78661-4ef4-4521-a5ad-2362e193f737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6fb843a2-acfb-4ceb-a2b5-299a2e7441be" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_e0a78661-4ef4-4521-a5ad-2362e193f737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d66040e3-d668-47db-80cf-097daae45ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_6463980d-1a27-4280-bb40-2d032f84b6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d66040e3-d668-47db-80cf-097daae45ad3" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_6463980d-1a27-4280-bb40-2d032f84b6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2cd9a9bf-5526-4c54-8e31-417d31d92236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d66040e3-d668-47db-80cf-097daae45ad3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2cd9a9bf-5526-4c54-8e31-417d31d92236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10ecfeeb-a04b-4bde-871d-780773c338bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredExtendedMaintenanceAndSupport_73b2ed98-59f8-437a-9f0b-22b8257bafb9" xlink:href="ekso-20201231.xsd#ekso_DeferredExtendedMaintenanceAndSupport"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10ecfeeb-a04b-4bde-871d-780773c338bd" xlink:to="loc_ekso_DeferredExtendedMaintenanceAndSupport_73b2ed98-59f8-437a-9f0b-22b8257bafb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredRoyalties_268accd5-1318-463e-9752-da230b1dde05" xlink:href="ekso-20201231.xsd#ekso_DeferredRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10ecfeeb-a04b-4bde-871d-780773c338bd" xlink:to="loc_ekso_DeferredRoyalties_268accd5-1318-463e-9752-da230b1dde05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredDeviceRevenue_e993233e-3e1d-494a-adae-2f4e040b2e20" xlink:href="ekso-20201231.xsd#ekso_DeferredDeviceRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10ecfeeb-a04b-4bde-871d-780773c338bd" xlink:to="loc_ekso_DeferredDeviceRevenue_e993233e-3e1d-494a-adae-2f4e040b2e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_37f477a4-722d-40ec-af4c-ce08ad1d8453" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10ecfeeb-a04b-4bde-871d-780773c338bd" xlink:to="loc_us-gaap_ContractWithCustomerLiability_37f477a4-722d-40ec-af4c-ce08ad1d8453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c619d20c-468c-47d3-8fa1-601921508c48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10ecfeeb-a04b-4bde-871d-780773c338bd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c619d20c-468c-47d3-8fa1-601921508c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_96f4b5d2-dfa6-4b6c-8dfc-a50818576b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10ecfeeb-a04b-4bde-871d-780773c338bd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_96f4b5d2-dfa6-4b6c-8dfc-a50818576b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails_1" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDeferredRevenueDetails_1"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDeferredRevenueActivityDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e5873ef1-1ed3-4e56-8d6e-5eba12ad1cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward_b9302109-2b56-4c96-8621-7660a7f60afb" xlink:href="ekso-20201231.xsd#ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e5873ef1-1ed3-4e56-8d6e-5eba12ad1cee" xlink:to="loc_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward_b9302109-2b56-4c96-8621-7660a7f60afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9602b707-67d4-4f98-ac37-2bbb610c3a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward_b9302109-2b56-4c96-8621-7660a7f60afb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9602b707-67d4-4f98-ac37-2bbb610c3a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractWithCustomerLiabilityDeferralOfRevenue_1c7106c4-44d3-401a-a4ed-6fbb30d72a29" xlink:href="ekso-20201231.xsd#ekso_ContractWithCustomerLiabilityDeferralOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward_b9302109-2b56-4c96-8621-7660a7f60afb" xlink:to="loc_ekso_ContractWithCustomerLiabilityDeferralOfRevenue_1c7106c4-44d3-401a-a4ed-6fbb30d72a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_afee2d1d-55df-46bc-b374-d9c9686e374a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward_b9302109-2b56-4c96-8621-7660a7f60afb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_afee2d1d-55df-46bc-b374-d9c9686e374a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_29654a2c-a380-4c70-971d-5dd294f699fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward_b9302109-2b56-4c96-8621-7660a7f60afb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_29654a2c-a380-4c70-971d-5dd294f699fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_194c100e-5f11-42a3-b128-c7b51fffdeed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_194c100e-5f11-42a3-b128-c7b51fffdeed" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:to="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e7226606-e8f9-4c93-8ad5-d0ae244b5a39" xlink:to="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aba3d3b0-122d-4af2-ad35-38aac859882b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:to="loc_srt_MinimumMember_aba3d3b0-122d-4af2-ad35-38aac859882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05d241da-a531-442a-b25b-f065d7381f44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a90b88bf-d4e2-4551-bf8d-647f264c2776" xlink:to="loc_srt_MaximumMember_05d241da-a531-442a-b25b-f065d7381f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_31e1f47f-0181-48eb-b95a-199229b24ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_31e1f47f-0181-48eb-b95a-199229b24ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01767c62-e214-4281-888f-ccd2098c1c4f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_14ccb76d-dc54-4111-ab57-c0079a27a05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_14ccb76d-dc54-4111-ab57-c0079a27a05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f5fc8c4f-2e79-4070-9f50-440204469dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f5fc8c4f-2e79-4070-9f50-440204469dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractwithCustomerLiabilityNonCancellableBacklog_df570161-a7b1-4f3e-8705-76dd96d27d1a" xlink:href="ekso-20201231.xsd#ekso_ContractwithCustomerLiabilityNonCancellableBacklog"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_ekso_ContractwithCustomerLiabilityNonCancellableBacklog_df570161-a7b1-4f3e-8705-76dd96d27d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f97f77da-3bc0-48a5-b89a-308ffc9214b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f97f77da-3bc0-48a5-b89a-308ffc9214b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_c7f1adfb-c72f-4710-8511-a8748c5fed57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_c7f1adfb-c72f-4710-8511-a8748c5fed57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d4fbd472-87ba-40f4-b350-fa354159faad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d4fbd472-87ba-40f4-b350-fa354159faad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_8a0ffbc1-78a2-4c73-a931-90e3b0d4202b" xlink:href="ekso-20201231.xsd#ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a52f058e-c807-4adf-800c-e54b6a78dc3a" xlink:to="loc_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration_8a0ffbc1-78a2-4c73-a931-90e3b0d4202b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails_1" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionAdditionalInformationDetails_1"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RevenueRecognitionSummaryofDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_834a20ad-7bb1-41f6-909b-4f01d67e0363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_81abf56e-8f33-4886-bd3a-bca80b9c5241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_834a20ad-7bb1-41f6-909b-4f01d67e0363" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_81abf56e-8f33-4886-bd3a-bca80b9c5241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7d230d34-b5a6-4797-a6da-9ec4e4833ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_81abf56e-8f33-4886-bd3a-bca80b9c5241" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7d230d34-b5a6-4797-a6da-9ec4e4833ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0e91de4b-5a90-4e4a-934b-056ba636b3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d230d34-b5a6-4797-a6da-9ec4e4833ca4" xlink:to="loc_us-gaap_SegmentDomain_0e91de4b-5a90-4e4a-934b-056ba636b3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoHealthMember_51774fcc-eb19-48b3-9948-74b50b2d665d" xlink:href="ekso-20201231.xsd#ekso_EksoHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0e91de4b-5a90-4e4a-934b-056ba636b3f7" xlink:to="loc_ekso_EksoHealthMember_51774fcc-eb19-48b3-9948-74b50b2d665d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoWorksMember_6557f4ea-32a1-428d-8453-11770cbfcec2" xlink:href="ekso-20201231.xsd#ekso_EksoWorksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0e91de4b-5a90-4e4a-934b-056ba636b3f7" xlink:to="loc_ekso_EksoWorksMember_6557f4ea-32a1-428d-8453-11770cbfcec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8df6a42e-8954-45a6-92ab-d9c019b77847" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_81abf56e-8f33-4886-bd3a-bca80b9c5241" xlink:to="loc_srt_ProductOrServiceAxis_8df6a42e-8954-45a6-92ab-d9c019b77847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8df6a42e-8954-45a6-92ab-d9c019b77847" xlink:to="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f3de26ad-87fe-4a03-96fa-9ac708a1c436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:to="loc_us-gaap_ProductMember_f3de26ad-87fe-4a03-96fa-9ac708a1c436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_f262e99f-024d-4c26-bebd-8959239b7da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:to="loc_us-gaap_ServiceMember_f262e99f-024d-4c26-bebd-8959239b7da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RentalsMember_cf5dcfd1-7be8-45de-a0d8-ad52ad4a7193" xlink:href="ekso-20201231.xsd#ekso_RentalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:to="loc_ekso_RentalsMember_cf5dcfd1-7be8-45de-a0d8-ad52ad4a7193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_32d5f197-fca9-49d2-81a3-1e84e9ce2a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_32d5f197-fca9-49d2-81a3-1e84e9ce2a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CollaborativeArrangementsMember_e0af2db7-120f-4f3b-adde-229e9ee64c50" xlink:href="ekso-20201231.xsd#ekso_CollaborativeArrangementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9295a28b-50c3-4771-8b02-7db0d9f64bf6" xlink:to="loc_ekso_CollaborativeArrangementsMember_e0af2db7-120f-4f3b-adde-229e9ee64c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_db4d7d74-23a1-4f08-9685-a47adbe88279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_81abf56e-8f33-4886-bd3a-bca80b9c5241" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_db4d7d74-23a1-4f08-9685-a47adbe88279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3ca6722e-5f75-44bb-ac45-3e12d0c13c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_db4d7d74-23a1-4f08-9685-a47adbe88279" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3ca6722e-5f75-44bb-ac45-3e12d0c13c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_31ab99cd-044f-4856-bff8-5e4d4a78e8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fd652c39-0286-41eb-b262-9a7f5c348a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_31ab99cd-044f-4856-bff8-5e4d4a78e8db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fd652c39-0286-41eb-b262-9a7f5c348a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49e35f35-9eab-4c43-80ed-2e98c336e6be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8d55c7cc-16bb-44d1-bcfb-822c2c70a788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49e35f35-9eab-4c43-80ed-2e98c336e6be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8d55c7cc-16bb-44d1-bcfb-822c2c70a788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_257085ca-12a9-4d54-a768-2142276314bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c5a6e90-ce26-4aa3-b9f9-c92c8cf62638" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_257085ca-12a9-4d54-a768-2142276314bf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c5a6e90-ce26-4aa3-b9f9-c92c8cf62638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4455be37-9bda-4966-97b2-abad7f3b2f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c5a6e90-ce26-4aa3-b9f9-c92c8cf62638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4455be37-9bda-4966-97b2-abad7f3b2f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4455be37-9bda-4966-97b2-abad7f3b2f12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransportationEquipmentMember_571d5d12-3391-49ad-a82e-b529566160e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransportationEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_TransportationEquipmentMember_571d5d12-3391-49ad-a82e-b529566160e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_bb0a06d8-a062-46b9-92d5-2768205d029f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_bb0a06d8-a062-46b9-92d5-2768205d029f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1039126f-4f37-4f2b-834e-26d9be74ab53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1039126f-4f37-4f2b-834e-26d9be74ab53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_c078bef7-532e-4746-8ae0-4772ea7df78b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_OfficeEquipmentMember_c078bef7-532e-4746-8ae0-4772ea7df78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_33c8fffe-0bfc-4aec-a7ee-9adcebbdb451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_33c8fffe-0bfc-4aec-a7ee-9adcebbdb451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_b6c96cd0-c008-4e60-a6e6-f0950c6cb30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_b6c96cd0-c008-4e60-a6e6-f0950c6cb30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d525d9e5-3498-451a-bfdc-084b233855f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3b855664-1157-4be3-bdcc-97697e3812be" xlink:to="loc_us-gaap_ComputerEquipmentMember_d525d9e5-3498-451a-bfdc-084b233855f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1313277d-0040-43cd-a27a-e640bb2a4438" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c5a6e90-ce26-4aa3-b9f9-c92c8cf62638" xlink:to="loc_srt_RangeAxis_1313277d-0040-43cd-a27a-e640bb2a4438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64252bca-1cad-4808-a34b-2c4a7474b804" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1313277d-0040-43cd-a27a-e640bb2a4438" xlink:to="loc_srt_RangeMember_64252bca-1cad-4808-a34b-2c4a7474b804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b8451a7a-d56a-4e84-b8a2-6a238ff19868" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_64252bca-1cad-4808-a34b-2c4a7474b804" xlink:to="loc_srt_MinimumMember_b8451a7a-d56a-4e84-b8a2-6a238ff19868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b581cd98-5cbe-4635-8c9b-9de1b9cc91db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_64252bca-1cad-4808-a34b-2c4a7474b804" xlink:to="loc_srt_MaximumMember_b581cd98-5cbe-4635-8c9b-9de1b9cc91db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c5a6e90-ce26-4aa3-b9f9-c92c8cf62638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bb82f2a3-2adc-4ccc-8c97-87b14530d6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bb82f2a3-2adc-4ccc-8c97-87b14530d6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_33a4194d-0804-4e79-9f55-201290670ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_33a4194d-0804-4e79-9f55-201290670ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f850d66f-dd92-4ce0-94d1-36cdbce19acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f850d66f-dd92-4ce0-94d1-36cdbce19acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e635b4e7-4c5b-471b-80f6-a3fd928ae419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7822d876-8df4-4857-88ca-71ffac528cd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e635b4e7-4c5b-471b-80f6-a3fd928ae419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#PropertyandEquipmentnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7c07563b-caaf-439b-a127-4bdfc52483bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_04f4fb58-2d9f-456d-a3b4-0bdcb44e6e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7c07563b-caaf-439b-a127-4bdfc52483bd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_04f4fb58-2d9f-456d-a3b4-0bdcb44e6e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_da6675fa-d553-4fd4-96e9-2489584a2dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_98cd8cdc-9186-4cbd-babb-f2ca209c8d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_da6675fa-d553-4fd4-96e9-2489584a2dd7" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_98cd8cdc-9186-4cbd-babb-f2ca209c8d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_f8936579-5e0b-4ca3-96b5-78b530f4426c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1786d0e6-40b3-40c3-ab05-856b850c7ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_f8936579-5e0b-4ca3-96b5-78b530f4426c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1786d0e6-40b3-40c3-ab05-856b850c7ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceAndWarrantyTableTextBlock_5d6d6a96-d933-40d4-b70b-2287f4a17e18" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceAndWarrantyTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_f8936579-5e0b-4ca3-96b5-78b530f4426c" xlink:to="loc_ekso_ProductMaintenanceAndWarrantyTableTextBlock_5d6d6a96-d933-40d4-b70b-2287f4a17e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_469ad10c-4b70-476e-90ab-9de901b8a656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f71c9621-65cf-45c0-82b9-4c7f75813096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_469ad10c-4b70-476e-90ab-9de901b8a656" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f71c9621-65cf-45c0-82b9-4c7f75813096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_794a58bf-6243-4cd6-ac25-e65ad20e4fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_469ad10c-4b70-476e-90ab-9de901b8a656" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_794a58bf-6243-4cd6-ac25-e65ad20e4fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedClinicalCostCurrent_d3f924e4-2e7c-42f6-9c6f-3180e9b103ff" xlink:href="ekso-20201231.xsd#ekso_AccruedClinicalCostCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_469ad10c-4b70-476e-90ab-9de901b8a656" xlink:to="loc_ekso_AccruedClinicalCostCurrent_d3f924e4-2e7c-42f6-9c6f-3180e9b103ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9d2aa0a6-1e5c-462c-bd53-d51cbdc6f17c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_469ad10c-4b70-476e-90ab-9de901b8a656" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9d2aa0a6-1e5c-462c-bd53-d51cbdc6f17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#AccruedLiabilitiesScheduleofWarrantyCostsDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_bfcd807f-b0dc-4a17-870e-dc3c424ae50a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedLiabilitiesTable_d150541f-24e0-49c5-84a5-b055c2835a71" xlink:href="ekso-20201231.xsd#ekso_AccruedLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_bfcd807f-b0dc-4a17-870e-dc3c424ae50a" xlink:to="loc_ekso_AccruedLiabilitiesTable_d150541f-24e0-49c5-84a5-b055c2835a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OtherliabilitiesAxis_994de724-3b77-4aa7-a512-8ef9e91728ca" xlink:href="ekso-20201231.xsd#ekso_OtherliabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesTable_d150541f-24e0-49c5-84a5-b055c2835a71" xlink:to="loc_ekso_OtherliabilitiesAxis_994de724-3b77-4aa7-a512-8ef9e91728ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OtherLiabilitiesDomain_22d3a8e8-e639-441e-9e1a-283e3331542a" xlink:href="ekso-20201231.xsd#ekso_OtherLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_OtherliabilitiesAxis_994de724-3b77-4aa7-a512-8ef9e91728ca" xlink:to="loc_ekso_OtherLiabilitiesDomain_22d3a8e8-e639-441e-9e1a-283e3331542a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_WarrantyMember_4555e117-84f5-4749-9b80-627bb2d1f0aa" xlink:href="ekso-20201231.xsd#ekso_WarrantyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_OtherLiabilitiesDomain_22d3a8e8-e639-441e-9e1a-283e3331542a" xlink:to="loc_ekso_WarrantyMember_4555e117-84f5-4749-9b80-627bb2d1f0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:href="ekso-20201231.xsd#ekso_AccruedLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesTable_d150541f-24e0-49c5-84a5-b055c2835a71" xlink:to="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:href="ekso-20201231.xsd#ekso_AccruedLiabilitiesRollforwardRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:to="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_580bc711-f35d-4d4c-8414-d5dac6059c79" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:to="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_580bc711-f35d-4d4c-8414-d5dac6059c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyAddition_edca58cf-768f-4dcd-af51-6f0c6402a6d7" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyAddition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:to="loc_ekso_ProductMaintenanceWarrantyAddition_edca58cf-768f-4dcd-af51-6f0c6402a6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyExpense_51324c84-1942-4d09-a4f9-2621329f040d" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:to="loc_ekso_ProductMaintenanceWarrantyExpense_51324c84-1942-4d09-a4f9-2621329f040d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_c1002568-912b-415b-8436-8e3e470f0a57" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesRollforwardRollForward_4408e229-2d74-4722-b945-69bfdba0cb62" xlink:to="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_c1002568-912b-415b-8436-8e3e470f0a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent_95edc066-f688-490d-bd4a-ac106b2988ba" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:to="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent_95edc066-f688-490d-bd4a-ac106b2988ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent_149eca51-cde1-45fe-ab3e-f8b309716f1d" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:to="loc_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent_149eca51-cde1-45fe-ab3e-f8b309716f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_b9b75cdb-9859-4c31-a1dc-28aa420e7555" xlink:href="ekso-20201231.xsd#ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:to="loc_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent_b9b75cdb-9859-4c31-a1dc-28aa420e7555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyDescription_4495ba5c-c456-4e19-90a0-df801b317c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyDescription"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_AccruedLiabilitiesLineItems_2bd18ff0-e106-4077-883d-2bcd17c879df" xlink:to="loc_us-gaap_StandardProductWarrantyDescription_4495ba5c-c456-4e19-90a0-df801b317c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/Notespayablenet" xlink:type="simple" xlink:href="ekso-20201231.xsd#Notespayablenet"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/Notespayablenet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_70941f10-74ef-4354-a9a5-84e7f6b3fdf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_fbfea752-e77d-489c-aabf-2c07807109a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_70941f10-74ef-4354-a9a5-84e7f6b3fdf7" xlink:to="loc_us-gaap_LongTermDebtTextBlock_fbfea752-e77d-489c-aabf-2c07807109a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/NotespayablenetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5148e880-af0b-4543-b5ff-6c278adcc504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8410984e-3701-4bbd-8bc0-9bd1db09da0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5148e880-af0b-4543-b5ff-6c278adcc504" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8410984e-3701-4bbd-8bc0-9bd1db09da0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_83ce4a2d-68a4-457b-8f4f-b21bb5690e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_83ce4a2d-68a4-457b-8f4f-b21bb5690e56" xlink:to="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0b419841-ba6b-464a-b9f3-3985f4fb504c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:to="loc_us-gaap_DebtInstrumentAxis_0b419841-ba6b-464a-b9f3-3985f4fb504c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6d510f8-3b69-46e6-9dc9-74de920cff1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0b419841-ba6b-464a-b9f3-3985f4fb504c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6d510f8-3b69-46e6-9dc9-74de920cff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LoanAgreementMember_1429a4f2-ccd6-40b7-87ed-0bf84204b55c" xlink:href="ekso-20201231.xsd#ekso_LoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6d510f8-3b69-46e6-9dc9-74de920cff1e" xlink:to="loc_ekso_LoanAgreementMember_1429a4f2-ccd6-40b7-87ed-0bf84204b55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_PWBLoanAgreementMember_4c0fddba-e812-4482-8005-de1d45cb9e13" xlink:href="ekso-20201231.xsd#ekso_PWBLoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6d510f8-3b69-46e6-9dc9-74de920cff1e" xlink:to="loc_ekso_PWBLoanAgreementMember_4c0fddba-e812-4482-8005-de1d45cb9e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_43d110e1-b588-4f95-b5ea-9e34a5dc16a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:to="loc_us-gaap_VariableRateAxis_43d110e1-b588-4f95-b5ea-9e34a5dc16a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e7110000-49a1-466a-b571-20b5cd63783c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_43d110e1-b588-4f95-b5ea-9e34a5dc16a5" xlink:to="loc_us-gaap_VariableRateDomain_e7110000-49a1-466a-b571-20b5cd63783c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_b9af1963-4ee7-49c1-91ac-ca630192d95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e7110000-49a1-466a-b571-20b5cd63783c" xlink:to="loc_us-gaap_PrimeRateMember_b9af1963-4ee7-49c1-91ac-ca630192d95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_29de0b48-ddec-4d95-a693-bdbf6c964afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_29de0b48-ddec-4d95-a693-bdbf6c964afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_071d0159-f494-4358-9701-100438f6a4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_29de0b48-ddec-4d95-a693-bdbf6c964afe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_071d0159-f494-4358-9701-100438f6a4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TermLoanMember_f69dcb19-c041-4090-a15f-490591b8a843" xlink:href="ekso-20201231.xsd#ekso_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_071d0159-f494-4358-9701-100438f6a4c2" xlink:to="loc_ekso_TermLoanMember_f69dcb19-c041-4090-a15f-490591b8a843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_83eb8699-fbf0-49ad-adf3-59ee56e31805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_071d0159-f494-4358-9701-100438f6a4c2" xlink:to="loc_us-gaap_UnsecuredDebtMember_83eb8699-fbf0-49ad-adf3-59ee56e31805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c543d7c2-0597-4614-a9b7-42f32acefe3b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_82e2b2e2-1887-42c3-8179-44d163aef45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_82e2b2e2-1887-42c3-8179-44d163aef45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8db1f55d-f72e-4fe3-9c28-a21ab0ac5b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8db1f55d-f72e-4fe3-9c28-a21ab0ac5b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DebtInstrumentDeferralPeriod_b66fc256-16b5-4f99-9ca0-1bbe1ebdd533" xlink:href="ekso-20201231.xsd#ekso_DebtInstrumentDeferralPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_ekso_DebtInstrumentDeferralPeriod_b66fc256-16b5-4f99-9ca0-1bbe1ebdd533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_c5a7e045-15b9-4676-bde9-c846d8b1c748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_c5a7e045-15b9-4676-bde9-c846d8b1c748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_94f5a341-0772-40e9-8820-e8585ecf26ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_94f5a341-0772-40e9-8820-e8585ecf26ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_9d9dda82-1b6c-40f4-a1b1-8d37fa7572b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_9d9dda82-1b6c-40f4-a1b1-8d37fa7572b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose_0849cc51-ecd9-41ca-811e-fa458e0486a4" xlink:href="ekso-20201231.xsd#ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose_0849cc51-ecd9-41ca-811e-fa458e0486a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ddde3004-b5a1-47f3-843f-bfc9a9cae3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_LongTermDebt_ddde3004-b5a1-47f3-843f-bfc9a9cae3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ee391fd-98cb-4464-9fe0-fc22aa7674f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ee391fd-98cb-4464-9fe0-fc22aa7674f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c009de02-18e7-4282-b356-700a519f76f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c009de02-18e7-4282-b356-700a519f76f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_392eb517-07ff-49f8-8540-32a8e205fcbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1596b34d-b6cc-406b-ad3e-fd75753f049a" xlink:to="loc_us-gaap_DebtInstrumentTerm_392eb517-07ff-49f8-8540-32a8e205fcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetDebtRepaymentDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f78958e8-1c27-4053-9034-3604f01fa6c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear_1ef3ab68-c0f5-4220-a1a7-cb64daeb258a" xlink:href="ekso-20201231.xsd#ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f78958e8-1c27-4053-9034-3604f01fa6c1" xlink:to="loc_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear_1ef3ab68-c0f5-4220-a1a7-cb64daeb258a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b9321d38-600f-44a0-b8af-31f24f93cf6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f78958e8-1c27-4053-9034-3604f01fa6c1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b9321d38-600f-44a0-b8af-31f24f93cf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e274babd-7090-474e-894a-f8454e639e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f78958e8-1c27-4053-9034-3604f01fa6c1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e274babd-7090-474e-894a-f8454e639e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0b4977e9-e28a-452c-beba-fc6248244cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f78958e8-1c27-4053-9034-3604f01fa6c1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0b4977e9-e28a-452c-beba-fc6248244cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7a51f6cd-2a00-42b8-b5f0-17070ee310bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f78958e8-1c27-4053-9034-3604f01fa6c1" xlink:to="loc_us-gaap_LongTermDebt_7a51f6cd-2a00-42b8-b5f0-17070ee310bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_85dc3748-b6e4-4ffa-8c15-1ccd67731de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f78958e8-1c27-4053-9034-3604f01fa6c1" xlink:to="loc_us-gaap_LongTermDebtCurrent_85dc3748-b6e4-4ffa-8c15-1ccd67731de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fe8705eb-3a8c-4d41-89ae-d308d4f7025f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f78958e8-1c27-4053-9034-3604f01fa6c1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fe8705eb-3a8c-4d41-89ae-d308d4f7025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_260c7404-c46c-4de0-814a-0ac776ba0170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails_1" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetDebtRepaymentDetails_1"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#NotespayablenetPrincipalRepaymentDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_06c9da88-38b5-4efd-a8b6-8f963b9392a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6ac40201-7523-4cac-9c26-892d0b45f35b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_06c9da88-38b5-4efd-a8b6-8f963b9392a2" xlink:to="loc_us-gaap_DebtInstrumentTable_6ac40201-7523-4cac-9c26-892d0b45f35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7c71f767-bd72-404d-b4b3-9bb1eeb9e211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ac40201-7523-4cac-9c26-892d0b45f35b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7c71f767-bd72-404d-b4b3-9bb1eeb9e211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_47176de6-664d-48a0-921c-907be707bb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7c71f767-bd72-404d-b4b3-9bb1eeb9e211" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_47176de6-664d-48a0-921c-907be707bb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_e735b961-79d0-4a3c-ad60-0e8a2fff728b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_47176de6-664d-48a0-921c-907be707bb6a" xlink:to="loc_us-gaap_UnsecuredDebtMember_e735b961-79d0-4a3c-ad60-0e8a2fff728b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ac40201-7523-4cac-9c26-892d0b45f35b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5d66dc72-8197-4207-b2c4-77abb32edacd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5d66dc72-8197-4207-b2c4-77abb32edacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_68fb3f6f-bde8-419a-9145-0e4c45a5f266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_68fb3f6f-bde8-419a-9145-0e4c45a5f266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ae85dda6-fbc0-4144-916c-6553a9e8d793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ae85dda6-fbc0-4144-916c-6553a9e8d793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0ae057b2-88ad-4b95-991a-2a64248d38af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_LongTermDebtCurrent_0ae057b2-88ad-4b95-991a-2a64248d38af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8cd0ac7b-5fcc-4738-a0d7-39a29298e902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8cd0ac7b-5fcc-4738-a0d7-39a29298e902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_04ee8724-7e5e-490f-a3d8-4be5be897f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c03135e-264f-4948-8def-5ce37b7a2ca6" xlink:to="loc_us-gaap_LongTermDebt_04ee8724-7e5e-490f-a3d8-4be5be897f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligations" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligations"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/LeaseObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_34365c75-746f-4750-865d-9e399fbfd602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_22bd555c-3561-4b28-80ab-37e3f8cb89fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_34365c75-746f-4750-865d-9e399fbfd602" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_22bd555c-3561-4b28-80ab-37e3f8cb89fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d3664015-de7a-467c-834c-dd094c245fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fb12861a-6c73-4eee-88e8-60fb279cff6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d3664015-de7a-467c-834c-dd094c245fb2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fb12861a-6c73-4eee-88e8-60fb279cff6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b64fbea5-5aff-4bcb-8887-151ed0bd6cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4d49fd4e-a3bf-4717-84bd-b0f6e2720ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b64fbea5-5aff-4bcb-8887-151ed0bd6cce" xlink:to="loc_us-gaap_DebtInstrumentTable_4d49fd4e-a3bf-4717-84bd-b0f6e2720ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_99a723fc-c675-4c4c-86e2-15f39dfb7847" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4d49fd4e-a3bf-4717-84bd-b0f6e2720ee5" xlink:to="loc_srt_StatementGeographicalAxis_99a723fc-c675-4c4c-86e2-15f39dfb7847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d4a80ce3-ab90-459b-be69-b0f961266718" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_99a723fc-c675-4c4c-86e2-15f39dfb7847" xlink:to="loc_srt_SegmentGeographicalDomain_d4a80ce3-ab90-459b-be69-b0f961266718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RichmondCaliforniaMember_bec908bb-2b18-492b-9c6d-a677397cc045" xlink:href="ekso-20201231.xsd#ekso_RichmondCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d4a80ce3-ab90-459b-be69-b0f961266718" xlink:to="loc_ekso_RichmondCaliforniaMember_bec908bb-2b18-492b-9c6d-a677397cc045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_HamburgGermanyMember_5084e6fa-4579-4d69-af63-e212742f3874" xlink:href="ekso-20201231.xsd#ekso_HamburgGermanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d4a80ce3-ab90-459b-be69-b0f961266718" xlink:to="loc_ekso_HamburgGermanyMember_5084e6fa-4579-4d69-af63-e212742f3874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4d49fd4e-a3bf-4717-84bd-b0f6e2720ee5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_eaca3759-95b6-487e-8afb-dc1daa6059a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_eaca3759-95b6-487e-8afb-dc1daa6059a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_431c8721-313f-461a-93d8-9d4f921a6f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_OperatingLeasePayments_431c8721-313f-461a-93d8-9d4f921a6f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_OperatingLeaseAbatement_1518c034-3722-479e-907e-a5a6c541b1ae" xlink:href="ekso-20201231.xsd#ekso_OperatingLeaseAbatement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_ekso_OperatingLeaseAbatement_1518c034-3722-479e-907e-a5a6c541b1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6edcd4a1-63e0-40bf-a219-7871baf9d729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_OperatingLeaseLiability_6edcd4a1-63e0-40bf-a219-7871baf9d729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_373cb5e5-e59a-4ab6-bda8-5e0a3d0b7172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_373cb5e5-e59a-4ab6-bda8-5e0a3d0b7172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_577a7697-bd99-4365-8eef-14f10e5c34ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccee0830-5b29-4735-a662-6097ea47fdea" xlink:to="loc_us-gaap_OperatingLeaseExpense_577a7697-bd99-4365-8eef-14f10e5c34ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3e1a11fe-a7f2-498b-9b23-523cca03fe37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3e1a11fe-a7f2-498b-9b23-523cca03fe37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1b17c6a2-4b63-4eb2-b4a5-72ac0673665f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1b17c6a2-4b63-4eb2-b4a5-72ac0673665f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c4d68d24-944f-4c5c-9c6d-2419554bcc68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c4d68d24-944f-4c5c-9c6d-2419554bcc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_28dc1c87-1d80-4784-bad5-8b2c33d6b6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_28dc1c87-1d80-4784-bad5-8b2c33d6b6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2eccf7fe-2e83-4e15-bc35-ddc35b8d77ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:to="loc_us-gaap_OperatingLeaseLiability_2eccf7fe-2e83-4e15-bc35-ddc35b8d77ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5cd5405f-4a49-441f-bb7c-05d490a2a889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5cd5405f-4a49-441f-bb7c-05d490a2a889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75779ac3-a09d-4946-85e3-ea6513c336b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75779ac3-a09d-4946-85e3-ea6513c336b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e2e392d4-449c-43e5-8d27-be9b558a1393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:to="loc_us-gaap_OperatingLeaseLiability_e2e392d4-449c-43e5-8d27-be9b558a1393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0c30f81e-1bc0-4a8d-87f0-2e416b925189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0c30f81e-1bc0-4a8d-87f0-2e416b925189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0f3a3c19-b79b-4dbd-be28-011c3a8796f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56139c50-8d02-4beb-858c-0cbd04d59fb5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0f3a3c19-b79b-4dbd-be28-011c3a8796f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails_1" xlink:type="simple" xlink:href="ekso-20201231.xsd#LeaseObligationsFutureMinimumPaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eksobionics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="ekso-20201231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7effc7d1-9943-48e0-8bb5-1556eb46df0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a9d1c6bb-6641-436b-b46c-a1dfbad365d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7effc7d1-9943-48e0-8bb5-1556eb46df0e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a9d1c6bb-6641-436b-b46c-a1dfbad365d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5e30f6ea-9e41-4b58-a80b-4c3613f24682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_a2be91bb-12cb-4f04-99db-1893177dc351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5e30f6ea-9e41-4b58-a80b-4c3613f24682" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_a2be91bb-12cb-4f04-99db-1893177dc351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_147f1414-8823-4607-9cd5-ee0f94574606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5e30f6ea-9e41-4b58-a80b-4c3613f24682" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_147f1414-8823-4607-9cd5-ee0f94574606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ekso-20201231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_56bec903-64ba-43a2-95d2-887c215ce546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_78a46367-796e-49bf-8f61-33b250067ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_56bec903-64ba-43a2-95d2-887c215ce546" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_78a46367-796e-49bf-8f61-33b250067ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5d67e6ad-9e6f-41cb-a0fa-fb5760705692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2cc2ad7e-9212-4f03-ad56-6506adcfce04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5d67e6ad-9e6f-41cb-a0fa-fb5760705692" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2cc2ad7e-9212-4f03-ad56-6506adcfce04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0d53b10d-d594-4d8e-9a72-61438e508ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2cc2ad7e-9212-4f03-ad56-6506adcfce04" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0d53b10d-d594-4d8e-9a72-61438e508ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fb68da45-f244-4180-90cc-ed1f355b4c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0d53b10d-d594-4d8e-9a72-61438e508ac8" xlink:to="loc_us-gaap_RelatedPartyDomain_fb68da45-f244-4180-90cc-ed1f355b4c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AngelPondCapitalLlcMember_82454696-f4ee-4672-ae88-aa1b90b4c09d" xlink:href="ekso-20201231.xsd#ekso_AngelPondCapitalLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_fb68da45-f244-4180-90cc-ed1f355b4c68" xlink:to="loc_ekso_AngelPondCapitalLlcMember_82454696-f4ee-4672-ae88-aa1b90b4c09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_357902c2-9f51-4447-95f1-e606c1722c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2cc2ad7e-9212-4f03-ad56-6506adcfce04" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_357902c2-9f51-4447-95f1-e606c1722c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RelatedPartyTransactionConsultingAgreement_b3ccd109-55a9-4aa3-a0ba-9fc52e7a0f5c" xlink:href="ekso-20201231.xsd#ekso_RelatedPartyTransactionConsultingAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_357902c2-9f51-4447-95f1-e606c1722c70" xlink:to="loc_ekso_RelatedPartyTransactionConsultingAgreement_b3ccd109-55a9-4aa3-a0ba-9fc52e7a0f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_8a82a797-6d87-48ed-a7ec-b797367e703e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_357902c2-9f51-4447-95f1-e606c1722c70" xlink:to="loc_us-gaap_PaymentsForFees_8a82a797-6d87-48ed-a7ec-b797367e703e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_538f5bbd-50aa-4745-8156-dc02b04e1fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_357902c2-9f51-4447-95f1-e606c1722c70" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_538f5bbd-50aa-4745-8156-dc02b04e1fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructure" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructure"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_ac718c32-9d9f-475a-95ed-80d96882c0a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizationLongtermDebtAndEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_adde97a2-0040-41ba-8e37-6085195d8149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_ac718c32-9d9f-475a-95ed-80d96882c0a9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_adde97a2-0040-41ba-8e37-6085195d8149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_fce0d073-462b-4a57-96f1-fa612ae91fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizationLongtermDebtAndEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ScheduleOfWarrantsOutstandingTableTextBlock_f0195d00-9545-405e-9ea1-b494dd322c03" xlink:href="ekso-20201231.xsd#ekso_ScheduleOfWarrantsOutstandingTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_fce0d073-462b-4a57-96f1-fa612ae91fe6" xlink:to="loc_ekso_ScheduleOfWarrantsOutstandingTableTextBlock_f0195d00-9545-405e-9ea1-b494dd322c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_00fcbb22-9ffa-4fd8-99a3-f9b614e329f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_fce0d073-462b-4a57-96f1-fa612ae91fe6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_00fcbb22-9ffa-4fd8-99a3-f9b614e329f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_f7127aaa-6c7d-4233-a521-66ab8cdb081a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizationLongtermDebtAndEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_f7127aaa-6c7d-4233-a521-66ab8cdb081a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_45d44e91-73bc-4b72-bc26-f2fb488387d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_45d44e91-73bc-4b72-bc26-f2fb488387d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ab8d661b-1c98-438d-905e-c3f0b860d40f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45d44e91-73bc-4b72-bc26-f2fb488387d9" xlink:to="loc_us-gaap_EquityComponentDomain_ab8d661b-1c98-438d-905e-c3f0b860d40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_18abe2ce-bd32-4fb7-bd6e-1dce62e4dca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ab8d661b-1c98-438d-905e-c3f0b860d40f" xlink:to="loc_us-gaap_CommonStockMember_18abe2ce-bd32-4fb7-bd6e-1dce62e4dca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_953f7c6b-4720-47f7-bad2-6ea37f170ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ab8d661b-1c98-438d-905e-c3f0b860d40f" xlink:to="loc_us-gaap_WarrantMember_953f7c6b-4720-47f7-bad2-6ea37f170ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c8003f76-ea11-4ca5-9214-91552d73009f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c8003f76-ea11-4ca5-9214-91552d73009f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b974f1a1-b693-4ef2-a1f2-3d87ce344ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c8003f76-ea11-4ca5-9214-91552d73009f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b974f1a1-b693-4ef2-a1f2-3d87ce344ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DirectOfferingMember_66959632-c2de-435b-8259-856be0db1574" xlink:href="ekso-20201231.xsd#ekso_DirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b974f1a1-b693-4ef2-a1f2-3d87ce344ecb" xlink:to="loc_ekso_DirectOfferingMember_66959632-c2de-435b-8259-856be0db1574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AtTheMarketOfferingMember_e97d0d5c-b3ce-4670-9f91-4cef7207238e" xlink:href="ekso-20201231.xsd#ekso_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b974f1a1-b693-4ef2-a1f2-3d87ce344ecb" xlink:to="loc_ekso_AtTheMarketOfferingMember_e97d0d5c-b3ce-4670-9f91-4cef7207238e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4162946b-f2e1-47a3-bfeb-2bc97f0d94a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4162946b-f2e1-47a3-bfeb-2bc97f0d94a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4162946b-f2e1-47a3-bfeb-2bc97f0d94a3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020WarrantsMember_dc2f8035-63e0-435c-839c-f37e0c7bbe2e" xlink:href="ekso-20201231.xsd#ekso_June2020WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_June2020WarrantsMember_dc2f8035-63e0-435c-839c-f37e0c7bbe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020InvestorWarrantsMember_45a85ded-ee00-4523-be26-912fe6569538" xlink:href="ekso-20201231.xsd#ekso_June2020InvestorWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_June2020WarrantsMember_dc2f8035-63e0-435c-839c-f37e0c7bbe2e" xlink:to="loc_ekso_June2020InvestorWarrantsMember_45a85ded-ee00-4523-be26-912fe6569538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020PlacementAgentWarrantsMember_57d67ad5-3469-4070-bc2a-c44030e4758a" xlink:href="ekso-20201231.xsd#ekso_June2020PlacementAgentWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_June2020WarrantsMember_dc2f8035-63e0-435c-839c-f37e0c7bbe2e" xlink:to="loc_ekso_June2020PlacementAgentWarrantsMember_57d67ad5-3469-4070-bc2a-c44030e4758a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_A2019WarrantsMember_c81f059b-5ef9-432a-bef0-e19e40e4658b" xlink:href="ekso-20201231.xsd#ekso_A2019WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_A2019WarrantsMember_c81f059b-5ef9-432a-bef0-e19e40e4658b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019PlacementAgentWarrantsMember_64059269-13ee-468e-8d43-426a8a052551" xlink:href="ekso-20201231.xsd#ekso_December2019PlacementAgentWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_December2019PlacementAgentWarrantsMember_64059269-13ee-468e-8d43-426a8a052551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_May2019WarrantsMember_611024a2-ca09-400a-a3cf-ecc3a41153eb" xlink:href="ekso-20201231.xsd#ekso_May2019WarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_May2019WarrantsMember_611024a2-ca09-400a-a3cf-ecc3a41153eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_InformationAgentWarrantsMember_7da7c35b-9e62-4959-ae6a-f61e5c50b9a4" xlink:href="ekso-20201231.xsd#ekso_InformationAgentWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_InformationAgentWarrantsMember_7da7c35b-9e62-4959-ae6a-f61e5c50b9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TwothousandFifteenWarrantsMember_5155e107-9d5f-476f-a07c-b774458af278" xlink:href="ekso-20201231.xsd#ekso_TwothousandFifteenWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bca1f06a-1d6c-4e5b-90d0-0a4fb163aeb4" xlink:to="loc_ekso_TwothousandFifteenWarrantsMember_5155e107-9d5f-476f-a07c-b774458af278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d21ef0b6-3913-48da-b86a-c6813775e115" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_srt_RangeAxis_d21ef0b6-3913-48da-b86a-c6813775e115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09e30bf1-9c65-43f7-8e46-3796a7556dfe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d21ef0b6-3913-48da-b86a-c6813775e115" xlink:to="loc_srt_RangeMember_09e30bf1-9c65-43f7-8e46-3796a7556dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_84b119ec-8e85-467c-a75a-17aebd429258" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_09e30bf1-9c65-43f7-8e46-3796a7556dfe" xlink:to="loc_srt_MinimumMember_84b119ec-8e85-467c-a75a-17aebd429258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_dc318f7f-02a8-4c03-aed1-967e5c64c4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_dc318f7f-02a8-4c03-aed1-967e5c64c4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4acd100d-cdd3-4927-95c9-e0b9ea427120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_dc318f7f-02a8-4c03-aed1-967e5c64c4c6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4acd100d-cdd3-4927-95c9-e0b9ea427120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputConversionPriceMember_a25d1ea7-67c5-4ef1-bc9f-006fae03c693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputConversionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4acd100d-cdd3-4927-95c9-e0b9ea427120" xlink:to="loc_us-gaap_MeasurementInputConversionPriceMember_a25d1ea7-67c5-4ef1-bc9f-006fae03c693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8fca8999-be1b-4808-b34e-15e774e51cde" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_03e1b65f-8436-4e43-8c7d-f9fb32314b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_03e1b65f-8436-4e43-8c7d-f9fb32314b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_NumberOfConsecutiveBusinessDays_42d328e5-e1a0-41ff-82e8-77f618d0bf17" xlink:href="ekso-20201231.xsd#ekso_NumberOfConsecutiveBusinessDays"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_NumberOfConsecutiveBusinessDays_42d328e5-e1a0-41ff-82e8-77f618d0bf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_02a057fa-44d0-4daf-8b60-88eca2bc6fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_02a057fa-44d0-4daf-8b60-88eca2bc6fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a27a21be-d78c-4c14-8dbb-22bfc27f0512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a27a21be-d78c-4c14-8dbb-22bfc27f0512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5712f66d-253d-4759-9f34-f4d654454fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_CommonStockSharesIssued_5712f66d-253d-4759-9f34-f4d654454fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6a55de91-af26-438b-b811-3c36add16a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6a55de91-af26-438b-b811-3c36add16a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a4d2a284-3c14-4a64-b547-d72ea57f6b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a4d2a284-3c14-4a64-b547-d72ea57f6b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ed33b179-4c42-4082-8299-752686df0110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ed33b179-4c42-4082-8299-752686df0110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79a0a492-1977-4598-a63c-ac7863dc6c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79a0a492-1977-4598-a63c-ac7863dc6c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2a3a098b-75e0-49e6-b101-6cc6999f5df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2a3a098b-75e0-49e6-b101-6cc6999f5df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants_767cfba3-8947-41ae-9aa8-fecd63a5316c" xlink:href="ekso-20201231.xsd#ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants_767cfba3-8947-41ae-9aa8-fecd63a5316c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_03bf9a70-80ca-4262-81d4-bd659bd4ae9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_03bf9a70-80ca-4262-81d4-bd659bd4ae9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightCashFeePercentage_6d8ccd2b-1eb4-4b98-8f27-33f28779e0d1" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightCashFeePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightCashFeePercentage_6d8ccd2b-1eb4-4b98-8f27-33f28779e0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightCashFee_6d0e8706-595d-4da0-9271-f9a445dc549d" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightCashFee"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightCashFee_6d0e8706-595d-4da0-9271-f9a445dc549d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightManagementFeePercentage_c19a181e-0272-4d33-8891-f6a7ffa02d17" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightManagementFeePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightManagementFeePercentage_c19a181e-0272-4d33-8891-f6a7ffa02d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightManagementFeeExpense_6eb9020c-6f20-4ac1-ac0d-f015529602af" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightManagementFeeExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightManagementFeeExpense_6eb9020c-6f20-4ac1-ac0d-f015529602af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock_d2f76d39-b938-4604-93be-16c79425b00a" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock_d2f76d39-b938-4604-93be-16c79425b00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightIssued_1339d36b-a428-4e48-80b7-35c595734a5e" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightIssued_1339d36b-a428-4e48-80b7-35c595734a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExpirationPeriod_30a765c6-ca70-46c2-a87f-a768f30f694a" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightExpirationPeriod_30a765c6-ca70-46c2-a87f-a768f30f694a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockConversionPrice_01e8d11a-e1f2-4d0f-83b7-73f751cc3114" xlink:href="ekso-20201231.xsd#ekso_StockConversionPrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_StockConversionPrice_01e8d11a-e1f2-4d0f-83b7-73f751cc3114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_37c4c7f1-df4b-43c0-afc4-df74a723d410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_37c4c7f1-df4b-43c0-afc4-df74a723d410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_WarrantIssuanceExpense_01f32295-0c28-49fa-819b-31c0d12074fa" xlink:href="ekso-20201231.xsd#ekso_WarrantIssuanceExpense"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_WarrantIssuanceExpense_01f32295-0c28-49fa-819b-31c0d12074fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_663badb6-685c-4e84-87a3-b514d6eec334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_663badb6-685c-4e84-87a3-b514d6eec334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_60bdfd65-8fb3-4349-b58f-cd923d55c740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_60bdfd65-8fb3-4349-b58f-cd923d55c740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f8b1d031-e695-48c1-82e2-f5d4e088dbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f8b1d031-e695-48c1-82e2-f5d4e088dbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightDurationOfPutOption_f2afac60-8d89-4109-9336-066b7af6ed1d" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightDurationOfPutOption"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightDurationOfPutOption_f2afac60-8d89-4109-9336-066b7af6ed1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod_0248d723-b77e-4ba5-a627-0d1c614a9e16" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod_0248d723-b77e-4ba5-a627-0d1c614a9e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExercised_5f04a6d2-fce4-421c-8432-514a306835ee" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExercised"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_ClassOfWarrantOrRightExercised_5f04a6d2-fce4-421c-8432-514a306835ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GainLossOnWarrantModification_14206753-0892-4c49-821e-9c3ce59116f5" xlink:href="ekso-20201231.xsd#ekso_GainLossOnWarrantModification"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_ekso_GainLossOnWarrantModification_14206753-0892-4c49-821e-9c3ce59116f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_13d42b54-5bdc-4097-864d-43b7592753df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d0a954a8-7a32-4b48-ab7e-e7382c73accd" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_13d42b54-5bdc-4097-864d-43b7592753df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_abace623-cce5-4d3c-af1d-33ae36ebf1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizationLongtermDebtAndEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_857ca993-9ebd-4969-9f2e-6b87fc793fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_abace623-cce5-4d3c-af1d-33ae36ebf1a6" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_857ca993-9ebd-4969-9f2e-6b87fc793fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5d1adf17-6b12-47bf-8271-a66e6b456a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_857ca993-9ebd-4969-9f2e-6b87fc793fa2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5d1adf17-6b12-47bf-8271-a66e6b456a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5d1adf17-6b12-47bf-8271-a66e6b456a98" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyInvestorWarrantsMember_0e2b09a3-86af-4be4-b611-a422a17d655b" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyInvestorWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_JuneTwentyTwentyInvestorWarrantsMember_0e2b09a3-86af-4be4-b611-a422a17d655b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember_e8613266-f1c4-4016-ac95-f9cd166af99e" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember_e8613266-f1c4-4016-ac95-f9cd166af99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019WarrantsMember_ff9e6453-17a2-45cd-8346-d7730a748149" xlink:href="ekso-20201231.xsd#ekso_December2019WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_December2019WarrantsMember_ff9e6453-17a2-45cd-8346-d7730a748149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019PlacementAgentWarrantsMember_57680f9e-8382-42bf-8599-68e8839695c3" xlink:href="ekso-20201231.xsd#ekso_December2019PlacementAgentWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_December2019PlacementAgentWarrantsMember_57680f9e-8382-42bf-8599-68e8839695c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_May2019WarrantsMember_4ffb4008-b91a-43c8-900f-379af2c391a0" xlink:href="ekso-20201231.xsd#ekso_May2019WarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_May2019WarrantsMember_4ffb4008-b91a-43c8-900f-379af2c391a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_A2017InformationAgentWarrantsMember_9846ce9d-aa3b-464a-afd4-6bbcd44652c2" xlink:href="ekso-20201231.xsd#ekso_A2017InformationAgentWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_A2017InformationAgentWarrantsMember_9846ce9d-aa3b-464a-afd4-6bbcd44652c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2015WarrantsMember_796bc6d6-f723-4044-b26c-4ba8e8cb42fb" xlink:href="ekso-20201231.xsd#ekso_December2015WarrantsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_December2015WarrantsMember_796bc6d6-f723-4044-b26c-4ba8e8cb42fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_Pre2014WarrantsMember_18156b8f-3c48-4c36-8519-9287279cac94" xlink:href="ekso-20201231.xsd#ekso_Pre2014WarrantsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3221d489-5492-4c55-b01b-1cfdb691ad05" xlink:to="loc_ekso_Pre2014WarrantsMember_18156b8f-3c48-4c36-8519-9287279cac94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0cc32906-4168-4138-bf55-e6537e9bbb9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_857ca993-9ebd-4969-9f2e-6b87fc793fa2" xlink:to="loc_srt_RangeAxis_0cc32906-4168-4138-bf55-e6537e9bbb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df2ff5ec-f79c-4be6-81ee-0283bbe1f1cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0cc32906-4168-4138-bf55-e6537e9bbb9a" xlink:to="loc_srt_RangeMember_df2ff5ec-f79c-4be6-81ee-0283bbe1f1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_34b0443c-8eae-47ef-bff8-8ff0897f45f6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_df2ff5ec-f79c-4be6-81ee-0283bbe1f1cd" xlink:to="loc_srt_MinimumMember_34b0443c-8eae-47ef-bff8-8ff0897f45f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_52a3528a-99a4-40da-bc6e-2619fc995c90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_df2ff5ec-f79c-4be6-81ee-0283bbe1f1cd" xlink:to="loc_srt_MaximumMember_52a3528a-99a4-40da-bc6e-2619fc995c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_677abfd8-5c15-459c-ab80-59cc66d5f4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_857ca993-9ebd-4969-9f2e-6b87fc793fa2" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_677abfd8-5c15-459c-ab80-59cc66d5f4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0fd03a5b-6438-495b-bec1-0633125464f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_677abfd8-5c15-459c-ab80-59cc66d5f4bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0fd03a5b-6438-495b-bec1-0633125464f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExpirationPeriod_20f3d96f-1ff2-4ec9-be12-e0abd4ae5b8c" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_677abfd8-5c15-459c-ab80-59cc66d5f4bb" xlink:to="loc_ekso_ClassOfWarrantOrRightExpirationPeriod_20f3d96f-1ff2-4ec9-be12-e0abd4ae5b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_677abfd8-5c15-459c-ab80-59cc66d5f4bb" xlink:to="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7c65373b-a69c-44d1-b8d5-b6a6da5c7349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7c65373b-a69c-44d1-b8d5-b6a6da5c7349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightIssued_9ea16fde-377b-4654-9315-dba5064b9a7a" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:to="loc_ekso_ClassOfWarrantOrRightIssued_9ea16fde-377b-4654-9315-dba5064b9a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExpired_866dbdfc-d615-4bda-a589-4859395994d8" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExpired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:to="loc_ekso_ClassOfWarrantOrRightExpired_866dbdfc-d615-4bda-a589-4859395994d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExercised_c2b54909-9090-4763-a799-04f5f0080fe3" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:to="loc_ekso_ClassOfWarrantOrRightExercised_c2b54909-9090-4763-a799-04f5f0080fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6280a423-d6c2-44a6-886d-e392823d7692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ekso_ClassOfWarrantOrRightOutstandingRollForward_c91bf012-ae4c-40fb-95b2-5910ce3e0a41" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6280a423-d6c2-44a6-886d-e392823d7692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_4666a44c-e5e4-4465-9aa8-2604aaba92a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizationLongtermDebtAndEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_17530f2e-2ee0-4d97-ad96-022ba52a7b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizationLongtermDebtAndEquityAbstract_4666a44c-e5e4-4465-9aa8-2604aaba92a6" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_17530f2e-2ee0-4d97-ad96-022ba52a7b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_50cdc6f6-d05d-4553-9c42-7c183d10262c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_17530f2e-2ee0-4d97-ad96-022ba52a7b00" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_50cdc6f6-d05d-4553-9c42-7c183d10262c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_50cdc6f6-d05d-4553-9c42-7c183d10262c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_0159e9ab-0c4b-431c-8f14-5eaffe3be670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_0159e9ab-0c4b-431c-8f14-5eaffe3be670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputConversionPriceMember_59c5c48e-5b73-4970-8370-9d404a922e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputConversionPriceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:to="loc_us-gaap_MeasurementInputConversionPriceMember_59c5c48e-5b73-4970-8370-9d404a922e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f9d6fba4-2422-4670-8c52-20986fad6cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f9d6fba4-2422-4670-8c52-20986fad6cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_eb093396-fa99-417e-8dd8-0cadbd0c4942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_eb093396-fa99-417e-8dd8-0cadbd0c4942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_6f99d060-37a0-4a48-b9af-62ce8d2ecc40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4999ce53-ff68-4ae9-9e9e-00d891bcd3b8" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_6f99d060-37a0-4a48-b9af-62ce8d2ecc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_09535eb7-a92b-4697-a9e9-50c11e4a40a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_17530f2e-2ee0-4d97-ad96-022ba52a7b00" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_09535eb7-a92b-4697-a9e9-50c11e4a40a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_09535eb7-a92b-4697-a9e9-50c11e4a40a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyInvestorWarrantsMember_5468bd02-e3fa-4057-b3c0-4f45789a61d4" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyInvestorWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:to="loc_ekso_JuneTwentyTwentyInvestorWarrantsMember_5468bd02-e3fa-4057-b3c0-4f45789a61d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember_83637074-dd50-4bbc-bf68-f76c6b1dfdd6" xlink:href="ekso-20201231.xsd#ekso_JuneTwentyTwentyPlacementAgentWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:to="loc_ekso_JuneTwentyTwentyPlacementAgentWarrantsMember_83637074-dd50-4bbc-bf68-f76c6b1dfdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019WarrantsMember_a09d7bfc-93f6-4182-9eca-17346f205c93" xlink:href="ekso-20201231.xsd#ekso_December2019WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:to="loc_ekso_December2019WarrantsMember_a09d7bfc-93f6-4182-9eca-17346f205c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_December2019PlacementAgentWarrantsMember_38ac5aea-6f0d-4951-b575-e7a8f9099e21" xlink:href="ekso-20201231.xsd#ekso_December2019PlacementAgentWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:to="loc_ekso_December2019PlacementAgentWarrantsMember_38ac5aea-6f0d-4951-b575-e7a8f9099e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_May2019WarrantsMember_66f7b282-d7d3-4b39-8c1e-f2df90cbc7bb" xlink:href="ekso-20201231.xsd#ekso_May2019WarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4f9ec4e-c7e6-4832-bd2e-5134c701bbfc" xlink:to="loc_ekso_May2019WarrantsMember_66f7b282-d7d3-4b39-8c1e-f2df90cbc7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_17530f2e-2ee0-4d97-ad96-022ba52a7b00" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3fa2d68f-1f44-4bf3-ae00-1aa0cc6bb182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:to="loc_us-gaap_SharePrice_3fa2d68f-1f44-4bf3-ae00-1aa0cc6bb182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_StockConversionPrice_87945eb0-c99c-42bd-abf6-d0a0742aa447" xlink:href="ekso-20201231.xsd#ekso_StockConversionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:to="loc_ekso_StockConversionPrice_87945eb0-c99c-42bd-abf6-d0a0742aa447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_8bf260ed-e453-4222-afa8-78bed9527686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_8bf260ed-e453-4222-afa8-78bed9527686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_08a20a6f-bc03-45a2-a730-ef0381bae7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_37b75bc6-1bcd-420c-b1a8-06e282cac06b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_08a20a6f-bc03-45a2-a730-ef0381bae7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95e89b59-7ee4-4252-9e03-ca7ecf751350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9dcf9678-b60c-4788-885c-8aaf169ac287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95e89b59-7ee4-4252-9e03-ca7ecf751350" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9dcf9678-b60c-4788-885c-8aaf169ac287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc4f752-67ba-495c-9d4b-90f5aae174fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9ab1279f-f396-4a9d-b469-5eff7b89e23d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc4f752-67ba-495c-9d4b-90f5aae174fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9ab1279f-f396-4a9d-b469-5eff7b89e23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_53eeb276-ba3f-49dd-a0f8-089a5dea9def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc4f752-67ba-495c-9d4b-90f5aae174fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_53eeb276-ba3f-49dd-a0f8-089a5dea9def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_59429caf-d375-4215-992f-52b56c68aa5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc4f752-67ba-495c-9d4b-90f5aae174fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_59429caf-d375-4215-992f-52b56c68aa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_00e5ab79-0aa8-484c-b189-a760a5dc3581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc4f752-67ba-495c-9d4b-90f5aae174fb" xlink:to="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_00e5ab79-0aa8-484c-b189-a760a5dc3581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6c05d2ec-6476-4929-b1dd-1d11850ba35b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc4f752-67ba-495c-9d4b-90f5aae174fb" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6c05d2ec-6476-4929-b1dd-1d11850ba35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensation2014EquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9620447c-41bd-4ef1-afe9-de50ce28da2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_025bfbdc-fa52-4684-a006-8135a8056cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9620447c-41bd-4ef1-afe9-de50ce28da2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_025bfbdc-fa52-4684-a006-8135a8056cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e7194151-7a90-4336-97e1-5e0b194fe35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_025bfbdc-fa52-4684-a006-8135a8056cef" xlink:to="loc_us-gaap_PlanNameAxis_e7194151-7a90-4336-97e1-5e0b194fe35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c66f9bab-cf48-40c8-ac65-1d52a904c955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e7194151-7a90-4336-97e1-5e0b194fe35e" xlink:to="loc_us-gaap_PlanNameDomain_c66f9bab-cf48-40c8-ac65-1d52a904c955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member_3829a1d1-2ad0-4b97-880b-01f8a31c3bcd" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c66f9bab-cf48-40c8-ac65-1d52a904c955" xlink:to="loc_ekso_EquityIncentivePlan2014Member_3829a1d1-2ad0-4b97-880b-01f8a31c3bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3177d738-23e3-4148-bf34-dd105e4416db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_025bfbdc-fa52-4684-a006-8135a8056cef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3177d738-23e3-4148-bf34-dd105e4416db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc3c08b0-d310-4089-995c-ba9ddbe5ce9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3177d738-23e3-4148-bf34-dd105e4416db" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc3c08b0-d310-4089-995c-ba9ddbe5ce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6f7bf761-b2c2-44e4-a4b7-9cc48223e05f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3177d738-23e3-4148-bf34-dd105e4416db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6f7bf761-b2c2-44e4-a4b7-9cc48223e05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e0df2de2-4fba-4310-8a6d-39482c316aff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3177d738-23e3-4148-bf34-dd105e4416db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e0df2de2-4fba-4310-8a6d-39482c316aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac12cd6d-1024-46c6-b02e-457f1ef57de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fb555d2-9783-4d80-82e4-0339ab5559ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac12cd6d-1024-46c6-b02e-457f1ef57de6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fb555d2-9783-4d80-82e4-0339ab5559ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_af5079ee-4e57-45b5-96eb-20d2944546d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fb555d2-9783-4d80-82e4-0339ab5559ae" xlink:to="loc_us-gaap_PlanNameAxis_af5079ee-4e57-45b5-96eb-20d2944546d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_df530f62-2354-40e0-9d78-7e9bd85735af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_af5079ee-4e57-45b5-96eb-20d2944546d4" xlink:to="loc_us-gaap_PlanNameDomain_df530f62-2354-40e0-9d78-7e9bd85735af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member_5f27bf4f-9255-4404-ac80-02a1bb4fb14d" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_df530f62-2354-40e0-9d78-7e9bd85735af" xlink:to="loc_ekso_EquityIncentivePlan2014Member_5f27bf4f-9255-4404-ac80-02a1bb4fb14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba9fec73-3e28-4c67-bfe2-87f007b43906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fb555d2-9783-4d80-82e4-0339ab5559ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba9fec73-3e28-4c67-bfe2-87f007b43906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a6dce4e7-0ee1-4841-ac53-521c5573c4de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba9fec73-3e28-4c67-bfe2-87f007b43906" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a6dce4e7-0ee1-4841-ac53-521c5573c4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3be2645e-1bdb-477e-8403-355c60991688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba9fec73-3e28-4c67-bfe2-87f007b43906" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3be2645e-1bdb-477e-8403-355c60991688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9b3efff5-fe28-407d-9aea-6468f4fafba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba9fec73-3e28-4c67-bfe2-87f007b43906" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9b3efff5-fe28-407d-9aea-6468f4fafba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccc48b9e-7d3c-4604-8421-8f08758f7773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8cdea8c4-075a-4851-9c7c-74fe6803f09e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccc48b9e-7d3c-4604-8421-8f08758f7773" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8cdea8c4-075a-4851-9c7c-74fe6803f09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_49eb6a0a-ad67-4df6-92e4-1cbd64a8f6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8cdea8c4-075a-4851-9c7c-74fe6803f09e" xlink:to="loc_us-gaap_PlanNameAxis_49eb6a0a-ad67-4df6-92e4-1cbd64a8f6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7b92c0e2-72f5-45d0-98ae-3eb51125ca38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_49eb6a0a-ad67-4df6-92e4-1cbd64a8f6e4" xlink:to="loc_us-gaap_PlanNameDomain_7b92c0e2-72f5-45d0-98ae-3eb51125ca38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member_bad0a9ee-bc7a-4bc4-b961-1a2f15224458" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7b92c0e2-72f5-45d0-98ae-3eb51125ca38" xlink:to="loc_ekso_EquityIncentivePlan2014Member_bad0a9ee-bc7a-4bc4-b961-1a2f15224458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1fd3079-64b5-4864-9455-ebabf9f39696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8cdea8c4-075a-4851-9c7c-74fe6803f09e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1fd3079-64b5-4864-9455-ebabf9f39696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1fd3079-64b5-4864-9455-ebabf9f39696" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_85a610ae-d699-4114-a502-1c41a8dfc02d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_85a610ae-d699-4114-a502-1c41a8dfc02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_668b1324-1ed2-49fb-92b8-354f90265c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_668b1324-1ed2-49fb-92b8-354f90265c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2fe2a737-bd85-4c0d-a8f7-c810e2574c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2fe2a737-bd85-4c0d-a8f7-c810e2574c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_49c7a912-bedd-48b5-a2b8-d7776afefc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_49c7a912-bedd-48b5-a2b8-d7776afefc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2f8332c2-a981-4b6e-bd6f-405a27e1e85f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2f8332c2-a981-4b6e-bd6f-405a27e1e85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5094654-9d3d-46b7-8a6e-34f9fedba067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f1832734-11d1-42fc-bdc2-f49b4b230270" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5094654-9d3d-46b7-8a6e-34f9fedba067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationStockOptionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9c6ff77-87a9-420d-ba13-e47c92a2fb82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a179b68f-2e53-4eb2-846a-87d0dfd53fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9c6ff77-87a9-420d-ba13-e47c92a2fb82" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a179b68f-2e53-4eb2-846a-87d0dfd53fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1a38be85-5a7e-4416-8e9b-b1219cc4ed17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a179b68f-2e53-4eb2-846a-87d0dfd53fce" xlink:to="loc_us-gaap_PlanNameAxis_1a38be85-5a7e-4416-8e9b-b1219cc4ed17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a5763ed9-43f3-48d6-a0a2-ad7b77c212a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1a38be85-5a7e-4416-8e9b-b1219cc4ed17" xlink:to="loc_us-gaap_PlanNameDomain_a5763ed9-43f3-48d6-a0a2-ad7b77c212a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member_3c72bc8e-b9d8-4ad2-b2e7-1ea9f7d08b0b" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a5763ed9-43f3-48d6-a0a2-ad7b77c212a3" xlink:to="loc_ekso_EquityIncentivePlan2014Member_3c72bc8e-b9d8-4ad2-b2e7-1ea9f7d08b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76149361-06e8-42bb-96e2-7ac14bc41d32" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a179b68f-2e53-4eb2-846a-87d0dfd53fce" xlink:to="loc_srt_RangeAxis_76149361-06e8-42bb-96e2-7ac14bc41d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b9aedb5-56ab-4687-ab60-9ad2dc811ef7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_76149361-06e8-42bb-96e2-7ac14bc41d32" xlink:to="loc_srt_RangeMember_0b9aedb5-56ab-4687-ab60-9ad2dc811ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_48987d4c-f781-4dec-acec-e53727f7124c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b9aedb5-56ab-4687-ab60-9ad2dc811ef7" xlink:to="loc_srt_MinimumMember_48987d4c-f781-4dec-acec-e53727f7124c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f5bbf0f9-f0c5-4fc5-952e-7ce2dc058ad9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b9aedb5-56ab-4687-ab60-9ad2dc811ef7" xlink:to="loc_srt_MaximumMember_f5bbf0f9-f0c5-4fc5-952e-7ce2dc058ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc21c5b-5984-479a-b06a-cd9825fec54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a179b68f-2e53-4eb2-846a-87d0dfd53fce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc21c5b-5984-479a-b06a-cd9825fec54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4b8f1ebb-3427-4801-b50d-ab45313c4181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc21c5b-5984-479a-b06a-cd9825fec54b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4b8f1ebb-3427-4801-b50d-ab45313c4181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_806e6053-9ce5-4ba0-b63b-54976f98d731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc21c5b-5984-479a-b06a-cd9825fec54b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_806e6053-9ce5-4ba0-b63b-54976f98d731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e67e32a-8196-4c4b-be8f-e69b7a109d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6d2fad2-9e23-4f19-8648-5e764d62b1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e67e32a-8196-4c4b-be8f-e69b7a109d33" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6d2fad2-9e23-4f19-8648-5e764d62b1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0b9cb71d-788a-4cd1-b930-a351a5057b87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6d2fad2-9e23-4f19-8648-5e764d62b1f4" xlink:to="loc_us-gaap_AwardTypeAxis_0b9cb71d-788a-4cd1-b930-a351a5057b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c020eed-44b5-496b-8df5-d5103aa4e9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0b9cb71d-788a-4cd1-b930-a351a5057b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c020eed-44b5-496b-8df5-d5103aa4e9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EquityIncentivePlan2014Member_960f835b-1805-4240-b6ce-2595add8b2df" xlink:href="ekso-20201231.xsd#ekso_EquityIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c020eed-44b5-496b-8df5-d5103aa4e9aa" xlink:to="loc_ekso_EquityIncentivePlan2014Member_960f835b-1805-4240-b6ce-2595add8b2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6d2fad2-9e23-4f19-8648-5e764d62b1f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8286a2b9-54ba-4357-bf8f-d56e4d2c0a67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8286a2b9-54ba-4357-bf8f-d56e4d2c0a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e260bf4d-af38-4d87-a32c-58aa374de964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e260bf4d-af38-4d87-a32c-58aa374de964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_acf9f626-5e1d-47bd-9a2c-5a7032de9fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_acf9f626-5e1d-47bd-9a2c-5a7032de9fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_df38abba-e8c8-43c0-9a1c-15d0b788017a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_df38abba-e8c8-43c0-9a1c-15d0b788017a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c979d622-6a53-4058-8ed3-85361b79ed8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c979d622-6a53-4058-8ed3-85361b79ed8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_df6879e6-21a8-484d-b875-e92efdbfdd25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cdefae7-4d1b-4cc1-9eb9-1d961b8e7200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_df6879e6-21a8-484d-b875-e92efdbfdd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_03de9ade-a14a-4345-8cc0-0e8b8dea5926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_03de9ade-a14a-4345-8cc0-0e8b8dea5926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_24d86156-f250-43b5-8f72-e9c190538738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_24d86156-f250-43b5-8f72-e9c190538738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3d4bfe83-e3ea-4eed-800d-94949cea98f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3d4bfe83-e3ea-4eed-800d-94949cea98f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5bcf4aad-5c0f-461b-9129-11aa6b1a0c60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5bcf4aad-5c0f-461b-9129-11aa6b1a0c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4fdb096d-a77b-4fdb-843e-a4019524e922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4fdb096d-a77b-4fdb-843e-a4019524e922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3e6ee85a-33a0-4847-99a6-cb65e975020c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3e6ee85a-33a0-4847-99a6-cb65e975020c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef2848bb-5738-48ad-881e-f73a15945f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef2848bb-5738-48ad-881e-f73a15945f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d455f641-d133-4302-98d7-175744d2d5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de06d71f-a7bd-49ad-a0e0-2bb84e5cb39c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d455f641-d133-4302-98d7-175744d2d5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cdaa19ef-f7d4-49ca-95aa-129287e4f53b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cdaa19ef-f7d4-49ca-95aa-129287e4f53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9477be1d-30d1-4462-a77a-27a55d2793b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9477be1d-30d1-4462-a77a-27a55d2793b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17bac7c7-6741-4635-805b-600c7772d813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17bac7c7-6741-4635-805b-600c7772d813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_68500da2-5567-4c5a-be18-0e3bf2fd1607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_68500da2-5567-4c5a-be18-0e3bf2fd1607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b32fd047-bb9b-43e5-a278-7aee48f14d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b32fd047-bb9b-43e5-a278-7aee48f14d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b438b262-4672-4c02-916a-3aeaa7a80528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b438b262-4672-4c02-916a-3aeaa7a80528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_248bc19f-cef5-4d94-a1ea-248088a1610f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_248bc19f-cef5-4d94-a1ea-248088a1610f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_09aa3df4-ac6c-418f-ab0d-8fd222685b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694b6eca-a0cb-47f8-b3d9-3a30b8156010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_09aa3df4-ac6c-418f-ab0d-8fd222685b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationExercisedOptionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9926462-ed2a-491c-986e-183473a84555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d934af1f-14ae-4ad1-9672-8d68946b04c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9926462-ed2a-491c-986e-183473a84555" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d934af1f-14ae-4ad1-9672-8d68946b04c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4d19cb28-814b-4e85-943e-b0f3085259a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d934af1f-14ae-4ad1-9672-8d68946b04c3" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4d19cb28-814b-4e85-943e-b0f3085259a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4117746c-d37d-4c99-8b5b-ab08c8e63839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4d19cb28-814b-4e85-943e-b0f3085259a4" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4117746c-d37d-4c99-8b5b-ab08c8e63839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_46ea06e2-b2bb-4b4c-9b57-f11a50f18a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4117746c-d37d-4c99-8b5b-ab08c8e63839" xlink:to="loc_us-gaap_EmployeeStockOptionMember_46ea06e2-b2bb-4b4c-9b57-f11a50f18a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d934af1f-14ae-4ad1-9672-8d68946b04c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8804d289-3de8-4d1e-9b9e-020e961cc48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8804d289-3de8-4d1e-9b9e-020e961cc48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1211d9ed-f829-41e5-92df-7bf63a018ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1211d9ed-f829-41e5-92df-7bf63a018ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e10e91d6-f2a2-432b-a39f-0110bafc34ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e10e91d6-f2a2-432b-a39f-0110bafc34ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_34ef34a7-f0fc-4c8a-bb9e-22e0fde82507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_34ef34a7-f0fc-4c8a-bb9e-22e0fde82507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d2529dad-2352-425b-aa8d-ccf0b6cba7d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d2529dad-2352-425b-aa8d-ccf0b6cba7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cba25abd-5c2f-4045-8300-98d585a7c384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87817f5d-5d2e-4637-b765-058264d5f615" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cba25abd-5c2f-4045-8300-98d585a7c384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofStockOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8842e027-8e8e-40dc-885f-32307a2e0b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ceccacff-ff0f-4fa5-89e6-ba5db4e4c526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8842e027-8e8e-40dc-885f-32307a2e0b3e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ceccacff-ff0f-4fa5-89e6-ba5db4e4c526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e9c4504f-d7a8-444a-b5d7-2b6426c29df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ceccacff-ff0f-4fa5-89e6-ba5db4e4c526" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e9c4504f-d7a8-444a-b5d7-2b6426c29df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e9c4504f-d7a8-444a-b5d7-2b6426c29df9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeOneMember_6822b112-1d5e-4173-b530-3d9f5956e768" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:to="loc_ekso_ExercisePriceRangeOneMember_6822b112-1d5e-4173-b530-3d9f5956e768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeTwoMember_9ab6ffbb-dad5-4756-9a3c-dad920d080bb" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:to="loc_ekso_ExercisePriceRangeTwoMember_9ab6ffbb-dad5-4756-9a3c-dad920d080bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeThreeMember_38e439b1-a766-4a03-9a58-ae0002901e0b" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:to="loc_ekso_ExercisePriceRangeThreeMember_38e439b1-a766-4a03-9a58-ae0002901e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ExercisePriceRangeFourMember_93588acb-74a0-4884-8f53-3dac1a763530" xlink:href="ekso-20201231.xsd#ekso_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_31e1768f-1baf-4f07-9ffc-0295ecac77ea" xlink:to="loc_ekso_ExercisePriceRangeFourMember_93588acb-74a0-4884-8f53-3dac1a763530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ceccacff-ff0f-4fa5-89e6-ba5db4e4c526" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_5c364c09-dae9-4faa-ba8d-baecfe018654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_5c364c09-dae9-4faa-ba8d-baecfe018654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4cdb8b96-2ab7-420c-a2d8-f7bcde6ec850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4cdb8b96-2ab7-420c-a2d8-f7bcde6ec850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f09dcc5f-430f-4924-bed0-253fc79ec5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f09dcc5f-430f-4924-bed0-253fc79ec5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_557be4c1-6044-4297-a8ec-760e14895144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_557be4c1-6044-4297-a8ec-760e14895144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_04cd3a02-e972-481b-b4d2-8db1566ce18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_04cd3a02-e972-481b-b4d2-8db1566ce18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_3f43926c-3c68-4b48-a740-0aadd6057c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_3f43926c-3c68-4b48-a740-0aadd6057c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8443ba22-57a1-497d-bb63-cac982db65a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcd3dc95-be7d-469c-863b-2abb9f01ca8f" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8443ba22-57a1-497d-bb63-cac982db65a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e9d4fec3-f5ac-4ac3-b799-eacfc032cfcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8af35f18-5e17-44c4-8b5d-b807dfe52e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e9d4fec3-f5ac-4ac3-b799-eacfc032cfcb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8af35f18-5e17-44c4-8b5d-b807dfe52e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_443519e6-4636-4123-988b-3d7d6bf5c0a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8af35f18-5e17-44c4-8b5d-b807dfe52e2c" xlink:to="loc_srt_RangeAxis_443519e6-4636-4123-988b-3d7d6bf5c0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4149986a-5fc9-4094-8e3e-5a65ef8dbd2e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_443519e6-4636-4123-988b-3d7d6bf5c0a9" xlink:to="loc_srt_RangeMember_4149986a-5fc9-4094-8e3e-5a65ef8dbd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2f8384cf-e07d-44ec-947e-f94a75b783c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4149986a-5fc9-4094-8e3e-5a65ef8dbd2e" xlink:to="loc_srt_MinimumMember_2f8384cf-e07d-44ec-947e-f94a75b783c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4b562aca-0dd7-4e45-a75f-30a86c9058fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4149986a-5fc9-4094-8e3e-5a65ef8dbd2e" xlink:to="loc_srt_MaximumMember_4b562aca-0dd7-4e45-a75f-30a86c9058fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8af35f18-5e17-44c4-8b5d-b807dfe52e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0218498f-1ff0-4ac4-9374-566367c7c431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0218498f-1ff0-4ac4-9374-566367c7c431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_393bcf85-b09e-4ff3-bd27-679c0db4e46d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_393bcf85-b09e-4ff3-bd27-679c0db4e46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b6fd85bd-bc15-47ad-aa63-1a96b9f1c51e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b6fd85bd-bc15-47ad-aa63-1a96b9f1c51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2f9169e-da2d-41f6-ae0a-745840c08766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2f9169e-da2d-41f6-ae0a-745840c08766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_231613ee-4e81-4178-ac46-d1e74d21ab0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_231613ee-4e81-4178-ac46-d1e74d21ab0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_658c2609-df03-40b2-aeb7-da0c96b3fdf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcf7e03-83d4-4ed4-8c24-38b1de15caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_658c2609-df03-40b2-aeb7-da0c96b3fdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_037a0044-5d31-4409-abb8-dc22bb5c3076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_acd6b14d-3acc-40c0-adc2-ad3a6b9ec9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_037a0044-5d31-4409-abb8-dc22bb5c3076" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_acd6b14d-3acc-40c0-adc2-ad3a6b9ec9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_00f22f1f-31fc-40ab-b737-6c29c9a02e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_acd6b14d-3acc-40c0-adc2-ad3a6b9ec9f4" xlink:to="loc_us-gaap_AwardTypeAxis_00f22f1f-31fc-40ab-b737-6c29c9a02e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc52512b-3884-4bbf-b12a-30c372e09a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_00f22f1f-31fc-40ab-b737-6c29c9a02e7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc52512b-3884-4bbf-b12a-30c372e09a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9361c0f1-fad1-44e5-946e-29fdeeec3f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc52512b-3884-4bbf-b12a-30c372e09a3f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9361c0f1-fad1-44e5-946e-29fdeeec3f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_acd6b14d-3acc-40c0-adc2-ad3a6b9ec9f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward_4da42657-83c5-4774-8d3a-bc180c75c6f7" xlink:href="ekso-20201231.xsd#ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward_4da42657-83c5-4774-8d3a-bc180c75c6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2805e991-03ac-4511-80e0-5e5e53bb5313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2805e991-03ac-4511-80e0-5e5e53bb5313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a5bdfa5d-fb5c-483d-b301-82a4b1f4bfb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a5bdfa5d-fb5c-483d-b301-82a4b1f4bfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_768878a0-2322-4989-b826-c6194e26b85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_768878a0-2322-4989-b826-c6194e26b85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0c8e9f7b-4f65-472d-9f54-e931715e0fba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0c8e9f7b-4f65-472d-9f54-e931715e0fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_f4942b7c-9aaa-494d-88ea-134a7bc6ada3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_9d90bf42-3fa0-47ba-86ff-1e717ecde67e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_f4942b7c-9aaa-494d-88ea-134a7bc6ada3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_fa20eff6-43eb-4fee-9d1a-ec8aad10889a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_fa20eff6-43eb-4fee-9d1a-ec8aad10889a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6b2683a-1cd2-44bb-a46b-6b879b008d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6b2683a-1cd2-44bb-a46b-6b879b008d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_890568e1-f668-4a78-b8f4-c1680672a56d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_890568e1-f668-4a78-b8f4-c1680672a56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_e496ff94-df3c-43bf-a59f-09845278219f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_e496ff94-df3c-43bf-a59f-09845278219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_162fd417-adaf-48a3-be79-584de55c7ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b4a25124-b582-446d-91fa-0501cdcd7e72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_162fd417-adaf-48a3-be79-584de55c7ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_29e8e3ac-22ba-4811-b97b-c46ceb60a9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_29e8e3ac-22ba-4811-b97b-c46ceb60a9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_77dce076-b097-43e4-a86d-c34f652b946a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_77dce076-b097-43e4-a86d-c34f652b946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bcb04ff9-ea98-4f9a-a552-c3d41aec887f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76a22c6a-fe78-44d8-bfd4-e2e78f50ee97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bcb04ff9-ea98-4f9a-a552-c3d41aec887f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1efcf8d1-ab56-4ae4-bd50-6a8a7a9d6c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9efc978-e386-41dc-9592-df0c7f1ee54a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1efcf8d1-ab56-4ae4-bd50-6a8a7a9d6c8a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9efc978-e386-41dc-9592-df0c7f1ee54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_41c4f757-d482-4f1e-bced-47fa009ff269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9efc978-e386-41dc-9592-df0c7f1ee54a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_41c4f757-d482-4f1e-bced-47fa009ff269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1c02483a-0ee8-4118-b980-0b7f694370c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41c4f757-d482-4f1e-bced-47fa009ff269" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1c02483a-0ee8-4118-b980-0b7f694370c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_7f29cdd1-8bf3-481f-8f12-8b089b02722e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1c02483a-0ee8-4118-b980-0b7f694370c6" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_7f29cdd1-8bf3-481f-8f12-8b089b02722e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fadbea30-0879-44b0-97c7-d3ae1668451a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1c02483a-0ee8-4118-b980-0b7f694370c6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fadbea30-0879-44b0-97c7-d3ae1668451a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4fe2cbb5-ee8c-4451-9c6f-2cc906408075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1c02483a-0ee8-4118-b980-0b7f694370c6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4fe2cbb5-ee8c-4451-9c6f-2cc906408075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76e0c5af-196d-4709-982e-a40891cf5015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9efc978-e386-41dc-9592-df0c7f1ee54a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76e0c5af-196d-4709-982e-a40891cf5015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9842bda6-1e15-4233-9e6c-3b2fc88abe50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76e0c5af-196d-4709-982e-a40891cf5015" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9842bda6-1e15-4233-9e6c-3b2fc88abe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ade8dee-59e4-4ad1-b657-82d7dec26861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16653acd-3980-46d8-b52b-9d3c72b4caee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ade8dee-59e4-4ad1-b657-82d7dec26861" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16653acd-3980-46d8-b52b-9d3c72b4caee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f9fb637f-85b1-434c-9328-5128731d5213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16653acd-3980-46d8-b52b-9d3c72b4caee" xlink:to="loc_us-gaap_PlanNameAxis_f9fb637f-85b1-434c-9328-5128731d5213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ae8a8e6f-30e0-4899-952d-b069bf038fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f9fb637f-85b1-434c-9328-5128731d5213" xlink:to="loc_us-gaap_PlanNameDomain_ae8a8e6f-30e0-4899-952d-b069bf038fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EmployeeStockPurchasePlanMember_12a6dec2-6eaf-4e77-ab97-0656477a8679" xlink:href="ekso-20201231.xsd#ekso_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ae8a8e6f-30e0-4899-952d-b069bf038fa3" xlink:to="loc_ekso_EmployeeStockPurchasePlanMember_12a6dec2-6eaf-4e77-ab97-0656477a8679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16653acd-3980-46d8-b52b-9d3c72b4caee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0dfeb1a2-775a-449c-9acd-3f7cb6c7ee57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0dfeb1a2-775a-449c-9acd-3f7cb6c7ee57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_61e09a88-abce-4fe1-beeb-887471348b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_61e09a88-abce-4fe1-beeb-887471348b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DefinedContributionPlanOfferingPeriod_3bbcaf17-2bef-4864-a51f-7fa21bf7a4fd" xlink:href="ekso-20201231.xsd#ekso_DefinedContributionPlanOfferingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:to="loc_ekso_DefinedContributionPlanOfferingPeriod_3bbcaf17-2bef-4864-a51f-7fa21bf7a4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter_16a2a9ca-c577-4951-a811-83463bfe6eef" xlink:href="ekso-20201231.xsd#ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fee333e-8de8-4de1-b041-b278553bb0f6" xlink:to="loc_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter_16a2a9ca-c577-4951-a811-83463bfe6eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4892d4ee-66b3-4a9e-8c74-bc71ce74f550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_94f909e4-969c-48e5-978c-43d258404c89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4892d4ee-66b3-4a9e-8c74-bc71ce74f550" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_94f909e4-969c-48e5-978c-43d258404c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_42d87063-eec1-4699-be3a-cad7e4f81dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_7bdc3c55-605d-42fc-9925-b9e8df8dc88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_42d87063-eec1-4699-be3a-cad7e4f81dd5" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_7bdc3c55-605d-42fc-9925-b9e8df8dc88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0ded8af9-49c7-4ab1-b7e6-e91783047eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_42d87063-eec1-4699-be3a-cad7e4f81dd5" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0ded8af9-49c7-4ab1-b7e6-e91783047eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6f2c70eb-4f83-4e11-92a7-76dd3535aa6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_42d87063-eec1-4699-be3a-cad7e4f81dd5" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6f2c70eb-4f83-4e11-92a7-76dd3535aa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_15334953-1487-4512-bc28-c6fb32baaeea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_42d87063-eec1-4699-be3a-cad7e4f81dd5" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_15334953-1487-4512-bc28-c6fb32baaeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a0b1aba2-53c2-4509-aeb8-d73251c89be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d7195b1d-6e2b-4db7-a49a-66c19a30bd32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a0b1aba2-53c2-4509-aeb8-d73251c89be7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d7195b1d-6e2b-4db7-a49a-66c19a30bd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bdd1c71f-7ca2-4ab0-bc98-e18ba3f9a5d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a0b1aba2-53c2-4509-aeb8-d73251c89be7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bdd1c71f-7ca2-4ab0-bc98-e18ba3f9a5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6e975020-45bc-41f5-a99d-6ed601820d42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a0b1aba2-53c2-4509-aeb8-d73251c89be7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6e975020-45bc-41f5-a99d-6ed601820d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0cc22725-dbaf-4853-9a63-40a913f401f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0cc22725-dbaf-4853-9a63-40a913f401f1" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_b9c0ab3e-6480-4f66-8a72-8b2aca205d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:to="loc_us-gaap_TaxPeriodAxis_b9c0ab3e-6480-4f66-8a72-8b2aca205d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_cc07336b-75b8-40c4-ba4d-723981bc5313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_b9c0ab3e-6480-4f66-8a72-8b2aca205d3a" xlink:to="loc_us-gaap_TaxPeriodDomain_cc07336b-75b8-40c4-ba4d-723981bc5313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GeneratedBefore2018Expire2027Member_6f4f3c1c-8637-4c91-8aef-29a970302845" xlink:href="ekso-20201231.xsd#ekso_GeneratedBefore2018Expire2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_cc07336b-75b8-40c4-ba4d-723981bc5313" xlink:to="loc_ekso_GeneratedBefore2018Expire2027Member_6f4f3c1c-8637-4c91-8aef-29a970302845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember_d5bc1507-7dcf-4e17-a896-7c00f2fdcb54" xlink:href="ekso-20201231.xsd#ekso_GeneratedBefore2018CarryforwardIndefinitelyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_cc07336b-75b8-40c4-ba4d-723981bc5313" xlink:to="loc_ekso_GeneratedBefore2018CarryforwardIndefinitelyMember_d5bc1507-7dcf-4e17-a896-7c00f2fdcb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2112ca3c-d9c4-465b-bc8b-774ff300f8e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2112ca3c-d9c4-465b-bc8b-774ff300f8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_88849315-70c9-4824-bac0-4d0628717f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2112ca3c-d9c4-465b-bc8b-774ff300f8e4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_88849315-70c9-4824-bac0-4d0628717f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_1502b4fc-0cee-442f-a931-7a324d8d6065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_88849315-70c9-4824-bac0-4d0628717f97" xlink:to="loc_us-gaap_DomesticCountryMember_1502b4fc-0cee-442f-a931-7a324d8d6065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_457d1906-dbf2-43b7-86fb-c2b3a79add4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_88849315-70c9-4824-bac0-4d0628717f97" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_457d1906-dbf2-43b7-86fb-c2b3a79add4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_459d1673-237f-4b3a-b952-9e306a51fe3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_88849315-70c9-4824-bac0-4d0628717f97" xlink:to="loc_us-gaap_ForeignCountryMember_459d1673-237f-4b3a-b952-9e306a51fe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2d94829d-ce5d-4040-8552-65ac01485df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2d94829d-ce5d-4040-8552-65ac01485df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_54ff7b71-e5b1-4525-a9cb-2758b9e50d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2d94829d-ce5d-4040-8552-65ac01485df6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_54ff7b71-e5b1-4525-a9cb-2758b9e50d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_4ded6634-39de-4199-ac1c-1c50655f0712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_54ff7b71-e5b1-4525-a9cb-2758b9e50d13" xlink:to="loc_us-gaap_ResearchMember_4ded6634-39de-4199-ac1c-1c50655f0712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fedf52ee-f72e-4ccb-a55b-594bb0de9809" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_8fc82cfd-eade-4e88-b1ea-524eb9c7d1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_8fc82cfd-eade-4e88-b1ea-524eb9c7d1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_dc91fb9c-5cc8-407c-a4a1-7e7b226edb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_dc91fb9c-5cc8-407c-a4a1-7e7b226edb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1743b43f-ef93-443d-85eb-4b767f0d3ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1743b43f-ef93-443d-85eb-4b767f0d3ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_82cb377f-b15b-48ff-bb42-1ad3da01e987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_26213c6a-6d36-4d96-8d79-3ed8e864dda3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_82cb377f-b15b-48ff-bb42-1ad3da01e987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5011a814-94eb-4a29-88f6-3a5c563e425f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0b9b5934-1a59-4000-888c-2ccf821674ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5011a814-94eb-4a29-88f6-3a5c563e425f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0b9b5934-1a59-4000-888c-2ccf821674ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4ad08f56-a325-4296-af55-185a7a26acc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5011a814-94eb-4a29-88f6-3a5c563e425f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4ad08f56-a325-4296-af55-185a7a26acc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ff579154-693c-4635-8958-141c5261e353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5011a814-94eb-4a29-88f6-3a5c563e425f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ff579154-693c-4635-8958-141c5261e353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_afdc538e-b266-44ed-af57-a7e821377d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5011a814-94eb-4a29-88f6-3a5c563e425f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_afdc538e-b266-44ed-af57-a7e821377d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant_a34965ba-a394-4d0c-a7ef-cc378cab5e71" xlink:href="ekso-20201231.xsd#ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5011a814-94eb-4a29-88f6-3a5c563e425f" xlink:to="loc_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant_a34965ba-a394-4d0c-a7ef-cc378cab5e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_05e3b2eb-dae8-4b6b-a60e-5420f4992e34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5011a814-94eb-4a29-88f6-3a5c563e425f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_05e3b2eb-dae8-4b6b-a60e-5420f4992e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_17adeff5-a7b6-4a44-9de0-b2e37bba3bba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5011a814-94eb-4a29-88f6-3a5c563e425f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_17adeff5-a7b6-4a44-9de0-b2e37bba3bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2a100348-592d-45f1-8b5d-b5646222fb29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5011a814-94eb-4a29-88f6-3a5c563e425f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2a100348-592d-45f1-8b5d-b5646222fb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4fae79ed-9b08-4838-bb04-c088b89cfe37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f246fe2c-7370-42c8-91cc-5c2426ff2109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4fae79ed-9b08-4838-bb04-c088b89cfe37" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f246fe2c-7370-42c8-91cc-5c2426ff2109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_c167445b-ec06-4f0a-88e2-f547b6ab8477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f246fe2c-7370-42c8-91cc-5c2426ff2109" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_c167445b-ec06-4f0a-88e2-f547b6ab8477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e78948bf-82a5-4f37-a165-979cebb5c23d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f246fe2c-7370-42c8-91cc-5c2426ff2109" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e78948bf-82a5-4f37-a165-979cebb5c23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7d45508d-df16-41d5-a6f0-c2b47fc6c3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f246fe2c-7370-42c8-91cc-5c2426ff2109" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7d45508d-df16-41d5-a6f0-c2b47fc6c3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_a99bc296-ffc3-4c81-8c14-1ef567196ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f246fe2c-7370-42c8-91cc-5c2426ff2109" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_a99bc296-ffc3-4c81-8c14-1ef567196ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e783446b-c8d4-4845-aa91-a4dac1e1c279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f246fe2c-7370-42c8-91cc-5c2426ff2109" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e783446b-c8d4-4845-aa91-a4dac1e1c279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fe226371-189b-4023-a442-229e08ceb120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f246fe2c-7370-42c8-91cc-5c2426ff2109" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fe226371-189b-4023-a442-229e08ceb120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_22f5460c-456f-407c-b0e9-96e5ac0b06ef" xlink:href="ekso-20201231.xsd#ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f246fe2c-7370-42c8-91cc-5c2426ff2109" xlink:to="loc_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_22f5460c-456f-407c-b0e9-96e5ac0b06ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e3e001f8-6557-4832-a4ed-4c17a5942257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f246fe2c-7370-42c8-91cc-5c2426ff2109" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e3e001f8-6557-4832-a4ed-4c17a5942257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bcfc873d-880e-436f-840b-1d8f85b5d921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4fae79ed-9b08-4838-bb04-c088b89cfe37" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bcfc873d-880e-436f-840b-1d8f85b5d921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability_6a73fc95-2079-47e9-9a37-a4d03340045d" xlink:href="ekso-20201231.xsd#ekso_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bcfc873d-880e-436f-840b-1d8f85b5d921" xlink:to="loc_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability_6a73fc95-2079-47e9-9a37-a4d03340045d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_139de4a9-9360-458f-a3d0-3342b60c6909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bcfc873d-880e-436f-840b-1d8f85b5d921" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_139de4a9-9360-458f-a3d0-3342b60c6909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_281a4b85-752a-4589-9054-cd744dc9fddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bcfc873d-880e-436f-840b-1d8f85b5d921" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_281a4b85-752a-4589-9054-cd744dc9fddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_805b17cd-fdc4-4fd4-8148-47f87760d878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bcfc873d-880e-436f-840b-1d8f85b5d921" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_805b17cd-fdc4-4fd4-8148-47f87760d878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1d33cf53-5a2b-4bde-9f6a-b5434e178349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_16bcc028-fcc1-4d52-8749-15dff683c7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1d33cf53-5a2b-4bde-9f6a-b5434e178349" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_16bcc028-fcc1-4d52-8749-15dff683c7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fd1221df-f9b2-4359-9a8f-f7349b39a954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_16bcc028-fcc1-4d52-8749-15dff683c7e5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fd1221df-f9b2-4359-9a8f-f7349b39a954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_08e9f022-7e42-4950-bda2-d8075b8f4ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_16bcc028-fcc1-4d52-8749-15dff683c7e5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_08e9f022-7e42-4950-bda2-d8075b8f4ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5b41ee53-6de5-4b2c-9abc-d49787bb8b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_16bcc028-fcc1-4d52-8749-15dff683c7e5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5b41ee53-6de5-4b2c-9abc-d49787bb8b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_44e40ee6-6a38-4703-a024-03a988d0ea84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_16bcc028-fcc1-4d52-8749-15dff683c7e5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_44e40ee6-6a38-4703-a024-03a988d0ea84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c72cb0de-df6d-45f1-918e-44972688caaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e3546186-cee1-422b-9737-a6c26f2711cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c72cb0de-df6d-45f1-918e-44972688caaf" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e3546186-cee1-422b-9737-a6c26f2711cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09b34986-3bae-44bd-8b03-8d40b7f79256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_b834ad69-c0d5-412d-b827-ad912a78041b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09b34986-3bae-44bd-8b03-8d40b7f79256" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_b834ad69-c0d5-412d-b827-ad912a78041b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_16836b84-21bf-461b-b375-d78be5266bb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_62977cc5-0e7a-487e-9d2e-c9e1907ff9a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_16836b84-21bf-461b-b375-d78be5266bb7" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_62977cc5-0e7a-487e-9d2e-c9e1907ff9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9f88a54d-a1af-4a17-b2a3-c66134e1bbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_62977cc5-0e7a-487e-9d2e-c9e1907ff9a5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9f88a54d-a1af-4a17-b2a3-c66134e1bbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c93c5935-5f60-4504-a9eb-35a612641d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9f88a54d-a1af-4a17-b2a3-c66134e1bbcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c93c5935-5f60-4504-a9eb-35a612641d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_5ea12320-19e0-48bc-9072-abfdf83d4370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c93c5935-5f60-4504-a9eb-35a612641d10" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_5ea12320-19e0-48bc-9072-abfdf83d4370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fc11b7ce-4fad-4981-b0d0-72d870965d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_62977cc5-0e7a-487e-9d2e-c9e1907ff9a5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fc11b7ce-4fad-4981-b0d0-72d870965d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77a6b658-5ee8-4e8f-9ea2-c0a86754e85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc11b7ce-4fad-4981-b0d0-72d870965d29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77a6b658-5ee8-4e8f-9ea2-c0a86754e85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember_ccb94bd5-fe24-4430-8db1-3b25c75449a8" xlink:href="ekso-20201231.xsd#ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77a6b658-5ee8-4e8f-9ea2-c0a86754e85e" xlink:to="loc_ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember_ccb94bd5-fe24-4430-8db1-3b25c75449a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_LicenseRevenueMember_a1d1a21c-4996-40f1-8526-a0210213cdba" xlink:href="ekso-20201231.xsd#ekso_LicenseRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77a6b658-5ee8-4e8f-9ea2-c0a86754e85e" xlink:to="loc_ekso_LicenseRevenueMember_a1d1a21c-4996-40f1-8526-a0210213cdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_62977cc5-0e7a-487e-9d2e-c9e1907ff9a5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_NumberOfLicenseAgreements_18295268-fb36-4fd9-ad1e-f1e3066da4a8" xlink:href="ekso-20201231.xsd#ekso_NumberOfLicenseAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:to="loc_ekso_NumberOfLicenseAgreements_18295268-fb36-4fd9-ad1e-f1e3066da4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_RoyaltyPercentage_206b5b1f-7271-492e-8abc-4e0806953493" xlink:href="ekso-20201231.xsd#ekso_RoyaltyPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:to="loc_ekso_RoyaltyPercentage_206b5b1f-7271-492e-8abc-4e0806953493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_83fb2dbd-63a6-46fc-871f-1fefd190b825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_83fb2dbd-63a6-46fc-871f-1fefd190b825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_a512150a-1f7d-4ce0-af3d-f1808844f9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8b71e629-9574-422d-b908-23526252ae7d" xlink:to="loc_us-gaap_PurchaseObligation_a512150a-1f7d-4ce0-af3d-f1808844f9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1105d889-a085-46dc-b52e-dbfed5c8e07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_6e804c04-e1f8-4977-8925-a8f90d6fe42f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1105d889-a085-46dc-b52e-dbfed5c8e07c" xlink:to="loc_us-gaap_OtherCommitmentsTable_6e804c04-e1f8-4977-8925-a8f90d6fe42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c5605c6e-bf41-4b58-95b0-bc668ab6666a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_6e804c04-e1f8-4977-8925-a8f90d6fe42f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c5605c6e-bf41-4b58-95b0-bc668ab6666a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ba63ccb-b47a-44a7-8315-2c3b2021d5f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c5605c6e-bf41-4b58-95b0-bc668ab6666a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ba63ccb-b47a-44a7-8315-2c3b2021d5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_TermLoanMember_b93a0b44-be2c-45e6-8b0d-38b475ac4864" xlink:href="ekso-20201231.xsd#ekso_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9ba63ccb-b47a-44a7-8315-2c3b2021d5f6" xlink:to="loc_ekso_TermLoanMember_b93a0b44-be2c-45e6-8b0d-38b475ac4864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8412a4dd-b202-43f0-bee8-020b408afe29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_6e804c04-e1f8-4977-8925-a8f90d6fe42f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8412a4dd-b202-43f0-bee8-020b408afe29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844aba0f-128e-4351-a936-e53686a3af14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8412a4dd-b202-43f0-bee8-020b408afe29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844aba0f-128e-4351-a936-e53686a3af14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_FacilityOperatingLeaseMember_091d09e2-3ea8-480e-b659-f87d47937050" xlink:href="ekso-20201231.xsd#ekso_FacilityOperatingLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844aba0f-128e-4351-a936-e53686a3af14" xlink:to="loc_ekso_FacilityOperatingLeaseMember_091d09e2-3ea8-480e-b659-f87d47937050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_6e804c04-e1f8-4977-8925-a8f90d6fe42f" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_2ce045b0-4d27-4cf5-93dd-ade58d80e375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:to="loc_us-gaap_ContractualObligation_2ce045b0-4d27-4cf5-93dd-ade58d80e375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_beb900c1-a4d9-4d08-9767-e656585debf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_beb900c1-a4d9-4d08-9767-e656585debf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_726988d4-223b-4118-97eb-06dc9017c777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_726988d4-223b-4118-97eb-06dc9017c777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_2f2dcf7f-79eb-46ed-8c3b-0beaf334479c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_207c9052-ebe4-4dba-b34b-6a8dc88650d9" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_2f2dcf7f-79eb-46ed-8c3b-0beaf334479c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosures" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosures"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8a095afa-4100-4c69-b19a-c6f9c778af7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_82bd9b46-94a0-429e-a98f-16930391d78d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8a095afa-4100-4c69-b19a-c6f9c778af7a" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_82bd9b46-94a0-429e-a98f-16930391d78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosuresTables" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0d9e435f-14f9-42d4-84bb-ff5348263686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b701a082-c39c-4fc3-bd19-e76ed3781415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0d9e435f-14f9-42d4-84bb-ff5348263686" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b701a082-c39c-4fc3-bd19-e76ed3781415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a2b49992-e2b8-40e8-b7fc-cb16f7af5c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0d9e435f-14f9-42d4-84bb-ff5348263686" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a2b49992-e2b8-40e8-b7fc-cb16f7af5c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosuresScheduleofSegmentReportingInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8382a202-0088-4ac7-8cbb-a23f5df41ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e8a094ec-7b81-4450-849a-c101ae9ef0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8382a202-0088-4ac7-8cbb-a23f5df41ffd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e8a094ec-7b81-4450-849a-c101ae9ef0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d8abb198-84de-41cd-bdea-bdfb891f14c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e8a094ec-7b81-4450-849a-c101ae9ef0d7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d8abb198-84de-41cd-bdea-bdfb891f14c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_34bb038a-ac15-4474-8d1f-18809fced4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d8abb198-84de-41cd-bdea-bdfb891f14c9" xlink:to="loc_us-gaap_SegmentDomain_34bb038a-ac15-4474-8d1f-18809fced4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoHealthMember_44ecd566-ed1c-48f7-b5ff-02bf5240af7f" xlink:href="ekso-20201231.xsd#ekso_EksoHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_34bb038a-ac15-4474-8d1f-18809fced4ef" xlink:to="loc_ekso_EksoHealthMember_44ecd566-ed1c-48f7-b5ff-02bf5240af7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_EksoWorksMember_feb682da-e154-49a0-adcb-bbec7ef5ae95" xlink:href="ekso-20201231.xsd#ekso_EksoWorksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_34bb038a-ac15-4474-8d1f-18809fced4ef" xlink:to="loc_ekso_EksoWorksMember_feb682da-e154-49a0-adcb-bbec7ef5ae95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_25111206-03a4-403f-9a55-e533dcc465f9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e8a094ec-7b81-4450-849a-c101ae9ef0d7" xlink:to="loc_srt_MajorCustomersAxis_25111206-03a4-403f-9a55-e533dcc465f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_59e29edd-a75f-4338-8003-f4f45eeba675" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_25111206-03a4-403f-9a55-e533dcc465f9" xlink:to="loc_srt_NameOfMajorCustomerDomain_59e29edd-a75f-4338-8003-f4f45eeba675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_CustomerOneMember_0b104ba7-2ac6-41dd-834f-0dca4e35dceb" xlink:href="ekso-20201231.xsd#ekso_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_59e29edd-a75f-4338-8003-f4f45eeba675" xlink:to="loc_ekso_CustomerOneMember_0b104ba7-2ac6-41dd-834f-0dca4e35dceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e8a094ec-7b81-4450-849a-c101ae9ef0d7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_9ef9baab-81bb-4838-aa6d-f9f5004b6d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:to="loc_us-gaap_NumberOfReportableSegments_9ef9baab-81bb-4838-aa6d-f9f5004b6d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0d3bb191-1ada-4382-8ec5-673311ddf238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0d3bb191-1ada-4382-8ec5-673311ddf238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e4600e6b-6c81-4928-abc6-36c230d2baa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e4600e6b-6c81-4928-abc6-36c230d2baa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_965dadbc-e986-4fb0-931d-cf80edbcb46d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f57a24c2-825e-48b2-8661-bda4c5810440" xlink:to="loc_us-gaap_GrossProfit_965dadbc-e986-4fb0-931d-cf80edbcb46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SegmentDisclosuresScheduleofGeographicRevenueInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_45ba550a-92de-46a0-8089-58c72ffe295d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_744073f4-2842-41c2-a160-1e7a4cfdf5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_45ba550a-92de-46a0-8089-58c72ffe295d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_744073f4-2842-41c2-a160-1e7a4cfdf5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a674e541-4154-4c9d-a4cc-68159af415e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_744073f4-2842-41c2-a160-1e7a4cfdf5a3" xlink:to="loc_srt_StatementGeographicalAxis_a674e541-4154-4c9d-a4cc-68159af415e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_63062746-01c0-4ba5-b0f8-f2a2c073eb04" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a674e541-4154-4c9d-a4cc-68159af415e6" xlink:to="loc_srt_SegmentGeographicalDomain_63062746-01c0-4ba5-b0f8-f2a2c073eb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_adf55521-55e1-4cf0-94e0-d4f800d726c8" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_63062746-01c0-4ba5-b0f8-f2a2c073eb04" xlink:to="loc_country_US_adf55521-55e1-4cf0-94e0-d4f800d726c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1c595c71-3743-468f-9d73-b71dcfd3dc1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_63062746-01c0-4ba5-b0f8-f2a2c073eb04" xlink:to="loc_us-gaap_NonUsMember_1c595c71-3743-468f-9d73-b71dcfd3dc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6ee83cc8-33d7-41af-a2c3-2d7674e865a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_744073f4-2842-41c2-a160-1e7a4cfdf5a3" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_6ee83cc8-33d7-41af-a2c3-2d7674e865a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a9bc6396-e6e0-4a94-98bf-393bbf6f92c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6ee83cc8-33d7-41af-a2c3-2d7674e865a9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a9bc6396-e6e0-4a94-98bf-393bbf6f92c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ekso-20201231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2a0b1cb7-13b7-4926-a040-088902586477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_d53290fd-0e27-47a7-9015-7f81782574f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2a0b1cb7-13b7-4926-a040-088902586477" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_d53290fd-0e27-47a7-9015-7f81782574f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eksobionics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ekso-20201231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.eksobionics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0b20c56d-c6b9-4745-841a-2a52a726bbd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0b20c56d-c6b9-4745-841a-2a52a726bbd9" xlink:to="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f3242a17-0056-43d2-a66b-7e4628ec5272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f3242a17-0056-43d2-a66b-7e4628ec5272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c635ee62-b01e-4d5b-8144-afe85c4cbd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f3242a17-0056-43d2-a66b-7e4628ec5272" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c635ee62-b01e-4d5b-8144-afe85c4cbd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_085f7bc8-1e8e-4cac-a2ea-88104c1df6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c635ee62-b01e-4d5b-8144-afe85c4cbd8b" xlink:to="loc_us-gaap_SubsequentEventMember_085f7bc8-1e8e-4cac-a2ea-88104c1df6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_61d27152-932f-4f02-b7c9-6a0db2f33b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_61d27152-932f-4f02-b7c9-6a0db2f33b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4c38da42-4264-4f51-8138-120f591c796a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_61d27152-932f-4f02-b7c9-6a0db2f33b2a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4c38da42-4264-4f51-8138-120f591c796a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_June2020WarrantsMember_fddb3c54-8daf-4d0d-a57a-5b276f3dc229" xlink:href="ekso-20201231.xsd#ekso_June2020WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4c38da42-4264-4f51-8138-120f591c796a" xlink:to="loc_ekso_June2020WarrantsMember_fddb3c54-8daf-4d0d-a57a-5b276f3dc229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_81ce28b9-b1c3-4fe6-830a-c444934cb532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_81ce28b9-b1c3-4fe6-830a-c444934cb532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c6f3e10-8d63-4805-bda4-ad727908a0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_81ce28b9-b1c3-4fe6-830a-c444934cb532" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c6f3e10-8d63-4805-bda4-ad727908a0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_78ae79b6-05a1-4e57-a8ba-9da4dedc8449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c6f3e10-8d63-4805-bda4-ad727908a0c6" xlink:to="loc_us-gaap_OverAllotmentOptionMember_78ae79b6-05a1-4e57-a8ba-9da4dedc8449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_AtTheMarketOfferingMember_4f06fa84-9dfb-4754-9200-b6eb7817a24e" xlink:href="ekso-20201231.xsd#ekso_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c6f3e10-8d63-4805-bda4-ad727908a0c6" xlink:to="loc_ekso_AtTheMarketOfferingMember_4f06fa84-9dfb-4754-9200-b6eb7817a24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fc932a2e-93a2-4235-9f86-e6fecad28aa1" xlink:to="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_82316ebe-76ce-4992-adb5-e30462364ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_82316ebe-76ce-4992-adb5-e30462364ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_15bf4e62-1cf1-49ef-aaa4-59e1f9f9700a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_15bf4e62-1cf1-49ef-aaa4-59e1f9f9700a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8dea877a-cf35-4acc-a6a6-67a2e3c904a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8dea877a-cf35-4acc-a6a6-67a2e3c904a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_009518ce-ce4b-48c8-90b8-11ebda24e1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_009518ce-ce4b-48c8-90b8-11ebda24e1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1128181e-794f-4434-9502-61873b6a148c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1128181e-794f-4434-9502-61873b6a148c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold_86f357b8-9ac7-4e99-8355-7df81280beab" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold_86f357b8-9ac7-4e99-8355-7df81280beab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71234371-ab15-4fbe-8e69-8f3bc8663a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71234371-ab15-4fbe-8e69-8f3bc8663a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_ClassOfWarrantOrRightExercised_a68a01df-f946-46bc-b4d2-ba7666309c3c" xlink:href="ekso-20201231.xsd#ekso_ClassOfWarrantOrRightExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_ekso_ClassOfWarrantOrRightExercised_a68a01df-f946-46bc-b4d2-ba7666309c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance_a810437a-ea90-4c46-9969-ee0f12231b83" xlink:href="ekso-20201231.xsd#ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dde648b8-de1d-4cb8-8d4d-ba3b5f634f98" xlink:to="loc_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance_a810437a-ea90-4c46-9969-ee0f12231b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>ekso-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:ekso="http://www.eksobionics.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ekso-20201231.xsd" xlink:type="simple"/>
    <context id="i297156716d884a2da3e85659f53b94b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d6f176932954c3ea9bd0f2f47990c67_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i725a7c78af424676baf1ece165c91377_I20210219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <instant>2021-02-19</instant>
        </period>
    </context>
    <context id="i8c95c1de992348a3bd61ef233bf1c041_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id632c7032c4140109d9f983f53b19765_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i846dd5585ada4e0498b73873e27cdcdc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i771c5968601e4ebbaee595d0efedc2df_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i001a198ae0ad4ccaabceb0a88f0757da_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8b330504326e4a9bbc4d3e4b7244e5fb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2ed408484abc4ce88899f293e7cfe8ad_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5cd59b28ca904e409d6a180ec9f55846_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia0c5a8bcf1214cdea5e114d7188288c6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib9f045d0163b47d080fcc09d4ec9b298_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8fdf493d0b2b4110824781819eb0a66c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0387f9eb02e44e3b6ba26b31874ce98_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i355702e247f64033a0ce80c82800d085_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i164b98fab8ca484db400c50acb2bde32_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id633f108918a485b94dd3575f357c6d1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8437b75fb864b51a8daec69829e7ede_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1244662c4107454f9abedb0d2c7dd95a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fb8ef54637c4de2a9b1091027aa5962_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56dbcebcd6d641bdb0fa75661fc45501_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4b0ba326b044c5d8a0bb299a3ec93ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic126d0c0305a496bb377ee4b4e95f356_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7fef623934b4bd19b22ecc59a17e7ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a01f618e3f9488cb29bae5e918482c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ef9cf6430ff4f8e9422f488739fa849_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i92564e533c5b46fca6e27927910f77db_D20210101-20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="idb89bd35b9ca4d7680abe71e8e1cb17e_D20210101-20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="i7b032681769845018b20e932f7d48c5b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic845df26b7574c9688eaf63d2b286340_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:PWBLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ekso:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6806a66d666343109c438a29d2361243_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ekso:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6634dcaf84414ad4a2238d4e3b472d60_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ekso:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c852fde248a46429a59913a353fcd78_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5526a54efe4b4f308ec50b4abcc4ccc1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i425546ef7c404c1fb5e6ce43069f77b8_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="id643b591bbe442ff89d7f6fedbd8777a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81b4652764f7496fae43691e5665e11e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc2375e404df4bee8066cbe643660925_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6fdcba7194b1415db1370657080e8199_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55263caaaf314901a8c536dda2b3d628_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i34328fdb308e40c6bf10ef8dcd50adb7_D20200324-20200324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <startDate>2020-03-24</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="i67594e576125433d9c1e6603131224a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibde6413b3f484fbb82f25ef7d5c4d24b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7c51e051811a48169af92a76d27be60a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bd0c434eb694450b138a39e7717b97d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i40711bfb573748f5b097264402445a5e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8fcc63d43e042fb816a4a8bb922bd22_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i50bf1458d43243298850ecebb3a893ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2bdafc8b87643a8940a27e6b36684f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb140a2a8bd1427c8038bc9cc6fc4ddd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84e30bf53c5f4d90befcffe3dcd462ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80a48682c16b4e88b27b2fa322d058d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i649dad9fb14749e9996c2dc8928958e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i84a84e7d32604e62861e794eea7d7ca1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ab6a2c45f8a47ecba7fe4b30e1dda70_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9396d4559e45441f873fc24b5a39358d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i411cf8f5b27a4e37a9f9854d5abc3f48_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ekso:ContingentSuccessFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42740a38dd614cefb84f83af69916e8d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ekso:ContingentSuccessFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0440a5ac3cb444bf8c87c1ca6ea5f57a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2871a384ac049ccbda9e8abc03f027c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ekso:ContingentSuccessFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63834f56293d4e708f774c76a532f46f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3036960b630e4dc68acd1c3ce4478d07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1189ad224a9542f99ef6b9177be8258c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f8795be88184c80b93b87063b29336c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5d78b1f57364d88a58dd74bda2ee22e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if2a856fa0deb4f4bbebb18b45f3772fe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6b6f83daf3c4c15b23e671334f13579_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i889b78375c774b5687a5747a1b43cb23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99c6f90a20b044e3acc886642e9c1309_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id38da83df0b94a2b83b0d1f8a9f1dc30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e574a2fabc1499f884fcd1b5951b4e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i033d5839f04849bfb1ee07ea7dc6b0f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7cd34bb1047b430b85a6b141bc79a7c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia43ebf9f36cf41eba45fa05244dc8ac4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i322cf066e9f44f9cbb3ec118a91e904c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib8235348a80e487c9f3e8030b4d8ce9a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3162a8935b1c4ff380fbdae542396c82_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic14005e4eb1146e986a9ef76f055084d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib881b817aa7445709d8070f5fe391132_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i75a7edc5f16340378382788c4c0dc691_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27aec484daea4c1dbfd941c2654431bb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if26d674e4b5d49679bf4f50fdb4b6c18_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i95975cc540d54a198ad22e25ed0dcb73_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5078e9375e6b4702909ac2925b30c4bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7f73b9d15a3b46ef9fe037af79d4534d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7e152e2c14f448a681c80c12f29fa109_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5b6c52ce74dc42cc9138e832cd3dd672_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifb1098ca438a48cd9e106e5843d6cd36_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia6d3ffd252aa43aa8bf3e178360945c2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:RentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i28c029fe6658433091f9348fc9d54912_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98f6ebc39e4f40b78d40104fb7855d08_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0f7abf2a1ea34998ba75e15db09892c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id2cedde1fd8d4e13817c08df4f3817d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i52ed2b595380454aa4357b1f8bbc92f8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia41bb0fad4e647a688e43967bb0bb7be_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ekso:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iabb99287795245cead94469bb0004c47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i015e0abf22814adbb2132f59a1724e19_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9f70fd4ec65c4972b421c5aa5b36941b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TransportationEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i660e36a98e0746cf8a42c3b13e52a56b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TransportationEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id479e8c373654ebbb87b0a250bcc1e8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TransportationEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3dd0c5c2bb3c4768abec83b24e2a64d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TransportationEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f923f15e82d409bac227a17e3701888_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d2e914eb0a5485b9d8820fc1baacc8d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i658969b097ae4314a93b0abea1d13868_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i763c0e7c9c9d44dcb6a9636b86af9d12_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i130b8496b8734097b3481b467f0807f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03553d669ad34441ba31a9b58507f565_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic54e4f7da48f45918ff0109be65c5330_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2abecebb024344bea34c7c37ce810974_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ec4203661dc40138fda63b48b530a85_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i049203243d424699b4e0dd6029b0888a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i165ec35cb06746f8ab56f69fe0d5c964_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22f933f335564a9fac29ff916331aa4e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1d35bea06791470faea4c0d59dbb1e5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2005fc6b0f7943b3ba42ed850a5c303e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c9feb071f8b40bfbfab0e7da695b5dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2dd9eb144ecd423dade80dac3f927d7c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i56395207f3fa42a797c5ba80cfdfc6b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia18e0975d5f84534ac0b1db267f24d9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88d7b8be94cd47d2b55ddb60df657ed4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i09b4c0d4a24e49a0a8ffd3a7005294c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27ca24a6e01a4c5e818349f32894630b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iac816c78ecee495db3e143bd5054df3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57a91e8c1fb344769e0f47516a30046c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ekso:OtherliabilitiesAxis">ekso:WarrantyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i79e076985ae14c239cf28cb82308d69e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ekso:OtherliabilitiesAxis">ekso:WarrantyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i663e54f1b87347028c8829a7b346f7be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ekso:OtherliabilitiesAxis">ekso:WarrantyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iccc8ff9bb9094f2ca094767c70c3d73f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ekso:OtherliabilitiesAxis">ekso:WarrantyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0d2406d983ae408d82890348c4593fe2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ekso:OtherliabilitiesAxis">ekso:WarrantyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b6df24c948e48979ba8b93b03bc8282_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ia26aaae57e1a4c82bb8d24f30b52abe8_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i75e32a08cd3c442a9b9ba9304b50179b_D20200429-20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="i820fe364817646f793de1bd99129025e_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:PWBLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ekso:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i414af477b5eb412594fd4faab7f47ca1_D20200801-20200830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:PWBLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ekso:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-30</endDate>
        </period>
    </context>
    <context id="i5f6e46cb0a00471f82de8d8582d4cbe4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ekso:PWBLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ekso:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied25b6065fd04927890a9579112ce304_I20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-20</instant>
        </period>
    </context>
    <context id="id59142af679b474d9606680f4928a206_D20200420-20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="icc71209ac60845e382225b8a55a86c3d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie41cddf1a88a4eeab4f0e94b552e1cad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ekso:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4013c40327cb4b46bc304ebb13174011_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ekso:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iae9cf36b522d452a848dfea8122fdd50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ekso:HamburgGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff102119cd6a456596f0197f90723327_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ekso:AngelPondCapitalLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i66089c57ef3447548266d31fba65e3f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ekso:AngelPondCapitalLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5b7783a67c59429aa5c50cce7d3f36a4_I20190916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <instant>2019-09-16</instant>
        </period>
    </context>
    <context id="i1332f3e466ea4d9886d520016e1fe9a9_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icdfb6150e11040dbbad6a66db73b4fdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4cc3408bdfbe4b5f8276263fd666f8e1_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i20c3fa9143d1494f9fa80ba4773d37c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8146ef51059a4e8588f8cfa2a49cc7c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35f4d4c9162e4396a697be5d9061262e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae50490cbb4b480698dbb2b1ea92f87e_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6260ae69ccdc47afb974156191ec17ed_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i656a19543c2446298336599b639f4ed9_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i60337cf454184d3fab3c487c42a73b04_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="ia03e27ee3b474253a9b6b29d30ad3245_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16884269eeb946c9a8d814ed9a37da17_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic069febcd575454ba36115614e1e67f4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c7551fdba7443329e59bdddaaf0a8c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18a8a6dd04bb4af0a97b953a6edf6367_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ecc4c18109a4778a6436d117e42e20d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i06d98523cf3c41fc9f81c5db24a92b70_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43dcca06f1114b118c295c1360b5597c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib21914757ec84913b068b738154fc31c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8eab057d5354f54a6a1f4b6e697e1fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i883563dff2a0452fb06639ade8f1ec83_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ae106f6d2ac4c01ae9d3275ad51c856_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16f2fc5bc8324b9c95780543103873be_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i425ea3e27fe44ae8ababe62ca6a2566d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2017InformationAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i474fb265033b492d99eef7003d923965_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2017InformationAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e758452b88142cebe39df57428e5d23_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2017InformationAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic67e632c480a4a389d734d7b66ce5c48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2015WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie460538640c64e2cba78df79c4755d79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2015WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7c1742f015b49289941792b99828fec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2015WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0318eadd0412421d9ab7a16182414edb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:Pre2014WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i493d79f55e7241dc9784879e595c2d55_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:Pre2014WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32847a63786c4c40911455a3c40434a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:Pre2014WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e9a44a009bc4cff8921788207667b9b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:Pre2014WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i66dedf87145f4fc990355ef06fe907ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:Pre2014WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia73bddff44ca4b2f9d2a82edae8e117f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1b04630ec1374a39bd730200d9ce743a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia50fed56d7e846008e27b2faa05cf892_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a3cb75354a8437c97c6a048fbb71d72_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i606b7f43b71a44adb687cff9e4202f75_I20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="i15042960a2014c12aeb3b609cd137087_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93802bef0c2445c789f2445d0a127497_D20200610-20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-10</startDate>
            <endDate>2020-06-10</endDate>
        </period>
    </context>
    <context id="iba22e1721af04a2e9319870ded4bd2de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3aa1cf0746c4b5baceaeb908424df8d_I20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="i084accc9ec374285be3b0a73a7a1090a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b12218955364d9da56354373add4e0a_I20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="ibd9481bf7e0140ac800169b45355f91d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5038cfc88eee4338ae569f8f794e2d53_I20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="i9c0e3631de7946a9b5dd656a12e3ee57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i917d2e433bec4af6a5015a89dffd0ec1_I20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="ic719e6ce8263469b8620118bde4798db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87826571264a49058ae7d9ecedc374f7_D20200610-20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-10</startDate>
            <endDate>2020-06-10</endDate>
        </period>
    </context>
    <context id="i970ae68e19f845e0a61ab8293e716384_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b14b8e6815740a780625da52773615e_I20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="i265b24fe236d4a33a086749d8f3bc1d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ffd06e2b41643a5851058ccd43c25f4_I20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="i885b3e5d68a84f4e90e8c7922cef7995_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51a2440d2a3b4d3d84b38c26002ea3ff_I20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:JuneTwentyTwentyPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="i6e10eafaaf69412a980b03f834b1e6dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i49b5955b1efd4de9a0856fc1539f6432_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3687529f69424becaeceedf73f6828ec_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id396d3085bb24e85baf89441852a463a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ide46f57c594c4d7e8de120bbe04cf45a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bc70242a8314a19af7cff0da761421c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0145713900c94e918e32d701921d1975_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0b034ea5e3e4dc5851a3ccb19e99abf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5aecd5d37d3b4bb4b4adf7077dc24cde_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6293a6a35cfd4251acaaf9a8e93b0369_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib7f8299a4e214d92957aee41ce77fb46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea7e5c100ba04f8687538cfb181146ee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia6df92243b17458caf062b597eca0bb0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8c6706df2ef4faca8ee7e3eab8da237_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia91c98835d204cc08859c956d9414520_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3215b84b357a450a985217089ba29281_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i069a96fbc276471e994ddb6c40a43503_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1857924bad947049734ec580f40b921_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e863bdfa06a4bdda07cfb2cdc16b526_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i054e3c8419c84d5cbbdb1d4f07127102_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4998d0b3b84c4399a118546128a7647b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38e0af14fe5042aa8dc04877b3a4299a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e2f59b7ba4641e584ab2ac68b96fe24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d99f049683342dab1c5c4e16251a30b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:December2019PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic650ec13b1084703a7916113f5898f77_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia0e15a98c6ae4762a3a129475340835f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie223919cfb0644d4b99679da636b322e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84041bbc80d94707bdd1c71475762b9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78706eee04a546a7a74922c746e3304a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c63f0a4b66643c095e667bc8734eabc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i460359c10d04485b8f24e8e8000ce638_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie74af6c07ea14138ab2b4641dd046986_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i283ae8fe845b4608857dda0e19da19e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i584a64da65b8465189421614a29d1307_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i163a45d096374a6caa35072e4bb91628_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f9096b4594d4ef887154e71f8bc2cfd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:May2019WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icdf0c791c34846d7948b3a5350feab73_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:InformationAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i7d2869ade03c4be1a192746ea93a57ed_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i67dc8fa5926e44009110a64d1f17ab86_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i8ef49a5dee2d41ff9b68a844e92232cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:TwothousandFifteenWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i579155917cc84c16b497230e8d059707_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:TwothousandFifteenWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i918faac37d3648509a88395256f45bfe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff2bfb667f574925a5837174b1cdfc30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd9f002eb2a44d11aabd8c0f84f46008_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b49ea1876014fb7ab34d29c8ee87415_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:A2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb64e100a4ea46aeaf2e021efaf9fc23_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i877dabd6d9f1456b80f4388fc9919198_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i15b635d7791d4729a41246f37fdd5040_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i8fba51ad7cb8481bae70c35bf580f079_D20170601-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i5fa56f65ff31460b927499357c824471_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i66f66be5e4ca4a3fbef0430494cb2a38_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8347ac776ecd461e8415e7b0e8c4a7fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i607f7ac1d3694172a81a41007edb3395_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4579f566e42442e9e3dc9eb88d2d447_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i10a66b0cab964a889263784aee1901fe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iec71a31edf584b3fbbe26a8ef6da1b57_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8724e49e7c1c44f9ae22762caedea6d7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4eccbe0a4d6f46a7beb0bc1fe08e5bab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ekso:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic57345e588804cfe860c750737f00dd8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id37bd0dc0daa4fb7b83159c71d2bfa17_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i311beee139874abaaa623022d8afd3cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if0686788f1e24c1290b7f0d92818a8ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32119daf61d74b55a3c8238a0cb3d15b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87e27b2516f148d697ece33f11777fc4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i082ff8dadd2c49fa8fbb80b8ffef3976_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e851d50c5564e38abf2c0a93b86475f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2948b44d394340328fd63500766a8e47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6df990af732247609512a586b14ed964_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9584796b78247a691fb1d74e4e04c73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ekso:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafd5100ca7f64a00831c51a479b855ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i214faac982094d0986fd63789ae5cc48_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2cb1ee725d64b848c8abc9e90945dbb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3cd9b4295544ce39f97760979ddef45_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i983c680de266493eb3b87d6e84973e71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6e43a3b8d704169bc941d426832f568_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if0580d79d27744dfa79750de680b753e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c9bf3c95d404943b8b37bf228a87293_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie50e530344ba4276bb503495928f0afe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f8787b85d56465398b389abe5c50313_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ekso:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bb6a31fa69b42789b1e10282b4ace5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10c35f66e6034eec83024df6ac610e24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ekso:GeneratedBefore2018Expire2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a5e4922e5c349469514d98ce6786b33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ekso:GeneratedBefore2018CarryforwardIndefinitelyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i319319b8233c4303ad3523ef6efcc360_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7df6497f41704a339bcb35d3d532dc6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6b25f2478684c8396497673025f1b5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia06204e374c64847aa8ca39f1c059324_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c8907ba268e43a890f1228c1a43a77e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ekso:SalesRevenueGoodsNetExcludingGovernmentSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if2504c7ec30a492e9cc1f890fccd8252_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ekso:LicenseRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4123648869a94d87948d26689a8190ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b339ba80adf48a59e5a09a23f722e4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ekso:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d1eb01e13aa4edd802e72c1ca0af002_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ekso:FacilityOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3cb3927a9fbf4e13a0140f4d17c94c07_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ekso:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ekso:EksoHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie155c69f21734a16917958178e1f51a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d6cdf8903fd44d7852fe7584e4e99cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9f0989d807f24270a4bd9f5c3d8d8d32_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3552c786c174ef89dfaa1c2526fc4e1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i632f81a051354fdf864a43648798ddbe_D20210201-20210226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="iaad6ab00ad864f69a9e847781dc8db64_I20210226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="i9b5c460bf8c84b56a0349fb3c3d0e654_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i16bf31763ef74fad820cf6aed9bb0918_I20210226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="i0cb8fcd93e684118ad89bca6e3dc19c7_D20210101-20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ekso:June2020WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="i226916c19ca6463c961b406e024eca43_I20210226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="ic513e7ac66894d34b00b95cd51300460_D20210225-20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ekso:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="days">
        <measure>ekso:days</measure>
    </unit>
    <unit id="license_agreement">
        <measure>ekso:license_agreement</measure>
    </unit>
    <unit id="segment">
        <measure>ekso:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF80L2ZyYWc6NWIzOTJmYmRiOGMwNDFlYzg3OGMwYWMyMWQ3YmEzNWMvdGFibGU6ZmQ3ZGU1OTc1M2I5NDUzMTkxOGNlMzY5YjdiMzkxMWMvdGFibGVyYW5nZTpmZDdkZTU5NzUzYjk0NTMxOTE4Y2UzNjliN2IzOTExY18zLTEtMS0xLTA_8fb17b65-e904-4187-81d7-8edf31a11e0c">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF80L2ZyYWc6NWIzOTJmYmRiOGMwNDFlYzg3OGMwYWMyMWQ3YmEzNWMvdGFibGU6ZmQ3ZGU1OTc1M2I5NDUzMTkxOGNlMzY5YjdiMzkxMWMvdGFibGVyYW5nZTpmZDdkZTU5NzUzYjk0NTMxOTE4Y2UzNjliN2IzOTExY181LTEtMS0xLTA_6a541dfc-160a-4cbb-bdc7-cc0c4033c6b4">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF80L2ZyYWc6NWIzOTJmYmRiOGMwNDFlYzg3OGMwYWMyMWQ3YmEzNWMvdGFibGU6ZmQ3ZGU1OTc1M2I5NDUzMTkxOGNlMzY5YjdiMzkxMWMvdGFibGVyYW5nZTpmZDdkZTU5NzUzYjk0NTMxOTE4Y2UzNjliN2IzOTExY182LTEtMS0xLTA_06138954-3810-411e-8572-81ca8f349f54">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF80L2ZyYWc6NWIzOTJmYmRiOGMwNDFlYzg3OGMwYWMyMWQ3YmEzNWMvdGFibGU6ZmQ3ZGU1OTc1M2I5NDUzMTkxOGNlMzY5YjdiMzkxMWMvdGFibGVyYW5nZTpmZDdkZTU5NzUzYjk0NTMxOTE4Y2UzNjliN2IzOTExY184LTEtMS0xLTA_e7778bc2-d04c-48dc-b27d-8e21760be113">0001549084</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id643b591bbe442ff89d7f6fedbd8777a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTIxNDU_cd4dc075-4b7e-413d-b6dc-6727130d268c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i34328fdb308e40c6bf10ef8dcd50adb7_D20200324-20200324"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjI3L2ZyYWc6MmViN2ZiNTg3ZWFhNGFmN2IxNmM2OGI4NzNhMzk4ZGIvdGV4dHJlZ2lvbjoyZWI3ZmI1ODdlYWE0YWY3YjE2YzY4Yjg3M2EzOThkYl8zMjk4NTM0ODgzMzM4_bc77d192-0955-4c7c-b9f1-11ebf91f869d"
      unitRef="number">0.0667</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i63834f56293d4e708f774c76a532f46f_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85Ny9mcmFnOjMyNmFjMWM5ZDc0ZDRlZDhhN2I3ZjRjODA3N2JjYzRjL3RhYmxlOmMxMTRlOTI1ZTQ4YjQyYmM4NmNkYTBhMmVhZWFmYjE5L3RhYmxlcmFuZ2U6YzExNGU5MjVlNDhiNDJiYzg2Y2RhMGEyZWFlYWZiMTlfMC0xLTEtMS0w_0aa57a83-4601-432f-8fd6-11cad36c63aa">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i3036960b630e4dc68acd1c3ce4478d07_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85Ny9mcmFnOjMyNmFjMWM5ZDc0ZDRlZDhhN2I3ZjRjODA3N2JjYzRjL3RhYmxlOmMxMTRlOTI1ZTQ4YjQyYmM4NmNkYTBhMmVhZWFmYjE5L3RhYmxlcmFuZ2U6YzExNGU5MjVlNDhiNDJiYzg2Y2RhMGEyZWFlYWZiMTlfMS0xLTEtMS0w_bf543942-4a5e-45de-adb1-1d49f3fa33b4">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i1189ad224a9542f99ef6b9177be8258c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85Ny9mcmFnOjMyNmFjMWM5ZDc0ZDRlZDhhN2I3ZjRjODA3N2JjYzRjL3RhYmxlOmMxMTRlOTI1ZTQ4YjQyYmM4NmNkYTBhMmVhZWFmYjE5L3RhYmxlcmFuZ2U6YzExNGU5MjVlNDhiNDJiYzg2Y2RhMGEyZWFlYWZiMTlfMi0xLTEtMS0w_6f5bf3e4-362f-4f0b-909b-1a94c4954b31"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i34328fdb308e40c6bf10ef8dcd50adb7_D20200324-20200324"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjM0L2ZyYWc6NzY1Y2YwNzgwZmFhNDEzOTgxNTdiMTliMmZkNWNjZDAvdGV4dHJlZ2lvbjo3NjVjZjA3ODBmYWE0MTM5ODE1N2IxOWIyZmQ1Y2NkMF8zODQ4MjkwNjk3MjIw_bc77d192-0955-4c7c-b9f1-11ebf91f869d"
      unitRef="number">0.0667</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <ekso:ClassOfWarrantOrRightPutOptionDurationOfPayPeriod
      contextRef="id396d3085bb24e85baf89441852a463a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NTAwMTE_96686e94-4d73-4fcb-ac01-69c8e1bec88a">P5D</ekso:ClassOfWarrantOrRightPutOptionDurationOfPayPeriod>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i34328fdb308e40c6bf10ef8dcd50adb7_D20200324-20200324"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjgzL2ZyYWc6ZGE2OGNiNWE3YjI2NDUzMzkwODZlN2Q1MDNjM2UyZGIvdGV4dHJlZ2lvbjpkYTY4Y2I1YTdiMjY0NTMzOTA4NmU3ZDUwM2MzZTJkYl8zMjk4NTM0ODgzMzgy_fbdd8d3b-31bc-4ee8-a5f0-a22a7f40f153"
      unitRef="number">0.067</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="iff2bfb667f574925a5837174b1cdfc30_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjgzL2ZyYWc6ZGE2OGNiNWE3YjI2NDUzMzkwODZlN2Q1MDNjM2UyZGIvdGV4dHJlZ2lvbjpkYTY4Y2I1YTdiMjY0NTMzOTA4NmU3ZDUwM2MzZTJkYl8zMjk4NTM0ODgzMzQz_2ef14bef-3cae-4924-b30b-fa2ef18f7327">P5Y6M</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="ifd9f002eb2a44d11aabd8c0f84f46008_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjgzL2ZyYWc6ZGE2OGNiNWE3YjI2NDUzMzkwODZlN2Q1MDNjM2UyZGIvdGV4dHJlZ2lvbjpkYTY4Y2I1YTdiMjY0NTMzOTA4NmU3ZDUwM2MzZTJkYl8zMjk4NTM0ODgzMzY2_59ffbb29-db07-4282-a84d-e6b120af2f70">P5Y6M</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i4b49ea1876014fb7ab34d29c8ee87415_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNjgzL2ZyYWc6ZGE2OGNiNWE3YjI2NDUzMzkwODZlN2Q1MDNjM2UyZGIvdGV4dHJlZ2lvbjpkYTY4Y2I1YTdiMjY0NTMzOTA4NmU3ZDUwM2MzZTJkYl8zMjk4NTM0ODgzMzk2_4c180010-2c87-4c6f-b86d-4b9ecb8b9a71">P6M1D</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <dei:DocumentType
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDQ4_53a012be-1309-464b-bcd1-78b801a8d0f2">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6NjZhZjEzZTBlZThhNDQzMTlhZDQ2MWM4OTg2MTcwOGYvdGFibGVyYW5nZTo2NmFmMTNlMGVlOGE0NDMxOWFkNDYxYzg5ODYxNzA4Zl8wLTAtMS0xLTE0MA_a8cf93e0-5faf-4e94-b522-1c6982e8b052">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDg1_46ef9cf7-6791-4999-b220-795023b47fcd">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDg1_664b86db-1e42-435e-a383-cfff658df062">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6MDI3ZWE0ZmE5ZTE0NGE0MjlhYjkyYmFkNTEzYmI3N2IvdGFibGVyYW5nZTowMjdlYTRmYTllMTQ0YTQyOWFiOTJiYWQ1MTNiYjc3Yl8wLTAtMS0xLTE0Mg_0463c821-73f9-4f6d-9aa9-86d82d4a2ed3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDg2_7426e21a-a16f-47e8-b7f1-f26f8c4a8ee3">001-37854</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDg4_1f3806d9-821e-46af-adb9-1293c699fadd">Ekso Bionics Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6ZTNjNDQwZjM2YTdkNDM0OWJkZTU5ZjJkYjI1YjMwMWMvdGFibGVyYW5nZTplM2M0NDBmMzZhN2Q0MzQ5YmRlNTlmMmRiMjViMzAxY18wLTAtMS0xLTE2Mg_be65bf50-23f1-4371-bfad-486de378c496">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6ZTNjNDQwZjM2YTdkNDM0OWJkZTU5ZjJkYjI1YjMwMWMvdGFibGVyYW5nZTplM2M0NDBmMzZhN2Q0MzQ5YmRlNTlmMmRiMjViMzAxY18wLTEtMS0xLTE2Mg_447f21e9-fd97-4391-afb4-227dcb26376a">99-0367049</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDg5_9613e467-1807-49cc-bd44-5617c6774667">1414 Harbour Way South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDkw_d2728153-0689-42c8-bbb4-994d92343c19">Suite 1201</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTA1_a25100f1-8b96-490b-bb2b-b29a2abf29eb">Richmond</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTA2_233fc2f4-d3d1-4c6e-8b4f-de5b928a15c0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NDky_453f5d6a-4a9d-4d04-8d4d-59c78630be49">94804</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTA5_b4a3c9ad-e8a3-48cc-8fa6-4c730789e0f9">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTA3_0c58b56d-3881-4fda-a730-cc34dc08b0d8">984-1761</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6MmVmOWVlZjIyOWI4NDM5YjlkZjc0ODFiY2FlYWZhODIvdGFibGVyYW5nZToyZWY5ZWVmMjI5Yjg0MzliOWRmNzQ4MWJjYWVhZmE4Ml8xLTAtMS0xLTA_686ed1be-d4e4-4c93-a15c-802a7728a924">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6MmVmOWVlZjIyOWI4NDM5YjlkZjc0ODFiY2FlYWZhODIvdGFibGVyYW5nZToyZWY5ZWVmMjI5Yjg0MzliOWRmNzQ4MWJjYWVhZmE4Ml8xLTEtMS0xLTIxNQ_8c3d4907-f8d2-4707-ae19-a48b46199575">EKSO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGFibGU6MmVmOWVlZjIyOWI4NDM5YjlkZjc0ODFiY2FlYWZhODIvdGFibGVyYW5nZToyZWY5ZWVmMjI5Yjg0MzliOWRmNzQ4MWJjYWVhZmE4Ml8xLTItMS0xLTMwNC90ZXh0cmVnaW9uOjhkN2IyMzE2ZTdhNjRmMjRhMjdhZmVlNmFlMDhhMjE1XzMyOTg1MzQ4ODMzNjE_ad61c234-bc44-416b-b6c7-49f2060a3149">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTE4_7aebfdc2-e610-4403-936e-2bcd2e7a7166">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTE5_72e0daae-53b4-4716-a13e-c963b48afd74">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTIw_be2f01e2-32ae-41c8-943d-1cb01d93fcf6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTIx_1761478a-4522-4e23-9563-94ba006d573f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTU3_62ae5926-4a2f-4289-baac-11f1559c70a2">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTI1_69bfa75f-f1f7-44f5-a3ab-c9ec551ec067">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTI4_049bbf16-f8fb-45f6-8e8e-1fdc79215d33">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTM1_da42bcff-8a6e-46ab-a50b-27e17253fb0e">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i2d6f176932954c3ea9bd0f2f47990c67_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8yNTE2_811ad4bd-9086-4b41-a36a-667fac10de6a"
      unitRef="usd">52257307</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i725a7c78af424676baf1ece165c91377_I20210219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8yNjk4_cb3a6acf-8b0b-436f-87a1-def3510de3d3"
      unitRef="shares">12599900</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xL2ZyYWc6Zjc2YmUyZDMwNTFmNGIwOWE3NDkxNTRiNzM2OGE1NGYvdGV4dHJlZ2lvbjpmNzZiZTJkMzA1MWY0YjA5YTc0OTE1NGI3MzY4YTU0Zl8zMjk4NTM0ODg2NTM2_0cf9bbec-cfac-4b0f-991a-0fd8fd5ff3de">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s Proxy Statement for the 2021 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNC0xLTEtMS0w_33a9b785-454a-4d89-b85b-44cc86cd965f"
      unitRef="usd">12862000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNC0zLTEtMS0w_394209fe-22fa-4a32-9256-79905ebb4499"
      unitRef="usd">10872000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNS0wLTEtMS0wL3RleHRyZWdpb246ZjI2MmNkNjczZGU3NDU5MDkzYTBjN2JmNGMyNTkyNmZfMzg0ODI5MDY5NzI5Mw_b7409031-8ad1-45ee-9283-4026945b6491"
      unitRef="usd">42000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNS0wLTEtMS0wL3RleHRyZWdpb246ZjI2MmNkNjczZGU3NDU5MDkzYTBjN2JmNGMyNTkyNmZfMzg0ODI5MDY5NzI5OQ_5c2bae69-e2a9-48e9-8a40-a6b4e83aff2d"
      unitRef="usd">121000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNS0xLTEtMS0w_12f2f072-ad8a-40b1-bb9f-d2b4c5adec88"
      unitRef="usd">3389000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNS0zLTEtMS0w_291f195a-0d9e-4d28-a57e-489888221f03"
      unitRef="usd">5208000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNi0xLTEtMS0w_f95fa37b-7926-4b4d-abbf-34c0d71267b9"
      unitRef="usd">1978000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNi0zLTEtMS0w_e9626257-2643-4fcd-b5c2-2bc4abdac886"
      unitRef="usd">2489000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNy0xLTEtMS0w_3e1e79ed-d427-486c-b3cc-8863fb3ae2c4"
      unitRef="usd">191000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfNy0zLTEtMS0w_da529cce-37a3-483b-9d9c-b754f90ffa1e"
      unitRef="usd">238000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfOC0xLTEtMS0w_ad1e96d8-3f2f-49c6-90c4-eea8781b0bd0"
      unitRef="usd">18420000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfOC0zLTEtMS0w_4d45a202-16df-4d4c-995b-cc6df6a38724"
      unitRef="usd">18807000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfOS0xLTEtMS0w_41e38bf4-ab14-49c1-83b1-de7bc8f5b20f"
      unitRef="usd">1172000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfOS0zLTEtMS0w_85853ef2-ef7a-416d-97c2-0dacd3ac1539"
      unitRef="usd">1657000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTAtMS0xLTEtMA_32a035de-71f3-40a5-b5e3-b560ff45a72b"
      unitRef="usd">685000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTAtMy0xLTEtMA_08a9a8d9-b822-40e2-b3e4-aa39ee5467cf"
      unitRef="usd">1084000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTEtMS0xLTEtMA_e1a00c5d-2279-4545-a259-6b1a91e49b44"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTEtMy0xLTEtMA_5d7fd432-c953-4427-a108-8527b698485f"
      unitRef="usd">189000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTItMS0xLTEtMA_756220c6-5064-45f5-9fda-5d3639e5e2b6"
      unitRef="usd">320000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTItMy0xLTEtMA_fbd07a9e-721f-4235-9bdf-2de529b13e94"
      unitRef="usd">178000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTMtMS0xLTEtMA_dcea8347-ba52-43fd-a0f8-2be5235d6546"
      unitRef="usd">20597000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTMtMy0xLTEtMA_44159b9f-63dc-4262-bc49-64303169cb8b"
      unitRef="usd">21915000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTctMS0xLTEtMA_6a2f3f8c-55e1-4846-b05a-84804ca5d21c"
      unitRef="usd">1501000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTctMy0xLTEtMA_5bc980b1-82e2-49d0-b1e6-15ec41736001"
      unitRef="usd">1903000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTgtMS0xLTEtMA_1d8f03b6-670b-4d10-9437-bef992135a72"
      unitRef="usd">1429000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTgtMy0xLTEtMA_72efe25c-4bca-4f0f-842f-ad4721540e7e"
      unitRef="usd">1683000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTktMS0xLTEtMA_8c9792d4-8a11-4040-bde7-6cd8887e3062"
      unitRef="usd">1496000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMTktMy0xLTEtMA_759f3ac2-4102-482b-b580-49cc9fae65a9"
      unitRef="usd">1492000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjAtMS0xLTEtMA_b19c0f46-9893-4395-a2df-1099245a9f24"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjAtMy0xLTEtMA_f86513f7-6100-4b81-9936-f48a6f37e531"
      unitRef="usd">2333000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjEtMS0xLTEtMA_cc8ec08e-dfdf-4405-aa2c-b6e2af90c274"
      unitRef="usd">548000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjEtMy0xLTEtMA_ed34d6a6-cffb-4652-8d6c-92467b3b594b"
      unitRef="usd">421000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjItMS0xLTEtMA_a88af7fd-62e7-4436-bd6b-a755601e1712"
      unitRef="usd">4974000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjItMy0xLTEtMA_54d67616-7b81-4527-beed-398e11e59296"
      unitRef="usd">7832000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjMtMS0xLTEtMA_132f5c0d-c9ef-43c9-8f00-4daa43d7b437"
      unitRef="usd">1806000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjMtMy0xLTEtMA_030aa669-3bc9-435b-a115-384e388c0316"
      unitRef="usd">1789000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjQtMS0xLTEtMA_7ea2dea8-6e57-4a47-a9ff-bee2f069cad6"
      unitRef="usd">3075000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjQtMy0xLTEtMA_91019969-6d4d-4f83-8a81-c0b168e84fa9"
      unitRef="usd">407000</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjUtMS0xLTEtMA_311c26d3-9b5b-4080-8ce4-7f2fd2a0daa0"
      unitRef="usd">233000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjUtMy0xLTEtMA_4f55ecd0-e3b5-4442-8b0c-175602965ba6"
      unitRef="usd">711000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjYtMS0xLTEtMA_741b9dd4-db5f-419f-9a5a-4e1efda8c6bc"
      unitRef="usd">6037000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjYtMy0xLTEtMA_f9175da9-a4ce-463e-93bc-40e5179b5ba4"
      unitRef="usd">4307000</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjctMS0xLTEtMA_5f666808-9530-440c-9287-c4c9d5003a7a"
      unitRef="usd">38000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjctMy0xLTEtMA_f25cf985-4c25-4b21-ac63-95c4f422eaa0"
      unitRef="usd">72000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjgtMS0xLTEtMA_82ef0b54-4f28-460b-abc0-8663a8fef61a"
      unitRef="usd">16163000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjgtMy0xLTEtMA_5b7c690c-3a9c-4eea-b548-7800d322d9e1"
      unitRef="usd">15118000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjktMS0xLTEtMA_8bd794ff-e580-43fd-86d8-7885d366a320"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMjktMy0xLTEtMA_5c23561b-292e-4c43-a91b-8b0e7895344b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNjE_63d57617-22f3-43e7-8b7c-283c7f66eddb"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNjE_b3eac00f-d729-4118-8389-c71cd14189cf"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNjk_5ea5a736-41b3-48f6-9b22-d553f61fdab4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNjk_d3410503-17cc-44b2-b7bc-a590ec8e6536"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNzM_200f7ab6-e51b-485d-b52d-c3e428c27bab"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNzM_585d170b-7885-4f0c-a159-57c30ff7d0fb"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNzM_6e5ce7f2-0a6b-4c7c-ab6c-0e8d80bbf711"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdiYTcyN2RmNjE0YTRhODhhYjAzYjQyYmI1YTQ5ZWYxXzM4NDgyOTA2OTczNzM_d58d88a6-119b-421a-bfb7-88786fc1d0c3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMS0xLTEtMA_d92dabd5-d0f2-4eb0-b000-3df03f98be68"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzEtMy0xLTEtMA_6055d5a1-6e67-4931-85f7-f5d2b5109c4e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczNzY_088339d4-7331-4619-9b97-77ee25509fb7"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczNzY_e6f30c55-db9a-43f8-9a28-33eb5cea64fb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczODU_9a37a21f-e031-4bf6-8600-f2b24fba70ab"
      unitRef="shares">141429000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczODU_b98c2567-b8c6-4b56-9130-cc81b20a75a9"
      unitRef="shares">141429000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczOTM_00907bf2-4b71-40d8-a54a-dacd61e0165d"
      unitRef="shares">8349000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTczOTM_7fe2d3cb-f36d-48fd-bffc-dd309b7daa4f"
      unitRef="shares">8349000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTc0MDE_85c48f05-0aee-4a49-b2d8-ddf303412407"
      unitRef="shares">5795000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlYjRmNTk1ZDkxYzQ5YWU4ZmY3ZWU3YWZjODc1MTNhXzM4NDgyOTA2OTc0MDE_979f0a4d-198f-450e-92f5-b85f65968410"
      unitRef="shares">5795000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMS0xLTEtMA_2611835e-276d-489b-ad2d-fb2c1c85bf49"
      unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzItMy0xLTEtMA_8f03763f-fa57-43b9-ae59-6b3fc00b0582"
      unitRef="usd">6000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzMtMS0xLTEtMA_acf135b0-b245-4593-a736-a5a53b427ebf"
      unitRef="usd">204376000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzMtMy0xLTEtMA_58c4005b-98bc-4018-aeeb-43c58797892f"
      unitRef="usd">190019000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzQtMS0xLTEtMA_ea7cb5b3-34e5-4283-b111-a7adee3b22cd"
      unitRef="usd">-847000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzQtMy0xLTEtMA_bdaded1b-4968-443e-acb4-74aaf96142c2"
      unitRef="usd">50000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzUtMS0xLTEtMA_0e8f253b-9d39-44ff-bf4a-fb0e7437071f"
      unitRef="usd">-199103000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzUtMy0xLTEtMA_39ee348a-27ff-41e1-b70b-cd74f1e524cc"
      unitRef="usd">-183278000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzYtMS0xLTEtMA_31a4b939-59ae-416b-9282-04792d3b4cae"
      unitRef="usd">4434000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzYtMy0xLTEtMA_4ec4d7a9-196b-491c-99b4-1353f686e43c"
      unitRef="usd">6797000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzctMS0xLTEtMA_f47f42b9-de71-418b-9666-fdc219111fdb"
      unitRef="usd">20597000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF81NS9mcmFnOjhlODc3ZTg3Zjk4MDRkMmI5ZjdhZTQ1NWY0ODlmZDdmL3RhYmxlOmIzMDcxNTdlMmI5MDQyYzRhYWVlMTYxYmQwOTNlYWI4L3RhYmxlcmFuZ2U6YjMwNzE1N2UyYjkwNDJjNGFhZWUxNjFiZDA5M2VhYjhfMzctMy0xLTEtMA_6fbad5e6-0a36-4b59-928c-29b49d3868f6"
      unitRef="usd">21915000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMi0xLTEtMS0w_947a65d4-2248-467d-b31b-948a6ff3a438"
      unitRef="usd">8882000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMi0zLTEtMS0w_c7e3dfd2-1220-4111-8008-e1b348e591c4"
      unitRef="usd">13917000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMy0xLTEtMS0w_b6c31977-8df2-4b98-ae1b-4597036626cc"
      unitRef="usd">3812000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMy0zLTEtMS0w_c8fde8f7-fd42-4793-b447-f54007b6060f"
      unitRef="usd">7153000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfNC0xLTEtMS0w_347e842f-2244-4826-a34d-5258f5450fe1"
      unitRef="usd">5070000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfNC0zLTEtMS0w_c07b4cd2-d885-4337-a6d2-0c973f73c789"
      unitRef="usd">6764000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfNy0xLTEtMS0w_a5e1155a-7fbd-471f-a316-0ed306a0cc7c"
      unitRef="usd">7752000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfNy0zLTEtMS0w_8b4f3555-9ee3-4eea-a84f-de1ba6e5235c"
      unitRef="usd">11398000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfOC0xLTEtMS0w_528a750c-396d-4261-abad-70ffeb186458"
      unitRef="usd">2474000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfOC0zLTEtMS0w_c65db4f3-f6ed-410b-9187-308fe88293fd"
      unitRef="usd">4596000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfOS0xLTEtMS0w_47ca9f18-20c7-4434-8944-2389d2910f9d"
      unitRef="usd">7702000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfOS0zLTEtMS0w_ca4c7e6d-d473-48f1-9b2f-5c6c9fdb5e99"
      unitRef="usd">7409000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTAtMS0xLTEtMTI5MQ_be47497a-766c-43c0-a5d7-21fb657b8a39"
      unitRef="usd">189000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTAtMy0xLTEtMTI5MQ_074bed6d-f5de-495a-8e87-392b108c4c5e"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:RestructuringCharges
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTAtMS0xLTEtMA_2dead2d9-1e48-4fd0-994f-b909d6073602"
      unitRef="usd">244000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTAtMy0xLTEtMA_d8b9bd00-2f1b-4957-adfb-993476ce9183"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTEtMS0xLTEtMA_ac0daf5a-95d3-450d-ba11-3f0242448b1c"
      unitRef="usd">18361000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTEtMy0xLTEtMA_78852f12-1c21-416c-ab76-1f9a94c8a6af"
      unitRef="usd">23403000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTMtMS0xLTEtMA_dd51f210-7599-43e2-aa00-f7a803781fba"
      unitRef="usd">-13291000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTMtMy0xLTEtMA_0f46eb92-ed7a-4b2c-8eeb-b6759d2757cd"
      unitRef="usd">-16639000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTYtMS0xLTEtMA_1c9763d3-eb6d-4b0a-8cbb-5fc2eb5588f8"
      unitRef="usd">139000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTYtMy0xLTEtMA_7cfc18a6-0d9a-454f-b9f9-d01006ba0eea"
      unitRef="usd">384000</us-gaap:InterestExpense>
    <ekso:WarrantIssuanceExpense
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTctMS0xLTEtMA_16f82520-66f8-48f1-baaa-e6d5eb09634c"
      unitRef="usd">329000</ekso:WarrantIssuanceExpense>
    <ekso:WarrantIssuanceExpense
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTctMy0xLTEtMA_d1260515-45f8-4a79-b420-197f7e796c0f"
      unitRef="usd">1096000</ekso:WarrantIssuanceExpense>
    <ekso:GainLossOnWarrantLiability
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTgtMS0xLTEtMA_00fc8be0-c19d-47e8-a788-473db1607eda"
      unitRef="usd">-3056000</ekso:GainLossOnWarrantLiability>
    <ekso:GainLossOnWarrantLiability
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTgtMy0xLTEtMA_b0344c95-ded8-4d73-8c8b-833dbf462390"
      unitRef="usd">6376000</ekso:GainLossOnWarrantLiability>
    <ekso:GainLossOnWarrantModification
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTktMS0xLTEtMA_9dd93e56-e233-41fd-9994-2c1c43547e04"
      unitRef="usd">0</ekso:GainLossOnWarrantModification>
    <ekso:GainLossOnWarrantModification
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMTktMy0xLTEtMA_2d70313d-21f0-47e6-a03f-075865445849"
      unitRef="usd">-257000</ekso:GainLossOnWarrantModification>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjAtMS0xLTEtMA_f8d464a4-bf9c-41be-af42-893ca61e850d"
      unitRef="usd">990000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjAtMy0xLTEtMA_2268df54-369a-45a1-81fb-fe7e14655c79"
      unitRef="usd">-132000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjEtMS0xLTEtMA_fb7df25b-aed8-4e6d-8f6c-e64f7f7faafd"
      unitRef="usd">-2534000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjEtMy0xLTEtMA_588754f0-ba82-49e4-ae85-f5558a15d841"
      unitRef="usd">4507000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjYtMS0xLTEtMA_4217ac9f-a393-47f6-97c7-031b188c89f0"
      unitRef="usd">-15825000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjYtMy0xLTEtMA_89b0ab3b-4647-4871-86d6-04f2e7670322"
      unitRef="usd">-12132000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjctMS0xLTEtMA_28bbde32-61e4-4417-9a59-f7d3bdad8b2d"
      unitRef="usd">-897000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjctMy0xLTEtMA_f7e72932-d9e1-4600-b8af-f75105d1c812"
      unitRef="usd">142000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjgtMS0xLTEtMA_06df7129-8bf5-4261-bd35-a0aeff00c751"
      unitRef="usd">-16722000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMjgtMy0xLTEtMA_a7f62284-d8c6-435e-9894-b000efd3991e"
      unitRef="usd">-11990000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMzAtMS0xLTEtMA_545fcf49-82b4-430e-825d-f1f9bb1c8a97"
      unitRef="usdPerShare">-2.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMzAtMy0xLTEtMA_c4b476c2-7907-4018-be4f-1c5a29ccf867"
      unitRef="usdPerShare">-2.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMzItMS0xLTEtMA_55bb4a46-4459-4449-9efa-1ea856afc4b7"
      unitRef="shares">7164000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82MS9mcmFnOjE0ODA0NWMwNDk1MTRkNDk5YzJkMTZmZmE0NDkzNDIxL3RhYmxlOjMwY2M3YTE2YjQzNjQyZjU5MjQ5OGNhNjNiYWU0YzY5L3RhYmxlcmFuZ2U6MzBjYzdhMTZiNDM2NDJmNTkyNDk4Y2E2M2JhZTRjNjlfMzItMy0xLTEtMA_22f1d12a-091e-48f8-97da-407abab44e60"
      unitRef="shares">4794000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i846dd5585ada4e0498b73873e27cdcdc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi0xLTEtMS0w_67796140-0ec2-42f5-a1b7-4c42a0fa8017"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i846dd5585ada4e0498b73873e27cdcdc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi0zLTEtMS0w_7f5d01db-e807-4040-ad06-17ffdee2648f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i771c5968601e4ebbaee595d0efedc2df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi01LTEtMS0w_b1ae72da-3922-41c2-b458-efdad8c4c33e"
      unitRef="shares">4198000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i771c5968601e4ebbaee595d0efedc2df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi03LTEtMS0w_9fc27227-df2e-41fc-b62d-25c0e4f007e8"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i001a198ae0ad4ccaabceb0a88f0757da_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi05LTEtMS0w_8f0e4f4d-d5db-46bd-be36-005e92e58b84"
      unitRef="usd">173962000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b330504326e4a9bbc4d3e4b7244e5fb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi0xMS0xLTEtMA_763d3a49-4cb4-472e-be14-b8a50b783611"
      unitRef="usd">-92000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ed408484abc4ce88899f293e7cfe8ad_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi0xMy0xLTEtMA_0f073f3a-600f-4f4d-b612-e55ad53eceaa"
      unitRef="usd">-171146000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5cd59b28ca904e409d6a180ec9f55846_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMi0xNS0xLTEtMA_c530f71c-2e23-499d-b1f1-b48991606dcd"
      unitRef="usd">2728000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia0c5a8bcf1214cdea5e114d7188288c6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMy0xMy0xLTEtMA_a4299af9-abc7-40a1-9aca-b118eb622d9f"
      unitRef="usd">-12132000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMy0xNS0xLTEtMA_89851fe9-f069-4a5e-b9c6-c3584c465565"
      unitRef="usd">-12132000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNS01LTEtMS0w_d33982d7-1089-4df1-8b61-85f88c5bb4e7"
      unitRef="shares">1534000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNS03LTEtMS0w_296f2f4a-52a3-4873-8387-c5788cab3c16"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNS05LTEtMS0w_c3c75f05-8554-488c-921c-fed827c873ac"
      unitRef="usd">12442000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNS0xNS0xLTEtMA_bacbbe2b-7476-4210-a714-d10ca757fa83"
      unitRef="usd">12444000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ekso:StockIssuedDuringPeriodShareEquiposisSalesEarnOut
      contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNi01LTEtMS0w_0f1a5483-c4ae-4a13-b3b0-3ea11c011294"
      unitRef="shares">1000</ekso:StockIssuedDuringPeriodShareEquiposisSalesEarnOut>
    <ekso:StockIssuedDuringPeriodValueEquiposisSalesEarnOuts
      contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNi05LTEtMS0w_bccba06d-75ae-4637-94cd-6e389324ff76"
      unitRef="usd">22000</ekso:StockIssuedDuringPeriodValueEquiposisSalesEarnOuts>
    <ekso:StockIssuedDuringPeriodValueEquiposisSalesEarnOuts
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNi0xNS0xLTEtMA_d8ff72f5-8f68-4c9d-96d7-8541cb4e64a4"
      unitRef="usd">22000</ekso:StockIssuedDuringPeriodValueEquiposisSalesEarnOuts>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNy01LTEtMS0w_2aaa9de6-a07d-4fc0-af51-a7f63b6a2d22"
      unitRef="shares">12000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNy05LTEtMS0w_b6fcf445-fbde-493e-9d26-e564035f9079"
      unitRef="usd">228000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfNy0xNS0xLTEtMA_e68b6a2d-825f-4cd1-a4ef-164aa17760c2"
      unitRef="usd">228000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOC01LTEtMS0w_43b1218f-10bc-481d-887e-488a03451b0e"
      unitRef="shares">9000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOC05LTEtMS0w_1d1d1391-dff1-49d9-a72f-2b48b6564061"
      unitRef="usd">191000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOC0xNS0xLTEtMA_3e437c76-b018-4c59-a6c0-8c3193f3892c"
      unitRef="usd">191000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i0a69537800df4d10a8bf29a9fc89c5f1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOS01LTEtMS0w_5864a038-506e-4a78-8e24-c565a27af2e0"
      unitRef="shares">41000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOS05LTEtMS0w_1a883a29-9c99-46cc-bcbd-fe4cab050eaa"
      unitRef="usd">919000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfOS0xNS0xLTEtMA_4280fac9-c4ab-489d-97b6-baca93414cb0"
      unitRef="usd">919000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i849b0c6b03434f2db3040aea9eaf8b16_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTAtOS0xLTEtMA_4820aefe-f284-464f-b01e-9fe1517f96af"
      unitRef="usd">2255000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTAtMTUtMS0xLTA_9095f546-1655-474c-a939-93a60ce078cd"
      unitRef="usd">2255000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib9f045d0163b47d080fcc09d4ec9b298_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTEtMTEtMS0xLTA_b9a4e882-45d2-4824-8bd0-7477e23bfcc4"
      unitRef="usd">142000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTEtMTUtMS0xLTA_983db78e-3da1-4ad5-b274-4b7fb2156926"
      unitRef="usd">142000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i8fdf493d0b2b4110824781819eb0a66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItMS0xLTEtMA_6da0a78e-de7f-4fa3-946c-7ec86faf5e3e"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8fdf493d0b2b4110824781819eb0a66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItMy0xLTEtMA_115a14d1-0b81-4e94-bbd1-7a86c26440e8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ia0387f9eb02e44e3b6ba26b31874ce98_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItNS0xLTEtMA_41ed3135-0ef7-4a89-b312-f369fe53dbc5"
      unitRef="shares">5795000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia0387f9eb02e44e3b6ba26b31874ce98_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItNy0xLTEtMA_31b78397-0735-4966-a28d-664f19b41a5f"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i355702e247f64033a0ce80c82800d085_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItOS0xLTEtMA_8a17c095-f7e9-4c83-9d5c-8fa70509a3e1"
      unitRef="usd">190019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i164b98fab8ca484db400c50acb2bde32_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItMTEtMS0xLTA_5e8ffb75-77fe-42cb-b3f2-c911af22dbcc"
      unitRef="usd">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id633f108918a485b94dd3575f357c6d1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItMTMtMS0xLTA_c62744bb-7721-48c4-a9e7-fccc09d04e30"
      unitRef="usd">-183278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTItMTUtMS0xLTA_21a9a99b-7469-4744-ab39-41ec42356d84"
      unitRef="usd">6797000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic8437b75fb864b51a8daec69829e7ede_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTMtMTMtMS0xLTA_fab51601-ae0f-4fab-a928-b79b27cdea2c"
      unitRef="usd">-15825000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTMtMTUtMS0xLTA_365743c0-8025-4ea3-b610-4910c2808d20"
      unitRef="usd">-15825000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTUtNS0xLTEtMA_f8826d42-06eb-4e7d-a0f3-8648c289e299"
      unitRef="shares">1748000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTUtNy0xLTEtMA_28ef0c61-1b93-47a8-8728-a412b5445bac"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTUtOS0xLTEtMA_ce85c8ec-8391-4176-8e04-0375c7a3e208"
      unitRef="usd">7080000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTUtMTUtMS0xLTA_52257cef-8eba-4019-983b-4cc88de8d82f"
      unitRef="usd">7082000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTYtNS0xLTEtMA_58804c85-f09b-465d-bac4-b0307bf95759"
      unitRef="shares">35000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <ekso:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctNS0xLTEtMTY0NA_852b1e08-15e4-4b5d-a077-59c88a4fa38e"
      unitRef="shares">723000</ekso:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <ekso:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctOS0xLTEtMTY0NA_2d49e278-1d49-40de-996e-ad87f2b4f999"
      unitRef="usd">7310000</ekso:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <ekso:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctMTUtMS0xLTI1Njg_9dab0fac-763b-4ad9-86ff-13620e29b76a"
      unitRef="usd">7310000</ekso:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctNS0xLTEtMA_5989cd11-0868-42fc-813e-00d87117317a"
      unitRef="shares">26000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctOS0xLTEtMA_3392a6f4-adb7-41cd-849d-9015a6c3cc02"
      unitRef="usd">155000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTctMTUtMS0xLTA_b0c0ebfa-bf1c-44dc-9fcb-153a8b6dd6d8"
      unitRef="usd">155000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTgtNS0xLTEtMA_73cf29da-d2ae-47f7-bfbd-cdadab0b7df1"
      unitRef="shares">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTgtOS0xLTEtMA_906806d7-e25b-4dae-a5d8-a8e788bf6d8d"
      unitRef="usd">50000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTgtMTUtMS0xLTA_cbc6cc8d-13fd-4f7f-b9d6-bd1c0bef73d0"
      unitRef="usd">50000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="i01af03aaba9e42f183607922e7b8b2b3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMTktNS0xLTEtMA_26a4cd75-d04d-42e3-932a-1cef52f47918"
      unitRef="shares">13000</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <ekso:AdjustmentsToAdditionalPaidInCapitalWarrantIssuance
      contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjEtOS0xLTEtMTY1MA_4b6d832c-5aa9-4da2-9bc8-19e2a44b6691"
      unitRef="usd">2322000</ekso:AdjustmentsToAdditionalPaidInCapitalWarrantIssuance>
    <ekso:AdjustmentsToAdditionalPaidInCapitalWarrantIssuance
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjEtMTUtMS0xLTI1NzM_1629fc5c-fef0-4bd3-8a85-b3fe381265a9"
      unitRef="usd">2322000</ekso:AdjustmentsToAdditionalPaidInCapitalWarrantIssuance>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ibf08ded0b1c843ef83989d5051c9af1a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjAtOS0xLTEtMA_e4999154-8b4a-4b14-a35e-a1c326ef7643"
      unitRef="usd">2084000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjAtMTUtMS0xLTA_571b8ef4-9ad8-4e69-8f25-4d407c3719e5"
      unitRef="usd">2084000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1244662c4107454f9abedb0d2c7dd95a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjEtMTEtMS0xLTA_fc85725c-bd81-4386-90d0-3c5fa85f3ac7"
      unitRef="usd">-897000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjEtMTUtMS0xLTA_bb1f3234-265f-411d-a992-2f7d4c0d97ac"
      unitRef="usd">-897000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i7fb8ef54637c4de2a9b1091027aa5962_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItMS0xLTEtMA_2b8fbafe-ed89-44ba-913c-791d5c7027a5"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7fb8ef54637c4de2a9b1091027aa5962_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItMy0xLTEtMA_67ab5e5e-0fec-4c2c-82da-5a0867f68337"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i56dbcebcd6d641bdb0fa75661fc45501_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItNS0xLTEtMA_51c6f5aa-8f36-47b0-9e8e-be4ed444b301"
      unitRef="shares">8349000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i56dbcebcd6d641bdb0fa75661fc45501_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItNy0xLTEtMA_d7904ad3-053f-4cdd-a7d6-ef877651b8a6"
      unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4b0ba326b044c5d8a0bb299a3ec93ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItOS0xLTEtMA_ebcad8a6-c446-4247-bd1a-fcc2e1a0312a"
      unitRef="usd">204376000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic126d0c0305a496bb377ee4b4e95f356_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItMTEtMS0xLTA_fd93cbce-009e-45e3-bd36-51c53e884965"
      unitRef="usd">-847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7fef623934b4bd19b22ecc59a17e7ca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItMTMtMS0xLTA_d8597d08-2a2f-431b-bee9-1667c74eba04"
      unitRef="usd">-199103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF82NC9mcmFnOjJiYzRhYzljYjViZTQ5ZmZhOGQwZmJiYTI4ZGM0OTNmL3RhYmxlOjdjNDg5OWMxMDg5ZTQyYzI4OThiNDNiYzQ5N2ViNDZiL3RhYmxlcmFuZ2U6N2M0ODk5YzEwODllNDJjMjg5OGI0M2JjNDk3ZWI0NmJfMjItMTUtMS0xLTA_0241f623-edaf-4c02-8981-556ee4c93849"
      unitRef="usd">4434000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMy0xLTEtMS0w_a6baf523-4dc3-4a56-b840-4747b405395f"
      unitRef="usd">-15825000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMy0zLTEtMS0w_efe1a95a-5406-4ba3-b9c6-71adcaeba45f"
      unitRef="usd">-12132000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNS0xLTEtMS0w_c0bc7627-e083-44e8-98a4-9e9f1b755a86"
      unitRef="usd">620000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNS0zLTEtMS0w_7b782da0-7953-49de-9cdb-151828c9e81c"
      unitRef="usd">690000</us-gaap:Depreciation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNy0xLTEtMS0w_137d4ca6-a0b7-4acd-996d-1f1f1b5c6739"
      unitRef="usd">65000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNy0zLTEtMS0w_c76f65eb-cda1-49e3-b8b2-f7426966e6cd"
      unitRef="usd">52000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfOC0xLTEtMS0w_132a52a1-a4f4-4e94-9728-60f0c047e6c8"
      unitRef="usd">189000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfOC0zLTEtMS0w_24c9fec1-e927-41b8-9eab-b41fa0022750"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfOS0xLTEtMS0w_1820dc7e-eea9-4633-a8e4-6fb512d54552"
      unitRef="usd">28000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfOS0zLTEtMS0w_831b2b2d-ba4e-442c-8639-bb41cc115e00"
      unitRef="usd">64000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <ekso:GainLossOnModificationOfOperatingLeaseLiabilities
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTAtMS0xLTEtMTMxMA_d19415bc-6299-43d5-b37c-db283ad49a05"
      unitRef="usd">-38000</ekso:GainLossOnModificationOfOperatingLeaseLiabilities>
    <ekso:GainLossOnModificationOfOperatingLeaseLiabilities
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTAtMy0xLTEtMTMxMA_538eca0b-62e6-4302-ab84-2fe0c2181da3"
      unitRef="usd">0</ekso:GainLossOnModificationOfOperatingLeaseLiabilities>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTAtMS0xLTEtMA_f46adc45-2621-4a67-8524-56163d9d8700"
      unitRef="usd">-66000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTAtMy0xLTEtMA_b297fb21-175c-4955-b52a-f1d1be178cff"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ekso:CommonStockContribution
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTEtMS0xLTEtMA_f44f7e1a-4720-4472-a502-bf6ccee40e93"
      unitRef="usd">169000</ekso:CommonStockContribution>
    <ekso:CommonStockContribution
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTEtMy0xLTEtMA_3d27e3ef-f7a8-466e-be3a-e35db47706c2"
      unitRef="usd">142000</ekso:CommonStockContribution>
    <us-gaap:ShareBasedCompensation
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTItMS0xLTEtMA_5c843d2d-7090-452c-8c47-8d733f03f84f"
      unitRef="usd">2410000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTItMy0xLTEtMA_33558296-143f-43be-b4ef-2d45c79ff0d9"
      unitRef="usd">2255000</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTMtMS0xLTEtMA_937b11b4-92a3-4bd5-8f56-f3f792ccb6ef"
      unitRef="usd">329000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTMtMy0xLTEtMA_af1eadb8-13c4-467f-bd92-a7544d4ab700"
      unitRef="usd">1096000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <ekso:GainLossOnWarrantLiability
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTQtMS0xLTEtMA_083f5999-22dc-4f2f-aad6-672308b7eb8f"
      unitRef="usd">-3056000</ekso:GainLossOnWarrantLiability>
    <ekso:GainLossOnWarrantLiability
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTQtMy0xLTEtMA_aefafe11-e4d5-4aba-a622-587bf88ee5d1"
      unitRef="usd">6376000</ekso:GainLossOnWarrantLiability>
    <ekso:GainLossOnWarrantModification
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTUtMS0xLTEtMA_a9d19c7a-41ea-4c2f-a2ee-c5279238c64e"
      unitRef="usd">0</ekso:GainLossOnWarrantModification>
    <ekso:GainLossOnWarrantModification
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTUtMy0xLTEtMA_1fc93fc1-bb7e-4844-84aa-88319fd8d58f"
      unitRef="usd">-257000</ekso:GainLossOnWarrantModification>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTYtMS0xLTEtMA_fad4f9a3-8aa2-47e9-a54d-3561e9adc290"
      unitRef="usd">947000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTYtMy0xLTEtMA_159479f2-8331-42d4-a561-21e08b3695e5"
      unitRef="usd">-133000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTgtMS0xLTEtMA_95908f4b-0d7b-41b1-bd87-29a5bda01e4d"
      unitRef="usd">-1754000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTgtMy0xLTEtMA_8a35f31e-e5cb-463a-b959-d992b6ff21e4"
      unitRef="usd">1599000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTktMS0xLTEtMA_369f10eb-b91a-46a1-9666-9c703f45db2e"
      unitRef="usd">-379000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMTktMy0xLTEtMA_2cc88e6c-4c0c-4cca-b3c8-e2013b0112d0"
      unitRef="usd">-959000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjAtMS0xLTEtMA_b46cb848-55eb-440d-8ae6-9cfeee4b0aa0"
      unitRef="usd">-247000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjAtMy0xLTEtMA_ee7067fb-ea24-47e0-9fb4-d485022149f9"
      unitRef="usd">-369000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjEtMS0xLTEtMA_18dd3aac-3708-4631-8871-dff511dee753"
      unitRef="usd">-402000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjEtMy0xLTEtMA_7160a865-2124-4077-9760-0f1eefe5ddd5"
      unitRef="usd">-1231000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjItMS0xLTEtMA_f702b2ec-6b90-484d-9e7d-568521b8ce11"
      unitRef="usd">-876000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjItMy0xLTEtMA_5f97f340-0b1d-403d-8c29-5fc93a706901"
      unitRef="usd">-1135000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjMtMS0xLTEtMA_692cdd67-8bb7-4431-a4a6-92042cee190f"
      unitRef="usd">21000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjMtMy0xLTEtMA_7552e3a7-f08d-490c-8f22-fbf5583dfd08"
      unitRef="usd">684000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjQtMS0xLTEtMA_23cc5010-f1c7-49be-8af1-ebab4ef8c92d"
      unitRef="usd">-8755000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjQtMy0xLTEtMA_bb251584-a6d9-4caa-9a19-8c4899afa45c"
      unitRef="usd">-15772000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjYtMS0xLTEtMA_be16a42d-cab7-43b5-9774-a028983faf82"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjYtMy0xLTEtMA_77310611-72dc-4923-89df-996db0ffb3d7"
      unitRef="usd">60000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjctMS0xLTEtMA_372addc7-f0d0-40ea-981d-b6b347e963e7"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjctMy0xLTEtMA_7dd62ece-2c46-4e96-982f-b12de0186d60"
      unitRef="usd">-60000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjktMS0xLTEtMA_b8af9fb8-e08f-461e-b519-be241704153b"
      unitRef="usd">7082000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMjktMy0xLTEtMA_e4d3cc54-9d85-4c1f-a1b5-ad7e6869ea04"
      unitRef="usd">21188000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzAtMS0xLTEtMA_ddf2b2c3-c65b-49f5-90f9-22d43f787f02"
      unitRef="usd">1278000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzAtMy0xLTEtMA_e0a9d4be-c844-4afc-88d5-b345fa08109f"
      unitRef="usd">2377000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzMtMS0xLTEtMTMyNw_47c92a85-9cc2-4647-9d82-c739690cc5b0"
      unitRef="usd">1512000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzMtMy0xLTEtMTMyNw_e3b5cde3-7d92-411f-959f-ddf0a10ba230"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzMtMS0xLTEtMA_5f06204f-0195-4ca8-8cb4-b422f22cfc1e"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzMtMy0xLTEtMA_752a8137-33e2-4a0d-8358-40dcb1ffc7ab"
      unitRef="usd">228000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzQtMS0xLTEtMA_2dfd1c69-c6e5-45fa-9706-10be1ec78367"
      unitRef="usd">3334000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzQtMy0xLTEtMA_13aebf50-7dab-4190-999d-1b39200a7399"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzUtMS0xLTEtMA_d5c21c66-40c1-410c-8dc6-e8fe970b771c"
      unitRef="usd">3078000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzUtMy0xLTEtMA_782c797c-25cb-4de5-bb6c-88df78cab7a2"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzYtMS0xLTEtMA_5816c625-858d-4bad-acc9-9a91cf45d7a4"
      unitRef="usd">10704000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzYtMy0xLTEtMA_9f34fdc5-8d6b-4a55-9c6d-b9687fd5b382"
      unitRef="usd">19039000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzctMS0xLTEtMA_043d3555-d19e-488e-8360-7dd4d22a8b63"
      unitRef="usd">41000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzctMy0xLTEtMA_d6ba313d-73d2-47ba-8a98-5bd226be5deb"
      unitRef="usd">10000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzgtMS0xLTEtMA_5deabd53-0997-41da-8718-6e1766be7326"
      unitRef="usd">1990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzgtMy0xLTEtMA_382267b2-2cc2-49c8-a656-017d420f7a4d"
      unitRef="usd">3217000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzktMS0xLTEtMA_e6d01a33-c040-4701-9cc1-7b13f5581d28"
      unitRef="usd">10872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5cd59b28ca904e409d6a180ec9f55846_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfMzktMy0xLTEtMA_cb58e6a4-7606-45a5-a9a7-a9aee36b8972"
      unitRef="usd">7655000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDAtMS0xLTEtMA_eb659a77-9be6-4f8a-a278-ee7ec03a4d19"
      unitRef="usd">12862000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDAtMy0xLTEtMA_0bdd7c47-e392-4ad4-982a-ef2de757d61e"
      unitRef="usd">10872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDMtMS0xLTEtMA_e511a144-a3df-4b76-94c5-171d04883d3b"
      unitRef="usd">109000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDMtMy0xLTEtMA_6a2dcbf1-4f6b-4ca9-9150-fc2dba1252f6"
      unitRef="usd">309000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDQtMS0xLTEtMA_0537e91a-398a-416f-8332-d7f4c2605d0c"
      unitRef="usd">6000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDQtMy0xLTEtMA_d92a5542-f178-44e2-abb2-5bb19deb724d"
      unitRef="usd">23000</us-gaap:InterestPaidNet>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDYtMS0xLTEtNjIzNQ_741dcbde-2a8f-40ab-b47c-6542fdb47277"
      unitRef="usd">3976000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDYtMy0xLTEtNjIzNQ_97970b7b-cc86-455c-b6e0-9c5ff52be7a9"
      unitRef="usd">0</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <ekso:SharesIssuedCapitalContribution
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDctMS0xLTEtNjIxMg_968dd601-d54f-472d-b0ee-14041cdfa368"
      unitRef="usd">155000</ekso:SharesIssuedCapitalContribution>
    <ekso:SharesIssuedCapitalContribution
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDctMy0xLTEtNjIxMg_cf1ce975-338e-41d6-a569-39525c7ff681"
      unitRef="usd">191000</ekso:SharesIssuedCapitalContribution>
    <ekso:TransferOfPropertyAndEquipmentFromInventory
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDgtMS0xLTEtNjIxOQ_e1708b52-5bc5-44a1-aa22-638f82bfce03"
      unitRef="usd">-132000</ekso:TransferOfPropertyAndEquipmentFromInventory>
    <ekso:TransferOfPropertyAndEquipmentFromInventory
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDgtMy0xLTEtNjIxOQ_6707352b-9356-4591-ae5b-5720134582fb"
      unitRef="usd">77000</ekso:TransferOfPropertyAndEquipmentFromInventory>
    <us-gaap:StockIssued1
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDktMS0xLTEtNjIyNA_40c46423-41f4-436b-95c0-ff42c03447b4"
      unitRef="usd">50000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDktMy0xLTEtNjIyNA_404dd797-def2-43d4-b710-b266f80bf8d0"
      unitRef="usd">919000</us-gaap:StockIssued1>
    <ekso:OperatingLeasesRightOfUseAssetInitialRecognition
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDctMS0xLTEtMA_a29cf048-7797-4ceb-b427-15caf1e77db9"
      unitRef="usd">0</ekso:OperatingLeasesRightOfUseAssetInitialRecognition>
    <ekso:OperatingLeasesRightOfUseAssetInitialRecognition
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDctMy0xLTEtMA_fcbadcf9-cbb4-40cd-a697-176ce6f95649"
      unitRef="usd">1454000</ekso:OperatingLeasesRightOfUseAssetInitialRecognition>
    <ekso:OperatingLeasesLiabilityInitialRecognition
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDgtMS0xLTEtMA_fab5cf26-1f7d-4e2a-8220-7e76dcbe867f"
      unitRef="usd">0</ekso:OperatingLeasesLiabilityInitialRecognition>
    <ekso:OperatingLeasesLiabilityInitialRecognition
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDgtMy0xLTEtMA_51abdad3-f42f-49e1-9466-d496ec5b9be9"
      unitRef="usd">1498000</ekso:OperatingLeasesLiabilityInitialRecognition>
    <ekso:RestrictedStockIssued
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNTItMS0xLTEtNjIzNw_6a0362b5-c83f-416a-a21f-a81acee1f2b0"
      unitRef="usd">0</ekso:RestrictedStockIssued>
    <ekso:RestrictedStockIssued
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNTItMy0xLTEtNjIzNw_e84b1ef5-c0fe-46ba-872e-e165e5e6f479"
      unitRef="usd">63000</ekso:RestrictedStockIssued>
    <ekso:OperatingLeasesIncreaseDecreaseInDeferredRent
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDktMS0xLTEtMA_3997e902-c8c6-4fb4-b659-07108d3ea3ba"
      unitRef="usd">0</ekso:OperatingLeasesIncreaseDecreaseInDeferredRent>
    <ekso:OperatingLeasesIncreaseDecreaseInDeferredRent
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNDktMy0xLTEtMA_b1d46981-a76d-49a3-a95a-34753dd12b46"
      unitRef="usd">44000</ekso:OperatingLeasesIncreaseDecreaseInDeferredRent>
    <ekso:SalesEarnout
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNTMtMS0xLTEtMA_42b39990-cf94-4694-b590-4e3aa87785f8"
      unitRef="usd">0</ekso:SalesEarnout>
    <ekso:SalesEarnout
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83MC9mcmFnOmVlMTEzMGZmM2E1ZjQ0NTY5OThiYjQ4NGY2NDE4MWM4L3RhYmxlOmUzNmNiY2NkMzVhMjRkMjA5NzJmMzg1OGM0MWFlYjE1L3RhYmxlcmFuZ2U6ZTM2Y2JjY2QzNWEyNGQyMDk3MmYzODU4YzQxYWViMTVfNTMtMy0xLTEtMA_2bf2a2bf-fdad-4cc0-ad0a-70bcc1f23dfc"
      unitRef="usd">22000</ekso:SalesEarnout>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNTM5OQ_597686fc-9f2f-421e-93de-2058796d25b6">Organization&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ekso Bionics Holdings, Inc. (the "Company"), designs, develops, sells, and rents exoskeleton products to augment human strength, endurance and mobility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and persons with physical disabilities. The Company has sold and rented devices that (i) enable individuals with neurological conditions affecting gait (acquired brain injury and spinal cord injury) to rehabilitate and to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Founded in 2005, the Company is headquartered in the San Francisco Bay area and listed on the Nasdaq Capital Market under the symbol &#x201c;EKSO&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise indicated, all dollar and share amounts included in these notes to the consolidated financial statements are in thousands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2020, the Company had an accumulated deficit of $199,103.&#160; Largely as a result of significant research and development activities related to the development of the Company&#x2019;s advanced technology and commercialization of such technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. In the year ended December 31, 2020, the Company received net proceeds of $7,082 from a registered direct offering and of $3,334 from warrant exercises, and used $8,755 of cash in its operations. Cash on hand at&#160;December 31, 2020&#160;was $12,862.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to year-end through February&#160;25, 2021 the Company received estimated net proceeds of $36,404 from an underwritten public offering, $1,416 from warrant exercises, and $664 from ATM sales. Refer to Note. 18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, management took several actions to alleviate the substantial doubt about the Company&#x2019;s ability to continue as a going concern that existed as of the date of issuance of the December 31, 2019 consolidated financial statements, including, but not limited to, the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;streamlined the Company's operations and reduced its workforce by approximately 35% to lower operating expenses and reduce cash burn;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;conducted a registered direct offering for net proceeds of $7,082;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;paid off the entire amount of $1,512 of the Company's indebtedness to Western Alliance Bank with proceeds from a new loan of $2,000 from Pacific Western Bank. The terms of the new loan agreement include monthly interest-only payments until August 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;invested in the development and reliability of its products;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;restructured the Company's commercial organization and strategy which has been gaining traction; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;received clearance from the U.S. Food and Drug Administration ("FDA") for Acquired Brain Injury ("ABI") to market the Company's product to a larger patient population increasing the value proposition to its customers.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note 9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes payable, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, borrowings under the Company&#x2019;s new secured term loan agreement with Pacific Western Bank have a liquidity covenant requiring minimum cash on hand equivalent to the current outstanding principal balance. As of December 31, 2020, $2,000 of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of December 31, 2020 is approximately $10,862. With this unrestricted cash balance, the impact of management's actions described above, and additional cash received after year-end, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of one year from the issuance of these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s actual capital requirements may vary significantly and will depend on many factors. The Company plans to continue its investments in its (i) sales initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation &lt;/span&gt;&lt;/div&gt;market, (ii) research, development and commercialization activities with respect to exoskeletons for rehabilitation, and (iii) development and commercialization of able-bodied exoskeletons for industrial use. Consequently, the Company may require significant additional financing in the future, which the Company intends to raise through corporate collaborations, public or private equity offerings, debt financings, or warrant solicitations. Sales of additional equity securities by the Company could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, the Company may be required to further reduce its discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfOTIx_0e8f253b-9d39-44ff-bf4a-fb0e7437071f"
      unitRef="usd">-199103000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i3a01f618e3f9488cb29bae5e918482c6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM1OTQ3Nw_22215f2e-b27b-4b11-b0ca-1db240deaf15"
      unitRef="usd">7082000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM1OTE0NA_e17d4a37-9565-4649-95b3-26a8bcbfb0d9"
      unitRef="usd">3334000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfMTI4Ng_ddc751e2-487b-4da4-bafd-47f4baf6e4d4"
      unitRef="usd">-8755000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjMzNzk1MQ_33a9b785-454a-4d89-b85b-44cc86cd965f"
      unitRef="usd">12862000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3ef9cf6430ff4f8e9422f488739fa849_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM1OTU1OQ_acf060bc-ce84-46df-98a2-0080b834cf6b"
      unitRef="usd">36404000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i92564e533c5b46fca6e27927910f77db_D20210101-20210225"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM1ODk0NQ_02923e06-1ed9-4951-956b-a4c4b7314153"
      unitRef="usd">1416000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idb89bd35b9ca4d7680abe71e8e1cb17e_D20210101-20210225"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM1ODk3Mw_77403403-dce3-424b-908d-29fb4b21bf1a"
      unitRef="usd">664000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfMzI5ODUzNDkwMjIzNA_e1d33b3f-f3c3-4d31-9b66-860b2553725b"
      unitRef="number">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i3a01f618e3f9488cb29bae5e918482c6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfMzI5ODUzNDkwMjIzOQ_22215f2e-b27b-4b11-b0ca-1db240deaf15"
      unitRef="usd">7082000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i7b032681769845018b20e932f7d48c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfMzI5ODUzNDkwMjI1MA_306db6a9-9316-471c-8f92-b10dc982ab57"
      unitRef="usd">1512000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic845df26b7574c9688eaf63d2b286340_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfMzI5ODUzNDkwMjI2MQ_d687d6db-a63b-482c-9e43-e2dbaaba7b7a"
      unitRef="usd">2000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ekso:DebtCovenantCovenantComplianceUnrestrictedCash
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM0MDIxMA_de0797ea-9cc4-4ebe-8e85-db45423b2060"
      unitRef="usd">2000000</ekso:DebtCovenantCovenantComplianceUnrestrictedCash>
    <ekso:UnrestrictedCash
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83Ni9mcmFnOjc3ODFhMzZmZmEyMzQ5Mjg5NzFmY2U5ZTQ1OGQyNzFlL3RleHRyZWdpb246Nzc4MWEzNmZmYTIzNDkyODk3MWZjZTllNDU4ZDI3MWVfNDk0NzgwMjM0MDIyMQ_ef49b286-e7e5-4bd3-865e-e6f965455110"
      unitRef="usd">10862000</ekso:UnrestrictedCash>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NjE_0fd52eec-018a-4d89-a7aa-388bf8295a92">Summary of Significant Accounting Policies and Estimates&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States or U.S. GAAP. In the opinion of management, all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented have been included and are normal and recurring in nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All significant intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year&#x2019;s presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All common share and per share amounts have been adjusted to reflect the one-for-fifteen reverse stock split completed on March 24, 2020. See Note 13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitalization and Equity Structure &#x2013; Reverse Stock Split&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive (loss) income as a component of stockholders&#x2019; equity.  Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive (Loss) Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accumulated other comprehensive (loss) income consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive (loss) income presented on the consolidated balance sheets for the year ended December 31, 2020, is reflected in the table below net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized loss on foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company places its cash in the custody of, financial institutions with high credit ratings. The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents or investments in money market funds as of December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &#160;The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia.  Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2020 and 2019. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020, the Company had two customers with an accounts receivable balance totaling 10% or more of the Company&#x2019;s total accounts receivable (13% and 10%, respectively), as compared with one customer at December 31, 2019 (11%). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no customers with sales of 10% or more of the Company&#x2019;s total revenue for the year ended December 31, 2020, as compared with one for the year ended December 31, 2019 (15%). Refer to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 17. Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand.&#160; Subsequent disposals of inventories are recorded as a reduction of inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Financial Accounting Standards Board ("FASB")&#160;issued Accounting Standard Update (&#x201c;ASU&#x201d;), No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. The Company adopted the standard effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. As a result, the Company no longer recognizes deferred rent on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May of 2020, the Company streamlined its operations and reduced its workforce by approximately 35% to lower operating expenses and reduce cash burn. The restructuring plan was completed by the end of the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded restructuring expense of $244 for the year ended December 31, 2020 comprised of termination benefit costs. As of December 31, 2020, there was no accrued restructuring cost remaining on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTIxNDU_cd4dc075-4b7e-413d-b6dc-6727130d268c"&gt;three&lt;/span&gt; to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the related term of the lease. The costs of repairs and maintenance are expensed when incurred, while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not be recoverable from the estimated future cash flows expected to result from the Company&#x2019;s use or eventual disposition. If estimates of future undiscounted net cash flows are insufficient to recover the carrying value of the assets, the Company will record an impairment loss in the amount by which the carrying value of the assets exceeds the fair value. If the assets are determined to be recoverable, but the useful lives are shorter than originally estimated, the Company will depreciate or amortize the net book value of the assets over the newly determined remaining useful lives. None of the Company&#x2019;s property and equipment or intangible assets were impaired as of December 31, 2020 and 2019. No impairment loss has been recognized in the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. The Company performs an annual impairment assessment, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill. The Company performs impairment tests using a fair value approach when necessary. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously maintained a goodwill balance as a result of a prior acquisition of intangible assets from Equipois, LLC in December 2015 consisting of mechanical balance and support arms technologies, including the rights to the ZeroG product.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of declining sales and gross margin, combined with the overall uncertainty about the future of the ZeroG product line, the Company performed an impairment assessment of goodwill utilizing the simplified method, which resulted in an impairment of goodwill of $189 reducing the goodwill balance to zero. In estimating the fair value, the Company utilized a discounted cash flow model, which is dependent on a number of assumptions, including forecasted revenues and profit margins. The following table sets forth the changes to goodwill for the year ended December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrant Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that it may need to settle the warrants in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where there is a possibility that the Company may have to settle warrants in cash, it estimates the fair value of the issued warrants as a liability at each reporting date and record changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants have been determined using the Black-Scholes option-pricing model (the &#x201c;Black-Scholes Model&#x201d;) and the Binomial Lattice model (the &#x201c;Lattice Model&#x201d;). The Black-Scholes Model requires inputs, such as the expected volatility, expected term, exercise price, risk-free interest rate, and the value of the underlying security. The Lattice Model provides for assumptions regarding expected volatility, expected term, exercise price, risk-free interest rates, the value of the underlying security, and the probability of and likely timing of a specific event within the period to maturity. These values are subject to a significant degree of the Company&#x2019;s judgment. The Company&#x2019;s common stock price represents a significant input that affects the valuation of the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements &#x2013; Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical device segment (EksoHealth) revenue is primarily generated through the sale and rental of the EksoNR and EksoGT, associated software (SmartAssist and VariableAssist), the sale and rental of the EksoUE, the sale of accessories, and the sale of support and maintenance contracts (Ekso Care). Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company&#x2019;s facility for sales of the EksoNR or EksoGT, software and accessories. Ekso Care support and maintenance contracts extend coverage beyond the Company&#x2019;s standard warranty agreements. The separately priced Ekso Care contracts range from&#160;12&#160;to&#160;48 months. The Company receives payment at the inception of the contract and recognizes revenue over the term of the agreement. Revenue from medical device rentals is recognized over the rental term, typically 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s industrial device segment (EksoWorks) revenue is generated through the sale and rental of the upper body exoskeletons (EksoVest and the recently introduced EVO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company&#x2019;s facility. Revenue from industrial device rentals is recognized over the rental term, typically 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for nonreciprocal government grants by applying the contributions received in accordance with guidance in ASC Topic 958-605. To determine if a grant is non-reciprocal or reciprocal and whether the application of ASC 606 is required, the Company considers whether the transfer of resources is one in which commensurate value is exchanged. If commensurate value is not exchanged for the goods or services provided, the Company assesses whether the grant is conditional or unconditional.&#160; Grants that contain both a barrier and right to return are considered conditional and revenue is deferred until such conditions are satisfied. In January 2019, the Company received a government grant from the Singapore Economic Development Board (&#x201c;SEDB&#x201d;) in the amount of approximately $1,500. The receipt of the funds is conditional upon certain operational milestones that must be met and maintained through December 31, 2021. Therefore, the Company has not recognized revenue related to the government grant from the SEBD nor received cash from the SEBD.  The Company expects to recognize revenue related to this grant in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs consist of costs incurred for internal research and development activities. These costs primarily include salaries and other personnel-related expenses, contractor fees, legal fees associated with developing and maintaining intellectual property, prototype materials, facility costs, supplies, and depreciation of equipment associated with the design and development of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method. Under this method, income tax expense or benefit is recognized for the amount of taxes payable or refundable for the current year and for deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company's consolidated financial statements or tax returns. The Company accounts for any income tax contingencies in accordance with accounting guidance for income taxes. The measurement of current and deferred tax assets and liabilities is based on provisions of currently enacted tax laws. The effects of any future changes in tax laws or rates have not been considered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the preparation of the Company's consolidated financial statements included herein, the Company estimates its income taxes and tax contingencies in each of the tax jurisdictions in which it operates prior to the completion and filing of its tax returns. This process involves estimating actual current tax expense together with assessing temporary differences resulting from differing treatment of items, such as deferred revenue, for tax and accounting purposes. These differences result in net deferred tax assets and liabilities. The Company must then assess the likelihood that the deferred tax assets will be realizable, and to the extent they believe that realizability is not likely, the Company must establish a valuation allowance. In assessing the need for any additional valuation allowance, the Company considers all the evidence available to it, both positive and negative, including historical levels of income, legislative developments, expectations and risks associated with estimates of future taxable income, and ongoing prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures stock-based compensation expense for certain stock-based awards made to employees and directors based on the estimated fair value of the award on the date of grant using the Black-Scholes Model and recognizes the fair value on a straight-line basis over the requisite service periods of the awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s determination of the fair value of stock options on the date of grant using the Black-Scholes Model is affected by the Company&#x2019;s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company&#x2019;s stock price, volatility over the term of the awards, and actual and projected employee stock option exercise behaviors (expected term). Due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the Company adopted the simplified method of estimating the expected term pursuant to SEC Staff Accounting Bulletin Topic 14. On this basis, the Company estimated the expected term of options granted by taking the average of the vesting term and the contractual term of the option.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation of restricted stock units (&#x201c;RSUs&#x201d;) is determined at the date of grant using the Company&#x2019;s closing stock price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. For awards with performance-based conditions, at the point that it becomes probable that the performance conditions will be met, the Company records a cumulative catch-up of the expense from the grant date to the current date, and then amortizes the remainder of the expense over the remaining service period. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has, from time to time, modified the terms of its stock options to employees. The Company accounts for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity&#x2019;s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2022 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Adopted in 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which eliminates the computation of the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will record a goodwill impairment charge based on the excess of a reporting unit&#x2019;s carrying amount over its fair value. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company adopted the new guidance as of January 1, 2020, which reduced the complexity surrounding the evaluation of goodwill for impairment. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard modifies the disclosure requirements on fair value measurements in Topic 820 by removing the requirement to disclose the reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The standard expands the disclosure requirements for Level 3 fair value measurement, primarily focused on changes in unrealized gains and losses included in other comprehensive income. The amendments in this update became effective for the Company in the first quarter of 2020. The Company adopted ASU 2018-03 as of January 1, 2020. The adoption of this ASU did not have a material impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NDk_4206e0e2-b3eb-4e69-9457-c60c499df95e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States or U.S. GAAP. In the opinion of management, all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented have been included and are normal and recurring in nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All significant intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year&#x2019;s presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All common share and per share amounts have been adjusted to reflect the one-for-fifteen reverse stock split completed on March 24, 2020. See Note 13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitalization and Equity Structure &#x2013; Reverse Stock Split&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MzE_16c28cc8-220d-4cfc-8f41-c4d86e61442c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2Nzc_f37a024e-3d11-47da-a321-706f3e25bc8b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive (loss) income as a component of stockholders&#x2019; equity.  Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNjU5NzA2OTc5OTI2MA_cdc096c2-8d6c-4938-b628-81b0ad756a66">Accumulated Other Comprehensive (Loss) Income The Company's accumulated other comprehensive (loss) income consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MjQ_2b852cb1-6915-4fc9-a364-894c9727dfcd">The change in accumulated other comprehensive (loss) income presented on the consolidated balance sheets for the year ended December 31, 2020, is reflected in the table below net of tax:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized loss on foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i164b98fab8ca484db400c50acb2bde32_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjhmNjQ4YWFjODMzZjQ3MjhhNTFlNjA4MjE3Yjk2NjIzL3RhYmxlcmFuZ2U6OGY2NDhhYWM4MzNmNDcyOGE1MWU2MDgyMTdiOTY2MjNfMS0xLTEtMS0w_bc18ad46-29da-4ea3-8d29-ddcd5e0f6b52"
      unitRef="usd">50000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1244662c4107454f9abedb0d2c7dd95a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjhmNjQ4YWFjODMzZjQ3MjhhNTFlNjA4MjE3Yjk2NjIzL3RhYmxlcmFuZ2U6OGY2NDhhYWM4MzNmNDcyOGE1MWU2MDgyMTdiOTY2MjNfMi0xLTEtMS0w_354c7fc7-0e78-4b35-9885-4f82433b29aa"
      unitRef="usd">-897000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ic126d0c0305a496bb377ee4b4e95f356_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjhmNjQ4YWFjODMzZjQ3MjhhNTFlNjA4MjE3Yjk2NjIzL3RhYmxlcmFuZ2U6OGY2NDhhYWM4MzNmNDcyOGE1MWU2MDgyMTdiOTY2MjNfMy0xLTEtMS0w_b93fe107-6c7e-4e1a-9a57-c91616249f98"
      unitRef="usd">-847000</us-gaap:StockholdersEquity>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNjU5NzA2OTc5OTI2MQ_b8ebf334-ff16-4f9f-be20-4fcefb7be01c">CashThe Company places its cash in the custody of, financial institutions with high credit ratings. The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MTA_1588cfa8-05de-428a-9c61-318e0af0339d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &#160;The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia.  Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2020 and 2019. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6806a66d666343109c438a29d2361243_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNDk0NzgwMjM2OTY2OQ_84fe885f-f3b4-401e-abb0-a1edda3a865d"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6634dcaf84414ad4a2238d4e3b472d60_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNDk0NzgwMjM2OTY2Mg_b05f9832-1b4c-428a-b6ff-ee4463bc609e"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4c852fde248a46429a59913a353fcd78_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfODkwMw_db0982e2-9dba-419d-8e6f-56af5a91baa0"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5526a54efe4b4f308ec50b4abcc4ccc1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNDk0NzgwMjM2OTYzOA_5686c814-fe34-4469-a7e0-157e65ed2982"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MTc_aed58e4b-16e0-4a9a-9519-803cdff2f1f1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand.&#160; Subsequent disposals of inventories are recorded as a reduction of inventory.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NDY_290d6c50-5a47-48fe-8bf7-875461267665">Inventories consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfMi0xLTEtMS0w_57673630-16f3-4935-a212-9d57f31a0687"
      unitRef="usd">1724000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfMi0zLTEtMS0w_55120f6a-0d55-4811-a633-56f10d40328e"
      unitRef="usd">2208000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfMy0xLTEtMS0w_c065dfd5-95a1-413d-918c-dddaf482e6d8"
      unitRef="usd">18000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfMy0zLTEtMS0w_c61724c6-fdee-441b-94a5-359f75fc4b47"
      unitRef="usd">29000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfNC0xLTEtMS0w_cf1ef81b-9cd9-42aa-a33e-64289bd4f96a"
      unitRef="usd">236000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfNC0zLTEtMS0w_6f76049c-7a7f-475c-89a5-9d979b3ca78a"
      unitRef="usd">252000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfNS0xLTEtMS0w_5dc19b99-0ed7-49ee-ad2f-dea3b3918791"
      unitRef="usd">1978000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjM0ZGQxN2Q0MzVhMjQ0Y2ZhMDFhZTk2YTJlOTJhZGQxL3RhYmxlcmFuZ2U6MzRkZDE3ZDQzNWEyNDRjZmEwMWFlOTZhMmU5MmFkZDFfNS0zLTEtMS0w_f9436c4e-7502-4295-859a-606936cb9bbd"
      unitRef="usd">2489000</us-gaap:InventoryNet>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NjM_06fce9f9-e1d2-4e43-a6e9-9d8d1b94d7fe">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Financial Accounting Standards Board ("FASB")&#160;issued Accounting Standard Update (&#x201c;ASU&#x201d;), No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. The Company adopted the standard effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. As a result, the Company no longer recognizes deferred rent on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i425546ef7c404c1fb5e6ce43069f77b8_D20200501-20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNDk0NzgwMjM2MzMxMg_685bc993-33f4-4a0d-95ac-399586bed4e1"
      unitRef="number">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNDk0NzgwMjM2MzQwMg_2dead2d9-1e48-4fd0-994f-b909d6073602"
      unitRef="usd">244000</us-gaap:RestructuringCharges>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2Mzg_3475652c-1d53-4fac-ba61-2ef0e54521f1">Property and Equipment, netProperty and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTIxNDU_cd4dc075-4b7e-413d-b6dc-6727130d268c"&gt;three&lt;/span&gt; to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the related term of the lease. The costs of repairs and maintenance are expensed when incurred, while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i81b4652764f7496fae43691e5665e11e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTIxNTE_317e4afa-a072-4f9a-bbb0-65ae1432e415">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MTk_907eb87c-9c6c-4e3e-bb8a-ecde13723907">Impairment of Long-Lived AssetsThe Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not be recoverable from the estimated future cash flows expected to result from the Company&#x2019;s use or eventual disposition. If estimates of future undiscounted net cash flows are insufficient to recover the carrying value of the assets, the Company will record an impairment loss in the amount by which the carrying value of the assets exceeds the fair value. If the assets are determined to be recoverable, but the useful lives are shorter than originally estimated, the Company will depreciate or amortize the net book value of the assets over the newly determined remaining useful lives.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTMzNjU_26389453-d83f-4370-bbef-e53a91001083"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTMzNjU_b144119d-4e34-4183-9c8f-aceb3574f7a8"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MTg_9d777e59-a512-4bcf-a419-65794939510d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. The Company performs an annual impairment assessment, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill. The Company performs impairment tests using a fair value approach when necessary. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously maintained a goodwill balance as a result of a prior acquisition of intangible assets from Equipois, LLC in December 2015 consisting of mechanical balance and support arms technologies, including the rights to the ZeroG product.&lt;/span&gt;&lt;/div&gt;As a result of declining sales and gross margin, combined with the overall uncertainty about the future of the ZeroG product line, the Company performed an impairment assessment of goodwill utilizing the simplified method, which resulted in an impairment of goodwill of $189 reducing the goodwill balance to zero. In estimating the fair value, the Company utilized a discounted cash flow model, which is dependent on a number of assumptions, including forecasted revenues and profit margins.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMzI5ODUzNDk1NDg1OQ_8103fbef-20ae-4d15-afab-bff29ddb8b04"
      unitRef="usd">189000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfNjU5NzA2OTgxNjYwNA_67205cb6-a6da-449f-9c13-137c8e25af53">The following table sets forth the changes to goodwill for the year ended December 31, 2020:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjZlZTA0OTYzODc3ODQ1NzQ5YWZhMTdmZjhmZTFiMWQzL3RhYmxlcmFuZ2U6NmVlMDQ5NjM4Nzc4NDU3NDlhZmExN2ZmOGZlMWIxZDNfMS0xLTEtMS0xNTUx_e864b302-2d64-4324-8431-c35499f6a408"
      unitRef="usd">189000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjZlZTA0OTYzODc3ODQ1NzQ5YWZhMTdmZjhmZTFiMWQzL3RhYmxlcmFuZ2U6NmVlMDQ5NjM4Nzc4NDU3NDlhZmExN2ZmOGZlMWIxZDNfMi0xLTEtMS0yNTk5_97357a3e-3a76-4080-8e41-a5509708f43c"
      unitRef="usd">189000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RhYmxlOjZlZTA0OTYzODc3ODQ1NzQ5YWZhMTdmZjhmZTFiMWQzL3RhYmxlcmFuZ2U6NmVlMDQ5NjM4Nzc4NDU3NDlhZmExN2ZmOGZlMWIxZDNfMy0xLTEtMS0xNTUx_2772b294-d3eb-403d-9616-b63f110e2727"
      unitRef="usd">0</us-gaap:Goodwill>
    <ekso:WarrantPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NTM_4d365010-9b20-4dd4-a354-a7e4c078b5a1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrant Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that it may need to settle the warrants in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where there is a possibility that the Company may have to settle warrants in cash, it estimates the fair value of the issued warrants as a liability at each reporting date and record changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants have been determined using the Black-Scholes option-pricing model (the &#x201c;Black-Scholes Model&#x201d;) and the Binomial Lattice model (the &#x201c;Lattice Model&#x201d;). The Black-Scholes Model requires inputs, such as the expected volatility, expected term, exercise price, risk-free interest rate, and the value of the underlying security. The Lattice Model provides for assumptions regarding expected volatility, expected term, exercise price, risk-free interest rates, the value of the underlying security, and the probability of and likely timing of a specific event within the period to maturity. These values are subject to a significant degree of the Company&#x2019;s judgment. The Company&#x2019;s common stock price represents a significant input that affects the valuation of the warrants.&lt;/span&gt;&lt;/div&gt;</ekso:WarrantPolicyTextBlock>
    <ekso:GoingConcernPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MDc_e3940851-9f99-4a29-a9e7-fb6d39668d4e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements &#x2013; Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.&lt;/span&gt;&lt;/div&gt;</ekso:GoingConcernPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NDE_4a5fd3a8-048c-4d78-bc17-707cdbfbd4b5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical device segment (EksoHealth) revenue is primarily generated through the sale and rental of the EksoNR and EksoGT, associated software (SmartAssist and VariableAssist), the sale and rental of the EksoUE, the sale of accessories, and the sale of support and maintenance contracts (Ekso Care). Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company&#x2019;s facility for sales of the EksoNR or EksoGT, software and accessories. Ekso Care support and maintenance contracts extend coverage beyond the Company&#x2019;s standard warranty agreements. The separately priced Ekso Care contracts range from&#160;12&#160;to&#160;48 months. The Company receives payment at the inception of the contract and recognizes revenue over the term of the agreement. Revenue from medical device rentals is recognized over the rental term, typically 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s industrial device segment (EksoWorks) revenue is generated through the sale and rental of the upper body exoskeletons (EksoVest and the recently introduced EVO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company&#x2019;s facility. Revenue from industrial device rentals is recognized over the rental term, typically 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration
      contextRef="ibc2375e404df4bee8066cbe643660925_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTgxMzU_c60e148d-218f-463b-bf5d-e3a1fb8d536d">P12M</ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration>
    <ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration
      contextRef="i6fdcba7194b1415db1370657080e8199_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTgxNDE_1bd9a57a-86e1-4a2c-ab5c-f7b68e127819">P48M</ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration>
    <ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration
      contextRef="ibc2375e404df4bee8066cbe643660925_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMzI5ODUzNDk1NDgyNg_f0c49c4c-0082-467f-8d2d-0840b0a42a93">P12M</ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration>
    <ekso:GovernmentGrantPolicyPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2MjE_f473efec-769e-4d38-abe7-4b70f7cb5ef8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for nonreciprocal government grants by applying the contributions received in accordance with guidance in ASC Topic 958-605. To determine if a grant is non-reciprocal or reciprocal and whether the application of ASC 606 is required, the Company considers whether the transfer of resources is one in which commensurate value is exchanged. If commensurate value is not exchanged for the goods or services provided, the Company assesses whether the grant is conditional or unconditional.&#160; Grants that contain both a barrier and right to return are considered conditional and revenue is deferred until such conditions are satisfied. In January 2019, the Company received a government grant from the Singapore Economic Development Board (&#x201c;SEDB&#x201d;) in the amount of approximately $1,500. The receipt of the funds is conditional upon certain operational milestones that must be met and maintained through December 31, 2021. Therefore, the Company has not recognized revenue related to the government grant from the SEBD nor received cash from the SEBD.  The Company expects to recognize revenue related to this grant in 2021.&lt;/span&gt;&lt;/div&gt;</ekso:GovernmentGrantPolicyPolicyTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="i55263caaaf314901a8c536dda2b3d628_I20190131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTk1MzY_1fe21faa-89ba-4b45-b434-44650ca29323"
      unitRef="usd">1500000</us-gaap:GrantsReceivable>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2ODI_2722ffdf-385a-4533-bfb9-085eb1eb3208">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs consist of costs incurred for internal research and development activities. These costs primarily include salaries and other personnel-related expenses, contractor fees, legal fees associated with developing and maintaining intellectual property, prototype materials, facility costs, supplies, and depreciation of equipment associated with the design and development of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NTY_915b3e7b-8ec9-4811-99a5-1b1f6d2a9b0c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method. Under this method, income tax expense or benefit is recognized for the amount of taxes payable or refundable for the current year and for deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company's consolidated financial statements or tax returns. The Company accounts for any income tax contingencies in accordance with accounting guidance for income taxes. The measurement of current and deferred tax assets and liabilities is based on provisions of currently enacted tax laws. The effects of any future changes in tax laws or rates have not been considered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the preparation of the Company's consolidated financial statements included herein, the Company estimates its income taxes and tax contingencies in each of the tax jurisdictions in which it operates prior to the completion and filing of its tax returns. This process involves estimating actual current tax expense together with assessing temporary differences resulting from differing treatment of items, such as deferred revenue, for tax and accounting purposes. These differences result in net deferred tax assets and liabilities. The Company must then assess the likelihood that the deferred tax assets will be realizable, and to the extent they believe that realizability is not likely, the Company must establish a valuation allowance. In assessing the need for any additional valuation allowance, the Company considers all the evidence available to it, both positive and negative, including historical levels of income, legislative developments, expectations and risks associated with estimates of future taxable income, and ongoing prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2OTM_74fd0d54-a406-4a38-aba6-45cac69c0581">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures stock-based compensation expense for certain stock-based awards made to employees and directors based on the estimated fair value of the award on the date of grant using the Black-Scholes Model and recognizes the fair value on a straight-line basis over the requisite service periods of the awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s determination of the fair value of stock options on the date of grant using the Black-Scholes Model is affected by the Company&#x2019;s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company&#x2019;s stock price, volatility over the term of the awards, and actual and projected employee stock option exercise behaviors (expected term). Due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the Company adopted the simplified method of estimating the expected term pursuant to SEC Staff Accounting Bulletin Topic 14. On this basis, the Company estimated the expected term of options granted by taking the average of the vesting term and the contractual term of the option.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation of restricted stock units (&#x201c;RSUs&#x201d;) is determined at the date of grant using the Company&#x2019;s closing stock price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. For awards with performance-based conditions, at the point that it becomes probable that the performance conditions will be met, the Company records a cumulative catch-up of the expense from the grant date to the current date, and then amortizes the remainder of the expense over the remaining service period. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.&lt;/span&gt;&lt;/div&gt;The Company has, from time to time, modified the terms of its stock options to employees. The Company accounts for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMjg2NzA_44f513bb-084f-4f16-846f-1c5a1bdaa1b9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity&#x2019;s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2022 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Adopted in 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which eliminates the computation of the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will record a goodwill impairment charge based on the excess of a reporting unit&#x2019;s carrying amount over its fair value. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company adopted the new guidance as of January 1, 2020, which reduced the complexity surrounding the evaluation of goodwill for impairment. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard modifies the disclosure requirements on fair value measurements in Topic 820 by removing the requirement to disclose the reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The standard expands the disclosure requirements for Level 3 fair value measurement, primarily focused on changes in unrealized gains and losses included in other comprehensive income. The amendments in this update became effective for the Company in the first quarter of 2020. The Company adopted ASU 2018-03 as of January 1, 2020. The adoption of this ASU did not have a material impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RleHRyZWdpb246YjkwMDRlMTJmNzI3NDA1N2JmNzQ1ZWU0ODU0YWEzMmNfNjk2_6efb1862-4c69-4a4f-aec3-c907e26d86f6">Net Loss Per Share of Common Stock&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted average number of shares of common stock, adjusted to include conversion of certain stock options and warrants for common stock and release of common stock in connection with restricted stock units during the period, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted net loss used for dilution calculation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive weighted-average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants for common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RleHRyZWdpb246YjkwMDRlMTJmNzI3NDA1N2JmNzQ1ZWU0ODU0YWEzMmNfNjg2_020a897d-7b14-4a9b-ab84-1dccb001d1ec">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted average number of shares of common stock, adjusted to include conversion of certain stock options and warrants for common stock and release of common stock in connection with restricted stock units during the period, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted net loss used for dilution calculation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive weighted-average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfNC0xLTEtMS0w_383019d5-2761-4830-b715-a8357741c73f"
      unitRef="usd">-15825000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfNC0zLTEtMS0w_adc2759a-32ff-4c3b-b85a-73574bad9aec"
      unitRef="usd">-12132000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfNi0xLTEtMS0w_c75e7705-b00e-430a-b406-56dad67a8886"
      unitRef="usd">-15825000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfNi0zLTEtMS0w_20f81ac9-81a2-47eb-bde1-e7f91edb82be"
      unitRef="usd">-12132000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfOS0xLTEtMS0w_39b1c99a-2f8d-419c-b927-32ebd2a481df"
      unitRef="shares">7164000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfOS0zLTEtMS0w_e964b4fc-e7e5-4655-bf47-67678077b3f3"
      unitRef="shares">4794000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTEtMS0xLTEtMA_44736574-82a7-4565-8e63-81447ed457ab"
      unitRef="shares">7164000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTEtMy0xLTEtMA_8759a9e4-6071-44a5-871d-feaa3b47e984"
      unitRef="shares">4794000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTQtMS0xLTEtMA_da305846-77bd-496d-ad34-55df221c747b"
      unitRef="usdPerShare">-2.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTQtMy0xLTEtMA_785ecd17-3bd7-4567-a1b4-27c53e0a8530"
      unitRef="usdPerShare">-2.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTUtMS0xLTEtMA_05142841-a021-4fc2-8277-b82b982bf3b1"
      unitRef="usdPerShare">-2.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjAyZDJjNDI5ZjZjYzQ0ZDFiNDhiYzc2Yjc4Zjk0ZjhiL3RhYmxlcmFuZ2U6MDJkMmM0MjlmNmNjNDRkMWI0OGJjNzZiNzhmOTRmOGJfMTUtMy0xLTEtMA_a6cc46e7-86c4-43af-89a7-17c932bd6f86"
      unitRef="usdPerShare">-2.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RleHRyZWdpb246YjkwMDRlMTJmNzI3NDA1N2JmNzQ1ZWU0ODU0YWEzMmNfNjg5_40497b68-1081-4144-90b7-dacee5b17441">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants for common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67594e576125433d9c1e6603131224a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfMi0xLTEtMS0w_928df115-fe2a-4143-870f-8b3fed993e29"
      unitRef="shares">529000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibde6413b3f484fbb82f25ef7d5c4d24b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfMi0zLTEtMS0w_9218cf5d-a490-43ba-a261-892ebae484c5"
      unitRef="shares">494000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7c51e051811a48169af92a76d27be60a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfMy0xLTEtMS0w_f031cdd0-3687-45dc-936f-22fd827dc0ed"
      unitRef="shares">143000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8bd0c434eb694450b138a39e7717b97d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfMy0zLTEtMS0w_7776d8e6-96fe-4457-81f5-0beedf95f67d"
      unitRef="shares">89000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i40711bfb573748f5b097264402445a5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfNC0xLTEtMS0w_16ad3b0a-1d08-4af2-9e92-17e8ecaa266d"
      unitRef="shares">1325000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia8fcc63d43e042fb816a4a8bb922bd22_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfNC0zLTEtMS0w_52f7407b-6a9d-4fbd-b851-b016fa9b7e5f"
      unitRef="shares">1178000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfNS0xLTEtMS0w_e3617710-9d55-4d34-956f-ca4d5157fb56"
      unitRef="shares">1997000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84NS9mcmFnOmI5MDA0ZTEyZjcyNzQwNTdiZjc0NWVlNDg1NGFhMzJjL3RhYmxlOjM1MTg3NzFkZjYyMTQ2ZmM5YmQxMWJkN2Q2YTJhYTI5L3RhYmxlcmFuZ2U6MzUxODc3MWRmNjIxNDZmYzliZDExYmQ3ZDZhMmFhMjlfNS0zLTEtMS0w_192e6a60-56e9-44b4-a11a-940900567f10"
      unitRef="shares">1761000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84OC9mcmFnOjMwMTk1MmRlNjJhOTQxNDg5YzU5YmNhNzU4OTExM2MwL3RleHRyZWdpb246MzAxOTUyZGU2MmE5NDE0ODljNTliY2E3NTg5MTEzYzBfNjU3OA_71e896cc-f11e-48b4-bde0-52b082cce146">Investment in Unconsolidated Affiliate&lt;div style="padding-right:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company, Zhejiang Youchuang Venture Capital Investment Co., Ltd and another partner (collectively, the &#x201c;JV Partners&#x201d;) received notice from the Committee on Foreign Investment in the United States (&#x201c;CFIUS&#x201d;) in connection with its review of the Company&#x2019;s and the JV Partners&#x2019; investment in Exoskeleton Intelligent Robotics Co. Limited (the &#x201c;China JV&#x201d;). The notice stated that CFIUS&#x2019;s prior national security concerns regarding the China JV could not be mitigated. In connection with such determination, on July 13, 2020, the Company and the JV Partners entered into a National Security Agreement (&#x201c;NSA&#x201d;), which, among other things, requires the termination of the Company&#x2019;s agreements and role with the China JV. The Company intends to work cooperatively with the JV Partners and CFIUS to implement the terms of the NSA. On August 12, 2020, the Company and the JV Partners agreed to terminate the agreements underlying the China JV. As of December 31, 2020, all agreements related to the China JV had been terminated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the above, during the year ended December 31, 2020, the Company recorded a $66 loss on investment in unconsolidated affiliate in the consolidated statements of operations and comprehensive loss related to the write-off of previously recorded direct costs related to establishing the China JV.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF84OC9mcmFnOjMwMTk1MmRlNjJhOTQxNDg5YzU5YmNhNzU4OTExM2MwL3RleHRyZWdpb246MzAxOTUyZGU2MmE5NDE0ODljNTliY2E3NTg5MTEzYzBfNDk0NzgwMjMzOTQxMA_f46adc45-2621-4a67-8524-56163d9d8700"
      unitRef="usd">-66000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RleHRyZWdpb246YmYwYTg1ZjRkYmNjNGI4YThjYTY0MGIzNTgyMTk5MzFfMjMyNQ_79d5cd0a-4138-4f24-ba88-14d18d468245">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s fair value hierarchies for its financial assets and liabilities which require fair value measurement on a recurring basis are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent success fee liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2020 and 2019, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and the valuation techniques used did not change compared to the Company&#x2019;s established practice.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the fair value of Company&#x2019;s Level 3 financial liabilities during the year ended December 31, 2020,&#160;which were measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent&lt;br/&gt;Success&#160;Fee&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Initial fair value of warrants in connection with June 2020 financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of warrants issued in June 2020, December 2019, May 2019 financing, and December 2015 equity financings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of warrant liability to equity upon exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on revaluation of contingent liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 13 in the notes to consolidated financial statements under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitalization and Equity Structure &#x2013; Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for a description of the warrants accounted for as a liability, including the method and inputs used to estimate their fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RleHRyZWdpb246YmYwYTg1ZjRkYmNjNGI4YThjYTY0MGIzNTgyMTk5MzFfMjMzMw_02c13c34-4e84-4a5e-8184-012c78d62799">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s fair value hierarchies for its financial assets and liabilities which require fair value measurement on a recurring basis are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent success fee liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="i50bf1458d43243298850ecebb3a893ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfMy0xLTEtMS0w_569b7440-28a5-4b83-83a0-9e0caeeb46a5"
      unitRef="usd">6037000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id2bdafc8b87643a8940a27e6b36684f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfMy0zLTEtMS0w_02d7bab8-99eb-4dd0-ba46-438c1699bc62"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ifb140a2a8bd1427c8038bc9cc6fc4ddd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfMy01LTEtMS0w_a2d5c20e-38d1-49c2-982f-566fe65686b9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i84e30bf53c5f4d90befcffe3dcd462ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfMy03LTEtMS0w_54ad188c-2ada-442e-a30b-5d2e534f27e8"
      unitRef="usd">6037000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i80a48682c16b4e88b27b2fa322d058d3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOC0xLTEtMS0w_5eb37cd1-6fb5-47ba-9205-683950153db4"
      unitRef="usd">4307000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i649dad9fb14749e9996c2dc8928958e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOC0zLTEtMS0w_7dab36f1-b98d-4753-ab6b-a3a31a0ac1c8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i84a84e7d32604e62861e794eea7d7ca1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOC01LTEtMS0w_0010e944-c987-4c57-9d04-b7ecf273fb82"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7ab6a2c45f8a47ecba7fe4b30e1dda70_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOC03LTEtMS0w_2977e45c-3109-43ea-8889-dc73f9207b20"
      unitRef="usd">4307000</us-gaap:DerivativeLiabilities>
    <ekso:ContingentSuccessFeeLiability
      contextRef="i80a48682c16b4e88b27b2fa322d058d3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOS0xLTEtMS0w_98ae85b4-3c02-479e-a725-6741f7591d3b"
      unitRef="usd">6000</ekso:ContingentSuccessFeeLiability>
    <ekso:ContingentSuccessFeeLiability
      contextRef="i649dad9fb14749e9996c2dc8928958e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOS0zLTEtMS0w_1e518a50-71fd-4634-9f75-9ac1a3c199ad"
      unitRef="usd">0</ekso:ContingentSuccessFeeLiability>
    <ekso:ContingentSuccessFeeLiability
      contextRef="i84a84e7d32604e62861e794eea7d7ca1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOS01LTEtMS0w_255eed5f-6c24-4583-a38c-fa38152efe4f"
      unitRef="usd">0</ekso:ContingentSuccessFeeLiability>
    <ekso:ContingentSuccessFeeLiability
      contextRef="i7ab6a2c45f8a47ecba7fe4b30e1dda70_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjBjNGJhNWQ1ZDAzNDRmNWRhNTg1ODcyY2JkYzM3ZDI2L3RhYmxlcmFuZ2U6MGM0YmE1ZDVkMDM0NGY1ZGE1ODU4NzJjYmRjMzdkMjZfOS03LTEtMS0w_e39ed620-be88-4fae-8dad-f2295302e2b8"
      unitRef="usd">6000</ekso:ContingentSuccessFeeLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RleHRyZWdpb246YmYwYTg1ZjRkYmNjNGI4YThjYTY0MGIzNTgyMTk5MzFfMjMyOA_336c9964-6d78-4fb2-a32b-221cb33f7131">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the fair value of Company&#x2019;s Level 3 financial liabilities during the year ended December 31, 2020,&#160;which were measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent&lt;br/&gt;Success&#160;Fee&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Initial fair value of warrants in connection with June 2020 financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of warrants issued in June 2020, December 2019, May 2019 financing, and December 2015 equity financings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of warrant liability to equity upon exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on revaluation of contingent liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9396d4559e45441f873fc24b5a39358d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfMS0xLTEtMS0w_d3185aef-a6da-477a-9211-473eee0ded61"
      unitRef="usd">4307000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i411cf8f5b27a4e37a9f9854d5abc3f48_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfMS0zLTEtMS0w_38b12ece-b9fd-4112-8fea-5569a3afd8ac"
      unitRef="usd">6000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfMi0xLTEtMS0w_ff014dee-bac3-4310-bbbc-106aaf4d171f"
      unitRef="usd">2650000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i42740a38dd614cefb84f83af69916e8d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfMi0zLTEtMS0w_44f2c1dd-85dc-4f97-aeb4-ada7ef6b7d56"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <ekso:GainLossOnWarrantLiability
      contextRef="ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNC0xLTEtMS0w_9b41725e-7c3e-49fd-8a46-e1020e844dd2"
      unitRef="usd">-3056000</ekso:GainLossOnWarrantLiability>
    <ekso:GainLossOnWarrantLiability
      contextRef="i42740a38dd614cefb84f83af69916e8d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNC0zLTEtMS0w_05d244d8-9e73-4ae5-b105-b7a774ca719b"
      unitRef="usd">0</ekso:GainLossOnWarrantLiability>
    <ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification
      contextRef="ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNS0xLTEtMS0w_3aeee738-d9bd-4651-a094-7935711c13fb"
      unitRef="usd">3976000</ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification>
    <ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification
      contextRef="i42740a38dd614cefb84f83af69916e8d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNS0zLTEtMS0w_c7deedeb-47ed-4f10-a9a3-a377818a3050"
      unitRef="usd">0</ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification>
    <ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement
      contextRef="ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNi0xLTEtMS0w_dab7fe14-4f36-4aa7-9a31-67018563b22a"
      unitRef="usd">0</ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement>
    <ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement
      contextRef="i42740a38dd614cefb84f83af69916e8d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNi0zLTEtMS0w_bb7ac942-fc58-49ed-9e81-498b4ac8bd46"
      unitRef="usd">6000</ekso:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0440a5ac3cb444bf8c87c1ca6ea5f57a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNy0xLTEtMS0w_418a828e-db81-428f-bc94-2c159fa255c7"
      unitRef="usd">6037000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if2871a384ac049ccbda9e8abc03f027c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85MS9mcmFnOmJmMGE4NWY0ZGJjYzRiOGE4Y2E2NDBiMzU4MjE5OTMxL3RhYmxlOjVmM2I2Y2YxODE1ZTRiNTM4NjYzMzI1NDEzNmUzM2I4L3RhYmxlcmFuZ2U6NWYzYjZjZjE4MTVlNGI1Mzg2NjMzMjU0MTM2ZTMzYjhfNy0zLTEtMS0w_c559e316-dc65-4bac-b95e-1e2dd8318646"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzg3NA_40af4978-1237-429f-801e-d5611f8933f6">Revenue Recognition&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the following five steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not directly observable, the Company estimates the selling price based on market conditions and entity-specific factors including features and functionality of the product and/or services, the geography of the Company&#x2019;s customers, type of the Company&#x2019;s markets. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Timing of revenue recognition may differ from the timing of invoicing to customers and receipt of payment. For the sale of its products, the Company generally recognizes revenue at a point in time through the ship-and-bill performance obligations. For the rental of its products, the Company generally recognizes revenue over the rental term commencing upon the completion of customer training.  For service agreements, the Company generally invoices customers at the beginning of the coverage period and records revenue related to the billed amounts over time, equivalent to the coverage period of the maintenance and support contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts (Ekso Care), but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred extended maintenance and support&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred device, rental revenues and advances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenues, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue activity consisted of the following for the year ended December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020, the Company&#x2019;s deferred revenue was&#160;$3,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company expects to recognize approximately&#160;$1,496&#160;of the deferred revenue during&#160;2021,&#160;$908&#160;in&#160;2022, and&#160;$898 thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition to deferred revenue, the Company has non-cancellable backlog of $515&#160;related to its contracts for rental units with its customers. These rental contracts typically have 12-month lease terms and rental income is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020 and 2019, accounts receivable, net of allowance for doubtful accounts, were $3,389 and $5,208, respectively, and are included in current assets on the Company&#x2019;s consolidated balance sheets. The allowance for doubtful accounts reflects the Company&#x2019;s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table disaggregates the Company&#x2019;s revenue by major source for the year ended December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.935%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoHealth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Device revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service and support&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rentals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Parts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaborative arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table disaggregates the Company&#x2019;s revenue by major source for the year ended December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoHealth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Device revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service and support&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rentals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Parts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaborative arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzg4Mg_cbdd93f5-6dd3-4c56-a52d-9cc8135ff21a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred extended maintenance and support&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred device, rental revenues and advances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenues, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue activity consisted of the following for the year ended December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <ekso:DeferredExtendedMaintenanceAndSupport
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMS0xLTEtMS0w_082a1fc3-d1a5-436f-80a7-1e13635d903f"
      unitRef="usd">2902000</ekso:DeferredExtendedMaintenanceAndSupport>
    <ekso:DeferredExtendedMaintenanceAndSupport
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMS0zLTEtMS0w_6a72cc71-816c-4a15-ace5-9745023b2d5a"
      unitRef="usd">2837000</ekso:DeferredExtendedMaintenanceAndSupport>
    <ekso:DeferredRoyalties
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMi0xLTEtMS0w_ff084765-42ee-4786-8279-b9af112b851d"
      unitRef="usd">282000</ekso:DeferredRoyalties>
    <ekso:DeferredRoyalties
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMi0zLTEtMS0w_ab2dba7b-1709-4b31-a400-75ad873bf658"
      unitRef="usd">290000</ekso:DeferredRoyalties>
    <ekso:DeferredDeviceRevenue
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMy0xLTEtMS0w_f543715d-37b4-4273-b188-09d2b54e9870"
      unitRef="usd">118000</ekso:DeferredDeviceRevenue>
    <ekso:DeferredDeviceRevenue
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfMy0zLTEtMS0w_bf979378-04b8-414c-bcb5-d7a50f46cd06"
      unitRef="usd">154000</ekso:DeferredDeviceRevenue>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfNi0xLTEtMS0w_63fee3c2-6b51-417f-85b8-3ff641071bb4"
      unitRef="usd">3302000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfNi0zLTEtMS0w_508dde89-05f7-4acd-adb2-5e4789cd08f0"
      unitRef="usd">3281000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfNy0xLTEtMS0w_8ea3f63f-c517-4af0-9ca8-3db038ad1fa2"
      unitRef="usd">1496000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfNy0zLTEtMS0w_ddb6f955-3b65-4eca-9792-5a5f86b07653"
      unitRef="usd">1492000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfOC0xLTEtMS0w_33ea7eb0-446d-44e3-b65d-37617de9df2d"
      unitRef="usd">1806000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjljMjY5OTcwNjU3MTQwNmRhNzBjODIwMzQzNGI1NTQ1L3RhYmxlcmFuZ2U6OWMyNjk5NzA2NTcxNDA2ZGE3MGM4MjAzNDM0YjU1NDVfOC0zLTEtMS0w_1fc6e116-1fbf-4920-985f-4141d57cb18c"
      unitRef="usd">1789000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjdkNTYxNjcxOWEzODQ4NmQ5ZmM3MmIwNTY5YjczNDM2L3RhYmxlcmFuZ2U6N2Q1NjE2NzE5YTM4NDg2ZDlmYzcyYjA1NjliNzM0MzZfMC0xLTEtMS0w_30f6976b-4ad1-4a87-9f92-b441be4ee4f2"
      unitRef="usd">3281000</us-gaap:ContractWithCustomerLiability>
    <ekso:ContractWithCustomerLiabilityDeferralOfRevenue
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjdkNTYxNjcxOWEzODQ4NmQ5ZmM3MmIwNTY5YjczNDM2L3RhYmxlcmFuZ2U6N2Q1NjE2NzE5YTM4NDg2ZDlmYzcyYjA1NjliNzM0MzZfMS0xLTEtMS0w_d0f2faac-a2d4-4234-bf98-a9350371544f"
      unitRef="usd">1922000</ekso:ContractWithCustomerLiabilityDeferralOfRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjdkNTYxNjcxOWEzODQ4NmQ5ZmM3MmIwNTY5YjczNDM2L3RhYmxlcmFuZ2U6N2Q1NjE2NzE5YTM4NDg2ZDlmYzcyYjA1NjliNzM0MzZfMi0xLTEtMS0w_1a0cf02c-9fa2-434d-aca5-15bfc99795db"
      unitRef="usd">1901000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjdkNTYxNjcxOWEzODQ4NmQ5ZmM3MmIwNTY5YjczNDM2L3RhYmxlcmFuZ2U6N2Q1NjE2NzE5YTM4NDg2ZDlmYzcyYjA1NjliNzM0MzZfMy0xLTEtMS0w_4b1797d6-3bec-450b-b9ad-8c859ad17d12"
      unitRef="usd">3302000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMjY2Mg_277a4b54-ad10-4eed-8197-0b9034eb6af7"
      unitRef="usd">3302000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i63834f56293d4e708f774c76a532f46f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMjc0Mg_e97be50a-7667-4be1-9606-da1de15b6a00"
      unitRef="usd">1496000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i3036960b630e4dc68acd1c3ce4478d07_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMjc4MA_de72f2a6-5548-41fa-8715-108938b5b093"
      unitRef="usd">908000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1189ad224a9542f99ef6b9177be8258c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMjc5NA_b989ce52-53b4-4ed8-a19b-8913e7db806a"
      unitRef="usd">898000</us-gaap:RevenueRemainingPerformanceObligation>
    <ekso:ContractwithCustomerLiabilityNonCancellableBacklog
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMjg4OA_f021633a-4c7c-446e-9c03-23c29e8a4a6a"
      unitRef="usd">515000</ekso:ContractwithCustomerLiabilityNonCancellableBacklog>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzg0ODI5MDcwMTU0OA_0a905909-b824-4ddb-b3ba-b0a82fffa9cc">P12M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzEzNA_87aae2a8-c0ec-420e-89d1-4d557594bcf1"
      unitRef="usd">3389000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzE0MQ_9a124a3a-d835-4142-a221-e02b87efa0d6"
      unitRef="usd">5208000</us-gaap:AccountsReceivableNetCurrent>
    <ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration
      contextRef="id643b591bbe442ff89d7f6fedbd8777a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzYzMA_e9947f89-3171-493b-b130-db1cb3cd7019">P30D</ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration>
    <ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration
      contextRef="i81b4652764f7496fae43691e5665e11e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzYzNg_a1fb4866-1444-495c-98bb-6000a66bb29b">P90D</ekso:ContractsWithCustomerAccountsReceivablePaymentTermsDuration>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RleHRyZWdpb246OTE4ZDNiNmYxYjc0NGM0NWI5OWQ3MDg5YmVlNDhiZjFfMzg3MQ_9d0470bd-4d77-49cb-9c25-1a8fe5bd027a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table disaggregates the Company&#x2019;s revenue by major source for the year ended December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.935%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoHealth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Device revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service and support&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rentals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Parts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaborative arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table disaggregates the Company&#x2019;s revenue by major source for the year ended December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoHealth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Device revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service and support&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rentals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Parts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaborative arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1f8795be88184c80b93b87063b29336c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMS0xLTEtMS0w_7f132c05-f0a1-4738-8120-8e1a556b6b62"
      unitRef="usd">5012000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic5d78b1f57364d88a58dd74bda2ee22e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMS0zLTEtMS0w_d9f72d45-15f2-4e13-b376-2b8ea486d7d1"
      unitRef="usd">689000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if2a856fa0deb4f4bbebb18b45f3772fe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMS01LTEtMS0w_d84f6af7-4533-47cd-bda4-ab9dcae2063e"
      unitRef="usd">5701000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id6b6f83daf3c4c15b23e671334f13579_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMi0xLTEtMS0w_0759d28c-9940-446d-ae9b-4bf7c6fb7d58"
      unitRef="usd">1723000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i889b78375c774b5687a5747a1b43cb23_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMi0zLTEtMS0w_e7288587-b1a4-4504-8f12-998dd0141141"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i99c6f90a20b044e3acc886642e9c1309_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMi01LTEtMS0w_9886f2c7-f2c4-4a88-8a9a-26d1689bd3e0"
      unitRef="usd">1723000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id38da83df0b94a2b83b0d1f8a9f1dc30_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy0xLTEtMS0yOTUx_ab5776e5-8db6-4061-9b35-7ca73c2d66be"
      unitRef="usd">782000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1e574a2fabc1499f884fcd1b5951b4e7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy0zLTEtMS0yOTUx_01ff501d-f1eb-4bbd-9dfd-ae3704980ee3"
      unitRef="usd">55000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i033d5839f04849bfb1ee07ea7dc6b0f4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy01LTEtMS0zMTEz_a243872f-7152-40e5-9a0f-9d5783891873"
      unitRef="usd">837000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7cd34bb1047b430b85a6b141bc79a7c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy0xLTEtMS0w_1a6b9078-71cb-44dc-a501-933bfaec3883"
      unitRef="usd">294000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia43ebf9f36cf41eba45fa05244dc8ac4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy0zLTEtMS0w_26f3df6e-f624-4ce4-86b2-f132612cbd2a"
      unitRef="usd">72000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i322cf066e9f44f9cbb3ec118a91e904c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfMy01LTEtMS0w_7943710f-0862-4327-8d7a-620912c55e8b"
      unitRef="usd">366000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib8235348a80e487c9f3e8030b4d8ce9a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNC0xLTEtMS0w_82eba04f-ba95-493d-bac4-602ace196fb5"
      unitRef="usd">255000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3162a8935b1c4ff380fbdae542396c82_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNC0zLTEtMS0w_2031e06a-2b46-4e6a-8b61-68b5ddfacaac"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic14005e4eb1146e986a9ef76f055084d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNC01LTEtMS0w_72c73446-82f0-4864-9c4a-4ba258508d11"
      unitRef="usd">255000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib881b817aa7445709d8070f5fe391132_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNS0xLTEtMS0w_15829b8b-a5e8-4cd2-9ae4-d1a37d0f0a10"
      unitRef="usd">8066000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i75a7edc5f16340378382788c4c0dc691_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNS0zLTEtMS0w_b1567f0a-8614-4a7e-a768-2bb87557ea64"
      unitRef="usd">816000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjgwOTQyMGIzNzc2YjRlODRiOWFiZDJlNTkwNjYzOWFmL3RhYmxlcmFuZ2U6ODA5NDIwYjM3NzZiNGU4NGI5YWJkMmU1OTA2NjM5YWZfNS01LTEtMS0w_d0dea0f2-7777-4405-97f0-b9fcdbe5de9e"
      unitRef="usd">8882000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i27aec484daea4c1dbfd941c2654431bb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMS0xLTEtMS0w_5f4e419b-b361-43db-a9e8-58aeec28402a"
      unitRef="usd">9064000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if26d674e4b5d49679bf4f50fdb4b6c18_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMS0zLTEtMS0w_53a3d216-4b4c-4aab-a476-826910262015"
      unitRef="usd">1726000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i95975cc540d54a198ad22e25ed0dcb73_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMS01LTEtMS0w_d0a94322-3d1b-4668-ba44-cc9f100f74bf"
      unitRef="usd">10790000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5078e9375e6b4702909ac2925b30c4bc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMi0xLTEtMS0w_f4592a6c-1e2e-4077-9fb3-35ea8e6454f7"
      unitRef="usd">1647000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7f73b9d15a3b46ef9fe037af79d4534d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMi0zLTEtMS0w_b770b406-7711-469e-862b-bfacf3806987"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7e152e2c14f448a681c80c12f29fa109_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMi01LTEtMS0w_c0e190c5-1214-45a0-8525-aebce4a59ada"
      unitRef="usd">1647000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5b6c52ce74dc42cc9138e832cd3dd672_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy0xLTEtMS0yOTY1_bef47798-43dc-40c9-9c62-9b7da69fd3ac"
      unitRef="usd">913000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ifb1098ca438a48cd9e106e5843d6cd36_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy0zLTEtMS0yOTY1_9c2803bf-b022-44fb-b1d6-725d14e8f3b8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia6d3ffd252aa43aa8bf3e178360945c2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy01LTEtMS0zMTE1_5caa8a44-a197-4357-ab55-2e8d6ae91b31"
      unitRef="usd">913000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i28c029fe6658433091f9348fc9d54912_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy0xLTEtMS0w_0cb4665d-e392-4f4f-9bab-3f51f5f43df6"
      unitRef="usd">259000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i98f6ebc39e4f40b78d40104fb7855d08_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy0zLTEtMS0w_28c7e021-7fe6-4c3a-a080-01ec9ef439ba"
      unitRef="usd">234000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0f7abf2a1ea34998ba75e15db09892c4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfMy01LTEtMS0w_dda063eb-f53d-4a2d-abf2-e752e9c471a3"
      unitRef="usd">493000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id2cedde1fd8d4e13817c08df4f3817d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNC0xLTEtMS0w_106f23c9-2f0e-4e5a-b475-80a825eb8fbf"
      unitRef="usd">74000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i52ed2b595380454aa4357b1f8bbc92f8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNC0zLTEtMS0w_d2204d0c-1d14-43ba-bc3d-923d5f5dc972"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia41bb0fad4e647a688e43967bb0bb7be_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNC01LTEtMS0w_7916db0a-c099-4915-85fd-4fa207419c4a"
      unitRef="usd">74000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iabb99287795245cead94469bb0004c47_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNS0xLTEtMS0w_9b6389bc-4b77-4f75-87aa-52eca0f67a08"
      unitRef="usd">11957000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i015e0abf22814adbb2132f59a1724e19_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNS0zLTEtMS0w_4bf05e00-3869-4112-9337-79bf67bea512"
      unitRef="usd">1960000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF85NC9mcmFnOjkxOGQzYjZmMWI3NDRjNDViOTlkNzA4OWJlZTQ4YmYxL3RhYmxlOjNlYzIwNDFiZWY5YTQ1NmI4ZTEwODEwOWZlMjQxMDhmL3RhYmxlcmFuZ2U6M2VjMjA0MWJlZjlhNDU2YjhlMTA4MTA5ZmUyNDEwOGZfNS01LTEtMS0w_ed0f88a6-6403-4bef-a6b1-f134193f9845"
      unitRef="usd">13917000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90ZXh0cmVnaW9uOjI3NTE0MTM0ODkyMTQ0MGFiZDIwNTI0NzBjODc2Y2FjXzIzMw_bfd77f8e-f313-4bfb-8c26-18ebf5798835">Property and Equipment, net&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Company-owned fleet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, office and leased equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tools, molds, dies and jigs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and peripherals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense of property and equipment, net totaled $620 and $690 for the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90ZXh0cmVnaW9uOjI3NTE0MTM0ODkyMTQ0MGFiZDIwNTI0NzBjODc2Y2FjXzIyOQ_09059d90-1637-4c42-8df2-b4b4f8600f2d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Company-owned fleet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, office and leased equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tools, molds, dies and jigs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and peripherals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9f70fd4ec65c4972b421c5aa5b36941b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzItMS0xLTEtMC90ZXh0cmVnaW9uOjgwZmM0NjJkYjMxMDQ2ODk4YTllNDAzNTRmM2E2ODUzXzM4NDgyOTA2OTcyMjQ_4593408e-e32c-4924-b7e1-642deda25740">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i660e36a98e0746cf8a42c3b13e52a56b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzItMS0xLTEtMC90ZXh0cmVnaW9uOjgwZmM0NjJkYjMxMDQ2ODk4YTllNDAzNTRmM2E2ODUzXzM4NDgyOTA2OTcyMjg_6c48a665-2781-4fcf-966d-13fdd7173ccc">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id479e8c373654ebbb87b0a250bcc1e8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzItMy0xLTEtMA_ecd0cc31-fc2b-4fb9-9775-72dee03b24e2"
      unitRef="usd">3326000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3dd0c5c2bb3c4768abec83b24e2a64d3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzItNS0xLTEtMA_29595bda-c449-4295-ba6c-8eff31ef176b"
      unitRef="usd">3385000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3f923f15e82d409bac227a17e3701888_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjM3NzE4MzA2NmZmNjQwNGM4MDU2Y2I2YjdhZjcwY2RmXzM4NDgyOTA2OTcyMjQ_cc343b0a-ff95-48b8-92d0-8b69cd11693f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3d2e914eb0a5485b9d8820fc1baacc8d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjM3NzE4MzA2NmZmNjQwNGM4MDU2Y2I2YjdhZjcwY2RmXzM4NDgyOTA2OTcyMjc_e83587bd-8f60-402f-a85b-d3afb259f6cb">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i658969b097ae4314a93b0abea1d13868_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzMtMy0xLTEtMA_564ddd53-bcda-468e-9c8e-ce936ad59338"
      unitRef="usd">851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i763c0e7c9c9d44dcb6a9636b86af9d12_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzMtNS0xLTEtMA_57237fc8-9bf6-4a86-a85f-fecce3b12002"
      unitRef="usd">851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i130b8496b8734097b3481b467f0807f8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjljNjI0YzI5ODIwNzRjYzg5M2Q0ZDEyNTlmZTM2ZTQ0XzM4NDgyOTA2OTcyMjU_0c567219-c96a-4aa7-8523-c3e937619431">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i03553d669ad34441ba31a9b58507f565_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjljNjI0YzI5ODIwNzRjYzg5M2Q0ZDEyNTlmZTM2ZTQ0XzM4NDgyOTA2OTcyMjk_1f95921e-577a-4903-8a3d-5b07a8231872">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic54e4f7da48f45918ff0109be65c5330_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzQtMy0xLTEtMA_e0d28394-f470-4f9e-9bba-5a181e7fd1c8"
      unitRef="usd">631000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2abecebb024344bea34c7c37ce810974_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzQtNS0xLTEtMA_4299b1f6-1109-4e6c-a8a1-6a6647168c22"
      unitRef="usd">631000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7ec4203661dc40138fda63b48b530a85_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjJhY2I4OTBmOTdlYjQ5ZjVhYTJiMjQwNzNhY2U2OTEyXzM4NDgyOTA2OTcyMjQ_b81b5032-1b7e-40f1-8ca4-028ec533e381">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i049203243d424699b4e0dd6029b0888a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjJhY2I4OTBmOTdlYjQ5ZjVhYTJiMjQwNzNhY2U2OTEyXzM4NDgyOTA2OTcyMjc_4c4922d0-824e-4c13-8cda-3c59eb3d9910">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i165ec35cb06746f8ab56f69fe0d5c964_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzUtMy0xLTEtMA_e810fed8-f059-4034-b428-0bedb6de0d57"
      unitRef="usd">557000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i22f933f335564a9fac29ff916331aa4e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzUtNS0xLTEtMA_f5a2df08-1a39-4f6c-acae-e2380d1cda2d"
      unitRef="usd">554000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1d35bea06791470faea4c0d59dbb1e5a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzYtMS0xLTEtMC90ZXh0cmVnaW9uOmE0ZDQ3NTJjZjhjMDQzYjI4YWI4M2I0ZDdmNWFjNzk1XzM4NDgyOTA2OTcyMjQ_45c33203-4917-47df-ad0a-af97bb8da8ad">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2005fc6b0f7943b3ba42ed850a5c303e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzYtMS0xLTEtMC90ZXh0cmVnaW9uOmE0ZDQ3NTJjZjhjMDQzYjI4YWI4M2I0ZDdmNWFjNzk1XzM4NDgyOTA2OTcyMjc_c28d481e-cc90-4723-ae51-f28399042a81">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7c9feb071f8b40bfbfab0e7da695b5dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzYtMy0xLTEtMA_ba7e0e69-5f8c-4cbc-b828-f090b60bea03"
      unitRef="usd">291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2dd9eb144ecd423dade80dac3f927d7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzYtNS0xLTEtMA_5c7a04f7-5bc2-453d-9c1f-b7f21af222a7"
      unitRef="usd">289000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i56395207f3fa42a797c5ba80cfdfc6b8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzctMS0xLTEtMC90ZXh0cmVnaW9uOmZiMTY2MTQ4ZGJhNzQzNjliN2ZhMmRjMDYyZDE0Zjk3XzM4NDgyOTA2OTcyMjI_2d30487a-c0f9-4669-aad1-4684ff06ac0c">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia18e0975d5f84534ac0b1db267f24d9b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzctMy0xLTEtMA_fee51f66-9384-408c-9e20-f174a169f82f"
      unitRef="usd">96000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i88d7b8be94cd47d2b55ddb60df657ed4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzctNS0xLTEtMA_f255ad44-bb4b-43f9-84ad-3734f6eb3e70"
      unitRef="usd">96000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i09b4c0d4a24e49a0a8ffd3a7005294c4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzgtMS0xLTEtMC90ZXh0cmVnaW9uOjg1N2RlZGUwNGI2ZDRlZDQ4NjExZjY4OTBiZjdhYTNlXzM4NDgyOTA2OTcyMjQ_0fb67738-7a68-4021-99f5-817f85430b02">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i27ca24a6e01a4c5e818349f32894630b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzgtMS0xLTEtMC90ZXh0cmVnaW9uOjg1N2RlZGUwNGI2ZDRlZDQ4NjExZjY4OTBiZjdhYTNlXzM4NDgyOTA2OTcyMjc_7572353a-c7f7-4e20-af2e-e3a86135a9b1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iac816c78ecee495db3e143bd5054df3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzgtMy0xLTEtMA_d5f74204-e841-4765-a0a7-bda63e6bc21e"
      unitRef="usd">77000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i57a91e8c1fb344769e0f47516a30046c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzgtNS0xLTEtMA_6c951f07-7ff2-44c1-9ff9-594e9206e010"
      unitRef="usd">77000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzktMy0xLTEtMA_11521650-5187-4aba-84ed-ba3b98b66e15"
      unitRef="usd">5829000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzktNS0xLTEtMA_d77bcf36-8834-4e8a-a680-1210d269ef33"
      unitRef="usd">5883000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzEwLTMtMS0xLTA_6a173559-7579-4917-88a8-48dd115a4cb1"
      unitRef="usd">4657000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzEwLTUtMS0xLTA_b21cb91b-7792-42cb-b8c9-c718b19901fd"
      unitRef="usd">4226000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzExLTMtMS0xLTA_b5fb0d59-1cc2-4d49-9f78-3b9728816866"
      unitRef="usd">1172000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90YWJsZTpmNDdiYzJhYWFmYmY0Y2ZjOTdiNmIxMTBhMWI3MDNlNi90YWJsZXJhbmdlOmY0N2JjMmFhYWZiZjRjZmM5N2I2YjExMGExYjcwM2U2XzExLTUtMS0xLTA_fe713a99-3554-47a0-bb66-eed6528ec5d6"
      unitRef="usd">1657000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90ZXh0cmVnaW9uOjI3NTE0MTM0ODkyMTQ0MGFiZDIwNTI0NzBjODc2Y2FjXzE3NA_520da64f-dd8a-4501-9684-29394193d7e6"
      unitRef="usd">620000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDAvZnJhZzoyNzUxNDEzNDg5MjE0NDBhYmQyMDUyNDcwYzg3NmNhYy90ZXh0cmVnaW9uOjI3NTE0MTM0ODkyMTQ0MGFiZDIwNTI0NzBjODc2Y2FjXzE4MQ_d53a5ae6-84ea-47aa-b8f7-badab7119424"
      unitRef="usd">690000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90ZXh0cmVnaW9uOjI1NjA3NTU5MDBmMDQzMWFiNzk1OWYwMTI4MjM3ZGRjXzExNDM_16816a8c-a3db-4df0-af0a-041084b0877a">Accrued Liabilities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, benefits and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Device warranty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warranty&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of devices generally include an initial warranty for parts and services for one year in the Americas, two years in Europe, the Middle East, Africa, and one or two years in the Asia Pacific region.  A liability for the estimated cost of product warranty is established at the time revenue is recognized based on the historical experience of known product failure rates and expected material and labor costs to provide warranty services. Specific additional warranty accruals may be made if unforeseen technical problems arise. Alternatively, if estimates are determined to be greater than the actual amounts necessary, a portion of the liability may be reversed in future periods.&#160;Warranty costs are reflected in the consolidated statements of operations and comprehensive loss as a component of costs of revenue. The current portion of the warranty liability is classified as a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;component of accrued liabilities, while the long-term portion of the warranty liability is classified as a component of other non-current liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warranty&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for estimated future expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90ZXh0cmVnaW9uOjI1NjA3NTU5MDBmMDQzMWFiNzk1OWYwMTI4MjM3ZGRjXzExNDY_341991d1-1683-4e8d-aa0e-7af9befbb350">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, benefits and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Device warranty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzItMS0xLTEtMA_70e32b79-0d4e-4fc3-8934-1a5ff83f3d3a"
      unitRef="usd">1194000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzItMy0xLTEtMA_029edc62-1bb3-409d-9b06-d464c9aceacc"
      unitRef="usd">1098000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzMtMS0xLTEtMA_bb9cb3ce-0e0b-4840-bb9a-071aff066658"
      unitRef="usd">188000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzMtMy0xLTEtMA_f138427b-bc3f-4f1a-88fc-fe7b60481c33"
      unitRef="usd">285000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <ekso:AccruedClinicalCostCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzQtMS0xLTEtMA_82667039-4894-4459-91b7-fec7b26d7d7c"
      unitRef="usd">47000</ekso:AccruedClinicalCostCurrent>
    <ekso:AccruedClinicalCostCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzQtMy0xLTEtMA_c41ec4bf-c4e9-4cad-b31d-8050d0fa524e"
      unitRef="usd">300000</ekso:AccruedClinicalCostCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzgtMS0xLTEtMA_7bda3e64-07bd-4514-8667-2659dc0914d6"
      unitRef="usd">1429000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZTo2MDE1Mzk4OTgxNzc0MGQwYmI3YjNkNDU1MzJkNWJkYy90YWJsZXJhbmdlOjYwMTUzOTg5ODE3NzQwZDBiYjdiM2Q0NTUzMmQ1YmRjXzgtMy0xLTEtMA_3c6d2712-5738-409b-a6d4-b83c9928131e"
      unitRef="usd">1683000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StandardProductWarrantyDescription
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90ZXh0cmVnaW9uOjI1NjA3NTU5MDBmMDQzMWFiNzk1OWYwMTI4MjM3ZGRjXzMyOTg1MzQ4ODQ1Mjg_8f165068-93cb-4f4a-b744-5b9f70b3d12c">Sales of devices generally include an initial warranty for parts and services for one year in the Americas, two years in Europe, the Middle East, Africa, and one or two years in the Asia Pacific region.</us-gaap:StandardProductWarrantyDescription>
    <ekso:ProductMaintenanceAndWarrantyTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90ZXh0cmVnaW9uOjI1NjA3NTU5MDBmMDQzMWFiNzk1OWYwMTI4MjM3ZGRjXzExNDA_6dc6a87d-aee2-4c51-b6e6-ab48ca1c542c">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warranty&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for estimated future expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ekso:ProductMaintenanceAndWarrantyTableTextBlock>
    <ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent
      contextRef="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzItMS0xLTEtMA_0d823766-6000-46a7-b789-6b52bd61661a"
      unitRef="usd">350000</ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent>
    <ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent
      contextRef="i79e076985ae14c239cf28cb82308d69e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzItMy0xLTEtMA_d3a7bfc9-5d46-4104-9c7c-28a4e05213ea"
      unitRef="usd">319000</ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent>
    <ekso:ProductMaintenanceWarrantyAddition
      contextRef="i663e54f1b87347028c8829a7b346f7be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzMtMS0xLTEtMA_f925e301-c674-47ec-add1-0a98acafdbb8"
      unitRef="usd">219000</ekso:ProductMaintenanceWarrantyAddition>
    <ekso:ProductMaintenanceWarrantyAddition
      contextRef="iccc8ff9bb9094f2ca094767c70c3d73f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzMtMy0xLTEtMA_76918272-6396-4242-9f26-f0c2864b6b14"
      unitRef="usd">416000</ekso:ProductMaintenanceWarrantyAddition>
    <ekso:ProductMaintenanceWarrantyExpense
      contextRef="i663e54f1b87347028c8829a7b346f7be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzQtMS0xLTEtMA_9a496cd0-3868-4e9d-88b4-1e7c58a5d46c"
      unitRef="usd">343000</ekso:ProductMaintenanceWarrantyExpense>
    <ekso:ProductMaintenanceWarrantyExpense
      contextRef="iccc8ff9bb9094f2ca094767c70c3d73f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzQtMy0xLTEtMA_50738ea1-287a-4ef3-9233-6ff4224595d0"
      unitRef="usd">385000</ekso:ProductMaintenanceWarrantyExpense>
    <ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent
      contextRef="i0d2406d983ae408d82890348c4593fe2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzUtMS0xLTEtMA_13939482-c80e-4185-843a-fe43f5e14b2f"
      unitRef="usd">226000</ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent>
    <ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent
      contextRef="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzUtMy0xLTEtMA_86cd3b68-7694-4475-87b9-e0d6c75c87aa"
      unitRef="usd">350000</ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent>
    <ekso:ProductMaintenanceWarrantyLiabilitiesCurrent
      contextRef="i0d2406d983ae408d82890348c4593fe2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzctMS0xLTEtMA_1514ffa2-b5f7-41ef-afce-713ada91e934"
      unitRef="usd">188000</ekso:ProductMaintenanceWarrantyLiabilitiesCurrent>
    <ekso:ProductMaintenanceWarrantyLiabilitiesCurrent
      contextRef="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzctMy0xLTEtMA_a3230c97-5dcc-4582-8c45-1308bbcc61d5"
      unitRef="usd">285000</ekso:ProductMaintenanceWarrantyLiabilitiesCurrent>
    <ekso:ProductMaintenanceWarrantyLiabilitiesNoncurrent
      contextRef="i0d2406d983ae408d82890348c4593fe2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzgtMS0xLTEtMA_95cb0f82-7951-4a12-b8ea-dc7fcf9dd24e"
      unitRef="usd">38000</ekso:ProductMaintenanceWarrantyLiabilitiesNoncurrent>
    <ekso:ProductMaintenanceWarrantyLiabilitiesNoncurrent
      contextRef="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzgtMy0xLTEtMA_2d5c9218-8cec-409b-b72a-7ae80d87e9c2"
      unitRef="usd">65000</ekso:ProductMaintenanceWarrantyLiabilitiesNoncurrent>
    <ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent
      contextRef="i0d2406d983ae408d82890348c4593fe2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzktMS0xLTEtMA_1a59588c-56e8-4a73-bc4e-9a8e810f712e"
      unitRef="usd">226000</ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent>
    <ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent
      contextRef="i99e9c419a2c0459480ba6741e3d6c3d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDYvZnJhZzoyNTYwNzU1OTAwZjA0MzFhYjc5NTlmMDEyODIzN2RkYy90YWJsZToyY2YwNmQwZDZkNmQ0YmE4YmRmNjk3MDdmY2ExYWMyMi90YWJsZXJhbmdlOjJjZjA2ZDBkNmQ2ZDRiYThiZGY2OTcwN2ZjYTFhYzIyXzktMy0xLTEtMA_b15964a0-4a6e-47a2-ba34-1651fa69e117"
      unitRef="usd">350000</ekso:ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzQwMjA_f696d2e5-1292-4e3c-9267-aa25bfd6f36d">Notes payable, net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;WAB and PWB Term Loans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;WAB Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company entered into a loan agreement with Western Alliance Bank ("WAB loan") and received a loan in the principal amount of $7,000 that&#160;bore interest on the outstanding daily balance at a floating per annum rate equal to the 30-day U.S. LIBOR plus 5.41%. The Company was required to pay accrued interest on the WAB loan on the first day of each month through and including January 1, 2018. Commencing on February 1, 2018, the Company was required to make equal monthly payments of principal, together with accrued and unpaid interest maturing on January 1, 2021. On April 29, 2020 the Company entered into a second amendment to the December 2016 WAB loan agreement to defer principal payments for three months beginning in May 2020, with adjustments when the principal payments resumed on August 1, 2020. During the three-month deferral period the Company was required to make interest only payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final payment fee, debt issuance costs, and the initial fair value of the success fee combined with the stated interest resulted in an effective interest rate for the WAB loan of 8.49% for the year ended December 31, 2020. The final payment fee, initial fair value of the success fee, and debt issuance costs were accreted/amortized to interest expense using the effective interest method over the life of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PWB Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into a new loan agreement (the "PWB Loan Agreement") with a different lender, Pacific Western Bank, and received a loan in the principal amount of $2,000 (the "PWB Term Loan") that bears interest on the outstanding daily balance at a rate equal to the greater of: (a) 0.50% above the variable rate of interest announced by the lender as its &#x201c;prime rate&#x201d; then in effect; or (b) 4.50%. The PWB Loan Agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds of the PWB Term Loan were used to pay off the entire amount of the Company's indebtedness on the WAB loan which amounted to $1,512. Pursuant to the PWB Loan Agreement, the remainder of the PWB Term Loan proceeds may be used for general corporate purposes which totaled $480, net of debt discounts and issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay accrued interest on the current loan on the 13th day of each month through and including August 13, 2023. The principal balance of the PWB Term Loan matures on August 13, 2023, at which time all unpaid principal and accrued and unpaid interest shall be due and payable in full. The interest rate of the PWB Term Loan is subject to increase in the event of late payments and after occurrence of and during the continuation of an event of default. Upon maturity, all unpaid principal and accrued and unpaid interest shall be due and payable in full. The Company may elect to prepay the PWB Term Loan at any time, in whole or in part, without penalty or premium.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of December 31, 2020. On December 31, 2020, with cash on hand of $12,862, the Company was compliant with this liquidity covenant and all other covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 4.64% for the year ended December 31, 2020. The debt issuance costs will be amortized to interest expense using the effective interest method over the life of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents scheduled principal payments of the Company's note payable as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 - 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less final payment fee, discount and issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 20, 2020, the Company received an unsecured loan in the principal amount of $1,086 under the Paycheck Protection Program (the &#x201c;PPP&#x201d;) administered by the U.S. Small Business Administration, or the SBA, pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;), or the PPP loan.  The PPP loan provides for an interest rate of 1.00% per year, and matures two years after the date of initial disbursement. The terms of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, or the PPP Flexibility Act, which was enacted on June 5, 2020.  Based on management's interpretation of the the PPP Flexibility Act, the Company expects to begin making principal and interest payments on the PPP loan beginning in 2022. The overall timing of payments with respect to the amounts of principal and interest due could change based on the ultimate determination of what may or may not be forgiven.  The PPP loan may be used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments, mortgage interest payments and interest payments on any other debt obligation that were incurred before February 15, 2020. Under the terms of the CARES Act and the PPP Flexibility Act, the Company may apply for and be granted forgiveness for all or a portion of loan granted under the PPP loan, with such forgiveness to be determined, subject to limitations (including where employees of the Company have been terminated and not re-hired by a certain date), based on the use of the loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness may also be subject to further requirements in regulations and guidelines adopted by the SBA. While the Company currently believes that the majority of the use of the PPP loan proceeds will meet the conditions for forgiveness under the PPP, no assurance is provided that the Company will obtain partial forgiveness of the loan.  Terms of the loan may change subject to future enactments relating to the PPP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The follow table presents the scheduled principal payments of the Company's PPP loan note payable as of December 31, 2020, shown if the loan is not forgiven:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7b6df24c948e48979ba8b93b03bc8282_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzk3_be2f2f00-da7c-407d-9fa1-19232f61185d"
      unitRef="usd">7000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia26aaae57e1a4c82bb8d24f30b52abe8_D20161201-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzIxOA_fe540437-050c-4a30-aa80-1ed0905ce229"
      unitRef="number">0.0541</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ekso:DebtInstrumentDeferralPeriod
      contextRef="i75e32a08cd3c442a9b9ba9304b50179b_D20200429-20200429"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk1NDg_87f3850d-d727-4b14-a142-c4be4ce55a50">P3M</ekso:DebtInstrumentDeferralPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzQ5NDc4MDIzMzE1Mjg_69d1e36a-281c-4ec8-8869-838ae05e4f36"
      unitRef="number">0.0849</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i820fe364817646f793de1bd99129025e_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk1NzE_080b37dd-3ce9-414f-bd7b-86138a491105"
      unitRef="usd">2000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i414af477b5eb412594fd4faab7f47ca1_D20200801-20200830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk1Nzk_f23f29cd-b37b-44c9-aad1-ce53a96fcc6c"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i820fe364817646f793de1bd99129025e_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk1ODU_a3339108-9557-4453-8b35-871da4c72d98"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk1OTY_ad9a7b0b-d1f3-4f2b-bf94-22bb58e9974c"
      unitRef="usd">1512000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <ekso:LineOfCreditFacilityCapacityAvailableForSpecificPurpose
      contextRef="ic845df26b7574c9688eaf63d2b286340_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk2MDQ_5a7d98f1-3a59-4d39-9772-e34324035a37"
      unitRef="usd">480000</ekso:LineOfCreditFacilityCapacityAvailableForSpecificPurpose>
    <us-gaap:LongTermDebt
      contextRef="ic845df26b7574c9688eaf63d2b286340_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk2MTA_b7f10f4c-0437-4525-b56d-384f9d3306ef"
      unitRef="usd">2000</us-gaap:LongTermDebt>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzQ5NDc4MDIzMzQyNjA_cee3d033-eb4b-4330-a554-fc4d6706678f"
      unitRef="usd">12862000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i5f6e46cb0a00471f82de8d8582d4cbe4_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzQ5NDc4MDIzNDcyMjU_eb597e63-6242-4ac9-bfb1-2dc52a8830ae"
      unitRef="number">0.0464</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzQwMjI_81720038-5624-4d2a-a863-68e3206a76f9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents scheduled principal payments of the Company's note payable as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 - 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less final payment fee, discount and issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The follow table presents the scheduled principal payments of the Company's PPP loan note payable as of December 31, 2020, shown if the loan is not forgiven:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <ekso:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzEtMS0xLTEtMA_e0346f97-0118-4ede-b699-bb4bd214f2b7"
      unitRef="usd">0</ekso:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzItMS0xLTEtMA_60f51d83-df3b-4d7d-9167-f0717c49bf15"
      unitRef="usd">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzMtMS0xLTEtMA_5588d336-83b9-43f1-9a6f-0c7f8193809f"
      unitRef="usd">2000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzQtMS0xLTEtMA_de3a0a71-0bd5-46f6-861e-82f5da45603c"
      unitRef="usd">11000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzUtMS0xLTEtMA_40fe3a08-23e9-4cb1-a8de-766b3d371239"
      unitRef="usd">1989000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzctMS0xLTEtMA_abadc16d-a40b-4c25-9001-a808ce9d671e"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzgtMS0xLTEtMA_63b860d2-0e9c-436d-ac85-63e46defc888"
      unitRef="usd">1989000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTo3NDg1MTdhYjRjMmE0NzdkODZiZGZhMzQwNzhlZTYxNC90YWJsZXJhbmdlOjc0ODUxN2FiNGMyYTQ3N2Q4NmJkZmEzNDA3OGVlNjE0XzktMS0xLTEtMA_8771a292-a673-414b-9b11-e2d4e77b2370"
      unitRef="usd">1989000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ied25b6065fd04927890a9579112ce304_I20200420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzY1OTcwNjk3Nzk2MTg_1d8a6178-401a-44a8-834c-fff66d5e3178"
      unitRef="usd">1086000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ied25b6065fd04927890a9579112ce304_I20200420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzkzNDU4NDg4NTkxNjA_494fc0eb-a53f-4797-afdf-a20b183c21a4"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="id59142af679b474d9606680f4928a206_D20200420-20200420"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90ZXh0cmVnaW9uOjFhMzUxNmIzNTQ5NDQwOThiMDg3MmRjYmEzZmY0ZGJhXzkzNDU4NDg4NTkxODY_b8759057-4051-4209-bb08-3389c73afce1">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzEtMS0xLTEtMTQ5Ng_1d9a02a3-5650-4399-baef-20876751d9a4"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzItMS0xLTEtMTQ5Ng_7cf3abbf-81ad-4b4e-b9dd-3c9aaa87b8c8"
      unitRef="usd">1086000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzQtMS0xLTEtMjYwNQ_3368ebd5-ca25-4289-b438-69127af0be3b"
      unitRef="usd">1086000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzYtMS0xLTEtMTUwMQ_e052fcdd-3b46-4c8c-9b09-fba35b44d9f7"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzctMS0xLTEtMTUwMQ_86c3ca4d-9089-4438-b5c6-da20e900b7b0"
      unitRef="usd">1086000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="icc71209ac60845e382225b8a55a86c3d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMDkvZnJhZzoxYTM1MTZiMzU0OTQ0MDk4YjA4NzJkY2JhM2ZmNGRiYS90YWJsZTphMDc5MzQ2N2JkODg0M2Q1YTBmNTBlZWJjNjMzNGI3OS90YWJsZXJhbmdlOmEwNzkzNDY3YmQ4ODQzZDVhMGY1MGVlYmM2MzM0Yjc5XzgtMS0xLTEtMjYwOA_7475edb5-cc5a-45e1-a618-2abd8364d5cf"
      unitRef="usd">1086000</us-gaap:LongTermDebt>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzMwMDM_3ae7ad1d-df84-402d-ba66-b3b81876acde">Lease Obligations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a five-year operating lease agreement for its headquarters and manufacturing facility in Richmond, California, or the Richmond Lease, which expires in May 2022, with no further options to extend or terminate. The lease includes non-lease components (i.e. common area maintenance costs) that are paid separately from rent based on actual costs incurred. In June 2020, the Company entered into an amendment to the Richmond Lease to make a one-time payment of $300 to cover its remaining lease obligations for the remainder of 2020, resulting in a $48 abatement and a lease payment deferral of $79 to be paid in equal monthly installments in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's five-year operating lease agreement for its European operations office in Hamburg, Germany expires in July 2022. It has an option to extend for another five-year term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through April 2019, the Company had an unoccupied leased sales office in Freiburg, Germany, which had a lease term that expired in December 2020. In April 2019, the Company entered an agreement with the lessor of the Freiburg office releasing the Company from future lease payments after April 30, 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s future lease payments as of December 31, 2020 are as follows, which are presented as lease liabilities on the Company&#x2019;s consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.497%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense under the Company&#x2019;s operating leases was $537 and $551, for the years ended December 31, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Practical Expedients&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;As part of the transition to ASC 842, the Company elected to use the modified retrospective transition method with the new standard being applied as of the January 1, 2019 adoption date. Additionally, the Company has elected, as of the adoption date, not to reassess whether expired or existing contracts contain leases under the new definition of a lease; the lease classification for expired or existing leases; or whether previously capitalized initial direct costs would qualify for capitalization under ASC 842.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie41cddf1a88a4eeab4f0e94b552e1cad_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzMyOTg1MzQ4OTU5Nzk_2966d644-d95d-4d58-ad94-b9500f1bf069">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeasePayments
      contextRef="i4013c40327cb4b46bc304ebb13174011_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzY1OTcwNjk3NzYzMzE_46daf4cf-615b-4b8f-98ea-3456b352fdc8"
      unitRef="usd">300000</us-gaap:OperatingLeasePayments>
    <ekso:OperatingLeaseAbatement
      contextRef="i4013c40327cb4b46bc304ebb13174011_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzY1OTcwNjk3NzYzMzc_980c93df-6bf6-4d35-bccb-fd106ecf4071"
      unitRef="usd">48000</ekso:OperatingLeaseAbatement>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie41cddf1a88a4eeab4f0e94b552e1cad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzY1OTcwNjk3NzYzNDI_149129ae-2a56-4489-ada5-af8ae93b7557"
      unitRef="usd">79000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iae9cf36b522d452a848dfea8122fdd50_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzMyOTg1MzQ4OTU5ODA_4cf72021-4d90-4319-be47-64885cf8808b">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="iae9cf36b522d452a848dfea8122fdd50_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzMyOTg1MzQ4OTU5ODE_d5797a75-6967-426a-a171-688da56792a7">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzMwMDk_d22d139b-1c6b-499d-a481-83b76d30071a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s future lease payments as of December 31, 2020 are as follows, which are presented as lease liabilities on the Company&#x2019;s consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.497%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzEtMi0xLTEtMA_d06f837c-eaae-4c40-b52a-e59ef817993b"
      unitRef="usd">599000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzItMi0xLTEtMA_9b016623-a691-4ca2-a65d-64446160bb1e"
      unitRef="usd">237000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzYtMi0xLTEtMA_b75de322-e353-4585-8968-2d83c5710f3f"
      unitRef="usd">836000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzctMi0xLTEtMA_84b8553b-0bcd-4cd9-b286-eb9d8702a1ee"
      unitRef="usd">55000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzgtMi0xLTEtMA_89180c9b-8199-4f96-834b-3ba80f380ee8"
      unitRef="usd">781000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzEwLTItMS0xLTA_c5e51635-b7f4-4522-8824-5ef04b07bad6"
      unitRef="usd">548000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzExLTItMS0xLTA_7be92f25-3a9b-4186-ab2e-b7ec75af583d"
      unitRef="usd">233000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzEyLTItMS0xLTA_0566b4c3-5608-4067-ab09-dd3ccd1b8f0c"
      unitRef="usd">781000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzE0LTItMS0xLTA_5f75e109-ab75-422e-9dab-b209240d01d0">P1Y5M8D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90YWJsZTozMjM2NDgyYjE1MTY0YjkzOGUwZDkzOGFmYjg2YjVhZi90YWJsZXJhbmdlOjMyMzY0ODJiMTUxNjRiOTM4ZTBkOTM4YWZiODZiNWFmXzE1LTItMS0xLTA_a5e28b9d-6fd8-4e6b-bb3e-ca03582e2295"
      unitRef="number">0.105</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzE5MzU_af255846-320d-4130-827e-0650c6505368"
      unitRef="usd">537000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTIvZnJhZzpiMzYyZWIyOWE3ZmE0MGVkYjRkMzhlOTE3ODM4NDliZC90ZXh0cmVnaW9uOmIzNjJlYjI5YTdmYTQwZWRiNGQzOGU5MTc4Mzg0OWJkXzE5NDI_cb8e1cf6-bf40-41f7-a347-8225f441a46e"
      unitRef="usd">551000</us-gaap:OperatingLeaseExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTgvZnJhZzo5YjNhNmY0Nzk1OTQ0OTNjYTAyNGNmNGRjZDlmNTEyZC90ZXh0cmVnaW9uOjliM2E2ZjQ3OTU5NDQ5M2NhMDI0Y2Y0ZGNkOWY1MTJkXzUzOA_265a037b-065f-4346-b59c-497965ed74ce">Employee Benefit PlanThe Company administers a 401(k) retirement plan, or the 401(k) Plan, in which all employees are eligible to participate. Each eligible employee may elect to contribute to the 401(k) Plan. The Company has made matching contributions in the form of shares of the Company's common stock to the 401(k) Plan in an amount equal to 50% of employee contributions (up to the statutory limit), subsequent to year-end. The expense related to the contribution was $169 and $142 for the years ended December 31, 2020 and 2019, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTgvZnJhZzo5YjNhNmY0Nzk1OTQ0OTNjYTAyNGNmNGRjZDlmNTEyZC90ZXh0cmVnaW9uOjliM2E2ZjQ3OTU5NDQ5M2NhMDI0Y2Y0ZGNkOWY1MTJkXzM1Ng_c3cff4f7-2e0d-4c63-8905-b10fc8040e9b"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTgvZnJhZzo5YjNhNmY0Nzk1OTQ0OTNjYTAyNGNmNGRjZDlmNTEyZC90ZXh0cmVnaW9uOjliM2E2ZjQ3OTU5NDQ5M2NhMDI0Y2Y0ZGNkOWY1MTJkXzQ4Mg_769bd413-deff-49f1-8192-96b7ccf3fdf3"
      unitRef="usd">169000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMTgvZnJhZzo5YjNhNmY0Nzk1OTQ0OTNjYTAyNGNmNGRjZDlmNTEyZC90ZXh0cmVnaW9uOjliM2E2ZjQ3OTU5NDQ5M2NhMDI0Y2Y0ZGNkOWY1MTJkXzQ4OQ_c73639bb-c9ef-4a77-8ec9-a6450828a291"
      unitRef="usd">142000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjEvZnJhZzozNDMzM2RjMDQ2Nzk0NDU0ODIwMDg3OWE2YmFhMDMwNi90ZXh0cmVnaW9uOjM0MzMzZGMwNDY3OTQ0NTQ4MjAwODc5YTZiYWEwMzA2XzE5ODk_b3d746db-4928-4e55-bc26-ad2ecd7f313a">Related Party Transactions&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One of the Company&#x2019;s directors, Dr. Ted Wang, is the founder, general partner and Chief Investment Officer of Puissance Capital Management LP, or Puissance Capital, which is an affiliate of Puissance Cross-Border Opportunities II LLC, one of the Company&#x2019;s largest stockholders until November 2020. Prior to Dr. Wang&#x2019;s appointment to the Board in connection with the Rights Offering in September 2017, the Company entered into a one-year consulting agreement with Angel Pond Capital LLC, or Angel Pond, an entity solely owned and managed by Dr. Wang and affiliated with Puissance Capital. Angel Pond provides consulting services to the Company with respect to strategic positioning in the Asia Pacific region, including introduction to potential strategic partners and the development of strategic partnerships for the sale and manufacture of the Company&#x2019;s products in that market. During the year ended December&#160;31, 2019, Angel Pond provided consulting services amounting to $30 during, which was expensed in the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, the Company sold EksoVest raw material inventory and tooling to the China JV for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$45.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <ekso:RelatedPartyTransactionConsultingAgreement
      contextRef="iff102119cd6a456596f0197f90723327_D20170901-20170930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjEvZnJhZzozNDMzM2RjMDQ2Nzk0NDU0ODIwMDg3OWE2YmFhMDMwNi90ZXh0cmVnaW9uOjM0MzMzZGMwNDY3OTQ0NTQ4MjAwODc5YTZiYWEwMzA2XzM4NDgyOTA2OTkyMDY_e0a7209a-e700-4e53-9835-96018a00fe51">P1Y</ekso:RelatedPartyTransactionConsultingAgreement>
    <us-gaap:PaymentsForFees
      contextRef="i66089c57ef3447548266d31fba65e3f3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjEvZnJhZzozNDMzM2RjMDQ2Nzk0NDU0ODIwMDg3OWE2YmFhMDMwNi90ZXh0cmVnaW9uOjM0MzMzZGMwNDY3OTQ0NTQ4MjAwODc5YTZiYWEwMzA2XzEzMjg_389eacc6-49e1-4e20-8310-f1585d227eba"
      unitRef="usd">30000</us-gaap:PaymentsForFees>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjEvZnJhZzozNDMzM2RjMDQ2Nzk0NDU0ODIwMDg3OWE2YmFhMDMwNi90ZXh0cmVnaW9uOjM0MzMzZGMwNDY3OTQ0NTQ4MjAwODc5YTZiYWEwMzA2XzE5ODM_dc6ad137-6c49-4587-afe9-a47d993645d5"
      unitRef="usd">45000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE4MTI4_4445454d-5a42-47ae-af5d-be80bc3a340f">Capitalization and Equity Structure&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the close of the stock market on March 24, 2020, the Company effected a 1-for-15 reverse split of its common stock (the "Reverse Stock Split"). As a result, all common stock share amounts included in this filing have been retroactively reduced by a factor of fifteen, rounded up to the nearest whole share, and all common stock per share amounts have been increased by a factor of fifteen, with the exception of the Company's common stock par value and the Company's authorized shares. Amounts affected include common stock outstanding, restricted stock units, common stock underlying stock options and warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, on September 16, 2019, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) informing the Company that because the closing bid price for the Company&#x2019;s common stock listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days, the Company did not meet the minimum closing bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split was effected in order to raise the per share trading price of its common stock above $1.00 and regain compliance with Nasdaq&#x2019;s listing requirements. On April 7, 2020, the Company regained compliance with the minimum bid price requirement required by the Nasdaq listing rules.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s authorized capital stock at December 31, 2020 consisted of 141,429 shares of common stock and 10,000 shares of preferred stock. The authorized capital was not reduced in connection with the Reverse Stock Split. At December 31, 2020, there were 8,349 shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of outstanding shares of common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the Board of Directors may determine. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting for the election of directors. The common stock is not entitled to preemptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of the Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of the common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. Each outstanding share of common stock is duly and validly issued, fully paid, and non-assessable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;June 2020 Common Stock and Warrants to Purchase Common Stock Offering&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into a securities purchase agreement, or the June 2020 Purchase Agreement, with certain purchasers. Pursuant to the June 2020 Purchase Agreement, the Company sold in a registered direct offering, or the June 2020 Offering, an aggregate of 1,748 shares of its common stock. Pursuant to such agreement, the Company also sold, in a concurrent private placement offering, warrants to purchase 874 shares of its common stock, or the June 2020 Investor Warrants. The gross proceeds of the June 2020 Offering and the concurrent private placement offering were $7,890, the June 2020 Gross Proceeds. Each June 2020 Investor Warrant has an exercise price of $5.18 per share, subject to adjustment in certain circumstances, and is exercisable immediately and will expire five and one-half years from issuance, or on December 10, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As compensation for services provided by the placement agent for the June 2020 Offering, or the Placement Agent, the Company paid a cash fee equal to 7.0% of the June 2020 Gross Proceeds ($552) and a management fee equal to 1.0% of the June 2020 Gross Proceeds ($79), and issued, in a concurrent private placement offering, warrants to purchase shares of the Company's common stock, or the June 2020 Placement Agent Warrants, in an amount equal to up to 7.0% of the aggregate number of shares of common stock sold in the June 2020 Offering, or 122 shares in the aggregate, in substantially the same form as the June 2020 Investor Warrants, except that the June 2020 Placement Agent Warrants will expire five years from the effective date of the June 2020 Offering, or on June 7, 2025, and have an exercise price per share equal to $5.64. In connection with the June 2020 Offering, the Company also incurred $98 in other expenses of the Placement Agent paid for or reimbursed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the $7,890 in proceeds, $2,650 was allocated to the June 2020 Investor Warrants and June 2020 Placement Agent Warrants, or, collectively, the June 2020 Warrants, based on the fair value method, with the remaining proceeds of $5,240 allocated to the common stock shares sold in the June 2020 Offering. In connection with the June 2020 Offering and concurrent private placement offerings, the Company incurred approximately $1,117 in direct financing costs, including a fair value of $309 of June 2020 Placement Agent Warrants. Financing costs of $808, excluding the fair value of the June 2020 Placement Agents Warrants, were allocated on the fair value basis between the common stock shares sold in the June 2020 Offering and the June 2020 Warrants, as follows: $329 was allocated to the June 2020 Warrants and expensed immediately in other income (expense), net in the accompanying consolidated statements of operations and comprehensive income (loss) and $479 was allocated to the common stock shares sold in the June 2020 Offering and recorded as a reduction to additional paid in capital. The direct financing cost of $309 associated with the June 2020 Placement Agent warrants was also allocated to the common stock shares sold in the June 2020 Offering and recorded as a reduction to additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At the Market Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright &amp;amp; Co., LLC (the "Agent"), under which the Company may issue and sell shares of its common stock, from time to time, to or through the Agent. Offers and sales of shares of common stock by the Company through the Agent may be made by any method deemed to be an &#x201c;at the market offering&#x201d; as defined under SEC Rule 415 or in privately negotiated transactions, subject to certain conditions. Such shares may be offered pursuant to the registration statement on Form S-3 (File No. 333-239203) (the &#x201c;Registration Statement&#x201d;), which was declared effective by the SEC on June 26, 2020, and a related prospectus supplement filed with the SEC on October 9, 2020 (the &#x201c;ATM Prospectus&#x201d;). Pursuant to the Registration Statement and the ATM Prospectus, shares having an aggregate offering price of up to $7,500 may be offered and sold, subject to certain SEC rules limiting the amount of shares of the Company&#x2019;s common stock that may be sold by the Company under the Registration Statement. Under the ATM Agreement, shares of the Company's common stock may not be sold for a price lower than $6.75 per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Company entered into a Controlled Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement with Cantor Fitzgerald &amp;amp; Co. (the "Cantor Agreement"). Prior to entering into the ATM Agreement, the Company terminated the Cantor Agreement in September 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not sell any shares of common stock under the Cantor Agreement or the ATM Agreement during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may issue shares of preferred stock from time to time in one or more series, each of which will have such distinctive designation or title as shall be determined by its Board of Directors and will have such voting powers, full or limited, or no voting powers, and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated in such resolution or resolutions providing for the issue of such class or series of preferred stock as may be adopted from time to time by the Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant shares outstanding as of December 31, 2019 and December 31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Source&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020 Investor Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020 Placement Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Placement Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2019 Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Information Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015 Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-2014 warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;June 2020 Investor Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company issued the June 2020 Investor Warrants, exercisable for up to 874 shares of the Company&#x2019;s common stock at an exercise price of $5.18 per share. The June 2020 Warrants were issued as exercisable immediately, and will expire five and one-half years from the date of issuance, or on December 10, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the June 2020 Investor Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its June 2020 Investor Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the June 2020 Investor Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company&#x2019;s common stock determined according to a formula set forth in the June 2020 Investor Warrant. The June 2020 Investor Warrants will be automatically exercised on a cashless basis on their expiration date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2020 Investor Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants. During the year ended December 31, 2020, 477 shares of the June 2020 Warrants were exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2020 Investor Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the June 2020 Investor Warrants, as defined in the June 2020 Investor Warrants, the holders of the June 2020 Investor Warrants will be entitled to receive upon exercise of the June 2020 Investor Warrants the kind and amount &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of securities, cash or other property that the holders would have received had they exercised the June 2020 Investor Warrants immediately prior to such fundamental transaction. Alternatively, the Company or any successor entity will, at the option of a holder of a June 2020 Investor Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder&#x2019;s June 2020 Investor Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder&#x2019;s June 2020 Investor Warrant. Because of this put-option provision, the June 2020 Investor Warrants are classified as a liability and are marked to market at each reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrant liability related to the June 2020 Investor Warrants is measured at fair value upon issuance and at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Investor Warrants:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 10, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;June 2020 Placement Agent Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company issued the June 2020 Placement Agent Warrants, exercisable for up to 122 shares of the Company&#x2019;s common stock, to the placement agent for such offering. The June 2020 Placement Agent Warrants have substantially the same form as the June 2020 Investor Warrants, including the put option described above, except that they have an exercise price per share equal to $5.64, subject to adjustment in certain circumstances, and will expire on June 7, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the put-option provision in the June 2020 Placement Agent Warrants, these warrants are classified as a liability and are marked to market at each reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrant liability related to the June 2020 Placement Agent Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Placement Agent Warrants:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 10, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;December 2019 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pursuant to a securities purchase agreement (the "December 2019 Offering") the Company issued warrants (the "December 2019 Warrants") to purchase 556 shares of common stock. The December 2019 Warrants are currently exercisable have an exercise price of $8.10 per share, and will expire five years from the date they initially became exercisable, or on June 21, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2019 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the December 2019 Warrants, the Company or any successor entity will, at the option of a holder of a December 2019 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder&#x2019;s December 2019 Warrant by paying to such holder an amount of cash equal to the Black-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scholes value of the remaining unexercised portion of such holder&#x2019;s December 2019 Warrant within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NTAwMTE_96686e94-4d73-4fcb-ac01-69c8e1bec88a"&gt;five&lt;/span&gt; trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the December 2019 Warrants are classified as a liability and are marked to market at each reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrant liability related to the December 2019 Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Warrants:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:503.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:318.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:90.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;December 2019 Placement Agent Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, in connection with the December 2019 Offering, the Company issued warrants to purchase 52 shares of the Company&#x2019;s common stock to the placement agent for such offering (the "December 2019 Placement Agent Warrants"). The December 2019 Placement Agent Warrants have substantially the same form as the December 2019 Warrants, except that they have an exercise price per share equal to $8.44, subject to adjustment in certain circumstances, and will expire on December 18, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrant liability related to the December 2019 Placement Agent Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Placement Agent Warrants:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:503.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:318.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:90.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has assessed that the likelihood of a Change of Control (as defined in the December 2019 Placement Agent Warrants), occurring during the term of the December 2019 Placement Agent Warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the warrants fair value is nominal.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;May 2019 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, pursuant to an underwriting agreement, (the "May 2019 Offering"), the Company issued warrants (the "May 2019 Warrants") to purchase 444 shares of common stock. The May 2019 Warrants are currently exercisable and have a current exercise price of $3.52 per share, and will expire five years from the date of their issuance, or on May 24, 2024. The May 2019 Warrants contain a price protection feature, pursuant to which, subject to certain exceptions, if shares of common stock are sold or issued in the future, or securities convertible or exercisable for shares of the Company&#x2019;s common stock are sold or issued in the future, for consideration, or with an exercise price or conversion price, as applicable, per share less than the exercise price per share then in effect for the May 2019 Warrants, the exercise price of the May 2019 Warrants is reduced to the consideration paid for, or the exercise price or conversion price of, as the case may be, the securities issued in such offering. Pursuant to this provision, in connection with the June 2020 Offering, the exercise price of the May 2019 Warrants was reduced to $3.52 per share, being the amount that is equal to the lower of (x) the consideration paid for the securities issued in the June 2020 Offering, or $4.51 per share, (y) the lowest exercise price of the June 2020 Warrants, or $5.18, and (z) the lowest one-day volume-weighted average price of the Company&#x2019;s Common Stock on the Nasdaq Capital Market as measured each day during &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the five trading day period starting on June 8, 2020, rounded to the nearest share, or $3.52. During the year ended December 31, 2020, 246 shares of the May 2019 warrants were exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, if the Company effects or enters into any issuance of common stock or options or convertible securities exercisable for or convertible into common stock at a price which varies or may vary with the market price of the shares of the Company's common stock, subject to certain exceptions, a May 2019 Warrant holder may, at the time of exercise of the holder&#x2019;s warrant, elect to exercise the warrant at such variable price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The May 2019 Warrants include a put option, whereby while the May 2019 Warrants are outstanding, if the Company enters into a Change of Control, as defined in the May 2019 Warrants, the Company or any successor entity will, at the option of a 2019 Warrant holder exercise within 90 days after the public disclosure of the Change of Control transaction, purchase such holder&#x2019;s May 2019 Warrants by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such warrants on the later date of consummation of the Change of Control transaction or two trading days after the notice of such request. Because of this put option provision, the May 2019 Warrants are classified as a liability and are marked to market at each reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrant liability related to the May 2019 Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in a combination of the Black-Scholes Model and the Lattice Model to measure the fair value of the May 2019 Warrants:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:318.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:90.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:98.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has assessed that the likelihood of a Change of Control occurring during the term of the warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the May 2019 Warrants fair value is nominal.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Information Agent Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, in connection with a rights offering in August 2017, the Company issued warrants (the "2017 Information Agents Warrants") to purchase 13 shares of the Company&#x2019;s common stock to an information agent. The 2017 Information Agent Warrants had an exercise price of $22.50 per share and became exercisable immediately upon issuance and remained exercisable until September 13, 2020. These warrants were recorded in stockholders&#x2019; equity on the Company&#x2019;s consolidated balance sheet. These warrants expired during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2015, the Company issued warrants (the "2015 Warrants") to purchase 141&#160;shares which are currently exercisable with a current exercise price of&#160;$41.25&#160;per share. The 2015 Warrants contained a put-option provision. Under this provision, while the 2015 Warrants were outstanding, if the Company entered into a Fundamental Transaction, as defined in the 2015 Warrants, the Company or any successor entity shall, at the option of each warrant holder, exercisable at any time concurrently with or within 30 days after the consummation of the Fundamental Transaction, purchase the warrant from the holder exercising such option by paying to the holder an amount of cash equal to the Black-Scholes Model value of the remaining unexercised portion of such holder&#x2019;s warrant on the date of the consummation of the Fundamental Transaction. Because of this put-option provision, the 2015 Warrants were classified as a liability and are marked to market at each reporting date. Through December 31, 2019,&#160;35&#160;shares of the 2015 Warrants were exercised. During the year ended December 31, 2020, none of the 2015 Warrants were exercised. In the year ended December 31, 2019, the Company recorded a $257 loss on the modification of these warrants related to an amendment which reduced the exercise price of the warrants. These warrants expired during the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pre-2014 Merger Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants to purchase preferred stock of Ekso Bionics Inc. outstanding prior to the Merger were converted into warrants to purchase 6 shares of common stock of the Company in connection with the Merger (the "Merger Warrants"). As a result of the May 2019 Offering, which was a firm commitment underwritten public offering, the Merger Warrants expired, in accordance with their terms.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5b7783a67c59429aa5c50cce7d3f36a4_I20190916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzU0OTc1NTgyMTE1NTI_10669845-4ebd-470a-b462-1630f663ce0a"
      unitRef="usdPerShare">1.00</us-gaap:SaleOfStockPricePerShare>
    <ekso:NumberOfConsecutiveBusinessDays
      contextRef="i5b7783a67c59429aa5c50cce7d3f36a4_I20190916"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzU0OTc1NTgyMTE1NTY_8bcb11a8-32f3-44ba-b199-50109588e91f"
      unitRef="days">30</ekso:NumberOfConsecutiveBusinessDays>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5b7783a67c59429aa5c50cce7d3f36a4_I20190916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzU0OTc1NTgyMTE1NjA_6f3129ef-0a99-43b9-a9f9-623a423998f9"
      unitRef="usdPerShare">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzExMw_077ccceb-2bcd-4a15-b099-564b5fb216ba"
      unitRef="shares">141429000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE0Mw_fe9cc4d6-4237-4a95-b1c5-e080b261d1ea"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE4MA_1aee757d-75f8-4070-99b2-2700e0f7a387"
      unitRef="shares">8349000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE4MA_5e077c3c-a5ff-4229-b175-85092f9c3146"
      unitRef="shares">8349000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzIzOA_d7b08877-812c-43c8-a13c-0af90faef24f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzIzOA_dfd34515-ec47-4d33-873d-ae9a40066415"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1332f3e466ea4d9886d520016e1fe9a9_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwMjQ_d5580eeb-f828-4f57-a0a0-241a68f7cf72"
      unitRef="shares">1748000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="icdfb6150e11040dbbad6a66db73b4fdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwMTk_e3fcdcd8-6617-400a-844a-7dec9b510b11"
      unitRef="shares">874000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants
      contextRef="i4cc3408bdfbe4b5f8276263fd666f8e1_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwMzE_9990020d-7a3a-4baf-a12a-b03eb0e02913"
      unitRef="usd">7890000</ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i20c3fa9143d1494f9fa80ba4773d37c2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwMzk_32cf2810-8f27-4c76-8aa0-56d420f21b51"
      unitRef="usdPerShare">5.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightCashFeePercentage
      contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNDY_d7775492-564d-452e-bc30-723804e15d36"
      unitRef="number">0.070</ekso:ClassOfWarrantOrRightCashFeePercentage>
    <ekso:ClassOfWarrantOrRightCashFee
      contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNTI_f63d10d7-01d1-4c70-ba48-5c3f792bc93b"
      unitRef="usd">552000</ekso:ClassOfWarrantOrRightCashFee>
    <ekso:ClassOfWarrantOrRightManagementFeePercentage
      contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNjM_caa15189-d1a4-456f-a93f-7e9dd19b3c8b"
      unitRef="number">0.010</ekso:ClassOfWarrantOrRightManagementFeePercentage>
    <ekso:ClassOfWarrantOrRightManagementFeeExpense
      contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNTg_b6262a51-5fe6-49e1-a765-3073410fdac6"
      unitRef="usd">79000</ekso:ClassOfWarrantOrRightManagementFeeExpense>
    <ekso:ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock
      contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNjk_6fd68c9d-81d6-4e66-9c88-ce064c2508d9"
      unitRef="number">0.070</ekso:ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwNzU_4a166417-7603-45fe-bce8-fad9ed110cc2"
      unitRef="shares">122000</ekso:ClassOfWarrantOrRightIssued>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i8146ef51059a4e8588f8cfa2a49cc7c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwOTE_dc3463f6-fada-474e-8c76-a78cdf86aee2">P5Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i35f4d4c9162e4396a697be5d9061262e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwODA_18113ef5-f06d-474c-99c9-5b2c17746869"
      unitRef="usdPerShare">5.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:WarrantIssuanceExpense
      contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkwODc_fd94449f-3946-4d07-b76c-6cb54310459b"
      unitRef="usd">98000</ekso:WarrantIssuanceExpense>
    <ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants
      contextRef="i4cc3408bdfbe4b5f8276263fd666f8e1_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxMDk_b2d6640f-721d-450a-a942-6b6bbe687cfe"
      unitRef="usd">7890000</ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants>
    <ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants
      contextRef="iae50490cbb4b480698dbb2b1ea92f87e_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxMTc_89ec4104-3916-4a39-afb1-fa478dee9caf"
      unitRef="usd">2650000</ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants>
    <ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants
      contextRef="i1332f3e466ea4d9886d520016e1fe9a9_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxMjU_07c1584e-e884-4352-85af-c31e9ac5531b"
      unitRef="usd">5240000</ekso:ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i4cc3408bdfbe4b5f8276263fd666f8e1_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxMzM_1e6f6601-4814-4266-87c5-1f09a753ded4"
      unitRef="usd">1117000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i6260ae69ccdc47afb974156191ec17ed_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxOTQ_1da98a1b-3484-4eab-b979-cb1a28295d04"
      unitRef="usd">309000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNDE_17d54966-96fb-4670-99e7-515c9b1fcc1f"
      unitRef="usd">808000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="iae50490cbb4b480698dbb2b1ea92f87e_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNDc_735f9ad2-b5e5-44b3-a848-876460ca1b4a"
      unitRef="usd">329000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1332f3e466ea4d9886d520016e1fe9a9_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNTM_1fb365d8-9fbe-45b4-93ce-c707ed4d1da4"
      unitRef="usd">479000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i6260ae69ccdc47afb974156191ec17ed_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNTk_f781b15b-0af8-4f4e-90bc-36ee6bc8abe8"
      unitRef="usd">309000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i656a19543c2446298336599b639f4ed9_D20201001-20201031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNjU_07ff2d7b-60e0-4094-b273-6b4c999d257b"
      unitRef="usd">7500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i60337cf454184d3fab3c487c42a73b04_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxNzM_04bc2f9c-646c-4113-b590-77977a119885"
      unitRef="usdPerShare">6.75</us-gaap:SaleOfStockPricePerShare>
    <ekso:ScheduleOfWarrantsOutstandingTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE4MTMw_99e25bcb-1598-49c0-8dff-36bc955458b1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant shares outstanding as of December 31, 2019 and December 31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Source&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020 Investor Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020 Placement Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Placement Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2019 Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Information Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015 Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-2014 warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ekso:ScheduleOfWarrantsOutstandingTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia03e27ee3b474253a9b6b29d30ad3245_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMS0xLTEtNzU1_23499abd-4348-4c03-bba9-81bea71c41d6"
      unitRef="usdPerShare">5.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i16884269eeb946c9a8d814ed9a37da17_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMy0xLTEtNzU1_86aae4b4-381b-4b1a-ab4b-5a7ec69b3d5e">P5Y6M</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic069febcd575454ba36115614e1e67f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtNS0xLTEtNzU1_1b55eb8d-208e-4ea0-bb75-7c719ed21c40"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="i16884269eeb946c9a8d814ed9a37da17_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtNy0xLTEtNzU1_b0afe565-ef03-4518-ab9a-4518d7aed62c"
      unitRef="shares">874000</ekso:ClassOfWarrantOrRightIssued>
    <ekso:ClassOfWarrantOrRightExpired
      contextRef="i16884269eeb946c9a8d814ed9a37da17_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtOS0xLTEtNzU1_3386393f-f648-4485-bedb-db25be2881fd"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExpired>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i16884269eeb946c9a8d814ed9a37da17_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMTEtMS0xLTc1NQ_0a7d3e5e-5a6a-48f4-897c-23a71e7a3299"
      unitRef="shares">477000</ekso:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia03e27ee3b474253a9b6b29d30ad3245_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMTMtMS0xLTkyMQ_1f48b382-b7d8-4987-b75b-7f87d4c0ce2b"
      unitRef="shares">397000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i5c7551fdba7443329e59bdddaaf0a8c4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMS0xLTEtNzU1_f219b129-5083-4d4e-b7e9-d70f4019232c"
      unitRef="usdPerShare">5.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i18a8a6dd04bb4af0a97b953a6edf6367_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMy0xLTEtNzU1_b348b780-79f4-4b0b-b0eb-b72af72dd641">P5Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5ecc4c18109a4778a6436d117e42e20d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItNS0xLTEtNzU1_d0528bbe-188e-45c4-b543-b155755a631e"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="i18a8a6dd04bb4af0a97b953a6edf6367_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItNy0xLTEtNzU1_7ffa4dc1-5b06-4d62-84fd-161d6dabbbc3"
      unitRef="shares">122000</ekso:ClassOfWarrantOrRightIssued>
    <ekso:ClassOfWarrantOrRightExpired
      contextRef="i18a8a6dd04bb4af0a97b953a6edf6367_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItOS0xLTEtNzY0_600c6923-5e13-454e-98d1-566f77ae76bf"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExpired>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i18a8a6dd04bb4af0a97b953a6edf6367_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMTEtMS0xLTc2NA_d604951f-533f-414b-ae83-81fbb01ad0cd"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5c7551fdba7443329e59bdddaaf0a8c4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMTMtMS0xLTkxNw_edc7ef22-0020-4ae2-9eac-688bea672bc9"
      unitRef="shares">122000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i06d98523cf3c41fc9f81c5db24a92b70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMS0xLTEtMA_64a2de84-d78a-485e-b6bb-3a453c9218b7"
      unitRef="usdPerShare">8.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i43dcca06f1114b118c295c1360b5597c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMy0xLTEtMA_8b8882ee-f75a-4d3d-8c73-222885fc07f1">P5Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib21914757ec84913b068b738154fc31c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtNS0xLTEtMA_39accf70-c053-4cc5-94fd-7a551f343106"
      unitRef="shares">556000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="i43dcca06f1114b118c295c1360b5597c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtNy0xLTEtMA_dadb5d99-45ab-4716-9739-a9f0717bd9bc"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightIssued>
    <ekso:ClassOfWarrantOrRightExpired
      contextRef="i43dcca06f1114b118c295c1360b5597c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtOS0xLTEtMA_6359bebd-5ddc-4b14-a2d5-e1519fa0d905"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExpired>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i43dcca06f1114b118c295c1360b5597c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMTEtMS0xLTA_aeed7847-d889-4c3a-9f8f-e38af69824a6"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i06d98523cf3c41fc9f81c5db24a92b70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEtMTMtMS0xLTA_5b38ed18-5f51-45b6-b73e-88db5115650a"
      unitRef="shares">556000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia8eab057d5354f54a6a1f4b6e697e1fe_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMS0xLTEtMA_f39020d0-53d1-464b-8a70-acd9fe5f31bb"
      unitRef="usdPerShare">8.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i883563dff2a0452fb06639ade8f1ec83_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMy0xLTEtMA_06bfc019-a72f-410e-8808-d2f78f9f688f">P5Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia8eab057d5354f54a6a1f4b6e697e1fe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItNS0xLTEtMA_df17d954-1d32-49e4-8541-13d12baf5d84"
      unitRef="shares">52000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="i883563dff2a0452fb06639ade8f1ec83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItNy0xLTEtMA_02a08ca5-3af8-4122-b9ca-e1c480bd0037"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightIssued>
    <ekso:ClassOfWarrantOrRightExpired
      contextRef="i883563dff2a0452fb06639ade8f1ec83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItOS0xLTEtMA_272e47a4-782d-423a-aa41-e2c5a2f95b31"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExpired>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i883563dff2a0452fb06639ade8f1ec83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMTEtMS0xLTA_3b678f50-e062-4046-9e24-b087600d44b7"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i0ae106f6d2ac4c01ae9d3275ad51c856_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzItMTMtMS0xLTA_8bbd4bec-27eb-4cf8-a88e-48b1c4edcc45"
      unitRef="shares">52000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtMS0xLTEtMA_92256575-2bd5-4328-82b6-06acc88d8926"
      unitRef="usdPerShare">3.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtMy0xLTEtMA_839d6967-8d14-4439-a9c2-3a95ecc111fd">P5Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i16f2fc5bc8324b9c95780543103873be_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtNS0xLTEtMA_87cd5ab0-a206-45a7-a348-0f008af7ac54"
      unitRef="shares">444000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtNy0xLTEtMA_0a1c5fe0-ed2e-425f-8351-36c023ee97ab"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightIssued>
    <ekso:ClassOfWarrantOrRightExpired
      contextRef="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtOS0xLTEtMA_20cb7a50-aa73-46cc-b7a0-02b5dbd7b64a"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExpired>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtMTEtMS0xLTA_5d86e237-9bf4-4202-a855-765b3c23fe14"
      unitRef="shares">246000</ekso:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzMtMTMtMS0xLTA_4f36708a-bfb3-4a37-9582-866d4b2c3320"
      unitRef="shares">198000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i425ea3e27fe44ae8ababe62ca6a2566d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtMS0xLTEtMA_b6ae65dc-d8e5-4968-8b3b-d0f8195d84f4"
      unitRef="usdPerShare">22.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i474fb265033b492d99eef7003d923965_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtMy0xLTEtMA_7dd28113-d855-4675-b913-6141d52fc426">P3Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1e758452b88142cebe39df57428e5d23_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtNS0xLTEtMA_4db65f83-df31-4fc7-8eb4-81d777130254"
      unitRef="shares">13000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="i474fb265033b492d99eef7003d923965_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtNy0xLTEtMA_e63fb9f4-f74c-45c7-9782-72aa15a6824f"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightIssued>
    <ekso:ClassOfWarrantOrRightExpired
      contextRef="i474fb265033b492d99eef7003d923965_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtOS0xLTEtMA_32d09607-07d7-4cee-8172-2cddd9bb1c74"
      unitRef="shares">13000</ekso:ClassOfWarrantOrRightExpired>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i474fb265033b492d99eef7003d923965_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtMTEtMS0xLTA_54236238-c233-4e3d-b053-18223c45552b"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i425ea3e27fe44ae8ababe62ca6a2566d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzQtMTMtMS0xLTA_669fbc83-6f6d-434f-b799-0e353072d3cc"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic67e632c480a4a389d734d7b66ce5c48_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtMS0xLTEtMA_aae4a846-df3b-466f-af12-fddf3f61d248"
      unitRef="usdPerShare">41.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="ie460538640c64e2cba78df79c4755d79_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtMy0xLTEtMA_17c17e11-0038-4d8e-b165-3b10fe360562">P5Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id7c1742f015b49289941792b99828fec_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtNS0xLTEtMA_ae435599-70a2-4d15-bcc6-9e62ff5aeeaf"
      unitRef="shares">107000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="ie460538640c64e2cba78df79c4755d79_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtNy0xLTEtMA_4c2300c3-9ee9-4a2b-b559-5ea6bc8cadd9"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightIssued>
    <ekso:ClassOfWarrantOrRightExpired
      contextRef="ie460538640c64e2cba78df79c4755d79_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtOS0xLTEtMA_3f223b1b-23e6-452f-b57d-01646f45ebea"
      unitRef="shares">107000</ekso:ClassOfWarrantOrRightExpired>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="ie460538640c64e2cba78df79c4755d79_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtMTEtMS0xLTA_80ba99d6-0b66-44df-98b7-e3759ca8d49a"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic67e632c480a4a389d734d7b66ce5c48_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzUtMTMtMS0xLTA_2993791d-4803-418b-89e9-bc6da6fee151"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0318eadd0412421d9ab7a16182414edb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktMS0xLTEtMA_d14cf5b8-4ec5-46fa-b38f-e825cb8e9f52"
      unitRef="usdPerShare">144.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i493d79f55e7241dc9784879e595c2d55_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktMy0xLTEtMC90ZXh0cmVnaW9uOjlmNWJjMTkyOWE1MzQxZjlhZjU4YjZhZTFkZGNhMGM0XzMyOTg1MzQ4ODMzMzc_a54a9358-cdaf-4ba2-a081-2efca50a4e35">P9Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i32847a63786c4c40911455a3c40434a8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktMy0xLTEtMC90ZXh0cmVnaW9uOjlmNWJjMTkyOWE1MzQxZjlhZjU4YjZhZTFkZGNhMGM0XzMyOTg1MzQ4ODMzNDI_02ec6a09-5746-4634-bfe7-c82294dfaefc">P10Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3e9a44a009bc4cff8921788207667b9b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktNS0xLTEtMA_b6ce4a53-10b7-4dbd-8dc4-5b4ab3e4b9fa"
      unitRef="shares">6000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="i66dedf87145f4fc990355ef06fe907ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktNy0xLTEtMA_2947b0cd-1920-468f-bb83-cfea667411ff"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightIssued>
    <ekso:ClassOfWarrantOrRightExpired
      contextRef="i66dedf87145f4fc990355ef06fe907ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktOS0xLTEtMA_537b20be-aa3c-4c85-bbea-46860e9dae4f"
      unitRef="shares">6000</ekso:ClassOfWarrantOrRightExpired>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i66dedf87145f4fc990355ef06fe907ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktMTEtMS0xLTA_52842053-c68e-4acb-aef1-64b63c52c1ac"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i0318eadd0412421d9ab7a16182414edb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzktMTMtMS0xLTA_4d06edfc-54e5-4274-88d3-15bfafd841f0"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEwLTUtMS0xLTA_07b36b69-8538-4c74-8b3d-0632eda89d27"
      unitRef="shares">1178000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEwLTctMS0xLTA_fc68fe33-bafe-4159-b7b8-e545c966027b"
      unitRef="shares">996000</ekso:ClassOfWarrantOrRightIssued>
    <ekso:ClassOfWarrantOrRightExpired
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEwLTktMS0xLTA_12d21e68-11ba-417d-b1de-23fa07db2309"
      unitRef="shares">126000</ekso:ClassOfWarrantOrRightExpired>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEwLTExLTEtMS0w_b45df1a2-af68-4497-9304-e97bdff410e0"
      unitRef="shares">723000</ekso:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo2ZWMxNDU3NzZkYjQ0N2I0OTg2NTIyY2FlNWRiYjI2Ny90YWJsZXJhbmdlOjZlYzE0NTc3NmRiNDQ3YjQ5ODY1MjJjYWU1ZGJiMjY3XzEwLTEzLTEtMS0w_fe555839-4b9e-4d91-972a-a4460bf626ff"
      unitRef="shares">1325000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia73bddff44ca4b2f9d2a82edae8e117f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxODI_33a8cefc-1c30-453e-9392-ac58af470076"
      unitRef="shares">874000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1b04630ec1374a39bd730200d9ce743a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc2OTY1ODE0MzkxODc_894d2eed-626b-4633-964e-fa4dae6b49c7"
      unitRef="usdPerShare">5.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia50fed56d7e846008e27b2faa05cf892_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzMyOTg1MzQ5NTU0Mzk_a3aa562e-bcbe-4aee-95f2-820954121d23"
      unitRef="shares">477000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzY1OTcwNjk4MTEyNDE_3dab62c0-2792-45d2-8ca3-aa5b39d87922">The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Investor Warrants:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 10, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Placement Agent Warrants:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 10, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Warrants:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:503.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:318.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:90.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:503.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:318.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:90.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;The following assumptions were used in a combination of the Black-Scholes Model and the Lattice Model to measure the fair value of the May 2019 Warrants:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:318.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:90.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:98.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="i7a3cb75354a8437c97c6a048fbb71d72_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzEtMS0xLTEtOTMx_795e4ce9-6fe0-47ea-94b6-a69541101e3d"
      unitRef="usdPerShare">6.13</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i606b7f43b71a44adb687cff9e4202f75_I20200610"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzEtMi0xLTEtOTI4_38525e4a-3819-44ff-bf02-154da3869027"
      unitRef="usdPerShare">3.81</us-gaap:SharePrice>
    <ekso:StockConversionPrice
      contextRef="i15042960a2014c12aeb3b609cd137087_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzItMS0xLTEtOTMx_4c1e076b-0619-4266-a53c-041a0c246c25"
      unitRef="usdPerShare">5.18</ekso:StockConversionPrice>
    <ekso:StockConversionPrice
      contextRef="i93802bef0c2445c789f2445d0a127497_D20200610-20200610"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzItMi0xLTEtOTI4_002ac6fe-394e-4b0d-b959-706b6d8d41fe"
      unitRef="usdPerShare">5.18</ekso:StockConversionPrice>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="iba22e1721af04a2e9319870ded4bd2de_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzMtMS0xLTEtOTMx_fe660513-f88a-42a0-8bce-f91e558bb6a3"
      unitRef="number">0.0035</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia3aa1cf0746c4b5baceaeb908424df8d_I20200610"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzMtMi0xLTEtOTI4_d3780150-ce6b-4d85-92ab-17f668fac278"
      unitRef="number">0.0039</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i084accc9ec374285be3b0a73a7a1090a_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzQtMS0xLTEtOTMx_a4c9fe2a-ffdf-435c-be0c-ba50ff614b8e">P4Y11M8D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i5b12218955364d9da56354373add4e0a_I20200610"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzQtMi0xLTEtOTI4_1979b29e-42d2-412e-b41d-00879c6fb7a0">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ibd9481bf7e0140ac800169b45355f91d_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzUtMS0xLTEtOTMx_6f37a1d7-262f-42a6-97fc-35db56ac8ec0"
      unitRef="number">1.053</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i5038cfc88eee4338ae569f8f794e2d53_I20200610"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo3NmYzZDQzM2RlNzY0MTZkOTQ1NDllYjFhNzM2NTZkYy90YWJsZXJhbmdlOjc2ZjNkNDMzZGU3NjQxNmQ5NDU0OWViMWE3MzY1NmRjXzUtMi0xLTEtOTI4_d56b8c18-16a1-44b6-8d94-0d8612595b80"
      unitRef="number">0.964</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <ekso:ClassOfWarrantOrRightIssued
      contextRef="i32858a5c53714596bf06e6ffd33955d0_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NDk5OTc_55a92a3c-55f2-42c4-b636-1366a5619857"
      unitRef="shares">122000</ekso:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6260ae69ccdc47afb974156191ec17ed_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NTAwMDU_06a38da2-907c-4230-a295-ed59c24da681"
      unitRef="usdPerShare">5.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="i9c0e3631de7946a9b5dd656a12e3ee57_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzEtMS0xLTEtOTA2_e0bc7571-b03a-494e-a281-ebf05d628f2e"
      unitRef="usdPerShare">6.13</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i917d2e433bec4af6a5015a89dffd0ec1_I20200610"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzEtMi0xLTEtOTI2_01b022fb-65cd-4b12-93c6-a1f1f66c6968"
      unitRef="usdPerShare">3.81</us-gaap:SharePrice>
    <ekso:StockConversionPrice
      contextRef="ic719e6ce8263469b8620118bde4798db_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzItMS0xLTEtOTA2_acc648e9-5371-4602-9d4b-87bf04a39683"
      unitRef="usdPerShare">5.64</ekso:StockConversionPrice>
    <ekso:StockConversionPrice
      contextRef="i87826571264a49058ae7d9ecedc374f7_D20200610-20200610"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzItMi0xLTEtOTI2_5d39bb16-ba3a-4460-b068-49c887a2e28c"
      unitRef="usdPerShare">5.64</ekso:StockConversionPrice>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i970ae68e19f845e0a61ab8293e716384_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzMtMS0xLTEtOTA2_bf5586ea-890a-4bde-b87f-ab942fdc167c"
      unitRef="number">0.0031</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i7b14b8e6815740a780625da52773615e_I20200610"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzMtMi0xLTEtOTI2_2eb99684-6fa0-44d5-a87d-de0da4c5ba16"
      unitRef="number">0.0033</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i265b24fe236d4a33a086749d8f3bc1d0_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzQtMS0xLTEtOTA2_636cc6fc-e435-4804-bf8c-a3f53848351d">P4Y5M8D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i1ffd06e2b41643a5851058ccd43c25f4_I20200610"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzQtMi0xLTEtOTI2_d3656905-3611-4b8e-875a-65f9d05bc537">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i885b3e5d68a84f4e90e8c7922cef7995_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzUtMS0xLTEtOTA2_9aebf5a6-fff1-4b46-a601-bbda8eacc1e3"
      unitRef="number">1.068</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i51a2440d2a3b4d3d84b38c26002ea3ff_I20200610"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZToxZjEwNjFmNmMxOWU0YmM4OTljMjVkZDBlNjA1ZjBjNi90YWJsZXJhbmdlOjFmMTA2MWY2YzE5ZTRiYzg5OWMyNWRkMGU2MDVmMGM2XzUtMi0xLTEtOTI2_6cbff034-1cda-416c-a940-8c383f5ca86e"
      unitRef="number">0.963</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i6e10eafaaf69412a980b03f834b1e6dd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc3MjE_f11e6dd4-9138-4f77-b01a-56aa16691076"
      unitRef="shares">556000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i49b5955b1efd4de9a0856fc1539f6432_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc4MDU_ebdd3a1d-738e-4bb4-80b7-648872e3480c"
      unitRef="usdPerShare">8.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i3687529f69424becaeceedf73f6828ec_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzc5OTU_ca274b0f-3855-4206-beee-799b28fdcc6c">P5Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <ekso:ClassOfWarrantOrRightDurationOfPutOption
      contextRef="id396d3085bb24e85baf89441852a463a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NTAwMjA_6ff89f19-36f9-4051-b148-324e2066eeb8">P30D</ekso:ClassOfWarrantOrRightDurationOfPutOption>
    <us-gaap:SharePrice
      contextRef="ide46f57c594c4d7e8de120bbe04cf45a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzEtMS0xLTEtMA_51c4185b-57bb-4285-81ab-705ea92ecf62"
      unitRef="usdPerShare">6.13</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i6bc70242a8314a19af7cff0da761421c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzEtMi0xLTEtMA_a4996259-77be-4509-b30a-b2389eab50ea"
      unitRef="usdPerShare">5.86</us-gaap:SharePrice>
    <ekso:StockConversionPrice
      contextRef="i0145713900c94e918e32d701921d1975_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzItMS0xLTEtMA_aa451fad-ddb7-4b41-a142-fce84f16b938"
      unitRef="usdPerShare">8.10</ekso:StockConversionPrice>
    <ekso:StockConversionPrice
      contextRef="id0b034ea5e3e4dc5851a3ccb19e99abf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzItMi0xLTEtMA_b224a5a3-4c23-4c1b-a098-2b51fa54e206"
      unitRef="usdPerShare">8.10</ekso:StockConversionPrice>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i5aecd5d37d3b4bb4b4adf7077dc24cde_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzMtMS0xLTEtMA_862f344f-304c-428e-84ce-c3f3acbeb004"
      unitRef="number">0.0031</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i6293a6a35cfd4251acaaf9a8e93b0369_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzMtMi0xLTEtMA_252a6dd1-9295-4456-91bd-9f73c87a8642"
      unitRef="number">0.0173</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ib7f8299a4e214d92957aee41ce77fb46_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzQtMS0xLTEtMA_f2771989-38f8-4a69-b00c-2c86b3e0fc33">P4Y5M19D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="iea7e5c100ba04f8687538cfb181146ee_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzQtMi0xLTEtMA_87e811a1-7d2e-491a-9462-a032761b97e7">P5Y5M19D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia6df92243b17458caf062b597eca0bb0_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzUtMS0xLTEtMA_24015082-ed17-4a4b-a1dd-aa49411fa864"
      unitRef="number">1.079</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="if8c6706df2ef4faca8ee7e3eab8da237_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0YTgxZTcyZWMxZjU0NGY0OTg2NzY5NzJmMTk3YmM3Ni90YWJsZXJhbmdlOjRhODFlNzJlYzFmNTQ0ZjQ5ODY3Njk3MmYxOTdiYzc2XzUtMi0xLTEtMA_cb192809-fc43-41f0-ae2e-e3e1be682fed"
      unitRef="number">0.957</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia8eab057d5354f54a6a1f4b6e697e1fe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzQ5NDc4MDIzNjUyMzM_df17d954-1d32-49e4-8541-13d12baf5d84"
      unitRef="shares">52000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia8eab057d5354f54a6a1f4b6e697e1fe_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2Xzk4NjE_f39020d0-53d1-464b-8a70-acd9fe5f31bb"
      unitRef="usdPerShare">8.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="ia91c98835d204cc08859c956d9414520_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzEtMS0xLTEtMA_7402236d-cc48-4973-9e6d-9d53d98e0302"
      unitRef="usdPerShare">6.13</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i3215b84b357a450a985217089ba29281_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzEtMi0xLTEtMA_f7473966-da88-4892-8ea6-b9dcabb8424f"
      unitRef="usdPerShare">5.86</us-gaap:SharePrice>
    <ekso:StockConversionPrice
      contextRef="i069a96fbc276471e994ddb6c40a43503_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzItMS0xLTEtMA_748dd0bb-4e5a-46ac-a591-89a362e78b96"
      unitRef="usdPerShare">8.44</ekso:StockConversionPrice>
    <ekso:StockConversionPrice
      contextRef="if1857924bad947049734ec580f40b921_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzItMi0xLTEtMA_023e8aa2-d457-4658-8544-2d892e60e878"
      unitRef="usdPerShare">8.44</ekso:StockConversionPrice>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i0e863bdfa06a4bdda07cfb2cdc16b526_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzMtMS0xLTEtMA_28575205-0bb5-42f8-8d54-1fc094feb4df"
      unitRef="number">0.0026</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i054e3c8419c84d5cbbdb1d4f07127102_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzMtMi0xLTEtMA_31031e5d-aab0-48d9-946d-44fab06cea49"
      unitRef="number">0.0169</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i4998d0b3b84c4399a118546128a7647b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzQtMS0xLTEtMA_ac14eb54-6f56-47a7-ab83-9e34abdd30f1">P3Y11M19D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i38e0af14fe5042aa8dc04877b3a4299a_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzQtMi0xLTEtMA_66aa1a25-6c79-4a19-b335-c8ada8db5075">P4Y11M19D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i2e2f59b7ba4641e584ab2ac68b96fe24_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzUtMS0xLTEtMA_243c40ca-7309-42a6-b196-db3e9eef6bb2"
      unitRef="number">1.094</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i1d99f049683342dab1c5c4e16251a30b_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTpkMzQzZDg2MmY2NmU0NDE0Yjk3ZTg4ZDEzYWNlMGEwZi90YWJsZXJhbmdlOmQzNDNkODYyZjY2ZTQ0MTRiOTdlODhkMTNhY2UwYTBmXzUtMi0xLTEtMA_b0fde918-beef-439d-b4a5-92ba94abd558"
      unitRef="number">0.931</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic650ec13b1084703a7916113f5898f77_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzMyOTg1MzQ5NTU0MzE_4555f5be-608c-4f13-8264-028a6f23b731"
      unitRef="shares">444000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ekso:StockConversionPrice
      contextRef="ia0e15a98c6ae4762a3a129475340835f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzQ5NDc4MDIzOTcyNjU_0b3ea96c-683f-4cea-8ddd-61cdc5ef8f04"
      unitRef="usdPerShare">3.52</ekso:StockConversionPrice>
    <ekso:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i7893a98ca0b84b88a8eae633fa44eb74_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzEwNDc3_839d6967-8d14-4439-a9c2-3a95ecc111fd">P5Y</ekso:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzExMzIx_92256575-2bd5-4328-82b6-06acc88d8926"
      unitRef="usdPerShare">3.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzQ5NDc4MDIzODY3Njc_d7b17e3f-b9ad-45db-999b-a489793031ec"
      unitRef="usdPerShare">4.51</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia03e27ee3b474253a9b6b29d30ad3245_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzQ5NDc4MDIzODY3NzE_23499abd-4348-4c03-bba9-81bea71c41d6"
      unitRef="usdPerShare">5.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifcc2063ad2304fcfaa0d7662eece88b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzExNzg3_92256575-2bd5-4328-82b6-06acc88d8926"
      unitRef="usdPerShare">3.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie223919cfb0644d4b99679da636b322e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzMyOTg1MzQ5NTU0MjM_5464040c-ebe0-4bff-82a1-04b08445c066"
      unitRef="shares">246000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="i84041bbc80d94707bdd1c71475762b9b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzEtMS0xLTEtMA_eee32525-1b84-418c-820c-c689500fba06"
      unitRef="usdPerShare">6.13</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i78706eee04a546a7a74922c746e3304a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzEtMi0xLTEtMA_53f2d48a-e740-40ab-b2a7-e1a83ed412db"
      unitRef="usdPerShare">5.86</us-gaap:SharePrice>
    <ekso:StockConversionPrice
      contextRef="ia0e15a98c6ae4762a3a129475340835f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzItMS0xLTEtMA_0b3ea96c-683f-4cea-8ddd-61cdc5ef8f04"
      unitRef="usdPerShare">3.52</ekso:StockConversionPrice>
    <ekso:StockConversionPrice
      contextRef="i0c63f0a4b66643c095e667bc8734eabc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzItMi0xLTEtMA_3da87899-b512-4b60-a295-df67d58a4873"
      unitRef="usdPerShare">5.70</ekso:StockConversionPrice>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i460359c10d04485b8f24e8e8000ce638_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzMtMS0xLTEtMA_054fc5c1-37f9-4e61-8432-ce30fb80c93c"
      unitRef="number">0.0021</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ie74af6c07ea14138ab2b4641dd046986_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzMtMi0xLTEtMA_1bb03e07-357f-4245-88a6-c1bf7943ac20"
      unitRef="number">0.0167</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i283ae8fe845b4608857dda0e19da19e4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzQtMS0xLTEtMA_f2e840c2-4a4e-47e9-bb39-be2bf937d5b4">P3Y4M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i584a64da65b8465189421614a29d1307_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzQtMi0xLTEtMA_859ab6f9-77ff-4437-83db-360e28c6d9bc">P4Y4M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i163a45d096374a6caa35072e4bb91628_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzUtMS0xLTEtMA_1a3426b3-01ae-4f9b-81e0-5f33aa12b5d9"
      unitRef="number">1.072</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i9f9096b4594d4ef887154e71f8bc2cfd_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90YWJsZTo0NmY3M2E3NDk4ZDc0YTA2YjUwYTRkYjY0MTQ2NjBjNy90YWJsZXJhbmdlOjQ2ZjczYTc0OThkNzRhMDZiNTBhNGRiNjQxNDY2MGM3XzUtMi0xLTEtMA_77791fa9-f2c3-4366-8343-be08537fb3b3"
      unitRef="number">0.939</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="icdf0c791c34846d7948b3a5350feab73_I20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzEzOTkz_9c28c313-d2d9-4b4e-a8c8-2f07027b5435"
      unitRef="shares">13000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="icdf0c791c34846d7948b3a5350feab73_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzQ5NDc4MDIzODcyMzk_768cf236-ef48-4116-bf39-e9c14a85de5f"
      unitRef="usdPerShare">22.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7d2869ade03c4be1a192746ea93a57ed_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE0NDQ0_154e5f7c-ae8f-486d-a763-1cec20eaedc6"
      unitRef="shares">141000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i67dc8fa5926e44009110a64d1f17ab86_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE0NDgw_95b245da-6052-4659-8d28-441b8822923f"
      unitRef="usdPerShare">41.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i8ef49a5dee2d41ff9b68a844e92232cd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE1MzI2_52a079f7-4a9d-446a-9463-d1eec9df8c36"
      unitRef="shares">35000</ekso:ClassOfWarrantOrRightExercised>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i579155917cc84c16b497230e8d059707_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE1Mzk5_1269d837-c0b7-4964-bb9f-b6e59de9796b"
      unitRef="shares">0</ekso:ClassOfWarrantOrRightExercised>
    <ekso:GainLossOnWarrantModification
      contextRef="i8ef49a5dee2d41ff9b68a844e92232cd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE2Mzc3_75a90828-1b8d-4339-b0d8-9f0143196cd9"
      unitRef="usd">-257000</ekso:GainLossOnWarrantModification>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i918faac37d3648509a88395256f45bfe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzE3NTAw_c3a72389-c367-48f5-86e5-ad9c76252a66"
      unitRef="shares">6000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMjM_3cc324ed-1b03-4c20-a880-91f3586ce20b">Stock-based Compensation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2014, prior to the Merger, the Board of Directors and a majority of the stockholders adopted the 2014 Equity Incentive Plan, or the 2014 Plan, allowing for the issuance of 137 shares of common stock. The 2014 Plan has since been amended and restated with approval by the stockholders to increase the maximum number of shares issuable, as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:422.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:298.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:120.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original share pool&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015 increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2017 increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2017 increase (ratified in June 2018)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020 increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2020 increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share authorized for grant as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the total shares authorized for grant under the 2014 Plan was&#160;1,974, of which 1,113 were available for future grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2014 Plan, the Board of Directors may award stock options, restricted stock, restricted stock units, stock appreciation rights and dividend equivalent rights having either a fixed or variable price related to the fair market value of the shares and with an exercise or conversion privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions or any other security with the value derived from the value of the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for future grant under the 2014 Plan was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:422.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:298.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:120.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares Available For Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share pool increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors may grant stock options under the 2014 Plan at a price of not less than 100% of the fair market value of the Company&#x2019;s common stock on the date the option is granted. The maximum term of an incentive stock option granted to participants may not exceed ten years. Subject to the limitations discussed above, the Board of Directors determines the term and exercise or purchase price of other awards granted under the 2014 Plan. The Board of Directors also determines the terms and conditions of awards, including the vesting schedule and any forfeiture provisions. Options granted under the 2014 Plan vest upon the passage of time, generally four years, or upon the attainment of certain performance criteria established by the Board of Directors. The Company may grant options to purchase common stock to non-employees for advisory and consulting services. Upon exercise of a stock option, the Company issues new shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity during the year ended December 31, 2020 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at year end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received $0 in cash from exercised stock options. The intrinsic value of the options exercised totaled $0 and $233, for the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted for the years ended&#160;December 31, 2020 and 2019 was $4.42 and $10.20, respectively. The total grant date fair value of stock option vested during the years ended December 31, 2020 and 2019 was $1,900 and $2,602, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, total unrecognized compensation cost related to unvested stock options was $2,203. This amount is expected to be recognized as stock-based compensation expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of 2.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about stock options outstanding as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Range of&lt;br/&gt;Exercise&lt;br/&gt;Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.55 - $9.15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.95 - $26.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$27.30 - $56.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$60.00 - $229.95&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense using the straight-line method over the requisite service period. The share fair value of each stock option was determined on the date of grant using the Black-Scholes Model under the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.962%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44% - 1.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.67% - 2.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.27 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%-102%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%-103%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues RSUs to employees and non-employee service providers. Each RSU represents the right to receive one share of the Company&#x2019;s common stock upon vesting and subsequent settlement. The fair value of RSUs is determined based on the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSU activity for the year ended December 31, 2020 is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Grant-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total grant-date fair value of RSUs&#160;that vested during the year ended December 31, 2020 was $251. As of December 31, 2020, $741 of total unrecognized compensation expense related to unvested RSUs was expected to be recognized over a weighted average period of 2.20 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation is included in the consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending upon the nature of services provided. Stock-based compensation expense related to stock options and RSUs granted to employees and non-employees was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an Employee Stock Purchase Plan, or ESPP. Under the ESPP, the Company has 500 shares of common stock reserved for issuance, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 25% of their eligible compensation, subject to any plan limitations. The ESPP provides for six-month offering periods. At the end of each offering period, employees can purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of December 31, 2020, the Company had not initiated employee enrollment to the plan.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="icb64e100a4ea46aeaf2e021efaf9fc23_I20141231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzIzOA_177b76d2-feb3-4f8e-ba37-b5a2c5e621c7"
      unitRef="shares">137000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMTE_9c6b1cac-50e6-4f73-8f23-753101fc9d49">The 2014 Plan has since been amended and restated with approval by the stockholders to increase the maximum number of shares issuable, as shown in the table below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:422.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:298.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:120.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original share pool&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015 increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2017 increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2017 increase (ratified in June 2018)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020 increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2020 increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share authorized for grant as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for future grant under the 2014 Plan was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:422.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:298.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:120.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares Available For Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share pool increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i877dabd6d9f1456b80f4388fc9919198_I20141231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzAtMS0xLTEtMA_c2ab6761-a1ac-47c9-86a3-d15391d07f44"
      unitRef="shares">137000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i15b635d7791d4729a41246f37fdd5040_D20150101-20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzEtMS0xLTEtMA_02d44910-8074-4348-9989-cc44907e9ea0"
      unitRef="shares">111000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i8fba51ad7cb8481bae70c35bf580f079_D20170601-20170630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzItMS0xLTEtMA_48a7e659-3408-477a-baad-a50657ae32ad"
      unitRef="shares">67000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i5fa56f65ff31460b927499357c824471_D20171201-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzMtMS0xLTEtMA_e359f984-6a21-4ce3-85f3-7077c1bcd076"
      unitRef="shares">293000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzQtMS0xLTEtMA_959d53f2-de2c-4b56-b3ff-cfd74f15929b"
      unitRef="shares">233000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i66f66be5e4ca4a3fbef0430494cb2a38_D20200301-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzUtMS0xLTEtMjY5Ng_73d571ea-a1ed-4b93-9fd0-003d038cffcc"
      unitRef="shares">333000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzYtMS0xLTEtMjY5Ng_e605a39b-7451-4757-901c-ca2f33715d8b"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8347ac776ecd461e8415e7b0e8c4a7fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkYzEwODg5ZjRlZmM0M2VlODFjMzI2ODhjMDQ2YjhhZS90YWJsZXJhbmdlOmRjMTA4ODlmNGVmYzQzZWU4MWMzMjY4OGMwNDZiOGFlXzUtMS0xLTEtMA_039e00e6-4a94-465b-aec9-3ca0ff476a4d"
      unitRef="shares">1974000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8347ac776ecd461e8415e7b0e8c4a7fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzQ5NDc4MDIzMzE5NzU_039e00e6-4a94-465b-aec9-3ca0ff476a4d"
      unitRef="shares">1974000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8347ac776ecd461e8415e7b0e8c4a7fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzUxOA_06040db0-4aca-4852-a201-d0b2152f4c50"
      unitRef="shares">1113000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i607f7ac1d3694172a81a41007edb3395_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzEtMS0xLTEtMA_78c39955-f346-48ba-ab80-5c59688ac67b"
      unitRef="shares">119000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ie4579f566e42442e9e3dc9eb88d2d447_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzItMS0xLTEtMA_72580e9e-f2b3-49bc-995f-611bb0af34ee"
      unitRef="shares">225000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="ie4579f566e42442e9e3dc9eb88d2d447_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzMtMS0xLTEtMA_2576f717-0701-46f5-99e3-8345481b7a0d"
      unitRef="shares">57000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="ie4579f566e42442e9e3dc9eb88d2d447_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzQtMS0xLTEtMA_e7a7da2a-9e8f-4019-87e1-b390ff796b5c"
      unitRef="shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i10a66b0cab964a889263784aee1901fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzUtMS0xLTEtMA_a4a5df65-2e52-4d21-a5b2-dca516954220"
      unitRef="shares">1133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8347ac776ecd461e8415e7b0e8c4a7fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTpkNTVmOWI0OGI5OTA0ODIwYWMzNDMyZDQwYWUwZDYzOS90YWJsZXJhbmdlOmQ1NWY5YjQ4Yjk5MDQ4MjBhYzM0MzJkNDBhZTBkNjM5XzYtMS0xLTEtMA_f355cb53-28b3-496b-99f0-9942fc0c6763"
      unitRef="shares">1113000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="iec71a31edf584b3fbbe26a8ef6da1b57_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzEzMTg_78f4b48e-0f90-43dd-aab1-23ee7206a379"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i8724e49e7c1c44f9ae22762caedea6d7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzE0OTY_2a977823-67fd-4a16-ba75-6ae655f3d7e6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="iec71a31edf584b3fbbe26a8ef6da1b57_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzE5MzI_1a3a1b14-a8c1-42ea-99f4-94001a7caa32">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMjA_3cb3d7c3-01da-44f3-bbe9-070bbbfb2486">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity during the year ended December 31, 2020 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at year end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about stock options outstanding as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Range of&lt;br/&gt;Exercise&lt;br/&gt;Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.55 - $9.15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.95 - $26.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$27.30 - $56.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$60.00 - $229.95&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4eccbe0a4d6f46a7beb0bc1fe08e5bab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzEtMS0xLTEtMA_70a214cb-ee0f-4c60-add2-981d54a29a3e"
      unitRef="shares">494000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4eccbe0a4d6f46a7beb0bc1fe08e5bab_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzEtMy0xLTEtMA_4f3ca69d-9619-4e6d-b542-d9926d9f3f22"
      unitRef="usdPerShare">36.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzItMS0xLTEtMA_18279bda-6781-4072-82fe-37719c050f2f"
      unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzItMy0xLTEtMA_73810e98-ca75-4f1e-84df-c8a754b8b369"
      unitRef="usdPerShare">5.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzMtMS0xLTEtMA_fce2ca96-4d55-4b76-834f-e18304014716"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzMtMy0xLTEtMA_65fce8e3-0017-4f1b-a36b-e62e896043b4"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzQtMS0xLTEtMA_4fa48975-6912-4883-8c02-1f990ce4946f"
      unitRef="shares">26000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzQtMy0xLTEtMA_61062a9b-2efa-4c71-a677-693967994f78"
      unitRef="usdPerShare">26.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzUtMS0xLTEtMA_3f1b230b-d36a-4c67-91e5-dfe6bfc4f792"
      unitRef="shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzUtMy0xLTEtMA_07ff523c-0720-44dd-ad68-f5e01c480bfc"
      unitRef="usdPerShare">41.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzYtMS0xLTEtMA_67277f92-167b-41fd-a9cc-3182c55f6eef"
      unitRef="shares">529000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzYtMy0xLTEtMA_5d2d7c0a-d170-4656-b9bb-0db0bbe275ec"
      unitRef="usdPerShare">31.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzYtNS0xLTEtMA_85e78d91-0d6b-4403-93c9-32e6c12bef0e">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzYtNy0xLTEtMA_4be34d43-de78-4680-9863-f0e3550c632b"
      unitRef="usd">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzctMS0xLTEtMA_1dde5fea-2d11-4975-b5e0-bc5da9269395"
      unitRef="shares">529000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzctMy0xLTEtMA_8dc84b1c-5423-49a1-8d4e-65ffe845e534"
      unitRef="usdPerShare">31.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzctNS0xLTEtMA_0b598580-dadc-4e8b-9993-5beccc32fcda">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzctNy0xLTEtMA_024fb673-81a9-42d9-872b-9492e76e296a"
      unitRef="usd">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzgtMS0xLTEtMA_6d994b06-b20a-4c1f-b43f-52ad0386429f"
      unitRef="shares">342000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzgtMy0xLTEtMA_88d7b32c-e810-4134-8653-5eb37fbf4ade"
      unitRef="usdPerShare">40.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4e27290e7e3b4ffe86c062a3a7ada9d3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzgtNS0xLTEtMA_2fabf7b5-d2a7-41f7-bfd0-d038fffbb632">P6Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i735a3aad369b4c09b74bbf9679dbfbdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMmIxODY2OTRmY2E0YmQ3YjE2MjA0YWM0MjQ5MjY2MC90YWJsZXJhbmdlOjEyYjE4NjY5NGZjYTRiZDdiMTYyMDRhYzQyNDkyNjYwXzgtNy0xLTEtMA_f9f927fb-6df9-4957-a926-ad9dbd589e0e"
      unitRef="usd">24000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzIzMzc_3dd16f8a-613b-44a7-9784-55c1e7820ff9"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ic57345e588804cfe860c750737f00dd8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI0MzE_799c13c5-1091-4948-a493-e9c267ad162b"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="id37bd0dc0daa4fb7b83159c71d2bfa17_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI0Mzg_892e5334-76b2-469d-953d-9bc494aa1349"
      unitRef="usd">233000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI1OTA_2520be33-cb37-44b2-9b0b-b20debd4d6d3"
      unitRef="usdPerShare">4.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i311beee139874abaaa623022d8afd3cd_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI1OTc_dc5ecf21-ab61-4ca7-bd4a-4b0f79e76b87"
      unitRef="usdPerShare">10.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI3MDc_38c86f03-91a5-486a-a3b1-4c87a97eb62b"
      unitRef="usd">1900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i311beee139874abaaa623022d8afd3cd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI3MTQ_2a9dfcb9-0d5e-413c-bbb3-acefc19ab203"
      unitRef="usd">2602000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ic57345e588804cfe860c750737f00dd8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzI4MTg_67cd3935-34df-4fda-9c5f-a27ab82ab1c8"
      unitRef="usd">2203000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzMwMzE_5806e9b1-f3e4-411a-97b7-94f5c1360667">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="if0686788f1e24c1290b7f0d92818a8ed_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItMC0xLTEtMC90ZXh0cmVnaW9uOmFjMTEwYjAzODE3ZjQwM2M4NmYyYTYwMTJiMDQ1NWMwXzMyOTg1MzQ4ODMzNTA_57d2dbc0-2d14-4177-984b-f11f90e42889"
      unitRef="usdPerShare">5.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="if0686788f1e24c1290b7f0d92818a8ed_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItMC0xLTEtMC90ZXh0cmVnaW9uOmFjMTEwYjAzODE3ZjQwM2M4NmYyYTYwMTJiMDQ1NWMwXzMyOTg1MzQ4ODMzNTc_3f8b0574-1eb7-4b07-baa4-4938b9f49485"
      unitRef="usdPerShare">9.15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i32119daf61d74b55a3c8238a0cb3d15b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItMi0xLTEtMA_f49394d4-41ca-431f-ba1a-3e57aeb41c0a"
      unitRef="shares">205000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="if0686788f1e24c1290b7f0d92818a8ed_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItNC0xLTEtMA_fb73c14a-05c3-483b-9222-aba62f84dce3">P8Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i32119daf61d74b55a3c8238a0cb3d15b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItNi0xLTEtMA_01d4fa5e-5e34-4125-be6f-05eb546b4bac"
      unitRef="usdPerShare">7.63</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i32119daf61d74b55a3c8238a0cb3d15b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItOC0xLTEtMA_fec89668-98e0-4a8e-b430-f8151805d6d8"
      unitRef="shares">87000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i32119daf61d74b55a3c8238a0cb3d15b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzItMTAtMS0xLTA_3ccfd9b7-3bc3-413c-85ce-0d31101d4bc7"
      unitRef="usdPerShare">6.94</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i87e27b2516f148d697ece33f11777fc4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI3MWYwYjRiMjE2MDRiOTZhMmIyOGQ4ODQ0ZmM0NDc4XzMyOTg1MzQ4ODMzNTA_1c2596ff-0180-4e51-b427-c21d915c65a4"
      unitRef="usdPerShare">16.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i87e27b2516f148d697ece33f11777fc4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI3MWYwYjRiMjE2MDRiOTZhMmIyOGQ4ODQ0ZmM0NDc4XzMyOTg1MzQ4ODMzNTc_9902f768-9a71-460d-a53f-0a17f1cd4db1"
      unitRef="usdPerShare">26.85</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i082ff8dadd2c49fa8fbb80b8ffef3976_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtMi0xLTEtMA_fa87e768-beed-4bea-aa74-02a4662a2688"
      unitRef="shares">101000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i87e27b2516f148d697ece33f11777fc4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtNC0xLTEtMA_d27bd56f-0dd1-4977-b7dd-c4c6a5c3da08">P7Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i082ff8dadd2c49fa8fbb80b8ffef3976_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtNi0xLTEtMA_f1937142-7e90-4fc1-84fc-275fadd3bc76"
      unitRef="usdPerShare">22.33</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i082ff8dadd2c49fa8fbb80b8ffef3976_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtOC0xLTEtMA_226e8d40-b3d2-4017-b75d-648e0c0ec045"
      unitRef="shares">66000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i082ff8dadd2c49fa8fbb80b8ffef3976_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzMtMTAtMS0xLTA_200749a9-a2dd-4638-a380-ed3c4c05ecdd"
      unitRef="usdPerShare">22.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i6e851d50c5564e38abf2c0a93b86475f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjJiN2NlYTMyMzZhNDRiZWFhMjlhOThhMmVlZDc1MDIxXzMyOTg1MzQ4ODMzNTA_20dfad9c-2fd5-42dc-a606-fbb4c132b2d9"
      unitRef="usdPerShare">27.30</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i6e851d50c5564e38abf2c0a93b86475f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjJiN2NlYTMyMzZhNDRiZWFhMjlhOThhMmVlZDc1MDIxXzMyOTg1MzQ4ODMzNTc_ed40d56c-7a7b-4988-b96e-a389e3a8bd1f"
      unitRef="usdPerShare">56.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i2948b44d394340328fd63500766a8e47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtMi0xLTEtMA_88ee6541-b159-445a-86dd-5ac75d84f586"
      unitRef="shares">163000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i6e851d50c5564e38abf2c0a93b86475f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtNC0xLTEtMA_123a84d5-6c90-49c7-8e6a-0747f3d0ea96">P6Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i2948b44d394340328fd63500766a8e47_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtNi0xLTEtMA_2360c664-4cbe-4d32-ba56-1a1baae506b4"
      unitRef="usdPerShare">34.89</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i2948b44d394340328fd63500766a8e47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtOC0xLTEtMA_a31fdfbd-0217-47d4-b2a5-58948e51799d"
      unitRef="shares">128000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i2948b44d394340328fd63500766a8e47_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzQtMTAtMS0xLTA_ab6505f7-44b5-474f-8426-bd55d301c6c4"
      unitRef="usdPerShare">35.64</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i6df990af732247609512a586b14ed964_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjk2ZTEwZGM4NWM2ZjQ2OWI4ZGVjMWU1NjVhNTEyZDQwXzMyOTg1MzQ4ODMzNTE_a571efe9-8402-45a8-b32d-8eb58e1e33ef"
      unitRef="usdPerShare">60.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i6df990af732247609512a586b14ed964_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjk2ZTEwZGM4NWM2ZjQ2OWI4ZGVjMWU1NjVhNTEyZDQwXzMyOTg1MzQ4ODMzNTk_4003f1e6-6082-4f7b-928f-74bed42face5"
      unitRef="usdPerShare">229.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ib9584796b78247a691fb1d74e4e04c73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtMi0xLTEtMA_2d5cfc05-ee1b-4674-8045-e3b5d5cf56bb"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i6df990af732247609512a586b14ed964_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtNC0xLTEtMA_4c46187d-69dd-44e7-882f-4acc08c6f4e1">P4Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ib9584796b78247a691fb1d74e4e04c73_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtNi0xLTEtMA_2d986d91-5005-4a6f-99e4-ebbfdeaccd0e"
      unitRef="usdPerShare">119.04</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ib9584796b78247a691fb1d74e4e04c73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtOC0xLTEtMA_511fa40d-a023-4679-b723-3ed9e668c92e"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ib9584796b78247a691fb1d74e4e04c73_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzUtMTAtMS0xLTA_c1851f9b-80b9-4ce9-b488-9a47f856db09"
      unitRef="usdPerShare">119.04</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzYtMi0xLTEtMA_c6f341b2-fb67-41cc-89b0-6460de630455"
      unitRef="shares">529000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzYtNC0xLTEtMA_d3385170-9e4a-4a5c-aaf5-66616cd394c5">P7Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzYtNi0xLTEtMA_d34811b1-7943-47f0-9efb-dde87ba5566d"
      unitRef="usdPerShare">31.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzYtOC0xLTEtMA_fcd2a77f-2e99-4886-9d69-1ddb8d564744"
      unitRef="shares">342000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo0NjIzZGYzZTgxNTA0N2ExYjcyNzQ4ZDdiMGZmOGY3Ny90YWJsZXJhbmdlOjQ2MjNkZjNlODE1MDQ3YTFiNzI3NDhkN2IwZmY4Zjc3XzYtMTAtMS0xLTA_e0ca2a93-0d6b-4cd5-901e-250cc639653e"
      unitRef="usdPerShare">40.63</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMjY_568b1169-0850-469c-8d63-922c084b93fc">The share fair value of each stock option was determined on the date of grant using the Black-Scholes Model under the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.962%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44% - 1.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.67% - 2.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.27 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%-102%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%-103%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzItMS0xLTEtMA_904fa8a7-be84-4431-9c27-1a0dfd7d5660"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzItMy0xLTEtMA_caad1ce4-af13-4df6-9eb5-6987655e19f1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjA0M2Y1ZDMzZGY1NzRlMjY5ZDQwNWI3ZjhmMzc4YmViXzMyOTg1MzQ4ODMzNTA_d1d0ac84-d592-495b-a895-43ef6a6ff520"
      unitRef="number">0.0144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjA0M2Y1ZDMzZGY1NzRlMjY5ZDQwNWI3ZjhmMzc4YmViXzMyOTg1MzQ4ODMzNTc_986881bc-1e95-43a6-9f23-bd3ef27ec3d7"
      unitRef="number">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjI5OGFjZDUzYTc4MTRhNjBhMjliYTJjZjcwOGMwNjE5XzMyOTg1MzQ4ODMzNDk_83cfafba-b67d-4fa9-84d5-5f7af8cca73f"
      unitRef="number">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjI5OGFjZDUzYTc4MTRhNjBhMjliYTJjZjcwOGMwNjE5XzMyOTg1MzQ4ODMzNTU_ea31f6e2-054f-44a4-ac35-784b9ff37bd8"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id643b591bbe442ff89d7f6fedbd8777a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjc1Yjc3NDI1MGNlZTQ2OGJiNTcwNjFiMmNhYjA1MmI1XzMyOTg1MzQ4ODMzNjU_30139aec-a33c-43b5-94d7-a75e40617fa0">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i81b4652764f7496fae43691e5665e11e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjc1Yjc3NDI1MGNlZTQ2OGJiNTcwNjFiMmNhYjA1MmI1XzMyOTg1MzQ4ODMzNzY_53512267-698a-4c33-ae82-c5ba4d7f3aa9">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzQtMy0xLTEtMC90ZXh0cmVnaW9uOjM1ZDU4OTA1MjdiZTRkODBiMmFhYjI4M2EwMDIyYzUyXzMyOTg1MzQ4ODMzNDM_9406524f-2e15-4841-8e40-9d3ae5507785">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjBhMzhhY2QwYjNkNzRkMjBiODA3Njk1Yjk3ODBhZjc4XzMyOTg1MzQ4ODMzNDU_b3561502-923a-47f4-ab02-589020f2ed94"
      unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjBhMzhhY2QwYjNkNzRkMjBiODA3Njk1Yjk3ODBhZjc4XzMyOTg1MzQ4ODMzNTE_27f968f9-cd68-46ca-b81e-39e5dd292d6f"
      unitRef="number">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjk2YTY2MWU3ZGNmNTQ4MTY5NThiYTgzZmU0ZWZlNWE3XzMyOTg1MzQ4ODMzNDM_ad2d62c1-ee4c-48cd-96ef-dcb6fccd8fb4"
      unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZToxMzMxNDAxZmQ3MDc0NGUxOTVhOTkwYzU0ODM0ZGUyNi90YWJsZXJhbmdlOjEzMzE0MDFmZDcwNzQ0ZTE5NWE5OTBjNTQ4MzRkZTI2XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjk2YTY2MWU3ZGNmNTQ4MTY5NThiYTgzZmU0ZWZlNWE3XzMyOTg1MzQ4ODMzNDk_2455be6f-6701-4493-921b-fb6b29287a8e"
      unitRef="number">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <ekso:ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward
      contextRef="iafd5100ca7f64a00831c51a479b855ff_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzMyOTg1MzQ4OTE5Njg_4e3e25b2-8507-4b91-a18a-85ed483ac4a3"
      unitRef="shares">1</ekso:ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMjE_1bc857cb-e308-46c9-aa7e-bc237376df80">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSU activity for the year ended December 31, 2020 is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Grant-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i214faac982094d0986fd63789ae5cc48_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzEtMS0xLTEtMA_0b61128a-c419-4eb8-ad0f-6a47bb15e187"
      unitRef="shares">89000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i214faac982094d0986fd63789ae5cc48_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzEtMy0xLTEtMA_011d25a2-39f6-43c7-a23a-6726b0f0e4da"
      unitRef="usdPerShare">10.77</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzItMS0xLTEtMA_2d816758-e917-4001-90d5-5756633b3dc6"
      unitRef="shares">135000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzItMy0xLTEtMA_2383686c-ad18-4db2-80a6-ccbd96108f97"
      unitRef="usdPerShare">4.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzMtMS0xLTEtMA_a5eace08-7b20-4256-ba60-b7c56a755d8f"
      unitRef="shares">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzMtMy0xLTEtMA_790f9d18-b711-4a4d-92c4-fdf2bf4c9b49"
      unitRef="usdPerShare">6.24</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzQtMS0xLTEtMA_8c8c29f6-daff-4902-b52d-7c7389478c07"
      unitRef="shares">31000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzQtMy0xLTEtMA_8091d1a1-397b-45ca-ab29-27a60dc4330c"
      unitRef="usdPerShare">10.96</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="iafd5100ca7f64a00831c51a479b855ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzUtMS0xLTEtMA_59b8005a-b77a-4a6b-b3e3-c51622b29909"
      unitRef="shares">143000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iafd5100ca7f64a00831c51a479b855ff_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTozOGZiYWM5Zjk2ZTQ0ODk0ODIzYmRhYzk1YTNmYjU0MS90YWJsZXJhbmdlOjM4ZmJhYzlmOTZlNDQ4OTQ4MjNiZGFjOTVhM2ZiNTQxXzUtMy0xLTEtMA_d0c2aed9-e4bd-424a-8b73-09f0672060ca"
      unitRef="usdPerShare">6.31</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzM4NjY_76ddc2f9-f158-4339-a340-1991f9c68a4b"
      unitRef="usd">251000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="iafd5100ca7f64a00831c51a479b855ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzM4ODA_2d19a27d-3d8c-45d9-ac51-1a9e1981b25e"
      unitRef="usd">741000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i019a65ec2ae346afbe0add0ea7913acc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzQwMTU_d574bd30-c720-478c-b0a0-b71d9ad42746">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzYxMjc_61809ae5-d2a2-4db8-bc92-6eda18742a47">Stock-based compensation expense related to stock options and RSUs granted to employees and non-employees was as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2cb1ee725d64b848c8abc9e90945dbb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzItMS0xLTEtMA_3295196c-067f-437a-806e-926a264acfd1"
      unitRef="usd">476000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3cd9b4295544ce39f97760979ddef45_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzItMy0xLTEtMA_f476b6e0-2bbd-492b-a78c-76a215aaa080"
      unitRef="usd">653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i983c680de266493eb3b87d6e84973e71_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzMtMS0xLTEtMA_ca43e7c6-baf7-4b9d-8af3-e16e05f03b96"
      unitRef="usd">293000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6e43a3b8d704169bc941d426832f568_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzMtMy0xLTEtMA_c0712d6f-7422-4066-836b-7b4fbbec6152"
      unitRef="usd">241000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if0580d79d27744dfa79750de680b753e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzQtMS0xLTEtMA_c07cdbed-1469-459c-a81e-aa1bb9ffbd67"
      unitRef="usd">1641000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c9bf3c95d404943b8b37bf228a87293_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzQtMy0xLTEtMA_726893b8-37ed-4723-b239-9e3ecf8c5ade"
      unitRef="usd">1361000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzUtMS0xLTEtMA_a9795200-ae7f-4168-a8ce-7f4aa9d6a3ae"
      unitRef="usd">2410000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90YWJsZTo3MWZmMGY4ZTI2YjM0NjJhOTgyYjU0NTlkYzU0N2ZmNC90YWJsZXJhbmdlOjcxZmYwZjhlMjZiMzQ2MmE5ODJiNTQ1OWRjNTQ3ZmY0XzUtMy0xLTEtMA_fd271407-adf5-4e1d-81da-75d4d413e38b"
      unitRef="usd">2255000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie50e530344ba4276bb503495928f0afe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzUzNzU_bb9b8776-929b-4659-a875-498109e2a5bc"
      unitRef="shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i5f8787b85d56465398b389abe5c50313_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzU2Nzc_331018ef-d515-4fc4-a8cb-fbb2b3e5167f"
      unitRef="number">0.25</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <ekso:DefinedContributionPlanOfferingPeriod
      contextRef="i5f8787b85d56465398b389abe5c50313_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzMyOTg1MzQ4OTE5ODk_58c90ea0-df29-4c25-87f4-7905d347ccb9">P6M</ekso:DefinedContributionPlanOfferingPeriod>
    <ekso:DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter
      contextRef="i5f8787b85d56465398b389abe5c50313_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzAvZnJhZzo1MmI0NzYwYTBjODI0ZTAwOTg2MjYxZDkzZDRhZWFiZi90ZXh0cmVnaW9uOjUyYjQ3NjBhMGM4MjRlMDA5ODYyNjFkOTNkNGFlYWJmXzU4NjQ_26bd2f66-9e6e-4d0b-8fea-99f542f239aa"
      unitRef="number">0.85</ekso:DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzQ5MTE_d608ce29-fa56-49c7-b326-1bff82bbaf49">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The domestic and foreign components of pre-tax loss for the years ended December 31, 2020 and 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no current or deferred federal and state income tax expense or benefit for the years ended December 31, 2020 and 2019 because the Company generated net operating losses, and currently management does not believe it is more likely than not that the net operating losses will be realized. The Company&#x2019;s non-U.S. tax obligation is primarily for business activities conducted through Germany and Singapore for which taxes were included in other expense, net for the years ended December 31, 2020 and 2019 and determined to be immaterial and accordingly, such amounts were excluded from the following tables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense (benefit) for the years ended December 31, 2020 and 2019 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences and related deferred tax assets and liabilities as of December 31, 2020 and 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of the Company&#x2019;s net deferred tax assets. The Company primarily considered such factors as the Company&#x2019;s history of operating losses, the nature of the Company&#x2019;s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. The Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance was established and no deferred tax assets were shown in the accompanying consolidated balance sheets. The valuation allowance increased by $3,192 and $3,899 in the years ended December 31, 2020 and December 31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For tax years beginning after December 31, 2018, the Global Intangible Low-taxed Income ("GILTI") took effect.  Due to the aggregated losses of the foreign subsidiaries, there was no GILTI inclusion for the years ended December 31, 2020 and December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 27, 2020 the U.S. enacted the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). On December 21, 2020, The U.S. Congress passed the Consolidation Appropriations Act, 2021 (the CAA Act).  We have evaluated the provisions of the CARES Act and CCA Act and determined that it did not result in a significant impact on our tax provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June 29, 2020 California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of California net operating losses and limits the use of California research tax credits for tax years beginning in 2020 and before 2023.  The suspension of net operating losses and the restriction of research tax credits  did not result in a significant impact on the value of our deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020 the Company had federal net operating loss carryforwards of $164,296. The federal net operating loss carryforwards of $120,792 generated before January 1, 2018 will begin to expire in 2027, and $43,503 will carryforward indefinitely but are subject to the 80% taxable income limitation. The Company also had federal research and development tax credit carryforwards of $1,943 that will expire beginning in 2031, if not utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company had state net operating loss carryforwards of $106,955, which will begin to expire in 2028. The Company also had state research and development tax credit carryforwards of $641, which have no expiration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company had foreign net operating loss carryforwards of $9,655. The foreign net operating loss carryforwards do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the Company&#x2019;s net operating losses and credit carryforwards may be subject to annual limitations in the event of a Section 382 ownership change. Such future limitations could result in the expiration of net operating losses and credit carryforwards before utilization as a result of such an ownership change.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase of unrecognized tax benefits taken in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase of unrecognized tax benefits related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company is able to recognize these uncertain tax positions, the unrecognized tax benefits would not impact the effective tax rate if the Company applies a full valuation allowance against the deferred tax assets, as provided in the Company&#x2019;s current policy.&lt;/span&gt;&lt;/div&gt;The Company had not incurred any material tax interest or penalties as of December 31, 2020. The Company does not anticipate any significant change within 12&#160;months of this reporting date of its uncertain tax positions. The Company is subject to taxation in the United States and various state jurisdictions, Germany, and Singapore. There are no ongoing examinations by taxing authorities at this time. The Company&#x2019;s tax years 2007 through 2020 will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss credits. The Company&#x2019;s 2016 to 2020 tax years will remain open for examination by the German tax authority for four years from the end of the year in which the applicable return was filed. The Company&#x2019;s 2018 to 2020 tax years will remain open for examination by the Singapore tax authority for four years from the date of  the applicable assessment.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzQ5MTc_8a71c4af-e5a0-413f-874a-f0d2b593b418">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The domestic and foreign components of pre-tax loss for the years ended December 31, 2020 and 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzItMS0xLTEtMA_4088c7de-7ca3-4bb0-abce-ce91fe23ea9e"
      unitRef="usd">-14954000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzItMy0xLTEtMA_9111692d-af94-4837-b279-913443d4ff3f"
      unitRef="usd">-10321000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzMtMS0xLTEtMA_f0b12e9a-3f70-4f7b-b308-ea28c59d268c"
      unitRef="usd">-871000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzMtMy0xLTEtMA_67176ab8-67e8-44f4-8a64-52eb3c693f4f"
      unitRef="usd">-1811000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzQtMS0xLTEtMA_8fd66ce3-8e18-4fd5-8fbe-dc90fb936fbb"
      unitRef="usd">-15825000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo4NGE4ZTc1NWU3YWM0YWQ3YjdhN2M1NzYyOGRhMmIxYy90YWJsZXJhbmdlOjg0YThlNzU1ZTdhYzRhZDdiN2E3YzU3NjI4ZGEyYjFjXzQtMy0xLTEtMA_cb0e9f7b-3c0c-4bd5-8f44-97ef34428c54"
      unitRef="usd">-12132000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE0Mg_0708dd20-5529-4794-8578-c862f0216b4c"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE0Mg_6446b5e1-e56b-479c-bc90-fb3d6f436bb5"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE0Mg_b929c218-1320-4031-a801-7904b5bf46d2"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE0Mg_f31d6cb6-af84-42dd-9e44-d5a53570a290"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzQ5MjE_7065878a-6686-4384-8f1c-7ac926c1b631">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense (benefit) for the years ended December 31, 2020 and 2019 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzItMS0xLTEtMA_9e997d25-cbb0-447a-956c-b31e7bc7c8ea"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzItMy0xLTEtMA_4376561f-99c6-4928-aee7-32faed269562"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzMtMS0xLTEtMA_470d8388-5ec1-4940-9fda-1d560b5f76ba"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzMtMy0xLTEtMA_58aab1b3-31d7-4ba9-a15c-f97f72560bc9"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzQtMS0xLTEtMA_f3677a28-a6d9-4e60-adbb-6c65b9997199"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzQtMy0xLTEtMA_5b818fd8-4326-4445-b061-f6e5b921b16e"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzUtMS0xLTEtMA_4bf1c4c4-7102-426b-b2fc-e8969ac7ff24"
      unitRef="number">-0.166</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzUtMy0xLTEtMA_1711a4f6-0d14-4755-93b4-74a4e4c6b078"
      unitRef="number">-0.272</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ekso:EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzYtMS0xLTEtMA_84c6e881-a37a-4652-ab9b-7c108e00255f"
      unitRef="number">-0.045</ekso:EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant>
    <ekso:EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzYtMy0xLTEtMA_7d22a7cc-607d-43ae-aae3-4f07c58edb1d"
      unitRef="number">0.087</ekso:EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzctMS0xLTEtMA_b622fbb6-c67a-4b84-89bd-2991812e83fc"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzctMy0xLTEtMA_23241dec-012e-4a20-846a-f01ac7d5d887"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzgtMS0xLTEtMA_4bd914d5-2602-4537-a107-4192179dee7a"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzgtMy0xLTEtMA_e60ff5d8-a628-49bd-8150-d091ca9c6eb1"
      unitRef="number">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzktMS0xLTEtMA_bc27e308-5702-4af2-9d97-d35e630e4540"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTo3NWM1MWRkMzhhNWE0Y2E0ODBlODVjZDVjM2E0NzdlNC90YWJsZXJhbmdlOjc1YzUxZGQzOGE1YTRjYTQ4MGU4NWNkNWMzYTQ3N2U0XzktMy0xLTEtMA_d2a8f93a-5f65-48e8-b1f3-1dc672e56e70"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzQ5MTg_04d845e4-15dd-4775-84ca-5b4b1418b7a4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences and related deferred tax assets and liabilities as of December 31, 2020 and 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzMtMS0xLTEtMA_73a3a1cf-f890-492e-9b68-aef1d0638288"
      unitRef="usd">235000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzMtMy0xLTEtMA_8070133d-48f3-4bd1-8fc8-45b62078a94d"
      unitRef="usd">263000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzQtMS0xLTEtMA_32d30999-01c5-4318-8ece-2cd9e73f4529"
      unitRef="usd">43241000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzQtMy0xLTEtMA_9f90119c-e7fe-419c-aa39-e0da4969aff5"
      unitRef="usd">40683000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzUtMS0xLTEtMA_37d75969-b838-454d-9d29-b8939d056cb0"
      unitRef="usd">1837000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzUtMy0xLTEtMA_57bccd7a-5148-4acc-baa6-f1b5274d57c7"
      unitRef="usd">1817000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzYtMS0xLTEtMA_325fa649-a123-475c-9545-51c0751ca311"
      unitRef="usd">380000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzYtMy0xLTEtMA_f29c77d3-b3d0-449d-a418-98e88e8804b0"
      unitRef="usd">289000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzctMS0xLTEtMA_79389b31-4cc5-4c64-870a-629a5b786e1c"
      unitRef="usd">401000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzctMy0xLTEtMA_731e48d7-1454-4784-8569-0563f95cd414"
      unitRef="usd">220000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzgtMS0xLTEtMA_182ef686-55d7-43ea-8355-faa15f6a818f"
      unitRef="usd">2547000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzgtMy0xLTEtMA_4cf0a4ce-4feb-4fe3-969a-0f4ce4230f6b"
      unitRef="usd">2197000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ekso:DeferredTaxAssetsOperatingLeaseRightOfUseAsset
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzktMS0xLTEtMA_817b1425-2a3c-4e41-8dd6-836899d713ed"
      unitRef="usd">110000</ekso:DeferredTaxAssetsOperatingLeaseRightOfUseAsset>
    <ekso:DeferredTaxAssetsOperatingLeaseRightOfUseAsset
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzktMy0xLTEtMA_a824e671-412f-43ef-a382-74a20873360b"
      unitRef="usd">224000</ekso:DeferredTaxAssetsOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzEwLTEtMS0xLTA_a75b3351-4f54-48c3-bacb-0ea2de00aef0"
      unitRef="usd">37000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzEwLTMtMS0xLTA_6656d29e-3fc8-4b72-aae6-812841ae93da"
      unitRef="usd">45000</us-gaap:DeferredTaxAssetsOther>
    <ekso:DeferredTaxLiabilitiesOperatingLeaseLiability
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzEzLTEtMS0xLTA_ac1d4264-7112-477d-b7ef-2f969b3977be"
      unitRef="usd">88000</ekso:DeferredTaxLiabilitiesOperatingLeaseLiability>
    <ekso:DeferredTaxLiabilitiesOperatingLeaseLiability
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzEzLTMtMS0xLTA_49c8abfc-c143-4943-b85e-4fafb2cdc75e"
      unitRef="usd">214000</ekso:DeferredTaxLiabilitiesOperatingLeaseLiability>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE0LTEtMS0xLTA_1a991055-90e0-4c52-a671-cd8c2f5cd51f"
      unitRef="usd">27000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE0LTMtMS0xLTA_59ab9797-4294-4549-b55a-28b80cc11e02"
      unitRef="usd">43000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE1LTEtMS0xLTA_6dc17df1-8ebd-4767-be00-c5ac90f0ff3a"
      unitRef="usd">48673000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE1LTMtMS0xLTA_05178494-d6e8-49df-a79f-3db62675ea37"
      unitRef="usd">45481000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE2LTEtMS0xLTA_06c6706e-590d-4d3d-9bff-25a8516bee33"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTowNTY4MzMxYWEzMzA0NmU0YmM2ODRjYWZiZTNlMDRmMi90YWJsZXJhbmdlOjA1NjgzMzFhYTMzMDQ2ZTRiYzY4NGNhZmJlM2UwNGYyXzE2LTMtMS0xLTA_6104d6d0-453d-409f-a69c-d0a17b698b47"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE3OTY_b21cb845-e3c0-4604-8656-db01b5852a98"
      unitRef="usd">3192000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzE4MDM_56691309-c2d9-4273-808f-dfc1a4fa559c"
      unitRef="usd">3899000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i8bb6a31fa69b42789b1e10282b4ace5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzIxNTI_0b7b9dcd-8747-4d90-8016-8a2c9b39c1ae"
      unitRef="usd">164296000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i10c35f66e6034eec83024df6ac610e24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzIyMDQ_389cf95a-c2bb-4b72-ace4-5a2167251191"
      unitRef="usd">120792000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i8a5e4922e5c349469514d98ce6786b33_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzIyNzI_46388f77-1dac-43bd-bb9e-8b1184978684"
      unitRef="usd">43503000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i319319b8233c4303ad3523ef6efcc360_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzI0NDI_c59bcf1e-87d1-41fe-8b38-9c2719d815c7"
      unitRef="usd">1943000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7df6497f41704a339bcb35d3d532dc6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzI1NjY_fe518427-3740-4289-aaeb-c412db893859"
      unitRef="usd">106955000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib6b25f2478684c8396497673025f1b5f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzI2ODQ_c36e8179-5c6e-4053-8a57-ee77d5574e85"
      unitRef="usd">641000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia06204e374c64847aa8ca39f1c059324_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzI3ODU_7178a507-6148-4a14-a9a6-e08c88eff9da"
      unitRef="usd">9655000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90ZXh0cmVnaW9uOmMyMTc5NGFlOWU3NTQ5MDM5MWE3ZWI3MDM0NTc0MzE0XzQ5MDc_1f82ef2d-4f0d-4835-9e2d-f68a3bd26278">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase of unrecognized tax benefits taken in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase of unrecognized tax benefits related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id632c7032c4140109d9f983f53b19765_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTpmN2Y0MDJhZjYxZTg0MDBkODA1ODUwNWE3ZjE3Njc1YS90YWJsZXJhbmdlOmY3ZjQwMmFmNjFlODQwMGQ4MDU4NTA1YTdmMTc2NzVhXzMtMS0xLTEtMA_18cb8be4-fdaa-44c6-9dd0-681f08639fe2"
      unitRef="usd">637000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTpmN2Y0MDJhZjYxZTg0MDBkODA1ODUwNWE3ZjE3Njc1YS90YWJsZXJhbmdlOmY3ZjQwMmFmNjFlODQwMGQ4MDU4NTA1YTdmMTc2NzVhXzQtMS0xLTEtMA_1c2015e5-ff89-4029-b41c-2d3874a2d9b2"
      unitRef="usd">1000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTpmN2Y0MDJhZjYxZTg0MDBkODA1ODUwNWE3ZjE3Njc1YS90YWJsZXJhbmdlOmY3ZjQwMmFmNjFlODQwMGQ4MDU4NTA1YTdmMTc2NzVhXzUtMS0xLTEtMA_05477bab-fbf3-4495-826a-86d966bbabef"
      unitRef="usd">7000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMzYvZnJhZzpjMjE3OTRhZTllNzU0OTAzOTFhN2ViNzAzNDU3NDMxNC90YWJsZTpmN2Y0MDJhZjYxZTg0MDBkODA1ODUwNWE3ZjE3Njc1YS90YWJsZXJhbmdlOmY3ZjQwMmFmNjFlODQwMGQ4MDU4NTA1YTdmMTc2NzVhXzYtMS0xLTEtMA_c771e5f8-63e3-4bd7-890d-56ea698cc060"
      unitRef="usd">645000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzIzMzg_05e3f4e0-f433-4541-a31e-990c5cd3ebd1">Commitments and Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Material Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two license agreements with the Regents of the University of California to maintain exclusive rights to patents. The Company is required to pay 1% of net sales of licensed medical devices sold to entities other than the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;government. In addition, the Company is required to pay 21% of consideration collected from any sub-licensee for the grant of the sub-license. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with acquisition of Equipois, LLC ("Equipois"), the Company assumed the rights and obligations of Equipois under a license agreement with the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants the Company an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, the Company is required to pay the developer a single-digit royalty on net receipts, subject to a $50 annual minimum royalty requirement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling&#160;$396&#160;as of&#160;December 31, 2020, which is expected to be paid within a year. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's outstanding contractual obligations, including interest payments, as of December 31, 2020 and the effect those obligations are expected to have on its liquidity and cash flows in future periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Payments Due By Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than&lt;br/&gt;one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1-3 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3-5 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Facility operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ekso:NumberOfLicenseAgreements
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzkw_dbea2522-5430-41d6-949f-22091529ca54"
      unitRef="license_agreement">2</ekso:NumberOfLicenseAgreements>
    <ekso:RoyaltyPercentage
      contextRef="i8c8907ba268e43a890f1228c1a43a77e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzIzMw_9ad8719c-cad6-428b-b90f-6cacc780fab3"
      unitRef="number">0.01</ekso:RoyaltyPercentage>
    <ekso:RoyaltyPercentage
      contextRef="if2504c7ec30a492e9cc1f890fccd8252_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzM3MA_6cbd286b-63ae-4316-a117-a47cc6ba1930"
      unitRef="number">0.21</ekso:RoyaltyPercentage>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="i4123648869a94d87948d26689a8190ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzk4NQ_8731a193-0b65-427f-9dd5-0dff477b4a9c"
      unitRef="usd">50000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligation
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzE1OTQ_6caf32a7-147c-4e0f-add6-a7957f57ec8c"
      unitRef="usd">396000</us-gaap:PurchaseObligation>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90ZXh0cmVnaW9uOmZlZGE3ODZkYzlkYTQ4YTI5NTAwYzFlNzM3MmM1Y2RlXzIzMzQ_f86d1984-a0cb-4f5c-a8d9-a51a6af7fba2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's outstanding contractual obligations, including interest payments, as of December 31, 2020 and the effect those obligations are expected to have on its liquidity and cash flows in future periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Payments Due By Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than&lt;br/&gt;one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1-3 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3-5 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Facility operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligation
      contextRef="i2b339ba80adf48a59e5a09a23f722e4b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzItMS0xLTEtMA_5a8939c8-ed94-43c9-9e21-4876cd6d88bd"
      unitRef="usd">3356000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="i2b339ba80adf48a59e5a09a23f722e4b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzItMy0xLTEtMA_3468a9a0-07c2-4ff0-97e2-6ca5c7f345f9"
      unitRef="usd">90000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="i2b339ba80adf48a59e5a09a23f722e4b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzItNS0xLTEtMA_895e085e-5293-48d3-9191-a98efcfe4d4f"
      unitRef="usd">3266000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="i2b339ba80adf48a59e5a09a23f722e4b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzItNy0xLTEtMA_b5d60d8d-29c2-4504-a9e4-c31c58f52db6"
      unitRef="usd">0</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligation
      contextRef="i6d1eb01e13aa4edd802e72c1ca0af002_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzMtMS0xLTEtMA_79450c5f-08fe-4bbb-9a32-938eb236c832"
      unitRef="usd">836000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="i6d1eb01e13aa4edd802e72c1ca0af002_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzMtMy0xLTEtMA_a586cfc5-c149-44c0-9d5b-7252f53f681e"
      unitRef="usd">599000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="i6d1eb01e13aa4edd802e72c1ca0af002_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzMtNS0xLTEtMA_78954be9-a56c-4526-b642-4013796ea6fb"
      unitRef="usd">237000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="i6d1eb01e13aa4edd802e72c1ca0af002_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzMtNy0xLTEtMA_6492abb5-e08c-46b3-a5f7-e62ab4fbcd23"
      unitRef="usd">0</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligation
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzUtMS0xLTEtMA_735e2735-8733-48c6-a073-d90f8321ee3e"
      unitRef="usd">4192000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzUtMy0xLTEtMA_d2921b07-8c8d-4f4d-84e7-16c624fb3ecc"
      unitRef="usd">689000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzUtNS0xLTEtMA_9a96610f-1728-4c43-9603-6a3f9ac765ec"
      unitRef="usd">3503000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="i8c95c1de992348a3bd61ef233bf1c041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDIvZnJhZzpmZWRhNzg2ZGM5ZGE0OGEyOTUwMGMxZTczNzJjNWNkZS90YWJsZTo3OGFhNzlkMTE1Nzk0YTU0OTk5ZWJmNjhkYjY5N2E0OC90YWJsZXJhbmdlOjc4YWE3OWQxMTU3OTRhNTQ5OTllYmY2OGRiNjk3YTQ4XzUtNy0xLTEtMA_6b63f4d7-d73d-48c0-8095-439e30ad631b"
      unitRef="usd">0</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90ZXh0cmVnaW9uOmRiY2EyOGU4YzU3NTRmOTdiYzY5ZjM3NjdlMjI5OTMyXzk1MA_51c8b5ea-7ea8-48af-adad-c7305ab6085d">Segment Disclosures&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two reportable segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, sells and rents exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, sells, and rents exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The reportable segments are each managed separately because they serve distinct markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates performance and allocates resources based on segment gross profit margin.  The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment reporting information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoHealth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from one customer of the Company&#x2019;s EksoHealth segment represented approximately $2,138 of the Company&#x2019;s consolidated revenues for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Geographic revenue information based on location of customer is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90ZXh0cmVnaW9uOmRiY2EyOGU4YzU3NTRmOTdiYzY5ZjM3NjdlMjI5OTMyXzQ2_811deeb8-e4ee-4206-9aa0-06785ef8c6f6"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90ZXh0cmVnaW9uOmRiY2EyOGU4YzU3NTRmOTdiYzY5ZjM3NjdlMjI5OTMyXzk0NA_c5b9f196-41cf-4094-a34a-9a9353e70b7a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment reporting information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoHealth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EksoWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib881b817aa7445709d8070f5fe391132_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzItMS0xLTEtMA_541e140f-e516-4edd-bb4c-bc38752afcc3"
      unitRef="usd">8066000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i75a7edc5f16340378382788c4c0dc691_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzItMy0xLTEtMA_7671e91e-3b5e-431b-99c4-6132fe5d022f"
      unitRef="usd">816000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzItNS0xLTEtMA_bd283b73-64f8-4a76-8281-b3b0333fbf1b"
      unitRef="usd">8882000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib881b817aa7445709d8070f5fe391132_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzMtMS0xLTEtMA_1761e712-40a6-4c0e-9d7c-4e215d153584"
      unitRef="usd">3219000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i75a7edc5f16340378382788c4c0dc691_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzMtMy0xLTEtMA_b00d6f4f-71ed-4303-a55e-17c4ed1a7144"
      unitRef="usd">593000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzMtNS0xLTEtMA_81ce7b85-ef5d-400d-a97a-29cf7a297cd5"
      unitRef="usd">3812000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="ib881b817aa7445709d8070f5fe391132_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzQtMS0xLTEtMA_a756c640-723e-46b8-a9a8-011ac9732a79"
      unitRef="usd">4847000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i75a7edc5f16340378382788c4c0dc691_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzQtMy0xLTEtMA_a3ec3d37-8193-4e21-bc91-96a562c22189"
      unitRef="usd">223000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzQtNS0xLTEtMA_6691ff51-d382-4923-8a92-a17ea635263f"
      unitRef="usd">5070000</us-gaap:GrossProfit>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iabb99287795245cead94469bb0004c47_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzctMS0xLTEtMA_1f132644-48c4-4d13-b8b8-a34a5266de3c"
      unitRef="usd">11957000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i015e0abf22814adbb2132f59a1724e19_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzctMy0xLTEtMA_bf99d906-e431-4347-8618-bc70e7fafd1b"
      unitRef="usd">1960000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzctNS0xLTEtMA_54c07c62-21af-4fec-b5be-a24b5381529e"
      unitRef="usd">13917000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iabb99287795245cead94469bb0004c47_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzgtMS0xLTEtMA_b436a538-bcd7-41d0-8aab-2b313982367f"
      unitRef="usd">5404000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i015e0abf22814adbb2132f59a1724e19_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzgtMy0xLTEtMA_6a577025-6cb4-45c9-9935-1ba47c5bca9d"
      unitRef="usd">1749000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzgtNS0xLTEtMA_91d74ce4-a39a-49a0-893c-132258406da1"
      unitRef="usd">7153000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="iabb99287795245cead94469bb0004c47_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzktMS0xLTEtMA_45e78c44-b7c2-4834-ac6a-ab6628aa0ef1"
      unitRef="usd">6553000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i015e0abf22814adbb2132f59a1724e19_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzktMy0xLTEtMA_e4e13b6e-4175-42b5-baa4-d9e2d69a6c6e"
      unitRef="usd">211000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTozZjlkYjBjYmExNTg0MmVjYjU3NTk0ZGE4Y2FjNTIyZi90YWJsZXJhbmdlOjNmOWRiMGNiYTE1ODQyZWNiNTc1OTRkYThjYWM1MjJmXzktNS0xLTEtMA_6aceaf1e-d6b2-4b8a-9367-e6c5a70149dd"
      unitRef="usd">6764000</us-gaap:GrossProfit>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3cb3927a9fbf4e13a0140f4d17c94c07_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90ZXh0cmVnaW9uOmRiY2EyOGU4YzU3NTRmOTdiYzY5ZjM3NjdlMjI5OTMyXzgyMQ_fac2a138-9ddf-4e22-807d-1114b727bd8f"
      unitRef="usd">2138000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90ZXh0cmVnaW9uOmRiY2EyOGU4YzU3NTRmOTdiYzY5ZjM3NjdlMjI5OTMyXzk1Mw_8bcd785d-80db-4606-83e5-03215ccb24e2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Geographic revenue information based on location of customer is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie155c69f21734a16917958178e1f51a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzItMS0xLTEtMA_b07fb71a-5e6d-4900-b16d-cc2229c84d54"
      unitRef="usd">5945000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2d6cdf8903fd44d7852fe7584e4e99cd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzItMy0xLTEtMA_f4e9c6b0-d6c7-4853-9c0f-1116ed49c70b"
      unitRef="usd">9071000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9f0989d807f24270a4bd9f5c3d8d8d32_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzMtMS0xLTEtMA_c22dd587-9be1-45a9-9dd1-1a17384897a6"
      unitRef="usd">2937000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib3552c786c174ef89dfaa1c2526fc4e1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzMtMy0xLTEtMA_15a6fcf3-1267-465c-84fa-27ed794a00e0"
      unitRef="usd">4846000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzQtMS0xLTEtMA_ef4eff3d-2552-4ff4-8d58-4267d9f15292"
      unitRef="usd">8882000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id23f8a04d968419dbd46e8d0ee3741d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDUvZnJhZzpkYmNhMjhlOGM1NzU0Zjk3YmM2OWYzNzY3ZTIyOTkzMi90YWJsZTpiOWNiOTZlOGJkYTE0NDJiODk1ZjMyMWJlMDI0N2FjOC90YWJsZXJhbmdlOmI5Y2I5NmU4YmRhMTQ0MmI4OTVmMzIxYmUwMjQ3YWM4XzQtMy0xLTEtMA_486810e6-eece-4cf6-ab3a-8157c8583445"
      unitRef="usd">13917000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i297156716d884a2da3e85659f53b94b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzY2OA_17d8db89-8273-4594-a31c-131dc79f98df">Subsequent Events&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company entered into an amended and restated underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright &amp;amp; Co., LLC ("Wainwright"), to sell 3,902 shares of the Company's common stock for public price per share of $10.25 per share, for gross proceeds of $40,000 (the "February 2021 Offering").  The Company estimates that the net proceeds from the February 2021 Offering will be approximately $36,404 after deducting underwriting discounts and commissions and estimated offering expenses. Pursuant to the Underwriting Agreement, the Company issued to certain designees of Wainwright 5-year warrants (the &#x201c;2021 Warrants&#x201d;) to purchase shares of Common Stock in an amount equal to 7.0% of the aggregate number of shares sold in the February 2021 Offering at an exercise price of $12.8125 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2021 through February&#160;25, 2021, the Company received proceeds of $1,416 from the exercise of 275 warrants and sold 78 shares of the Company's common stock under the ATM Agreement at an average price per share of $10.72 for proceeds of $664, net of commission and issuance costs. As of February 25, 2021, the Company has $6,668 available for future offerings under the prospectus filed with respect to the ATM Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i632f81a051354fdf864a43648798ddbe_D20210201-20210226"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQ2OTk_e66b59fa-22bd-4a7e-987c-58fe764dfcee"
      unitRef="shares">3902000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iaad6ab00ad864f69a9e847781dc8db64_I20210226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQ3MTQ_e021a9a0-bcb8-4e9a-81c8-dd6c84fd7b86"
      unitRef="usdPerShare">10.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i632f81a051354fdf864a43648798ddbe_D20210201-20210226"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQ2NzM_541fb296-1c7a-4a99-b811-c1af1d3783a0"
      unitRef="usd">40000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3ef9cf6430ff4f8e9422f488739fa849_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQ3MzE_acf060bc-ce84-46df-98a2-0080b834cf6b"
      unitRef="usd">36404000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="iaad6ab00ad864f69a9e847781dc8db64_I20210226"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzMyOTg1MzQ4OTU4Mzg_b96364d3-d17d-44c5-beb7-9278a877dc16">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ekso:ClassOfWarrantOrRightPercentageOfAggregateSharesSold
      contextRef="i9b5c460bf8c84b56a0349fb3c3d0e654_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzY1OTcwNjk3NzgxMDI_4047e477-6c4d-439c-baa3-8226954e8dbc"
      unitRef="number">0.070</ekso:ClassOfWarrantOrRightPercentageOfAggregateSharesSold>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i16bf31763ef74fad820cf6aed9bb0918_I20210226"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzY1OTcwNjk3NzgxMTA_ac5dbde2-adb3-4a5b-bb05-e5e64cb6a843"
      unitRef="usdPerShare">12.8125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i92564e533c5b46fca6e27927910f77db_D20210101-20210225"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzA1ODI_02923e06-1ed9-4951-956b-a4c4b7314153"
      unitRef="usd">1416000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ekso:ClassOfWarrantOrRightExercised
      contextRef="i0cb8fcd93e684118ad89bca6e3dc19c7_D20210101-20210225"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzA1ODg_7b374414-4566-44cc-810c-9974f99912f6"
      unitRef="shares">275000</ekso:ClassOfWarrantOrRightExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="idb89bd35b9ca4d7680abe71e8e1cb17e_D20210101-20210225"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQyNjQ_b77e3b17-062e-4b4f-baff-e797911bf614"
      unitRef="shares">78000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i226916c19ca6463c961b406e024eca43_I20210226"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQyNzA_87dbfeb8-c4d9-4bb2-954f-f02569c48286"
      unitRef="usdPerShare">10.72</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idb89bd35b9ca4d7680abe71e8e1cb17e_D20210101-20210225"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzQ0MjM_77403403-dce3-424b-908d-29fb4b21bf1a"
      unitRef="usd">664000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ekso:SaleOfStockValueOfSharesAvailableForFutureIssuance
      contextRef="ic513e7ac66894d34b00b95cd51300460_D20210225-20210225"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xNDgvZnJhZzo0N2Y2ZjI4N2QyNTk0NTc2YTNhNmZjODdjM2E5ZDBiOS90ZXh0cmVnaW9uOjQ3ZjZmMjg3ZDI1OTQ1NzZhM2E2ZmM4N2MzYTlkMGI5XzQ5NDc4MDIzMzc2OTU_ad364a1c-0f71-4063-bd7b-677b084db6e9"
      unitRef="usd">6668000</ekso:SaleOfStockValueOfSharesAvailableForFutureIssuance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523697523224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 19, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Ekso Bionics Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">99-0367049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1414 Harbour Way South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Richmond<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">984-1761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EKSO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,257,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,599,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001549084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s Proxy Statement for the 2021 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2020.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702015080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 12,862<span></span>
</td>
<td class="nump">$ 10,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $42 and $121, respectively</a></td>
<td class="nump">3,389<span></span>
</td>
<td class="nump">5,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,978<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,420<span></span>
</td>
<td class="nump">18,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">685<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,597<span></span>
</td>
<td class="nump">21,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,501<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">1,429<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues, current</a></td>
<td class="nump">1,496<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,974<span></span>
</td>
<td class="nump">7,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net</a></td>
<td class="nump">3,075<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">6,037<span></span>
</td>
<td class="nump">4,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">16,163<span></span>
</td>
<td class="nump">15,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 141,429 shares authorized; 8,349 and 5,795 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">204,376<span></span>
</td>
<td class="nump">190,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(847)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(199,103)<span></span>
</td>
<td class="num">(183,278)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="nump">6,797<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 20,597<span></span>
</td>
<td class="nump">$ 21,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523696691688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">141,429,000<span></span>
</td>
<td class="nump">141,429,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">8,349,000<span></span>
</td>
<td class="nump">5,795,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">8,349,000<span></span>
</td>
<td class="nump">5,795,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523700891960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 8,882<span></span>
</td>
<td class="nump">$ 13,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">3,812<span></span>
</td>
<td class="nump">7,153<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,070<span></span>
</td>
<td class="nump">6,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">7,752<span></span>
</td>
<td class="nump">11,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,474<span></span>
</td>
<td class="nump">4,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,702<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,361<span></span>
</td>
<td class="nump">23,403<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,291)<span></span>
</td>
<td class="num">(16,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_WarrantIssuanceExpense', window );">Finance cost associated with warrant issuance</a></td>
<td class="num">(329)<span></span>
</td>
<td class="num">(1,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GainLossOnWarrantLiability', window );">(Loss) gain on warrant liabilities</a></td>
<td class="num">(3,056)<span></span>
</td>
<td class="nump">6,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GainLossOnWarrantModification', window );">Loss on modification of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">990<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(2,534)<span></span>
</td>
<td class="nump">4,507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,825)<span></span>
</td>
<td class="num">(12,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(897)<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (16,722)<span></span>
</td>
<td class="num">$ (11,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share applicable to common shareholders (in dollars per share)</a></td>
<td class="num">$ (2.21)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">7,164<span></span>
</td>
<td class="nump">4,794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_GainLossOnWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_GainLossOnWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_GainLossOnWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Warrant Modification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_GainLossOnWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_WarrantIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Amount of expense incurred on issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_WarrantIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702620216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Convertible Preferred Stock</div>
</th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 2,728<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 173,962<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
<td class="num">$ (171,146)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_IssuanceOfCommonStockUnderAbstract', window );"><strong>Issuance of common stock under:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Equity financing, net</a></td>
<td class="nump">12,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">12,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Equity financing, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts', window );">Equipois sales earn-out</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut', window );">Equipois sales earn-out (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity incentive plan</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity incentive plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Matching contribution to 401(k) plan</a></td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Matching contribution to 401(k) plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">In lieu of employee cash bonus</a></td>
<td class="nump">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">In lieu of cash compensation / bonus (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">6,797<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">190,019<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(183,278)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,825)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_IssuanceOfCommonStockUnderAbstract', window );"><strong>Issuance of common stock under:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Equity financing, net</a></td>
<td class="nump">7,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">7,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Equity financing, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity incentive plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">7,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Matching contribution to 401(k) plan</a></td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Matching contribution to 401(k) plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">In lieu of employee cash bonus</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">In lieu of cash compensation / bonus (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Shares issued as a result of rounding due to reverse-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance', window );">Issuance of warrants</a></td>
<td class="num">(2,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 4,434<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 204,376<span></span>
</td>
<td class="num">$ (847)<span></span>
</td>
<td class="num">$ (199,103)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Warrant Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_IssuanceOfCommonStockUnderAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock Under</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_IssuanceOfCommonStockUnderAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Share Equiposis Sales Earn Out</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Equiposis Sales Earn Out</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121321822&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121323062&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702414984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,825)<span></span>
</td>
<td class="num">$ (12,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Changes in allowance for doubtful accounts</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Amortization of debt discount, change in contingent liability and accretion of final payment fee</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GainLossOnModificationOfOperatingLeaseLiabilities', window );">Gain on modification of operating lease liabilities</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on investment of unconsolidated affiliate</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_CommonStockContribution', window );">Common stock contribution to 401(k) plan</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,410<span></span>
</td>
<td class="nump">2,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Finance cost attributable to issuance of warrants</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GainLossOnWarrantLiability', window );">Loss (gain) on revaluation of warrant liabilities</a></td>
<td class="nump">3,056<span></span>
</td>
<td class="num">(6,376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GainLossOnWarrantModification', window );">Loss on modification of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized (gain) loss on foreign currency transactions</a></td>
<td class="num">(947)<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,754<span></span>
</td>
<td class="num">(1,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expense, operating lease right-of-use assets, and other assets, current and noncurrent</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(1,231)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and lease liabilities</a></td>
<td class="num">(876)<span></span>
</td>
<td class="num">(1,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,755)<span></span>
</td>
<td class="num">(15,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="nump">7,082<span></span>
</td>
<td class="nump">21,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="num">(1,278)<span></span>
</td>
<td class="num">(2,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment of remaining balance on long-term debt</a></td>
<td class="num">(1,512)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">3,334<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of financing costs</a></td>
<td class="nump">3,078<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,704<span></span>
</td>
<td class="nump">19,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash</a></td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">3,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of the year</a></td>
<td class="nump">10,872<span></span>
</td>
<td class="nump">7,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of the year</a></td>
<td class="nump">12,862<span></span>
</td>
<td class="nump">10,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for interest</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of warrant liability to equity upon exercise of warrants</a></td>
<td class="nump">3,976<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SharesIssuedCapitalContribution', window );">Share issuance for common stock contribution to 401(k) plan</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_TransferOfPropertyAndEquipmentFromInventory', window );">Transfer of inventory to (from) property and equipment</a></td>
<td class="nump">132<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Share issuance in lieu of cash compensation</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_OperatingLeasesRightOfUseAssetInitialRecognition', window );">Initial recognition of operating right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_OperatingLeasesLiabilityInitialRecognition', window );">Initial recognition of operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_RestrictedStockIssued', window );">Share issuance for vesting of restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent', window );">Change in deferred rent associated with ASC 842</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SalesEarnout', window );">Equipois sales earn-out</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_CommonStockContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_CommonStockContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_GainLossOnModificationOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Modification Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_GainLossOnModificationOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_GainLossOnWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_GainLossOnWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_GainLossOnWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Warrant Modification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_GainLossOnWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_OperatingLeasesIncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Increase (Decrease) In Deferred Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_OperatingLeasesIncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_OperatingLeasesLiabilityInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Liability, Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_OperatingLeasesLiabilityInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_OperatingLeasesRightOfUseAssetInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Right Of Use Asset, Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_OperatingLeasesRightOfUseAssetInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_RestrictedStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Stock Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_RestrictedStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_SalesEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_SalesEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_SharesIssuedCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_SharesIssuedCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_TransferOfPropertyAndEquipmentFromInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_TransferOfPropertyAndEquipmentFromInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=120519210&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523697926440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text">Organization<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ekso Bionics Holdings, Inc. (the "Company"), designs, develops, sells, and rents exoskeleton products to augment human strength, endurance and mobility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and persons with physical disabilities. The Company has sold and rented devices that (i) enable individuals with neurological conditions affecting gait (acquired brain injury and spinal cord injury) to rehabilitate and to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Founded in 2005, the Company is headquartered in the San Francisco Bay area and listed on the Nasdaq Capital Market under the symbol &#8220;EKSO&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all dollar and share amounts included in these notes to the consolidated financial statements are in thousands.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, the Company had an accumulated deficit of $199,103.&#160; Largely as a result of significant research and development activities related to the development of the Company&#8217;s advanced technology and commercialization of such technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. In the year ended December 31, 2020, the Company received net proceeds of $7,082 from a registered direct offering and of $3,334 from warrant exercises, and used $8,755 of cash in its operations. Cash on hand at&#160;December 31, 2020&#160;was $12,862.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to year-end through February&#160;25, 2021 the Company received estimated net proceeds of $36,404 from an underwritten public offering, $1,416 from warrant exercises, and $664 from ATM sales. Refer to Note. 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, management took several actions to alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern that existed as of the date of issuance of the December 31, 2019 consolidated financial statements, including, but not limited to, the following:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">streamlined the Company's operations and reduced its workforce by approximately 35% to lower operating expenses and reduce cash burn;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducted a registered direct offering for net proceeds of $7,082;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">paid off the entire amount of $1,512 of the Company's indebtedness to Western Alliance Bank with proceeds from a new loan of $2,000 from Pacific Western Bank. The terms of the new loan agreement include monthly interest-only payments until August 2023.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">invested in the development and reliability of its products;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restructured the Company's commercial organization and strategy which has been gaining traction; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">received clearance from the U.S. Food and Drug Administration ("FDA") for Acquired Brain Injury ("ABI") to market the Company's product to a larger patient population increasing the value proposition to its customers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes payable, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, borrowings under the Company&#8217;s new secured term loan agreement with Pacific Western Bank have a liquidity covenant requiring minimum cash on hand equivalent to the current outstanding principal balance. As of December 31, 2020, $2,000 of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of December 31, 2020 is approximately $10,862. With this unrestricted cash balance, the impact of management's actions described above, and additional cash received after year-end, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of one year from the issuance of these consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s actual capital requirements may vary significantly and will depend on many factors. The Company plans to continue its investments in its (i) sales initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation </span></div>market, (ii) research, development and commercialization activities with respect to exoskeletons for rehabilitation, and (iii) development and commercialization of able-bodied exoskeletons for industrial use. Consequently, the Company may require significant additional financing in the future, which the Company intends to raise through corporate collaborations, public or private equity offerings, debt financings, or warrant solicitations. Sales of additional equity securities by the Company could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, the Company may be required to further reduce its discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523696428056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Estimates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies and Estimates</a></td>
<td class="text">Summary of Significant Accounting Policies and Estimates<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation and Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States or U.S. GAAP. In the opinion of management, all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented have been included and are normal and recurring in nature. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year&#8217;s presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All common share and per share amounts have been adjusted to reflect the one-for-fifteen reverse stock split completed on March 24, 2020. See Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalization and Equity Structure &#8211; Reverse Stock Split</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive (loss) income as a component of stockholders&#8217; equity.  Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive (Loss) Income </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accumulated other comprehensive (loss) income consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive (loss) income presented on the consolidated balance sheets for the year ended December 31, 2020, is reflected in the table below net of tax:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on foreign currency translation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(897)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company places its cash in the custody of, financial institutions with high credit ratings. The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents or investments in money market funds as of December 31, 2020 and 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &#160;The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia.  Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2020 and 2019. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company had two customers with an accounts receivable balance totaling 10% or more of the Company&#8217;s total accounts receivable (13% and 10%, respectively), as compared with one customer at December 31, 2019 (11%). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no customers with sales of 10% or more of the Company&#8217;s total revenue for the year ended December 31, 2020, as compared with one for the year ended December 31, 2019 (15%). Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 17. Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand.&#160; Subsequent disposals of inventories are recorded as a reduction of inventory.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board ("FASB")&#160;issued Accounting Standard Update (&#8220;ASU&#8221;), No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. The Company adopted the standard effective January 1, 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. As a result, the Company no longer recognizes deferred rent on the balance sheet.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May of 2020, the Company streamlined its operations and reduced its workforce by approximately 35% to lower operating expenses and reduce cash burn. The restructuring plan was completed by the end of the second quarter of 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded restructuring expense of $244 for the year ended December 31, 2020 comprised of termination benefit costs. As of December 31, 2020, there was no accrued restructuring cost remaining on the Company&#8217;s consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTIxNDU_cd4dc075-4b7e-413d-b6dc-6727130d268c">three</span> to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the related term of the lease. The costs of repairs and maintenance are expensed when incurred, while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not be recoverable from the estimated future cash flows expected to result from the Company&#8217;s use or eventual disposition. If estimates of future undiscounted net cash flows are insufficient to recover the carrying value of the assets, the Company will record an impairment loss in the amount by which the carrying value of the assets exceeds the fair value. If the assets are determined to be recoverable, but the useful lives are shorter than originally estimated, the Company will depreciate or amortize the net book value of the assets over the newly determined remaining useful lives. None of the Company&#8217;s property and equipment or intangible assets were impaired as of December 31, 2020 and 2019. No impairment loss has been recognized in the years ended December 31, 2020 and 2019.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. The Company performs an annual impairment assessment, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill. The Company performs impairment tests using a fair value approach when necessary. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously maintained a goodwill balance as a result of a prior acquisition of intangible assets from Equipois, LLC in December 2015 consisting of mechanical balance and support arms technologies, including the rights to the ZeroG product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of declining sales and gross margin, combined with the overall uncertainty about the future of the ZeroG product line, the Company performed an impairment assessment of goodwill utilizing the simplified method, which resulted in an impairment of goodwill of $189 reducing the goodwill balance to zero. In estimating the fair value, the Company utilized a discounted cash flow model, which is dependent on a number of assumptions, including forecasted revenues and profit margins. The following table sets forth the changes to goodwill for the year ended December 31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:82.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.025%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that it may need to settle the warrants in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where there is a possibility that the Company may have to settle warrants in cash, it estimates the fair value of the issued warrants as a liability at each reporting date and record changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants have been determined using the Black-Scholes option-pricing model (the &#8220;Black-Scholes Model&#8221;) and the Binomial Lattice model (the &#8220;Lattice Model&#8221;). The Black-Scholes Model requires inputs, such as the expected volatility, expected term, exercise price, risk-free interest rate, and the value of the underlying security. The Lattice Model provides for assumptions regarding expected volatility, expected term, exercise price, risk-free interest rates, the value of the underlying security, and the probability of and likely timing of a specific event within the period to maturity. These values are subject to a significant degree of the Company&#8217;s judgment. The Company&#8217;s common stock price represents a significant input that affects the valuation of the warrants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements &#8211; Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical device segment (EksoHealth) revenue is primarily generated through the sale and rental of the EksoNR and EksoGT, associated software (SmartAssist and VariableAssist), the sale and rental of the EksoUE, the sale of accessories, and the sale of support and maintenance contracts (Ekso Care). Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company&#8217;s facility for sales of the EksoNR or EksoGT, software and accessories. Ekso Care support and maintenance contracts extend coverage beyond the Company&#8217;s standard warranty agreements. The separately priced Ekso Care contracts range from&#160;12&#160;to&#160;48 months. The Company receives payment at the inception of the contract and recognizes revenue over the term of the agreement. Revenue from medical device rentals is recognized over the rental term, typically 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s industrial device segment (EksoWorks) revenue is generated through the sale and rental of the upper body exoskeletons (EksoVest and the recently introduced EVO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company&#8217;s facility. Revenue from industrial device rentals is recognized over the rental term, typically 12 months.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Grants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for nonreciprocal government grants by applying the contributions received in accordance with guidance in ASC Topic 958-605. To determine if a grant is non-reciprocal or reciprocal and whether the application of ASC 606 is required, the Company considers whether the transfer of resources is one in which commensurate value is exchanged. If commensurate value is not exchanged for the goods or services provided, the Company assesses whether the grant is conditional or unconditional.&#160; Grants that contain both a barrier and right to return are considered conditional and revenue is deferred until such conditions are satisfied. In January 2019, the Company received a government grant from the Singapore Economic Development Board (&#8220;SEDB&#8221;) in the amount of approximately $1,500. The receipt of the funds is conditional upon certain operational milestones that must be met and maintained through December 31, 2021. Therefore, the Company has not recognized revenue related to the government grant from the SEBD nor received cash from the SEBD.  The Company expects to recognize revenue related to this grant in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist of costs incurred for internal research and development activities. These costs primarily include salaries and other personnel-related expenses, contractor fees, legal fees associated with developing and maintaining intellectual property, prototype materials, facility costs, supplies, and depreciation of equipment associated with the design and development of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. Under this method, income tax expense or benefit is recognized for the amount of taxes payable or refundable for the current year and for deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company's consolidated financial statements or tax returns. The Company accounts for any income tax contingencies in accordance with accounting guidance for income taxes. The measurement of current and deferred tax assets and liabilities is based on provisions of currently enacted tax laws. The effects of any future changes in tax laws or rates have not been considered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the preparation of the Company's consolidated financial statements included herein, the Company estimates its income taxes and tax contingencies in each of the tax jurisdictions in which it operates prior to the completion and filing of its tax returns. This process involves estimating actual current tax expense together with assessing temporary differences resulting from differing treatment of items, such as deferred revenue, for tax and accounting purposes. These differences result in net deferred tax assets and liabilities. The Company must then assess the likelihood that the deferred tax assets will be realizable, and to the extent they believe that realizability is not likely, the Company must establish a valuation allowance. In assessing the need for any additional valuation allowance, the Company considers all the evidence available to it, both positive and negative, including historical levels of income, legislative developments, expectations and risks associated with estimates of future taxable income, and ongoing prudent and feasible tax planning strategies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock-based compensation expense for certain stock-based awards made to employees and directors based on the estimated fair value of the award on the date of grant using the Black-Scholes Model and recognizes the fair value on a straight-line basis over the requisite service periods of the awards. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s determination of the fair value of stock options on the date of grant using the Black-Scholes Model is affected by the Company&#8217;s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company&#8217;s stock price, volatility over the term of the awards, and actual and projected employee stock option exercise behaviors (expected term). Due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the Company adopted the simplified method of estimating the expected term pursuant to SEC Staff Accounting Bulletin Topic 14. On this basis, the Company estimated the expected term of options granted by taking the average of the vesting term and the contractual term of the option.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of restricted stock units (&#8220;RSUs&#8221;) is determined at the date of grant using the Company&#8217;s closing stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. For awards with performance-based conditions, at the point that it becomes probable that the performance conditions will be met, the Company records a cumulative catch-up of the expense from the grant date to the current date, and then amortizes the remainder of the expense over the remaining service period. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has, from time to time, modified the terms of its stock options to employees. The Company accounts for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification.&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2022 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Adopted in 2020</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates the computation of the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will record a goodwill impairment charge based on the excess of a reporting unit&#8217;s carrying amount over its fair value. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company adopted the new guidance as of January 1, 2020, which reduced the complexity surrounding the evaluation of goodwill for impairment. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard modifies the disclosure requirements on fair value measurements in Topic 820 by removing the requirement to disclose the reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The standard expands the disclosure requirements for Level 3 fair value measurement, primarily focused on changes in unrealized gains and losses included in other comprehensive income. The amendments in this update became effective for the Company in the first quarter of 2020. The Company adopted ASU 2018-03 as of January 1, 2020. The adoption of this ASU did not have a material impact on the Company's consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523694146872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share of Common Stock</a></td>
<td class="text">Net Loss Per Share of Common Stock<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted average number of shares of common stock, adjusted to include conversion of certain stock options and warrants for common stock and release of common stock in connection with restricted stock units during the period, as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.653%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net loss used for dilution calculation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,825)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive weighted-average number of shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,794&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.653%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants for common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523693009400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Unconsolidated Affiliate<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment in Unconsolidated Affiliate</a></td>
<td class="text">Investment in Unconsolidated Affiliate<div style="padding-right:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company, Zhejiang Youchuang Venture Capital Investment Co., Ltd and another partner (collectively, the &#8220;JV Partners&#8221;) received notice from the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) in connection with its review of the Company&#8217;s and the JV Partners&#8217; investment in Exoskeleton Intelligent Robotics Co. Limited (the &#8220;China JV&#8221;). The notice stated that CFIUS&#8217;s prior national security concerns regarding the China JV could not be mitigated. In connection with such determination, on July 13, 2020, the Company and the JV Partners entered into a National Security Agreement (&#8220;NSA&#8221;), which, among other things, requires the termination of the Company&#8217;s agreements and role with the China JV. The Company intends to work cooperatively with the JV Partners and CFIUS to implement the terms of the NSA. On August 12, 2020, the Company and the JV Partners agreed to terminate the agreements underlying the China JV. As of December 31, 2020, all agreements related to the China JV had been terminated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the above, during the year ended December 31, 2020, the Company recorded a $66 loss on investment in unconsolidated affiliate in the consolidated statements of operations and comprehensive loss related to the write-off of previously recorded direct costs related to establishing the China JV.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523694116616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s fair value hierarchies for its financial assets and liabilities which require fair value measurement on a recurring basis are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent success fee liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020 and 2019, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and the valuation techniques used did not change compared to the Company&#8217;s established practice.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of Company&#8217;s Level 3 financial liabilities during the year ended December 31, 2020,&#160;which were measured at fair value on a recurring basis:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"><tr><td style="width:1.0%"/><td style="width:68.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.467%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant<br/>Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent<br/>Success&#160;Fee<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial fair value of warrants in connection with June 2020 financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of warrants issued in June 2020, December 2019, May 2019 financing, and December 2015 equity financings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liability to equity upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on revaluation of contingent liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,037&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13 in the notes to consolidated financial statements under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalization and Equity Structure &#8211; Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a description of the warrants accounted for as a liability, including the method and inputs used to estimate their fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523693009400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the following five steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not directly observable, the Company estimates the selling price based on market conditions and entity-specific factors including features and functionality of the product and/or services, the geography of the Company&#8217;s customers, type of the Company&#8217;s markets. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Timing of revenue recognition may differ from the timing of invoicing to customers and receipt of payment. For the sale of its products, the Company generally recognizes revenue at a point in time through the ship-and-bill performance obligations. For the rental of its products, the Company generally recognizes revenue over the rental term commencing upon the completion of customer training.  For service agreements, the Company generally invoices customers at the beginning of the coverage period and records revenue related to the billed amounts over time, equivalent to the coverage period of the maintenance and support contract.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts (Ekso Care), but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred extended maintenance and support</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred device, rental revenues and advances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues, non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,789&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue activity consisted of the following for the year ended December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferral of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company&#8217;s deferred revenue was&#160;$3,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company expects to recognize approximately&#160;$1,496&#160;of the deferred revenue during&#160;2021,&#160;$908&#160;in&#160;2022, and&#160;$898 thereafter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to deferred revenue, the Company has non-cancellable backlog of $515&#160;related to its contracts for rental units with its customers. These rental contracts typically have 12-month lease terms and rental income is recognized on a straight-line basis over the lease term.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, accounts receivable, net of allowance for doubtful accounts, were $3,389 and $5,208, respectively, and are included in current assets on the Company&#8217;s consolidated balance sheets. The allowance for doubtful accounts reflects the Company&#8217;s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 90 days.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company&#8217;s revenue by major source for the year ended December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.935%"><tr><td style="width:1.0%"/><td style="width:35.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.483%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoHealth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoWorks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company&#8217;s revenue by major source for the year ended December 31, 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"><tr><td style="width:1.0%"/><td style="width:35.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoHealth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoWorks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,957&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,917&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523694116616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company-owned fleet</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, office and leased equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tools, molds, dies and jigs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and peripherals</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense of property and equipment, net totaled $620 and $690 for the years ended December 31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523693882552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warranty</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of devices generally include an initial warranty for parts and services for one year in the Americas, two years in Europe, the Middle East, Africa, and one or two years in the Asia Pacific region.  A liability for the estimated cost of product warranty is established at the time revenue is recognized based on the historical experience of known product failure rates and expected material and labor costs to provide warranty services. Specific additional warranty accruals may be made if unforeseen technical problems arise. Alternatively, if estimates are determined to be greater than the actual amounts necessary, a portion of the liability may be reversed in future periods.&#160;Warranty costs are reflected in the consolidated statements of operations and comprehensive loss as a component of costs of revenue. The current portion of the warranty liability is classified as a </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of accrued liabilities, while the long-term portion of the warranty liability is classified as a component of other non-current liabilities in the consolidated balance sheets.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.544%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warranty</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for estimated future expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523700867912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes payable, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Notes Payable, Net</a></td>
<td class="text">Notes payable, net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WAB and PWB Term Loans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WAB Term Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company entered into a loan agreement with Western Alliance Bank ("WAB loan") and received a loan in the principal amount of $7,000 that&#160;bore interest on the outstanding daily balance at a floating per annum rate equal to the 30-day U.S. LIBOR plus 5.41%. The Company was required to pay accrued interest on the WAB loan on the first day of each month through and including January 1, 2018. Commencing on February 1, 2018, the Company was required to make equal monthly payments of principal, together with accrued and unpaid interest maturing on January 1, 2021. On April 29, 2020 the Company entered into a second amendment to the December 2016 WAB loan agreement to defer principal payments for three months beginning in May 2020, with adjustments when the principal payments resumed on August 1, 2020. During the three-month deferral period the Company was required to make interest only payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final payment fee, debt issuance costs, and the initial fair value of the success fee combined with the stated interest resulted in an effective interest rate for the WAB loan of 8.49% for the year ended December 31, 2020. The final payment fee, initial fair value of the success fee, and debt issuance costs were accreted/amortized to interest expense using the effective interest method over the life of the loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PWB Term Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into a new loan agreement (the "PWB Loan Agreement") with a different lender, Pacific Western Bank, and received a loan in the principal amount of $2,000 (the "PWB Term Loan") that bears interest on the outstanding daily balance at a rate equal to the greater of: (a) 0.50% above the variable rate of interest announced by the lender as its &#8220;prime rate&#8221; then in effect; or (b) 4.50%. The PWB Loan Agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the PWB Term Loan were used to pay off the entire amount of the Company's indebtedness on the WAB loan which amounted to $1,512. Pursuant to the PWB Loan Agreement, the remainder of the PWB Term Loan proceeds may be used for general corporate purposes which totaled $480, net of debt discounts and issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay accrued interest on the current loan on the 13th day of each month through and including August 13, 2023. The principal balance of the PWB Term Loan matures on August 13, 2023, at which time all unpaid principal and accrued and unpaid interest shall be due and payable in full. The interest rate of the PWB Term Loan is subject to increase in the event of late payments and after occurrence of and during the continuation of an event of default. Upon maturity, all unpaid principal and accrued and unpaid interest shall be due and payable in full. The Company may elect to prepay the PWB Term Loan at any time, in whole or in part, without penalty or premium.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of December 31, 2020. On December 31, 2020, with cash on hand of $12,862, the Company was compliant with this liquidity covenant and all other covenants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 4.64% for the year ended December 31, 2020. The debt issuance costs will be amortized to interest expense using the effective interest method over the life of the loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents scheduled principal payments of the Company's note payable as of December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:87.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 - 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less final payment fee, discount and issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program Loan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 20, 2020, the Company received an unsecured loan in the principal amount of $1,086 under the Paycheck Protection Program (the &#8220;PPP&#8221;) administered by the U.S. Small Business Administration, or the SBA, pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;), or the PPP loan.  The PPP loan provides for an interest rate of 1.00% per year, and matures two years after the date of initial disbursement. The terms of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, or the PPP Flexibility Act, which was enacted on June 5, 2020.  Based on management's interpretation of the the PPP Flexibility Act, the Company expects to begin making principal and interest payments on the PPP loan beginning in 2022. The overall timing of payments with respect to the amounts of principal and interest due could change based on the ultimate determination of what may or may not be forgiven.  The PPP loan may be used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments, mortgage interest payments and interest payments on any other debt obligation that were incurred before February 15, 2020. Under the terms of the CARES Act and the PPP Flexibility Act, the Company may apply for and be granted forgiveness for all or a portion of loan granted under the PPP loan, with such forgiveness to be determined, subject to limitations (including where employees of the Company have been terminated and not re-hired by a certain date), based on the use of the loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness may also be subject to further requirements in regulations and guidelines adopted by the SBA. While the Company currently believes that the majority of the use of the PPP loan proceeds will meet the conditions for forgiveness under the PPP, no assurance is provided that the Company will obtain partial forgiveness of the loan.  Terms of the loan may change subject to future enactments relating to the PPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The follow table presents the scheduled principal payments of the Company's PPP loan note payable as of December 31, 2020, shown if the loan is not forgiven:</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:87.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523694200376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Lease Obligations</a></td>
<td class="text">Lease Obligations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a five-year operating lease agreement for its headquarters and manufacturing facility in Richmond, California, or the Richmond Lease, which expires in May 2022, with no further options to extend or terminate. The lease includes non-lease components (i.e. common area maintenance costs) that are paid separately from rent based on actual costs incurred. In June 2020, the Company entered into an amendment to the Richmond Lease to make a one-time payment of $300 to cover its remaining lease obligations for the remainder of 2020, resulting in a $48 abatement and a lease payment deferral of $79 to be paid in equal monthly installments in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's five-year operating lease agreement for its European operations office in Hamburg, Germany expires in July 2022. It has an option to extend for another five-year term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through April 2019, the Company had an unoccupied leased sales office in Freiburg, Germany, which had a lease term that expired in December 2020. In April 2019, the Company entered an agreement with the lessor of the Freiburg office releasing the Company from future lease payments after April 30, 2019.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future lease payments as of December 31, 2020 are as follows, which are presented as lease liabilities on the Company&#8217;s consolidated balance sheets:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.497%"><tr><td style="width:1.0%"/><td style="width:62.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense under the Company&#8217;s operating leases was $537 and $551, for the years ended December 31, 2020 and 2019, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Practical Expedients</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.</span></div>As part of the transition to ASC 842, the Company elected to use the modified retrospective transition method with the new standard being applied as of the January 1, 2019 adoption date. Additionally, the Company has elected, as of the adoption date, not to reassess whether expired or existing contracts contain leases under the new definition of a lease; the lease classification for expired or existing leases; or whether previously capitalized initial direct costs would qualify for capitalization under ASC 842.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523694096696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanThe Company administers a 401(k) retirement plan, or the 401(k) Plan, in which all employees are eligible to participate. Each eligible employee may elect to contribute to the 401(k) Plan. The Company has made matching contributions in the form of shares of the Company's common stock to the 401(k) Plan in an amount equal to 50% of employee contributions (up to the statutory limit), subsequent to year-end. The expense related to the contribution was $169 and $142 for the years ended December 31, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523698920440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the Company&#8217;s directors, Dr. Ted Wang, is the founder, general partner and Chief Investment Officer of Puissance Capital Management LP, or Puissance Capital, which is an affiliate of Puissance Cross-Border Opportunities II LLC, one of the Company&#8217;s largest stockholders until November 2020. Prior to Dr. Wang&#8217;s appointment to the Board in connection with the Rights Offering in September 2017, the Company entered into a one-year consulting agreement with Angel Pond Capital LLC, or Angel Pond, an entity solely owned and managed by Dr. Wang and affiliated with Puissance Capital. Angel Pond provides consulting services to the Company with respect to strategic positioning in the Asia Pacific region, including introduction to potential strategic partners and the development of strategic partnerships for the sale and manufacture of the Company&#8217;s products in that market. During the year ended December&#160;31, 2019, Angel Pond provided consulting services amounting to $30 during, which was expensed in the consolidated statement of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company sold EksoVest raw material inventory and tooling to the China JV for</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$45.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695262344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and Equity Structure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizationLongtermDebtAndEquityAbstract', window );"><strong>Capitalization, Long-term Debt and Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capitalization and Equity Structure</a></td>
<td class="text">Capitalization and Equity Structure<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the close of the stock market on March 24, 2020, the Company effected a 1-for-15 reverse split of its common stock (the "Reverse Stock Split"). As a result, all common stock share amounts included in this filing have been retroactively reduced by a factor of fifteen, rounded up to the nearest whole share, and all common stock per share amounts have been increased by a factor of fifteen, with the exception of the Company's common stock par value and the Company's authorized shares. Amounts affected include common stock outstanding, restricted stock units, common stock underlying stock options and warrants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on September 16, 2019, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) informing the Company that because the closing bid price for the Company&#8217;s common stock listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days, the Company did not meet the minimum closing bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split was effected in order to raise the per share trading price of its common stock above $1.00 and regain compliance with Nasdaq&#8217;s listing requirements. On April 7, 2020, the Company regained compliance with the minimum bid price requirement required by the Nasdaq listing rules.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s authorized capital stock at December 31, 2020 consisted of 141,429 shares of common stock and 10,000 shares of preferred stock. The authorized capital was not reduced in connection with the Reverse Stock Split. At December 31, 2020, there were 8,349 shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of outstanding shares of common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the Board of Directors may determine. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting for the election of directors. The common stock is not entitled to preemptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of the Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of the common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. Each outstanding share of common stock is duly and validly issued, fully paid, and non-assessable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2020 Common Stock and Warrants to Purchase Common Stock Offering</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a securities purchase agreement, or the June 2020 Purchase Agreement, with certain purchasers. Pursuant to the June 2020 Purchase Agreement, the Company sold in a registered direct offering, or the June 2020 Offering, an aggregate of 1,748 shares of its common stock. Pursuant to such agreement, the Company also sold, in a concurrent private placement offering, warrants to purchase 874 shares of its common stock, or the June 2020 Investor Warrants. The gross proceeds of the June 2020 Offering and the concurrent private placement offering were $7,890, the June 2020 Gross Proceeds. Each June 2020 Investor Warrant has an exercise price of $5.18 per share, subject to adjustment in certain circumstances, and is exercisable immediately and will expire five and one-half years from issuance, or on December 10, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As compensation for services provided by the placement agent for the June 2020 Offering, or the Placement Agent, the Company paid a cash fee equal to 7.0% of the June 2020 Gross Proceeds ($552) and a management fee equal to 1.0% of the June 2020 Gross Proceeds ($79), and issued, in a concurrent private placement offering, warrants to purchase shares of the Company's common stock, or the June 2020 Placement Agent Warrants, in an amount equal to up to 7.0% of the aggregate number of shares of common stock sold in the June 2020 Offering, or 122 shares in the aggregate, in substantially the same form as the June 2020 Investor Warrants, except that the June 2020 Placement Agent Warrants will expire five years from the effective date of the June 2020 Offering, or on June 7, 2025, and have an exercise price per share equal to $5.64. In connection with the June 2020 Offering, the Company also incurred $98 in other expenses of the Placement Agent paid for or reimbursed by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the $7,890 in proceeds, $2,650 was allocated to the June 2020 Investor Warrants and June 2020 Placement Agent Warrants, or, collectively, the June 2020 Warrants, based on the fair value method, with the remaining proceeds of $5,240 allocated to the common stock shares sold in the June 2020 Offering. In connection with the June 2020 Offering and concurrent private placement offerings, the Company incurred approximately $1,117 in direct financing costs, including a fair value of $309 of June 2020 Placement Agent Warrants. Financing costs of $808, excluding the fair value of the June 2020 Placement Agents Warrants, were allocated on the fair value basis between the common stock shares sold in the June 2020 Offering and the June 2020 Warrants, as follows: $329 was allocated to the June 2020 Warrants and expensed immediately in other income (expense), net in the accompanying consolidated statements of operations and comprehensive income (loss) and $479 was allocated to the common stock shares sold in the June 2020 Offering and recorded as a reduction to additional paid in capital. The direct financing cost of $309 associated with the June 2020 Placement Agent warrants was also allocated to the common stock shares sold in the June 2020 Offering and recorded as a reduction to additional paid in capital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At the Market Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright &amp; Co., LLC (the "Agent"), under which the Company may issue and sell shares of its common stock, from time to time, to or through the Agent. Offers and sales of shares of common stock by the Company through the Agent may be made by any method deemed to be an &#8220;at the market offering&#8221; as defined under SEC Rule 415 or in privately negotiated transactions, subject to certain conditions. Such shares may be offered pursuant to the registration statement on Form S-3 (File No. 333-239203) (the &#8220;Registration Statement&#8221;), which was declared effective by the SEC on June 26, 2020, and a related prospectus supplement filed with the SEC on October 9, 2020 (the &#8220;ATM Prospectus&#8221;). Pursuant to the Registration Statement and the ATM Prospectus, shares having an aggregate offering price of up to $7,500 may be offered and sold, subject to certain SEC rules limiting the amount of shares of the Company&#8217;s common stock that may be sold by the Company under the Registration Statement. Under the ATM Agreement, shares of the Company's common stock may not be sold for a price lower than $6.75 per share.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement with Cantor Fitzgerald &amp; Co. (the "Cantor Agreement"). Prior to entering into the ATM Agreement, the Company terminated the Cantor Agreement in September 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not sell any shares of common stock under the Cantor Agreement or the ATM Agreement during the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may issue shares of preferred stock from time to time in one or more series, each of which will have such distinctive designation or title as shall be determined by its Board of Directors and will have such voting powers, full or limited, or no voting powers, and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated in such resolution or resolutions providing for the issue of such class or series of preferred stock as may be adopted from time to time by the Board of Directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant shares outstanding as of December 31, 2019 and December 31, 2020 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020 Investor Warrants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020 Placement Agent Warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Placement Agent Warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2019 Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Information Agent Warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-2014 warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9-10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(723)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2020 Investor Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company issued the June 2020 Investor Warrants, exercisable for up to 874 shares of the Company&#8217;s common stock at an exercise price of $5.18 per share. The June 2020 Warrants were issued as exercisable immediately, and will expire five and one-half years from the date of issuance, or on December 10, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the June 2020 Investor Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its June 2020 Investor Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the June 2020 Investor Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company&#8217;s common stock determined according to a formula set forth in the June 2020 Investor Warrant. The June 2020 Investor Warrants will be automatically exercised on a cashless basis on their expiration date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2020 Investor Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants. During the year ended December 31, 2020, 477 shares of the June 2020 Warrants were exercised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2020 Investor Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the June 2020 Investor Warrants, as defined in the June 2020 Investor Warrants, the holders of the June 2020 Investor Warrants will be entitled to receive upon exercise of the June 2020 Investor Warrants the kind and amount </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of securities, cash or other property that the holders would have received had they exercised the June 2020 Investor Warrants immediately prior to such fundamental transaction. Alternatively, the Company or any successor entity will, at the option of a holder of a June 2020 Investor Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder&#8217;s June 2020 Investor Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder&#8217;s June 2020 Investor Warrant. Because of this put-option provision, the June 2020 Investor Warrants are classified as a liability and are marked to market at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant liability related to the June 2020 Investor Warrants is measured at fair value upon issuance and at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Investor Warrants:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"/><td style="width:62.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 10, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.94</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2020 Placement Agent Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company issued the June 2020 Placement Agent Warrants, exercisable for up to 122 shares of the Company&#8217;s common stock, to the placement agent for such offering. The June 2020 Placement Agent Warrants have substantially the same form as the June 2020 Investor Warrants, including the put option described above, except that they have an exercise price per share equal to $5.64, subject to adjustment in certain circumstances, and will expire on June 7, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the put-option provision in the June 2020 Placement Agent Warrants, these warrants are classified as a liability and are marked to market at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant liability related to the June 2020 Placement Agent Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Placement Agent Warrants:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"/><td style="width:62.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 10, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.44</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2019 Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pursuant to a securities purchase agreement (the "December 2019 Offering") the Company issued warrants (the "December 2019 Warrants") to purchase 556 shares of common stock. The December 2019 Warrants are currently exercisable have an exercise price of $8.10 per share, and will expire five years from the date they initially became exercisable, or on June 21, 2025. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the December 2019 Warrants, the Company or any successor entity will, at the option of a holder of a December 2019 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder&#8217;s December 2019 Warrant by paying to such holder an amount of cash equal to the Black-</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scholes value of the remaining unexercised portion of such holder&#8217;s December 2019 Warrant within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF8xMjQvZnJhZzowNzY2NzM3MzVmMjk0MWIyODkxNjc5NjIzYTEzZWYyNi90ZXh0cmVnaW9uOjA3NjY3MzczNWYyOTQxYjI4OTE2Nzk2MjNhMTNlZjI2XzM4NDgyOTA3NTAwMTE_96686e94-4d73-4fcb-ac01-69c8e1bec88a">five</span> trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the December 2019 Warrants are classified as a liability and are marked to market at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant liability related to the December 2019 Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Warrants:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:503.25pt"><tr><td style="width:1.0pt"/><td style="width:318.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2019 Placement Agent Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, in connection with the December 2019 Offering, the Company issued warrants to purchase 52 shares of the Company&#8217;s common stock to the placement agent for such offering (the "December 2019 Placement Agent Warrants"). The December 2019 Placement Agent Warrants have substantially the same form as the December 2019 Warrants, except that they have an exercise price per share equal to $8.44, subject to adjustment in certain circumstances, and will expire on December 18, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant liability related to the December 2019 Placement Agent Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Placement Agent Warrants:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:503.25pt"><tr><td style="width:1.0pt"/><td style="width:318.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.97</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has assessed that the likelihood of a Change of Control (as defined in the December 2019 Placement Agent Warrants), occurring during the term of the December 2019 Placement Agent Warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the warrants fair value is nominal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2019 Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, pursuant to an underwriting agreement, (the "May 2019 Offering"), the Company issued warrants (the "May 2019 Warrants") to purchase 444 shares of common stock. The May 2019 Warrants are currently exercisable and have a current exercise price of $3.52 per share, and will expire five years from the date of their issuance, or on May 24, 2024. The May 2019 Warrants contain a price protection feature, pursuant to which, subject to certain exceptions, if shares of common stock are sold or issued in the future, or securities convertible or exercisable for shares of the Company&#8217;s common stock are sold or issued in the future, for consideration, or with an exercise price or conversion price, as applicable, per share less than the exercise price per share then in effect for the May 2019 Warrants, the exercise price of the May 2019 Warrants is reduced to the consideration paid for, or the exercise price or conversion price of, as the case may be, the securities issued in such offering. Pursuant to this provision, in connection with the June 2020 Offering, the exercise price of the May 2019 Warrants was reduced to $3.52 per share, being the amount that is equal to the lower of (x) the consideration paid for the securities issued in the June 2020 Offering, or $4.51 per share, (y) the lowest exercise price of the June 2020 Warrants, or $5.18, and (z) the lowest one-day volume-weighted average price of the Company&#8217;s Common Stock on the Nasdaq Capital Market as measured each day during </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the five trading day period starting on June 8, 2020, rounded to the nearest share, or $3.52. During the year ended December 31, 2020, 246 shares of the May 2019 warrants were exercised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the Company effects or enters into any issuance of common stock or options or convertible securities exercisable for or convertible into common stock at a price which varies or may vary with the market price of the shares of the Company's common stock, subject to certain exceptions, a May 2019 Warrant holder may, at the time of exercise of the holder&#8217;s warrant, elect to exercise the warrant at such variable price. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The May 2019 Warrants include a put option, whereby while the May 2019 Warrants are outstanding, if the Company enters into a Change of Control, as defined in the May 2019 Warrants, the Company or any successor entity will, at the option of a 2019 Warrant holder exercise within 90 days after the public disclosure of the Change of Control transaction, purchase such holder&#8217;s May 2019 Warrants by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such warrants on the later date of consummation of the Change of Control transaction or two trading days after the notice of such request. Because of this put option provision, the May 2019 Warrants are classified as a liability and are marked to market at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant liability related to the May 2019 Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in a combination of the Black-Scholes Model and the Lattice Model to measure the fair value of the May 2019 Warrants:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:318.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:98.50pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has assessed that the likelihood of a Change of Control occurring during the term of the warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the May 2019 Warrants fair value is nominal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Information Agent Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, in connection with a rights offering in August 2017, the Company issued warrants (the "2017 Information Agents Warrants") to purchase 13 shares of the Company&#8217;s common stock to an information agent. The 2017 Information Agent Warrants had an exercise price of $22.50 per share and became exercisable immediately upon issuance and remained exercisable until September 13, 2020. These warrants were recorded in stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet. These warrants expired during the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, the Company issued warrants (the "2015 Warrants") to purchase 141&#160;shares which are currently exercisable with a current exercise price of&#160;$41.25&#160;per share. The 2015 Warrants contained a put-option provision. Under this provision, while the 2015 Warrants were outstanding, if the Company entered into a Fundamental Transaction, as defined in the 2015 Warrants, the Company or any successor entity shall, at the option of each warrant holder, exercisable at any time concurrently with or within 30 days after the consummation of the Fundamental Transaction, purchase the warrant from the holder exercising such option by paying to the holder an amount of cash equal to the Black-Scholes Model value of the remaining unexercised portion of such holder&#8217;s warrant on the date of the consummation of the Fundamental Transaction. Because of this put-option provision, the 2015 Warrants were classified as a liability and are marked to market at each reporting date. Through December 31, 2019,&#160;35&#160;shares of the 2015 Warrants were exercised. During the year ended December 31, 2020, none of the 2015 Warrants were exercised. In the year ended December 31, 2019, the Company recorded a $257 loss on the modification of these warrants related to an amendment which reduced the exercise price of the warrants. These warrants expired during the year ended December 31, 2020. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-2014 Merger Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase preferred stock of Ekso Bionics Inc. outstanding prior to the Merger were converted into warrants to purchase 6 shares of common stock of the Company in connection with the Merger (the "Merger Warrants"). As a result of the May 2019 Offering, which was a firm commitment underwritten public offering, the Merger Warrants expired, in accordance with their terms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationLongtermDebtAndEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationLongtermDebtAndEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523694084632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, prior to the Merger, the Board of Directors and a majority of the stockholders adopted the 2014 Equity Incentive Plan, or the 2014 Plan, allowing for the issuance of 137 shares of common stock. The 2014 Plan has since been amended and restated with approval by the stockholders to increase the maximum number of shares issuable, as shown in the table below:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:422.25pt"><tr><td style="width:1.0pt"/><td style="width:298.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:120.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original share pool</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2017 increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2017 increase (ratified in June 2018)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020 increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2020 increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share authorized for grant as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the total shares authorized for grant under the 2014 Plan was&#160;1,974, of which 1,113 were available for future grants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2014 Plan, the Board of Directors may award stock options, restricted stock, restricted stock units, stock appreciation rights and dividend equivalent rights having either a fixed or variable price related to the fair market value of the shares and with an exercise or conversion privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions or any other security with the value derived from the value of the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant under the 2014 Plan was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:422.25pt"><tr><td style="width:1.0pt"/><td style="width:298.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:120.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares Available For Grant</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share pool increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors may grant stock options under the 2014 Plan at a price of not less than 100% of the fair market value of the Company&#8217;s common stock on the date the option is granted. The maximum term of an incentive stock option granted to participants may not exceed ten years. Subject to the limitations discussed above, the Board of Directors determines the term and exercise or purchase price of other awards granted under the 2014 Plan. The Board of Directors also determines the terms and conditions of awards, including the vesting schedule and any forfeiture provisions. Options granted under the 2014 Plan vest upon the passage of time, generally four years, or upon the attainment of certain performance criteria established by the Board of Directors. The Company may grant options to purchase common stock to non-employees for advisory and consulting services. Upon exercise of a stock option, the Company issues new shares of common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity during the year ended December 31, 2020 is presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at year end</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received $0 in cash from exercised stock options. The intrinsic value of the options exercised totaled $0 and $233, for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted for the years ended&#160;December 31, 2020 and 2019 was $4.42 and $10.20, respectively. The total grant date fair value of stock option vested during the years ended December 31, 2020 and 2019 was $1,900 and $2,602, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, total unrecognized compensation cost related to unvested stock options was $2,203. This amount is expected to be recognized as stock-based compensation expense in the Company&#8217;s consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of 2.0 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding as of December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of<br/>Exercise<br/>Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.55 - $9.15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.95 - $26.85</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$27.30 - $56.70</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60.00 - $229.95</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense using the straight-line method over the requisite service period. The share fair value of each stock option was determined on the date of grant using the Black-Scholes Model under the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"/><td style="width:62.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44% - 1.65%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67% - 2.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27 - 6.08</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%-102%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%-103%</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues RSUs to employees and non-employee service providers. Each RSU represents the right to receive one share of the Company&#8217;s common stock upon vesting and subsequent settlement. The fair value of RSUs is determined based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity for the year ended December 31, 2020 is summarized below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Grant-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant-date fair value of RSUs&#160;that vested during the year ended December 31, 2020 was $251. As of December 31, 2020, $741 of total unrecognized compensation expense related to unvested RSUs was expected to be recognized over a weighted average period of 2.20 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is included in the consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending upon the nature of services provided. Stock-based compensation expense related to stock options and RSUs granted to employees and non-employees was as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"/><td style="width:66.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.388%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an Employee Stock Purchase Plan, or ESPP. Under the ESPP, the Company has 500 shares of common stock reserved for issuance, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 25% of their eligible compensation, subject to any plan limitations. The ESPP provides for six-month offering periods. At the end of each offering period, employees can purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of December 31, 2020, the Company had not initiated employee enrollment to the plan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695286216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of pre-tax loss for the years ended December 31, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"/><td style="width:66.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,954)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,321)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,811)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,825)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,132)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no current or deferred federal and state income tax expense or benefit for the years ended December 31, 2020 and 2019 because the Company generated net operating losses, and currently management does not believe it is more likely than not that the net operating losses will be realized. The Company&#8217;s non-U.S. tax obligation is primarily for business activities conducted through Germany and Singapore for which taxes were included in other expense, net for the years ended December 31, 2020 and 2019 and determined to be immaterial and accordingly, such amounts were excluded from the following tables.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) for the years ended December 31, 2020 and 2019 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"><tr><td style="width:1.0%"/><td style="width:65.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on warrant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences and related deferred tax assets and liabilities as of December 31, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of the Company&#8217;s net deferred tax assets. The Company primarily considered such factors as the Company&#8217;s history of operating losses, the nature of the Company&#8217;s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. The Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance was established and no deferred tax assets were shown in the accompanying consolidated balance sheets. The valuation allowance increased by $3,192 and $3,899 in the years ended December 31, 2020 and December 31, 2019, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For tax years beginning after December 31, 2018, the Global Intangible Low-taxed Income ("GILTI") took effect.  Due to the aggregated losses of the foreign subsidiaries, there was no GILTI inclusion for the years ended December 31, 2020 and December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020 the U.S. enacted the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). On December 21, 2020, The U.S. Congress passed the Consolidation Appropriations Act, 2021 (the CAA Act).  We have evaluated the provisions of the CARES Act and CCA Act and determined that it did not result in a significant impact on our tax provision.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 29, 2020 California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of California net operating losses and limits the use of California research tax credits for tax years beginning in 2020 and before 2023.  The suspension of net operating losses and the restriction of research tax credits  did not result in a significant impact on the value of our deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 the Company had federal net operating loss carryforwards of $164,296. The federal net operating loss carryforwards of $120,792 generated before January 1, 2018 will begin to expire in 2027, and $43,503 will carryforward indefinitely but are subject to the 80% taxable income limitation. The Company also had federal research and development tax credit carryforwards of $1,943 that will expire beginning in 2031, if not utilized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had state net operating loss carryforwards of $106,955, which will begin to expire in 2028. The Company also had state research and development tax credit carryforwards of $641, which have no expiration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had foreign net operating loss carryforwards of $9,655. The foreign net operating loss carryforwards do not expire.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the Company&#8217;s net operating losses and credit carryforwards may be subject to annual limitations in the event of a Section 382 ownership change. Such future limitations could result in the expiration of net operating losses and credit carryforwards before utilization as a result of such an ownership change.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:87.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase of unrecognized tax benefits taken in prior years</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase of unrecognized tax benefits related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is able to recognize these uncertain tax positions, the unrecognized tax benefits would not impact the effective tax rate if the Company applies a full valuation allowance against the deferred tax assets, as provided in the Company&#8217;s current policy.</span></div>The Company had not incurred any material tax interest or penalties as of December 31, 2020. The Company does not anticipate any significant change within 12&#160;months of this reporting date of its uncertain tax positions. The Company is subject to taxation in the United States and various state jurisdictions, Germany, and Singapore. There are no ongoing examinations by taxing authorities at this time. The Company&#8217;s tax years 2007 through 2020 will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss credits. The Company&#8217;s 2016 to 2020 tax years will remain open for examination by the German tax authority for four years from the end of the year in which the applicable return was filed. The Company&#8217;s 2018 to 2020 tax years will remain open for examination by the Singapore tax authority for four years from the date of  the applicable assessment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695443560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Contracts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two license agreements with the Regents of the University of California to maintain exclusive rights to patents. The Company is required to pay 1% of net sales of licensed medical devices sold to entities other than the U.S. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government. In addition, the Company is required to pay 21% of consideration collected from any sub-licensee for the grant of the sub-license. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with acquisition of Equipois, LLC ("Equipois"), the Company assumed the rights and obligations of Equipois under a license agreement with the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants the Company an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, the Company is required to pay the developer a single-digit royalty on net receipts, subject to a $50 annual minimum royalty requirement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling&#160;$396&#160;as of&#160;December 31, 2020, which is expected to be paid within a year. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's outstanding contractual obligations, including interest payments, as of December 31, 2020 and the effect those obligations are expected to have on its liquidity and cash flows in future periods:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payments Due By Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than<br/>one year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3-5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility operating lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695225352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Disclosures</a></td>
<td class="text">Segment Disclosures<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two reportable segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, sells and rents exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, sells, and rents exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The reportable segments are each managed separately because they serve distinct markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates performance and allocates resources based on segment gross profit margin.  The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment reporting information is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"><tr><td style="width:1.0%"/><td style="width:39.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.042%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoHealth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoWorks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from one customer of the Company&#8217;s EksoHealth segment represented approximately $2,138 of the Company&#8217;s consolidated revenues for the year ended December 31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geographic revenue information based on location of customer is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"/><td style="width:65.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,846&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695468680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into an amended and restated underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright &amp; Co., LLC ("Wainwright"), to sell 3,902 shares of the Company's common stock for public price per share of $10.25 per share, for gross proceeds of $40,000 (the "February 2021 Offering").  The Company estimates that the net proceeds from the February 2021 Offering will be approximately $36,404 after deducting underwriting discounts and commissions and estimated offering expenses. Pursuant to the Underwriting Agreement, the Company issued to certain designees of Wainwright 5-year warrants (the &#8220;2021 Warrants&#8221;) to purchase shares of Common Stock in an amount equal to 7.0% of the aggregate number of shares sold in the February 2021 Offering at an exercise price of $12.8125 per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021 through February&#160;25, 2021, the Company received proceeds of $1,416 from the exercise of 275 warrants and sold 78 shares of the Company's common stock under the ATM Agreement at an average price per share of $10.72 for proceeds of $664, net of commission and issuance costs. As of February 25, 2021, the Company has $6,668 available for future offerings under the prospectus filed with respect to the ATM Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702604792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Estimates (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation and Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation and Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States or U.S. GAAP. In the opinion of management, all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented have been included and are normal and recurring in nature. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year&#8217;s presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All common share and per share amounts have been adjusted to reflect the one-for-fifteen reverse stock split completed on March 24, 2020. See Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalization and Equity Structure &#8211; Reverse Stock Split</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive (loss) income as a component of stockholders&#8217; equity.  Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text">Accumulated Other Comprehensive (Loss) Income The Company's accumulated other comprehensive (loss) income consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text">CashThe Company places its cash in the custody of, financial institutions with high credit ratings. The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &#160;The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia.  Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2020 and 2019. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand.&#160; Subsequent disposals of inventories are recorded as a reduction of inventory.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board ("FASB")&#160;issued Accounting Standard Update (&#8220;ASU&#8221;), No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. The Company adopted the standard effective January 1, 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. As a result, the Company no longer recognizes deferred rent on the balance sheet.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, netProperty and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNlOTc5YmQ4ODEyMzQzYmU4MGQ4YmRlMzk4N2Q2OGRkL3NlYzozZTk3OWJkODgxMjM0M2JlODBkOGJkZTM5ODdkNjhkZF83OS9mcmFnOmRiOWJmZmE4MTIwZTQ1MzRiMzM5YTUyOTUyZjg1ZGFkL3RleHRyZWdpb246ZGI5YmZmYTgxMjBlNDUzNGIzMzlhNTI5NTJmODVkYWRfMTIxNDU_cd4dc075-4b7e-413d-b6dc-6727130d268c">three</span> to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the related term of the lease. The costs of repairs and maintenance are expensed when incurred, while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not be recoverable from the estimated future cash flows expected to result from the Company&#8217;s use or eventual disposition. If estimates of future undiscounted net cash flows are insufficient to recover the carrying value of the assets, the Company will record an impairment loss in the amount by which the carrying value of the assets exceeds the fair value. If the assets are determined to be recoverable, but the useful lives are shorter than originally estimated, the Company will depreciate or amortize the net book value of the assets over the newly determined remaining useful lives.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. The Company performs an annual impairment assessment, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill. The Company performs impairment tests using a fair value approach when necessary. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously maintained a goodwill balance as a result of a prior acquisition of intangible assets from Equipois, LLC in December 2015 consisting of mechanical balance and support arms technologies, including the rights to the ZeroG product.</span></div>As a result of declining sales and gross margin, combined with the overall uncertainty about the future of the ZeroG product line, the Company performed an impairment assessment of goodwill utilizing the simplified method, which resulted in an impairment of goodwill of $189 reducing the goodwill balance to zero. In estimating the fair value, the Company utilized a discounted cash flow model, which is dependent on a number of assumptions, including forecasted revenues and profit margins.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_WarrantPolicyTextBlock', window );">Warrant Valuation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that it may need to settle the warrants in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where there is a possibility that the Company may have to settle warrants in cash, it estimates the fair value of the issued warrants as a liability at each reporting date and record changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants have been determined using the Black-Scholes option-pricing model (the &#8220;Black-Scholes Model&#8221;) and the Binomial Lattice model (the &#8220;Lattice Model&#8221;). The Black-Scholes Model requires inputs, such as the expected volatility, expected term, exercise price, risk-free interest rate, and the value of the underlying security. The Lattice Model provides for assumptions regarding expected volatility, expected term, exercise price, risk-free interest rates, the value of the underlying security, and the probability of and likely timing of a specific event within the period to maturity. These values are subject to a significant degree of the Company&#8217;s judgment. The Company&#8217;s common stock price represents a significant input that affects the valuation of the warrants.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements &#8211; Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical device segment (EksoHealth) revenue is primarily generated through the sale and rental of the EksoNR and EksoGT, associated software (SmartAssist and VariableAssist), the sale and rental of the EksoUE, the sale of accessories, and the sale of support and maintenance contracts (Ekso Care). Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company&#8217;s facility for sales of the EksoNR or EksoGT, software and accessories. Ekso Care support and maintenance contracts extend coverage beyond the Company&#8217;s standard warranty agreements. The separately priced Ekso Care contracts range from&#160;12&#160;to&#160;48 months. The Company receives payment at the inception of the contract and recognizes revenue over the term of the agreement. Revenue from medical device rentals is recognized over the rental term, typically 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s industrial device segment (EksoWorks) revenue is generated through the sale and rental of the upper body exoskeletons (EksoVest and the recently introduced EVO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company&#8217;s facility. Revenue from industrial device rentals is recognized over the rental term, typically 12 months.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GovernmentGrantPolicyPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Grants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for nonreciprocal government grants by applying the contributions received in accordance with guidance in ASC Topic 958-605. To determine if a grant is non-reciprocal or reciprocal and whether the application of ASC 606 is required, the Company considers whether the transfer of resources is one in which commensurate value is exchanged. If commensurate value is not exchanged for the goods or services provided, the Company assesses whether the grant is conditional or unconditional.&#160; Grants that contain both a barrier and right to return are considered conditional and revenue is deferred until such conditions are satisfied. In January 2019, the Company received a government grant from the Singapore Economic Development Board (&#8220;SEDB&#8221;) in the amount of approximately $1,500. The receipt of the funds is conditional upon certain operational milestones that must be met and maintained through December 31, 2021. Therefore, the Company has not recognized revenue related to the government grant from the SEBD nor received cash from the SEBD.  The Company expects to recognize revenue related to this grant in 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist of costs incurred for internal research and development activities. These costs primarily include salaries and other personnel-related expenses, contractor fees, legal fees associated with developing and maintaining intellectual property, prototype materials, facility costs, supplies, and depreciation of equipment associated with the design and development of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. Under this method, income tax expense or benefit is recognized for the amount of taxes payable or refundable for the current year and for deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company's consolidated financial statements or tax returns. The Company accounts for any income tax contingencies in accordance with accounting guidance for income taxes. The measurement of current and deferred tax assets and liabilities is based on provisions of currently enacted tax laws. The effects of any future changes in tax laws or rates have not been considered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the preparation of the Company's consolidated financial statements included herein, the Company estimates its income taxes and tax contingencies in each of the tax jurisdictions in which it operates prior to the completion and filing of its tax returns. This process involves estimating actual current tax expense together with assessing temporary differences resulting from differing treatment of items, such as deferred revenue, for tax and accounting purposes. These differences result in net deferred tax assets and liabilities. The Company must then assess the likelihood that the deferred tax assets will be realizable, and to the extent they believe that realizability is not likely, the Company must establish a valuation allowance. In assessing the need for any additional valuation allowance, the Company considers all the evidence available to it, both positive and negative, including historical levels of income, legislative developments, expectations and risks associated with estimates of future taxable income, and ongoing prudent and feasible tax planning strategies.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock-based compensation expense for certain stock-based awards made to employees and directors based on the estimated fair value of the award on the date of grant using the Black-Scholes Model and recognizes the fair value on a straight-line basis over the requisite service periods of the awards. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s determination of the fair value of stock options on the date of grant using the Black-Scholes Model is affected by the Company&#8217;s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company&#8217;s stock price, volatility over the term of the awards, and actual and projected employee stock option exercise behaviors (expected term). Due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the Company adopted the simplified method of estimating the expected term pursuant to SEC Staff Accounting Bulletin Topic 14. On this basis, the Company estimated the expected term of options granted by taking the average of the vesting term and the contractual term of the option.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of restricted stock units (&#8220;RSUs&#8221;) is determined at the date of grant using the Company&#8217;s closing stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. For awards with performance-based conditions, at the point that it becomes probable that the performance conditions will be met, the Company records a cumulative catch-up of the expense from the grant date to the current date, and then amortizes the remainder of the expense over the remaining service period. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.</span></div>The Company has, from time to time, modified the terms of its stock options to employees. The Company accounts for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements/Accounting Pronouncements Adopted in 2020</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2022 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Adopted in 2020</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates the computation of the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will record a goodwill impairment charge based on the excess of a reporting unit&#8217;s carrying amount over its fair value. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company adopted the new guidance as of January 1, 2020, which reduced the complexity surrounding the evaluation of goodwill for impairment. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard modifies the disclosure requirements on fair value measurements in Topic 820 by removing the requirement to disclose the reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The standard expands the disclosure requirements for Level 3 fair value measurement, primarily focused on changes in unrealized gains and losses included in other comprehensive income. The amendments in this update became effective for the Company in the first quarter of 2020. The Company adopted ASU 2018-03 as of January 1, 2020. The adoption of this ASU did not have a material impact on the Company's consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_GovernmentGrantPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government Grant, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_GovernmentGrantPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_WarrantPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_WarrantPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523698948856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Estimates (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">The change in accumulated other comprehensive (loss) income presented on the consolidated balance sheets for the year ended December 31, 2020, is reflected in the table below net of tax:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on foreign currency translation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(897)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text">Inventories consisted of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text">The following table sets forth the changes to goodwill for the year ended December 31, 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:82.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.025%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523700862296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted average number of shares of common stock, adjusted to include conversion of certain stock options and warrants for common stock and release of common stock in connection with restricted stock units during the period, as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.653%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net loss used for dilution calculation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,825)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive weighted-average number of shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,794&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.653%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants for common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695573544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchies for Financial Assets and Liabilities on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s fair value hierarchies for its financial assets and liabilities which require fair value measurement on a recurring basis are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent success fee liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Level 3 Financial Liabilities on Recurring Basis</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of Company&#8217;s Level 3 financial liabilities during the year ended December 31, 2020,&#160;which were measured at fair value on a recurring basis:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"><tr><td style="width:1.0%"/><td style="width:68.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.467%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant<br/>Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent<br/>Success&#160;Fee<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial fair value of warrants in connection with June 2020 financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of warrants issued in June 2020, December 2019, May 2019 financing, and December 2015 equity financings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liability to equity upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on revaluation of contingent liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,037&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523693015864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Deferred Revenue Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred extended maintenance and support</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred device, rental revenues and advances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues, non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,789&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue activity consisted of the following for the year ended December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferral of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Disaggregation of Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company&#8217;s revenue by major source for the year ended December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.935%"><tr><td style="width:1.0%"/><td style="width:35.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.483%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoHealth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoWorks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company&#8217;s revenue by major source for the year ended December 31, 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"><tr><td style="width:1.0%"/><td style="width:35.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoHealth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoWorks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,957&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,917&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695287736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company-owned fleet</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, office and leased equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tools, molds, dies and jigs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and peripherals</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695458200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProductMaintenanceAndWarrantyTableTextBlock', window );">Schedule of Warranty Costs</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.544%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warranty</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for estimated future expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ProductMaintenanceAndWarrantyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ProductMaintenanceAndWarrantyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523693964152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes payable, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Principal Payments of Long-term Debt and Final Payment Fee</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents scheduled principal payments of the Company's note payable as of December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:87.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 - 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less final payment fee, discount and issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The follow table presents the scheduled principal payments of the Company's PPP loan note payable as of December 31, 2020, shown if the loan is not forgiven:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:87.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695284648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Lease Payments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future lease payments as of December 31, 2020 are as follows, which are presented as lease liabilities on the Company&#8217;s consolidated balance sheets:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.497%"><tr><td style="width:1.0%"/><td style="width:62.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695260008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and Equity Structure (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizationLongtermDebtAndEquityAbstract', window );"><strong>Capitalization, Long-term Debt and Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ScheduleOfWarrantsOutstandingTableTextBlock', window );">Schedule of Warrant Share Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant shares outstanding as of December 31, 2019 and December 31, 2020 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020 Investor Warrants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020 Placement Agent Warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Placement Agent Warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2019 Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Information Agent Warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-2014 warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9-10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(723)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value</a></td>
<td class="text">The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Investor Warrants:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"/><td style="width:62.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 10, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.94</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table>The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Placement Agent Warrants:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"/><td style="width:62.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 10, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.44</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table>The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Warrants:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:503.25pt"><tr><td style="width:1.0pt"/><td style="width:318.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:503.25pt"><tr><td style="width:1.0pt"/><td style="width:318.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.97</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table>The following assumptions were used in a combination of the Black-Scholes Model and the Lattice Model to measure the fair value of the May 2019 Warrants:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:318.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:98.50pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current share price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ScheduleOfWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ScheduleOfWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationLongtermDebtAndEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationLongtermDebtAndEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523696269032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Shares Available for Future Grant</a></td>
<td class="text">The 2014 Plan has since been amended and restated with approval by the stockholders to increase the maximum number of shares issuable, as shown in the table below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:422.25pt"><tr><td style="width:1.0pt"/><td style="width:298.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:120.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original share pool</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2017 increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2017 increase (ratified in June 2018)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020 increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2020 increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share authorized for grant as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant under the 2014 Plan was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:422.25pt"><tr><td style="width:1.0pt"/><td style="width:298.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:120.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares Available For Grant</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share pool increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity during the year ended December 31, 2020 is presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at year end</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding as of December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of<br/>Exercise<br/>Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.55 - $9.15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.95 - $26.85</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$27.30 - $56.70</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60.00 - $229.95</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Share Fair Value of Each Stock Option on Date of Grant using Black-Scholes Model Assumptions</a></td>
<td class="text">The share fair value of each stock option was determined on the date of grant using the Black-Scholes Model under the following assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"/><td style="width:62.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44% - 1.65%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67% - 2.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27 - 6.08</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%-102%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%-103%</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of Unvested Restricted Stock Units Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity for the year ended December 31, 2020 is summarized below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Grant-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense Related to Stock Options and RSUs Granted to Employees and Non-employees</a></td>
<td class="text">Stock-based compensation expense related to stock options and RSUs granted to employees and non-employees was as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"/><td style="width:66.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.388%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523699025992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Domestic and Foreign Components of Pre-tax Loss</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of pre-tax loss for the years ended December 31, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"/><td style="width:66.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,954)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,321)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,811)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,825)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,132)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Expense (Benefit) Differed from Amounts Computed by Applying Statutory Federal Income Tax Rate to Pretax Income (Loss)</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) for the years ended December 31, 2020 and 2019 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"><tr><td style="width:1.0%"/><td style="width:65.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on warrant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Tax Effects of Temporary Differences and Related Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences and related deferred tax assets and liabilities as of December 31, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:87.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase of unrecognized tax benefits taken in prior years</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase of unrecognized tax benefits related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523880750776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Summary of Outstanding Contractual Obligations Including Interest Payments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's outstanding contractual obligations, including interest payments, as of December 31, 2020 and the effect those obligations are expected to have on its liquidity and cash flows in future periods:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payments Due By Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than<br/>one year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3-5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility operating lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523694115496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment reporting information is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"><tr><td style="width:1.0%"/><td style="width:39.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.042%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoHealth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EksoWorks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Geographic Revenue Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geographic revenue information based on location of customer is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"/><td style="width:65.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,846&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523697225016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Sep. 16, 2019</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,103,000<span></span>
</td>
<td class="nump">$ 183,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,755,000<span></span>
</td>
<td class="nump">15,772,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,862,000<span></span>
</td>
<td class="nump">10,872,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction on workforce</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,334,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_DebtCovenantCovenantComplianceUnrestrictedCash', window );">Debt covenant, unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_UnrestrictedCash', window );">Unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ekso_LoanAgreementMember', window );">Loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,512,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ekso_PWBLoanAgreementMember', window );">PWB loan agreement | Term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ekso_DirectOfferingMember', window );">Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,082,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_DebtCovenantCovenantComplianceUnrestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Covenant Compliance, Unrestricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_DebtCovenantCovenantComplianceUnrestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_UnrestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_UnrestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ekso_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ekso_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ekso_PWBLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ekso_PWBLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ekso_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ekso_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ekso_DirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ekso_DirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523697060360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Estimates - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 24, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.0667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction on workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment loss on long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Government grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration', window );">Accounts receivable payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | EksoHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration', window );">Accounts receivable payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration', window );">Accounts receivable payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | EksoHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration', window );">Accounts receivable payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer concentration risk | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer concentration risk | Accounts receivable | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer concentration risk | Accounts receivable | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer concentration risk | Revenue benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contracts With Customer, Accounts Receivable, Payment Terms, Duration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ekso_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ekso_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ekso_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ekso_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523700645768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Estimates - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">$ 6,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">4,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net unrealized loss on foreign currency translation</a></td>
<td class="num">(897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="num">$ (847)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523693942680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Estimates - Schedule of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,724<span></span>
</td>
<td class="nump">$ 2,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="nump">$ 2,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523699240888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Estimates - Schedule of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="num">(189)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523696516104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (15,825)<span></span>
</td>
<td class="num">$ (12,132)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Adjusted net loss used for dilution calculation</a></td>
<td class="num">$ (15,825)<span></span>
</td>
<td class="num">$ (12,132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares outstanding (in shares)</a></td>
<td class="nump">7,164<span></span>
</td>
<td class="nump">4,794<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Dilutive weighted-average number of shares outstanding (in shares)</a></td>
<td class="nump">7,164<span></span>
</td>
<td class="nump">4,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (2.21)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (2.21)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702083032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">1,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695935064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Unconsolidated Affiliate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on investment of unconsolidated affiliate</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523700618712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Fair Value Hierarchies for Financial Assets and Liabilities on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">$ 6,037<span></span>
</td>
<td class="nump">$ 4,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">6,037<span></span>
</td>
<td class="nump">4,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContingentSuccessFeeLiability', window );">Contingent success fee liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContingentSuccessFeeLiability', window );">Contingent success fee liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContingentSuccessFeeLiability', window );">Contingent success fee liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">$ 6,037<span></span>
</td>
<td class="nump">4,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContingentSuccessFeeLiability', window );">Contingent success fee liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ContingentSuccessFeeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ContingentSuccessFeeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523697481064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Changes in Fair Value of Level 3 Financial Liabilities on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GainLossOnWarrantLiability', window );">Loss on revaluation of warrants issued in June 2020, December 2019, May 2019 financing, and December 2015 equity financings</a></td>
<td class="nump">$ 3,056<span></span>
</td>
<td class="num">$ (6,376)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">4,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial fair value of warrants in connection with June 2020 financing</a></td>
<td class="nump">2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GainLossOnWarrantLiability', window );">Loss on revaluation of warrants issued in June 2020, December 2019, May 2019 financing, and December 2015 equity financings</a></td>
<td class="nump">3,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification', window );">Reclassification of warrant liability to equity upon exercise of warrants</a></td>
<td class="num">(3,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement', window );">Gain on revaluation of contingent liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">6,037<span></span>
</td>
<td class="nump">4,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ekso_ContingentSuccessFeeMember', window );">Contingent Success&#160;Fee Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial fair value of warrants in connection with June 2020 financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GainLossOnWarrantLiability', window );">Loss on revaluation of warrants issued in June 2020, December 2019, May 2019 financing, and December 2015 equity financings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification', window );">Reclassification of warrant liability to equity upon exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement', window );">Gain on revaluation of contingent liability</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Reclassification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_GainLossOnWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_GainLossOnWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ekso_ContingentSuccessFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ekso_ContingentSuccessFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695681432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Summary of Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_DeferredExtendedMaintenanceAndSupport', window );">Deferred extended maintenance and support</a></td>
<td class="nump">$ 2,902<span></span>
</td>
<td class="nump">$ 2,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_DeferredRoyalties', window );">Deferred royalties</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_DeferredDeviceRevenue', window );">Deferred device, rental revenues and advances</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total deferred revenues</a></td>
<td class="nump">3,302<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Less current portion</a></td>
<td class="num">(1,496)<span></span>
</td>
<td class="num">(1,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">$ 1,806<span></span>
</td>
<td class="nump">$ 1,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_DeferredDeviceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Device Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_DeferredDeviceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_DeferredExtendedMaintenanceAndSupport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Extended Maintenance And Support</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_DeferredExtendedMaintenanceAndSupport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_DeferredRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_DeferredRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523701124168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Summary of Deferred Revenue Activity (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward', window );"><strong>Change In Contract With Customer, Liability Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 3,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContractWithCustomerLiabilityDeferralOfRevenue', window );">Deferral of revenue</a></td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of deferred revenue</a></td>
<td class="num">(1,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 3,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability Rollforward [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ContractWithCustomerLiabilityDeferralOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deferral Of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ContractWithCustomerLiabilityDeferralOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523696989336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total deferred revenues</a></td>
<td class="nump">$ 3,302<span></span>
</td>
<td class="nump">$ 3,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContractwithCustomerLiabilityNonCancellableBacklog', window );">Non-cancellable backlog</a></td>
<td class="nump">$ 515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances</a></td>
<td class="nump">$ 3,389<span></span>
</td>
<td class="nump">$ 5,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation, amount</a></td>
<td class="nump">$ 1,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation, amount</a></td>
<td class="nump">$ 908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation, amount</a></td>
<td class="nump">$ 898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration', window );">Payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration', window );">Payment terms</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contracts With Customer, Accounts Receivable, Payment Terms, Duration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ContractwithCustomerLiabilityNonCancellableBacklog">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Non-Cancellable Backlog</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ContractwithCustomerLiabilityNonCancellableBacklog</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523697039560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Summary of Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 8,882<span></span>
</td>
<td class="nump">$ 13,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Device revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">5,701<span></span>
</td>
<td class="nump">10,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service and support</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ekso_RentalsMember', window );">Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Parts and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ekso_CollaborativeArrangementsMember', window );">Collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember', window );">EksoHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">11,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember', window );">EksoHealth | Device revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">5,012<span></span>
</td>
<td class="nump">9,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember', window );">EksoHealth | Service and support</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember', window );">EksoHealth | Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">782<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember', window );">EksoHealth | Parts and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember', window );">EksoHealth | Collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember', window );">EksoWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember', window );">EksoWorks | Device revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember', window );">EksoWorks | Service and support</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember', window );">EksoWorks | Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember', window );">EksoWorks | Parts and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember', window );">EksoWorks | Collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ekso_RentalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ekso_RentalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ekso_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ekso_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523698177320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 5,829<span></span>
</td>
<td class="nump">$ 5,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(4,657)<span></span>
</td>
<td class="num">(4,226)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 1,172<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TransportationEquipmentMember', window );">Company-owned fleet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 3,326<span></span>
</td>
<td class="nump">3,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TransportationEquipmentMember', window );">Company-owned fleet | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TransportationEquipmentMember', window );">Company-owned fleet | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 851<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 631<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Furniture, office and leased equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Furniture, office and leased equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Furniture, office and leased equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Tools, molds, dies and jigs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and peripherals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and peripherals | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and peripherals | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TransportationEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TransportationEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523694085768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 620<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523700658504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries, benefits and related expenses</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="nump">$ 1,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Device warranty</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_AccruedClinicalCostCurrent', window );">Other</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="nump">$ 1,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_AccruedClinicalCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_AccruedClinicalCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68070138&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523698915192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Warranty Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_AccruedLiabilitiesRollforwardRollForward', window );"><strong>Accrued Liabilities, Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyDescription', window );">Standard Product Warranty Description</a></td>
<td class="text">Sales of devices generally include an initial warranty for parts and services for one year in the Americas, two years in Europe, the Middle East, Africa, and one or two years in the Asia Pacific region.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_OtherliabilitiesAxis=ekso_WarrantyMember', window );">Warranty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_AccruedLiabilitiesRollforwardRollForward', window );"><strong>Accrued Liabilities, Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent', window );">Balance at beginning of the period</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProductMaintenanceWarrantyAddition', window );">Additions for estimated future expense</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProductMaintenanceWarrantyExpense', window );">Incurred costs</a></td>
<td class="num">(343)<span></span>
</td>
<td class="num">(385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent', window );">Balance at end of the period</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent', window );">Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent', window );">Long-term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent', window );">Total</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_AccruedLiabilitiesRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Rollforward [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_AccruedLiabilitiesRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ProductMaintenanceWarrantyAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ProductMaintenanceWarrantyAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ProductMaintenanceWarrantyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ProductMaintenanceWarrantyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ProductMaintenanceWarrantyLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value of current portion of product maintenance and warranty liabilities as on the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ProductMaintenanceWarrantyLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value of noncurrent portion of product maintenance and warranty liabilities as on the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the nature of the product warranty, including the approximate term of the product warranty, how the product warranty arose, and the events or circumstances that would require the warrantor to perform under the product warranty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12069-110248<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_OtherliabilitiesAxis=ekso_WarrantyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_OtherliabilitiesAxis=ekso_WarrantyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523697033512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes payable, net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2020</div></th>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Aug. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment of remaining balance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,512,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Note payable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,989,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,862,000<span></span>
</td>
<td class="nump">$ 10,872,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">prime rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Note payable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ekso_LoanAgreementMember', window );">Loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_DebtInstrumentDeferralPeriod', window );">Deferral principal payment period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ekso_PWBLoanAgreementMember', window );">PWB loan agreement | Term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">prime rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose', window );">Available for corporate purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Note payable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ekso_PWBLoanAgreementMember', window );">PWB loan agreement | Prime rate | Term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_DebtInstrumentDeferralPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Deferral Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_DebtInstrumentDeferralPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Capacity Available For Specific Purpose</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ekso_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ekso_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ekso_PWBLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ekso_PWBLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ekso_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ekso_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523698459528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes payable, net - Debt Repayment (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear', window );">2021 - 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal payments</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less final payment fee, discount and issuance cost</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Note payable, net</a></td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term portion</a></td>
<td class="nump">$ 1,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt Maturities Repayments Of Principal Remainder to Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523699123976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes payable, net - Principal Repayment (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal payments</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term portion</a></td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Note payable, net</a></td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal payments</a></td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term portion</a></td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Note payable, net</a></td>
<td class="nump">$ 1,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523699075976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ekso_RichmondCaliforniaMember', window );">Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_OperatingLeaseAbatement', window );">Operating Lease, Abatement</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ekso_HamburgGermanyMember', window );">Hamburg, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_OperatingLeaseAbatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Abatement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_OperatingLeaseAbatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ekso_RichmondCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ekso_RichmondCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ekso_HamburgGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ekso_HamburgGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695626616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Future Minimum Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">$ 421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, noncurrent</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">$ 711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining term (in years)</a></td>
<td class="text">1 year 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695531112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution expense</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695303352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of inventory parts and tooling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ekso_AngelPondCapitalLlcMember', window );">Angel Pond Capital LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_RelatedPartyTransactionConsultingAgreement', window );">Consulting agreement term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Aggregate payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_RelatedPartyTransactionConsultingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_RelatedPartyTransactionConsultingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ekso_AngelPondCapitalLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ekso_AngelPondCapitalLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523686920664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and Equity Structure - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 24, 2020</div></th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 16, 2019 </div>
<div>days </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of shares (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_NumberOfConsecutiveBusinessDays', window );">Number of Consecutive Business days | days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,429,000<span></span>
</td>
<td class="nump">141,429,000<span></span>
</td>
<td class="nump">141,429,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,795,000<span></span>
</td>
<td class="nump">8,349,000<span></span>
</td>
<td class="nump">5,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,795,000<span></span>
</td>
<td class="nump">8,349,000<span></span>
</td>
<td class="nump">5,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number warrants called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">996,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_WarrantIssuanceExpense', window );">Warrant expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Merger/PPO warrant shares exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GainLossOnWarrantModification', window );">Loss on modification of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.0667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020WarrantsMember', window );">June 2020 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Class of warrant or right expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020InvestorWarrantsMember', window );">June 2020 Investor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Class of warrant or right expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020PlacementAgentWarrantsMember', window );">June 2020 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightCashFeePercentage', window );">Class of warrant or right cash fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightCashFee', window );">Class of warrant or right cash fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightManagementFeePercentage', window );">Class of warrant or right management fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightManagementFeeExpense', window );">Class of warrant or right management fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock', window );">Percentage of warrants issued to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Class of warrant or right expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_WarrantIssuanceExpense', window );">Warrant expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_A2019WarrantsMember', window );">December 2019 warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Class of warrant or right expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">6 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightDurationOfPutOption', window );">Duration of put option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod', window );">Put option pay period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019PlacementAgentWarrantsMember', window );">December 2019 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Class of warrant or right expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Merger/PPO warrant shares exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019PlacementAgentWarrantsMember', window );">December 2019 Placement Agent Warrants | Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockConversionPrice', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.44<span></span>
</td>
<td class="nump">8.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_May2019WarrantsMember', window );">May 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Class of warrant or right expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Merger/PPO warrant shares exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_May2019WarrantsMember', window );">May 2019 Warrants | Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockConversionPrice', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_InformationAgentWarrantsMember', window );">Information agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number warrants called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_TwothousandFifteenWarrantsMember', window );">2015 warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Merger/PPO warrant shares exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_GainLossOnWarrantModification', window );">Loss on modification of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ekso_DirectOfferingMember', window );">Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants', window );">Aggregate proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ekso_DirectOfferingMember', window );">Direct offering | June 2020 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants', window );">Aggregate proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ekso_AtTheMarketOfferingMember', window );">At-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of shares (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Value of shares sold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | June 2020 Investor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number warrants called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | May 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number warrants called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number warrants called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants', window );">Aggregate proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Direct offering | June 2020 Investor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number warrants called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">874,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">874,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Direct offering | May 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number warrants called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number warrants called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants for common stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightCashFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Cash Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightCashFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightCashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Cash Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightCashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightDurationOfPutOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Duration Of Put Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightDurationOfPutOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Management Fee Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightManagementFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Management Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightManagementFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Percentage Of Warrants Issued To Purchase Shares Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Put Option, Duration Of Pay Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_GainLossOnWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Warrant Modification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_GainLossOnWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_NumberOfConsecutiveBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Consecutive Business days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_NumberOfConsecutiveBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_StockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_StockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_WarrantIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Amount of expense incurred on issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_WarrantIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_A2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_A2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_May2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_May2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_InformationAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_InformationAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_TwothousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_TwothousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ekso_DirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ekso_DirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ekso_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ekso_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523792064680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and Equity Structure - Schedule of Warrant Share Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class Of Warrant Or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1,178<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_JuneTwentyTwentyInvestorWarrantsMember', window );">June 2020 Investor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class Of Warrant Or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember', window );">June 2020 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class Of Warrant Or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019WarrantsMember', window );">December 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class Of Warrant Or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019PlacementAgentWarrantsMember', window );">December 2019 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class Of Warrant Or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_May2019WarrantsMember', window );">May 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class Of Warrant Or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_A2017InformationAgentWarrantsMember', window );">2017 Information Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class Of Warrant Or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2015WarrantsMember', window );">2015 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class Of Warrant Or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_Pre2014WarrantsMember', window );">Pre-2014 warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class Of Warrant Or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_Pre2014WarrantsMember', window );">Pre-2014 warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_Pre2014WarrantsMember', window );">Pre-2014 warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExpirationPeriod', window );">Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_JuneTwentyTwentyInvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_JuneTwentyTwentyInvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_May2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_May2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_A2017InformationAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_A2017InformationAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2015WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_December2015WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_Pre2014WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_Pre2014WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523698383192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and Equity Structure - Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 10, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Current share price | June 2020 Investor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Current share price (in dollars per share)</a></td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Current share price | June 2020 placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Current share price (in dollars per share)</a></td>
<td class="nump">3.81<span></span>
</td>
<td class="nump">6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Current share price | December 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Current share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.13<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Current share price | December 2019 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Current share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.13<span></span>
</td>
<td class="nump">5.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Current share price | May 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Current share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.13<span></span>
</td>
<td class="nump">5.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion price | June 2020 Investor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">5.18<span></span>
</td>
<td class="nump">5.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion price | June 2020 placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="nump">5.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion price | December 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.10<span></span>
</td>
<td class="nump">8.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion price | December 2019 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.44<span></span>
</td>
<td class="nump">8.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion price | May 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_StockConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | June 2020 Investor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input percentage</a></td>
<td class="nump">0.0039<span></span>
</td>
<td class="nump">0.0035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | June 2020 placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input percentage</a></td>
<td class="nump">0.0033<span></span>
</td>
<td class="nump">0.0031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | December 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0031<span></span>
</td>
<td class="nump">0.0173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | December 2019 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0026<span></span>
</td>
<td class="nump">0.0169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | May 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0021<span></span>
</td>
<td class="nump">0.0167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | June 2020 Investor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">4 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | June 2020 placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | December 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 5 months 19 days<span></span>
</td>
<td class="text">5 years 5 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | December 2019 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 11 months 19 days<span></span>
</td>
<td class="text">4 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | May 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility of stock | June 2020 Investor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input percentage</a></td>
<td class="nump">0.964<span></span>
</td>
<td class="nump">1.053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility of stock | June 2020 placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input percentage</a></td>
<td class="nump">0.963<span></span>
</td>
<td class="nump">1.068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility of stock | December 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.079<span></span>
</td>
<td class="nump">0.957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility of stock | December 2019 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.094<span></span>
</td>
<td class="nump">0.931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility of stock | May 2019 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.072<span></span>
</td>
<td class="nump">0.939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_StockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_StockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_JuneTwentyTwentyInvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_JuneTwentyTwentyInvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_JuneTwentyTwentyPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_JuneTwentyTwentyPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_December2019PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_May2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_May2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523696499960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-based Compensation - 2014 Equity Incentive Plan (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member', window );">2014 Equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523695862344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Increase in Maximum Number of Shares Issuable to Stockholders (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Original share pool (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase (in shares)</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member', window );">2014 Equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Original share pool (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total share authorized for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523696609256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Shares Available for Future Grant (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Shares Available For Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share pool increase (in shares)</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member', window );">2014 Equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Shares Available For Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share pool increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523693913608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Options Narrative (Details) - 2014 Equity incentive plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ekso_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523697069064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Option Activity (Details) - 2014 Equity incentive plan<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year (in shares) | shares</a></td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year (in shares) | shares</a></td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares) | shares</a></td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at year end (in shares) | shares</a></td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 36.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">5.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">26.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">41.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year (in dollars per share) | $ / shares</a></td>
<td class="nump">31.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">31.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at year end (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 40.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years), Ending Balance</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Vested and expected to vest</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Exercisable</a></td>
<td class="text">6 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance | $</a></td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest | $</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ekso_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ekso_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523700463832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Exercised Options Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="nump">$ 10.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of vested shares</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 2,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of unrecognized compensation expense</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523698739048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Options Outstanding (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Option Outstanding, Number of Shares (in shares) | shares</a></td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted-Average Remaining Contractual Life (Years)</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Price (in dollars per share)</a></td>
<td class="nump">$ 31.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares (in shares) | shares</a></td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Price (in dollars per share)</a></td>
<td class="nump">$ 40.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeOneMember', window );">$5.55 - $9.15</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, Lower (in dollars per share)</a></td>
<td class="nump">5.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, Upper (in dollars per share)</a></td>
<td class="nump">$ 9.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Option Outstanding, Number of Shares (in shares) | shares</a></td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted-Average Remaining Contractual Life (Years)</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Price (in dollars per share)</a></td>
<td class="nump">$ 7.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares (in shares) | shares</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Price (in dollars per share)</a></td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeTwoMember', window );">$16.95 - $26.85</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, Lower (in dollars per share)</a></td>
<td class="nump">16.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, Upper (in dollars per share)</a></td>
<td class="nump">$ 26.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Option Outstanding, Number of Shares (in shares) | shares</a></td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted-Average Remaining Contractual Life (Years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Price (in dollars per share)</a></td>
<td class="nump">$ 22.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares (in shares) | shares</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Price (in dollars per share)</a></td>
<td class="nump">$ 22.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeThreeMember', window );">$27.30 - $56.70</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, Lower (in dollars per share)</a></td>
<td class="nump">27.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, Upper (in dollars per share)</a></td>
<td class="nump">$ 56.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Option Outstanding, Number of Shares (in shares) | shares</a></td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted-Average Remaining Contractual Life (Years)</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Price (in dollars per share)</a></td>
<td class="nump">$ 34.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares (in shares) | shares</a></td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Price (in dollars per share)</a></td>
<td class="nump">$ 35.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeFourMember', window );">$60.00 - $229.95</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, Lower (in dollars per share)</a></td>
<td class="nump">60.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, Upper (in dollars per share)</a></td>
<td class="nump">$ 229.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Option Outstanding, Number of Shares (in shares) | shares</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted-Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Price (in dollars per share)</a></td>
<td class="nump">$ 119.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares (in shares) | shares</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Price (in dollars per share)</a></td>
<td class="nump">$ 119.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ekso_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523701983560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Share Fair Value of Each Stock Option on Date of Grant using Black-Scholes Model Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.44%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="nump">103.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702666648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Unvested Restricted Stock Units Activity (Details) - RSUs<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward', window );">Right to receive per award</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested, beginning balance (in shares)</a></td>
<td class="nump">89,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited (in shares)</a></td>
<td class="num">(31,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested, ending balance (in shares)</a></td>
<td class="nump">143,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>&#160;Weighted Average Grant- Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">4.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">6.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">10.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of vested shares | $</a></td>
<td class="nump">$ 251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense | $</a></td>
<td class="nump">$ 741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of unrecognized compensation expense</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement By Share-Based Payment Award, Right To Receive Per Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702169864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-based Compensation Expense Related to Stock Options and RSUs Granted to Employees and Non-employees (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 2,410<span></span>
</td>
<td class="nump">$ 2,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 1,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523797823912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Employee Stock Purchase Plan (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ekso_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_DefinedContributionPlanOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter', window );">Maximum annual contribution percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Maximum Annual Contributions Percentage,Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_DefinedContributionPlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_DefinedContributionPlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ekso_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ekso_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523696160248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Domestic and Foreign Components of Pre-tax Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (14,954)<span></span>
</td>
<td class="num">$ (10,321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(871)<span></span>
</td>
<td class="num">(1,811)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">$ (15,825)<span></span>
</td>
<td class="num">$ (12,132)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523698223944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Current federal and state income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Deferred federal and state income tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">3,192,000<span></span>
</td>
<td class="nump">$ 3,899,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">164,296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and development tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">1,943,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">106,955,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and development tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">641,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">9,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ekso_GeneratedBefore2018Expire2027Member', window );">Generated before 2018, expire 2027 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">120,792,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ekso_GeneratedBefore2018CarryforwardIndefinitelyMember', window );">Generated before 2018, carryforward indefinitely | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 43,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ekso_GeneratedBefore2018Expire2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ekso_GeneratedBefore2018Expire2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ekso_GeneratedBefore2018CarryforwardIndefinitelyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ekso_GeneratedBefore2018CarryforwardIndefinitelyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702691640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Expense (Benefit) Differed from Amounts Computed by Applying Statutory Federal Income Tax Rate to Pretax Income (Loss) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal tax effect</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D credit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(16.60%)<span></span>
</td>
<td class="num">(27.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant', window );">Unrealized gain on warrant</a></td>
<td class="num">(4.50%)<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign exchange</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total tax expense (benefit)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrealized gain/loss on warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702367272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Tax Effects of Temporary Differences and Related Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and other</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">43,241<span></span>
</td>
<td class="nump">40,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation expense</a></td>
<td class="nump">2,547<span></span>
</td>
<td class="nump">2,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset', window );">Lease assets</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(48,673)<span></span>
</td>
<td class="num">(45,481)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset (liability)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_DeferredTaxLiabilitiesOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_DeferredTaxLiabilitiesOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523698926840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase of unrecognized tax benefits taken in prior years</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase of unrecognized tax benefits related to current year</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702708552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>license_agreement</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_NumberOfLicenseAgreements', window );">Number of license agreements | license_agreement</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Obligation due in less than one year</a></td>
<td class="nump">$ 689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty agreement terms</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Obligation due in less than one year</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty agreement terms | Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty agreement terms | License fees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ekso_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ekso_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523702256552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Outstanding Contractual Obligations Including Interest Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 4,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Less than one year</a></td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">1-3 Years</a></td>
<td class="nump">3,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">3-5 Years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ekso_FacilityOperatingLeaseMember', window );">Facility operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Less than one year</a></td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">1-3 Years</a></td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">3-5 Years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ekso_TermLoanMember', window );">Term loans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">3,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Less than one year</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">1-3 Years</a></td>
<td class="nump">3,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">3-5 Years</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ekso_FacilityOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ekso_FacilityOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ekso_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ekso_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523696715800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures - Schedule of Segment Reporting Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 8,882<span></span>
</td>
<td class="nump">$ 13,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">3,812<span></span>
</td>
<td class="nump">7,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,070<span></span>
</td>
<td class="nump">6,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember', window );">EksoHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">11,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">3,219<span></span>
</td>
<td class="nump">5,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,847<span></span>
</td>
<td class="nump">6,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember', window );">EksoHealth | Customer one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember', window );">EksoWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">593<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ekso_EksoHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ekso_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ekso_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ekso_EksoWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523792196808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures - Schedule of Geographic Revenue Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 8,882<span></span>
</td>
<td class="nump">$ 13,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">5,945<span></span>
</td>
<td class="nump">9,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="nump">$ 4,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140523697703128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 25, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Feb. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,082<span></span>
</td>
<td class="nump">$ 21,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ekso_AtTheMarketOfferingMember', window );">At-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Value of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Value of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold', window );">Warrants to purchase common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.8125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Value of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | At-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance', window );">Available for future offerings</a></td>
<td class="nump">$ 6,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | June 2020 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ekso_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant Or Right, Percentage Of Aggregate Shares Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Value Of Shares Available For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ekso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ekso_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ekso_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ekso_June2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>103
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M+BNY^W:Q.]%BG77SET)K$6>' 6<8*/, WE\)H0\GY@7Y%Z3K_P%02P,$%
M  @ V(%94I:^>)<=!@  11D  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6RM66UOVS80_BN$$6 MX,0B*5E2FQAH$VPKL)>@:=?/C$3'1"71(RFGV:_?
M478L6:28 -N7Q)+OR.>.=_?<T9>/4GW7&\X-^E%7C;Z:;8S9OELL=+'A-=,7
M<LL;^&8M5<T,/*J'A=XJSLI.J:X6)(J6BYJ)9K:Z[-[=JM6E;$TE&GZKD&[K
MFJFGC[R2CU<S/'M^\5D\;(Q]L5A=;MD#O^/FZ_96P=/BN$HI:MYH(1ND^/IJ
M]@&_NZ:Q5>@D_A+\40\^(VO*O93?[<.G\FH6642\XH6Q2S#XM^/7O*KL2H#C
M[\.BL^.>5G'X^7GUGSOCP9A[IOFUK+Z)TFRN9MD,E7S-VLI\EH^_\H-!B5VO
MD)7N_J+'@VPT0T6KC:P/RH"@%LW^/_MQ<,1  <<3"N2@0%ZK0 \*M#-TCZPS
MZX89MKI4\A$I*PVKV0^=;SIML$8T]ACOC()O!>B9U;5LM*Q$R0POT4=6L:;@
MZ,XNI]$Y^GIW@]Z<O45G2#3HRT:VFC6EOEP8V-GJ+XK#+A_WNY")76YX<8$H
MGB,2D<BC?OUJ=9R?JB_ WJ/1Y&@TZ=:C4T:W2O'&(*8UV/DNL"(]KDB[%>.I
M%9G>^-RRUTHZ+9M1NQ4FV9)<+G9#ZSU249;V4B>0XB.D. CI0U'(MH%C5+S@
M8L?N*SY'#10&N4:L@O2U1ZWMTUE,$)PK.L,$?*RXWO(NN:HGGTG[79<#L)1F
M^<@B5R@A4>8W*#D:E 0-^M3LX-"D$MP;@8FS)<[3;(3+%2+Q /P)KN41US*(
MZU;Q+1,EXC^@MFIPJ?6E-!NN((&'@>9#O?2@QB/0K@RA$[Y,CYC3(.8OTK#J
M%?!2%UX6VQ0^ >B3RJ+4#S$[0LQ><"MPE3)/G3OYWZW8 GN8+H1]2#,7 T['
MB>816B83./,CSCR(LV.^<[D^;S4/>#)WMEYFR0B>*P-U(/;#PU%?X:,@P%^D
M+!]%57G+=N1L.3Y<CPB>2AD\H!T<!/5GEQ_3[CJHGY09)^X\0CB=R S<DP,F
MK\B- #3BYF.4Y.D8G$<,<CN9@-<S#::O(J]*L'M1"0/E,,1@N.<+_$K"V+(G
MRQ9>V]W"CI-H7+!\4GE$)RSOZS\.$P  5"VT*0/+O1@]3!"3,4/YI);9%,:>
M"W"8#&[XFL/YE$"CP%8MU_/G*NN%ZBG_<;X<0_5*3;0'N*< '.: /Z3ASV<=
M1NG6=R<371%"Z90W>PK 80[XC4.'/CSO,$ZWO"?QN /P",4$3P#M.0"'2>"4
M3U\*4+?.QWD:CX&Z4FE&)TZ=]&Q PFS@"=!&-N<!MQ(? 43C(/5)I5,\07J>
M(&&>L$&J^RB=('_B88LH'=.K1RJ>ZE+(8)8(TX43HUZ 'C(8I,<!GRN4XHG0
M)#U?D/!H\HTIQ5X.RL,J)PU*1,>DYI&*Z:0/>^HA8>K9=P.#.'P1K6<*&6>Z
M1V9JIB(]!Y$P!^T3_25T/F[!2^>\/6()QA,-#.DYB(0YZ%K6M3"V6][/(H5L
MC&@>>%, 7O2FJ_MX^=:+/+BRO5-ZI[>LX%>S+<R)7.WX;(5\ _W_L-"I]3VM
MD338']T967S?R*KD2O_4#0[F*=0@D9Z-2)B-KB5,H,H(J$0(4!_JJ+;[S=%9
M=!%%&"J50CM6M?P]PM$\BB*D-TS9H; U&YA=_^'E>PCTY[=":]O1=!-C:[2!
M#W!2B!ET U-[?0]9\7QMT@FY%R"'<W-9;4S109%3C_2T1\*T9R---@$7Q'@.
MK9?/!]F<QGEG4S)/\^2_..3E.POB<JE3+3P#FM\]M.=:&N;:#V4I[&4E5 Q[
M0W N&E2PK8 *XKTK<AF41#%-QTSKD8/NN@L,+]R>:VF8:Z&_;NNVZJX"#_<7
MLH9 W]A;VQU';RJI]5LD&GCMG0ZH2[#G63SF$(]4,A&)M&=A&F;A(?:2KT4A
MO(T"=2GV'.<YCL:UV2L([=?4>$D'-X5A/MXSB/94*2]@#^'&=-PK>J26:3Y!
MR[2G91JF98?LNI1[-?38N=;TS<D^,<^<O!C<<=L?&'YGZD$T&E5\#7K110H+
MJ/V=_?[!R&UW[7TOC9%U]W'#&8"V O#]6@(/'A[L3?KQEY/5OU!+ P04
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M07'#%.^0H*P!/E]*:5XF]I92W4HG?P%02P,$%     @ V(%94L9=P')P!0
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M9:?N@\[W]YO4/,SHVGGIQG2IMBI W2KP,[I-:JI 3Q=,#RZSW*>?V^:N&'0
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MRWOT"Q(U^GTONY;517L^5P!!3S3/A]=][E]' J_#!/TJ:[5OT9>ZX,7+">:
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M+GAM;)U8VW+<N!']%=1$R<I5]-QTL6Q=JG2QLJ[$NRIK'3^D\@"2&!(1"%
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M#NSDJ5*(=RFN4 X!U"@0R,5"%T@33&Q5U$2]O$_@-:E0Q!>T7;L2H;YV'2_
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M^;(\6^55!U+#HFD C!=6MVMMA5]F9*TL607F$YG/CI\73A>YW60K,H66Q\4
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MMUO^$W>RF0X/T.^KMNW=!TS@_]6D[_\'4$L#!!0    ( -B!65+:Y_BNNP,
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M5XO990IUU4I@8-I7*.C?,2+4*#/*H/SI0AK1<:A9:.N=<Y^P"^UKY9QX58M
MKL-H.G3$<@A?)<R:@L8\C)/_JZBGD;GH'6?T-CUZ#<U<+3;/JS^$F4]/HQ2K
M)2G9C5/25XA^ (TB=)[:;Y^29=0X*'>I0^^P-%4Z8]1[.U'84JUP !F5N<6Q
M0::I(>@\> E"GS<-!(I'=@Q^/CD!H8QQO;>_YYK]"<>V$ZZ="GNK?BL%<J1
M6T4R\!*GE%9CZ>X:*PS9GBFPIE[%=RK/G7?MAH9JC.@!S:@34TN1S+Y\A)<M
M!3?E=\5XZ22)>R=YA;KP]Q7C=JVTX5#??MU>B6;A)K S#_>I&Z8+3OP$YN0Z
M&KX_CD"'.TIXL:KV]P(:4'3+\(\E7>M0.P-:SY6RW8M+L+TH3O\#4$L#!!0
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M"\)+42HY5Z7R&_$$EG2K?(1\*I0.GG"G,U7+D@$JX[R0^4IJCR8VC8,Z[1>
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MTYFRDI'0DT=35++<"O56!2E#J!2RCW2IMW0CRS5\@1W]QCAU%,.E^-Y75?H
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M+S=*9LJ2 -ZOC/'M#6W0?5>_^R]02P,$%     @ V(%94J]23<<B P  ] 8
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M_VZ:"%>?;>J'8'?Q/+&V :>3>+O%<9 <&^!]86UH'SA =\!<_@-02P,$%
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M7U 6>./#B#D&6)NDX HZF(Y&(I*Y&VZ*Y5DBNBVGVR%#T1:BD<DEKT4+$17
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M>Q' ?>%<[%[$P?9_@?/_ %!+ P04    " #8@5E2"VRLK.,"  !O!@  &0
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M( H^!M(16@<")LGH:/.>KT>?7<WV S 6B$7[[658DQ5L2YF7()0"W/MAB$5
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M."9AEF;^$@0XG'W?8&$,6,.QTH0>-:@99;;([64.6X'G%.?#<##PI RW& \
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M+] "_#XWQC<W9&#[ENG\_U!+ P04    " #8@5E2M;"*BCP&  !4#@  &0
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MZ2H1(&*LMB62-!;;C<HVB2*_']&P=#J<$9TC7P,"NV.%WMXNNDJUU9' .>C
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MILQ>N*XB4M"G>_[[^S\^Z&@A&.Y!H9,^DTF71R9=++,WMNFV+GO1E*8<#O"
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M=[!=A-W2- CAJUGVHF_)S<ZR2U?E@H8O>R2D""XB&W)C>7 .HC>FY%PEQ[W
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MB2/+!X=YTPY4!A,NG*&1D5"_;G+)#(/^^:U.;#2QR5G<N]",D)0C]''F-9=
MF.S2VR H7^%"/*@^<3' U_ C7&8!7XA>]$%N*9YZET>C2G!X,\47+K[H0O#
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M!^CWM;6=_X )PC]_\_/_ 5!+ P04    " #8@5E2[.6@=(P#  #!"   &0
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MLG0A\*\YW<!0NP":7RME]P-7H+W3S?\%4$L#!!0    ( -B!65+$0,7+_0,
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MNBMZF*&R"^C_4DK3#ZR#X:DW_P=02P,$%     @ V(%94JDDDU8* P  :@8
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MXV()QEXI.*NEHANF":DV/,L=GH:"9[(HF5A_T""H1S8M LPYT+U@L4#5WLT
MYJBX3&!2R(H*(5T(IW:)X 3>O^M'8?39BEV(.D$0P),T-NF_Z6OS+6H-J3N;
MQ@(I4H,F='<N@3T[KG7%1(P02VT@#.%^AVG=S"<0=J[Z5S"KE+(@I51N&FPY
M;>]D8ZLC#F/MJ?1-B1'Y!?V+PR6>- [_1\I&["=E+?OZU]^9"P6JI9M^&MP!
MUB.BU;8#=E+/E:U[/9WOF%IRH2''E$*#L\MS#U0]\6K!R-)-F84T-+/<-J.?
M!"KK0/94$O5&L G:W\[X+U!+ P04    " #8@5E2#C\WG^0"   _!@  &0
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M<,>+G;3O;-O1HC)OVZG0^%(VS25GR*<D@/-S(733(0/M/SLN_P502P,$%
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ML,CILPA94311)CM1BC9*%C!=I(LFTFW10'.DE%;?>\\!EW7 CGY$)4&#W-#
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MM-WK^O.AOK&J=$?VN;+T >"6*_KB0LT"]'ZAE&UOV$'W#7?^+U!+ P04
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M1WW*JFH;<[LQLG'-<"$-I<$M2_K+4%D!NE]*:78;:Z#['2=_ 5!+ P04
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MFR?"0:YJQ-I^0Z64;<D3IV!-7HJJ&JKRQLG>PAE#D)&78'S>;5'8;JM*@W_
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M#2[;)*V+/E!,K%KEM7>N+%7R?)A0[T3M#M#^0BF[G3B!JAL/_@!02P,$%
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M*]_7:0D5U1>R!H%?<JDJ:M!4A:]K!31SH(K[41#$?D69\)*IVUNI9"H;PYF
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M6465-<#]M91F/[$?J!YJT[]02P,$%     @ V(%94H6R*NH, P  K0H  !D
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M:&> SV=*V>V%2]#\H##]%U!+ P04    " #8@5E2 >H-=O<$  !+'   &0
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M-MC![K3:8H,D?*G%&=2V]&P0M3,?]!@-]@K8T O;Z=50]O6- ZZ-7Q//7]@
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M/K+8N2I.E#CDFS]/0BD1YX=[SC9<9@;Z_E8(=3[)%JCV#Y?_ U!+ P04
M" #8@5E2<#D!!,H%  ">)   &0   'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6R]FF%OVR@8Q[\*BO9BD[HE@"')U$;:VNUNTBI5ZW;WXG0O:$P:WVR38=RL
MTWWXPX[KQTD<<"^MWS2V\_#GX6_X!2BG:Z6_9TLI#?J9Q&EV-E@:LWH['&;S
MI4Q$]D:M9&J_62B="&-O]>TP6VDIPK)0$@_):,2'B8C2P>RT?':E9Z<J-W&4
MRBN-LCQ)A+Y_+V.U/AO@P<.#+]'MTA0/AK/3E;B5U])\6UUI>S>L5<(HD6D6
MJ11IN3@;O,-OS\>CHD 9\4<DUUGC&A5-N5'J>W'S*3P;C(J,9"SGII 0]N-.
MGLLX+I1L'C\JT4%=9U&P>?V@_K%LO&W,C<CDN8K_C$*S/!M,!BB4"Y''YHM:
M_RZK!K%";Z[BK/R+UE7L:(#F>6944A6V&211NOD4/RLC&@4P/U" 5 7(;H'@
M0 %:%:!E0S>9E<VZ$$;,3K5:(UU$6[7BHO2F+&U;$Z7%:[PVVGX;V7)F=J5M
MC]#F'HDT1!]^Y-'*OB-S@E+;@UZC:]MKPCR62"W00^0)NHI%:K8+H)<7TH@H
MSE[94M^N+]#+%Z_0"Q2EZ.M2Y9F-S4Z'QN9;U#J<5[F]W^1&#N2&";I4J5EF
MZ$,:RG!;8&@;6K>6/+3V/7$J7LCY&T3Q"2(C,FI)Z+QS<3QUI$-K\VFI1SWF
MMUOZUV<;CCX9F61_.RH+ZLJ"LK*@RYN6\*9_TRIK?3D;.5;*%32XF[$)L<V^
M:QK6%C2A==!6IJS.E#DS?3>?YTD>"R-#.R(MG>:1V(QYF[E(E#;1K_)!6]8;
M:=Y(Z'7 V7@G[;8H0GA[WKS.F_\OA^U8:LN4[UF'\9CL),KW$L7-UFSE.:[S
M'#OSO(S2*,D31Y^:U$J3Y^_ T[JRJ3/M#YF)DK)3Q-%"MCGJ+D_1O10Z<V2"
M1T#-D=M"\=-C(6X0&#^_B9A =>1(&ST">.0W$@B(J5/L7"4KD=Z_5NO49K2(
MY>Y8V=8%V.&@!U.!6-B-K$?#M=)KCGY*&P#:C'Z\SRE*)ZQ]^&/@%':#JL5T
M]"_R8P$#8?"X!_L!0WAR;)]V"W1@ V *NSESP%TO,0C0AXR>WUT"@"+X2'<]
M H'770+X(F[Z%.[F1MJ5B%J8M=#2I0H8(CW,Q C0B3SQ7(SLS[,F#._0H@KB
M!X*V<P6T$3?:]@SOA H","*\!^N!3,0]^>G0F=T"?E00X!9Q8Z?56S\H $5D
M^OS>4N 2=<^*_-YZ!)C76PK4HF[H?)9V=;]4<8BB9*75G2S:[%(&!%'2@ZN-
M1:)[BO1H6%1Z35APN@N+*H@?"-K.%<!&W6!K-;T3,"@ B;(>[ <^4?=DJ4.G
M=@MTZ-1 +^J&ST%_O="@ "7:PZ*. J/HL<LZCT"']4@ " O<!/J8ZS0RN98G
M2"T6T5R6S8\+VQN#SU45 "KH8=T7 +4"]\3I\?L_9']O9V\CI0KB6T%!.T8"
M0%[@1EZWM]")*T%C?ZR')6, & O<\RI_O_<(^"<B 4 N<#.JN^%>T 0 LZ"'
M16( 7 N.721Z!,9^PX%Z@1M:EV*^M(_TSG!T:#-@&.MA><B 8\P]T7HT6"J]
M)EC(='=^4@4UP4(FTP,;RP!!YH;@ =L[D80!OE@/JTD&X&+N29>_8WL$_"1A
MC;U[-Y4<#GO1P8!7K(=%(P-2L6,7C1X!/SH8<(RY,?15J3@[08F=!=J/,))9
MV?Q_HENG/J")];!HY$ K?NRBT2/@GU]S8!E_8I;Q?99-=W=Q^3[*IH?^U00D
MX]WVP38OWR8=K992B]CI Q",]T P#@3C3[P?QO?WP\:[4U-WS':F@#?>;3=L
MS_9./R&\\:_$'@#' 7#\6,!Y!/P_(1P Q[OMBK5Z[/T1X0 ZW@/HQ@"Z\;&@
M\P@X0#=LG !)I+XM#\9D:*[RU&P.@]1/Z\,W[\HC)T,(WYS<N13Z-DHS._E?
MV**C-V,[(/3F,,SFQJA5>9[D1AFCDO)R*44H=1%@OU\H91YNB@KJ(TFS_P!0
M2P,$%     @ V(%94KR:(4)+ @  -P4  !D   !X;"]W;W)K<VAE971S+W-H
M965T-30N>&ULC53?;]HP$/Y7K*@/K<0(!,K6"B(5Z+0]=$+MNCU,>S#)0:PZ
M=FI?@.ZOW]D.*:U*MY?$/M_WW0_?Y_%6FP=; "#;E5+9250@5I=Q;+,"2FZ[
MN@)%)RMM2HZT->O85@9X[D&EC)->;Q277*@H'7O;PJ1C7:,4"A:&V;HLN7F:
M@M3;2=2/]H9;L2[0&>)T7/$UW '>5PM#N[AER44)R@JMF('5)+KJ7\Z&SM\[
M_!"PM0=KYBI9:OW@-E_S2=1S"8&$#!T#I]\&9B"E(Z(T'AO.J WI@(?K/?MG
M7SO5LN069EK^%#D6D^A3Q')8\5KBK=Y^@::><\>7:6G]EVV#[\?SB&6U15TV
M8,J@%"K\^:[IPP&@/SH"2!I \AHP/ (8-("!+S1DYLN:<^3IV.@M,\Z;V-S"
M]\:CJ1JAW"W>H:%303A,%X8&PN 3XRIGUX^UJ.B*L,,4#= ']HT;PUV?V>D<
MD MIS\AZ?S=GIR=G[(0)Q;X7NK8$MN,8*1_'&F=-[&F(G1R)W4_8C5986':M
M<LA?$L142%M-LJ]FFKS+.(>LRP;]#DMZ2>^-A&;_#>]?O)/.H&WNP/,-_M'<
M#EM(KO!EC]FOJZ5%0W/\^YU0PS;4T(<:'DV=1)P)'K1!<7BI#8H_P0 [4KV%
MMZXHT)Y[6B?Y33IRK=L<=NT-GXMGGY!O?#"#)9BUEZ9EF:X5A@MLK:WZK_S0
MO[)/Z54((GZF"4_*#3=KH2R3L"+*7M>)T 29A@WJRD_Z4B/IQB\+>MG . <Z
M7VF-^XT+T+Z5Z5]02P,$%     @ V(%94M5%4$1R @  :P8  !D   !X;"]W
M;W)K<VAE971S+W-H965T-34N>&ULE95=;YLP%(;_BH5ZT4I=^0Q-*H*4)IHV
M:=.JIMTNIETX< A6C9W9)J3_?K:A*$U(U-V /\[[GN<<P"0-%R^R!%!H5U$F
MITZIU.;.=6560H7E#=\ TSL%%Q56>BK6KMP(P+D55=0-/"]V*TR8DR9V[4&D
M":\5)0P>!))U56'Q>@^4-U/'=]X6'LFZ5&;!39,-7L,2U//F0>B9V[ODI (F
M"6=(0#%U9O[=/#;Q-N G@4;NC9&I9,7YBYE\S:>.9X" 0J:, ]:W+<R!4F.D
M,?YVGDZ?T@CWQV_NGVWMNI85EC#G]!?)53EUQ@[*H< U58^\^0)=/2/CEW$J
M[14U7:SGH*R6BE>=6!-4A+5WO.OZL"?PHQ."H!,$'Q6$G2"TA;9DMJP%5CA-
M!&^0,-':S0QL;ZQ:5T.8>8I+)?0NT3J5SK),U)"C;P2O""6*@$2?T%*_+'E-
M ?$"#45<+D!A0N65CGU>+M#EQ16Z0(2AIY+7$K-<)J[2=":'FW4D]RU)<()D
M =D-"OUK%'B!-R"??UCN3][+7=V3OC%!WYC ^H7_T1A=&/JA2A#O5G_/5E()
M_3[^.9,V[-.&-FUT(NT24RRTZS5: 8."J#:K (J5IH&=_GPE#+:W-1Y98_/Q
M;E/?GT2)N]UOXD"0-QGW0>^8HYXY.LN\@"W) #58",S4ZQ!;:Q#OIQV/#]".
M8X+Q:)ALU).-SI+9AS7$,SK*%=T>X!R'A)XWC!/W./%9G">N,!W"B8^?2A1,
M#H &@N)Q>$#D[AT%YAC^CL6:,(DH%%KFW=QJO6B/MG:B^,:>#BNN]%ECAZ7^
M&X P 7J_X%R]3<R!T_]?TG]02P,$%     @ V(%94M;$98'8 P  5PP  !D
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MQCG0^49K/&Q<@&XJIW\ 4$L#!!0    ( -B!65(6T#<JN (  (T'   9
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;+55W6^;,!#_5TZH#ZVT%4(^5R61
MVF33*J52U+3;P[0'%RZ :FQF.TGSW^]L"(LRPK:'O8!M_/NX.WP>[Z1ZU2FB
M@;><"SWQ4F.*&]_748HYT]>R0$%?UE+ES-!4);XN%++8@7+NAT$P\'.6"6\Z
M=FM+-1W+C>&9P*4"O<ESIO9WR.5NXG6\P\)CEJ3&+OC3<<$27*%Y+I:*9G[-
M$F<Y"IU) 0K7$^^V<S,?V?UNPY<,=_IH##:2%RE?[>0^GGB!-80<(V,9&+VV
M.$/.+1'9^%%Q>K6D!1Z/#^R?7.P4RPO3.)/\:Q:;=.*-/(AQS3;</,K=9ZSB
MZ5N^2'+MGK K]PY"#Z*--C*OP.0@ST3Y9F]5'HX Q-,,""M > H8G %T*T#W
M%- [ ^A5@)[+3!F*R\.<&38=*[D#97<3FQVX9#HTA9\)6_:54?0U(YR9/B)G
M!F-8,F7V\*28T,Q51,/E' W+N+Z"]_"\FL/EQ15<0";@*94;S42LQ[XA"Y;(
MCRJYNU(N/"/7@0<I3*KAHX@Q;L#/_H /6PA\BKU.0'A(P%W8RKC"XAJZP3L(
M@\ZPR5 [?(X1P3L6'@8-\/E?PSL?6J+IUN7L.K[NOY83OBUH*]P;S/7W%J%>
M+=1S0KTS0DLE(\18PUK)'#3C"')-/\<6A9%J#P49T$ _"1@I"9PTI;:4Z#L)
MVY^VTUY_[&\;;/5K6_U66[<B00Y+2;HS5F2&<5@L9BWQ#FKBP?]-[+ 6&K9&
M,*.C1SV+,@8L48C48@T85'G386NGZL >F6KQ-*H]C=JSFI"3A.*GLNZMH::3
M/Q_]5LUN<%)-_ZA1Y:@2U_ U1'(C3'EDZ]7Z3KEUK?1D?49W37DU_*(I+ZH'
MII*,NA?'-5$&UT,RI,KF7TZ,+%P[?)&&FJL;IG1?HK(;Z/M:2G.86('Z!I[^
M!%!+ P04    " #8@5E2O>*/<_\)  #?/P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970V-"YX;6R]6UMOV[@2_BN$L0=H@=;6C;HLD@!MG*0)VMV@.=T^')P'
M5:9MH;IX*3EI%OOCE[K8(UGBB/9&S4-\(X=S_69(CLZ>4OX]6S.6DQ]QE&3G
MDW6>;WZ=S;)@S6(_FZ8;EHA?EBF/_5Q\Y*M9MN',7Y23XFAF:)H]B_TPF5R<
ME=_=\XNS=)M'8<+N.<FV<>SSY_<L2I_.)_ID]\7G<+7.BR]F%V<;?\4>6/YE
M<\_%I]F>RB*,69*%:4(X6YY/WNF_WND:+6:40_X(V5/6>$\*6;ZEZ??BP^WB
M?*(5++&(!7E!PQ<OC^R215%!2C#R9TUULE^TF-A\OZ-^74HOI/GF9^PRC;Z&
MBWQ]/G$G9,&6_C;*/Z=/'U@M4<E@D$99^9\\U6.U"0FV69[&]63!01PFU:O_
MH]9$8X)N2288]03C8(*I2R:8]03S<((CF6#5$ZS#"3(9:#V!JJY@UQ-LU0E.
M/<$YF&"XD@EN/<%5E<&K)WBJ$W1M9SFM]*#*Y*6_S/W<OSCCZ1/AQ7A!KWA3
M.ETY7[A)F!0!\I!S\6LHYN47E_XFS/TH_,NOW#59D*L_MV'^3,2H;9!O.2-O
MR6\^YW[AR.35G.5^&&6OR2]D1K*USUE&PH1\2<(\>R.^%.__NTZWF:"4G<UR
MP6*QT"RHV7E?L6-(V/GD\RDQK#?$T RM9_HE/OWW()\24Z^F?WF8DU>_O 8^
M>^C-<7IWVT30TR3TI%2O<*IS%NRXU#T%<M?*Y(YA\N8()M6I?L"I/K#-E.AV
M177A/V>H=6X5B%76T1T%WN[4):8XN9F(LGVH&?M0,TKZIBS4(C_+2+HD7XMH
M2G*2<E(F)/*_CV(HN<U9G/T?6<C<+V26"UDRO?@1*]:IH_.5",E%&D4^S\B&
M\>KKU^1O@NK^0[4&+=<HTNSCA7XV>^QAR]JS9:%L_;:-OXGE!6.7:9*Q8%L"
MROMM)L8)Q13>()@J7OK8J6C;#79,K9\?NN>'HOQ<IG$L($^ ;/#]S4Y9_C9?
MISS\BRU*O57?ONZ+<=IA2+=TR_ T#?BJPE=YY(W*R):L]EY6&Y7U7E0=C',A
MU:GBVEW6M.KO0%K5@3<* UNR.GM9G>/M&F;9=EA(I\,2=3S:E;$[SC6M'GL.
MTVM)Z.XE=(^74%2_62ZR;IBLAL1T%<7LCNL7<YA>2TQO+Z9WDM.JV=+K,'4H
MWN"(&VQ$2R1=@WI+.TFH(\Q7KX")-CSD!AW2%JY13.HJ$/]4);B,!'X4#5KJ
MKB9Z 'M2]]$AX>H&RL[7'1]*'G-=4VORX7FVG _(QSJ>D'<)G_T0^]J,%:FW
M=_UNRC4-[]!L/7E9\VP)BY";=3PY?V)\Q?CL_O[WG?5VCLE^,!Z$F8+ZNBG:
M,4RY^B!/ZWBB_I@6=5-"XG01+L.@VJF(,F+O9C)]THZJ.D'0'6)01\(P)%L=
MS[:?V2/CPLYEA)-L$X5Y[U:HHN(U^9MJMBU;'Q*@CF= L6UAY6Y@5VIBY:L.
M64=WQRU@=4!^'8?^_5)/L!0OEQ(Q%/+*!40Q&Z:+7LOCU"EY9D4U; N72O(U
M6MP#L!LXL(/2;Y-')DS/5;1O +8:^KC:-QH;%1PWK^J0)QL>!NS$#<2\7L1M
ME@53W3W(5$.CVB( Y!HXY/Y+!QJ@?HP# 00;. 2# ]U'?L!B)KA^MRK^J_@1
MH*E!1_8CP$$#Q\$7\B.[QT-LZ]"/!D:U10 H-08V$U(_"OQL39:,%:($PDK^
MBO5RC]-WIIKV'TS9@,[&P*9@F-/^/#FO"3>3(*6&1', X<:I$![[B5!6Z=\*
M^L-7T0?T9P)^FSA^*_,KT6)-OJE%Q^M7H@F@;^(%]?U>-ZV"IZYG\Y1LMCQ8
M^T6M46\CEB1H[ Y[&<67'/)($]*(^9+E]]SLEM^Z84CK1[-Q'#9J+AB@7N<"
M3&.0 DP\!:AM%.8UE::K>9*,:4)>,/$J^U88R4\$3 =I)JVIYV;WB,K59&M#
MHC#Q1''MAYP\^M&6*=3U<[-[<F1JLE #I#=Q))XSD7.+W6MQ-+WG 3,K0+,Y
M<N%L NJ:.!Z^2,J]KA=I)E-W*CO^!82U3D58E3B\&J#>&X>5. ,S=U4<T8O3
M9\0,%N"VA8/H?,OWV]3-5DBZ*3[UW<(,$#*UGA/Q-E. QQ:.Q_=[1LC&?Y9K
M^F: #AUD":#9PL&S'70GU+U6X_;!&C<(+8!2"X?2%PG"JWJ1=A!:!W7OS="H
MM@B R!:.R$<>G5E=2):D;0L V3JU]%9*VP/4A].V!?ANX:7W"QR>6=TS=)D"
M(1=8>"Y0"R[AAY=I4AQ8E?HL/!91"@6TI]JX\48!;2D.DH?\GYKVZF4&(JX>
M59R?*X0<!7BF.*Q^$IA<6DH!]B@@+#5'-@,@+,6KUY>I/>I%FD8PI[+M*&U<
M]N*8?"2@T6Z=*[MN!DRE.*;^2T ;H#X,:!2@E^+@^-"Y:#O%D$['D-:42JI(
M"F!+1P=;V@5;PY)?]%! 7(HC;B>$CP-7&\#5'AE<;0!7^^> J]T%UU9<UTT!
MW5%T*KD0L0%:;1Q:;Y.JE;1L<2NSG\+^S@:,M4?&6!LPUE9JHCGNAO76[E[-
MZ?*;.1M U?X)A>ZMW2UA#6-*)<PU6EYP0"S:N)3L#+!H.R/;&5#.'AWE;*RD
MK*.M.\24]VW8@(,VCH,GWMC>U&25KF,= $L'W]_/0\X"8:SE4N369(78QP%4
M=$:^C7, O!P<O-ZM5IRM_+R(LC1@;"$]&'.Z)ZB.Z\G:J0#>''R3KG8R6!-I
M88RNRXP'@.?@@'=@/+'Z4;?;#F"9,_*]F /(Y.#(=(1%N_MJPZ8RBS8ZY/#Z
M3M&B#MJ/TEX;D,W!D>U=_C9?L[>QS[\SM: $V'&\<4WH J:X.*:\2(_M9;U(
M,_/94T>2^5P )Q<OV?[8G:37W&5IM) 8^;(FU;JVHM(&10 M%P>M9HMB*V:/
M:8YP :+<D2LP%P#)':$"NW:[%9CE./).4( M5[V+62CZF$,$%P#+M4=6+T"3
MBT/3B>KM=MIB.SJWT6FKWFHKU*M>2KB 6N[(J.4!:GDX:D$+?A,9!NYEO6ZC
MJ.Y8KKR]%W#*&Z%=],KKMHM2:G>[DH?'M=D&;/->JB"K";4Z*PQ+Q@"@G?<2
M!9G7[12U9!T)'L"?A\,?'A G0[T'@.>-7*=Y 'L>7J>=Y)]SKUNSN8[5[:X?
M'M=F&R#44W\ HM=$QR0)#Z#2&_F6VVL\&(#O+T\T3+>=W[+D"M>U9E,_#JS[
M\[ZE$%K>@'- O]%7KXV\W=2U1M>\AN/;:2EX1[6I7J1Y7FMTSVM*[?-=Y1:N
M'"9AO(U1R1M-\-K(=\3%D^*PV$\X/+O;K=(Z9M>GQN$F8M9X1KAX]/V3SU=A
MDI&(+<4\;5KLCGGU,'GU(4\WY6/#W](\3^/R[9KY"\:+ >+W99KFNP_%D\C[
M9_HO_@%02P,$%     @ V(%94KNHJ=G6!@  OC,  !D   !X;"]W;W)K<VAE
M971S+W-H965T-C4N>&ULO=M;;]LV% #@OT(8>VB!QC)OHE0D 9*TPS(L2-!T
M*X9B#XK-Q$)U<24Y3H;]^%&7^"B1*+$+IY?4%Q[JZ$C\2IG2X2[-ON5K*0OT
M$$=)?C1;%\7FO>/DR[6,@WR>;F2BOKE-LS@HU-OLSLDWF0Q655 <.62Q<)TX
M")/9\6'UV55V?)ANBRA,Y%6&\FT<!]GCJ8S2W=$,SYX^^!3>K8OR ^?X<!/<
MR6M9_+ZYRM0[9]_+*HQEDH=I@C)Y>S0[P>_/?%H&5"W^".4N;[U&Y:[<I.FW
M\LWYZFBV*#.2D5P691>!^N=>GLDH*GM2>7QO.IWMMUD&ME\_]?YSM?-J9VZ"
M7)ZET9=P5:R/9MX,K>1ML(V*3^GN%]GL$"_[6Z917OU%NZ;M8H:6V[Q(XR98
M91"'2?UO\- 4HA5 =0&D"2"F ;0)J"KGU)E5N_4A*(+CPRS=H:QLK7HK7U2U
MJ:+5WH1)>1BOBTQ]&ZJXXO@LV(1%$(5_!W55DQ7Z^'T;%H](M=HNBVTFT0&Z
M5F?/:AM)E-ZB+T&6!4F!KM>!^NZD/ QE\S<?9!&$4?X6Y>47.0H3]'F=;G/5
M97[H%"K7<HO.LLGKM,Z+:/+"Z")-BG6./B8KN>J)/QN))P,=.*I(^TJ1ITJ=
MDL$>/\CE'%'\#I$%]G]"3K.?]=^^!(V[(XOA[IZE2_<'EE;]4]V!C8(\1Y=P
MO"XS5 W2=^AR6^2%.BQA<H>^?DJC"*D1L0NRU5\#VV7[[;)JNTRSW69S.4I;
M6WFC3H9ZS][V5:KNT:UZ+-VY/\98>(?.?4\>?)\'-\LCS/.M7(VEP#LI^+[;
MGX&[S\ URT ^;,)L/ 6WD\(!)IH<Q#X'89J#S)9A/IZ%Z&8A".W/PMMGX=D^
M)TZ]X7.B3K:G$26\/UE_GZP_F.ROVT16@Q*=)_=2 9P]#:&A88D7 .YB<&"V
M+7VN[[LG>K_^IF+0>2'C?&A(XA;R>'"?/C9''VVR<"FKTJ_4N ^R'&UD5A^&
MM^@?! [UBEMOQ&N5F\^Q9IQB LF1P>0^RRQ&;_Z4*IO>,W(DG*/',A2Y**[
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MA9\];72Y@I[NJ)[<Q$H!5HJIK!1@I9C"2M&UDN&Y[JX& 5B*UV$Y$CX^WQ2
MI9@62P%8"OM8BAXL%YH%4@%:"JM:"F,M!6@I[&HI^K345J)UBY+U>Y2,N13
MI;#/I>CALE6/)EEC+P5X*8:]O,KD@3*3H=VXF1Z8Z4UEI@=F>E.8Z77-Q(S-
M?<UM:V"F1R:%R@,B/6H=JJ;+]IFFN0SS $S/$$PSICSC570/I/0,I31DRNM2
M>:"K UCI&5MIB)1G?'7N 96>(94_<B-E%\N7:S$]372IMF[Y'/:T0Y0:Q!=A
M$L;;>&B  (&>/Q%6/@#I+UXUA1H)]T>G4#ZXZ0^[V5O>X&&DO#[(YP_+9[&\
M8)X_;-YH>8?#\4)?7Z?UA$0LL[OJP9$<+=-M4M0/2^P_W3^<<E(]DN% \_K)
MEHL@NPN3'$7R5H4NYN7,+*L?%JG?%.FF>M[B)BV*-*Y>KF6PDEG90'U_FZ;%
MTYMR _M'=H[_!5!+ P04    " #8@5E23PL=Z*H&  #*+0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V-BYX;6R]FMMNVS@0AE^%,/:B!5I;% ^RBR1 Z[38
M%AL@:+'MQ6(O&)N)A>C@4G3<+/KP2\FR1I8E2G(2Y<*Q[.&(Y"?^_#W2V396
M]\E*2HU^A4&4G(]66J_?32;)8B5#D8SCM8S,-[>Q"H4VA^INDJR5%,NL41A,
M7,?ADU#XT>CB+/OL6EV<Q1L=^)&\5BC9A*%0CQ]D$&_/1WBT_^"K?[?2Z0>3
MB[.UN)/?I/Y[?:W,T:3(LO1#&25^'"$E;\]'[_&[2X^G#;*([[[<)J7W*!W*
M31S?IP>?E^<C)^V1#.1"IRF$^?<@YS((TDRF'S_SI*/BG&G#\OM]]D_9X,U@
M;D0BYW'PPU_JU?EH.D)+>2LV@?X:;_^4^8!8FF\1!TGVBK9YK#-"BTVBXS!O
M;'H0^M'NO_B53T2I@4L;&KAY [?:@#<T('D#TK4!S1O0;&9V0\GFX5)H<7&F
MXBU2:;3)EK[))C-K;8;O1RGW;UJ9;WW33E_,Q=K7(O#_$SL,T1)]_+GQ]2,R
M49N%WBB)WJ)OYG);;@*)XEOT/C'7R#J-3M FD4OD1^A#(!;W;TU4',@$7<5+
M&2 =HRLIDC3!)^$K]%T$&XE>74HM_"!Y?3;1IOMI)R:+O*L?=EUU&[KZ91.-
M$7;>(-=QG3_0!"4KH612DVAN3W0I%V-$<(=$EYT3X5E3HHDA4F!Q"RQNEIDV
M8=DH)2.]2XC6RE](]!N9&9!9I]'GZ$&::T.A'T(I$6G;.4EQ3I*=DS2<LPSY
M\+)XL[\F_OG+M$&?M0R3?RUGI,49:>]1OC*7TS(. J$2M)9J]UWMU;++/<UR
MI_+V<$'&4WPV>2A?"<=!?(Q)$730;59TFST)SMJL!AFF$48YS>NVG1$O3LT'
M8N059_1>D-$N-W;LD&JBFBE-BXY/3Z!DEJP,;TR?TR7;9?7,BM/-!B*#'=!N
MY^78S//DS=.>2Z!SM(38>,KKX>#2OH.?C.>Z6$COLX74 1<&A<7N4,! 83%Y
M26"D&[":, LQ$&O<7ZU_HROQV'DM85!8S(:" ]**^4O"X=W@U(19X(!*XQ:9
MCHTC4)D;?YI;P*"O>#H4(Q!9/.LWS.Y;49ZY,O-X6MF+6L,._1QHM=NBU39
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M,-_?QK'>'Z1/YQ:/;U_\#U!+ P04    " #8@5E2\;TX.:@"  #E!P  &0
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M- ;X?R6$W@V,@ZI+G_P&4$L#!!0    ( -B!65+@P&#Y4@,  -,+   9
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M;N!N>"[A\Z A>H/FZ/4K'_JM/IBUP&%\1KE_I'SC>=UFZ4$E/6B5AE"N";U
M?' DW@V:I5WG\QYR6L7G[QD5YZ5+EL/]<T)[[PYTOWBK+TK&P]3O[:Y#3[Q/
M3[SV*+#H/\JO)*OMWMH67S1:U6-F[[40*1$;TQU*%/*<J>) KF:K#O3>]%VU
M^8E[-W,;YN>Z8S4MRR=]T>["A0K;3J*$K$'*N0W@>!%%!UD,%,], [/B"MHA
M\QE#UTV$-H#_:\[5;J %JCY^_ ]02P,$%     @ V(%94JC2JAN- @  &0<
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M49YVE W%\^*$X9$KQ=/B<H4T1F$&Z/L+SM6V81S49T[S?P%02P,$%     @
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MD9()7NQ8%B>2K<TNX1V3DF7F<$5)3+D>H.XO&).[$^V@W#>>_0]02P,$%
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MB'@#\24*_7,4>(%W@-#XO]/];@.=L'(QM'CA,1=3+*"T9X)?]-],H:'0@B_
MC,^W-B56\#'.B<*4_(7D' TSOM+1O[YH2'2O()._&PBU*D(M2ZAUA-"K;P2*
MEQ_RK4!I6Q1SXJP'0<O7@J[K6AX("MKM*N@5P79%L-U(<(9I^?GITVL)BK!%
M0]E1A1I]#!\Z%:'.N_A0H$0UB5N=:,^&MS%1.SSLPE5%[ZJ1WA0D8!&G5HX$
MUOI6R8U0#95W*^CNQ[#"]W9'K?<N9I0P=:6#;KCGQJ&@EG_8#K]V&_B-%.^
M@<#4:H(3?=\0J00V-VV3 L$./O@@INQ.3C]\'U/"-Z>0']4$+UTY$!5&^[:X
MM?LZ [&P;8Q$L:FPN(.JU:I5&MH&86]]9%HHVP?L8(K^ZP&+!='7+X6YAO0N
M.YJ2*%J:8J)X;KN")ZYTCV&'J6X#09@ O3_G7&TGY@558SGX!U!+ P04
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M16$.Z/V,<W6:F NZ)GGY'U!+ P04    " #8@5E2DF>4!*P#   <#   &0
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MS:"2+1,S&H*T!N9\+81^V=AII1PV)[\ 4$L#!!0    ( -B!65*M8LS$E ,
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M'H"@X(*F&BPC2..L^L=/.A$M '1[ $@#T*$ 1P.<0P&N!KB' D8:,#H4X&F
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M(VOV>M$LO.?N/HERP?L6F$-KT/D1PV"-: QO$24K24Q4CABA6VN>&4,JJ)!
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M;%!+ 0(4 Q0    ( -B!65+,1F-T[P   "L"   1              "  :\
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M2P$"% ,4    " #8@5E2+Z-3MA,#  "A"@  &               @($]%0
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ V(%94L9=P')P
M!0  AQ,  !@              ("!AA@  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( -B!65(@ P7F9P8  #D>   8              "
M@2P>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #8@5E2
M@X"Q+ H)  ![)@  &               @('))   >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ V(%94N"5GSXC"0  >Q0  !@
M     ("!"2X  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M -B!65(AW^01S"$  $%I   8              " @6(W  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #8@5E2VN?XKKL#   ]"0  &
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M970Q,RYX;6Q02P$"% ,4    " #8@5E201,;2)@$  !L"@  &0
M    @('[=   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M -B!65*AW8,""PL  (X>   9              " @<IY  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ V(%94ER8)091!0  %PP  !D
M             ("!#(4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #8@5E2"VRLK.,"  !O!@  &0              @(&4B@  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( -B!65)C^)2Z%@0
M #X)   9              " @:Z-  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ V(%94HFHA3W_%P  5UT  !D              ("!
M^Y$  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #8@5E2
MLD?26ZD+  !\'P  &0              @($QJ@  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( -B!65+'<;3!O D  '$:   9
M      " @1&V  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ V(%94K6PBHH\!@  5 X  !D              ("!!,   'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #8@5E2Z(HGC4($  "["0
M&0              @(%WQ@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( -B!65(BVZU5%P0  & )   9              " @?#*  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ V(%94B-7]4W8
M'P  "F<  !D              ("!/L\  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #8@5E2[.6@=(P#  #!"   &0
M@(%-[P  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -B!
M65(_%:&M^@,  /D)   9              " @1#S  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ V(%94AY\]-O1 P  WPD  !D
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M=#,R+GAM;%!+ 0(4 Q0    ( -B!65(./S>?Y (  #\&   9
M  " @?<( 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MV(%94D<^_<5Z!   KPP  !D              ("!$@P! 'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #8@5E2/>5#_JH&  #X$   &0
M            @('#$ $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( -B!65)HF@IM: 4  ,\-   9              " @:07 0!X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ V(%94DJ?!&<) P
M8@8  !D              ("!0QT! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #8@5E2GSG7)PH#   I!P  &0              @(&#
M( $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -B!65(J
ML_,!-P0  /@/   9              " @<0C 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ V(%94A?AW49L!   GQ4  !D
M     ("!,B@! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -B!65*%LBKJ# ,  *T*   9              "
M@<@X 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ V(%9
M4G?/%P%8 @  2P4  !D              ("!"SP! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " #8@5E2YWNW/RX#   G#0  &0
M        @(&:/@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( -B!65(VOA?5*00  "(0   9              " @?]! 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ V(%94F,4/:#+ @  [P<
M !D              ("!7T8! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " #8@5E2GRF:&8L"   ?!@  &0              @(%A20$
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -B!65+ &'[X
M^P,  %P0   9              " @2-, 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ V(%94@'J#7;W!   2QP  !D
M ("!55 ! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #8
M@5E2<#D!!,H%  ">)   &0              @(&#50$ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( -B!65*\FB%"2P(  #<%   9
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M970U."YX;6Q02P$"% ,4    " #8@5E2J9U'1JT"  #%"   &0
M    @('T:P$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M -B!65+?Z;G5* ,  ,0*   9              " @=AN 0!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ V(%94BC%0F$. P  20D  !D
M             ("!-W(! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " #8@5E2*.DF,5L"  "A!0  &0              @(%\=0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( -B!65(6T#<JN (
M (T'   9              " @0YX 0!X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ V(%94KWBCW/_"0  WS\  !D              ("!
M_7H! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #8@5E2
MNZBIV=8&  "^,P  &0              @($SA0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( -B!65)/"QWHJ@8  ,HM   9
M      " @4", 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ V(%94O&].#FH @  Y0<  !D              ("!(9,! 'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #8@5E2PC)V,FH#  "Q"P
M&0              @($ E@$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( -B!65+@P&#Y4@,  -,+   9              " @:&9 0!X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ V(%94JC2JAN-
M @  &0<  !D              ("!*IT! 'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    " #8@5E2)ZJUKG8$  !_$@  &0
M@('NGP$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( -B!
M65*)1!6A7P,  #$*   9              " @9ND 0!X;"]W;W)K<VAE971S
M+W-H965T-S(N>&UL4$L! A0#%     @ V(%94DZZ1Q1:!0  0QX  !D
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M=#<W+GAM;%!+ 0(4 Q0    ( -B!65*<,]XZF (  'D&   9
M  " @2>\ 0!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @
MV(%94G-LUP#> P  [@\  !D              ("!]KX! 'AL+W=O<FMS:&5E
M=',O<VAE970W.2YX;6Q02P$"% ,4    " #8@5E2DOJ9'F #   P"P  &0
M            @($+PP$ >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4
M Q0    ( -B!65*29Y0$K ,  !P,   9              " @:+& 0!X;"]W
M;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ V(%94FH2K8.N @
MD08  !D              ("!A<H! 'AL+W=O<FMS:&5E=',O<VAE970X,BYX
M;6Q02P$"% ,4    " #8@5E2X1Q1$1\#  !I"@  &0              @(%J
MS0$ >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( -B!65(_
M2Q;S#P,  '@*   9              " @<#0 0!X;"]W;W)K<VAE971S+W-H
M965T.#0N>&UL4$L! A0#%     @ V(%94JUBS,24 P  8 T  !D
M     ("!!M0! 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4
M" #8@5E2"#X_(K0"  #:!P  &0              @('1UP$ >&PO=V]R:W-H
M965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( -B!65*LQW$@J@0  - 4   9
M              " @;S: 0!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L!
M A0#%     @ V(%94OCKMOUA @  2@T   T              ( !G=\! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #8@5E2EXJ[',     3 @  "P
M        @ $IX@$ 7W)E;',O+G)E;'-02P$"% ,4    " #8@5E2!68>7"\&
M  !L.0  #P              @ $2XP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ V(%94D#*==&. @  3#,  !H              ( !;ND! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ V(%94B';^;$Q @
MS3$  !,              ( !-.P! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     %\ 7P 0&@  ENX!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>318</ContextCount>
  <ElementCount>481</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>96</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies and Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates</Role>
      <ShortName>Summary of Significant Accounting Policies and Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Net Loss Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/NetLossPerShareofCommonStock</Role>
      <ShortName>Net Loss Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Investment in Unconsolidated Affiliate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate</Role>
      <ShortName>Investment in Unconsolidated Affiliate</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - Notes payable, net</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eksobionics.com/role/Notespayablenet</Role>
      <ShortName>Notes payable, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/LeaseObligations</Role>
      <ShortName>Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2145112 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Capitalization and Equity Structure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/CapitalizationandEquityStructure</Role>
      <ShortName>Capitalization and Equity Structure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2152114 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2165115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2172116 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2176117 - Disclosure - Segment Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SegmentDisclosures</Role>
      <ShortName>Segment Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2180118 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies and Estimates (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Estimates (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies and Estimates (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables</Role>
      <ShortName>Summary of Significant Accounting Policies and Estimates (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Net Loss Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables</Role>
      <ShortName>Net Loss Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/NetLossPerShareofCommonStock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/FairValueMeasurement</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/RevenueRecognition</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/AccruedLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Notes payable, net (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eksobionics.com/role/NotespayablenetTables</Role>
      <ShortName>Notes payable, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/Notespayablenet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/LeaseObligationsTables</Role>
      <ShortName>Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/LeaseObligations</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2348309 - Disclosure - Capitalization and Equity Structure (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/CapitalizationandEquityStructureTables</Role>
      <ShortName>Capitalization and Equity Structure (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/CapitalizationandEquityStructure</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2353310 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/StockbasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2366311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2373312 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2377313 - Disclosure - Segment Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SegmentDisclosuresTables</Role>
      <ShortName>Segment Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/SegmentDisclosures</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/Organization</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies and Estimates - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Estimates - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Estimates - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Estimates - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Estimates - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Net Loss Per Share of Common Stock - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Investment in Unconsolidated Affiliate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliateDetails</Role>
      <ShortName>Investment in Unconsolidated Affiliate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Fair Value Measurement - Schedule of Fair Value Hierarchies for Financial Assets and Liabilities on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Schedule of Fair Value Hierarchies for Financial Assets and Liabilities on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Fair Value Measurement - Summary of Changes in Fair Value of Level 3 Financial Liabilities on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Summary of Changes in Fair Value of Level 3 Financial Liabilities on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Revenue Recognition - Summary of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails</Role>
      <ShortName>Revenue Recognition - Summary of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Revenue Recognition - Summary of Deferred Revenue Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails</Role>
      <ShortName>Revenue Recognition - Summary of Deferred Revenue Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Revenue Recognition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Revenue Recognition - Summary of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Summary of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Property and Equipment, net - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property and Equipment, net - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Property and Equipment, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/PropertyandEquipmentnetNarrativeDetails</Role>
      <ShortName>Property and Equipment, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Accrued Liabilities - Schedule of Warranty Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Warranty Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Notes payable, net - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails</Role>
      <ShortName>Notes payable, net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Notes payable, net - Debt Repayment (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails</Role>
      <ShortName>Notes payable, net - Debt Repayment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Notes payable, net - Principal Repayment (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails</Role>
      <ShortName>Notes payable, net - Principal Repayment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Lease Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails</Role>
      <ShortName>Lease Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Lease Obligations - Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails</Role>
      <ShortName>Lease Obligations - Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2449426 - Disclosure - Capitalization and Equity Structure - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails</Role>
      <ShortName>Capitalization and Equity Structure - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2450427 - Disclosure - Capitalization and Equity Structure - Schedule of Warrant Share Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails</Role>
      <ShortName>Capitalization and Equity Structure - Schedule of Warrant Share Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - Capitalization and Equity Structure - Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails</Role>
      <ShortName>Capitalization and Equity Structure - Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - Stock-based Compensation - 2014 Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails</Role>
      <ShortName>Stock-based Compensation - 2014 Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2455430 - Disclosure - Stock-based Compensation - Summary of Increase in Maximum Number of Shares Issuable to Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Increase in Maximum Number of Shares Issuable to Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2456431 - Disclosure - Stock-based Compensation - Summary of Shares Available for Future Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Shares Available for Future Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2457432 - Disclosure - Stock-based Compensation - Stock Options Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Stock Options Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - Stock-based Compensation - Exercised Options Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Exercised Options Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2460435 - Disclosure - Stock-based Compensation - Summary of Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2461436 - Disclosure - Stock-based Compensation - Summary of Share Fair Value of Each Stock Option on Date of Grant using Black-Scholes Model Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Share Fair Value of Each Stock Option on Date of Grant using Black-Scholes Model Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2462437 - Disclosure - Stock-based Compensation - Schedule of Unvested Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Unvested Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2463438 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense Related to Stock Options and RSUs Granted to Employees and Non-employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-based Compensation Expense Related to Stock Options and RSUs Granted to Employees and Non-employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2464439 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2467440 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Pre-tax Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails</Role>
      <ShortName>Income Taxes - Schedule of Domestic and Foreign Components of Pre-tax Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2468441 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2469442 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) Differed from Amounts Computed by Applying Statutory Federal Income Tax Rate to Pretax Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Expense (Benefit) Differed from Amounts Computed by Applying Statutory Federal Income Tax Rate to Pretax Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2470443 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences and Related Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Tax Effects of Temporary Differences and Related Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2471444 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2474445 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2475446 - Disclosure - Commitments and Contingencies - Summary of Outstanding Contractual Obligations Including Interest Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Outstanding Contractual Obligations Including Interest Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2478447 - Disclosure - Segment Disclosures - Schedule of Segment Reporting Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails</Role>
      <ShortName>Segment Disclosures - Schedule of Segment Reporting Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2479448 - Disclosure - Segment Disclosures - Schedule of Geographic Revenue Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails</Role>
      <ShortName>Segment Disclosures - Schedule of Geographic Revenue Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ekso-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2481449 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eksobionics.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eksobionics.com/role/SubsequentEvents</ParentRole>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ekso-20201231.htm">ekso-20201231.htm</File>
    <File>ekso-20201231.xsd</File>
    <File>ekso-20201231_cal.xml</File>
    <File>ekso-20201231_def.xml</File>
    <File>ekso-20201231_lab.xml</File>
    <File>ekso-20201231_pre.xml</File>
    <File>exhibit1030.htm</File>
    <File>exhibit21112312020.htm</File>
    <File>exhibit23112312020.htm</File>
    <File>exhibit31112312020.htm</File>
    <File>exhibit31212312020.htm</File>
    <File>exhibit32112312020.htm</File>
    <File>exhibit32212312020.htm</File>
    <File>exhibit410.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>109
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ekso-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 32,
   "contextCount": 318,
   "dts": {
    "calculationLink": {
     "local": [
      "ekso-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ekso-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ekso-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ekso-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ekso-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ekso-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 672,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 7,
    "http://www.eksobionics.com/20201231": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 4,
    "total": 15
   },
   "keyCustom": 68,
   "keyStandard": 413,
   "memberCustom": 43,
   "memberStandard": 50,
   "nsprefix": "ekso",
   "nsuri": "http://www.eksobionics.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.eksobionics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Investment in Unconsolidated Affiliate",
     "role": "http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate",
     "shortName": "Investment in Unconsolidated Affiliate",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Fair Value Measurement",
     "role": "http://www.eksobionics.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Revenue Recognition",
     "role": "http://www.eksobionics.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Property and Equipment, net",
     "role": "http://www.eksobionics.com/role/PropertyandEquipmentnet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Accrued Liabilities",
     "role": "http://www.eksobionics.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - Notes payable, net",
     "role": "http://www.eksobionics.com/role/Notespayablenet",
     "shortName": "Notes payable, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Lease Obligations",
     "role": "http://www.eksobionics.com/role/LeaseObligations",
     "shortName": "Lease Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - Employee Benefit Plan",
     "role": "http://www.eksobionics.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145112 - Disclosure - Related Party Transactions",
     "role": "http://www.eksobionics.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Capitalization and Equity Structure",
     "role": "http://www.eksobionics.com/role/CapitalizationandEquityStructure",
     "shortName": "Capitalization and Equity Structure",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152114 - Disclosure - Stock-based Compensation",
     "role": "http://www.eksobionics.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165115 - Disclosure - Income Taxes",
     "role": "http://www.eksobionics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172116 - Disclosure - Commitments and Contingencies",
     "role": "http://www.eksobionics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2176117 - Disclosure - Segment Disclosures",
     "role": "http://www.eksobionics.com/role/SegmentDisclosures",
     "shortName": "Segment Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2180118 - Disclosure - Subsequent Events",
     "role": "http://www.eksobionics.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies and Estimates (Policies)",
     "role": "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies",
     "shortName": "Summary of Significant Accounting Policies and Estimates (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies and Estimates (Tables)",
     "role": "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables",
     "shortName": "Summary of Significant Accounting Policies and Estimates (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Net Loss Per Share of Common Stock (Tables)",
     "role": "http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables",
     "shortName": "Net Loss Per Share of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.eksobionics.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://www.eksobionics.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://www.eksobionics.com/role/PropertyandEquipmentnetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.eksobionics.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Notes payable, net (Tables)",
     "role": "http://www.eksobionics.com/role/NotespayablenetTables",
     "shortName": "Notes payable, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Lease Obligations (Tables)",
     "role": "http://www.eksobionics.com/role/LeaseObligationsTables",
     "shortName": "Lease Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ekso:ScheduleOfWarrantsOutstandingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348309 - Disclosure - Capitalization and Equity Structure (Tables)",
     "role": "http://www.eksobionics.com/role/CapitalizationandEquityStructureTables",
     "shortName": "Capitalization and Equity Structure (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ekso:ScheduleOfWarrantsOutstandingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353310 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2366311 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.eksobionics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2373312 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.eksobionics.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2377313 - Disclosure - Segment Disclosures (Tables)",
     "role": "http://www.eksobionics.com/role/SegmentDisclosuresTables",
     "shortName": "Segment Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization (Details)",
     "role": "http://www.eksobionics.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ekso:DebtCovenantCovenantComplianceUnrestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SellingAndMarketingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i425546ef7c404c1fb5e6ce43069f77b8_D20200501-20200531",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies and Estimates - Narrative (Details)",
     "role": "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies and Estimates - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "id632c7032c4140109d9f983f53b19765_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Summary of Significant Accounting Policies and Estimates - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i1244662c4107454f9abedb0d2c7dd95a_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Inventories (Details)",
     "role": "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails",
     "shortName": "Summary of Significant Accounting Policies and Estimates - Schedule of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "id632c7032c4140109d9f983f53b19765_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Goodwill (Details)",
     "role": "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails",
     "shortName": "Summary of Significant Accounting Policies and Estimates - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "role": "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails",
     "shortName": "Net Loss Per Share of Common Stock - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "shortName": "Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Investment in Unconsolidated Affiliate (Details)",
     "role": "http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliateDetails",
     "shortName": "Investment in Unconsolidated Affiliate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Fair Value Measurement - Schedule of Fair Value Hierarchies for Financial Assets and Liabilities on Recurring Basis (Details)",
     "role": "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Schedule of Fair Value Hierarchies for Financial Assets and Liabilities on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i50bf1458d43243298850ecebb3a893ff_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ekso:GainLossOnWarrantLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Fair Value Measurement - Summary of Changes in Fair Value of Level 3 Financial Liabilities on Recurring Basis (Details)",
     "role": "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Summary of Changes in Fair Value of Level 3 Financial Liabilities on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "ib3118b648a6d4313bd6a708e80b670c0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ekso:DeferredExtendedMaintenanceAndSupport",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Revenue Recognition - Summary of Deferred Revenue (Details)",
     "role": "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails",
     "shortName": "Revenue Recognition - Summary of Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ekso:DeferredExtendedMaintenanceAndSupport",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i5cd59b28ca904e409d6a180ec9f55846_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i5cd59b28ca904e409d6a180ec9f55846_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "id632c7032c4140109d9f983f53b19765_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Revenue Recognition - Summary of Deferred Revenue Activity (Details)",
     "role": "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails",
     "shortName": "Revenue Recognition - Summary of Deferred Revenue Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ekso:ContractWithCustomerLiabilityDeferralOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Revenue Recognition - Additional Information (Details)",
     "role": "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails",
     "shortName": "Revenue Recognition - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ekso:ContractwithCustomerLiabilityNonCancellableBacklog",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Revenue Recognition - Summary of Disaggregation of Revenue (Details)",
     "role": "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Summary of Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "if2a856fa0deb4f4bbebb18b45f3772fe_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Property and Equipment, net - Schedule of Property, Plant and Equipment (Details)",
     "role": "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property and Equipment, net - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Property and Equipment, net - Narrative (Details)",
     "role": "http://www.eksobionics.com/role/PropertyandEquipmentnetNarrativeDetails",
     "shortName": "Property and Equipment, net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "role": "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StandardProductWarrantyDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Accrued Liabilities - Schedule of Warranty Costs (Details)",
     "role": "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails",
     "shortName": "Accrued Liabilities - Schedule of Warranty Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StandardProductWarrantyDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Notes payable, net - Additional Information (Details)",
     "role": "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
     "shortName": "Notes payable, net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ekso:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Notes payable, net - Debt Repayment (Details)",
     "role": "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails",
     "shortName": "Notes payable, net - Debt Repayment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ekso:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Notes payable, net - Principal Repayment (Details)",
     "role": "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails",
     "shortName": "Notes payable, net - Principal Repayment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "icc71209ac60845e382225b8a55a86c3d_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statement of Cash Flows",
     "role": "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
     "shortName": "Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Lease Obligations - Narrative (Details)",
     "role": "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails",
     "shortName": "Lease Obligations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Lease Obligations - Future Minimum Payments (Details)",
     "role": "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails",
     "shortName": "Lease Obligations - Future Minimum Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://www.eksobionics.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.eksobionics.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i5b7783a67c59429aa5c50cce7d3f36a4_I20190916",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449426 - Disclosure - Capitalization and Equity Structure - Narrative (Details)",
     "role": "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
     "shortName": "Capitalization and Equity Structure - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i5b7783a67c59429aa5c50cce7d3f36a4_I20190916",
      "decimals": "0",
      "lang": "en-US",
      "name": "ekso:NumberOfConsecutiveBusinessDays",
      "reportCount": 1,
      "unique": true,
      "unitRef": "days",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ekso:ScheduleOfWarrantsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "id632c7032c4140109d9f983f53b19765_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450427 - Disclosure - Capitalization and Equity Structure - Schedule of Warrant Share Activity (Details)",
     "role": "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails",
     "shortName": "Capitalization and Equity Structure - Schedule of Warrant Share Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ekso:ScheduleOfWarrantsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ekso:ClassOfWarrantOrRightExpired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i606b7f43b71a44adb687cff9e4202f75_I20200610",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - Capitalization and Equity Structure - Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value (Details)",
     "role": "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails",
     "shortName": "Capitalization and Equity Structure - Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i606b7f43b71a44adb687cff9e4202f75_I20200610",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i877dabd6d9f1456b80f4388fc9919198_I20141231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - Stock-based Compensation - 2014 Equity Incentive Plan (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails",
     "shortName": "Stock-based Compensation - 2014 Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i877dabd6d9f1456b80f4388fc9919198_I20141231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455430 - Disclosure - Stock-based Compensation - Summary of Increase in Maximum Number of Shares Issuable to Stockholders (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails",
     "shortName": "Stock-based Compensation - Summary of Increase in Maximum Number of Shares Issuable to Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i66f66be5e4ca4a3fbef0430494cb2a38_D20200301-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456431 - Disclosure - Stock-based Compensation - Summary of Shares Available for Future Grant (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails",
     "shortName": "Stock-based Compensation - Summary of Shares Available for Future Grant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "ie4579f566e42442e9e3dc9eb88d2d447_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.eksobionics.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "iec71a31edf584b3fbbe26a8ef6da1b57_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457432 - Disclosure - Stock-based Compensation - Stock Options Narrative (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails",
     "shortName": "Stock-based Compensation - Stock Options Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "iec71a31edf584b3fbbe26a8ef6da1b57_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i4eccbe0a4d6f46a7beb0bc1fe08e5bab_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i4eccbe0a4d6f46a7beb0bc1fe08e5bab_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - Stock-based Compensation - Exercised Options Narrative (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails",
     "shortName": "Stock-based Compensation - Exercised Options Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i795cd2e4cd914b94949dde7b6cd4d5ec_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460435 - Disclosure - Stock-based Compensation - Summary of Stock Options Outstanding (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails",
     "shortName": "Stock-based Compensation - Summary of Stock Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461436 - Disclosure - Stock-based Compensation - Summary of Share Fair Value of Each Stock Option on Date of Grant using Black-Scholes Model Assumptions (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails",
     "shortName": "Stock-based Compensation - Summary of Share Fair Value of Each Stock Option on Date of Grant using Black-Scholes Model Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "iafd5100ca7f64a00831c51a479b855ff_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ekso:ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462437 - Disclosure - Stock-based Compensation - Schedule of Unvested Restricted Stock Units Activity (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails",
     "shortName": "Stock-based Compensation - Schedule of Unvested Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "iafd5100ca7f64a00831c51a479b855ff_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ekso:ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463438 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense Related to Stock Options and RSUs Granted to Employees and Non-employees (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails",
     "shortName": "Stock-based Compensation - Schedule of Stock-based Compensation Expense Related to Stock Options and RSUs Granted to Employees and Non-employees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i877dabd6d9f1456b80f4388fc9919198_I20141231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464439 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)",
     "role": "http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Stock-based Compensation - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "ie50e530344ba4276bb503495928f0afe_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467440 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Pre-tax Loss (Details)",
     "role": "http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails",
     "shortName": "Income Taxes - Schedule of Domestic and Foreign Components of Pre-tax Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468441 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies and Estimates",
     "role": "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates",
     "shortName": "Summary of Significant Accounting Policies and Estimates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469442 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) Differed from Amounts Computed by Applying Statutory Federal Income Tax Rate to Pretax Income (Loss) (Details)",
     "role": "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails",
     "shortName": "Income Taxes - Schedule of Income Tax Expense (Benefit) Differed from Amounts Computed by Applying Statutory Federal Income Tax Rate to Pretax Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470443 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences and Related Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Tax Effects of Temporary Differences and Related Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "id632c7032c4140109d9f983f53b19765_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471444 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "id632c7032c4140109d9f983f53b19765_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ekso:NumberOfLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "license_agreement",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474445 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ekso:NumberOfLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "license_agreement",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475446 - Disclosure - Commitments and Contingencies - Summary of Outstanding Contractual Obligations Including Interest Payments (Details)",
     "role": "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails",
     "shortName": "Commitments and Contingencies - Summary of Outstanding Contractual Obligations Including Interest Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i8c95c1de992348a3bd61ef233bf1c041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478447 - Disclosure - Segment Disclosures - Schedule of Segment Reporting Information (Details)",
     "role": "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails",
     "shortName": "Segment Disclosures - Schedule of Segment Reporting Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479448 - Disclosure - Segment Disclosures - Schedule of Geographic Revenue Information (Details)",
     "role": "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails",
     "shortName": "Segment Disclosures - Schedule of Geographic Revenue Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "ie155c69f21734a16917958178e1f51a1_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i5b7783a67c59429aa5c50cce7d3f36a4_I20190916",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2481449 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.eksobionics.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i92564e533c5b46fca6e27927910f77db_D20210101-20210225",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Net Loss Per Share of Common Stock",
     "role": "http://www.eksobionics.com/role/NetLossPerShareofCommonStock",
     "shortName": "Net Loss Per Share of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ekso-20201231.htm",
      "contextRef": "i297156716d884a2da3e85659f53b94b0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 96,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ekso_A2017InformationAgentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Information Agent Warrants [Member]",
        "label": "2017 Information Agent Warrants [Member]",
        "terseLabel": "2017 Information Agent Warrants"
       }
      }
     },
     "localname": "A2017InformationAgentWarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_A2019WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Warrants [Member]",
        "label": "2019 Warrants [Member]",
        "terseLabel": "December 2019 warrants"
       }
      }
     },
     "localname": "A2019WarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_AccruedClinicalCostCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Clinical Cost Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "AccruedClinicalCostCurrent",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_AccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Line Items]",
        "terseLabel": "Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "AccruedLiabilitiesLineItems",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ekso_AccruedLiabilitiesRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Rollforward [Roll Forward]",
        "label": "Accrued Liabilities, Rollforward [Roll Forward]",
        "terseLabel": "Accrued Liabilities, Rollforward [Roll Forward]"
       }
      }
     },
     "localname": "AccruedLiabilitiesRollforwardRollForward",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ekso_AccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Table]",
        "terseLabel": "Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "AccruedLiabilitiesTable",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ekso_AdjustmentsToAdditionalPaidInCapitalWarrantIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Warrant Issuance",
        "label": "Adjustments To Additional Paid In Capital, Warrant Issuance",
        "negatedTerseLabel": "Issuance of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuance",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_AngelPondCapitalLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Angel Pond Capital LLC [Member]",
        "terseLabel": "Angel Pond Capital LLC"
       }
      }
     },
     "localname": "AngelPondCapitalLlcMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Offering [Member]",
        "label": "At-The-Market Offering [Member]",
        "terseLabel": "At-the-market offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_ChangeInContractWithCustomerLiabilityRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability Rollforward [Roll Forward]",
        "label": "Change In Contract With Customer, Liability Rollforward [Roll Forward]",
        "terseLabel": "Change In Contract With Customer, Liability Rollforward [Roll Forward]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollforwardRollForward",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ekso_ClassOfWarrantOrRightCashFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Cash Fee",
        "label": "Class Of Warrant Or Right, Cash Fee",
        "terseLabel": "Class of warrant or right cash fee"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCashFee",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_ClassOfWarrantOrRightCashFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Cash Fee Percentage",
        "label": "Class Of Warrant Or Right, Cash Fee Percentage",
        "terseLabel": "Class of warrant or right cash fee percentage"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCashFeePercentage",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ekso_ClassOfWarrantOrRightDurationOfPutOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Duration Of Put Option",
        "label": "Class Of Warrant Or Right, Duration Of Put Option",
        "terseLabel": "Duration of put option"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDurationOfPutOption",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ekso_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights exercised.",
        "label": "Class of Warrant or Right Exercised",
        "negatedLabel": "Warrants exercised (in shares)",
        "terseLabel": "Warrants exercised (in shares)",
        "verboseLabel": "Merger/PPO warrant shares exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ekso_ClassOfWarrantOrRightExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right Expiration Period",
        "terseLabel": "Class of warrant or right expiration period",
        "verboseLabel": "Term (Years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationPeriod",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ekso_ClassOfWarrantOrRightExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Expired",
        "negatedLabel": "Warrants expired (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpired",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ekso_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Issued",
        "terseLabel": "Warrants issued (in shares)",
        "verboseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ekso_ClassOfWarrantOrRightManagementFeeExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Management Fee Expense",
        "label": "Class Of Warrant Or Right, Management Fee Expense",
        "terseLabel": "Class of warrant or right management fee"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightManagementFeeExpense",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_ClassOfWarrantOrRightManagementFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Management Fee Percentage",
        "label": "Class Of Warrant Or Right, Management Fee Percentage",
        "terseLabel": "Class of warrant or right management fee percentage"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightManagementFeePercentage",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ekso_ClassOfWarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Outstanding [Roll Forward]",
        "label": "Class Of Warrant Or Right, Outstanding [Roll Forward]",
        "terseLabel": "Class Of Warrant Or Right, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingRollForward",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ekso_ClassOfWarrantOrRightPercentageOfAggregateSharesSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant Or Right, Percentage Of Aggregate Shares Sold",
        "label": "Class of Warrant Or Right, Percentage Of Aggregate Shares Sold",
        "terseLabel": "Warrants to purchase common stock, percent"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPercentageOfAggregateSharesSold",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ekso_ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right Percentage Of Warrants Issued To Purchase Shares Of Common Stock",
        "label": "Class of Warrant or Right Percentage Of Warrants Issued To Purchase Shares Of Common Stock",
        "terseLabel": "Percentage of warrants issued to purchase shares of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPercentageOfWarrantsIssuedToPurchaseSharesOfCommonStock",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ekso_ClassOfWarrantOrRightPutOptionDurationOfPayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Put Option, Duration Of Pay Period",
        "label": "Class Of Warrant Or Right, Put Option, Duration Of Pay Period",
        "terseLabel": "Put option pay period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPutOptionDurationOfPayPeriod",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ekso_CollaborativeArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements",
        "label": "Collaborative Arrangements [Member]",
        "terseLabel": "Collaborative arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_CommonStockContribution": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Contribution",
        "terseLabel": "Common stock contribution to 401(k) plan"
       }
      }
     },
     "localname": "CommonStockContribution",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_ContingentSuccessFeeLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Success Fee Liability",
        "verboseLabel": "Contingent success fee liability"
       }
      }
     },
     "localname": "ContingentSuccessFeeLiability",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_ContingentSuccessFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Success Fee [Member]",
        "terseLabel": "Contingent Success\u00a0Fee Liability"
       }
      }
     },
     "localname": "ContingentSuccessFeeMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_ContractWithCustomerLiabilityDeferralOfRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Deferral Of Revenue",
        "label": "Contract With Customer, Liability, Deferral Of Revenue",
        "terseLabel": "Deferral of revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeferralOfRevenue",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_ContractsWithCustomerAccountsReceivablePaymentTermsDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts With Customer, Accounts Receivable, Payment Terms, Duration",
        "label": "Contracts With Customer, Accounts Receivable, Payment Terms, Duration",
        "terseLabel": "Payment terms",
        "verboseLabel": "Accounts receivable payment terms"
       }
      }
     },
     "localname": "ContractsWithCustomerAccountsReceivablePaymentTermsDuration",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ekso_ContractwithCustomerLiabilityNonCancellableBacklog": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Non-Cancellable Backlog",
        "label": "Contract with Customer, Liability, Non-Cancellable Backlog",
        "terseLabel": "Non-cancellable backlog"
       }
      }
     },
     "localname": "ContractwithCustomerLiabilityNonCancellableBacklog",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One [Member]",
        "label": "Customer One [Member]",
        "terseLabel": "Customer one"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_DebtCovenantCovenantComplianceUnrestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Covenant Compliance, Unrestricted Cash",
        "label": "Debt Covenant, Covenant Compliance, Unrestricted Cash",
        "terseLabel": "Debt covenant, unrestricted cash"
       }
      }
     },
     "localname": "DebtCovenantCovenantComplianceUnrestrictedCash",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_DebtInstrumentDeferralPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Deferral Period",
        "label": "Debt Instrument, Deferral Period",
        "terseLabel": "Deferral principal payment period"
       }
      }
     },
     "localname": "DebtInstrumentDeferralPeriod",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ekso_December2015WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2015 Warrants [Member]",
        "label": "December 2015 Warrants [Member]",
        "terseLabel": "2015 Warrants"
       }
      }
     },
     "localname": "December2015WarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_December2019PlacementAgentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Placement Agent Warrants [Member]",
        "label": "December 2019 Placement Agent Warrants [Member]",
        "terseLabel": "December 2019 Placement Agent Warrants",
        "verboseLabel": "December 2019 Placement Agent Warrants"
       }
      }
     },
     "localname": "December2019PlacementAgentWarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_December2019WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Warrants [Member]",
        "label": "December 2019 Warrants [Member]",
        "terseLabel": "December 2019 Warrants",
        "verboseLabel": "December 2019 Warrants"
       }
      }
     },
     "localname": "December2019WarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_DeferredDeviceRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Device Revenue",
        "label": "Deferred Device Revenue",
        "terseLabel": "Deferred device, rental revenues and advances"
       }
      }
     },
     "localname": "DeferredDeviceRevenue",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_DeferredExtendedMaintenanceAndSupport": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Extended Maintenance And Support",
        "label": "Deferred Extended Maintenance And Support",
        "terseLabel": "Deferred extended maintenance and support"
       }
      }
     },
     "localname": "DeferredExtendedMaintenanceAndSupport",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_DeferredRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Royalties",
        "label": "Deferred Royalties",
        "terseLabel": "Deferred royalties"
       }
      }
     },
     "localname": "DeferredRoyalties",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_DeferredTaxAssetsOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Right Of Use Asset",
        "label": "Deferred Tax Assets, Operating Lease, Right Of Use Asset",
        "terseLabel": "Lease assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_DeferredTaxLiabilitiesOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease, Liability",
        "label": "Deferred Tax Liabilities, Operating Lease, Liability",
        "negatedTerseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseLiability",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Maximum Annual Contributions Percentage,Thereafter",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Percentage,Thereafter",
        "terseLabel": "Maximum annual contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPercentageThereafter",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ekso_DefinedContributionPlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Offering Period",
        "label": "Defined Contribution Plan, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "DefinedContributionPlanOfferingPeriod",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ekso_DirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct Offering [Member]",
        "label": "Direct Offering [Member]",
        "terseLabel": "Direct offering"
       }
      }
     },
     "localname": "DirectOfferingMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrealized gain/loss on warrant.",
        "label": "Effective Income Tax Rate Reconciliation Unrealized Gain Loss on Warrant",
        "verboseLabel": "Unrealized gain on warrant"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ekso_EksoHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EksoHealth [Member]",
        "label": "EksoHealth [Member]",
        "terseLabel": "EksoHealth",
        "verboseLabel": "EksoHealth"
       }
      }
     },
     "localname": "EksoHealthMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_EksoWorksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EksoWorks [Member]",
        "label": "EksoWorks [Member]",
        "terseLabel": "EksoWorks",
        "verboseLabel": "EksoWorks"
       }
      }
     },
     "localname": "EksoWorksMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_EquityIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Equity incentive plan",
        "verboseLabel": "2014 Equity incentive plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2014Member",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$60.00 - $229.95"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$5.55 - $9.15"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$27.30 - $56.70"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$16.95 - $26.85"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_FacilityOperatingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility operating lease [Member]",
        "terseLabel": "Facility operating lease"
       }
      }
     },
     "localname": "FacilityOperatingLeaseMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Changes Due To Re-measurement",
        "negatedLabel": "Gain on revaluation of contingent liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangesDueToRemeasurement",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Reclassification",
        "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Reclassification",
        "negatedTerseLabel": "Reclassification of warrant liability to equity upon exercise of warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValueReclassification",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_GainLossOnModificationOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Modification Of Operating Lease Liabilities",
        "label": "Gain (Loss) On Modification Of Operating Lease Liabilities",
        "terseLabel": "Gain on modification of operating lease liabilities"
       }
      }
     },
     "localname": "GainLossOnModificationOfOperatingLeaseLiabilities",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_GainLossOnWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Warrant Liability",
        "label": "Gain (Loss) On Warrant Liability",
        "negatedLabel": "Loss (gain) on revaluation of warrant liabilities",
        "negatedTerseLabel": "Loss on revaluation of warrants issued in June 2020, December 2019, May 2019 financing, and December 2015 equity financings",
        "verboseLabel": "(Loss) gain on warrant liabilities"
       }
      }
     },
     "localname": "GainLossOnWarrantLiability",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_GainLossOnWarrantModification": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Warrant Modification",
        "label": "Gain (Loss) On Warrant Modification",
        "negatedNetLabel": "Loss on modification of warrants",
        "negatedTerseLabel": "Loss on modification of warrants",
        "terseLabel": "Loss on modification of warrants"
       }
      }
     },
     "localname": "GainLossOnWarrantModification",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_GeneratedBefore2018CarryforwardIndefinitelyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generated Before 2018, Carryforward Indefinitely [Member]",
        "label": "Generated Before 2018, Carryforward Indefinitely [Member]",
        "terseLabel": "Generated before 2018, carryforward indefinitely"
       }
      }
     },
     "localname": "GeneratedBefore2018CarryforwardIndefinitelyMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_GeneratedBefore2018Expire2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generated Before 2018, Expire2027 [Member]",
        "label": "Generated Before 2018, Expire 2027 [Member]",
        "terseLabel": "Generated before 2018, expire 2027"
       }
      }
     },
     "localname": "GeneratedBefore2018Expire2027Member",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_GoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern [Policy Text Block]",
        "verboseLabel": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernPolicyTextBlock",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ekso_GovernmentGrantPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Grant, Policy [Policy Text Block]",
        "label": "Government Grant, Policy [Policy Text Block]",
        "terseLabel": "Government Grants"
       }
      }
     },
     "localname": "GovernmentGrantPolicyPolicyTextBlock",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ekso_HamburgGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hamburg, Germany",
        "label": "Hamburg, Germany [Member]",
        "terseLabel": "Hamburg, Germany"
       }
      }
     },
     "localname": "HamburgGermanyMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_InformationAgentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Information Agent Warrants [Member]",
        "terseLabel": "Information agent warrants"
       }
      }
     },
     "localname": "InformationAgentWarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_IssuanceOfCommonStockUnderAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Common Stock Under",
        "label": "Issuance Of Common Stock Under [Abstract]",
        "terseLabel": "Issuance of common stock under:"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderAbstract",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ekso_June2020InvestorWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2020 Investor Warrants",
        "label": "June 2020 Investor Warrants [Member]",
        "terseLabel": "June 2020 Investor Warrants"
       }
      }
     },
     "localname": "June2020InvestorWarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_June2020PlacementAgentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2020 Placement Agent Warrants",
        "label": "June 2020 Placement Agent Warrants [Member]",
        "terseLabel": "June 2020 Placement Agent Warrants"
       }
      }
     },
     "localname": "June2020PlacementAgentWarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_June2020WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2020 Warrants",
        "label": "June 2020 Warrants [Member]",
        "terseLabel": "June 2020 Warrants"
       }
      }
     },
     "localname": "June2020WarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_JuneTwentyTwentyInvestorWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June Twenty Twenty Investor Warrants",
        "label": "June Twenty Twenty Investor Warrants [Member]",
        "terseLabel": "June 2020 Investor Warrants"
       }
      }
     },
     "localname": "JuneTwentyTwentyInvestorWarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_JuneTwentyTwentyPlacementAgentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June Twenty Twenty Placement Agent Warrants",
        "label": "June Twenty Twenty Placement Agent Warrants [Member]",
        "terseLabel": "June 2020 placement agent warrants"
       }
      }
     },
     "localname": "JuneTwentyTwentyPlacementAgentWarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_JuneTwentyTwentyPlacementAgentsWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June Twenty Twenty Placement Agents Warrants",
        "label": "June Twenty Twenty Placement Agents Warrants [Member]",
        "terseLabel": "June 2020 Placement Agent Warrants"
       }
      }
     },
     "localname": "JuneTwentyTwentyPlacementAgentsWarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_LicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Revenue [Member]",
        "verboseLabel": "License fees"
       }
      }
     },
     "localname": "LicenseRevenueMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_LineOfCreditFacilityCapacityAvailableForSpecificPurpose": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Capacity Available For Specific Purpose",
        "label": "Line Of Credit Facility, Capacity Available For Specific Purpose",
        "terseLabel": "Available for corporate purposes"
       }
      }
     },
     "localname": "LineOfCreditFacilityCapacityAvailableForSpecificPurpose",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]",
        "terseLabel": "Loan agreement"
       }
      }
     },
     "localname": "LoanAgreementMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt Maturities Repayments Of Principal Remainder to Year Two",
        "label": "Long Term Debt Maturities Repayments Of Principal Remainder to Two Year",
        "terseLabel": "2021 - 2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_May2019WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2019 Warrants [Member]",
        "label": "May 2019 Warrants [Member]",
        "terseLabel": "May 2019 Warrants",
        "verboseLabel": "May 2019 Warrants"
       }
      }
     },
     "localname": "May2019WarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_NumberOfConsecutiveBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Consecutive Business days",
        "label": "Number of Consecutive Business days",
        "terseLabel": "Number of Consecutive Business days"
       }
      }
     },
     "localname": "NumberOfConsecutiveBusinessDays",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ekso_NumberOfLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of License Agreements",
        "label": "Number Of License Agreements",
        "terseLabel": "Number of license agreements"
       }
      }
     },
     "localname": "NumberOfLicenseAgreements",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ekso_OperatingLeaseAbatement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Abatement",
        "label": "Operating Lease, Abatement",
        "terseLabel": "Operating Lease, Abatement"
       }
      }
     },
     "localname": "OperatingLeaseAbatement",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_OperatingLeasesIncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Increase (Decrease) In Deferred Rent",
        "label": "Operating Leases, Increase (Decrease) In Deferred Rent",
        "terseLabel": "Change in deferred rent associated with ASC 842"
       }
      }
     },
     "localname": "OperatingLeasesIncreaseDecreaseInDeferredRent",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_OperatingLeasesLiabilityInitialRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Liability, Initial Recognition",
        "label": "Operating Leases, Liability, Initial Recognition",
        "terseLabel": "Initial recognition of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasesLiabilityInitialRecognition",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_OperatingLeasesRightOfUseAssetInitialRecognition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Right Of Use Asset, Initial Recognition",
        "label": "Operating Leases, Right Of Use Asset, Initial Recognition",
        "terseLabel": "Initial recognition of operating right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeasesRightOfUseAssetInitialRecognition",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_OtherLiabilitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities [Domain]",
        "terseLabel": "Other Liabilities [Domain]"
       }
      }
     },
     "localname": "OtherLiabilitiesDomain",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_OtherliabilitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherLiabilities [Axis]",
        "terseLabel": "OtherLiabilities [Axis]"
       }
      }
     },
     "localname": "OtherliabilitiesAxis",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ekso_PWBLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PWB Loan Agreement",
        "label": "PWB Loan Agreement [Member]",
        "terseLabel": "PWB loan agreement"
       }
      }
     },
     "localname": "PWBLoanAgreementMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_Pre2014WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre 2014 Warrants [Member]",
        "terseLabel": "Pre-2014 warrants"
       }
      }
     },
     "localname": "Pre2014WarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and from issuance of rights to purchase common shares at a predetermined price.",
        "label": "Proceeds From Issuance Of Common Stock Preference Stock And Warrants",
        "terseLabel": "Aggregate proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_ProductMaintenanceAndWarrantyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Maintenance And Warranty [Table Text Block]",
        "verboseLabel": "Schedule of Warranty Costs"
       }
      }
     },
     "localname": "ProductMaintenanceAndWarrantyTableTextBlock",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ekso_ProductMaintenanceWarrantyAddition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Maintenance Warranty Addition",
        "verboseLabel": "Additions for estimated future expense"
       }
      }
     },
     "localname": "ProductMaintenanceWarrantyAddition",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_ProductMaintenanceWarrantyExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Maintenance Warranty Expense",
        "negatedLabel": "Incurred costs"
       }
      }
     },
     "localname": "ProductMaintenanceWarrantyExpense",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_ProductMaintenanceWarrantyLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails": {
       "order": 1.0,
       "parentTag": "ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value of current portion of product maintenance and warranty liabilities as on the balance sheet date.",
        "label": "Product Maintenance Warranty Liabilities Current",
        "verboseLabel": "Current portion"
       }
      }
     },
     "localname": "ProductMaintenanceWarrantyLiabilitiesCurrent",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Maintenance Warranty Liabilities Current Noncurrent",
        "periodEndLabel": "Balance at end of the period",
        "periodStartLabel": "Balance at beginning of the period",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_ProductMaintenanceWarrantyLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails": {
       "order": 2.0,
       "parentTag": "ekso_ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value of noncurrent portion of product maintenance and warranty liabilities as on the balance sheet date.",
        "label": "Product Maintenance Warranty Liabilities Noncurrent",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ProductMaintenanceWarrantyLiabilitiesNoncurrent",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_RelatedPartyTransactionConsultingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Consulting Agreement",
        "label": "Related Party Transaction, Consulting Agreement",
        "terseLabel": "Consulting agreement term"
       }
      }
     },
     "localname": "RelatedPartyTransactionConsultingAgreement",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ekso_RentalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rentals",
        "label": "Rentals [Member]",
        "terseLabel": "Rentals"
       }
      }
     },
     "localname": "RentalsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_RestrictedStockIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Issued",
        "label": "Restricted Stock Issued",
        "terseLabel": "Share issuance for vesting of restricted stock"
       }
      }
     },
     "localname": "RestrictedStockIssued",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_RichmondCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Richmond, California",
        "label": "Richmond, California [Member]",
        "terseLabel": "Richmond, California"
       }
      }
     },
     "localname": "RichmondCaliforniaMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_RoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Percentage",
        "terseLabel": "Royalty percentage"
       }
      }
     },
     "localname": "RoyaltyPercentage",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ekso_SaleOfStockValueOfSharesAvailableForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Value Of Shares Available For Future Issuance",
        "label": "Sale Of Stock, Value Of Shares Available For Future Issuance",
        "terseLabel": "Available for future offerings"
       }
      }
     },
     "localname": "SaleOfStockValueOfSharesAvailableForFutureIssuance",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_SalesEarnout": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales earn-out",
        "terseLabel": "Equipois sales earn-out"
       }
      }
     },
     "localname": "SalesEarnout",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_SalesRevenueGoodsNetExcludingGovernmentSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Revenue Goods Net Excluding Government Sales [Member]",
        "verboseLabel": "Net sales"
       }
      }
     },
     "localname": "SalesRevenueGoodsNetExcludingGovernmentSalesMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_ScheduleOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Significant Accounting Policies [Table]",
        "terseLabel": "Schedule Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "ScheduleOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ekso_ScheduleOfWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding [Table Text Block]",
        "terseLabel": "Schedule of Warrant Share Activity"
       }
      }
     },
     "localname": "ScheduleOfWarrantsOutstandingTableTextBlock",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ekso_ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement By Share-Based Payment Award, Right To Receive Per Award",
        "label": "Share-Based Payment Arrangement By Share-Based Payment Award, Right To Receive Per Award",
        "terseLabel": "Right to receive per award"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementByShareBasedPaymentAwardRightToReceivePerAward",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ekso_SharesIssuedCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued ,Capital Contribution",
        "terseLabel": "Share issuance for common stock contribution to 401(k) plan"
       }
      }
     },
     "localname": "SharesIssuedCapitalContribution",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ekso_StockConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "StockConversionPrice",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ekso_StockIssuedDuringPeriodShareEquiposisSalesEarnOut": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Share Equiposis Sales Earn Out",
        "label": "Stock Issued During Period Share Equiposis Sales Earn Out",
        "terseLabel": "Equipois sales earn-out (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareEquiposisSalesEarnOut",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ekso_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "label": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ekso_StockIssuedDuringPeriodValueEquiposisSalesEarnOuts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Equiposis Sales Earn Out",
        "label": "Stock Issued During Period Value Equiposis Sales Earn Outs",
        "terseLabel": "Equipois sales earn-out"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEquiposisSalesEarnOuts",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Exercise Of Warrants",
        "label": "Stock Issued During Period, Value, Exercise Of Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan [Member]",
        "terseLabel": "Term loans"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails",
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_TransferOfPropertyAndEquipmentFromInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfer Of Property And Equipment From Inventory",
        "negatedLabel": "Transfer of inventory to (from) property and equipment"
       }
      }
     },
     "localname": "TransferOfPropertyAndEquipmentFromInventory",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_TwothousandFifteenWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousand Fifteen Warrants [Member]",
        "verboseLabel": "2015 warrants"
       }
      }
     },
     "localname": "TwothousandFifteenWarrantsMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ekso_UnrestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrestricted Cash",
        "terseLabel": "Unrestricted cash"
       }
      }
     },
     "localname": "UnrestrictedCash",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_WarrantIssuanceExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Amount of expense incurred on issuance of warrants.",
        "label": "Warrant Issuance Expense",
        "negatedTerseLabel": "Finance cost associated with warrant issuance",
        "terseLabel": "Warrant expense"
       }
      }
     },
     "localname": "WarrantIssuanceExpense",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ekso_WarrantPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrant liability.",
        "label": "Warrant Liability [Policy Text Block]",
        "terseLabel": "Warrant Valuation"
       }
      }
     },
     "localname": "WarrantPolicyTextBlock",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ekso_WarrantyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warranty [Member]",
        "terseLabel": "Warranty"
       }
      }
     },
     "localname": "WarrantyMember",
     "nsuri": "http://www.eksobionics.com/20201231",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "verboseLabel": "Summary of Outstanding Contractual Obligations Including Interest Payments"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r201",
      "r278",
      "r284",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r310",
      "r311",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r508",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails",
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r310",
      "r311",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r508",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails",
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r201",
      "r278",
      "r284",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r196",
      "r278",
      "r282",
      "r467",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r196",
      "r278",
      "r282",
      "r467",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r290",
      "r310",
      "r311",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r508",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails",
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r290",
      "r310",
      "r311",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r508",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails",
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r197",
      "r198",
      "r278",
      "r283",
      "r510",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r278",
      "r283",
      "r510",
      "r520",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "verboseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r18",
      "r203",
      "r204"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances",
        "verboseLabel": "Accounts receivable, net of allowances of $42 and $121, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]",
        "terseLabel": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails",
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r228"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r59",
      "r60",
      "r61",
      "r497",
      "r517",
      "r518"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r58",
      "r61",
      "r62",
      "r118",
      "r119",
      "r120",
      "r394",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r351"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r315",
      "r344",
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r25",
      "r205",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r178",
      "r185",
      "r192",
      "r208",
      "r391",
      "r395",
      "r416",
      "r481",
      "r495"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r54",
      "r112",
      "r208",
      "r391",
      "r395",
      "r416"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r317",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r117",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizationLongtermDebtAndEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalization, Long-term Debt and Equity [Abstract]",
        "terseLabel": "Capitalization, Long-term Debt and Equity [Abstract]"
       }
      }
     },
     "localname": "CapitalizationLongtermDebtAndEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r34",
      "r100"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r101",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r92",
      "r100",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash at end of the year",
        "periodStartLabel": "Cash at beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r419"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosure of non-cash activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r110",
      "r112",
      "r134",
      "r135",
      "r136",
      "r139",
      "r141",
      "r150",
      "r151",
      "r152",
      "r208",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r263",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number warrants called (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding (in shares)",
        "periodStartLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r263",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r48",
      "r242",
      "r485",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "verboseLabel": "Original share pool (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 141,429 shares authorized; 8,349 and 5,795 shares issued and outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "verboseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r75",
      "r489",
      "r505"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "verboseLabel": "Computers and peripherals"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r201",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r201",
      "r414",
      "r415",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r201",
      "r414",
      "r415",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r155",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r159",
      "r160",
      "r201",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r201",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation and Basis of Presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Deferred Revenue Activity"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r265",
      "r266",
      "r279"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Total deferred revenues",
        "totalLabel": "Total deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails",
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r279"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "negatedLabel": "Less current portion",
        "verboseLabel": "Deferred revenues, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r279"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Recognition of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDeferredRevenueActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Five",
        "verboseLabel": "3-5 Years"
       }
      }
     },
     "localname": "ContractualObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year One",
        "terseLabel": "Obligation due in less than one year",
        "verboseLabel": "Less than one year"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Three",
        "verboseLabel": "1-3 Years"
       }
      }
     },
     "localname": "ContractualObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r80",
      "r467"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "netLabel": "Cost of revenue",
        "verboseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Current federal and state income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r158",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Lease Obligations"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r482",
      "r483",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r14",
      "r250",
      "r483",
      "r494"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Total principal payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails",
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r431",
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r45",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "prime rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails",
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r46",
      "r114",
      "r257",
      "r258",
      "r259",
      "r260",
      "r430",
      "r431",
      "r433",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails",
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r251",
      "r432"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "verboseLabel": "Less final payment fee, discount and issuance cost"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Deferred federal and state income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset (liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "verboseLabel": "Depreciation and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r376",
      "r378",
      "r379"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "verboseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "verboseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesandRelatedDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contribution expense"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/EmployeeBenefitPlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r98",
      "r226"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Amortization of debt discount, change in contingent liability and accretion of final payment fee"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r98",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r55",
      "r56",
      "r411"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r278",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Summary of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r76",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r131",
      "r134",
      "r139",
      "r140",
      "r141",
      "r145",
      "r146",
      "r490",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share applicable to common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "verboseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r76",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r134",
      "r139",
      "r140",
      "r141",
      "r145",
      "r146",
      "r490",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total tax expense (benefit)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r362",
      "r386"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Federal tax at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r362",
      "r386"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r362",
      "r386"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Foreign exchange"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r362",
      "r386"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r362",
      "r386"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State tax, net of federal tax effect"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r362",
      "r386"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "R&amp;D credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDifferedfromAmountsComputedbyApplyingStatutoryFederalIncomeTaxRatetoPretaxIncomeLossDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Salaries, benefits and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period of unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r122",
      "r128",
      "r130",
      "r149",
      "r210",
      "r256",
      "r261",
      "r348",
      "r349",
      "r350",
      "r382",
      "r383",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investment in Unconsolidated Affiliate"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of debt amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r401",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r306",
      "r402",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r401",
      "r402",
      "r404",
      "r405",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r291",
      "r293",
      "r298",
      "r306",
      "r402",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r291",
      "r293",
      "r298",
      "r306",
      "r402",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r306",
      "r402",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r406",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r406",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Summary of Changes in Fair Value of Level 3 Financial Liabilities on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Initial fair value of warrants in connection with June 2020 financing"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementSummaryofChangesinFairValueofLevel3FinancialLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r306",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementScheduleofFairValueHierarchiesforFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r99",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Unrealized (gain) loss on foreign currency transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "verboseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r217",
      "r219",
      "r480"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r107",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r98",
      "r218",
      "r220",
      "r222"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairment of goodwill",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Government grant"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r79",
      "r112",
      "r178",
      "r184",
      "r188",
      "r191",
      "r194",
      "r208",
      "r416"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r98",
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment loss on long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r224",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r115",
      "r385"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r115",
      "r385"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "verboseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r115",
      "r178",
      "r184",
      "r188",
      "r191",
      "r194"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofPretaxLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r72",
      "r98",
      "r175",
      "r207",
      "r486",
      "r502"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Loss on investment of unconsolidated affiliate"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.eksobionics.com/role/InvestmentinUnconsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r363",
      "r370",
      "r375",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r107",
      "r360",
      "r361",
      "r370",
      "r371",
      "r374",
      "r380",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r94",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "verboseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued and lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expense, operating lease right-of-use assets, and other assets, current and noncurrent"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r71",
      "r172",
      "r429",
      "r432",
      "r491"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r91",
      "r93",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r215"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r51"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r52",
      "r107",
      "r148",
      "r213",
      "r214",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r215"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r215"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "verboseLabel": "Finance cost attributable to issuance of warrants"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvement"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r112",
      "r186",
      "r208",
      "r392",
      "r395",
      "r396",
      "r416"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r112",
      "r208",
      "r416",
      "r484",
      "r499"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r112",
      "r208",
      "r392",
      "r395",
      "r396",
      "r416"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r252",
      "r483",
      "r496"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Note payable, net",
        "totalLabel": "Note payable, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails",
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails",
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r116",
      "r248"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r116",
      "r248"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r116",
      "r248"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetDebtRepaymentDetails",
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "verboseLabel": "Notes Payable, Net"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/Notespayablenet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "verboseLabel": "Notes payable, net"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails",
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r46",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails",
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "verboseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputConversionPriceMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using price per share at which convertible share can be converted into common stock.",
        "label": "Measurement Input, Conversion Price [Member]",
        "terseLabel": "Conversion price",
        "verboseLabel": "Conversion price"
       }
      }
     },
     "localname": "MeasurementInputConversionPriceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "verboseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "verboseLabel": "Volatility of stock"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Current share price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r96",
      "r99"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r63",
      "r66",
      "r73",
      "r99",
      "r112",
      "r121",
      "r123",
      "r124",
      "r125",
      "r126",
      "r129",
      "r130",
      "r137",
      "r178",
      "r184",
      "r188",
      "r191",
      "r194",
      "r208",
      "r416",
      "r487",
      "r503"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r131",
      "r132",
      "r138",
      "r141",
      "r178",
      "r184",
      "r188",
      "r191",
      "r194"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r133",
      "r138",
      "r141"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Adjusted net loss used for dilution calculation"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements/Accounting Pronouncements Adopted in 2020"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "All Other"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "verboseLabel": "Note payable, current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Furniture, office and leased equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r178",
      "r184",
      "r188",
      "r191",
      "r194"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Total lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails",
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "netLabel": "Lease liabilities, current",
        "verboseLabel": "Lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r437",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r442",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r441",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/LeaseObligationsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r254",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r64",
      "r67",
      "r70",
      "r74",
      "r256",
      "r420",
      "r425",
      "r426",
      "r488",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net unrealized loss on foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "verboseLabel": "Other (expense) income, net:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-allotment option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees",
        "terseLabel": "Aggregate payments"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Payment of remaining balance on long-term debt",
        "terseLabel": "Payment of remaining balance of long-term debt"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Acquisition of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r290",
      "r292",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "verboseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r317",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Convertible preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "verboseLabel": "Convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "verboseLabel": "Convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Convertible preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock and warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt, net of financing costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from direct offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from sale of inventory parts and tooling"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r86",
      "r347"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "verboseLabel": "Parts and other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "verboseLabel": "Device revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r43",
      "r244",
      "r246"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "verboseLabel": "Device warranty"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r37",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails",
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r233",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r36",
      "r227"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r229",
      "r500"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r107",
      "r229",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesSummaryofOutstandingContractualObligationsIncludingInterestPaymentsDetails",
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r78",
      "r212"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Changes in allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "verboseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "auth_ref": [
      "r255",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "terseLabel": "Reclassification of warrant liability to equity upon exercise of warrants"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r300",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r300",
      "r448",
      "r451",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r446",
      "r447",
      "r449",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Principal payments on notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r356",
      "r534"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r107",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Reduction on workforce"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/OrganizationDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r98",
      "r234",
      "r236",
      "r237"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r261",
      "r351",
      "r498",
      "r516",
      "r518"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r122",
      "r128",
      "r130",
      "r210",
      "r348",
      "r349",
      "r350",
      "r382",
      "r383",
      "r513",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r169",
      "r170",
      "r183",
      "r189",
      "r190",
      "r196",
      "r197",
      "r201",
      "r277",
      "r278",
      "r467"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r159",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r281",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "verboseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Geographic Revenue Information"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty agreement terms"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Value of shares sold"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/OrganizationDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of shares (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/OrganizationDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r61",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Capitalization, Equity [Line Items]",
        "terseLabel": "Schedule of Capitalization, Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule of Capitalization, Equity [Table]",
        "terseLabel": "Schedule of Capitalization, Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails",
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofWarrantShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Tax Effects of Temporary Differences and Related Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of Income Tax Expense (Benefit) Differed from Amounts Computed by Applying Statutory Federal Income Tax Rate to Pretax Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r315",
      "r343",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r315",
      "r343",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense Related to Stock Options and RSUs Granted to Employees and Non-employees"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value Hierarchies for Financial Assets and Liabilities on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r221",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "verboseLabel": "Schedule of Domestic and Foreign Components of Pre-tax Loss"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "verboseLabel": "Schedule of Principal Payments of Long-term Debt and Final Payment Fee"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r37",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r113",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r178",
      "r181",
      "r187",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r178",
      "r181",
      "r187",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r331",
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "verboseLabel": "Summary of Shares Available for Future Grant"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r317",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r323",
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Summary of Share Fair Value of Each Stock Option on Date of Grant using Black-Scholes Model Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r369",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "verboseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "verboseLabel": "Schedule of Unvested Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r165",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r201",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r165",
      "r167",
      "r168",
      "r178",
      "r182",
      "r188",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segment Disclosures"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofGeographicRevenueInformationDetails",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "verboseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseRelatedtoStockOptionsandRSUsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "verboseLabel": "Service and support"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "verboseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "verboseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "verboseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "verboseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations",
        "terseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "terseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Share pool increase (in shares)",
        "verboseLabel": "Increase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Total share authorized for grant (in shares)",
        "verboseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofIncreaseinMaximumNumberofSharesIssuabletoStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensation2014EquityIncentivePlanDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at year end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "netLabel": "Exercisable at year end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "In lieu of cash compensation / bonus (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "netLabel": "Aggregate Intrinsic Value, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r325",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of year (in shares)",
        "periodStartLabel": "Outstanding at beginning of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of year (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "netLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "netLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "negatedTerseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r314",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "verboseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r107",
      "r317",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of Exercise Prices, Lower (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "netLabel": "Options Exercisable, Number of Shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "netLabel": "Option Outstanding, Number of Shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of Exercise Prices, Upper (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Current share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r340",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofShareFairValueofEachStockOptiononDateofGrantusingBlackScholesModelAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "netLabel": "Aggregate Intrinsic Value, Exercisable",
        "verboseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Life (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Unvested, ending balance (in shares)",
        "periodStartLabel": "Unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "netLabel": "Shares Available For Grant",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofSharesAvailableforFutureGrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Unvested, ending balance (in dollars per share)",
        "periodStartLabel": "Unvested, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant- Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Life (Years), Ending Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Life (Years), Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of vested shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationExercisedOptionsNarrativeDetails",
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationScheduleofUnvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options Exercisable, Weighted Average Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options Outstanding, Weighted Average Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Outstanding, Weighted-Average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies and Estimates"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "verboseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StandardProductWarrantyDescription": {
     "auth_ref": [
      "r245",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of the product warranty, including the approximate term of the product warranty, how the product warranty arose, and the events or circumstances that would require the warrantor to perform under the product warranty.",
        "label": "Standard Product Warranty Description",
        "terseLabel": "Standard Product Warranty Description"
       }
      }
     },
     "localname": "StandardProductWarrantyDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/AccruedLiabilitiesScheduleofWarrantyCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r165",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r201",
      "r221",
      "r231",
      "r235",
      "r238",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/RevenueRecognitionSummaryofDisaggregationofRevenueDetails",
      "http://www.eksobionics.com/role/SegmentDisclosuresScheduleofSegmentReportingInformationDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r110",
      "r112",
      "r134",
      "r135",
      "r136",
      "r139",
      "r141",
      "r150",
      "r151",
      "r152",
      "r208",
      "r256",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r50",
      "r118",
      "r119",
      "r120",
      "r122",
      "r128",
      "r130",
      "r149",
      "r210",
      "r256",
      "r261",
      "r348",
      "r349",
      "r350",
      "r382",
      "r383",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r149",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r313",
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "In lieu of employee cash bonus"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r103",
      "r104",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Share issuance in lieu of cash compensation"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "verboseLabel": "Matching contribution to 401(k) plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r256",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Equity financing, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Shares issued as a result of rounding due to reverse-stock split"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r256",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity incentive plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r256",
      "r261",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Stock Issued During Period, Value, Employee Benefit Plan",
        "terseLabel": "Matching contribution to 401(k) plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r256",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Equity financing, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r261",
      "r316",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity incentive plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r112",
      "r206",
      "r208",
      "r416"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets",
      "http://www.eksobionics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r261",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Capitalization and Equity Structure"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r427",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/OrganizationDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r427",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r427",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/OrganizationDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r427",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/OrganizationDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/OrganizationDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow activities"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ToolsDiesAndMoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.",
        "label": "Tools, Dies and Molds [Member]",
        "verboseLabel": "Tools, molds, dies and jigs"
       }
      }
     },
     "localname": "ToolsDiesAndMoldsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransportationEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used for the primary purpose of moving people and products from one place to another.",
        "label": "Transportation Equipment [Member]",
        "verboseLabel": "Company-owned fleet"
       }
      }
     },
     "localname": "TransportationEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/PropertyandEquipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r359",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "verboseLabel": "Increase of unrecognized tax benefits related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase of unrecognized tax benefits taken in prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesScheduleofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails",
      "http://www.eksobionics.com/role/NotespayablenetPrincipalRepaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r153",
      "r154",
      "r156",
      "r157",
      "r161",
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "verboseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NotespayablenetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants for common stock",
        "verboseLabel": "Warrants for common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails",
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "verboseLabel": "Measurement input percentage"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/CapitalizationandEquityStructureScheduleofAssumptionsusedinBlackScholesModeltoMeasureFairValueDetails",
      "http://www.eksobionics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r133",
      "r141"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Dilutive weighted-average number of shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average number of shares outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r131",
      "r141"
     ],
     "calculation": {
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted-average number of shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eksobionics.com/role/NetLossPerShareofCommonStockScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r537": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r538": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r539": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r541": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r542": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r543": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r544": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>110
<FILENAME>0001549084-21-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001549084-21-000012-xbrl.zip
M4$L#!!0    ( -F!65*:Z3BV+T0# +E/'P 1    96MS;RTR,#(P,3(S,2YH
M=&WLO6M7&TFR+OQ]_PJ]/N<]>V:MD9V7R)NGQV?1!KOI;0D;RV;@BU=>(J%
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MC.]#CN!6YJ8IG<H ?4PZ:>"!K$#V1FG-<P2EV!W.SJNSO[Z=:8,06/!2Z,
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M>F5SZ9W!H#M:KW!$)[8&W;220Y.>6V3.J*2R+14U?&2!IR"TR0*2"RMF,N\
MTULQE]8F$VQ !V0N35E>0NXL:):R5@;3JJ4K[Q2F.9I*YD()<\ +0'">>9MS
MDMX0I14$71UJHO\47L\'O>.3,0X?DI4_648QDL1XC8Q3F*S0<BO!92FL RW9
MRDXDOA.Q6=WA1A\MU]%8C$C61J4@D5/$G!13D++T*^:[?U1:EL5W*U.V,["1
MYR !C';(,AC%M9>,@5ZU4.=.89JC[W8.703NO(@,E /+@M<&.)820C*YY85I
MLDQKLB:_6_E0=:MQ84Y?5G#M^+*\<GQ6$R ,*0AIB56>S%D4TL4L;"Q[2S";
M2'LF0-@'(/X "#LW(+26J"#SR20ZPP@$:X7S93*=SK-%R$M.2Q:'R.+I08R1
MP@\7@F,.LHB>_F.TB8:1.3,RUV"=ZG+ MZ!EQDD T\E9Z1'(\EF*!I@$&\DY
MR8QB>=G=,IC!>4X"#SIE 9$H 8)UQ@5O0YG!+T,D4*:3P/4R G%!R=8QC#>I
M X8GY<)+2+P:^/[:_A#QUGF:GAL<7FCO/2J#)5BV(@1+FI(I3%9E4M^TO K!
M,35K#[A\S[A-D+F9<=/S&ZE3*(5G-B89 81W@;3*209!,4X:-J,6(%SSXL,#
MB'].,* IW,T(QI53_\KN\H)EE!HL-[HP0B<3\I <40G'A,*IAV)V>17PU:"_
M3Z%JKV#X)9*=H->AGPN"\QJQ_T,Q>;WSZYV9X0*^G8\9!@X^@S%!80 N*&#.
M";+WP="OT5]LXV-GP0%) 7N0@J?O_9 H41>W2>6^+K)'9Y>?5T#@OC9-]L:Q
M3Y%.-@?3I+)&T#$P3[ZCS <1"8E"J[(D/ :LTT#,_;!1BP^7,0D5--,JIS)Y
MW%"TY9TRCG,1D9C)S)N!J)D=NSCZKD^/<#+$5 [?MI,AAL'FX&22<IS882Y[
M1(&!Y @?;5DF?*P73'^FB:SY ,Z/<45V0X-\^=2_E(PR%)(Y'S7U*Y%_*P2I
MF_5*>5O2Z\N;S5@* &\EL8' 8TJ9>VL](/H F:&C$$P)Y-$O,29E8/=S[;J7
M.-@?^N.#*OKNY?+W53SH#?KIN>]6>3#L5[XFL)0U;A&8%"8&"*!#).^#(7#)
M#1V[8-;Z@EGKY6/6RX+/UW9/WYR(ZOD048\N9JF#$L0\E? 6;,KH+1<BIZ26
M>$GP33#\S??"R7#_)9E%WZ]+/C=GS@3G+B;M06GE=&;<F>R8$9*T;I) -,Q-
M$XCT8?GTZ\+K;&.7 $JO29+/)D6[?"P5NT:_GET^<@FPM?X^=E]/M.ZX&OON
MJVZ\Y?2B:3)WP_3BY-2Y:)TFEN&B,IC+C L%5FB=),_!:^(>N0Z;1=8(X@5M
M$F:,E5Z;J!P(Y[V*BL6()A&^I-C3Z1K,<7W;R/[80(@K0L[US]FQDWXU??WD
MST:?WZN'?D34<PI_.7)Q]<6!B^_E\FL[DY/=RQ)!:_0495FKDRKI$8T\H_.N
M!I3CFY+&9?[1^*S,1AKT\7-)XTNSE(A\O!T/XM&\LB=O3\*H2I4?GKWU7=S*
MD\8O*>9Z-<0XWLJ9(.[OKR+9B2D'S15#SAFP%((G%TN6-QA)L46JP6*"YUT_
M&FWEV0CUUG"[VC^XG C[_:2/Y1TV^Q]Q-!X,9R?.?^.#>R>]MQ-*Q2B!V4!R
M678;SU88+;3,26N=+=8AE%H6?!9O702+,GO'028.#K++OLS1!&-DDB8N\828
M6[8NRZ)M4EAE"P^3A@.%52$SC;JL@)&N[*A6(VV[*5*ONSY.[/7:/OVY/;P6
MKWV6E_VW%6?*>4 "VF8;LQ<>7(PFZAJ-J"T[N NH=*PR)(@4+(G)/D->.Q-0
M)<<T%_3;ZIC6N\+T5@RL1\6HYV(H>6'+M+-E]YG T9=]Q0S6R,#.E<[,74I6
MV9 3 68>-5GM%,'X')P!KC1W'",W.!OU66;966I=OP+37UE\H;3G3H&, D +
M9Z74RKF@I<N :9:2X>S"W[+EM<W?T_6U<>< 6WYXA'<7OW!V<R?+YE0%GDD*
M4S(HX!82A3)E,Q%K8JFI(</%!),'('_(L[(Y>58F41A$6::9""4]*5H0+DGF
MDQ2@5H, =3Y1FV?3OS6-,;FV%H1VB,&!CL[;1)$)V4,O3?+<K%@8<K>(+3X0
MB:R4VPPQ*:/(4 8O-2_D!)"C-KD&=4Z6#]7;*0H5C5(\I^ -@)3"H7(AI>1]
M9M[&&I1*_5&@KK+)4=WLIO76ZY084/!8,*( WY&?TYBREGJ5[>:= ;=X\ZDP
M1HB\E+ O>7%"'*1.G,(Z$!02I=4SGPO0RGG6BRKK>Y60,5,HP'-TV?*H4A#@
MG0AFB6>'W12O=8R3:TNWU<QD@DPQ>J8SYQP"YS8*IR*7F@6EG(DK9#+O!J7%
MV\<@>*E'K0Q&"XY3U*UM,-)2E^<H>0U*\2P'DK=B#+U%'Y@R24F"0X'7GF<(
M&K4S91[2:H%S]\G).4)EK51:IIR%9Z!$)CW2TI4:OIF7G7%7U#3>GP%!YI&3
MY]-)>"*4C'MT20JC?%(\6J57BYC4>E PQRB8ECX)R<B+9>]9,EH+I!>T-JQ
M)-[R9S6DC\8ZZ9TE!ADL!&N+>T,M2Q%MP&#JM 1YX0 MWB!RG46.*I!S$Q!<
M=,I8ID!R)JV1807(R1UJV1R9" B%OHS=9 3P:'WP ;6(1!Z%TGJ)US#>%)>U
MLC)FLY\'PYXO*S_JZ*/ 0 Y"*R9E ">2<XC9,":3$]+5:D_5)8-K"2PC&F4I
M"" 7QT%$#"A=RLJ L*B(E-3?,BY, ^=H)Z,V1#Y$!,L\>&E=,A*2"5I'5/1K
M_>WD)4*O:F8>$313TFI@40.*&+RQ*1L7P2B5C%LA\W@W*"W>*B83.9G 3*]9
M/)YU#KAQ(CAGA<VX6IG&.]&W>0Z[2$[!6!D,Y0($3\X'X[GF5D"92[("Z]1>
M#Y%> &IF!\%)LG99*32$1(K.6+"F3"U0422U2C3QQP#Z[FWOUWXI4E@P7DMC
M=80(S'$.2OE2-04D^#KL2';[6T0NW$0L@9R@\P">,1=(3G*V3G!CK6!&:Q.F
MFYO5VPG?H9V?H__5.F'*MJP2S)"C<TR2S<],9W3,Q#IL++ T "U>R\KL]91R
M!H@>@L@N"6\%)H\6.3=Y=1:4/*SZK\72&1Y8V38-(Y<&O'0A&5DD,+F(!B[V
MQ;J' KDL 'G%,B:EDT$+FC&+PI#A\)ZI6)QT_>.OVEF,90D!#;'X8,H,(&]!
M&@H!H_8,; [!\&161#3^P@* &S]':UK\J3S]9O_XY)J:I5^?\?; #_'UL(K?
MJT&^+,*BF2[EYB6)1N'Y*6AKB.8[!+I--NK"T/-:&_I[+BSD=/A<6($JNXAH
MY@L?CUQX##)HYF(BFL!LG59 _#A:SP<D.,/2RDT@6Q;QK64XY*1E(E T6Q9N
MJVBLR^5#8IX+ ^Y"SL@H-9?=.CW(V0_4<> WK:A^^=2_,I?="X'<".XS R_0
M2>ZL80D3A"12#6JV_+AX;5>CHQ=#Q$WJAR$A/,_]4I9/QFZGAHSTGL?,#.@(
M004?D3QA@59 RC8M/V=Z$)L%L"?"T,<8'4999O:H@#(P;Z0WGC/':K#7>'VI
M]L;I,<8QIK+=3TVLC I<"&Z=4E)#<LDK32&])'E)"9#YY;<R#^)RA]8E) >6
MAVR08C/FHRVUIUT )97*CJ_ +-[E%9<)47\_Z/IQV:FW+ILX*"9MS-%:1 0I
MK4>E7;;9.$"1E'PP,*LB,?.R,2XRE%KRA"0CVKN@4IH461,H$959/1OS4\O:
M;E%N:I=?=MRD4A!5!HS@L_:*8/76I9Q3&5Y</2-S;T5F7E8F&NY01[1"2R *
M8S79%&Y#0C"E7&N-LLQUEYT?RT76,M=L#<F9,EQH\(2_(AID$L7HF$J8GNN4
M:WZ0MJ7/.#M3"@=;Y$2T05$4K[D/5CB)AFMI5V"E^;(+V4\D,I>%2YG (5@2
M'ZX,A?C&,BU4\DH8(S57^,"E5E!XYL6JR,D% 1F%U F\E)Y9;< EFV6(/*U
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M'342PI";"55PPGJN(GOT[#GI/'5XO_HFD+XS^_YZ0 AW]ZKCVB9+YF;@SSZ
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MQG%#1R4M[)+?/XHK^G6S4$FAG5QB ;UVQ1LS/B;\>=2SPM^+Q-2PIY@UTV0
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MH0N3@N:>A*(LJLKM:789RF;.&)_%(J-%590EYZY;6I%V,STZ2^<CH)45$@[
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M4V4+ZRQM:.1Z0K(=B$Y?6B$;K#3]+LV858D3L<JCQ^D\SCNNDIYJY9\%G'C
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MD6XCVF*>-[9B-DRFM\/B\%Y%]5F1M]$G%*8B*T.W*7,98D?.L#)\8K;&ROD
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MY<+%2BKIGTY7= (ODMBA45\5P9TJ\@HO2KGFP^9^G<_#2EUN6.(!QD>EZ<S
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M&11>"U$Q,B)C8I(I.)P1QK+9Q.]*UZ74XL3\T0B-?+@D7$ALNZ]7GNRDJ3I
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M6$JSB8^#AZ15T-'$9Z2E$MO&BAC$HD,,,HIMG!NL>WZU @+3O#.;.M&/U8H
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MU%*S@PO;7B#G74T-FS!6K:E];L,F<!/O[C=(!$B,YIH!@11RWQZ!)19&/<,
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MD9"(,;Z8JU%LES:)BOTPJF^>4;L] @,*:Z"<(@.$#AX16-@X^M#^A9U ZEU
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M7<X?ZPSIMC'\-DVU7_O:>!+<D]1-2"&8?+TW7>)$LYZ[V-^\"ME^!##YH4W
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M*I4WCJI>DE$&'[ZLBHZ:DM'\)[3KH1L(T+ARTAA1-I!,MX+T%, 7<\K0P3-
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MDS"Y)8G7K_B"%"['M:V&HJ=<0<UC+!^B\>B1<:ZI>?.78,F;A!"L&<:_0BB
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MM\/DF)%?<-E%/P'D*&0C-66N%5A[[.>>M?)416335=YEXCZJV1GN^* G.;\
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MX&^,*\S@)?_FE^BIUR"[:?+KK\\2+H5D]'ESX8JI ,YKP!I*V1ZB4:5'^TO
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M^^E1/#S4TSRF>48T B^AQ->55^X\\1-&5O]D_S!-CEJ$70,1WL'!XT>'?OF
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M?_JTM ?7KO%1!MDUU6Q8BO4?+2Z[GGEHG+HSAB',&_>3_.,IY*J*;/%3CJU
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M]P_N<.%L-^BK(Z3N8*RM=8![BY"*<XI$,LHM*V?0,**MD7AI&R#XE #!WC9
ML/:;=+1WUY3==I.^MFE]<E=4^W:+OK9A_4TVZ!Y:!?<P2/ JM$."AAQ5-0&"
MQVV(X.[1Z"??!AVRW:);;Q&2M!X\W6[3>F_31IVD+WA=#-/=XAR_T<Z5LR]"
M>?QH]_@6KQ\@% ;P^LXA?KN_B%GCB*/V@2G7(VK7[R4@\,XU;=V-@>%^"Q+X
M%,_EZ-L8QMLM^L(W_G:;MB?IJR XMS?^/;[Q[Z&S_[Z"/GC5$HSV6[O[*VL-
M[Z,RVW^2'C[:_S0/YG8+L2Z^S?>VLP>'Z='>)W*P;'=VG7<6V-N.[HY*V+A-
MO8];]_71)&N3F9!!;$2YV<V':3O"^S_"[[9X[5>HZ,?.W:'9Z;>VN^^CNM\_
M3 ].MA1KZ[Q#C])'AR?;'5K;'0*2PKO636TWZ:O;M7M;NW83[-KM,^[1,[X'
M2_1->^'JY $'?Q\F>3FN9BY-2M=N^12VS]CR*43X2.BDYII6<B5;G,2GN&QW
M\ ;6.+.[H=MS^.3N[*#;[?EJ2:>CX\W!1FSF%CUX]-4/T-JX:AMM*;_,RZP<
M.S\_;P!D35.-\ZQUD^0J;R^2JZRNL[)-\J;IX%/;8.XG7#T'VSCA&F_/?KIW
M\M6KP;<;=/L"UT??AM1XNT6W/T./O]\P[D8'!AY 0O=A<I[E95*5:@T4>3;*
MB[S-/Q%5^9U;TH?IWO&6+&Y]-^A1>OCXKAQ+VTWZVJ?H)#WZ^J1^WSJ/LRVF
MV!93?'5 E[_Y9]4DG_I!P=H!AP); EMPU[9 ?T.WZ<'!\5?OHKG=GMMG#+Y1
MJZ-OG9O>&@#WV "XAQ$ PM$0>B; :1!'LW7][[R:)R>?V&)V'=V6S=RB!_L;
MXE5NYO;L [/RYIRAK>O_?=S\]]#U9QZ%U3C:;^W[;UP/ZX/T^/ .()N[+L.Z
M>#O?X=8>I<=[G^BO;K=W_;?WP>-T[^CNY9J;N+7W<??V[Y*-W3#X@@QB(ZK0
M;G6@MH/<E$%^M\5MKUV;%%7S1;)OM[RT:/X_'7KAF%3=J'"WO[_7;CE__,2+
M^Y9KL-ZW@K_]TB<'QY]JO-QN#;ZQ ;.5Z>]-I@_2.X5QMS*]E>EUE^G#]-')
MX4:+](;[F8=WS?UME*OYYS;S8B=1=/R?KSRR [H:'B:OJS:9N:STBSKMBCB\
MKP/[K_\8U7_^KQ5__ *CQB?^E+=^]\;1/!X/SN.=NW1EY^XV^(%\T-^[ILVG
MBZ\O)W86R<2-:Y<U;I+\>+R[E_@W%7E5IDE5)X>/_I0F4_^/]L(E"Y?5B2LG
M_H//W=C-1LY_8#]-#O8.]E*O/V;SK/9_:RO\=)/-7#+W(ZLF@%D\V-L_V4W>
M7^2-OB^YRAK\6IW#R_V',CJC/Q[NGL@PZ#?ZE;Q,7GQLJK^XK&BI[;1\9W]W
M__KO?*CJCTWB7S;+:K^8R<1/W8\U2^P'+ZNB\^/V8YFY"1QH:&N=CV$ZA5_Y
M29W[-4M&"YQB[F<\QJY6\-.S-W][]7QG_R3Q6SEQLWR<)GY^55<G8[_-U<S5
M3=)<Y%,H[_2?SVL82U5C(0<,9%X[6$!<;IB8W]_LW/%'1UWC]Z_Q(\!>&OA"
M><_NW45MS<_7+S4@7]_6U31O/]ODUN[\T2SG.$M["/=W'T>'\.#X,QU".A=P
M$E-S#K*VK?-1AS=$?" FYCC88[";T-#] \[S$H]Q-O?S^,,_LG7^D<>/__0)
M \Z2<_M8_]*CD_ <.Q7_5](G=AP-I$=YW$NG_,*ONW]QYN]I.%2-\\OKCY'_
MW-AO*+P#5,3K=_[,EM%SJGE5"^YZ4"7 2.&I19'4K%!A4ISO3I.BNO(O[DJ_
MQ_YIDVZ,3X-Z[R8E+5*VX??^+2_^]B9%!<!C]M*%K^-9[B8;=]S?:+N %_UV
M ??S9CU#R2 E7G]T42<$>](/=Q_%U^W!Y[QNTYLN.S>;%]7"D<#ZP5&!@0X4
MCK67Z:8K\([+DFE7%U5WSO>N_Y-(K7^6'_48'_I;5H_I$[]E"QZL?\C<C0'V
M42SD1,@1Y-?!VZY<N""KY#*?N,H/K9RZVI5C_]G4_ZYN.W\"VSK+2_RV/W$M
M+755PD8D,"B:B+\<JY(Z4/O_RGO/N4EUV!GXLO_4!-Y>7249#!1O93J&L+K9
MJ'% T^"78>S?@EK :\VL:'3\O,+P:5C.PLEY!@M@!C6<\3=AK>##T[QNVN0?
M75:W?G1B*7W: 6 A/#K8?0RXFF70S54^:2_83;!?9 ]U+WS%S]CK_G;U5\QA
M&SN@L/I&9^UPOP<1,O][H1FVN=?Z.R,O^1]W,B]@]4]9<94MFA_^',UIEI<[
MO37L3W_E)*?33YGDR2WF2-ZF/[@5B?)/WDMU-2&D_B-;EZ$D%[6;_N</_R<_
M=">/3T:3)T_V#PZ/#D?NR=[DR6CB#D^>/)X\>C*9_+_'/_S7>S0VO+ _\R]T
M6,J4_=?0/JZC=G_G&J=*SML"KJCFV-YV2,4?!+<$5?S19_6HUE7%T[?M0.89
M[#/^P1L%_NV@>=$*^GSNR]I)RB]\U^!R3+QVR>DZNG1A"X*Q^>/>[F$L*U]:
M5(*I"UM4N',_5A[8)]Y Z[/TW&<:G71N/SV^\"8TJAV_U >RU.B_U*#28''Y
M5KY^N?%8B!LN':V3458@EY-?V7^ZNMI-7E?AC\O#Z+]V^-[?F+,0]0)5J^E?
MWPLX6VC?!.F/[2]4<.;5\P+E'G47GHV#O=WD@S\SK3\),QCX!&VVT$2!W^'W
MG/]T5=4?21N.%CW7]_#X3S ,LC67^Z"91R7CK+E(1EU=0ES,]48I"^3MW\9K
M#8J/J39O'+B<(&SS; %"M<E:E!;'7$0#R^IMC\)?/PWO?^G_VFF]M,A$5BYV
MO#T'RLX;N:B'T>G(05Q@%?TJ%YFWQD'BR#F/-X4%BT0SW'WHNO@S[O_K'U57
ME_!9"0JH&(%NG4[S<0[.# 11WGA)FE;C#D8/#@+6>E?S-I_E_Q3E@KQP,@0G
M[D15GV=E_D]\[!T5]=KX_ 1M?R'0]E<,;7_M-CCBUZ?ZM8:BT8)X^3\Z^I08
MVNTO?])07B+):H,P%(W-2ZLC4?22YG\W\Q_U<]Y@!2,\"[6[S(JN3[-@"9?P
MOCH,)OTM=P@CI#UR1](N0R]LD/!1C8+C%+<0;PZZK'YA1JA;CO?1[M$=Q@O"
M8N[3%6/BT6 ,%E47&O9^'=TU*^D_Y768D43-IGB3J#SG8&H'3GLU_DC!V>]
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M&PP'?XSJP/1DT!N_CF[KI+1;Z9XCC#[]H2>,9 99)V5P8X4BVA;(>4R(]LA
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M6E^.Q.-&FGL(%+P(D_@:4.BK:UR/9N!9"GC>+T0**-+26@JL9AY0)#V0BBE
M71"=5<(4VFSM%%U(VN2,Y$A!:XR$K+KWJ[J- @P9K .K)%#4.$ +XH DVL2^
MG0SQ:/(K&I.82(XCW+/B5<V[PGJ#=>58/@E/9:W=O!H@DUV46\+- M$F\T51
M""B 9 3&FHN8QRTX,-1(RR DBJNM'9)++AZQAJZUHU?6T+5H:,,@P,P$<3!
M#0[_:(R ,@4)"FNHIQB[%.[CCY#+H=760%5MD:LL-B"\D#V3VP+1 ONDP,Y#
MS2B@'HO@F4 -E#80B*(@2GCG"Q1,!51T4;&NVO!<7_&H=/U^ZRNRKB^KZTW2
M:VX*&9P!HJ0!U#D%@N8+P 6$EF!LI8NDUZR+T+K:B>;*BG6TL!F>G/3&)RXV
M.HD]BJ+ZA;&[@8E=BWY)I%.H^'65-D4WDM,4(._&#OA>]IX->OW_LS4>3=S%
M#.C9$NP.[//F F0<N $.++)":LLE]1ZXQ" 7^UR*PD8<$+'I=Z$(AE&_SB'
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M7UWGE_ZP+'_M] ;AS^Z)]3WXY5Z,C#+,,_QT 9/F@DE4J<^;8ME+XO@KB.;
MC0_]D?J>L6HIK%IHE>@4-YII @AUP=3 @@"-$ KVAK+.$8VQL5L[@E[D4+_
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M@-.Q]E)#!831&C!OL-.,">%%=!E6L3/RM7R+E7,-_D)6SK4J9R,2;;Q!0A4
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MMA[#36RUU@_8['FZ#W:K;7"0=L&A3V?+X7P'7'7,Y!C538Z9O06;EVE-%2T
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MHM\_>/&OS_N?P[/^W(OC#<_]0CZ\VX,')__R^[TZ'> -_/:QX%P6B$( G<&
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MAM,IN)F%-:F_.L<;<T7P%'BI5FHBNDP'Y VZR:SOKE>BY7CX,W?]U#Y9P%G
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M@L8): 2.3$E0L'789AG95D6V1OF#4(@;*!GPW$E C2! 6F: \(I#!J4B+I$
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M-77._JLY>,!DPD#=2.XXX59P(C*6DS1RD8YX!CHG7]ND^5T1$W6>A!64TCO
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MI"HATF0VS5-A89$Q776=YOD*"?3S J27H9 "\.A(]K'@W[N>L6G'8#BVMZ,
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M<#"EX1^5P*_<QE+F698G+E\-YUV7\]?IH$>C:.FTS2VTS0RP,>68A'^(,Q(
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M'K*?87NO? J-,U_7O32K;I?X7?(ZVMM"+G+#99P1 2M!>,H%_*1BPE*9*ZU
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MM0D2GV]= ;IYYLB7?TT[Y"-"/DX]*NU(U@ (;U(:CYX"V]=, 8UF4UYC!71
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MP65?+[OV1,Q;(9[>V +!WXP4PW:: 3%L+\&3/'M@7X%(#UYY3*C/6G0>U=;
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MN;-YGF"S2<4)CZ@E4JF(2&H-6&TR3Q.SMDGC)<TF43%<<Y5A<8V6+N><<FG
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M)B)"<$>4B(1)HRQ.([:VR?C%NJ,K$63.$TW5IHO?!,H.K"MJ(.YAV[)>./Z
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MR7P=W\*T-65;H31L'K75UMH(3#+?WF8,2UICE!E\:Q$43A'>M'*O@6X H9:
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MAZFL=A3'Q_25HL!HIF6C5U(\:I(B-L[>F'' 9Z>ME&<95)HWOS!U6?JIB(G
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MM;5W$ ^[MK_?VAV<^H/3_-,_, >PYEMO[7$W1YIJ,_-VL+;:^@O()> '_'<
MCQJVCNWPI __^UN^K!)]YE>]\_(U_]]_:4KQOS_\T_I/^:%1\2_DW[^WAM%'
M^&3(%WFZ/K82>!CCIAUU3TXB;'+]UKO!$/K1;\VNCORQS^ YP;<+\!VU?JO>
M]/;=UN>_)^^ C\*\]F/I:YUU3PY:W9,1O/I[%\:UNMA3#47^$E'_'A5=R_]^
MJ='P.WA>O16;/P:C;[$73P:Y?2>Q!Q.=?_5IX'*71GFT6G]UCXIV_E8;CK<'
ML'? \\?M7&OE6U'5.(Q.BA5?W'.:]*9HV/&P.Q@"<N7.Y M2I9-VGKOHX["?
M^[5OAZ&X5Y7[5;T%?I^O-N7[4BZVH#7=_?R&-6CSE=$9P1H !Q(VJ*)H!/S[
M:IZ%#Z>]\Q9AJU<7T+S1:A4[7'$K"S9-V^J,6_SWN,7K^\-8[)B3>>O\O3X>
MC=76V4'7'ZSFS0BZ4JZQDX.2, QSI#/?"\OOK#5SX62.WU3.ZW  W*GH:7V$
MRO$?]ZB;:54H-ORSP? ;C-'@.!=@+Y;U],OU#N='%W.5O]0].NZ5G1NW<7*'
M#'JYUMKNM]9/]P$.6H3>=$2+;H3\]'&?8_&96O=*.GE^>?;76NO%Z^N7=*J7
MVEZO_H#"-ZI>4E\^!S;?BXO]Z:O#5<YVK4OV9)AG/;#M #2M-NG6#;['U5:
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MP1=7X'_X W 08F:B/I84=7)O?L+G<Q8=--R.1O&D-<CN0;>$L"&T*\'>:EL
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M%@E<AF0I5IQD5?HEVYY?PV'!4TOJO;1[:(VDYV+\=LX8JI4R@G+AHPV&<VD
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MEA@30G)KDO74I&2(9(Q8RV/C%#Z)F=:<PB0L#0EK1"P#,TW9*?0VHDB9QH'
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M] +\3^C"D[,[>-C=7USSLSD/G)0.E,P(BE5B"1B[549YX:S&/H5,YYLLT26
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M6^OR,JSW7J=DG#/8\$2]A3^45%YA<)X42S<&+VX8]B<Q[-BB ".0:*HHDLR
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M*@Q/@2=KG8)/O26U6M>U6@<2Q(V#?N]$]G4O49:H\7D:.Y 6Y]Z MQX( L^
M62.3]QE$!J\N2++]JV4=*,1"#-_J':[H!*30B+QLMPN2R>?)(>>5NBS"+L\B
M:8.&_K__I2G%OX$@.ZHN+A^0W_)/BYBKE/%O>5K<+^ZV5/8#\NVF5F,9OQ/
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MQJZ259^[H_S#>GTH[ZL"PK5N*#^M3Z=4\V_%1IS=3IQ-#3,/D5EL%4'8!8'
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M:RXBTY12X;05PFKI6;B_<M)K.^^W8%$[9['S+6[V\AC=)Y]8JRH(C@\VU[V
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MYLN,*]KI#4[[RS.+:V>C9M!C8,S=\R__;)QO__..?3EZAX%1ONX>?ORZ>7$
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M<[Q 7&KD;\&!_[N7*[**!-V<5YTC5S61O\QY#X9KXI**F'!LO<:82..X8$*
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M> 45SF&]LF;PP_E"E.C]&;B+XSCQ^U&OR#&8O1^>'H+/>/&<DJ1>!'K--)3
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MA@TIC.4R]=KMWFG^KKU<\S<WAHNNZVS']L&CGAA8 M1K_)=L48G2A+F&!Y4
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M&F5<T!KT@3,7-0[:A0C:HX+4(>P3)E>FKGKRHI_2!R#BT2N-M[H@,G''?M\
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M$M827*M(P0%>&+/[T]3:O'":G*UQ\<&/382A/8YEQ<-)O^CUJX2'A_#HO&(
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MWAFX76=_QW[FM;$'EST3$'UU,@76Q>F^L4$K8CSR%@2*4^V0@TE&TEOO%7C
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M# !_[+ $H6X<7LI76;F3_SK_?K 7PJ;FXD,J<V(RX)]PAE/B24?#*4U<:\4
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M'3WIA]3^><(<X)]L[\&>1+^<YFORN/[)G.3GA;92-+>WSQ&-M8%D>+@5 $7
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MAR\]-MJ=FW:GWFN2K^T_FQU<=5Y<:'Y+]/ I8K1\B8:9VD":F4!=YIT-PG'
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M%YO8>, 5%GYOR")H N=G:889TR 9 1K&CLRO3?!J]NZ*M,"* 5B&!"P)6'G
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M8DSK"?1I_$"ISZH/ !E"=$YS,;_[\.0PPM@_Q&X8"+=!Z+LVN^^,AC^I1R?
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MB__6Q?:A;=,+J1VS[  ,086N%D%N;D2$7X,,;;"-^AA<&XS<6&0_C6DH?F
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MSWZX33QB@_J$/IV Y$ 8#A_)8)E@GC$ZC@A<Y)%Q\,"W?(Z2/F\'.M#P4M"
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M^W$TJ;7MJ=4_JRDYJU93IE&&2$-0:21D&B&=TI#/4&H($RJA5=KZW8S9%<I
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M5'$3#TVG'$^C!-).##)U'VJ&'UEF+?MZ57&O] C?='G??@@/V2^A@.BO@"S
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MS4])=V%D,1N!W(MN(AQ)!/FKO%8=+B;S?$YL^<:V@/@J"/"V;LULU*M:U.#
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M-14_55.>Z]/$TOBF*9^U\^P9GJ/??_I_4$L#!!0    ( -F!65)K'*[_>RH
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MQ;+]&01(^3]9<9=V#(/V)],7MNNN0/;7/@!E40L)I%C!(N+@\2&C*$<I&I+
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MGP0.A85>SJ8L3OB^OW:IP-E=D)8]XF62XGWW8FR;\WZ$.:;"28>2]B&7.5#
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MNJ\HOR)*_P@TM#/X&S\Y;9M]S[*N&:604!^CKY(0]E\>-HY532#5EH;[4]W
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MH:2GN<DE6!B@*-]H$%HCI;"))$1IV!/[0T]KE"M!YP M#!S2KW/;]SMOO]W
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MU,DES)ZIRGW!YYG[W[)_4$^/6TT[C+YVET!-O>1/WU\4._6WQRQUI;XU?X.
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MQJ.06*RM^4>N9?K/O_Q_4$L#!!0    ( -F!65+ **[RZ8D  '0;!@ 5
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M-6U^F$_B/R\GHX2&]\__?3.<?ZFIP0VCM]7:4]-9TY0Q21K<+4 Y)@.G08G
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M0-O;B'.TU!ND9JYA>KW843N!&JR5+*A)B8VH:AH.V^HN["#"\=J;M!)];[S
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MEL!Q=Z3%)=2).)<D25&8:!V#:.13)X<'//<LN-!:WA5O2RV@/@)C;' Y2$'
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MCJK?$5'J2?/["+>!R;P$MMQSLDC M<>=QF0@TE,T$'3&'<Q'0ZUG4;9I7/4
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MF3<)R3^O*-Q!,'@L"G>(.MK'9+I0\Z*B< >IY_'@S#&R':#&3I,/BMF#DH6
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ML3"EGF_WSZ/_Q+./G^J*_H*+\!&O7<5UA4VU;<K&MLG(3+:\0*A.HZ*539I
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M0S#2>_>B^Y&R"]RDEADG1.1< ,\:07$K24Z2@<R^:*\-$M'[$K/VO60JCN2
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MB((B33*(4"9XE&HN$^*G\X9./3W%U]GCU>-<@Z4!#<U6V!1K3TTX&'P/"\5
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M8.E< [4AM$R=!B6&/9= \4*DU5O</L)X/F,O3G8\QWYO=/0?:RNJ]:X<WW1
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M3^@$4D432!)[2B3.-YXE0:T1_.>>FG'.D0ZV:7>.\8IZJT?JTM[B.DI^<3R
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MO:^Q#R+M?8U;1QBQK[$/)[M]C;W>Z)I\]=7JBLO5T]^6JS_LI6NUE+HHRMJ
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M$Y+8LP=AU_U3(>/""0PT<111D_$XU3*@7UCO^(^C_[H^C."'_]3V4NUYE0Z
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M4!T%/?QZ=2F4HUZV@E&\Z/+5!LU05[&C<[[8Q:P-@;9K6NM[':.ZCD=P5H[
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M[.;YL F^HCB31F(%TS1)(<EHXB)ZI0M[(V7*0$("DX0N)VIJHN!D*=8MMJY
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M]-!CVG'##_UQ. A!#'BU:T#S4==MV6_E5_VM_)=BEK(89;$AT%XF)20XC:'
MVD4>)D3)F)K,Z-"P9H]YIR=_ZI/?-,%05V"A/:O@AB'N*8/Z1G%H*=02V5$2
M?04LV=4#/3A-.L'4;QBTS\0C!T,'8'$8$AWR<L<2":5!=Q9KF:3*,!CC.(;$
M9(F]QV4<,F&(B366*?'JU[ [;- =;:P6#)U\*C5,?G(BG/F!!<%U.\?AR?0[
M#/::ZUZ-/&XJ^@XW!YGBN__:;9=]TG-G!_C(5^NGSRN^*'B9VG#T)F]$3*DR
M%#+D4IE2KB$S(H62*17K-$I$J,<S8/;IZ0 U\:"D'FR3'[:#0Y; ;YL/!.O
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M[W#BR85=H'>DPH$!'9H)C?C0R@^L K-]^&%=L-4(&Y#M>D 5E.RZR#$NU_5
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MPF;IJ7>J^O/#ZM-&/;.%;):6NJ?5PZHZ1*B6F7D<*XV3)(>VAHKM9D<A94S
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M4_<WK%#2CF$&*+<W#S:8_UM9S/C-R^&2>B?T8,P,^3-;;/[!ECM;16KWU#3
M?%9B:Z-.?RRD6DD;<#'G7*<X9Q(F5%&(LR2%%)$(9CDA(L6IB)AG\Z/!99[>
MSJ>1#KPLU/)V']A7FF+'[=*4IFWH;995!'*K"3C6%ARI6V:Y'EW7'"&5.L^
MU1J4:H,CO6>@T1SLWXG/07JSC#Y-0?=W@PL][KYPK#FXV$^.-G#7MNQU)9;2
MSV<LDL=-679?EF,;$[N4;IXF&HDL2J!6=G^*D8"<4P8QBI"*1$Y2A'Q[L[L,
M/+V%HW*%;LL^<<^-#E5S]AEX9AOPHV28/LYXS[EQ6RS"XSTPX^\%KIJW6X_
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MH?DFE3'=18QR%&.N4L]L3N?!I[=VOU//&R7JOIVV7/%Z^]VU.T0'\-U6\6$
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MZ=A)9B4VMMSM.U7]^6'5E+S]?;']_G97;,W^<G.HHTJCG)@O-8.*&Z,*9U1
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MHQ[(C>4X.D"E02DD^'0'J@ZNHW8<PGJ/;HPUL@.I7>-+']*=Z[NQQ..SLHG
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MKS;30Q_IU8KMY_BZE^AXEHL9V*MX/(VCERCL/P%#ER[L(>&KES3LCZY+J<,
MHW1N:F7W8F5#^@7?V0$^F2^CKG&[^95MQ7?#72>_5QO;IN)1E[^<<Y5'6HL,
M8H3*'J4"4I5(&'&"4\Z3+$N\:AGTEFARIG@M.7BJ1;=^&RLO^^89T]I_LMQH
M?M0I&)C9:UW L;# :C,#^XEI%#JY: 9JG>R:4%X1M!-7&( #]^KJ*=38W;S"
M8'BEWU>@!_M1LK 5Z3<O\]^^S(4B69HB#G,I!,0Z8M"0; I5)@G.41*KW"F=
M^/#(J9'B;ZM%5?'(V,F.EN\1/NTTUDWK@7GHMX\?OKY_![Y\??CZ_DM_)KG4
ML:4T6WUQ107U/\Y9X.B!HWS&EPHTW^&5W_0(QKRL)'W4T_V6UZZVOM[_9;[K
M1:&*#ZNJ<O_ORAYS*_E@-IYF]6Y^_\D>9,]SGL>YT 91QAC$/#:;"!)C2'(D
M%4EHDI#,<V,]J@+3VW@WXE6AF7*]7+)-44:]E$Z%+E&:X[T.CCOJR4[Q*$$T
M[3&;A6O0YAX$8-Z3"H89:(  -1+[JT")1>#8S='G,'@(YW@:C!_).?KL7 WH
M'%^*#O$E)P_Z;,4[%"+((IW07"#(8[O7)]18J*GY)\YR&G$:"Z*<"IC>&VAJ
MUNJ_I?^1I@""?\O_(TX]PA#:L'0(_0B$T-!>KQ-:!:6<0Y1V<$"CU8/?=O]X
M'GH'+4X\\"[7=S./K1>C=&(<2FH5!X> 3'(L2)Y"&N61V8(J9:.S%:0\5;G*
M.4MR3VNV=;SI&9]'3IY?%;/2/GFG/K9#[&8A!H-M8!HXPNM(4O#'('X0)U!"
M6DCM XYJT#CI?FY_N-W4C4@^JNU;5GS_M%G_6$@EW[S\9DR8#ZM]HF7=NVEQ
M% E"B4 D2QG,N31[91%)F.>"0HK2)&&$)1E+_-C%7XCI4<XA=YCMI?4CG Y3
MX<9"P\([,#79XLA6>M"(;_>5/UD-S'[Q;^  ^T&+0<)SNH,8DLHZ2#$JOW5'
MZ9ST>CRI:U\GPZ;?UTMS1U$%"=F*( ?*/:S]:1111:,$)AA+B#$GD.N,0"3R
M%$N=I[8'IU>/)\>1I[:UVG?EK4Y_;*!<'4;W9;O9"1M(Y=OZR74.'$_HAD!V
MZ,.U(YG_O<'3BGUDF@UDF7G#%;9OE.O@(_>0\L3DLI^4[P,Z-L2L8_<?^7+Q
MK<I_B'B66SZ",LTSB'G$84X2 AF2:9K9X'")_"RURT&F9XDU,H+U7DC/5I>7
M2+K133]T!N:5/2R/]V'Q[UIY4_.@72HO1QFW*^5-+2^Z4-Z^<IAVX<>!9S?Z
M4:=,2<J8L5ABPLV^+<TAI0F'@M,TSH342/JUINPMTM3LF>-@X>.8X$;ZL&W#
M':;,T<H9=2)&]"U>;2=>*3*1MN+NT([98MQ!JE>/S>V&HF_K<8\G=^/E!U&&
MO!15DKA]<N-NXVF$56Z(-DYM1$G.(!,Y@7DF%:,BXCB6/FQ[:Z"I<6@C9UWH
MQ+_XZTU$W<@P!$X#4]P>HH., S0.O =$2$*Z.=:H-'-/XW/RN'M]R-"UBH0>
M5O+#RH:;VH(2YJ4H/JV7"_$RIYE(9<:EP3:F$&N90:ZXAH1'.$."2JYHB/BS
M5BFFMY4KZ?M*H%&(X+'V"7&TO(8%^75-+?!')?% EE5WZ(:/GFH78P(A4$XX
MN<4QN3W*OU.%;<QC@^K_[WK3-,"H>T)A(F-&B:$X(7-;EAG!/,(1Y"3+",4T
MIC1S[5IQ<Y2IV47[QBE^#;;:D6QGJ6#X#,Q#[M!X-;FXJWK?AA>W!QBM^<5=
M'8\;8=R_N$O(H=;*;JR4H0_SQ*_LK\]LJXQ)981?+!<EQ?RVVBCK)E+R[V:T
M7]9%\;BJ2XW,:<2XR'(%8ZP%Q%A&D.520\0S)#&GF)N1G"R?$.),SP0Z" N^
M&6EM?OJ?E:P^L8P])ZF=9\8&?F ZVFL"*E6 T0589<"I-N!H:JP^P"IDY^?W
MT>?'H^S5B/,T5NFK?4:N/;C=?E= +G13B8RK[9]*K<!&/:\WVS)HI)S3K9E3
M]9<U@A3XB:N5THOMWTH/MOVIN'NE^=7S;EM%H[#GY^6+#4$IQS;W%-N% %H9
M!F5+4!C]=[:#]/$#-S9UKJRXM5'VW_6O?EH:K/]65>@R$[)=K';VN>LJZ,$6
M*&#;*G&Q/#0P]^].Z>%_+.MWL.:(4!6Z KTU[3&^/<<8,0XX#!JGL<*!GMFU
ME(!Y$44URL.3^5+JF ZS+7@0PKRCYN\?U7:.16+^GV!(L2(01UD":90AJ'5"
M94+2F$3$KV" T[A3,^:/1;6D(VUS6+DHRO.D&1#?RSAZLR14'_$WNYMNFK&\
ME"S#&NWL[7JQ.C3/,L3A75K ;?+<SC0&F)*!%^QCB6?@9&XLU'NI9\#(';(0
M@!=08=/]W88>.:G?"X_+U'V_VSOL5>QS=DK^<FB+5/J"YA$AJ:(,0Y%+"G&<
M<,@X5S"7*HJ%V85(Z<1J;8-,CL(J,<&1G+4GU:??[2U$'38, 7 :WD_C#9&?
M674'@U9SZ=:]XYE!=Z0_,6_N7=O1U;+CA?JOG5DUW_\P__EJGE*?C"$2&5/%
M6":"V29+*E7&4-%E(V^:9BE))/4J*7ISI*E]UP=!02DIL*)Z'CK>A]?1/1("
MM*&=(-WP\O=WW,,BJ%?CYF#C^B[NZ7SAH;A[PRNW=CMKZI4G"&4BHS#"&D$L
M"8:Y=6Q02N),H1@3DLV?RY3O+UNV<6PT.9"T/A_=N<Q#GF]6LLX 5]\6JY4]
M[^!L6=8F?_VF;F?S'9&89"B1,(]0"C%'"-(T,HN,EE&<894)RNOY?K\:NWE?
MW]EN)!YCKM5*3GJB/=S_KSMU(X8(!.O.]R_1B^]?J/?>_R]Z[8W<6R](+[U&
MJK=+5A2/NCZ*?=R4C8-J2UE$*HFTB"&)=0QQC+%9,E &XRA1BJE8FU7#9R/2
M,M;4MB*EJ/8CKX4UF-:]MKIM1]I@=B/L0. -'0_1'3=OOG1 )"3GM0TW*F\Y
MZ'W./2ZW=$T]9MN2O0P?760+[I/]181)SJ6 6:XUQ$(FD&(6094R3C,4498[
M%7#R&G5JG+(7>I^D<YXJV[4ABMLD.!J&H:$=VLP+@6J'=&,/E,*F&KL,/'*:
ML0<6ERG&/C=WXZA]X85?E+&MS@K8O:M=G]9E78=CS%,=I2SC',;,TE6:"4BU
MEC#.8B$10C03V(>N? 68&G,U$D-6E[1L_,5E,(@?5WE/AAMM#0GQP QVJ -3
MRGZE@F@C?QG*M2\0'X[-NH(7DMB\91B5X[HB=$YWG9_3C?GV 3GO_V)/BU6Y
MX_QEL5(?#.<6\]S<DZ7*;.VHV=7AQ' =TUED6 ]E9GN7I;9RM ?-M8XV-4X[
M"I \$A?\804&I<2>1E@[UFXL%@S!@2FK#WC>[.0$2D@J:A]P5-YQTOV<9-QN
M&JBX_9UZPH^[;;%EY1%Z6R7AS^OE4J\W9:?XF..4*5ON-Y'&&LN2##**4Q@G
M@D5IEN"(>J4CCZ_"U+BO:XGRJ;P1'BZ.R<[SOY#WXPB(N^7MA]EMO]I,CEKM
M/KP6$TCW'&.6O*O>#R=)QU*VM4OG<YGJ8:/+OJAO97G^.4JY0!S9OJF40)QB
M958_PB'!.>622F/!>YU%W!YJ:JO4P=.ZV<L*BEI8S_JTM_%U6TO"H#8PYQ\
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M(J(0ISJ"N8H43')%2)I&A*=)OP8OW2;CE9J\7)F*@&"[<78H" =F[BO]7V:
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M!8MD%&FI)-6!_1)N%6E\1O'GS=/3O#I%L5:=.J@:N5@N@-,RX5N- C,H;IU
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M2(.WA_6O5'GEZHYGH4_:$<OBX;VVW',4//1)/_+9HOW'>JLJ*<*440T*4T"
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M(KJLO.&X>+AP\0'#'2OXZ'%PH.!U0S<K_6Y>@=Y4\7K&7&UD18$-LB:U.T;
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M\4B7+^]&LO9)KU9:S=:O^&KUPRQ7;@?ZP;X(KY?N0'C**)0B(Q0@1"# 12J
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M=%@6>"A@%S/"O1\V7'9XJ'X'F>+!-W<.K=SY1Q;JDU[/ZB7]1*>BHLA28K0
M"F4N-HHBP#+(@2P8Q8QD4L"@YBX!8X]ML=W)FK297)W[0H5,@=]&H"=@>V;[
MCIAVB:D,12=RN*7W\$-'8H;B<B)(,_@1'38&K^:\+.]-0X3WJT^N!<S]+HSY
MTW(^?UMG0$U5SE/!D 902.'2S0G@0J9 "2BH*8H"I\I[;Q P\-@8JQ+=U8UM
MA$_N5TDE_B394R#YPZF0-#J$6%0A<^)AK?:$=,\4-B:0 RS7GL >R'B-"WJ8
M"=L!N8M6;,CSAC-D.VAY8,MVN;^CRWTC2OV?C7WIWGRS?WQQ$3Q3I"#)2%&
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MS<*S2(SA1NZP?_BX6JJ-7/_*9XNU7KA>X4WG@Q][,2)M4BB"5!)C-Q8%2C'
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MH\@U*-G&1/*8C:,^NW-5$??FU5FZGV;EG[_HA?SZR%=_-D8+P]#(@A!+Q5(
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M+3R?H1'4N?/YW5W+(%I+SS5X>??XM+(;_XH+6ZL+:J&-(< 82TO8F!PP07/
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MN:KYB:(UU^\9N'[MA^6B[FM;A\?L)4=8(8V>K:T]7$X+@3$J) ,9IPQ@DFG
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M:28H+*4]T2Z2'!(B#58\5:G,E2"2^.13C^X_M82J;;/<*$X/RZ@>X^?VQM^
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MDSB/TR^;03+UU2DQ9X N#K* )7?@3=9@:FH>,J>=/])HE+O$]3;&8AAH/(K
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M&\./94M:5*$FU!<.IK!DA.>)C,_OZ8%IN)?A33LO7F?:&(; -7%&::8@.JF
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M-08U@U76<8*Y1$7U>WR?T\U57I<'S+C_KT[(4SU]T<8*[UCRSZ84A;;,Z8C
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M*T%ZIW?]AYAJ4F_Q]5;F!\Q)TGT6+:-9W1U8?L,/=[-#DDF:L^) !N.)CFS
MI^C)Z4C9"Q9+X4V&OSZUH9Z ,U[0S^+F2*[/G9?TRQI7K]YM<KXW'88KX5$5
M ;&6,BH6:J)_3G60E5."J:!U?,F6>>KC/2'@6)&M)^3?W/)_\U_?/4:"BJRD
M%!"RXP*4<@(<8QI2YDGI&'SF<A $'O_^O!7$TZ-@ BYV<(W\$S?+>IN^Q>O]
M^&N9.&>9M*.NH=KB-?TN(_@L%>H4N<$FL[H.-](37$ZW-TYB<V<PV1^<;(D
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M_9=2$T4PD]&<?0;&DB.C*289FL2AGM[2O)":1N0#<'0$_SM$TJZ9PBX^=E=
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M' 0X99#8F5@J2<L2_TXO:Y9>-@:][=++QF"@ QOH0>H+1^D"&6F@T6:H#6/
M91\@<,%K?Z.<>!.[Y5M,+QN%@^?2R\8(I2- [;-H4%LC<Z+S* NQP24#R.JX
MVF2#M5%P@4T"#-VFEXT2Y_/I96-XVW=ZF8Q6A.C(7?3)@<(D((AL@6?TA0Z,
M"RR\9/U=6'K9*.&-Z+([@I.S5G=M-]>+MU67[DZ%-5QY:7@=CTW;%B'4Q@X"
M+$9><^1XDD,L3_KH/15!?SI4#P]6_5;2NXZY:HYG_XR:Y/.F]V!GP2,YPJ1+
M#8;:W-<"!L/ $^Q3=)SG,L1>&8Z:.?7("1([E/D1[)M9ZK\N5[5%W'[CRGG"
MMHI0;'UG3#D"1OJ%X&^%+98+-60:S""Y/UAY9LD?([?U%$R<6_JW#0+W&R\Z
MA,**A\*B!E7H%Z]%!ALSD<^TP^0GD_[]E>>Y+R:3_M%,[,"KF""QD\586T,$
MT-XI4-8C!$:W9$S>"5URU.J2>_&WR\3HPB4^,P!Z@?PQ88\W-YOXGO[RS689
M;U_2[EJKO,F;ZC4L5'"%9S(9I!*6? \";= UQR0H+;DDZZ'1@--F)'600'M&
M<$Z5=CXM4B[YS'Q)#MDG.CJRJPTC->5CIOLQ((-@)(E'>6N*=\G*OH[((04=
M),5>X(DX"0<7W!+D2Z#R5;Q>_KF\_M2P$<C3BYVK_<= <ON(RLIL;):"["3N
M#:BH H1,5E0V/ECDS"?Y=]./9\S.9)(H]2'49T%F9^$>G%$.=+9&)2,"+TV:
M)OP=E1V+WG91V3$8Z,".N=TY_>/=6Q]Y_#%8GL ZA\3"1$:8EPQ0:HZ::1M<
MD[#L@UU\*W'944A83R66#C!U/..^D+U*!U$L$PDZ.2=0NVI9;P*X5#0DS9E$
M5-DCSO*H<@0Q\R+\!&R-?2II+>B^8\W>L.(D^17<,:)$J&K1QPQ">XTIN2!2
M><G"[3W6/#\$AD>LQ\CCLON1?O%MC:_)\1$!6:P]6(N#(),'B9(%Q[5AO%W_
MA[];HIQH!IP9 )=@.SQ%\3[Y^?7-]?8:5VFY>G<_[9[%E OFVF6+$Q=BY"2.
MX($G;WAPV1(M71V#9\GI7.5/#,JISL1T"/FVSLEM=<C""6=0$,5:[<8GZMH@
MF=SGI$U6242&G942/47)A9Z.">'9[L0<@97+[V>R9\.N5FI[UZ#B/S?K[7:1
MA6&AJ 18I*LS52PY3B*"=HC2JI2]:?/B-STM%QK&Z??8G(J7/ER0&L"X;<WR
MP\V&N'M+S6TEX?VJLQ__RINX)$XL,!9?C#!DX7)RX6RHO>TKC6B9%$1BB6TN
MDM%;[:#Q2&>0;ROM4_OT='$-W.N>\KE94:+3C(&NPNPB'6L9:Y(<C\!U8L$Z
MQ[B=YW%R/"T=- OI[$S,C)=OXM#<:XGRF0G16Y^,$&"P)NDQ[<#E),%I24*Q
M/B?75[.=IVGIH _(MW5H3L7+-W%HOO:[4C&."#4@.+HZBBY!<%9#]B*7%$I*
MHJ_^;R?YZ&W[?'Q;!^8TK$S:U&.^ _//7?.55ZN:7)=C;>RXKG_U-6^8),,4
M4P;DJKY?* TNTB7,L@LN9=1>]-4H?B2!%^K+]_% W 1%?3CS)]_*.Z^OAK7V
M+! J.4/B@"(T(Q8$8D&Q@I1,Y)YIZ6R;F2Z34W*A3P%]G)C3</%-'(U[VN&_
M\O+=^ZI!:'_X+M\]E>Q*'ZJY4/;F0LK,),L+8'TT4:1)2':9@0C!J:QCD'Y(
M;>F<QMQ 4B_T3:&/P]486=]6+/,Y#BUD4J%D)R'+3/=U33!RC"7PBOYOS.A=
MZ=U[>HZ^;R;NV03F\YS*49B[G$CIDRE/CX:^GF60#K$H)-'IR HH<I3!<T%.
M,T<T@9/"-?-DYDQ'XX5Z8YT>S)FP=QE6ZDO,N:-_&']428%Y0]*SELP>^A,X
M)<G?58Q[+53V8I[I]9.2>:&NWX4>SW8(_#9.Z"/APN<-C&QR=AI!2F3UF=>"
M]V@@!J.SMYI.V#Q>Y,2$7J@/>:&GM"4*OXUS^DB$\ED.Y2*<<B& MC7SRY$X
MG>,9BI7(M5>ZB#[/Z4A"OYE0^$6<TY8HO(QS.I&?GI36Q2@.B4L)2C(!M>4&
M<*NM4DDD'=IU8>GD;>@2XNU=G,H9,/<_)D+_+,=B0N0^%])729%4(X+7B$!.
MNW VJZ)E7YWU)B'[0J_4/L(G9T3<Y4[!_CJ.^RQ3O")OO*9[2U:'&"DCJG^.
M("QJG83U,G092!E(WX5>EGV<MQ88ZN-@A9>9$D9;!&]S[7A ?__]>K5K8W2#
M5W_DS0>QX#9@M-&"L60B*",U.*8#&,:BM58DQ]L-S#XOK8,.G/V6#US'V.K'
M#3R!24]8 4\KJZ=XQQ?&:<82"M#:6%!1(Y ><\"R#$64Q UK5R?=!0L&'5?W
M]W'M"8G?Q"D^ADE!$B>8LA"")UG+7 <P6P<6<U:N<)5<E]=HJW/I_SZ7LV"K
MGP,XS<O6S\2+Y6J[C/_$JYN\"$JZ(,B(5\;2+[&^97&#)+J,:)&L"]%E(OB3
M% W+IF/?\FF:'2A]^'W3/S[=TS6OWKW;[$H.#]@DE N1^P(Q%PTJ>07(,[G'
MRC'GD!O.2H_GZ6B*AYVW_M)7^SAOYP%:'^=QFDO^(1OX@GE$F0I1'TT$Q5T!
M#"R!*TD(0:9VL$-F/<UI)QZ0-.Q$]9=WVIT]> I4)CHRYYK3\+FORZ!9\J<,
M:7AQI;83&L81VL=XANB],/6A/">!H#R/X)W)P)U45J)36C<)NWPSXQF\5%AX
M :XPUXFU''PU0ETRSBL3F(IMG@+^'L\P$KT-QS.,P$ 'I7&WVNEGTCU_59MN
MUYIKL[UM<_VYA;M*W,<@'#BNZ)JL([]]39(.K$CFM- >FS0A'+*Y;V:8PQC<
MK!L+\0* N>_DKCBW5I&5E*1-Y.U[#R[H4.TE%UTVTLDF5O6P[<T+SNEA,1)W
M1\BH ^3]2#;G^E/.]]H1WLT9-AE9'4T=ZI!J%13=,$%;*+Q.LBC<H6S24.S)
M'?6-KV/$OVXAB\M^&O_BKCKKN"TZ@4XBUZBZA6"-!J8=63Y)%\/[2HOZY9N;
MM7#"+7UF '2@2=]LUC'GM/V))/)X<U?GF$K">9 IUW;%/-,I]AGJ>!9O>(S*
M-2E:>7%G%]KKX$BHK%O*K1_MV^:UC@O.D\\)BA,>%,]D08E4P(9B)#+NTN$4
MIF_B8;?G=]U3P-\)4OHY-2=$C9YME;#[X0]XG7_"Y>8V5I0YJ0^>:E<O%*"D
M("M1^D+@YRQ@B5+E+H.2(^F\T(8 $YZO3C'5SZ$[.0'PCD&?&<$7E5(R7\E'
M8B62(^:PYA5E$"*S0O>XT#TGEGY-T(56[/=Q34V"D@Y\C,\O!'GSYS+FQZ7R
MVWKUYVT"0^7 ]H_U-5[=_WD-+?RVOO[?^?IMCNMWJ^5_YW3?\%TDH85/F$!(
M34I$U.<+= EB+"R8&-"F)OU\ST+=Q9?_G7*.^L//MWRH]MIFO=G_5?UW?$'T
M"XVAMLD2!12K?8XE8[5863N--DK7)+YT7C(OONJORV-V.J(F.V_GRJ'Y_>;#
M!]Q\6I?[*N9>0NSDJ31#%VR;47,4V7TDUCBGR'H2%EQV=')8BN"<+B"%9!;I
M1Z%-X.A;2:R).4:,I4 IM8]B03K.=?)$0)V"RBKJ1N,4_DZL&8G>=HDU8S#0
M@0GU.+F[O]V^NKE^O][4V^L?I)LV]_19'2A/?'C8=:8R:!>KSSXJS52!9.O$
M%:7(-=/)@@A&"1/)PBSM4HBGI>5;2=L9A<I!+V'G@\AEGY*O&;#/-Y \<VM<
M 1ZPBH19\*5$8,+K3,*R-I]Q5N))M/08A3PC/J<[+Y. 9<;S4LWDQ==$O%[E
M?3J,<4($S@7PI.F.YE827R4#F7S17IM,1+YD_+^TR,6B<1KIKQN(HC](_?'O
M]9X.C\&4$@(D3!J4U0;\_VWORYK;2)(TW_>_^&[<Q\N:J<ZM,55))JFZ;9Y@
M<7A(F*( #0!J2O]^/4" I"A"Q)&!#+![>II-$E2F'U]$^!7N0:;ZHQ<L,\=B
M/!)2MR_I,=/<#:2.4T6'D")T;!>'=*BDCQR"-0948)(XT0X",D8B8IR\B6-!
M=?>:'A.L_<#J2'7T!ZQ?YM>+[0J1VKF0(EBU[@_M%+BB)6VZ(7%B3M(.?"2N
M[M[28\*Q&U@=J8QNG9"#0N,E99F3UQ"QUC@;G\ 9&4&$&'UA/ 775^'*R^=6
MF3N\(]X, -U"_LB]Y.7\?W!Q\]WTXW0UT4D:E9@G\P1]507Y>#79&0.F@HP[
MHYND\UHRU:/OTPZ@+1WO4]#RW%;.GY\^?24+E7)TT9NJ%0M*L 1!9 ?%QI31
M8'+ZC+/*AF&J1Q?O,E?.*6AY;BOG9@SPJW(O_[NMM2G,YY1TJ0WOZ8L7BC27
M&0@M2[(>D\9V98[M^>O1M[W,]300ACIM6G2D4+X5QMY-?[6VD0QM#H8I1?N1
MMQ <)K"&(5?.:Z[:V7WC\]]C=."\"W-\'1R$P5[.Q+.)[:M_\@.^G\ZJ#'\(
M]+A4VTZ102$#$X"^=DYT/$)4N5YNC5P;0W_2,(C1B1 NOA;Z<A;Q@&CL924/
M;9G<NTNXM4QD4=(+DT FXVK? P?!*EI6(>1LF+;)7XYU^RU_%U\DW9UU>R*&
MGI=U^ZTPOK<I\8E32L8@!&@;./D!I-(8C804DG<B1Z/;=+X:D^F+'Y;2S1'8
M$FT7?&NA"O/VPN&\_!S2AWNRG,_J_=UY65_EO5Y6D^ JI+_>I@_T[.7O\XQ7
M+Y;+ZX\W FUXUZ$%F>>Z(=%<Q'W<JT"?5<$DH>B00 7Z+EKO 4,JB4E!7YN,
M:WPN]RI<*%(7[D CMZ!44K4U%^TZCME<4 ML-#/ZW_<J#D1ONWL5AV!@1#]K
MN5A-[LJ(Z:#4O*;WE9'TA?9T\,Y%D-EF$XM.+.QS$X(>>@^T]--#P'[UUN=R
M9^$@C<]/%7\/F-GV#.3*>V<"Z)(\*.:)<90(.AB-Q>68Q3[7\/9'S9AUTR=H
M[*'.CQ#?R%K_?3J;?KS^N"%<%">=2@6058= 80*O+$+Q*E@=K9-IG]E!>^G]
MJS>/K/EC]#8?0HAC:S_\?8]P%;41(05@.=-VATH#$5Q LN!,\DR[LL]]H/VT
M?__-XU0^#*;]HX78;33VH"B"R*E89!*<K(.YD;ZX)!1(%WE&KA.=HO\NZ>S-
M3AD) )<,^=LXP3V??SOEZ:?IYVDF1_\-^3,3)KA3OA:+E\*JOZ+ 2ZM &[(I
M;+))2=[5BMB7LXLO[CP(JD.ME":XZ:<#WU B>3-=_O7+ FLS4"1DK:I(-I;5
M1'H94W$:(O,(JA0)=!S7J=D^L779NLG=KZCO,'CQM9_=+*RA4/0OLKYN;-=)
M-"4['<ED2+S>FPP90C 2>/ F^L*3YDWZ[IR+P8NO!>U[?1V!HG[6US&]0;]W
MI-],I"ZB>&YHF\E!9%"\F'I7-(!5VBF6F+.F32>F9BQ=?-GFR6MH?*3TLVJ&
M-H3_,;^BQUQ-5U_NG]A"<L,E8IVWQ&N+" =D%1O('*W*@H?X\!9\A^?2=UF\
M^#K*;DZFX9#T+[/*-N>VT:0Q4V\6%M*C8E'0#A0M;4@LT<DM2R[[A/V[7&4'
MV'\]5TOVOLJ.0-* J^QLI5F;D.V\_+EIP/N&OBZF52#K?_'G;+I:ODBKZ6<2
MS/ E5T>]OG$IU>DBZ:-$BDD;6+T+H[.D T(1B$.,#G(2(D:=)+--#/9>2J3V
M:CS]XFK]2/KN57G86GI-Z4U"(J1L(E<99$@)JA$+@>1(7V0@3Q"3+VVJ@5MP
M<]&E4X>@>G?IU%C8Z"!;=)-FVPZ!9:P(4<<:2EYG?K 0(5IIH39D3#XP@;9)
M'/HK*GHIKQH-%?.A5-0!OH[/_=ZQ/<NUKOZ/\'';K2HE+307D<Q#1]9BC 4B
M%P$D2](*9#[(<;HL'<',N&@_ 5N'6N&M%=T!V!\S#=^\_?.V&YKAB14.I8Z+
M5:I._5,&0?B2$3')HINDS;]+5><I[^:@F;?28!=!EF&.L#LWW9H@1#(!"MK:
MM3D[B(5\=:2=P17-$-M<.AV8CUX*HWJQ,,:$R=C=1+_=7IX.'+VIE_?>S4D*
M./V,)(+U;R<J!R6,MN!DJOE!J\"1]&NZT+%D=3+EP>K8T7MT.)K&W=Y'Q=5\
M?"5W8)(<G=C;7%2]'<6UO49^<P7VS?SJZI?Y8BT1GSV+10F0I79YM3& ,Z4
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M\/60G$Z"6H/:,@,(ODOX;%:<<TYYR358ECRY!74F5$ATJ&=FA+/<%M\V\_&
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M.VM8U+Q/]X$7]TWZM9J^^N,)BSYJ+Q7M*-J3"<48B<6E.A^L.,&-56TN/P]
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M]CG[QW5=KJ_*9A'?.D/+"7?"$[T.2JPS5DOV$#)'*!PE,R8'M>=QNO,5%^N
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M0*EVL-D\..E?WA81Y(Q&N>@@(Z_#T.D[EU6&&&34Q4A5?),+C[L(&OFJ4..
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MU7IY&:C60@:*A&-TVF-ZQQ3N3!@-0*$!>%+.I)WO)&5:BAB9*B"4B9X6O?8
M"+A"-IYIM0X()!L"U@4N>]VU)]@U)'5J.T*(N5#VKB93;#A$P@3^@@]!Y%.6
M)@)\%HRB<4ER]"AN]/(\QV![/ =XZ_K]SD-%,UT/1:@+;_]4WY"$@1"^A%E\
MHR*V--Q09@&!$'C2_AC9TP<0HT2?.Q9QJ$(.^%NKO7WCM(ZM6HV< ;6B,B1[
MN_5:S8#9F[7:_D*"ZQ*#J]MXDJ4+R"V&5_@4C9\0(M'IU.<Z$?$(KO8HDVNU
MJT@.J!A#97?4 M^^L9JU-3_[8BD4]^)[XN3$NT"(&JO LIS8[)7XHUE;%WU4
MDD/!4D\>^.^GT30N\[M2"LNB*J03]K%8A./@!1!F#Q1-*ES9J1OUFF7:MJ*>
MCZJ3).MST,VN>M%-M?J!B"(Q.:KEM]!!*/PX6KWEN<ODRSN%H&*5%\5RZ;Q<
MHX.3-3J,96[+(W8PD(Q^.5"5M"/JSP#5%@7W]VZ&V"C?TDT)C<Z&C,.WJ8=5
M#2Z@ONF4H\)/1:4'U*?(C3&]P,!0T[PAV':M:30[;;/5WB_X&M=ETX189WX/
M'$^:TP.(&,9P*6+((@BK!,:,8SH_@6.5;8!5""\O/<-!*>+1F)PQ5^?3Z]92
M1M-VFH9EMTT N 1S=NL-PVH"N#CD*X0$=RP@$Q#$.-S/TB=EL6]/92^QHJ"'
M\.>$P?Y-@,WN?\^DVRVCT7',>C.9\Y-ZF?5DMR(%V[5LHV'53:>]O!E&A>SM
M/H*;II@KC;"B,<1*18:9J)]!0/L8J"%J<FI=>VA"61#FT3EJ[%(U(K,\T%LI
M)CKCK=HF?J=!3.6<:!VU<AN9,1]BZ#W+WL^4/T_[(SZH^XTBS]T%C+!LTVFF
MFDZ!:4!HCN?"V!WG ^#%K8Y1=SIF8[&+X@P#=*3)GY+9=Q5M2"DO<-YSF)T+
M3!D[3& <M7=A!//&)Z:%&$Q[XH&E-&:>X-0R5@QF-))LA'6 9!GE84H3HV6#
M3QMF> A@9#F&4[/-3E+3+DNYLOU,'H9C66!,3=LRZ[:AJRW!ZMQW';L%+ RI
MGDG^F(I !P3N0D(YC2.PL2:%?#'#64@VH3S0^V,MC[14W=JP4Q"_9#L+5JZ*
M1NE#]/#XH)F(?3C.RD%?:QWR511R[#HMHPE<NF673&,\+JC:%$%L,9OXE%?G
M"K4Q[.Y%[0D$0?Q7ZN.Q(8W]*.W,PN*_TB2M^ %A7WFHK$(9=Y[P0UR9"Q4Z
MSU/%5G6/6*:6LF_H(3(^HMF*"\-S5<+3%F@0F-**AUY$LVRC,S@;J#R67(6&
MI7G")'1Q)7ELSI@"0"@O=E7A4J<O,Z@JG$%S7Q'@$G0H[%=H37DTAM]0   +
M$VW.P[0*FI4L#1CR3HVQ4KU4E\$SDZSJA0;1E>TJ(7UM[X65Z*73&,(NJK*9
MX$= $!YV36"1V6<H4N64\BFH^<&#06>&L53%+IU<! 71N<6D,P,FHD6LLBAY
M27C$D6JH\C)?I*?95O )3(###3 AW$(<#Q!.K0AN2+QO(:-3TMSM)[/V,IT9
M%9D[)A4RD;*OH,-A"'*<49![2#AHF&[<QT([[)&/'FK(X%1N-EDM'UW9DOVH
M(GR2I,@:!-)N"W>^*2F1&A0,'*9ZG3=:-$PG<X :3$(6*93110/-&X2+?:&I
M"Z8!L"-?-0N :TM+L!+#)I?[//.J)=QZ&C?!K7 FUDT(8$2*S*4+!OM@@4<E
MF3/XH2%I:>Q%$@;W9!J=V)1NE5A-SUB-F@J,6LVG=ES?*,8_($S9!MW.L[O+
M,B=B ).E&C-117*FF'1,+Y'I'/>+F@]D-4K+AJP >-B!PX<)1CZP1\@D5R+"
M''3&A,'N % Q"2>2/%P029Q<7B8KSD!WS63*E2/@?2L;JN:Z0M8Y>=92P*#P
M-1(S*KWP/NJ8M/IDP84R$?1BR@-@;\\Z9ZNM/N6TBQU'NDU+F476Y)-:2!)P
M@*&!BTWBBP6O4' ;>F98]"TT P%8I-5RB?,4"<M.0"_=3CP+=X5,MXII1[D7
M[JL]!:758V-WDG:=JTT@.=)B.X^F"DK2K^7+[RE?8L>-Z\?*6M!S*2J:]Y+E
M3DM1 ^6N$F^A?86(8!".[B'C'7F/W[?:P#:F:/Z!:6_[N=/>K2=(>RLV]L])
M>S_8[S^"+#CF*E=X4>7[=J6-7^V'-GXES-,CO4"%4\E[6E6^A)90]C7YN4)3
M;IJITU0IS5$5J@L+;2<&$ 1W3(,1P] $*Q3(8?(@92'PJ+X+Z,6_/8A;^"K!
M[Y%@2GL3!<^B!G!.2%9'3/%?).(!1'G).^^K:1J5#1'!T.=NE+VMF7>LITF>
MUXWZ_HTJ2#2+GUXE_922UD8P$C#3LB]3/.JUJ%7"L?Y5^&VA&]5U"Z[0C6]W
M"_ZFM@^#IDLZJYIFO!KD$Q@D>"5MD\G[E;J.$$8R3E(L3%-+E<C M*GT5#TB
MZQ3VZ2P#SEM,A.$O^?N_S_K>U+K@HK/5UNYNC[5;9K-]O[6?)Z6:C_BZ8%)R
M_D%OC[Q:_3-9_83.B7H'?\#T:Z"8Y5U\+7LF>12Q0 =K&BI@,0D^Y#7(-,;3
M58L?;N?;FT3 #)CWDMX!Z 41EX57WZO,YE9NXB\^"Y[%-&E@&:YDL57MB";5
M(J9W/[?V8J2Y:.3:ZR>OEF>U(0IH(=<\1+^A.H5S##]!A-4HR;&RDCXI- AH
MHX_UE 1SC(<\7'6@)4]_UD^#K(.?9HE:?H4\@[TDGG&*M4(F<;M?Z<4+PYXU
M] *8!?O*W#BIB6.7,%JY6]AEG0P&1 A%?FW63@&6%,482 0%6 )HX+H0KIJG
M-A(1 ZNZ"X5SE6Y><SVV9JH*,,B21D)REO6HJ$[-PH0?]^FO%1#YX>"P?K\N
MKLCGB_Y5[_:6?,:O%5R?+W;5JK=VLVUYS7Q];XXQBX_5QTETCT5&LO'-YN<F
MSQ5UUEYVK\XNKV_.[G^?KW?5?= G1=:\-E'=ZXKIIQ,WK:[W[]MK\O[B^NKB
M]-8@%U>G);?:VIXU=DM]$W*3 +IKO_3X_7!J.Y4(Q,(OKLWU"U85P0O,X3XR
MI1IG0_63_&[>F.1:1OCMF(N+BPU2_]$*19(_VSV[CS2@(R9+:J-5G7T24K5"
MWO]YY 6%%.. G)OD-Y\%P2;(V/2SNN6!D%^"'EP!:UUPI-NE" _5SZ[DU'^N
MR932Q$?ZZHI\$RK!1I:%G]/?9MW8*N4X/;\NK1(/[JLK6]6^OZ_.ME>_"-VR
M"TU[/SK@29Q0=3'7_3[H1;@:'3E6#>-_)UGFN%?9Z^GW2Y,\V/?\+3O&Z^5Q
M=>&G_H]AU']1<_)_4$L#!!0    ( -F!65(NH]I2" ,  '@/   6    97AH
M:6)I=#(Q,3$R,S$R,#(P+FAT;>576T_;,!1^WZ\P01N;1.(DO4#34 G:#CJQ
M@MH@M*?)B=W6(HDCVVWH?OV<V[BT'4.;MA7R$,67<_Q]YWPZ\7%W>A==[\ME
M'\QD%(++JY/S01=H.H37M2Z$/:\'SKS/YZ!NF!;P.(H%E93%*(2P/]2 -I,R
M<2!,T]1(:P;C4^B-8.:J#D/&!#&PQ%K'S6;4FR#<>>/NZ#KHL6 >D5B"@!,D
M"09S0>,IN,9$W !=+W=U6;+D=#J3P#9M"UPS?D,7J%B75(:D4_EQ83%V87Z(
MZS.\[+B8+@#%1QH]M*W)Y!!9K6;3JOOHT ^:R)[8+=)0,V8C^&HID%!M+VR$
M7(;D2(MHK,](=KY3MXV#1B+;*<5RYEBF^5;+MW;<"8NE.H\K^^*S<+/B3));
MJ:.03F,GIZ05IM5RP$+&G5TS?]K9BCY!$0V7SIY'(R+ D*1@Q"(4[^T+E09=
M$$XGQ49!OQ&%2<'+AVD!^4#Y"6E,*@J6G8'NW\ZH3U5 +<-ZB/AIK&MHKC<*
M5$8(_T<,QU<GXT%O<#P:],?@XB/PSOI@U#\=C+W1\=!;@?\KU"+$ITH+/I.2
M14ZF@W)&LB0;*J82^2&I]ON,8\)UQ3A$B2!.]='&5"0A6CHTSG'G1NT%X9(&
M*"R#IWR6,FNUC,-&+5.:5. DKMR7(C1R$4*)5]?J#<.T-R^;AK5Q[6=N;=-H
M-%M_W&U-:=':;'K?+<PC441#154D*#[2:EIED"",51UQ[.066"I-]S09DHE\
M'.HBH7]?IWGY&**(_%!<R7MK*-774GJW:S7-]M:26I^G3W-.!:9!]M\#; (&
M<<!XPCC*)AYP?4*<957(:H;B# 0+*085_O\S(NO3W+\1#)PH]C00^UD\C*U-
M^6_J^,6DM$="E").GJ/G;>)W7[+@-/+/7JMBMXG4*>'*Q_)5:/+]L:#H [B4
MQ #G$AO@&;DT,ZK:BTG[6 %%Z@>[IAC!_,:\YH;^J$U+6-&G.ES5-4D79*5Q
MNZO@^9W>O#-!OBKC<[G99%.CL[$++-]%3YIWQYWO4$L#!!0    ( -F!65*0
MF'N.*P,  )P)   6    97AH:6)I=#(S,3$R,S$R,#(P+FAT;=U6WV_;-A!^
MWU]Q5;!T 2R)E&3+L5T#K:RTQA([L!4$>QHHB;*XR*1!TG'=OWZ4%"-.FA3M
M0[=A?B!\NA_\[CO>D:,WDWF4_'$=0ZG7%5S??+B<1F#9KGOK1ZX[22;P*;FZ
MA,!!&!))N&*:"4XJUXUG%EBEUIN!Z^YV.V?G.T*NW&3AUJ$"MQ)"42?7N34>
MU5_,2DD^_F7TQK9A(K+MFG(-F:1$TQRVBO$5W.94W8%M/UA%8K.7;%5J\)"'
MX5;(.W9/6KUFNJ+C0YR1V\HCM]EDE(I\/Q[E[!Y8_LYB!/L%+5 :Y#@+4%KT
MTY &P7F&0A1ZA&9_8@/2->:MC]+[BKZSUHS;):WW'P2>$W8W>KACN2X'&*%?
MK<9T/"H$UV8_:?S;OVV8KX)I^EG;I&(K/FA2LEK7@SH3E9"#$]3\AK7&+LB:
M5?O!VX2MJ8(9W<%"K E_VU&F#+:BDA6MH6)?J,%DX#7BKH4<FC@5X_20 O9J
MT/'GDJ7,$.H[^"GBE['^M56:%7OKU41?=LM,3:C\EW*,YK-E/$M@?@'3V22^
MCLUBQ$7\<;I,XD4\.9SS]U$TOYDET]E'N)@NKGXXL>^FXWM8_-E<!<^YPEW#
MU2V%3'!5MZ(6H$L*C&=";H0D=:-#N@=)"RHISVI58[&@*Z;T@\%2F_ZM6U"!
MD2Z$7,/2[L-O,^& [_LV/N_[W; #!]E#(?;QD>RA/NH?RUZOYQ_+/>0?^_LH
M0,&Q['6Q=RSW NP!X?G1I[#KA6>= SK_&%TW[/O/T(3/O,\]Y)\UWQX"X,<
M1ML+S\] %!#?*0$?#"<L4_!)5+F9:*H#4YXYM5ILI:'2$*LA;T;>!4WEELC]
MZ0GNH:'7[313KF.,*D.MF88/!:GK(RK6.A6,$YXQ4IF#\DC\MS??E2PK@6PV
ME$C5%I$I>,_YUH19M) .M</(_MWYB8/AJ=L_>-J;R7!Z$H1#U:PPO[F"TQ._
M/X1H[L#EY?7_-NLE,<65];%1F>A 9# 50G)&_OO07^X1>&5X?KL>SZ[RC6C?
M,H.VW^[I5Y?[P3$56HOU #VZD-1TY%:_[O(#-\:3M7VW-"^H\=]02P,$%
M  @ V8%94C#D=(J?!P  $B4  !8   !E>&AI8FET,S$Q,3(S,3(P,C N:'1M
M[5IM;]LX$OY^OX+KXKHIX#?Y99LX:8 V2;'9W6N+(H?B/ATHD;)YH40M2=GQ
M_?I[AI2=.$ZVR>:VZ_:N0!U)' YG. ^?&5(Z^N[T_<G%/SZ<L9DO-/OP]S>_
MG)^P5J?7^S0\Z?5.+T[9CQ=_^X6-NOV$75A>.N65*;GN]<[>M5AKYGTUZ?46
MBT5W,>P:.^U=?.R1JE%/&^-D5WC1.CZB)_B57!S_Y>B[3H>=FJPN9.E99B7W
M4K#:J7+*/@GI+EFGTTB=F&IIU73FV: _2-@G8R_5G,=VK[R6QRL]1[UX?]0+
M@QRE1BR/CX2:,R5>M908\Q$7:3;,DM%(YAE/]@]X/QT=#(:<BV'ZSP1&]B >
M^SB_U/)5JU!E9R9I_,EHT'TYKOSA0@D_FR3]_E];0?3X*#>EQW@6_>-E5+.E
MS,LKW^%:3<M)<*D5NZZ:,Z.-G3SKAW^'U-+)>:'T<O+]A2JD8^_D@GTT!2^_
M;SN$H>.D57D4=.K?$C;!O'"[B":_A!ZM2KER(1F0T6=7,Y4JSX9)-]FT^&Y;
M,TRNM'^2L2=G'R_.WYZ?O+XX?_]NR]I[Y_YN3_Y5.Z_RY1_NRNA.5\[;[">>
M7;(/LK8\F[59)BV9P_R,^^?/QON'C_?AMUTON)T"P*GQWA2P F967 @LLXZ6
MN9^,1WBRK3L^4J5 X">=P<OJCT?JW3.VE[Q8^?;EA]^<JF3<'8YH(L[9C,\E
MLW*NY *LY6?*,5Z6-==X6!GKF2G96V,+EO0[/S.3L[-+9]@;<*;*'/O1:-+J
MVNR\S+H(^\']8?_JXS?8O?B]X0Y10XB*);LLS4)+,97M&,8F?L+ AM(@,V$(
MKDJ$=\GJTMM:P@7DJI"V$%C."MQ9A=#G/,,CRTP!9O4FRFT)E#*3SG&[))&"
M7TJ,>T.GPS,!8S"D#CD/8Y! IBQR',1*=(<E0EJVF*ELQEQ-/]?]%]+*1@DY
M4"BGD0PIKRZ4G\%!5\DL&$AZ*YAF!-R<HYM@Z?+F-'SCT!Q^1="4+%<E@D\X
MN@YV&[B$.)KMC795YN >3B4:KC-="^@$H&Y$M@TP*JN7K (>",H$<:VOL=K
MQ-T:&LM!A-JO31*UA@  :H"B,)P+]F3<S5BNS<*MT6N*BE80IR?1:)C8OH%
MM[)DR]3_%@AW 7&CW4/<Q75XGC_;'R0O#UT#J*8V(>8P>:YPN^=>A-B=,VYE
M@ A"KE(M*9I, I>I5FY&/4BL '$2>=*]4"[3QM56!DJU1D>L5-9D4N"Q8WM
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MWZW<^WU.\QN_%@K?+1W_!U!+ P04    " #9@5E2&"IN@)@'  #=)   %@
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MRS$<E@@R;#J2Z8C9TG\LQT_)4#6)=V LK4+&\\ES*MT(#MJ"TF"@G[> :5K
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M'"A6H%C>LD>?JO=D<2H1W;N0%!FS-!]W><9GQ(-K_17N_@\X^@M02P,$%
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MYJ_Q[O\%COX%4$L! A0#%     @ V8%94IKI.+8O1 , N4\? !$
M     ( !     &5K<V\M,C R,#$R,S$N:'1M4$L! A0#%     @ V8%94E.S
M$>23&0  '28! !$              ( !7D0# &5K<V\M,C R,#$R,S$N>'-D
M4$L! A0#%     @ V8%94FL<KO][*@  K,(! !4              ( !(%X#
M &5K<V\M,C R,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( -F!65+ **[RZ8D
M '0;!@ 5              "  <Z( P!E:W-O+3(P,C Q,C,Q7V1E9BYX;6Q0
M2P$"% ,4    " #9@5E2$AU8JRX] 0#J- T %0              @ 'J$@0
M96MS;RTR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @ V8%94C5JD@3@R0
M:U0) !4              ( !2U % &5K<V\M,C R,#$R,S%?<')E+GAM;%!+
M 0(4 Q0    ( -F!65)_/QU/!1   /UF   /              "  5X:!@!E
M>&AI8FET,3 S,"YH=&U02P$"% ,4    " #9@5E2+J/:4@@#  !X#P  %@
M            @ &0*@8 97AH:6)I=#(Q,3$R,S$R,#(P+FAT;5!+ 0(4 Q0
M   ( -F!65*0F'N.*P,  )P)   6              "  <PM!@!E>&AI8FET
M,C,Q,3(S,3(P,C N:'1M4$L! A0#%     @ V8%94C#D=(J?!P  $B4  !8
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M:70S,C(Q,C,Q,C R,"YH=&U02P$"% ,4    " #9@5E2/<Y629(&  !R&
M#@              @ $"2P8 97AH:6)I=#0Q,"YH=&U02P4&      X #@";
) P  P%$&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
